<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Topical benzoyl peroxide for acne - Yang, Z - 2020 | Cochrane Library</title> <meta content="Topical benzoyl peroxide for acne - Yang, Z - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011154.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Topical benzoyl peroxide for acne - Yang, Z - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011154.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011154.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Topical benzoyl peroxide for acne" name="citation_title"/> <meta content="Zhirong Yang" name="citation_author"/> <meta content="zy266@medschl.cam.ac.uk" name="citation_author_email"/> <meta content="Yuan Zhang" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="Elvira Lazic Mosler" name="citation_author"/> <meta content="Jing Hu" name="citation_author"/> <meta content="School of Public Health, Peking University" name="citation_author_institution"/> <meta content="Hang Li" name="citation_author"/> <meta content="Yanchang Zhang" name="citation_author"/> <meta content="Yale School of Public Health" name="citation_author_institution"/> <meta content="Jia Liu" name="citation_author"/> <meta content="Xuanwu Hospital, Capital Medical University" name="citation_author_institution"/> <meta content="Qian Zhang" name="citation_author"/> <meta content="The University of Nottingham" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD011154.pub2" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/03/16" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011154.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011154.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011154.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acne Vulgaris [complications, *drug therapy]; Benzoyl Peroxide [*therapeutic use]; Cicatrix [etiology, prevention &amp; control]; Dermatologic Agents [*therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011154.pub2&amp;doi=10.1002/14651858.CD011154.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011154.pub2&amp;doi=10.1002/14651858.CD011154.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011154.pub2&amp;doi=10.1002/14651858.CD011154.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011154.pub2&amp;doi=10.1002/14651858.CD011154.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011154.pub2&amp;doi=10.1002/14651858.CD011154.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011154.pub2&amp;doi=10.1002/14651858.CD011154.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011154.pub2&amp;doi=10.1002/14651858.CD011154.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011154.pub2&amp;doi=10.1002/14651858.CD011154.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011154.pub2&amp;doi=10.1002/14651858.CD011154.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011154.pub2&amp;doi=10.1002/14651858.CD011154.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011154.pub2&amp;doi=10.1002/14651858.CD011154.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011154.pub2&amp;doi=10.1002/14651858.CD011154.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011154.pub2&amp;doi=10.1002/14651858.CD011154.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011154.pub2&amp;doi=10.1002/14651858.CD011154.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011154.pub2&amp;doi=10.1002/14651858.CD011154.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011154.pub2&amp;doi=10.1002/14651858.CD011154.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011154.pub2&amp;doi=10.1002/14651858.CD011154.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011154.pub2&amp;doi=10.1002/14651858.CD011154.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011154.pub2&amp;doi=10.1002/14651858.CD011154.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011154.pub2&amp;doi=10.1002/14651858.CD011154.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011154.pub2&amp;doi=10.1002/14651858.CD011154.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011154.pub2&amp;doi=10.1002/14651858.CD011154.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011154.pub2&amp;doi=10.1002/14651858.CD011154.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="p32VIvbS";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011154\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011154\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011154\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011154\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","hr","de","zh_HANS","zh_HANT","th","ko","fa","fr","ro"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011154.pub2",title:"Topical benzoyl peroxide for acne",firstPublishedDate:"Mar 16, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Skin Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=p32VIvbS&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011154.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011154.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011154.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011154.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011154.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011154.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ro&quot;,&quot;title&quot;:&quot;Sumar&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011154.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011154.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011154.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011154.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>13474 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011154.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011154.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011154.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011154.pub2/full#CD011154-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011154.pub2/full#CD011154-sec-0569"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011154.pub2/full#CD011154-sec-0050"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011154.pub2/full#CD011154-sec-0051"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011154.pub2/full#CD011154-sec-0059"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011154.pub2/full#CD011154-sec-0060"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011154.pub2/full#CD011154-sec-0088"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011154.pub2/full#CD011154-sec-0552"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011154.pub2/appendices#CD011154-sec-0578"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/table_n/CD011154StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/table_n/CD011154StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011154.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011154.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011154.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011154.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011154.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011154.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Topical benzoyl peroxide for acne</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011154.pub2/information#CD011154-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Zhirong Yang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011154.pub2/information#CD011154-cr-0003">Yuan Zhang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011154.pub2/information#CD011154-cr-0004">Elvira Lazic Mosler</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011154.pub2/information#CD011154-cr-0005">Jing Hu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011154.pub2/information#CD011154-cr-0006">Hang Li</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011154.pub2/information#CD011154-cr-0007">Yanchang Zhang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011154.pub2/information#CD011154-cr-0008">Jia Liu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011154.pub2/information#CD011154-cr-0009">Qian Zhang</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/information/en#CD011154-sec-0592">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 16 March 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011154.pub2">https://doi.org/10.1002/14651858.CD011154.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011154-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011154-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011154-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011154-abs-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011154-abs-0018">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD011154-abs-0014">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD011154-abs-0012">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011154-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011154-abs-0001" lang="en"> <section id="CD011154-sec-0001"> <h3 class="title" id="CD011154-sec-0001">Background</h3> <p>Acne is a common, economically burdensome condition that can cause psychological harm and, potentially, scarring. Topical benzoyl peroxide (BPO) is a widely used acne treatment; however, its efficacy and safety have not been clearly evaluated. </p> </section> <section id="CD011154-sec-0002"> <h3 class="title" id="CD011154-sec-0002">Objectives</h3> <p>To assess the effects of BPO for acne.</p> </section> <section id="CD011154-sec-0003"> <h3 class="title" id="CD011154-sec-0003">Search methods</h3> <p>We searched the following databases up to February 2019: the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS. We also searched five trials registers and checked the reference lists of relevant randomised controlled trials (RCTs) and systematic reviews. </p> </section> <section id="CD011154-sec-0004"> <h3 class="title" id="CD011154-sec-0004">Selection criteria</h3> <p>We included RCTs that compared topical BPO used alone (including different formulations and concentrations of BPO) or as part of combination treatment against placebo, no treatment, or other active topical medications for clinically diagnosed acne (used alone or in combination with other topical drugs not containing BPO) on the face or trunk. </p> </section> <section id="CD011154-sec-0005"> <h3 class="title" id="CD011154-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures as expected by Cochrane. Primary outcome measures were 'participant global self‐assessment of acne improvement' and 'withdrawal due to adverse events in the whole course of a trial'. 'Percentage of participants experiencing any adverse event in the whole course of a trial' was a key secondary outcome. </p> </section> <section id="CD011154-sec-0006"> <h3 class="title" id="CD011154-sec-0006">Main results</h3> <p>We included 120 trials (29,592 participants randomised in 116 trials; in four trials the number of randomised participants was unclear). Ninety‐one studies included males and females. When reported, 72 trials included participants with mild to moderate acne, 26 included participants with severe acne, and the mean age of participants ranged from 18 to 30 years. </p> <p>Our included trials assessed BPO as monotherapy, as add‐on treatment, or combined with other active treatments, as well as BPO of different concentrations and BPO delivered through different vehicles. Comparators included different concentrations or formulations of BPO, placebo, no treatment, or other active treatments given alone or combined. Treatment duration in 80 trials was longer than eight weeks and was only up to 12 weeks in 108 trials. Industry funded 50 trials; 63 trials did not report funding. We commonly found high or unclear risk of performance, detection, or attrition bias. Trial setting was under‐reported but included hospitals, medical centres/departments, clinics, general practices, and student health centres. We reported on outcomes assessed at the end of treatment, and we classified treatment periods as short‐term (two to four weeks), medium‐term (five to eight weeks), or long‐term (longer than eight weeks). </p> <p>For 'participant‐reported acne improvement', BPO may be more effective than placebo or no treatment (risk ratio (RR) 1.27, 95% confidence interval (CI) 1.12 to 1.45; 3 RCTs; 2234 participants; treatment for 10 to 12 weeks; low‐certainty evidence). Based on low‐certainty evidence, there may be little to no difference between BPO and adapalene (RR 0.99, 95% CI 0.90 to 1.10; 5 RCTs; 1472 participants; treatment for 11 to 12 weeks) or between BPO and clindamycin (RR 0.95, 95% CI 0.68 to 1.34; 1 RCT; 240 participants; treatment for 10 weeks) (outcome not reported for BPO versus erythromycin or salicylic acid). </p> <p>For 'withdrawal due to adverse effects', risk of treatment discontinuation may be higher with BPO compared with placebo or no treatment (RR 2.13, 95% CI 1.55 to 2.93; 24 RCTs; 13,744 participants; treatment for 10 to 12 weeks; low‐certainty evidence); the most common causes of withdrawal were erythema, pruritus, and skin burning. Only very low‐certainty evidence was available for the following comparisons: BPO versus adapalene (RR 1.85, 95% CI 0.94 to 3.64; 11 RCTs; 3295 participants; treatment for 11 to 24 weeks; causes of withdrawal not clear), BPO versus clindamycin (RR 1.93, 95% CI 0.90 to 4.11; 8 RCTs; 3330 participants; treatment for 10 to 12 weeks; causes of withdrawal included local hypersensitivity, pruritus, erythema, face oedema, rash, and skin burning), erythromycin (RR 1.00, 95% CI 0.07 to 15.26; 1 RCT; 60 participants; treatment for 8 weeks; withdrawal due to dermatitis), and salicylic acid (no participants had adverse event‐related withdrawal; 1 RCT; 59 participants; treatment for 12 weeks). There may be little to no difference between these groups in terms of withdrawal; however, we are unsure of the results because the evidence is of very low certainty. </p> <p>For 'proportion of participants experiencing any adverse event', very low‐certainty evidence leaves us uncertain about whether BPO increased adverse events when compared with placebo or no treatment (RR 1.40, 95% CI 1.15 to 1.70; 21 RCTs; 11,028 participants; treatment for 10 to 12 weeks), with adapalene (RR 0.71, 95% CI 0.50 to 1.00; 7 RCTs; 2120 participants; treatment for 11 to 24 weeks), with erythromycin (no participants reported any adverse events; 1 RCT; 89 participants; treatment for 10 weeks), or with salicylic acid (RR 4.77, 95% CI 0.24 to 93.67; 1 RCT; 41 participants; treatment for 6 weeks). Moderate‐certainty evidence shows that the risk of adverse events may be increased for BPO versus clindamycin (RR 1.24, 95% CI 0.97 to 1.58; 6 RCTs; 3018 participants; treatment for 10 to 12 weeks); however, the 95% CI indicates that BPO might make little to no difference. Most reported adverse events were mild to moderate, and local dryness, irritation, dermatitis, erythema, application site pain, and pruritus were the most common. </p> </section> <section id="CD011154-sec-0007"> <h3 class="title" id="CD011154-sec-0007">Authors' conclusions</h3> <p>Current evidence suggests that BPO as monotherapy or add‐on treatment may be more effective than placebo or no treatment for improving acne, and there may be little to no difference between BPO and either adapalene or clindamycin. Our key efficacy evidence is based on participant self‐assessment; trials of BPO versus erythromycin or salicylic acid did not report this outcome. </p> <p>For adverse effects, the evidence is very uncertain regarding BPO compared with adapalene, erythromycin, or salicylic acid. However, risk of treatment discontinuation may be higher with BPO compared with placebo or no treatment. Withdrawal may be linked to tolerability rather than to safety. Risk of mild to moderate adverse events may be higher with BPO compared with clindamycin. </p> <p>Further trials should assess the comparative effects of different preparations or concentrations of BPO and combination BPO versus monotherapy. These trials should fully assess and report adverse effects and patient‐reported outcomes measured on a standardised scale. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011154-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011154-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD011154-abs-0008">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD011154-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011154-abs-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011154-abs-0019">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011154-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD011154-abs-0015">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011154-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ro#CD011154-abs-0020">Română</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011154-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD011154-abs-0013">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011154-abs-0010">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD011154-abs-0011">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011154-abs-0003" lang="en"> <h3>Topical benzoyl peroxide for acne</h3> <p><b>Review question</b> </p> <p>We reviewed the evidence showing effects and safety of topical benzoyl peroxide (BPO), used alone or in combination. Eligible comparisons included placebo (an identical but inactive treatment), no treatment, or other active (medical) topical medications for treating acne (used alone or in combination with other topical drugs not containing BPO) (evidence is current to February 2019). </p> <p>The main outcomes of interest in this review were participant‐reported acne improvement and withdrawal from the study due to any side effects. More generally, we also considered the percentage of participants experiencing any side effects over the whole course of a trial. </p> <p><b>Background</b> </p> <p>As a common skin disease, acne vulgaris affects the physical, mental, and social well‐being of millions of adolescents and young adults. A wide range of treatments for acne vulgaris are available, and topical BPO has been recommended as a priority therapy to be used alone or combined with other topical or oral treatments, depending on acne severity. However, the benefits and harms of BPO have yet to be evaluated. </p> <p><b>Study characteristics</b> </p> <p>We included 120 studies (which comprised 29,592 people randomised in 116 trials; in four trials the number of randomised participants was unclear). Through our search, we found studies assessing different concentrations of BPO, BPO delivered through various means, or BPO used alone or given with other treatments that may or may not be considered as the primary treatment. These studies compared treatments against different concentrations or formulations of BPO, placebo, no treatment, or other medical treatments given alone or in combination. </p> <p>Most of the studies included male and female participants with mild to moderate acne; only 67% of studies reported participant age, which ranged between 18 and 30 years. Participants were treated for over eight weeks in nearly two‐thirds of the trials. Industry financially supported approximately two‐fifths of the trials, and more than half of the trials did not report their funding sources. Few studies reported where they were set, but locations included hospitals, medical centres, national medical institutes, clinics, medical departments, and general practices. </p> <p><b>Key results</b> </p> <p>We found low‐certainty evidence to suggest that long‐term (i.e. given for longer than eight weeks) BPO treatment may increase self‐reported treatment success compared to placebo or no BPO treatment (three studies), but there may be little to no difference when BPO treatment is compared to adapalene (five studies) or clindamycin (one study). This outcome was not reported by studies comparing BPO treatment to erythromycin or salicylic acid. </p> <p>Long‐term BPO may lead to an increased chance of treatment discontinuation compared to placebo or no treatment (24 studies), with the most common causes being redness, itch, and skin burning (low‐certainty evidence). When medium‐ to long‐term BPO was compared to adapalene (11 studies), clindamycin (eight studies), erythromycin (one study), or salicylic acid (one study), we found only very low‐certainty evidence, meaning that although there may be little to no difference in withdrawal between these groups, we are not sure of the results. It should be noted that participant withdrawal may be linked to issues around treatment acceptability (dermatitis, rash, facial swelling, sensitivity) rather than to safety. </p> <p>Very low‐certainty evidence means that we are uncertain if BPO leads to more side effects among participants receiving medium‐ to long‐term BPO than among those given no treatment/placebo (21 studies), adapalene (seven studies), erythromycin (one study), or salicylic acid (one study). Medium‐term treatment with BPO may lead to increased risk of side effects when compared against clindamycin, but the effects of this treatment vary, so the treatment chosen may make little to no difference (six studies; moderate‐certainty evidence). Side effects reported in these studies were usually mild to moderate, and the most common were local dryness, irritation, eczema, redness, pain at the site of application, and pruritus. </p> <p><b>Certainty of the evidence</b> </p> <p>For our key comparisons, we rated the certainty of evidence for 'participant‐reported acne improvement' as low. For the outcomes 'withdrawal due to adverse effects' and ‘percentage of participants having any adverse events', the evidence was mainly of very low certainty. </p> <p>Included trials were at high or unclear risk of bias, participant numbers were small, results were not consistent across trials, and we suspected publication bias. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011154-sec-0569" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011154-sec-0569">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011154-sec-0656">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011154-sec-0569"></div> <h3 class="title" id="CD011154-sec-0570">Implications for practice</h3> <section id="CD011154-sec-0570"> <p>Our review's primary efficacy evidence is based on participant self‐assessment. Low‐certainty evidence suggests that BPO (as monotherapy or as add‐on treatment) may lead to better participant self‐reported acne improvement when compared to no treatment or placebo, and low‐certainty evidence suggests there may be little to no difference between BPO compared to clindamycin or adapalene for this outcome. This indicates that BPO could potentially be used as a replacement for clindamycin in combination treatments to reduce the risk of antibiotic resistance. Our primary efficacy outcome was not assessed by studies comparing BPO with erythromycin or salicylic acid. </p> <p>Regarding safety, low‐certainty evidence suggests that compared with placebo or no treatment, BPO (as monotherapy or as add‐on treatment) may be associated with higher risk of discontinuation of treatment due to adverse events, which may negatively influence treatment adherence. However, these events may be related to tolerability, mostly cutaneous irritation, such as erythema, pruritus, and skin burning. </p> <p>As we found only very low‐certainty evidence for withdrawal due to adverse effects for the comparisons BPO versus adapalene, clindamycin, erythromycin, or salicylic acid, we cannot draw conclusions regarding these treatment comparisons for that particular outcome. </p> <p>More broadly, BPO may increase the risk of adverse events when compared against clindamycin, based on moderate‐certainty evidence; although the 95% confidence interval indicates that BPO might make little to no difference. Adverse events tended to be mild to moderate and well tolerated; the most common were local dryness, irritation, dermatitis, erythema, application site pain, and pruritus. </p> <p>Very low‐certainty evidence regarding the risk of adverse events for BPO compared against adapalene, clindamycin, erythromycin, or salicylic acid means we cannot draw conclusions regarding these treatment comparisons for that particular outcome. </p> <p>The 43 studies in <a href="./references#CD011154-bbs1-0003" title="">Studies awaiting classification</a> may alter the conclusions of the review if assessed. </p> </section> <h3 class="title" id="CD011154-sec-0571">Implications for research</h3> <section id="CD011154-sec-0571"> <p>This systematic review highlights the need for large‐scale well‐conducted RCTs to assess the benefits and harms of BPO for treating acne, with focus on the comparative effects of different preparations or concentrations and combination versus monotherapy. </p> <section id="CD011154-sec-0572"> <h5 class="title">Design</h5> <p>No RCTs included in our review were regarded as being at low risk of bias in all assessment domains. To improve the quality of clinical trials in this field, <a href="./references#CD011154-bbs2-0334" title="U.S. Department of Health and Human Services, Food , Drug Administration. Center for Drug Evaluation and Research. Guidance for Industry. Acne vulgaris: developing drugs for treatment Draft Guidance. www.fda.gov/downloads/Drugs/.../Guidances/UCM071292.pdf (accessed before 1 December 2017). ">FDA 2005</a> has presented guidelines for assessing drugs for treating acne vulgaris. However, our review suggests that further improvement of study quality is needed. Future trials need to ensure that allocation concealment and blinding are properly conducted. </p> </section> <section id="CD011154-sec-0573"> <h5 class="title">Outcomes</h5> <p>Our review suggests three limitations in outcome assessment. First, it was uncommon to assess patient‐reported efficacy outcomes in the included trials, which could be helpful in informing both participants and clinicians (<a href="./references#CD011154-bbs2-0334" title="U.S. Department of Health and Human Services, Food , Drug Administration. Center for Drug Evaluation and Research. Guidance for Industry. Acne vulgaris: developing drugs for treatment Draft Guidance. www.fda.gov/downloads/Drugs/.../Guidances/UCM071292.pdf (accessed before 1 December 2017). ">FDA 2005</a>). Only 31% of trials reported patient self‐assessed acne improvement. These outcomes should be consistently included in future acne trials. Second, standardisation of outcome measurements needs to be improved for acne trials. Likert‐like scales used for patient self‐assessed acne improvement, for example, varied in different studies, which challenges synthesis of data for this outcome. Although the importance of standardisation of outcome measurements for acne trials has been acknowledged (<a href="./references#CD011154-bbs2-0318" title="BarrattH , HamiltonF , CarJ , LyonsC , LaytonA , MajeedA . Outcome measures in acne vulgaris: systematic review. British Journal of Dermatology2009;160(1):132‐6. [MEDLINE: 19067711] ">Barratt 2009</a>), substantial improvement in standardisation is still needed to facilitate comparisons between studies and to promote evidence synthesis. The work on standardisation of outcome measurement may significantly benefit from ongoing collaborative initiatives, including the Acne Core Outcomes Research Network (ACORN) (<a href="./references#CD011154-bbs2-0313" title="Acne Core Outcomes Research Network. sites.psu.edu/acnecoreoutcomes/ (accessed before 14 May 2018). ">ACORN</a>), the Core Outcome Measures in Effectiveness Trials (COMET) (<a href="./references#CD011154-bbs2-0326" title="Core Outcome Measures in Effectiveness Trials Initiative. www.cometinitiative.org (accessed before 14 May 2018). ">COMET</a>), and the Cochrane Skin Group Outcomes Research Initiative (<a href="./references#CD011154-bbs2-0371" title="SchmittJ , DeckertS , AlamM , ApfelbacherC , BarbaricJ , BauerA , et al. Report from the kick‐off meeting of the Cochrane Skin Group Core Outcome Set Initiative (CSG‐COUSIN). British Journal of Dermatology2016;174(2):287‐95. [MEDLINE: 26779929] ">Schmitt 2016</a>). Finally, long‐term outcome assessment (at least six months) was rare, with only four included trials following participants for at least 24 weeks (<a href="./references#CD011154-bbs2-0026" title="DrenoB , TanJ , RivierM , MartelP , BissonnetteR . Adapalene 0.1%/benzoyl peroxide 2.5% gel reduces the risk of atrophic scar formation in moderate inflammatory acne: a split‐face randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2017;31(4):737‐42. [CENTRAL: CN‐01424729; MEDLINE: 27790756] ">Dreno 2016</a>; <a href="./references#CD011154-bbs2-0027" title="DrénoB , BissonnetteR , Gagné‐HenleyA , BarankinB , LyndeC , KerroucheN , et al. Prevention and reduction of atrophic acne scars with adapalene 0.3%/benzoyl peroxide 2.5% gel in subjects with moderate or severe facial acne: results of a 6‐month randomized, vehicle‐controlled trial using intra‐individual comparison. American Journal of Clinical Dermatology2018;19(2):275‐86. [CENTRAL: CN‐01572577] NCT02735421 . Adapalene 0.3% ‐ Benzoyl Peroxide 2.5% Gel and Risk of Formation of Atrophic Acne Scars (OSCAR). clinicaltrials.gov/ct2/show/NCT02735421 (first received 7 April 2016). ">Dréno 2018</a>; <a href="./references#CD011154-bbs2-0050" title="IftikharU , AmanS , NadeemM , KazmiAH . A comparison of efficacy and safety of topical 0.1% adapalene and 4% benzoyl peroxide in the treatment of mild to moderate acne vulgaris. Journal of Pakistan Association of Dermatologists2009;19(3):141‐5. [www.jpad.com.pk/index.php/jpad/article/view/530] ">Iftikhar 2009</a>; <a href="./references#CD011154-bbs2-0060" title="KawashimaM , NagareT , KatsuramakiT . Open‐label, randomized, multicenter, phase III study to evaluate the safety and efficacy of benzoyl peroxide gel in long‐term use in patients with acne vulgaris: a secondary publication. Journal of Dermatology2017; Vol. 44, issue 6:635‐43. [CENTRAL: CN‐01459134; MEDLINE: 28150367] MorimotoH , KikukawaY , MurakamiN . Pharmacological profiles and clinical effects of benzoyl peroxide gel as treatments for acne vulgaris. Nippon Yakurigaku Zasshi ‐ Folia Pharmacologica Japonica2015;146(4):225‐32. [PUBMED: 26656967] ">Kawashima 2017a</a>; <a href="./references#CD011154-bbs2-0063" title="KorkutC , PiskinS . Benzoyl peroxide, adapalene, and their combination in the treatment of acne vulgaris. Journal of Dermatology2005;32(3):169‐73. [CENTRAL: CN‐00512006] ">Korkut 2005</a>). Future trials need to strengthen the long‐term evidence base. </p> </section> <section id="CD011154-sec-0574"> <h5 class="title">Interventions</h5> <p>Although BPO as monotherapy or used in combination with topical retinoid or antibiotics has been consistently recommended for first‐line treatment of acne by recent clinical guidelines (<a href="./references#CD011154-bbs2-0336" title="GohCL , Abad‐CasintahanF , AwDC , BabaR , ChanLC , HungNT , et al. South‐East Asia study alliance guidelines on the management of acne vulgaris in South‐East Asian patients. Journal of Dermatology2015;42(10):945‐53. [MEDLINE: 26211507] ">Goh 2015</a>; <a href="./references#CD011154-bbs2-0355" title="LeCleachL , Lebrun‐VignesB , BachelotA , BeerF , BergerP , BrugèreS , et al. Guidelines for the management of acne: recommendations from a French multidisciplinary group. British Journal of Dermatology2017;177(4):908‐13. [MEDLINE: 29052890] ">Le Cleach 2017</a>; <a href="./references#CD011154-bbs2-0389" title="ZaengleinAL , PathyAL , SchlosserBJ , AlikhanA , BaldwinHE , BersonDS , et al. Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology2016;74(5):945‐73. [MEDLINE: 26897386] ">Zaenglein 2016</a>), available evidence supporting this recommendation is not of high quality in terms of participant self‐evaluation, as suggested in our review. BPO is available in various concentrations and vehicles; however, insufficient evidence suggests the comparative efficacy of its different formulations. The quality of evidence regarding safety (most adverse effects were cited as cutaneous intolerability) is mostly low or even very low. These findings in our review highlight the need for high‐quality evidence for comparisons between BPO monotherapy and other active topical treatments, between BPO combination and monotherapy, and between different formulations. </p> </section> <section id="CD011154-sec-0575"> <h5 class="title">Reporting issues</h5> <p>Future trials need to enhance reporting quality by following the CONSORT statement (<a href="./references#CD011154-bbs2-0372" title="SchulzKF , AltmanDG , MoherD , for the CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ2010;340:c332. [MEDLINE: 20332509] ">Schulz 2010</a>). Incomplete reporting, which impairs risk of bias assessment, is very common in acne trials (<a href="./references#CD011154-bbs2-0342" title="IngramJR , GrindlayDJ , WilliamsHC . Problems in the reporting of acne clinical trials: a spot check from the 2009 Annual Evidence Update on Acne Vulgaris. Trials2010;11:77. [MEDLINE: 20624287] ">Ingram 2010</a>). Lack of sufficient reported information leads to substantial uncertainty in the risk of bias for most included trials. Poor reporting also challenges evidence synthesis. For example, a majority of the trials assessed change in acne lesion counts but seldom reported essential statistics for data synthesis and results interpretation, such as standard deviation, 95% confidence interval, and P value for estimates of effect size. Although adverse events were observed in most trials, the number of participants having adverse events in each group was not generally reported. These problems should be properly tackled in future research. </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011154-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011154-sec-0050"></div> <div class="table" id="CD011154-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Benzoyl peroxide compared to placebo or no treatment for acne</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Benzoyl peroxide compared to placebo or no treatment for acne</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> acne vulgaris<br/> <b>Setting:</b> unspecified (probably outpatient)<br/> <b>Intervention:</b> benzoyl peroxide<br/> <b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or no treatment<sup>a</sup> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with benzoyl peroxide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant's global self‐assessment of improvement (long‐term data)<br/> assessed with any greater improvement above the first category of improvement on a Likert or Likert‐like scale<br/> Treatment duration: range 10 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>550 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>699 per 1000<br/> (616 to 798) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.27<br/> (1.12 to 1.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2234<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse effects (long‐term data)<br/> Treatment duration: range 10 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000<br/> (6 to 11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.13<br/> (1.55 to 2.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,744<br/> (24 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of participants with any adverse events (long‐term data)<br/> Treatment duration: range 10 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>79 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000<br/> (91 to 135) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.40<br/> (1.15 to 1.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,028<br/> (21 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝ ⊝<br/> Very low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The control group risk estimate is the median control group risk across studies. </p> <p><sup>b</sup>Downgraded by two levels to low‐quality evidence due to study limitations (risk of bias) and publication bias. <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a> was classified as high risk of bias due to "incomplete outcome data". Although ITT strategy was taken, 14.3% of participants discontinued and withdrawal due to adverse events was higher in the adapalene‐BPO combination gel group. Both <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a> and <a href="./references#CD011154-bbs2-0066" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM . Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] LeydenJ , et al. Treatment of acne vulgaris with a combination benzoyl peroxide/clindamycin topical gel Abstract P‐013. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S144. [CENTRAL: CN‐00478651] LeydenJJ , BergerRS , DunlapFE , EllisCN , ConnollyMA , LevySF . Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. American Journal of Clinical Dermatology2001;2(1):33‐9. [CENTRAL: CN‐00363426; MEDLINE: 11702619] ">Leyden 2001a</a> were classified as "unclear risk of bias" for randomisation, allocation concealment, and blinding of participants and outcome assessors. In <a href="./references#CD011154-bbs2-0053" title="JawadeSA , SaigaonkarVA , KondalkarAR . Efficacy and tolerability of adapalene 0.1%‐benzoyl peroxide 2.5% combination gel in treatment of acne vulgaris in Indian patients: a randomized investigator‐blind controlled trial. Iranian Journal of Dermatology2016;19(4):105‐12. [CENTRAL: CN‐01405922] ">Jawade 2016</a>, the proportion of withdrawals was high and participants were excluded from analysis because of non‐compliance with the treatment regimen or duration and protocol violation. In addition, all studies were judged to be unclear for at least one risk of bias domain. There was potential risk of publication bias because we identified trials starting before 2015 but still "ongoing" as shown in the trial registries. </p> <p><sup>c</sup>Downgraded by two levels to low‐quality evidence due to study limitations (risk of bias). Ten studies were classified as “high risk of bias” for at least one risk of bias domain, including <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>, <a href="./references#CD011154-bbs2-0059" title="KawashimaM , HashimotoH , Alio SaenzAB , OnoM , YamadaM . Clindamycin phosphate 12%‐benzoyl peroxide 30% fixed‐dose combination gel has an effective and acceptable safety and tolerability profile for the treatment of acne vulgaris in Japanese patients: a phase III, multicentre, randomised, single‐blinded, active‐controlled, parallel‐group study. British Journal of Dermatology2015;172(2):494‐503. [CENTRAL: CN‐01115087] KawashimaM , YamadaM , ParishC . Clindamycin 1%/benzoyl peroxide 3% gel, a new topical combination product, is effective in Japanese patients with acne vulgaris. Journal of Investigative Dermatology2013;133:S160. [CENTRAL: CN‐01026775] ">Kawashima 2015</a>, and <a href="./references#CD011154-bbs2-0115" title="2015‐004909‐16 . A multicentre, randomized, assessor‐blind, comparator‐controlled, parallel‐group clinical trial to establish the efficacy and safety of Duac™ (1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide) once daily gel compared with clindamycin phosphate gel (1% clindamycin as clindamycin phosphate) twice daily in the treatment of mild to moderate acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2015‐004909‐16/results (results published 29 December 2016). NCT01915732 . Efficacy and safety of Duac™ compared with clindamycin phosphate gel in the treatment of mild to moderate acne vulgaris. clinicaltrials.gov/ct2/show/NCT01915732 (first received 5 April 2013). XuJ , LuQ , HuangJ , SunQ , HaoF , GuJ , et al. A multicenter, randomized, single‐blind study of topical clindamycin 1%/benzoyl peroxide 5% once‐daily fixed dose combination gel (Duac) vs. clindamycin 1% twice‐daily gel in treatment of Chinese acne vulgaris patients. Journal of Investigative Dermatology2015;135(Suppl 2):S34, 192. [CENTRAL: CN‐01130701] XuJH , LuQJ , HuangJH , HaoF , SunQN , FangH , et al. A multicentre, randomized, single‐blind comparison of topical clindamycin 1%/benzoyl peroxide 5% once‐daily gel versus clindamycin 1% twice‐daily gel in the treatment of mild to moderate acne vulgaris in Chinese patients. Journal of the European Academy of Dermatology and Venereology2016;30(7):1176‐82. [CENTRAL: CN‐01178389; MEDLINE: 27075705] ">Xu 2016</a>, for blinding of participants and healthcare providers; <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>, <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>, <a href="./references#CD011154-bbs2-0052" title="JaffeGV , GrimshawJJ , ConstadD . Benzoyl peroxide in the treatment of acne vulgaris: a double‐blind, multi‐centre comparative study of 'Quinoderm' cream and 'Quinoderm' cream with hydrocortisone versus their base vehicle alone and a benzoyl peroxide only gel preparation. Current Medical Research &amp; Opinion1989;11(7):453‐62. [CENTRAL: CN‐00062342; MEDLINE: 2528439] ">Jaffe 1989</a>, <a href="./references#CD011154-bbs2-0053" title="JawadeSA , SaigaonkarVA , KondalkarAR . Efficacy and tolerability of adapalene 0.1%‐benzoyl peroxide 2.5% combination gel in treatment of acne vulgaris in Indian patients: a randomized investigator‐blind controlled trial. Iranian Journal of Dermatology2016;19(4):105‐12. [CENTRAL: CN‐01405922] ">Jawade 2016</a>, <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>, <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>, and <a href="./references#CD011154-bbs2-0115" title="2015‐004909‐16 . A multicentre, randomized, assessor‐blind, comparator‐controlled, parallel‐group clinical trial to establish the efficacy and safety of Duac™ (1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide) once daily gel compared with clindamycin phosphate gel (1% clindamycin as clindamycin phosphate) twice daily in the treatment of mild to moderate acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2015‐004909‐16/results (results published 29 December 2016). NCT01915732 . Efficacy and safety of Duac™ compared with clindamycin phosphate gel in the treatment of mild to moderate acne vulgaris. clinicaltrials.gov/ct2/show/NCT01915732 (first received 5 April 2013). XuJ , LuQ , HuangJ , SunQ , HaoF , GuJ , et al. A multicenter, randomized, single‐blind study of topical clindamycin 1%/benzoyl peroxide 5% once‐daily fixed dose combination gel (Duac) vs. clindamycin 1% twice‐daily gel in treatment of Chinese acne vulgaris patients. Journal of Investigative Dermatology2015;135(Suppl 2):S34, 192. [CENTRAL: CN‐01130701] XuJH , LuQJ , HuangJH , HaoF , SunQN , FangH , et al. A multicentre, randomized, single‐blind comparison of topical clindamycin 1%/benzoyl peroxide 5% once‐daily gel versus clindamycin 1% twice‐daily gel in the treatment of mild to moderate acne vulgaris in Chinese patients. Journal of the European Academy of Dermatology and Venereology2016;30(7):1176‐82. [CENTRAL: CN‐01178389; MEDLINE: 27075705] ">Xu 2016</a> for incomplete outcome data; and <a href="./references#CD011154-bbs2-0011" title="ChalkerDK , ShalitaA , SmithJG , SwannRW . A double‐blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. Journal of the American Academy of Dermatology1983;9(6):933‐6. [CENTRAL: CN‐00334175; MEDLINE: 6227643] ">Chalker 1983</a> and <a href="./references#CD011154-bbs2-0052" title="JaffeGV , GrimshawJJ , ConstadD . Benzoyl peroxide in the treatment of acne vulgaris: a double‐blind, multi‐centre comparative study of 'Quinoderm' cream and 'Quinoderm' cream with hydrocortisone versus their base vehicle alone and a benzoyl peroxide only gel preparation. Current Medical Research &amp; Opinion1989;11(7):453‐62. [CENTRAL: CN‐00062342; MEDLINE: 2528439] ">Jaffe 1989</a> for selective reporting of outcomes. In addition, all studies were judged to be unclear for at least one risk of bias domain. There was potential risk of publication bias because we identified trials starting before 2015 but still "ongoing" as shown in the trial registries. </p> <p><sup>d</sup>Downgraded by three levels to very low‐quality evidence due to study limitations (risk of bias) and inconsistency. Ten studies were classified as “high risk of bias” for at least one risk of bias domain, including <a href="./references#CD011154-bbs2-0023" title="DraelosZD , TanghettiEA . Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis; Cutaneous Medicine for the Practitioner2002;69(2 Suppl):20‐9. [CENTRAL: CN‐00409023; MEDLINE: 12095065] ">Draelos 2002</a>, <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>, <a href="./references#CD011154-bbs2-0059" title="KawashimaM , HashimotoH , Alio SaenzAB , OnoM , YamadaM . Clindamycin phosphate 12%‐benzoyl peroxide 30% fixed‐dose combination gel has an effective and acceptable safety and tolerability profile for the treatment of acne vulgaris in Japanese patients: a phase III, multicentre, randomised, single‐blinded, active‐controlled, parallel‐group study. British Journal of Dermatology2015;172(2):494‐503. [CENTRAL: CN‐01115087] KawashimaM , YamadaM , ParishC . Clindamycin 1%/benzoyl peroxide 3% gel, a new topical combination product, is effective in Japanese patients with acne vulgaris. Journal of Investigative Dermatology2013;133:S160. [CENTRAL: CN‐01026775] ">Kawashima 2015</a>, <a href="./references#CD011154-bbs2-0082" title="NCT02073461 . Efficacy and safety study of 2 different concentrations of CD1579 gels versus vehicle in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02073461 (first received 20 February 2014). ">NCT02073461</a>, <a href="./references#CD011154-bbs2-0115" title="2015‐004909‐16 . A multicentre, randomized, assessor‐blind, comparator‐controlled, parallel‐group clinical trial to establish the efficacy and safety of Duac™ (1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide) once daily gel compared with clindamycin phosphate gel (1% clindamycin as clindamycin phosphate) twice daily in the treatment of mild to moderate acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2015‐004909‐16/results (results published 29 December 2016). NCT01915732 . Efficacy and safety of Duac™ compared with clindamycin phosphate gel in the treatment of mild to moderate acne vulgaris. clinicaltrials.gov/ct2/show/NCT01915732 (first received 5 April 2013). XuJ , LuQ , HuangJ , SunQ , HaoF , GuJ , et al. A multicenter, randomized, single‐blind study of topical clindamycin 1%/benzoyl peroxide 5% once‐daily fixed dose combination gel (Duac) vs. clindamycin 1% twice‐daily gel in treatment of Chinese acne vulgaris patients. Journal of Investigative Dermatology2015;135(Suppl 2):S34, 192. [CENTRAL: CN‐01130701] XuJH , LuQJ , HuangJH , HaoF , SunQN , FangH , et al. A multicentre, randomized, single‐blind comparison of topical clindamycin 1%/benzoyl peroxide 5% once‐daily gel versus clindamycin 1% twice‐daily gel in the treatment of mild to moderate acne vulgaris in Chinese patients. Journal of the European Academy of Dermatology and Venereology2016;30(7):1176‐82. [CENTRAL: CN‐01178389; MEDLINE: 27075705] ">Xu 2016</a>, and <a href="./references#CD011154-bbs2-0117" title="ZeichnerJA , WongV , LinknerRV , HaddicanM . Efficacy and safety of tretinoin 0.025%/clindamycin phosphate 1.2% gel in combination with benzoyl peroxide 6% cleansing cloths for the treatment of facial acne vulgaris. Journal of Drugs in Dermatology2013;12(3):277‐82. [CENTRAL: CN‐00876866; MEDLINE: 23545909] ">Zeichner 2013</a> for blinding of participants and healthcare providers; <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>, <a href="./references#CD011154-bbs2-0052" title="JaffeGV , GrimshawJJ , ConstadD . Benzoyl peroxide in the treatment of acne vulgaris: a double‐blind, multi‐centre comparative study of 'Quinoderm' cream and 'Quinoderm' cream with hydrocortisone versus their base vehicle alone and a benzoyl peroxide only gel preparation. Current Medical Research &amp; Opinion1989;11(7):453‐62. [CENTRAL: CN‐00062342; MEDLINE: 2528439] ">Jaffe 1989</a>, <a href="./references#CD011154-bbs2-0059" title="KawashimaM , HashimotoH , Alio SaenzAB , OnoM , YamadaM . Clindamycin phosphate 12%‐benzoyl peroxide 30% fixed‐dose combination gel has an effective and acceptable safety and tolerability profile for the treatment of acne vulgaris in Japanese patients: a phase III, multicentre, randomised, single‐blinded, active‐controlled, parallel‐group study. British Journal of Dermatology2015;172(2):494‐503. [CENTRAL: CN‐01115087] KawashimaM , YamadaM , ParishC . Clindamycin 1%/benzoyl peroxide 3% gel, a new topical combination product, is effective in Japanese patients with acne vulgaris. Journal of Investigative Dermatology2013;133:S160. [CENTRAL: CN‐01026775] ">Kawashima 2015</a>, <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>, <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>, and <a href="./references#CD011154-bbs2-0115" title="2015‐004909‐16 . A multicentre, randomized, assessor‐blind, comparator‐controlled, parallel‐group clinical trial to establish the efficacy and safety of Duac™ (1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide) once daily gel compared with clindamycin phosphate gel (1% clindamycin as clindamycin phosphate) twice daily in the treatment of mild to moderate acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2015‐004909‐16/results (results published 29 December 2016). NCT01915732 . Efficacy and safety of Duac™ compared with clindamycin phosphate gel in the treatment of mild to moderate acne vulgaris. clinicaltrials.gov/ct2/show/NCT01915732 (first received 5 April 2013). XuJ , LuQ , HuangJ , SunQ , HaoF , GuJ , et al. A multicenter, randomized, single‐blind study of topical clindamycin 1%/benzoyl peroxide 5% once‐daily fixed dose combination gel (Duac) vs. clindamycin 1% twice‐daily gel in treatment of Chinese acne vulgaris patients. Journal of Investigative Dermatology2015;135(Suppl 2):S34, 192. [CENTRAL: CN‐01130701] XuJH , LuQJ , HuangJH , HaoF , SunQN , FangH , et al. A multicentre, randomized, single‐blind comparison of topical clindamycin 1%/benzoyl peroxide 5% once‐daily gel versus clindamycin 1% twice‐daily gel in the treatment of mild to moderate acne vulgaris in Chinese patients. Journal of the European Academy of Dermatology and Venereology2016;30(7):1176‐82. [CENTRAL: CN‐01178389; MEDLINE: 27075705] ">Xu 2016</a> for incomplete outcome data; and <a href="./references#CD011154-bbs2-0011" title="ChalkerDK , ShalitaA , SmithJG , SwannRW . A double‐blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. Journal of the American Academy of Dermatology1983;9(6):933‐6. [CENTRAL: CN‐00334175; MEDLINE: 6227643] ">Chalker 1983</a> and <a href="./references#CD011154-bbs2-0052" title="JaffeGV , GrimshawJJ , ConstadD . Benzoyl peroxide in the treatment of acne vulgaris: a double‐blind, multi‐centre comparative study of 'Quinoderm' cream and 'Quinoderm' cream with hydrocortisone versus their base vehicle alone and a benzoyl peroxide only gel preparation. Current Medical Research &amp; Opinion1989;11(7):453‐62. [CENTRAL: CN‐00062342; MEDLINE: 2528439] ">Jaffe 1989</a> for selective reporting of outcomes. All were classified as “unclear risk of bias” for at least one risk of bias domain. We further downgraded the evidence by one level because of inconsistency: point estimates varied, and I² was 72%. There was potential risk of publication bias because we identified trials starting before 2015 but still "ongoing" as shown in the trial registries. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011154-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Benzoyl peroxide compared to adapalene for acne</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Benzoyl peroxide compared to adapalene for acne</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> acne vulgaris<br/> <b>Setting:</b> unspecified (probably outpatient)<br/> <b>Intervention:</b> benzoyl peroxide<br/> <b>Comparison:</b> adapalene </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with adapalene</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with benzoyl peroxide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant's global self‐assessment of improvement (long‐term data)<br/> assessed with any greater improvement above the first category of improvement on a Likert or Likert‐like scale<br/> Treatment duration: range 11 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>785 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>777 per 1000<br/> (707 to 864) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.99<br/> (0.90 to 1.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1472<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse effects (long‐term data)<br/> Treatment duration: range 11 weeks to 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/> (2 to 5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.85<br/> (0.94 to 3.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3295<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of participants with any adverse events (long‐term data)<br/> Treatment duration: range 11 weeks to 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>203 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>144 per 1000<br/> (101 to 203) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.71<br/> (0.50 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2120<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The control group risk estimate is the median control group risk across studies. </p> <p><sup>b</sup>Downgraded by two levels to low‐quality evidence due to study limitations (risk of bias) as three studies were classified as "high risk of bias" for incomplete outcome data and one study for blinding of participants. In <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>, although ITT strategy was taken, 14.3% of participants discontinued and withdrawal due to adverse events was higher in the adapalene‐BPO combination gel group. In <a href="./references#CD011154-bbs2-0022" title="do NascimentoLV , GuedesAC , MagalhaesGM , deFariaFA , GuerraRM , deAlmeidaF . Single‐blind and comparative clinical study of the efficacy and safety of benzoyl peroxide 4% gel (BID) and adapalene 0.1% Gel (QD) in the treatment of acne vulgaris for 11 weeks. Journal of Dermatological Treatment2003;14(3):166‐71. [CENTRAL: CN‐00559227; MEDLINE: 14522627] ">do Nascimento 2003</a>, comparing dropout rates between groups revealed that the adapalene group showed the higher rate of participants who withdrew from the study before completion of treatment. In <a href="./references#CD011154-bbs2-0053" title="JawadeSA , SaigaonkarVA , KondalkarAR . Efficacy and tolerability of adapalene 0.1%‐benzoyl peroxide 2.5% combination gel in treatment of acne vulgaris in Indian patients: a randomized investigator‐blind controlled trial. Iranian Journal of Dermatology2016;19(4):105‐12. [CENTRAL: CN‐01405922] ">Jawade 2016</a>, the proportion of withdrawal was high and participants were excluded from analysis because of non‐compliance with the treatment regimen or duration schedule and protocol violation. In <a href="./references#CD011154-bbs2-0048" title="2017‐001575‐23 . Clinical evaluation of efficacy at 2 weeks of Duac fixed dose combination gel in treatment of facial acne vulgaris in Japanese subjects. www.clinicaltrialsregister.eu/ctr‐search/trial/2017‐001575‐23/results (first received 21 September 2017). HayashiN , KurokawaI , SiakpereO , EndoA , HatanakaT , YamadaM , et al. Clindamycin phosphate 1.2%/benzoyl peroxide 3% fixed‐dose combination gel versus topical combination therapy of adapalene 0.1% gel and clindamycin phosphate 1.2% gel in the treatment of acne vulgaris in Japanese patients: a multicenter, randomized, investigator‐blind, parallel‐group study. Journal of Dermatology2018;45(8):951‐62. [CENTRAL: CN‐01629242] NCT02557399 . DUAC® early onset efficacy study in Japanese subjects. clinicaltrials.gov/ct2/show/NCT02557399 (first received 23 September 2015). ">Hayashi 2018</a>, only investigators, not participants, were blinded. There was potential risk of publication bias because we identified trials starting before 2015 but still "ongoing" as shown in the trial registries. </p> <p><sup>c</sup>Downgraded by three levels to very low‐quality evidence: one level due to study limitations (risk of bias) as eight included studies were classified as “high risk of bias” in at least one risk of bias domain. <a href="./references#CD011154-bbs2-0048" title="2017‐001575‐23 . Clinical evaluation of efficacy at 2 weeks of Duac fixed dose combination gel in treatment of facial acne vulgaris in Japanese subjects. www.clinicaltrialsregister.eu/ctr‐search/trial/2017‐001575‐23/results (first received 21 September 2017). HayashiN , KurokawaI , SiakpereO , EndoA , HatanakaT , YamadaM , et al. Clindamycin phosphate 1.2%/benzoyl peroxide 3% fixed‐dose combination gel versus topical combination therapy of adapalene 0.1% gel and clindamycin phosphate 1.2% gel in the treatment of acne vulgaris in Japanese patients: a multicenter, randomized, investigator‐blind, parallel‐group study. Journal of Dermatology2018;45(8):951‐62. [CENTRAL: CN‐01629242] NCT02557399 . DUAC® early onset efficacy study in Japanese subjects. clinicaltrials.gov/ct2/show/NCT02557399 (first received 23 September 2015). ">Hayashi 2018</a>, <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>, <a href="./references#CD011154-bbs2-0050" title="IftikharU , AmanS , NadeemM , KazmiAH . A comparison of efficacy and safety of topical 0.1% adapalene and 4% benzoyl peroxide in the treatment of mild to moderate acne vulgaris. Journal of Pakistan Association of Dermatologists2009;19(3):141‐5. [www.jpad.com.pk/index.php/jpad/article/view/530] ">Iftikhar 2009</a>, and <a href="./references#CD011154-bbs2-0063" title="KorkutC , PiskinS . Benzoyl peroxide, adapalene, and their combination in the treatment of acne vulgaris. Journal of Dermatology2005;32(3):169‐73. [CENTRAL: CN‐00512006] ">Korkut 2005</a> were at high risk of bias due to unblinded or partially blinded design. <a href="./references#CD011154-bbs2-0022" title="do NascimentoLV , GuedesAC , MagalhaesGM , deFariaFA , GuerraRM , deAlmeidaF . Single‐blind and comparative clinical study of the efficacy and safety of benzoyl peroxide 4% gel (BID) and adapalene 0.1% Gel (QD) in the treatment of acne vulgaris for 11 weeks. Journal of Dermatological Treatment2003;14(3):166‐71. [CENTRAL: CN‐00559227; MEDLINE: 14522627] ">do Nascimento 2003</a>, <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>, <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>, <a href="./references#CD011154-bbs2-0053" title="JawadeSA , SaigaonkarVA , KondalkarAR . Efficacy and tolerability of adapalene 0.1%‐benzoyl peroxide 2.5% combination gel in treatment of acne vulgaris in Indian patients: a randomized investigator‐blind controlled trial. Iranian Journal of Dermatology2016;19(4):105‐12. [CENTRAL: CN‐01405922] ">Jawade 2016</a>, and <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a> were classified as high risk of bias for incomplete participant data. All included studies were classified as unclear for at least one risk of bias domain. Evidence was downgraded by a further one level due to imprecision as the confidence interval includes 1; could not exclude the possibility of no effect compared with adapalene. The estimate was based on a small number of events. There was potential risk of publication bias because we identified trials starting before 2015 but still "ongoing" as shown in the trial registries. </p> <p><sup>d</sup>Downgraded by three levels to very low‐quality evidence: one level due to study limitations (risk of bias) as four included studies were classified as “high risk of bias” in at least one risk of bias domain. <a href="./references#CD011154-bbs2-0048" title="2017‐001575‐23 . Clinical evaluation of efficacy at 2 weeks of Duac fixed dose combination gel in treatment of facial acne vulgaris in Japanese subjects. www.clinicaltrialsregister.eu/ctr‐search/trial/2017‐001575‐23/results (first received 21 September 2017). HayashiN , KurokawaI , SiakpereO , EndoA , HatanakaT , YamadaM , et al. Clindamycin phosphate 1.2%/benzoyl peroxide 3% fixed‐dose combination gel versus topical combination therapy of adapalene 0.1% gel and clindamycin phosphate 1.2% gel in the treatment of acne vulgaris in Japanese patients: a multicenter, randomized, investigator‐blind, parallel‐group study. Journal of Dermatology2018;45(8):951‐62. [CENTRAL: CN‐01629242] NCT02557399 . DUAC® early onset efficacy study in Japanese subjects. clinicaltrials.gov/ct2/show/NCT02557399 (first received 23 September 2015). ">Hayashi 2018</a> and <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a> were at high risk of bias due to unblinded or partially blinded design. Three trials ‐ <a href="./references#CD011154-bbs2-0022" title="do NascimentoLV , GuedesAC , MagalhaesGM , deFariaFA , GuerraRM , deAlmeidaF . Single‐blind and comparative clinical study of the efficacy and safety of benzoyl peroxide 4% gel (BID) and adapalene 0.1% Gel (QD) in the treatment of acne vulgaris for 11 weeks. Journal of Dermatological Treatment2003;14(3):166‐71. [CENTRAL: CN‐00559227; MEDLINE: 14522627] ">do Nascimento 2003</a>, <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>, and <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a> ‐ were classified as high risk of bias for incomplete participant data. All included studies were classified as unclear for at least one risk of bias domain. Evidence was also downgraded by one level due to inconsistency as I² = 70% and point estimates were not similar. There was potential risk of publication bias because we identified trials starting before 2015 but still "ongoing" as shown in the trial registries. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011154-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Benzoyl peroxide compared to clindamycin for acne</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Benzoyl peroxide compared to clindamycin for acne</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> acne vulgaris<br/> <b>Setting:</b> unspecified (probably outpatient)<br/> <b>Intervention:</b> benzoyl peroxide<br/> <b>Comparison:</b> clindamycin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with clindamycin</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with benzoyl peroxide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant's global self‐assessment of improvement (long‐term data)<br/> assessed with any greater improvement above the first category of improvement on a Likert or Likert‐like scale<br/> Treatment duration: 10 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>367 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>348 per 1000<br/> (249 to 491) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.95<br/> (0.68 to 1.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Withdrawal due to adverse effects (long‐term data)<br/> Treatment duration: range 10 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Low risk: 0 per 1000<sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.93<br/> (0.90 to 4.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3330<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>High risk: 46 per 1000<sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>89 per 1000 (41 to 189)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of participants with any adverse events (long‐term data)<br/> Treatment duration: range 10 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>91 per 1000<br/> (71 to 116) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.24<br/> (0.97 to 1.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3018<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The control group risk estimate is the median control group risk across studies. </p> <p><sup>b</sup>Downgraded by two levels to low‐quality evidence: one level due to imprecision as the confidence interval is wide and includes 1; could not exclude the possibility of no effect compared with clindamycin. The estimate was based on a small number of events. One further level due to study limitations (risk of bias), as <a href="./references#CD011154-bbs2-0066" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM . Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] LeydenJ , et al. Treatment of acne vulgaris with a combination benzoyl peroxide/clindamycin topical gel Abstract P‐013. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S144. [CENTRAL: CN‐00478651] LeydenJJ , BergerRS , DunlapFE , EllisCN , ConnollyMA , LevySF . Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. American Journal of Clinical Dermatology2001;2(1):33‐9. [CENTRAL: CN‐00363426; MEDLINE: 11702619] ">Leyden 2001a</a> was classified as “unclear risk of bias” for most risk of bias domains because the report did not provide sufficient information to allow judgement. </p> <p><sup>c</sup>We assume a range of risks according to risks in the control groups of included studies, where we expect different populations to experience different risks of events of interest. In this case, the lower limit of the risk is 0, and the upper limit is the highest control group risk in the included studies. </p> <p><sup>d</sup>Downgraded by three levels to very low‐quality evidence: two levels due to very serious imprecision as the confidence interval includes 1; could not exclude the possibility of no effect compared with clindamycin, and there were very few events. One further level due to study limitations (risk of bias) as seven of the included studies were classified as “unclear risk of bias” for most risk of bias domains because reports did not provide sufficient information to allow judgement. In addition, in <a href="./references#CD011154-bbs2-0023" title="DraelosZD , TanghettiEA . Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis; Cutaneous Medicine for the Practitioner2002;69(2 Suppl):20‐9. [CENTRAL: CN‐00409023; MEDLINE: 12095065] ">Draelos 2002</a>, the nurse may be aware of erythromycin/benzoyl peroxide treatment after randomisation. This study has a high proportion of withdrawal, and it is unclear whether numbers of withdrawals and corresponding reasons were balanced between groups. In addition, ITT analysis was not conducted. In <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>, 10% of participants did not complete the treatment duration within each group and reasons were not balanced across groups. Besides, trial authors did not compare characteristics between participants who completed and discontinued treatment. </p> <p><sup>e</sup>Downgraded by one level to moderate‐quality evidence due to risk of bias as five included studies were classified as “unclear risk of bias” for most risk of bias domains because reports did not provide sufficient information to allow judgement. In addition, in <a href="./references#CD011154-bbs2-0023" title="DraelosZD , TanghettiEA . Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis; Cutaneous Medicine for the Practitioner2002;69(2 Suppl):20‐9. [CENTRAL: CN‐00409023; MEDLINE: 12095065] ">Draelos 2002</a>, the nurse may be aware of the erythromycin/benzoyl peroxide treatment after randomisation. This study has a high proportion of withdrawal, and it is unclear whether numbers of withdrawals and corresponding reasons were balanced between groups. In addition, ITT analysis was not conducted. In <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>, 10% of participants did not complete the treatment duration within each group and reasons were not balanced across groups. Besides, trial authors did not compare characteristics between participants who completed and discontinued treatment. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011154-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Benzoyl peroxide compared to erythromycin for acne</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Benzoyl peroxide compared to erythromycin for acne</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> acne vulgaris<br/> <b>Setting:</b> unspecified (probably outpatient)<br/> <b>Intervention:</b> benzoyl peroxide<br/> <b>Comparison:</b> erythromycin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with erythromycin<sup>a</sup> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with benzoyl peroxide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant's global self‐assessment of improvement (long‐term data) ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neither long‐ nor medium‐term data for this outcome were reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse effects (medium‐term data)<br/> Treatment duration: 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00 (0.07 to 15.26)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of participants with any adverse events (long‐term data)<br/> Treatment duration: 10 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were zero events in either group, so absolute risks and relative effect could not be calculated </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The control group risk estimate is the median control group risk across studies. </p> <p><sup>b</sup>Downgraded by three levels due to serious risk of bias and very serious imprecision. We downgraded by one level due to risk of bias because <a href="./references#CD011154-bbs2-0008" title="BurkeB , EadyEA , CunliffeWJ . Benzoyl peroxide versus topical erythromycin in the treatment of acne vulgaris. British Journal of Dermatology1983;108(2):199‐204. [CENTRAL: CN‐00568861; MEDLINE: 6218815] ">Burke 1983</a> was a study without sufficient information in the report to allow judgement about risk of bias. In <a href="./references#CD011154-bbs2-0011" title="ChalkerDK , ShalitaA , SmithJG , SwannRW . A double‐blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. Journal of the American Academy of Dermatology1983;9(6):933‐6. [CENTRAL: CN‐00334175; MEDLINE: 6227643] ">Chalker 1983</a>, trial authors did not provide sufficient information on randomisation and blinding, although they described this study as "randomised" and "double‐blind". We further downgraded by two levels due to very serious imprecision because of a very small number of events. </p> <p><sup>c</sup>Downgraded by three levels due to serious risk of bias and very serious imprecision. We downgraded by one level due to risk of bias because in <a href="./references#CD011154-bbs2-0011" title="ChalkerDK , ShalitaA , SmithJG , SwannRW . A double‐blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. Journal of the American Academy of Dermatology1983;9(6):933‐6. [CENTRAL: CN‐00334175; MEDLINE: 6227643] ">Chalker 1983</a>, trial authors did not provide sufficient information on randomisation and blinding, although they described this study as "randomised" and "double‐blind". We further downgraded by two levels due to very serious imprecision because there were zero events in either group and the effect was not estimable. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011154-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Benzoyl peroxide compared to salicylic acid for acne</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Benzoyl peroxide compared to salicylic acid for acne</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> acne vulgaris<br/> <b>Setting:</b> unspecified (probably outpatient)<br/> <b>Intervention:</b> benzoyl peroxide<br/> <b>Comparison:</b> salicylic acid </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with salicylic acid<sup>a</sup> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with benzoyl peroxide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant's global self‐assessment of improvement (long‐term data) ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neither long‐ nor medium‐term data for this outcome were reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse effects (long‐term data)<br/> Treatment duration: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No withdrawals in either group, so absolute risks and relative effect could not be calculated </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of participants with any adverse events (medium‐term data)</p> <p>Treatment duration: 6 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.77 (0.24 to 93.67)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were zero events in the salicylic acid group and 2 events in the BPO group​, so absolute risks could not be calculated </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The control group risk estimate is the median control group risk across studies. </p> <p><sup>b</sup>Downgraded by three levels due to serious risk of bias and very serious imprecision. We downgraded by one level due to risk of bias because in <a href="./references#CD011154-bbs2-0004" title="BissonnetteR , BolducC , SeiteS , NigenS , ProvostN , MaariC , et al. Randomized study comparing the efficacy and tolerance of a lipophillic hydroxy acid derivative of salicylic acid and 5% benzoyl peroxide in the treatment of facial acne vulgaris. Journal of Cosmetic Dermatology2009;8(1):19‐23. [CENTRAL: CN‐00698297; MEDLINE: 19250161] ">Bissonnette 2009</a>, a high proportion (21/80) of participants withdrew from the trial. No information on comparisons of reasons for withdrawal between groups was available, with no ITT analysis being conducted. We further downgraded by two levels due to very serious imprecision because there were zero events in either group and the effect was not estimable. </p> <p><sup>c</sup>Downgraded by three levels due to serious risk of bias and very serious imprecision. We downgraded by one level due to risk of bias because the included study, <a href="./references#CD011154-bbs2-0013" title="ChantalatJ , LiuJC . Six‐week safety and efficacy evaluation of a synergistic microgel complex versus 10% benzoyl peroxide in the treatment of mild to moderate acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB14. [CENTRAL: CN‐00602658] ChantalatJ , LuedtkeK , WiegandB , LiuJC . Significant improvement in acne quality of life by a topical treatment containing a synergistic microgel complex and 2% salicylic acid. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN‐00602548] ChantalatJ , StamatasG , LiuJ C , ChenT . Treating emerging acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN‐00602574] ">Chantalat 2006</a>, was classified as “unclear risk of bias” for most risk of bias domains because the report did not provide sufficient information to allow judgement. We further downgraded by two levels due to very serious imprecision because of the very small number of events. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011154-sec-0051" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011154-sec-0051">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011154-sec-0602">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD011154-sec-0051"></div> <section id="CD011154-sec-0052"> <h3 class="title" id="CD011154-sec-0052">Description of the condition</h3> <p>Acne vulgaris is a common, chronic inflammatory disease of pilosebaceous units. It is characterised by increased sebum production and the formation of comedones, erythematous papules, pustules, and nodules, which may lead to scarring (<a href="./references#CD011154-bbs2-0314" title="ArcherCB ,  CohenSN ,  BaronSE . Guidance on the diagnosis and clinical management of acne. Clinical &amp; Experimental Dermatology2012;37(Suppl 1):1‐6. [MEDLINE: 22486762] ">Archer 2012</a>). </p> <p>For an explanation of the terminology used throughout the text, please refer to the glossary in <a href="#CD011154-tbl-0006">Table 1</a>. </p> <div class="table" id="CD011154-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of unfamiliar terms</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Term</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Definition</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne inversa</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A chronic disease of the apocrine glands occurring mainly in the axillae and in groin regions. It is caused by poral occlusion with secondary bacterial infection, evolving into abscesses that eventually rupture. The chronic phase is characterised by ulcers, sinus tracts, fistulas, fibrosis, and scarring </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne vulgaris</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic acne involving mainly the face, chest, and shoulders, which is common among adolescents, and characterised by the intermittent formation of discrete papular and/or pustular lesions, sometimes resulting in scarring </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alpha‐hydroxy acids</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Organic acids, such as glycolic, lactic, citric, and mandelic acids, containing a hydroxyl group bonded to the carbon atom adjacent to the carboxylic acid group. They are used in skin care preparations for their exfoliating properties </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Androgen</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A steroid hormone, such as testosterone or androsterone, that controls the development and maintenance of masculine characteristics. Androgens stimulate sebaceous glands to grow and produce sebum, and therefore cause acne </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azelaic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A natural material that kills bacteria in the skin and decreases the production of keratin. It is used to treat and prevent mild and moderate acne that is caused by bacteria </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial resistance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The ability of bacteria to resist the effects of an antibiotic</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Benzoyl peroxide</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An organic compound in the peroxide family used for acne treatment. It works as a peeling agent. It increases skin turnover, clearing pores and reducing the bacterial count (specifically <i>C acnes</i>) as well as acting directly as an anti‐microbial agent </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chloracne</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An acneiform eruption due to exposure to chlorine compounds</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clindamycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A lincosamide antibiotic, commonly used for topical treatment of acne</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Colonisation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The presence of bacteria on a body surface (like on the skin, mouth, intestines or airway) without causing disease in the person </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comedolytic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The term used to describe a product or medication that inhibits the formation of comedones. Comedolytic products work by helping the skin to shed more effectively, keeping the pores from becoming plugged </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comedone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A blocked pore in the form of a yellow or black bump or plug on the skin</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Corticosteroids</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any of a class of steroid hormones formed in the cortex of the adrenal gland or chemically similar synthesised hormones that have anti‐inflammatory properties </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cyst</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A closed sac having a distinct membrane compared to nearby tissue, which may contain air, fluids, or semi‐solid material </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cytokines</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A diverse group of soluble molecules important for cell signalling in the generation of an immune response, where they act as intercellular mediators or signalling molecules </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Differentiation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The process by which a less specialised cell becomes a more specialised cell.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug‐induced acne</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne caused or exacerbated by several types of drugs, such as anti‐epileptics, halogens, and steroids </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eczema</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An acute or chronic non‐contagious inflammation of the skin, often caused by allergy and characterised by itching, scaling, and blistering </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blanching reddening of the skin due to local vasodilatation</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A macrolide antibiotic, commonly used for topical treatment of acne</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypercolonisation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abnormal increase in the number of bacteria otherwise normally present on a body surface without causing disease in the person </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infantile acne</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne that presents at the age of 2 to 6 months and persists until the age of 3 to 4 years </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Keratinisation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The process of keratin production that forms an epidermal barrier in stratified squamous epithelial tissue </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Microcomedones</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Microscopic comedones, not visible to the naked eye</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nodule</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A deep skin‐seated dome‐shaped solid lump</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Occupational acne</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne caused by exposure to extraneous agents or adverse conditions in a working environment. The agents and conditions that most commonly cause problems are oils, tars, and excessive humidity </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Papule</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Small, solid, raised lesion, usually dome‐shaped</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pilosebaceous unit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The hair follicle and sebaceous gland</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Polycystic ovarian syndrome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A condition caused by the imbalance of female sex hormones. It is associated with absence of ovulation resulting in irregular menstrual cycles and infertility, insulin resistance causing obesity, and high levels of masculinising hormones causing excessive hair growth and acne </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pustule</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A visible collection of pus</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reactive oxygen species</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chemically reactive molecules containing oxygen. Increased levels of reactive oxygen species may result in significant damage to cell structures, which is called <i>oxidative stress</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Resorcinol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A dihydroxy benzene compound used in many acne treatment products. It helps prevent comedones by removing buildup of dead skin cells </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retinoids</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A class of chemical compound related chemically to vitamin A, topically used for acne treatment due to the way they regulate epithelial cell growth </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rosacea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A chronic dermatitis of the face, especially of the nose and cheeks, characterised by a red or rosy colouration, caused by dilation of capillaries, and the appearance of acne‐like pimples </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sebaceous glands</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Glands that produce sebum and deliver it to the surface of the skin. They are larger and greater in number on the face and upper parts of the trunk, which makes these the acne‐prone areas </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sebum</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An oily substance produced by the sebaceous glands of the skin. Its main function is to protect and waterproof the hair and skin. Oily skin and acne are the result of excessive sebum production </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scar</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The fibrous tissue replacing normal tissues destroyed by injury, disease, or surgery</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sodium sulphacetamide</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A sulphonamid antibiotic used topically for fighting bacteria on the skin in the treatment of acne, dandruff, and seborrhoeic dermatitis </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetracycline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A broad‐spectrum antibiotic synthesised from chlortetracycline or derived from certain micro‐organisms of the genus <i>Streptomyces</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical therapy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A medication in the form of a cream, foam, gel, lotion, or ointment that is applied to body surfaces to treat ailments </p> </td> </tr> </tbody> </table> </div> <section id="CD011154-sec-0053"> <h4 class="title">Epidemiology</h4> <p>Acne vulgaris affects nearly all adolescents and adults at some time in their lives (<a href="./references#CD011154-bbs2-0383" title="WebsterGF . Acne vulgaris. BMJ2002;325(7362):475‐9. [MEDLINE: 12202330] ">Webster 2002</a>). It is estimated that up to 40 to 50 million individuals in the USA have acne, with an 85% prevalence in those aged 12 to 24 years (<a href="./references#CD011154-bbs2-0319" title="BhateK , WilliamsHC . Epidemiology of acne vulgaris. British Journal of Dermatology2013;168(3):474‐85. [MEDLINE: 23210645] ">Bhate 2013</a>; <a href="./references#CD011154-bbs2-0385" title="WhiteGM . Recent findings in the epidemiologic evidence, classification, and subtypes of acne vulgaris. Journal of the American Academy of Dermatology1998;39:S34‐7. [MEDLINE: 9703121] ">White 1998</a>). Moderate to severe acne constitutes 15% to 20% of all cases (<a href="./references#CD011154-bbs2-0319" title="BhateK , WilliamsHC . Epidemiology of acne vulgaris. British Journal of Dermatology2013;168(3):474‐85. [MEDLINE: 23210645] ">Bhate 2013</a>; <a href="./references#CD011154-bbs2-0330" title="DrénoB . Recent data on epidemiology of acne. Annales de Dermatologie et de Venereologie2010;137(Suppl 2):S49‐51. [PUBMED: 21095494] ">Dréno 2010</a>; <a href="./references#CD011154-bbs2-0352" title="LawMP , ChuhAA , MolinariN , LeeA . Acne prevalence and beyond: acne disability and its predictive factors among Chinese late adolescents in Hong Kong. Clinical &amp; Experimental Dermatology2010;35:16‐21. [MEDLINE: 19486044] ">Law 2010</a>; <a href="./references#CD011154-bbs2-0384" title="WeiB , PangY , ZhuH , QuL , XiaoT , WeiHC , et al. The epidemiology of adolescent acne in North East China. Journal of the European Academy of Dermatology &amp; Venereology2010;24:953‐7. [MEDLINE: 20337811] ">Wei 2010</a>). Girls are likely to suffer from acne earlier than boys (<a href="./references#CD011154-bbs2-0314" title="ArcherCB ,  CohenSN ,  BaronSE . Guidance on the diagnosis and clinical management of acne. Clinical &amp; Experimental Dermatology2012;37(Suppl 1):1‐6. [MEDLINE: 22486762] ">Archer 2012</a>), but boys appear to be more susceptible to the disease (<a href="./references#CD011154-bbs2-0340" title="HalvorsenJA , SternRS , DalgardF , ThoresenM , BjertnessE , LienL . Suicidal ideation, mental health problems, and social impairment are increased in adolescents with acne: a population‐based study. Journal of Investigative Dermatology2011;131(2):363‐70. [MEDLINE: 20844551] ">Halvorsen 2011</a>). Acne may decrease with age, but 64% of people aged 20 to 29 years and 43% of people aged 30 to 39 years may still have visible acne (<a href="./references#CD011154-bbs2-0319" title="BhateK , WilliamsHC . Epidemiology of acne vulgaris. British Journal of Dermatology2013;168(3):474‐85. [MEDLINE: 23210645] ">Bhate 2013</a>; <a href="./references#CD011154-bbs2-0373" title="SchäferT , NienhausA , VielufD , BergerJ , RingJ . Epidemiology of acne in the general population: the risk of smoking. British Journal of Dermatology2001;145(1):100‐4. [PUBMED: 11453915] ">Schäfer 2001</a>). Globally, acne is the second most disabling skin disease after eczema (<a href="./references#CD011154-bbs2-0360" title="MurrayCJ , VosT , LozanoR , NaghaviM , FlaxmanAD , MichaudC , et al. Disability‐adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990‐2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet2012;380(9859):2197‐223. [MEDLINE: 23245608] ">Murray 2012</a>). </p> </section> <section id="CD011154-sec-0054"> <h4 class="title">Pathogenesis</h4> <p>Multiple factors are involved in the development of acne. An increased level of androgens at puberty, greater sebum production, and abnormal hyperproliferation of keratinocytes lead to the development of small microscopic lesions called microcomedones. In this lipid‐rich and anaerobic environment, <i>Cutibacterium acnes</i> (<i>C acnes</i> , formerly <i>Propionibacterium acnes</i> ), which is present in normal follicles, proliferates abnormally. Conventionally, it is believed that abnormal colonisation of <i>P acnes</i> initiates the production of inflammatory and chemotactic mediators, which drives the inflammatory processes (<a href="./references#CD011154-bbs2-0323" title="BrownSK ,  ShalitaAR . Acne vulgaris. Lancet1998;351(9119):1871‐6. [MEDLINE: 9652685] ">Brown 1998</a>; <a href="./references#CD011154-bbs2-0324" title="BurkhartCG ,  BurkhartCN ,  LehmannPF . Acne: a review of immunologic and microbiologic factors. Postgraduate Medical Journal1999;75(884):328‐31. [MEDLINE: 10435165] ">Burkhart 1999</a>; <a href="./references#CD011154-bbs2-0328" title="CunliffeWJ , HollandDB , ClarkSM , StablesGI . Comedogenesis: some new aetiological, clinical and therapeutic strategies. British Journal of Dermatology2000;142(6):1084‐91. [MEDLINE: 10848729] ">Cunliffe 2000</a>; <a href="./references#CD011154-bbs2-0338" title="GollnickH ,  CunliffeW ,  BersonD ,  DrenoB ,  FinlayA ,  LeydenJJ ,  etal . Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. Journal of the American Academy of Dermatology2003;49(Suppl 1):S1‐37. [MEDLINE: 12833004] ">Gollnick 2003</a>). Evidence also suggests that involvement of inflammation at all stages of acne development (<a href="./references#CD011154-bbs2-0344" title="JeremyAH , HollandDB , RobertsSG , ThomsonKF , CunliffeWJ . Inflammatory events are involved in acne lesion initiation. Journal of Investigative Dermatology2003;121(1):20‐7. [MEDLINE: 12839559] ">Jeremy 2003</a>; <a href="./references#CD011154-bbs2-0380" title="TanghettiEA . The role of inflammation in the pathology of acne. Journal of Clinical &amp; Aesthetic Dermatology2013;6(9):27‐35. [MEDLINE: 24062871] ">Tanghetti 2013</a>), as well as the exact sequence of events and the interaction between these events and other possible factors (genes, diet, smoking, sunlight, etc), remains unclear (<a href="./references#CD011154-bbs2-0386" title="WilliamsHC ,  DellavalleRP ,  GarnerS . Acne vulgaris. Lancet2012;379(9813):361‐72. [MEDLINE: 21880356] ">Williams 2012</a>). </p> </section> <section id="CD011154-sec-0055"> <h4 class="title">Diagnosis and outcome measures</h4> <p>Clinical diagnosis of acne is usually straightforward. The condition tends to affect the face (99%), the back (60%), and the chest (15%) (<a href="./references#CD011154-bbs2-0314" title="ArcherCB ,  CohenSN ,  BaronSE . Guidance on the diagnosis and clinical management of acne. Clinical &amp; Experimental Dermatology2012;37(Suppl 1):1‐6. [MEDLINE: 22486762] ">Archer 2012</a>), where the lesions are comedones (whiteheads and blackheads), which are non‐inflamed lesions (<a href="./references#CD011154-bbs2-0376" title="SimpsonN , CunliffeW . Disorders of sebaceous glands. In: BurnsT , BreathnachS , CoxN , GrifﬁthsC editor(s). Rook's Textbook of Dermatology. 7th Edition. Malden, MA, USA: Wiley, Blackwell Science Ltd, 2008:43.1. ">Simpson 2008</a>). Inflammatory lesions such as papules, pustules, nodules, and cysts may develop after non‐inflamed lesions appear (<a href="./references#CD011154-bbs2-0354" title="LaytonAM . Disorders of sebaceous glands. In: BurnsT , BreathnachS , CoxN , GrifﬁthsC editor(s). Rook's Textbook of Dermatology. Oxford: Wiley‐Blackwell, 2010:42.1‐42.89. ">Layton 2010</a>). Papules and pustules are superficial lesions, but they may evolve into deep pustules or nodules in more severe forms of the disease. In conglobate acne, suppurative nodules can extend deeply and over larger areas, leading to exudative sinus tracts and tissue destruction, resulting in extensive and disfiguring scarring. </p> <p>Classification of acne severity at the time of diagnosis is important because guidelines for subsequent treatment are based on the severity of disease (<a href="./references#CD011154-bbs2-0361" title="NastA , DrénoB , BettoliV , DegitzK , ErdmannR , FinlayAY , et al. European evidence‐based (S3) guidelines for the treatment of acne. Journal of the European Academy of Dermatology and Venereology2012;26(Suppl 1):1‐29. [MEDLINE: 22356611] ">Nast 2012</a>; <a href="./references#CD011154-bbs2-0378" title="StraussJS , KrowchukDP , LeydenJJ , LuckyAW , ShalitaAR , SiegfriedEC ,  etal . Guidelines of care for acne vulgaris management. Journal of the American Academy of Dermatology2007;56(4):651‐63. [MEDLINE: 17276540] ">Strauss 2007</a>; <a href="./references#CD011154-bbs2-0382" title="ThiboutotD , GollnickH , BettoliV ,  DrénoB ,  KangS ,  LeydenJJ ,  etal . New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne Group. Journal of the American Academy of Dermatology2009;60(5 Suppl):S1‐50. [MEDLINE: 19376456] ">Thiboutot 2009</a>). Acne can be assessed and subsequently classified from two perspectives: as an objective disease activity based on measurement of the visible signs of acne by an investigator, or as a patient assessment of the impact of the condition on their quality of life (<a href="./references#CD011154-bbs2-0361" title="NastA , DrénoB , BettoliV , DegitzK , ErdmannR , FinlayAY , et al. European evidence‐based (S3) guidelines for the treatment of acne. Journal of the European Academy of Dermatology and Venereology2012;26(Suppl 1):1‐29. [MEDLINE: 22356611] ">Nast 2012</a>). More than 25 acne assessment scales have been described, and they are inconsistently used across different trials (<a href="./references#CD011154-bbs2-0356" title="LehmannHP , RobinsonKA , AndrewsJS , HollowayV , GoodmanSN . Acne therapy: a methodologic review. Journal of the American Academy of Dermatology2002;47(2):231‐40. [MEDLINE: 12140469] ">Lehmann 2002</a>). This does not allow a direct comparison of the results of separate trials (<a href="./references#CD011154-bbs2-0361" title="NastA , DrénoB , BettoliV , DegitzK , ErdmannR , FinlayAY , et al. European evidence‐based (S3) guidelines for the treatment of acne. Journal of the European Academy of Dermatology and Venereology2012;26(Suppl 1):1‐29. [MEDLINE: 22356611] ">Nast 2012</a>; <a href="./references#CD011154-bbs2-0390" title="ZarchiK , JemecGBE . Severity assessment and outcome measures in acne vulgaris. Current Dermatology Reports2012;1(3):131‐6. [EMBASE: 2012710458] ">Zarchi 2012</a>). Additionally, grading is a subjective measure that may vary from one dermatologist to another (<a href="./references#CD011154-bbs2-0368" title="RamliR ,  MalikAS ,  HaniAF ,  JamilA . Acne analysis, grading and computational assessment methods: an overview. Skin Research &amp; Technology2012;18(1):1‐14. [MEDLINE: 21605170] ">Ramli 2012</a>). In clinical trials, assessment of the severity of acne before and after the intervention is essential to determine the therapeutic effect (<a href="./references#CD011154-bbs2-0390" title="ZarchiK , JemecGBE . Severity assessment and outcome measures in acne vulgaris. Current Dermatology Reports2012;1(3):131‐6. [EMBASE: 2012710458] ">Zarchi 2012</a>). Grading and lesion counting appear to be most frequently used for this purpose (<a href="./references#CD011154-bbs2-0390" title="ZarchiK , JemecGBE . Severity assessment and outcome measures in acne vulgaris. Current Dermatology Reports2012;1(3):131‐6. [EMBASE: 2012710458] ">Zarchi 2012</a>), as is described in the revised Leeds acne grading system, which includes numerical grading systems for the back and chest, as well as for the face (<a href="./references#CD011154-bbs2-0356" title="LehmannHP , RobinsonKA , AndrewsJS , HollowayV , GoodmanSN . Acne therapy: a methodologic review. Journal of the American Academy of Dermatology2002;47(2):231‐40. [MEDLINE: 12140469] ">Lehmann 2002</a>). </p> </section> </section> <section id="CD011154-sec-0056"> <h3 class="title" id="CD011154-sec-0056">Description of the intervention</h3> <p>Treatments for acne target the pathophysiological processes, and a wide range of topical and systemic treatments are currently available (<a href="./references#CD011154-bbs2-0346" title="KatsambasAD , StefanakiC , CunliffeWJ . Guidelines for treating acne. Clinics in Dermatology2004;22(5):439‐44. [MEDLINE: 15556732] ">Katsambas 2004</a>). Topical therapies, including benzoyl peroxide (BPO), tretinoin, antibiotics, and salicylic acid, can be used for non‐inflammatory comedones or mild to moderate inflammatory acne (<a href="./references#CD011154-bbs2-0378" title="StraussJS , KrowchukDP , LeydenJJ , LuckyAW , ShalitaAR , SiegfriedEC ,  etal . Guidelines of care for acne vulgaris management. Journal of the American Academy of Dermatology2007;56(4):651‐63. [MEDLINE: 17276540] ">Strauss 2007</a>; <a href="./references#CD011154-bbs2-0382" title="ThiboutotD , GollnickH , BettoliV ,  DrénoB ,  KangS ,  LeydenJJ ,  etal . New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne Group. Journal of the American Academy of Dermatology2009;60(5 Suppl):S1‐50. [MEDLINE: 19376456] ">Thiboutot 2009</a>). The underlying mechanism can be action primarily against comedones (retinoids and salicylic acid) or against inflammatory lesions (antibacterials and antibiotics). </p> <p>BPO is an oxidising agent that is bactericidal for <i>C acnes</i> . Besides its primary bactericidal effect on <i>C acnes</i>, BPO has mild anti‐inflammatory, as well as comedolytic, activity (<a href="./references#CD011154-bbs2-0364" title="PatelM , BoweWP , HeughebaertC , ShalitaAR . The development of antimicrobial resistance due to the antibiotic treatment of acne vulgaris: a review. Journal of Drugs in Dermatology2010;9(6):655‐64. [MEDLINE: 20645527] ">Patel 2010</a>; <a href="./references#CD011154-bbs2-0378" title="StraussJS , KrowchukDP , LeydenJJ , LuckyAW , ShalitaAR , SiegfriedEC ,  etal . Guidelines of care for acne vulgaris management. Journal of the American Academy of Dermatology2007;56(4):651‐63. [MEDLINE: 17276540] ">Strauss 2007</a>). Treatment of acne vulgaris with BPO alone or in combination with other topical treatments (antibiotics, retinoid, salicylic acid, or zinc) at concentrations of 2% to 5% is the standard of care for mild to moderate acne (<a href="./references#CD011154-bbs2-0321" title="BojarRA , EadyEA , JonesCE , CunliffeWJ ,  HollandKT . Inhibition of erythromycin‐resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. British Journal of Dermatology1994;130(3):329‐36. [MEDLINE: 8148274] ">Bojar 1994</a>; <a href="./references#CD011154-bbs2-0331" title="DutilM . Benzoyl peroxide: enhancing antibiotic efficacy in acne management. Skin Therapy Letter2010;15(10):5‐7. [MEDLINE: 21076800] ">Dutil 2010</a>; <a href="./references#CD011154-bbs2-0338" title="GollnickH ,  CunliffeW ,  BersonD ,  DrenoB ,  FinlayA ,  LeydenJJ ,  etal . Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. Journal of the American Academy of Dermatology2003;49(Suppl 1):S1‐37. [MEDLINE: 12833004] ">Gollnick 2003</a>; <a href="./references#CD011154-bbs2-0069" title="LookingbillDP , ChalkerDK , LindholmJS , KatzHI , KempersSE , HuerterCJ , et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double‐blind investigations. Journal of the American Academy of Dermatology1997;37(4):590‐5. [CENTRAL: CN‐00144503; MEDLINE: 9344199] LookingbillDP , ChallenDK , LindholmJS . Treatment of acne with a combination of clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined result of two double blind investigations (Abstract no. 1). Indian Journal of Dermatology, Venerology and Leprology1995;61:398. ">Lookingbill 1997</a>; <a href="./references#CD011154-bbs2-0378" title="StraussJS , KrowchukDP , LeydenJJ , LuckyAW , ShalitaAR , SiegfriedEC ,  etal . Guidelines of care for acne vulgaris management. Journal of the American Academy of Dermatology2007;56(4):651‐63. [MEDLINE: 17276540] ">Strauss 2007</a>). The most common fixed‐combination products containing BPO are BPO with clindamycin, erythromycin, or adapalene (<a href="./references#CD011154-bbs2-0353" title="LaytonAM , EadyEA . Benzoyl peroxide and adapalene fixed combination: a novel agent for acne. British Journal of Dermatology2009;161(5):971‐6. [MEDLINE: 19857206] ">Layton 2009</a>; <a href="./references#CD011154-bbs2-0381" title="TaylorGA , ShalitaAR . Benzoyl peroxide‐based combination therapies for acne vulgaris: a comparative review. American Journal of Clinical Dermatology2004;5(4):261‐5. [MEDLINE: 15301572] ">Taylor 2004</a>). Besides BPO, other potentially efficient over‐the‐counter agents for acne treatment include azelaic acid, alpha‐hydroxy acids, resorcinol, sulphur, and zinc, but evidence of their effectiveness from randomised controlled clinical trials and studies comparing their efficacy with other topical treatments is lacking. </p> <p>An increasingly wide range of non‐drug‐based approaches have been developed for treating acne, among which low‐concentration chemical peels with glycolic, salicylic, or trichloroacetic acid are beneficial for reduction of comedones (<a href="./references#CD011154-bbs2-0347" title="KempiakSJ , UebelhoerN . Superficial chemical peels and microdermabrasion for acne vulgaris. Seminars in Cutaneous Medicine and Surgery2008;27(3):212‐20. [PUBMED: 18786500] ">Kempiak 2008</a>; <a href="./references#CD011154-bbs2-0369" title="RendonMI , BersonDS , CohenJL , RobertsWE , StarkerI , WangB . Evidence and considerations in the application of chemical peels in skin disorders and aesthetic resurfacing. Journal of Clinical and Aesthetic Dermatology2010;3(7):32‐43. [PUBMED: 20725555] ">Rendon 2010</a>). In addition, comedo extractions, light electrocautery, electrofulguration, and cryotherapy present other therapeutic options for comedonal acne. In addition, acne can be treated by photodynamic therapy, utilising topical 5‐aminolevulinic acid together with various light sources (e.g. blue, red, intense pulsed) or lasers (e.g. pulsed dye, 635‐nm red diode), as well as methyl aminolevulinate plus red light. Blue or intense pulsed light alone and lasers such as pulsed dye, the 1320‐nm neodymium: yttrium‐aluminum‐garnet (YAG), and especially the 1450‐nm diode may be of therapeutic benefit for inflammatory acne (<a href="./references#CD011154-bbs2-0366" title="RaiR , NatarajanK . Laser and light based treatments of acne. Indian Journal of Dermatology, Venereology, &amp; Leprology2013;79(3):300‐9. [MEDLINE: 23619435] ">Rai 2013</a>). For deep, inflamed nodules and cysts, intralesional injections of corticosteroids, such as triamcinolone acetate, are beneficial (<a href="./references#CD011154-bbs2-0357" title="LevineRM , RasmussenJE . Intralesional corticosteroids in the treatment of nodulocystic acne. Archives of Dermatology1983;119(6):480‐1. [PUBMED: 6222700] ">Levine 1983</a>; <a href="./references#CD011154-bbs2-0378" title="StraussJS , KrowchukDP , LeydenJJ , LuckyAW , ShalitaAR , SiegfriedEC ,  etal . Guidelines of care for acne vulgaris management. Journal of the American Academy of Dermatology2007;56(4):651‐63. [MEDLINE: 17276540] ">Strauss 2007</a>). Besides, some plant extracts (such as tea tree oil, <i>Casuarina equisetifolia, Zimade Muhasa</i>, green tea polyphenols, and resveratrol) and synthetic chemicals (such as isolutrol and superoxidised solution) are available for cosmetic use or as medicine for acne given their potential anti‐bacterial, anti‐inflammatory, or anti‐oxidant activities. </p> <p>Commercially available over‐the‐counter preparations of BPO include gels, creams, lotions, soaps, and washes, ranging from 2.5% to 10% in concentration (<a href="./references#CD011154-bbs2-0378" title="StraussJS , KrowchukDP , LeydenJJ , LuckyAW , ShalitaAR , SiegfriedEC ,  etal . Guidelines of care for acne vulgaris management. Journal of the American Academy of Dermatology2007;56(4):651‐63. [MEDLINE: 17276540] ">Strauss 2007</a>; <a href="./references#CD011154-bbs2-0388" title="ZaengleinAL , ThiboutotDM . Expert committee recommendations for acne management. Pediatrics2006;118(3):1188‐99. [MEDLINE: 16951015] ">Zaenglein 2006</a>). The choice of vehicle depends largely on skin type and the patient's preference (<a href="./references#CD011154-bbs2-0323" title="BrownSK ,  ShalitaAR . Acne vulgaris. Lancet1998;351(9119):1871‐6. [MEDLINE: 9652685] ">Brown 1998</a>). Irritant dermatitis (erythema, scaling, burning, and itching) is the primary limitation of BPO for some people; this primarily occurs within the first few days of treatment but generally subsides with continued use (<a href="./references#CD011154-bbs2-0338" title="GollnickH ,  CunliffeW ,  BersonD ,  DrenoB ,  FinlayA ,  LeydenJJ ,  etal . Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. Journal of the American Academy of Dermatology2003;49(Suppl 1):S1‐37. [MEDLINE: 12833004] ">Gollnick 2003</a>; <a href="./references#CD011154-bbs2-0370" title="SagranskyM , YentzerBA , FeldmanSR . Benzoyl peroxide: a review of its current use in the treatment of acne vulgaris. Expert Opinion on Pharmacotherapy2009;10(15):2555‐62. [MEDLINE: 19761357] ">Sagransky 2009</a>). However, when in contact with hair, clothing, and other fabrics, BPO can cause bleaching (<a href="./references#CD011154-bbs2-0322" title="BojarRA , CunliffeWJ , HollandKT . The short‐term treatment of acne vulgaris with benzoyl peroxide: effects on the surface and follicular cutaneous microﬂora. British Journal of Dermatology1995;132(2):204‐8. [MEDLINE: 7888356] ">Bojar 1995</a>; <a href="./references#CD011154-bbs2-0370" title="SagranskyM , YentzerBA , FeldmanSR . Benzoyl peroxide: a review of its current use in the treatment of acne vulgaris. Expert Opinion on Pharmacotherapy2009;10(15):2555‐62. [MEDLINE: 19761357] ">Sagransky 2009</a>). </p> </section> <section id="CD011154-sec-0057"> <h3 class="title" id="CD011154-sec-0057">How the intervention might work</h3> <p>BPO acts through three fundamental mechanisms: it is bactericidal to <i>C acnes</i>, it has mild comedolytic and anti‐inflammatory properties (<a href="./references#CD011154-bbs2-0331" title="DutilM . Benzoyl peroxide: enhancing antibiotic efficacy in acne management. Skin Therapy Letter2010;15(10):5‐7. [MEDLINE: 21076800] ">Dutil 2010</a>; <a href="./references#CD011154-bbs2-0364" title="PatelM , BoweWP , HeughebaertC , ShalitaAR . The development of antimicrobial resistance due to the antibiotic treatment of acne vulgaris: a review. Journal of Drugs in Dermatology2010;9(6):655‐64. [MEDLINE: 20645527] ">Patel 2010</a>; <a href="./references#CD011154-bbs2-0378" title="StraussJS , KrowchukDP , LeydenJJ , LuckyAW , ShalitaAR , SiegfriedEC ,  etal . Guidelines of care for acne vulgaris management. Journal of the American Academy of Dermatology2007;56(4):651‐63. [MEDLINE: 17276540] ">Strauss 2007</a>), and it is lipophilic, concentrating inside the sebaceous follicles to produce benzoic acid and reactive oxygen species. By oxidising bacterial proteins, BPO can inhibit protein and nucleotide synthesis and mitochondrial activity (<a href="./references#CD011154-bbs2-0331" title="DutilM . Benzoyl peroxide: enhancing antibiotic efficacy in acne management. Skin Therapy Letter2010;15(10):5‐7. [MEDLINE: 21076800] ">Dutil 2010</a>; <a href="./references#CD011154-bbs2-0333" title="FakhouriT , YentzerBA , FeldmanSR . Advancement in benzoyl peroxide‐based acne treatment: methods to increase both efficacy and tolerability. Journal of Drugs in Dermatology2009;8(7):657‐61. [MEDLINE: 19588642] ">Fakhouri 2009</a>; <a href="./references#CD011154-bbs2-0350" title="KrakowskiAC , StendardoS , EichenfieldLF . Practical considerations in acne treatment and the clinical impact of topical combination therapy. Pediatric Dermatology2008;25(Suppl 1):1‐14. [MEDLINE: 18494684] ">Krakowski 2008</a>). The response to BPO appears to be rapid; it has been shown that significant reductions in surface and follicular micro‐organisms may be obtained after 48 hours' treatment with 5% BPO in aqueous gel (<a href="./references#CD011154-bbs2-0322" title="BojarRA , CunliffeWJ , HollandKT . The short‐term treatment of acne vulgaris with benzoyl peroxide: effects on the surface and follicular cutaneous microﬂora. British Journal of Dermatology1995;132(2):204‐8. [MEDLINE: 7888356] ">Bojar 1995</a>), and clinical improvement has been noted as early as five days after the start of treatment (<a href="./references#CD011154-bbs2-0343" title="JamesWD . Acne. New England Journal of Medicine2005;352(14):1463‐72. [MEDLINE: 15814882] ">James 2005</a>). A significant reduction in <i>C acnes</i> is seen within 20 hours of a single application of 5% BPO in solution, which implies that the vehicle in topical therapy is important (<a href="./references#CD011154-bbs2-0367" title="RamirezJ , BatraRS , MillerT , MastejJ . Evaluation of in‐vivo antimicrobial efficacy of three formulations containing benzoyl peroxide on P. acnes. 64th Annual Meeting of the American Academy of Dermatology 2006. sadpas.co.za/wp‐content/uploads/2016/06/Ramirez‐Batra‐et‐al‐270.pdf (accessed before 22 May 2018). ">Ramirez 2006</a>). </p> <p>The action mechanisms of BPO are considered complementary to antibiotics (reducing inflammation and <i>C acnes</i> counts) and retinoids (reducing sebum production and keratinisation); their combinations may thus contribute to the synergistic activity. The combination therapy can be prescribed as separate products used together or as fixed combinations in a single product, with the former being less expensive and the latter potentially enhancing patient compliance and adherence (<a href="./references#CD011154-bbs2-0335" title="GambleR , DunnJ , DawsonA , PetersenB , McLaughlinL , SmallA , et al. Topical antimicrobial treatment of acne vulgaris: an evidence‐based review. American Journal of Clinical Dermatology2012;13(3):141‐52. [MEDLINE: 22268388] ">Gamble 2012</a>). However, no evidence has demonstrated that combination therapy as separate products is superior or inferior to a fixed combination (<a href="./references#CD011154-bbs2-0335" title="GambleR , DunnJ , DawsonA , PetersenB , McLaughlinL , SmallA , et al. Topical antimicrobial treatment of acne vulgaris: an evidence‐based review. American Journal of Clinical Dermatology2012;13(3):141‐52. [MEDLINE: 22268388] ">Gamble 2012</a>). Topical monotherapy with antibiotics is no longer recommended due to the risk of developing antibiotic resistance (<a href="./references#CD011154-bbs2-0364" title="PatelM , BoweWP , HeughebaertC , ShalitaAR . The development of antimicrobial resistance due to the antibiotic treatment of acne vulgaris: a review. Journal of Drugs in Dermatology2010;9(6):655‐64. [MEDLINE: 20645527] ">Patel 2010</a>). </p> <p>Resistance to <i>C acnes</i> , which commonly develops during monotherapy with topical antibiotics, has not been reported with BPO because of its direct toxicity to <i>C acnes</i>, which is due to its ability to inhibit bacterial protein and nucleotide synthesis, metabolic pathways, and mitochondrial activity (<a href="./references#CD011154-bbs2-0331" title="DutilM . Benzoyl peroxide: enhancing antibiotic efficacy in acne management. Skin Therapy Letter2010;15(10):5‐7. [MEDLINE: 21076800] ">Dutil 2010</a>). This mechanism allows BPO to be used as long‐term therapy for acne, either as monotherapy or in combination with topical antibiotics, without the hazard of development of bacterial resistance. However, any relationship between skin colonisation with antibiotic‐resistant <i>C acnes</i> and treatment outcomes remains unclear. </p> <p>Besides topical antibiotics, topical retinoids (adapalene and tazarotene) are frequently used as combination therapy with BPO. Retinoids regulate the differentiation and proliferation of keratinocytes and have an anti‐inflammatory effect (<a href="./references#CD011154-bbs2-0325" title="ChivotM . Retinoid therapy for acne. A comparative review. American Journal of Clinical Dermatology2005;6(1):13‐9. [MEDLINE: 15675886] ">Chivot 2005</a>; <a href="./references#CD011154-bbs2-0386" title="WilliamsHC ,  DellavalleRP ,  GarnerS . Acne vulgaris. Lancet2012;379(9813):361‐72. [MEDLINE: 21880356] ">Williams 2012</a>). Because BPO oxidises retinoids if applied simultaneously, it has been suggested that BPO should be used in the morning and the retinoid at night to minimise any possible interaction (<a href="./references#CD011154-bbs2-0338" title="GollnickH ,  CunliffeW ,  BersonD ,  DrenoB ,  FinlayA ,  LeydenJJ ,  etal . Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. Journal of the American Academy of Dermatology2003;49(Suppl 1):S1‐37. [MEDLINE: 12833004] ">Gollnick 2003</a>; <a href="./references#CD011154-bbs2-0349" title="KraftJ , FreimanA . Management of acne. Canadian Medical Association Journal2011;183(7):E430‐5. [MEDLINE: 21398228] ">Kraft 2011</a>). However, modern formulations allow the stable combination of topical retinoids and BPO (<a href="./references#CD011154-bbs2-0379" title="TanJK . Adapalene 0.1% and benzoyl peroxide 2.5%: a novel combination for treatment of acne vulgaris. Skin Therapy Letter2009;14(6):4‐5. [MEDLINE: 19609474] ">Tan 2009</a>). </p> </section> <section id="CD011154-sec-0058"> <h3 class="title" id="CD011154-sec-0058">Why it is important to do this review</h3> <p>Effective treatment of individuals with this condition is important. Acne is a common skin disease in adolescence that can cause psychological harm to an individual and the possibility of long‐term scarring. It also involves an economic burden. </p> <p>More than half of people with acne may experience shame, embarrassment, anxiety, lack of confidence, and impaired social contact (<a href="./references#CD011154-bbs2-0316" title="BachM , BachD . Psychiatric and psychometric issues in acne excoriée. Psychotherapy &amp; Psychosomatics1993;60(3‐4):207‐10. [MEDLINE: 8272479] ">Bach 1993</a>; <a href="./references#CD011154-bbs2-0327" title="CunliffeWJ . Acne and unemployment. British Journal of Dermatology1986;115(3):386. [MEDLINE: 2944538] ">Cunliffe 1986</a>; <a href="./references#CD011154-bbs2-0345" title="JowettS , RyanT . Skin disease and handicap: an analysis of the impact of skin conditions. Social Science &amp; Medicine1985;20(4):425‐9. [MEDLINE: 3158080] ">Jowett 1985</a>). Severe acne may increase anger and anxiety (<a href="./references#CD011154-bbs2-0354" title="LaytonAM . Disorders of sebaceous glands. In: BurnsT , BreathnachS , CoxN , GrifﬁthsC editor(s). Rook's Textbook of Dermatology. Oxford: Wiley‐Blackwell, 2010:42.1‐42.89. ">Layton 2010</a>). Acne itself induces stress, which may also exacerbate the condition (<a href="./references#CD011154-bbs2-0314" title="ArcherCB ,  CohenSN ,  BaronSE . Guidance on the diagnosis and clinical management of acne. Clinical &amp; Experimental Dermatology2012;37(Suppl 1):1‐6. [MEDLINE: 22486762] ">Archer 2012</a>). Furthermore, acne episodes impose a financial burden on healthcare providers as well as the individuals themselves: an acne episode costs a total of USD690 on average, ranging from USD360 to USD870 (<a href="./references#CD011154-bbs2-0335" title="GambleR , DunnJ , DawsonA , PetersenB , McLaughlinL , SmallA , et al. Topical antimicrobial treatment of acne vulgaris: an evidence‐based review. American Journal of Clinical Dermatology2012;13(3):141‐52. [MEDLINE: 22268388] ">Gamble 2012</a>; <a href="./references#CD011154-bbs2-0387" title="YentzerBA ,  HickJ ,  ReeseEL ,  UhasA ,  FeldmanSR ,  BalkrishnanR . Acne vulgaris in the United States: a descriptive epidemiology. Cutis; Cutaneous Medicine for the Practitioner2010;86(2):94‐9. [MEDLINE: 20919604] ">Yentzer 2010</a>). The average cost of a 30‐day supply of a topical treatment depends on the drugs but ranges from USD21 to more than USD100, and generic BPO costs USD21 to USD60 per 30‐day course of treatment (<a href="./references#CD011154-bbs2-0335" title="GambleR , DunnJ , DawsonA , PetersenB , McLaughlinL , SmallA , et al. Topical antimicrobial treatment of acne vulgaris: an evidence‐based review. American Journal of Clinical Dermatology2012;13(3):141‐52. [MEDLINE: 22268388] ">Gamble 2012</a>; <a href="./references#CD011154-bbs2-0350" title="KrakowskiAC , StendardoS , EichenfieldLF . Practical considerations in acne treatment and the clinical impact of topical combination therapy. Pediatric Dermatology2008;25(Suppl 1):1‐14. [MEDLINE: 18494684] ">Krakowski 2008</a>). The annual direct cost of acne management is over USD2.5 billion, and among skin diseases, it ranks second only to the cost of treating skin ulcers and wounds (<a href="./references#CD011154-bbs2-0320" title="BickersDR , LimHW , MargolisD , WeinstockMA , GoodmanC , FaulknerE , et al. The burden of skin diseases: 2004 ‐ a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. Journal of the American Academy of Dermatology2006;55(3):490‐500. [MEDLINE: 16908356] ">Bickers 2006</a>). </p> <p>Multiple treatments for acne have been developed, among which topical BPO has been recommended for first‐line treatment of acne and is one of the least costly acne therapies. Current evidence‐based clinical guidelines have recommended BPO as monotherapy or combined with adapalene or with clindamycin for mild to moderate acne, or in conjunction with a topical retinoid and/or systemic antibiotic therapy for moderate to severe acne (<a href="./references#CD011154-bbs2-0315" title="AsaiY , BaibergenovaA , DutilM , HumphreyS , HullP , LyndeC , et al. Management of acne: Canadian clinical practice guideline. Canadian Medical Association Journal2016;188(2):118‐26. ">Asai 2016</a>; <a href="./references#CD011154-bbs2-0362" title="ZaengleinAL , PathyAL , SchlosserBJ , AlikhanA , Baldwin NastA , DrénoB , et al. European evidence‐based (S3) guideline for the treatment of acne ‐ update 2016 ‐ short version. Journal of the European Academy of Dermatology and Venereology2016;30(8):1261‐8. ">Nast 2016</a>; <a href="./references#CD011154-bbs2-0363" title="OonHH , WongSN , AwDCW , CheongWK , GohCL , TanHH . Acne management guidelines by the Dermatological Society of Singapore. Journal of Clinical and Aesthetic Dermatology2019;12(7):34‐50. ">Oon 2019</a>; <a href="./references#CD011154-bbs2-0389" title="ZaengleinAL , PathyAL , SchlosserBJ , AlikhanA , BaldwinHE , BersonDS , et al. Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology2016;74(5):945‐73. [MEDLINE: 26897386] ">Zaenglein 2016</a>). </p> <p>Several relevant systematic reviews (or meta‐analyses) were conducted for BPO versus placebo (<a href="./references#CD011154-bbs2-0351" title="LamelSA , SivamaniRK , RahvarM , MaibachHI . Evaluating clinical trial design: systematic review of randomized vehicle‐controlled trials for determining efficacy of benzoyl peroxide topical therapy for acne. Archives of Dermatological Research2015;307:757‐66. ">Lamel 2015</a>; <a href="./references#CD011154-bbs2-0375" title="SeidlerEM ,  KimballAB . Meta‐analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne. Journal of the American Academy of Dermatology2010;63(1):52‐62. [MEDLINE: 20488582] ">Seidler 2010</a>), BPO versus adapalene (<a href="./references#CD011154-bbs2-0348" title="KolliSS , PeconeD , PonaA , ClineA , FeldmanSR . Topical retinoids in acne vulgaris: a systematic review. American Journal of Clinical Dermatology2019;20(3):345‐65. [PUBMED: 30674002] ">Kolli 2019</a>), BPO versus clindamycin (<a href="./references#CD011154-bbs2-0375" title="SeidlerEM ,  KimballAB . Meta‐analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne. Journal of the American Academy of Dermatology2010;63(1):52‐62. [MEDLINE: 20488582] ">Seidler 2010</a>), BPO/adapalene versus placebo (<a href="./references#CD011154-bbs2-0329" title="DresslerC , RosumeckS , NastA . How much do we know about maintaining treatment response after successful acne therapy? Systematic review on the efficacy and safety of acne maintenance therapy. Dermatology2016;232:371‐80. [MEDLINE: 27220773] ">Dressler 2016</a>; <a href="./references#CD011154-bbs2-0337" title="GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] ">Gold 2016a</a>; <a href="./references#CD011154-bbs2-0348" title="KolliSS , PeconeD , PonaA , ClineA , FeldmanSR . Topical retinoids in acne vulgaris: a systematic review. American Journal of Clinical Dermatology2019;20(3):345‐65. [PUBMED: 30674002] ">Kolli 2019</a>; <a href="./references#CD011154-bbs2-0391" title="ZhouR , JiangX . Effects of adapalene‐benzoyl peroxide combination gel in treatment or maintenance therapy of moderate or severe acne vulgaris: a meta‐analysis. Annals of Dermatology2014;26(1):43‐52. [MEDLINE: 24648685] ">Zhou 2014</a>), BPO/adapalene versus adapalene (<a href="./references#CD011154-bbs2-0348" title="KolliSS , PeconeD , PonaA , ClineA , FeldmanSR . Topical retinoids in acne vulgaris: a systematic review. American Journal of Clinical Dermatology2019;20(3):345‐65. [PUBMED: 30674002] ">Kolli 2019</a>), BPO/clindamycin versus placebo (<a href="./references#CD011154-bbs2-0375" title="SeidlerEM ,  KimballAB . Meta‐analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne. Journal of the American Academy of Dermatology2010;63(1):52‐62. [MEDLINE: 20488582] ">Seidler 2010</a>), BPO/clindamycin versus adapalene (<a href="./references#CD011154-bbs2-0348" title="KolliSS , PeconeD , PonaA , ClineA , FeldmanSR . Topical retinoids in acne vulgaris: a systematic review. American Journal of Clinical Dermatology2019;20(3):345‐65. [PUBMED: 30674002] ">Kolli 2019</a>), BPO plus salicylic acid versus placebo (<a href="./references#CD011154-bbs2-0375" title="SeidlerEM ,  KimballAB . Meta‐analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne. Journal of the American Academy of Dermatology2010;63(1):52‐62. [MEDLINE: 20488582] ">Seidler 2010</a>), BPO plus salicylic acid versus clindamycin (<a href="./references#CD011154-bbs2-0375" title="SeidlerEM ,  KimballAB . Meta‐analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne. Journal of the American Academy of Dermatology2010;63(1):52‐62. [MEDLINE: 20488582] ">Seidler 2010</a>), and BPO 10% versus 5% versus 2.5% (<a href="./references#CD011154-bbs2-0333" title="FakhouriT , YentzerBA , FeldmanSR . Advancement in benzoyl peroxide‐based acne treatment: methods to increase both efficacy and tolerability. Journal of Drugs in Dermatology2009;8(7):657‐61. [MEDLINE: 19588642] ">Fakhouri 2009</a>). However, none of these reviews has provided a comprehensive picture of evidence on the comparative effects of BPO (as monotherapy or add‐on treatment) versus other topical treatments for acne. Most of these reviews had some major issues of conduct and reporting quality, including incomprehensive literature search, lack of risk of bias assessment, neglect of treatment duration, and/or incorrect method for evidence synthesis. </p> <p>A comprehensive and transparent assessment of the efficacy and safety of topical BPO treatment for acne is important, and this is what we planned to do in our Cochrane Review. We did not apply any restriction on the concentration of BPO nor on the treatment duration, in the hope of providing sufficient evidence to inform physicians when treating people with this skin condition. </p> <p>Plans for this review were published as a protocol titled "Topical benzoyl peroxide for acne" (<a href="./references#CD011154-bbs2-0392" title="YangZ , ZhangY , Lazic MoslerE , LiH , HuJ , ZhangY , et al. Topical benzoyl peroxide for acne. Cochrane Database of Systematic Reviews2014, Issue 6. [DOI: 10.1002/14651858.CD011154] ">Yang 2014</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011154-sec-0059" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011154-sec-0059">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011154-sec-0610">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011154-sec-0059"></div> <p>To assess the effects of benzoyl peroxide for acne.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011154-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011154-sec-0060">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011154-sec-0611">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011154-sec-0060"></div> <section id="CD011154-sec-0061"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011154-sec-0062"> <h4 class="title">Types of studies</h4> <p>We considered randomised controlled trials (RCTs) with a parallel or cross‐over design eligible for our review. We included only the first‐phase data from cross‐over trials because of the possibility that the effects of the acne interventions may carry over to subsequent periods. For parallel design, if participants were re‐randomised to assess the maintenance effect upon completion of the first phase of a trial, the second‐phase data after re‐randomisation were excluded in light of the possibility of carry‐over effects from the first phase. Although split‐face design was also included, data from this kind of study were not combined with those from studies of parallel or cross‐over design but were only summarised narratively based on potential correlated effects within individuals in split‐face design. For studies simultaneously analysing individual participant data from two or more trials, we considered each trial as an independent study. </p> </section> <section id="CD011154-sec-0063"> <h4 class="title">Types of participants</h4> <p>We considered participants with a clinical diagnosis by a healthcare practitioner of acne vulgaris on the face or trunk, regardless of age, gender, severity, setting, and previous treatment. We excluded studies in which individuals were diagnosed with rosacea, chloracne, acne inversa, infantile acne, occupational acne, drug‐induced acne, or acne associated with polycystic ovary syndrome. We included the study reporting the most complete data only when the same population or subsets of the same population were investigated in multiple studies. </p> </section> <section id="CD011154-sec-0064"> <h4 class="title">Types of interventions</h4> <p>We included BPO of any treatment regimen (including wash‐off and leave‐on), dose, duration, and vehicle (e.g. gel, cream, lotion), used alone or as an ingredient in any combination treatment. </p> <p>We made comparisons between BPO (used alone or in combination with other active topical treatment) versus placebo, no treatment, and other active topical pharmacological treatments (such as retinoids, antibiotics, azelaic acid, salicylic acid, etc., used alone or in combination with other topical drugs not containing BPO). We also made comparisons between different formulations and concentrations of BPO when available. We did not consider comparisons with any multi‐step regimens (usually including cleanser, toner, and moisturiser) involving multiple active ingredients with different formulations and concentrations. We also excluded comparisons between different brand products of the same formulation and concentration of BPO. We allowed other topical or oral co‐interventions if they were offered equivalently to both groups in the trial. </p> </section> <section id="CD011154-sec-0065"> <h4 class="title">Types of outcome measures</h4> <p>We considered short‐term (two to four weeks), medium‐term (five to eight weeks), and long‐term (longer than eight weeks) treatment duration for each outcome. Besides the long‐term outcomes, we were interested in shorter treatment periods given that they can indicate early improvement, which may encourage participants to continue the treatments. As the time units used in different studies may vary from day to week to month, we stipulated that four weeks is roughly equivalent to 30 days or one month when we analysed the outcome data. When there was more than one follow‐up point within the same period, we extracted and analysed the data collected at the latest time point. </p> <section id="CD011154-sec-0066"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011154-list-0001"> <li> <p>Participant global self‐assessment of acne improvement. Treatment success was defined as any greater improvement above the first category of improvement on a Likert or Likert‐like scale. For example, if there is a 5‐point Likert‐like scale ‐ much worse, worse, same, improved, much improved ‐ we counted "much improved" as treatment success. For a similar 6‐point scale, we compared everything better than "improved" versus the rest </p> </li> <li> <p>Withdrawal due to adverse events over the whole course of a trial</p> </li> </ul> </p> </section> <section id="CD011154-sec-0067"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011154-list-0002"> <li> <p>Investigator‐assessed absolute or percentage change in lesion counts (total (TL), inflamed (IL), and non‐inflamed (NIL) lesions, separately) from baseline to the last available evaluation. If the change in lesion counts with its standard deviation was not available from the publication or from liaisons with study authors, we described in the review the lesion counts at the last available evaluation </p> </li> <li> <p>Percentage of participants rated 'clear' or 'almost clear' on the Investigator Global Assessment (IGA) scale of acne severity </p> </li> <li> <p>Change in quality of life (assessed with a validated instrument such as Skindex‐16, Skindex‐29, or Cardiff Acne Disability Index) </p> </li> <li> <p>Reduction in <i>C acnes</i> strains (total and resistant) </p> </li> <li> <p>Percentage of participants experiencing any adverse events over the whole course of a trial </p> </li> </ul> </p> </section> </section> </section> <section id="CD011154-sec-0068"> <h3 class="title">Search methods for identification of studies</h3> <p>We aimed to identify all relevant RCTs regardless of language or publication status (published, unpublished, in press, or in progress). </p> <section id="CD011154-sec-0069"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Information Specialist searched the following databases up to 28 February 2019 using strategies based on the draft strategy for MEDLINE in our published protocol (<a href="./references#CD011154-bbs2-0392" title="YangZ , ZhangY , Lazic MoslerE , LiH , HuJ , ZhangY , et al. Topical benzoyl peroxide for acne. Cochrane Database of Systematic Reviews2014, Issue 6. [DOI: 10.1002/14651858.CD011154] ">Yang 2014</a>). </p> <p> <ul id="CD011154-list-0003"> <li> <p>Cochrane Skin Group Specialised Register via the search strategy in <a href="./appendices#CD011154-sec-0579">Appendix 1.</a> </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 2), in the Cochrane Library, via the strategy in <a href="./appendices#CD011154-sec-0580">Appendix 2.</a> </p> </li> <li> <p>MEDLINE via Ovid (from 1946) via the strategy in <a href="./appendices#CD011154-sec-0581">Appendix 3</a>. </p> </li> <li> <p>Embase via Ovid (from 1974) via the strategy in <a href="./appendices#CD011154-sec-0582">Appendix 4</a>. </p> </li> <li> <p>Latin American and Caribbean Health Science Information database (LILACS) (from 1982) via the strategy in <a href="./appendices#CD011154-sec-0583">Appendix 5</a>. </p> </li> </ul> </p> <section id="CD011154-sec-0070"> <h5 class="title">Trials registers</h5> <p>We (ZY) searched the following trials registers up to 28 February 2019. Search strategies for each register are presented in <a href="./appendices#CD011154-sec-0584">Appendix 6</a>. </p> <p> <ul id="CD011154-list-0004"> <li> <p>International Standard Randomized Controlled Trials Number (ISRCTN) registry (<a href="http://www.isrctn.com" target="_blank">www.isrctn.com</a>). </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>). </p> </li> <li> <p>Australian New Zealand Clinical Trials Registry (<a href="http://www.anzctr.org.au" target="_blank">www.anzctr.org.au</a>). </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>). </p> </li> <li> <p>EU Clinical Trials Register (<a href="https://www.clinicaltrialsregister.eu/" target="_blank">www.clinicaltrialsregister.eu</a>). </p> </li> </ul> </p> </section> </section> <section id="CD011154-sec-0071"> <h4 class="title">Searching other resources</h4> <section id="CD011154-sec-0072"> <h5 class="title">References from published studies</h5> <p>We checked the bibliographies of included primary studies and related systematic reviews for further references to relevant trials. </p> </section> <section id="CD011154-sec-0073"> <h5 class="title">Unpublished literature</h5> <p>We attempted to identify unpublished studies and grey literature through correspondence with study authors and pharmaceutical companies. We also requested missing data or clarification on the primary outcomes and confirmation of duplicates. </p> </section> <section id="CD011154-sec-0074"> <h5 class="title">Adverse effects</h5> <p>We did not perform a separate search for adverse effects of the target intervention. However, we critically examined data on adverse effects and the methods used to collect these from the included studies. </p> </section> </section> </section> <section id="CD011154-sec-0075"> <h3 class="title" id="CD011154-sec-0075">Data collection and analysis</h3> <p>We included 'Summary of findings' tables in our review to summarise the primary outcomes and the secondary safety outcome for the main comparisons, which included comparisons between BPO or BPO fixed combination treatments and placebo or other active treatments, and comparisons between different concentrations of BPO. </p> <section id="CD011154-sec-0076"> <h4 class="title">Selection of studies</h4> <p>Two review authors (ZY, ELM) examined the titles and abstracts of each reference retrieved through the search to determine those potentially related to our review. Based on this first assessment, we then obtained the full texts of these articles to ascertain further whether they should be included in our review. Throughout this process, we selected studies independently and resolved any disagreements by consultation with a third review author (YZ). We recorded the reasons for exclusion of each study and drew a PRISMA flow chart of study selection (<a href="./references#CD011154-bbs2-0358" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJPA , et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine2009;6(7):e1000100. [MEDLINE: 19621070] ">Liberati 2009</a>; <a href="./references#CD011154-bbs2-0359" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA Statement. PLoS Medicine2009;6(7):e1000097. [MEDLINE: 19621072] ">Moher 2009</a>). </p> </section> <section id="CD011154-sec-0077"> <h4 class="title">Data extraction and management</h4> <p>We pre‐designed a data extraction form (<a href="./appendices#CD011154-sec-0585">Appendix 7</a>). Using a piloted data extraction form, two review authors (ZY, YZ) independently extracted the data from the full text of eligible studies, with any disagreements resolved by a third review author (HL). We compiled the following information from the included studies. </p> <p> <ul id="CD011154-list-0005"> <li> <p>Publication details (e.g. year, country, authors, registration number).</p> </li> <li> <p>Study objectives.</p> </li> <li> <p>Study design.</p> </li> <li> <p>Setting, inclusion and exclusion criteria.</p> </li> <li> <p>Population characteristics (e.g. age, gender, severity of the acne).</p> </li> <li> <p>Details of the intervention (e.g. regimen, concentration, duration, co‐interventions).</p> </li> <li> <p>Outcome measures and corresponding data.</p> </li> <li> <p>Treatment duration.</p> </li> <li> <p>Type of data analyses (e.g. intention‐to‐treat (ITT)).</p> </li> </ul> </p> <p>When outcome data, for example, the change in acne lesions, were presented only in a figure in a published article, we extracted data from the figure using a Java programme called "Plot Digitizer" (<a href="./references#CD011154-bbs2-0365" title="http://plotdigitizer.sourceforge.net/. Accessed 30 June 2018. Plot Digitizer 2015. http://plotdigitizer.sourceforge.net/. Accessed 30 June 2018. ">Plot Digitizer</a>). Although most of the trial registration numbers were not published in the journal articles, we matched the articles and the numbers from trial registries by examining the similarity in population characteristics, interventions compared, and sample sizes specified in the articles and registration records. We used all the above information to populate the <a href="./references#CD011154-sec-0598" title="">Characteristics of included studies</a> table for each included study (<a href="./appendices#CD011154-sec-0585">Appendix 7</a>). </p> </section> <section id="CD011154-sec-0078"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Independently, two review authors (ZY, JH) performed assessment of risk of bias using the Cochrane tool (<a href="./references#CD011154-bbs2-0341" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). If necessary, we resolved disagreements through discussion with a third review author (YCZ). </p> <p>We assigned 'low', 'high', or 'unclear' risk of bias for each of the following 'Risk of bias' domains based on the judgement criteria (<a href="./appendices#CD011154-sec-0585">Appendix 7</a>) (<a href="./references#CD011154-bbs2-0341" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <p> <ul id="CD011154-list-0006"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other sources of bias.</p> </li> </ul> </p> </section> <section id="CD011154-sec-0079"> <h4 class="title">Measures of treatment effect</h4> <p>We expressed dichotomous outcomes as risk ratios (RRs), with 95% confidence intervals (CIs). We expressed continuous outcomes as mean differences (MDs), with 95% CIs. We presented RR or MD only for the outcomes of interest in this review. </p> </section> <section id="CD011154-sec-0080"> <h4 class="title">Unit of analysis issues</h4> <p>When we included cross‐over trials, we included only the first phase of the intervention, as we expected that interventions for acne may have a lasting effect and minimal data were available on the effectiveness of wash‐out periods for the treatment. In the case of within‐participant studies (split‐face design), in which different treatments had been allocated to different body parts, we considered the body part as a unit of analysis and described the data separately. </p> </section> <section id="CD011154-sec-0081"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the authors of the included trials to attempt to acquire the missing information (<a href="./appendices#CD011154-sec-0587">Appendix 8</a>). We conducted ITT analysis when data were available, in which case we analysed all participants in the group to which they were allocated, regardless of whether or not they received the allocated intervention. When we failed to obtain missing data for ITT analysis, we used the method of last observation carried forward for continuous data if available in the trials. For dichotomous data, we assumed that none of the missing participants experienced the outcome event. For example, when we assessed the primary outcome of participant global self‐assessment of acne improvement, those who did not provide data for this outcome would be regarded as experiencing treatment failure. </p> </section> <section id="CD011154-sec-0082"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity using the I² statistic and the thresholds provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011154-bbs2-0341" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We planned to explore potential sources of heterogeneity through pre‐specified subgroup analyses, which we had suggested under <a href="#CD011154-sec-0085">Subgroup analysis and investigation of heterogeneity</a>. </p> </section> <section id="CD011154-sec-0083"> <h4 class="title">Assessment of reporting biases</h4> <p>We generated funnel plots using the log of the effect measure for individual studies by its standard error to assess reporting bias for each primary outcome and for the secondary safety outcome if more than 10 studies were included in the meta‐analysis. Additionally, we performed Egger's test for assessment of publication bias using STATA (<a href="./references#CD011154-bbs2-0332" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315:629‐34. [MEDLINE: 9310563] ">Egger 1997</a>). Due to the limited number of included studies for most of the outcomes in all comparisons, we created a funnel plot and performed Egger's test only for the safety outcomes (long‐term data) for BPO versus placebo or no treatment and for BPO versus adapalene. </p> </section> <section id="CD011154-sec-0084"> <h4 class="title">Data synthesis</h4> <p>We expected that clinical heterogeneity would exist across included studies, mainly because of the various tools used for grading acne and the various concentrations and vehicles of benzoyl peroxide employed, which may introduce differences in treatment effects across studies. Therefore we used a random‐effects model a priori for data synthesis for all outcomes. </p> <p>For dichotomous outcomes, we pooled RRs and corresponding 95% CIs from individual studies. For continuous outcomes, we pooled MDs and corresponding 95% CIs from individual studies. When data provided in a trial were not sufficient to estimate RR or MD, we described the results only as presented by trial authors. </p> <p>We made only direct comparisons; we did not perform indirect comparisons because we expected that an assumption of consistency was invalid in the current therapeutic field of acne. We did not analyse outcomes that were not considered in our review, but we described them in a narrative way in the tables (included studies) if any were reported in an included trial report. </p> </section> <section id="CD011154-sec-0085"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform exploratory subgroup meta‐analyses (if each subgroup included at least three studies) to assess whether treatment effects were different between subgroups. Possible factors for which we planned to conduct subgroup analysis included the following. </p> <p> <ul id="CD011154-list-0007"> <li> <p>Disease factors at baseline.</p> <ul id="CD011154-list-0008"> <li> <p>Site.</p> </li> <li> <p>Severity.</p> </li> </ul> </li> <li> <p>Treatment factors.</p> <ul id="CD011154-list-0009"> <li> <p>Concentration.</p> </li> <li> <p>Vehicle.</p> </li> <li> <p>Co‐intervention.</p> </li> </ul> </li> </ul> </p> <p>However, none of the comparisons met the prerequisite (each subgroup including at least three studies) for the subgroup analysis. For post hoc analysis, we conducted subgroup analyses only to explore whether the effects of BPO would differ with different co‐interventions, regardless of the number of trials included in a specific comparison. We conducted a Q test to examine the differences between subgroups. </p> </section> <section id="CD011154-sec-0086"> <h4 class="title">Sensitivity analysis</h4> <p>If possible (i.e. if at least three studies were included in a meta‐analysis), we planned to perform exploratory sensitivity analyses to examine treatment effects by excluding studies of low methodological quality (more than three items rated as 'high risk' or 'unclear risk' based on the Cochrane tool for assessing risk of bias). As per our protocol, however, we conducted only two sensitivity analyses for the secondary safety outcome in the two main comparisons (BPO versus placebo or no treatment and BPO versus adapalene) because numbers of trials for all other outcomes were small and/or most of the included studies were rated as having low methodological quality for each comparison. </p> <p>When applicable, we also conducted a sensitivity analysis post hoc for the primary outcome 'participant‐self reported acne improvement' in the main comparisons by including all studies that reported data for this outcome when applicable, regardless of the scales and criteria used in the included studies to determine improvement. </p> <section id="CD011154-sec-0087"> <h5 class="title">Quality of the evidence</h5> <p>We used the GRADE approach to assess the quality of evidence for the following outcomes: participant global self‐assessment of acne improvement, withdrawal due to adverse events, and percentage of participants experiencing any adverse event (<a href="./references#CD011154-bbs2-0374" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editors. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group. Available from guidelinedevelopment.org/handbook (accessed 1 May 2018). ">Schünemann 2013</a>). Long‐term outcomes were of primary interest; when long‐term data for an outcome were not available, we summarised the quality of evidence for the medium term. We developed 'Summary of findings' (SoF) tables for the most important comparisons using the GRADEpro Guideline Development Tool in consideration of five aspects (<a href="./references#CD011154-bbs2-0339" title="McMaster University (developed by Evidence Prime, Inc.). GRADEpro GDT: GRADEpro Guideline Development Tool. Version 2015. McMaster University (developed by Evidence Prime, Inc.), 2015. ">GRADEpro GDT 2015</a>): study limitations, consistency, imprecision, indirectness, and publication bias. </p> <p>We deemed the following comparisons the most important:</p> <p> <ul id="CD011154-list-0010"> <li> <p>benzoyl peroxide compared to placebo or no treatment;</p> </li> <li> <p>benzoyl peroxide compared to adapalene;</p> </li> <li> <p>benzoyl peroxide compared to clindamycin;</p> </li> <li> <p>benzoyl peroxide compared to erythromycin; and</p> </li> <li> <p>benzoyl peroxide compared to salicylic acid.</p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011154-sec-0088" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011154-sec-0088"></div> <section id="CD011154-sec-0089"> <h3 class="title">Description of studies</h3> <p>We summarised trial characteristics in the <a href="./references#CD011154-sec-0598" title="">Characteristics of included studies</a> tables for eligible trials with published results; in the <a href="./references#CD011154-sec-0600" title="">Characteristics of studies awaiting classification</a> tables for trials that were completed but with no published results, or trials whose eligibility could not be confirmed based on available abstracts; in the <a href="./references#CD011154-sec-0601" title="">Characteristics of ongoing studies</a> tables for potentially eligible ongoing trials; and in the <a href="./references#CD011154-sec-0599" title="">Characteristics of excluded studies</a> tables for each trial that we excluded based on the published full text. </p> <section id="CD011154-sec-0090"> <h4 class="title">Results of the search</h4> <p>Searches of the five databases (see <a href="#CD011154-sec-0069">Electronic searches</a>) yielded 627 records. Our searches of trial registries revealed 221 further studies, of which 87 duplicates were removed. Our searches of other resources revealed three additional studies that met the inclusion criteria. We therefore had a total of 764 records. </p> <p>We excluded 381 records based on review of titles and abstracts. We obtained full texts of the remaining 383 records. We excluded 127 studies (see <a href="./references#CD011154-sec-0599" title="">Characteristics of excluded studies</a>), classified 43 studies reported in 46 records as awaiting classification (see <a href="./references#CD011154-sec-0600" title="">Characteristics of studies awaiting classification</a>), and identified 22 ongoing studies (see <a href="./references#CD011154-sec-0601" title="">Characteristics of ongoing studies</a>). </p> <p>We included 120 studies reported in 188 references. For a further description of our screening process, please see the study flow diagram (<a href="#CD011154-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD011154-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011154-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD011154-sec-0091"> <h4 class="title">Included studies</h4> <p>We included a total of 120 randomised controlled trials (188 reports), with 29,592 people randomised in 116 trials; the numbers randomised in four trials were unclear (<a href="./references#CD011154-bbs2-0012" title="ChantalatJ , StamatasG , KolliasN , LiuJC . Comparative efficacy of target acne lesion resolution using a novel 2% salicylic acid composition versus 10% benzoyl peroxide. Journal of the European Academy of Dermatology and Venereology2005;19(Suppl 2):37. [CENTRAL: CN‐00602613] ">Chantalat 2005</a>; <a href="./references#CD011154-bbs2-0019" title="DelRossoJ , KircikL . Comparison of the tolerability of benzoyl peroxide microsphere wash versus a gentle cleanser, when used in combination with a clindamycin and tretinoin gel: a multicenter, investigator‐blind, randomized study. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.100] ">Del 2009a</a>; <a href="./references#CD011154-bbs2-0069" title="LookingbillDP , ChalkerDK , LindholmJS , KatzHI , KempersSE , HuerterCJ , et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double‐blind investigations. Journal of the American Academy of Dermatology1997;37(4):590‐5. [CENTRAL: CN‐00144503; MEDLINE: 9344199] LookingbillDP , ChallenDK , LindholmJS . Treatment of acne with a combination of clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined result of two double blind investigations (Abstract no. 1). Indian Journal of Dermatology, Venerology and Leprology1995;61:398. ">Lookingbill 1997</a>; <a href="./references#CD011154-bbs2-0071" title="MakinoE , MehtaR . A nondrying acne regimen provides rapid reduction in erythema and efficacy comparable to adapalene/benzoyl peroxide 0.1%/2.5% combination. Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB4. [CENTRAL: CN‐01088986] ">Makino 2015</a>). Of these 120 included studies, 73 studies contributed to the quantitative analysis. For specific details about each study, please refer to the <a href="./references#CD011154-sec-0598" title="">Characteristics of included studies</a> tables. </p> <section id="CD011154-sec-0092"> <h5 class="title">Design</h5> <p>Of these 120 trials, one used a cross‐over design (<a href="./references#CD011154-bbs2-0093" title="ShalitaAR . Comparison of a salicylic acid cleanser and a benzoyl peroxide wash in the treatment of acne vulgaris. Clinical Therapeutics1989;11(2):264‐7. [CENTRAL: CN‐00185376; MEDLINE: 2525420] ">Shalita 1989</a>), and nine were of split‐face (within‐individual) design (<a href="./references#CD011154-bbs2-0003" title="BikowskiJ , DelRossoJ , DesaiA , BenesV . Double‐blind, randomized, split‐face comparison of skin tolerability of benzoyl peroxide 4% wash vs a nonmedicated synthetic detergent skin cleanser. Abstract P151. American Academy of Dermatology, 64th Annual Meeting, March 3‐7, 2006. Journal of the American Academy of Dermatology2006;54:AB27. [CENTRAL: CN‐00602224] ">Bikowski 2006</a>; <a href="./references#CD011154-bbs2-0026" title="DrenoB , TanJ , RivierM , MartelP , BissonnetteR . Adapalene 0.1%/benzoyl peroxide 2.5% gel reduces the risk of atrophic scar formation in moderate inflammatory acne: a split‐face randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2017;31(4):737‐42. [CENTRAL: CN‐01424729; MEDLINE: 27790756] ">Dreno 2016</a>; <a href="./references#CD011154-bbs2-0027" title="DrénoB , BissonnetteR , Gagné‐HenleyA , BarankinB , LyndeC , KerroucheN , et al. Prevention and reduction of atrophic acne scars with adapalene 0.3%/benzoyl peroxide 2.5% gel in subjects with moderate or severe facial acne: results of a 6‐month randomized, vehicle‐controlled trial using intra‐individual comparison. American Journal of Clinical Dermatology2018;19(2):275‐86. [CENTRAL: CN‐01572577] NCT02735421 . Adapalene 0.3% ‐ Benzoyl Peroxide 2.5% Gel and Risk of Formation of Atrophic Acne Scars (OSCAR). clinicaltrials.gov/ct2/show/NCT02735421 (first received 7 April 2016). ">Dréno 2018</a>; <a href="./references#CD011154-bbs2-0040" title="FyrandO , JakobsenHB . Water‐based versus alcohol‐based benzoyl peroxide preparations in the treatment of acne vulgaris. Dermatologica1986;172(5):263‐7. [CENTRAL: CN‐00044206; MEDLINE: 2943613] ">Fyrand 1986</a>; <a href="./references#CD011154-bbs2-0045" title="GoreshiR , SamraoA , EhstBD . A double‐blind, randomized, bilateral comparison of skin irritancy following application of the combination acne products clindamycin/tretinoin and benzoyl peroxide/adapalene. Journal of Drugs in Dermatology2012;11(12):1422‐6. [CENTRAL: CN‐00877482; MEDLINE: 23377511] GoreshiR , SamraoA , EhstBD . Double‐blind, randomized, bilateral comparison of skin irritancy following application of the combination acne products clindamycin/tretinoin and benzoyl peroxide/adapalene. Journal of Investigative Dermatology2012;132:S86. ">Goreshi 2012</a>; <a href="./references#CD011154-bbs2-0077" title="NCT00787943 . Study of two different 10.0% benzoyl peroxide creams for mild to moderate acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00787943 (first received 6 November 2008). ">NCT00787943</a>; <a href="./references#CD011154-bbs2-0081" title="NCT01522456 . Split‐face tolerability comparison between adapalene‐benzoyl peroxide gel versus tretinoin gel. www.clinicaltrials.gov/ct2/show/NCT01522456 (first received 23 January 2012). ">NCT01522456</a>; <a href="./references#CD011154-bbs2-0088" title="PrinceRA , HarrisJM , MarocJA . Comparative trial of benzoyl peroxide versus benzoyl peroxide with urea in inflammatory acne. Cutis; Cutaneous Medicine for the Practitioner1982;29(6):638‐40, 644‐5. [CENTRAL: CN‐00028602; MEDLINE: 6213380] ">Prince 1982</a>; <a href="./references#CD011154-bbs2-0120" title="ZhengY , YinS , XiaY , ChenJ , YeC , ZengQ , et al. Efficacy and safety of 2% supramolecular salicylic acid compared with 5% benzoyl peroxide/0.1% adapalene in the acne treatment: a randomized, split‐face, open‐label, single‐center study. Cutaneous &amp; Ocular Toxicology2019;38(1):48‐54. [CENTRAL: CN‐01741062] ">Zheng 2019</a>). The other 110 trials employed a parallel design. The included trials consisted of 78 two‐arm trials, 24 three‐arm trials, 16 four‐arm trials, one five‐arm trial, and one six‐arm trial. Treatment duration was longer than eight weeks in 80 trials and was only up to 12 weeks in 108 trials, with a median of 12 weeks (minimum 2 weeks; maximum 52 weeks). Total trial duration was equivalent to the treatment duration. </p> </section> <section id="CD011154-sec-0093"> <h5 class="title">Sample sizes</h5> <p>We noted a huge difference in the numbers of participants in the included studies, ranging from 8 to 2813. </p> </section> <section id="CD011154-sec-0094"> <h5 class="title">Participants</h5> <p>Seventy‐two trials clearly reported that included participants had mild or moderate acne, or both. Severe acne was included in 26 trials (severity was unclear in the other trials). Ninety‐one trials mentioned that both male and female participants were included, and two trials included females only; the sex ratio in the remaining studies was unclear. Among 80 trials reporting age, 71 described mean age ranging from 18 to 30 years. Most trials excluded (1) pregnant or lactating females, and (2) those using topical or oral anti‐acne medication within a certain period before randomisation. Of 16 trials reporting duration of acne, 12 specified mean duration between 2.1 and 6.8 years, and the other four reported the ranges of individuals' duration (more than 6 months, 1 month to 7 years, 2 months to 17 years, and 5 to 6 years, respectively). </p> </section> <section id="CD011154-sec-0095"> <h5 class="title">Interventions</h5> <p>BPO‐related topical treatments assessed in comparisons included the following.</p> <p> <ul id="CD011154-list-0011"> <li> <p>BPO used as monotherapy or as add‐on treatment (21 comparisons).</p> </li> <li> <p>BPO fixed combination treatment used as monotherapy or as add‐on treatment (19 comparisons).</p> </li> <li> <p>Different BPO concentrations (five comparisons).</p> </li> <li> <p>Different BPO vehicles (four comparisons).</p> </li> </ul> </p> <p>Our included studies evaluated many different comparators. The most common comparators were different concentrations or formulations of BPO or placebo/no treatment. Antibiotics alone or in combination with other active treatment, topical retinoids, acids, and herbal medicines were comparators in our included studies, as were other miscellaneous topical treatments assessed in a few included trials, such as sulphur, chloroxylenol/salicylic acid, and viaminate. </p> <p>Concentrations of BPO in included products ranged from 2.5% to 20%, with 2.5% and 5% being the most common concentrations, as assessed in 27 and 66 trials, respectively. Gel was the most common formulation and was used in 92 trials. Only six trials assessed wash‐off BPO medications. Investigational BPO products were reported to be used once or twice daily, in 64 and 45 trials, respectively. BPO/adapalene, BPO/clindamycin, and BPO/erythromycin were the most common fixed combination treatments assessed in included trials. We summarised all comparisons under <a href="#CD011154-sec-0122">Effects of interventions</a>. </p> </section> <section id="CD011154-sec-0096"> <h5 class="title">Co‐interventions</h5> <p>A total of 33 trials reported that co‐interventions were used across all the groups. Among these trials, 18 trials only used non‐medicated co‐interventions, which could include mild soap/cleanser or moisturiser or sunscreen or both. Active anti‐acne treatments were given as co‐interventions in 15 trials. These co‐interventions included topical treatments (adapalene, clindamycin, tretinoin, tazarotene, dapsone, and nadifloxacin) and oral treatments (doxycycline and lymecycline). In six of these 15 trials, participants additionally received non‐medicated co‐interventions. </p> </section> <section id="CD011154-sec-0097"> <h5 class="title">Outcomes</h5> <p>Of the 120 included trials, 113 reported at least one outcome of interest in this review. </p> <section id="CD011154-sec-0098"> <h6 class="title">Primary outcomes</h6> <section id="CD011154-sec-0099"> <p><b>Participant global self‐assessment of acne improvement</b></p> <p>A total of 39 trials addressed this outcome. Of these, 33 used Likert or Likert‐like scales, with categories/points ranging from 3 to 7. One trial used a 100‐mm visual analog scale (<a href="./references#CD011154-bbs2-0075" title="MiyachiY , MizziF , MitaT , BaiL , IkomaA . Efficacy and safety of a fixed dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% in Japanese patients with acne vulgaris ‐ a multicenter, randomized, double‐blinded, active‐controlled, parallel group phase III study. [Japanese]. Skin Research2016;15(4):278‐93. NCT02073448 . Efficacy and safety study of GK530G versus CD0271 0.1% gel and CD1579 2.5% gel in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02073448 (first received 20 February 2014). ">Miyachi 2016</a>). In the other five studies, it was unclear which method was used (<a href="./references#CD011154-bbs2-0013" title="ChantalatJ , LiuJC . Six‐week safety and efficacy evaluation of a synergistic microgel complex versus 10% benzoyl peroxide in the treatment of mild to moderate acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB14. [CENTRAL: CN‐00602658] ChantalatJ , LuedtkeK , WiegandB , LiuJC . Significant improvement in acne quality of life by a topical treatment containing a synergistic microgel complex and 2% salicylic acid. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN‐00602548] ChantalatJ , StamatasG , LiuJ C , ChenT . Treating emerging acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN‐00602574] ">Chantalat 2006</a>; <a href="./references#CD011154-bbs2-0017" title="CunliffeW . A comparison of the clinical and antimicrobial efficacy of clinoxin AQ gel (1 % w/v clindamycin/5% w/v benzoyl peroxide) and 1% (w/v) clindamycin gel in the treatment of acne. British Journal of Dermatology2000;143(Suppl 57):72. [CENTRAL: CN‐00547635] CunliffeWJ , HollandKT , BojarR , LevySF . A randomized, double‐blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clinical Therapeutics2002;24(7):1117‐33. [CENTRAL: CN‐00404978; MEDLINE: 12182256] ">Cunliffe 2002</a>; <a href="./references#CD011154-bbs2-0071" title="MakinoE , MehtaR . A nondrying acne regimen provides rapid reduction in erythema and efficacy comparable to adapalene/benzoyl peroxide 0.1%/2.5% combination. Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB4. [CENTRAL: CN‐01088986] ">Makino 2015</a>; <a href="./references#CD011154-bbs2-0111" title="TungR , BerardescaE , Dall'OglioF , MicaliG , SinagraJ , NodzenskiM , et al. Novel over‐the‐counter hydrogen peroxide based acne kit in treating acne: randomized, controlled, multicenter study of a hydrogen peroxide‐based acne system versus the benzoyl peroxide‐based acne system in the treatment of mild to moderate acne vulgaris. P8511. Journal of the American Academy of Dermatology2014;70(5 Suppl 1):AB9. [www.jaad.org/article/S0190‐9622(14)00039‐5/pdf] ">Tung 2014</a>; <a href="./references#CD011154-bbs2-0118" title="ZengX , LiuW L , ZhaoT . Effects of Chinese medical facial mask comprehensive therapy in treating acne vulgaris. Zhongguo Zhong Xi Yi Jie He za Zhi [Chinese Journal of Integrated Traditional and Western Medicine]2012;32(5):624‐7. [CENTRAL: CN‐00961274; MEDLINE: 22679722] ">Zeng 2012</a>). This outcome was assessed at the end of treatment duration in all of these trials (ranging from 4 weeks to 16 weeks), with repeat measurements conducted in four trials (<a href="./references#CD011154-bbs2-0048" title="2017‐001575‐23 . Clinical evaluation of efficacy at 2 weeks of Duac fixed dose combination gel in treatment of facial acne vulgaris in Japanese subjects. www.clinicaltrialsregister.eu/ctr‐search/trial/2017‐001575‐23/results (first received 21 September 2017). HayashiN , KurokawaI , SiakpereO , EndoA , HatanakaT , YamadaM , et al. Clindamycin phosphate 1.2%/benzoyl peroxide 3% fixed‐dose combination gel versus topical combination therapy of adapalene 0.1% gel and clindamycin phosphate 1.2% gel in the treatment of acne vulgaris in Japanese patients: a multicenter, randomized, investigator‐blind, parallel‐group study. Journal of Dermatology2018;45(8):951‐62. [CENTRAL: CN‐01629242] NCT02557399 . DUAC® early onset efficacy study in Japanese subjects. clinicaltrials.gov/ct2/show/NCT02557399 (first received 23 September 2015). ">Hayashi 2018</a>; <a href="./references#CD011154-bbs2-0064" title="LangnerA , Sheehan‐DareR , LaytonA . A randomized, single‐blind comparison of topical clindamycin + benzoyl peroxide (Duac) and erythromycin + zinc acetate (Zineryt) in the treatment of mild to moderate facial acne vulgaris. Journal of the European Academy of Dermatology &amp; Venereology2007;21(3):311‐9. [CENTRAL: CN‐00586947; MEDLINE: 17309451] ">Langner 2007</a>; <a href="./references#CD011154-bbs2-0087" title="AlexisAF , Cook‐BoldenF , LinT , BulleyB . Treatment of moderate‐to‐severe acne vulgaris in a Hispanic population: a post‐hoc analysis of the efficacy and tolerability of clindamycin 1.2%/benzoyl peroxide 3.75% gel. Journal of Clinical and Aesthetic Dermatology2017;10(6):36‐43. [CENTRAL: CN‐01471496; MEDLINE: 28979655] Cook‐BoldenFE . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate or severe adolescent acne vulgaris. Journal of Clinical &amp; Aesthetic Dermatology2015;8(5):28‐32. [CENTRAL: CN‐01074689; MEDLINE: 26029332] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015; Vol. 8, issue 12:22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] HarperJC . The efficacy and tolerability of a fixed combination clindamycin (1.2%) and benzoyl peroxide (3.75%) aqueous gel in patients with facial acne vulgaris: gender as a clinically relevant outcome variable. Journal of Drugs in Dermatology2015;14(4):381‐4. [CENTRAL: CN‐01070825; MEDLINE: 25844612] PariserDM , RichP , Cook‐BoldenFE , KorotzerA . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once daily treatment of moderate‐to‐severe acne vulgaris: assessment of safety in 498 patients. Journal of Clinical and Aesthetic Dermatology2015;8(5 Suppl 1):S6. PariserDM , RichP , Cook‐BoldenFE , KorotzerA . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once‐daily treatment of moderate to severe acne vulgaris. Journal of Drugs in Dermatology2014;13(9):1083‐9. [CENTRAL: CN‐01113744; MEDLINE: 25226009] Stein GoldL . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate and severe acne vulgaris subpopulations. Journal of Drugs in Dermatology2015; Vol. 14, issue 9:969‐74. [CENTRAL: CN‐01165932; MEDLINE: 26355615] ">Pariser 2014</a>; <a href="./references#CD011154-bbs2-0089" title="2013‐004158‐81 . A multi‐centre, single‐blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1%/benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2013‐004158‐81/results (results published 15 March 2016). NCT02058628 . Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02058628 (first received 6 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single‐blind, parallel‐group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild‐to‐moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016; Vol. 30, issue 6:966‐73. [CENTRAL: CN‐01369030; MEDLINE: 26915831] ">Schaller 2016</a>). All four trials evaluated this outcome at weeks 2, 4, 8, and 12, and two trials additionally measured the outcome after the first week of treatment (<a href="./references#CD011154-bbs2-0048" title="2017‐001575‐23 . Clinical evaluation of efficacy at 2 weeks of Duac fixed dose combination gel in treatment of facial acne vulgaris in Japanese subjects. www.clinicaltrialsregister.eu/ctr‐search/trial/2017‐001575‐23/results (first received 21 September 2017). HayashiN , KurokawaI , SiakpereO , EndoA , HatanakaT , YamadaM , et al. Clindamycin phosphate 1.2%/benzoyl peroxide 3% fixed‐dose combination gel versus topical combination therapy of adapalene 0.1% gel and clindamycin phosphate 1.2% gel in the treatment of acne vulgaris in Japanese patients: a multicenter, randomized, investigator‐blind, parallel‐group study. Journal of Dermatology2018;45(8):951‐62. [CENTRAL: CN‐01629242] NCT02557399 . DUAC® early onset efficacy study in Japanese subjects. clinicaltrials.gov/ct2/show/NCT02557399 (first received 23 September 2015). ">Hayashi 2018</a>; <a href="./references#CD011154-bbs2-0064" title="LangnerA , Sheehan‐DareR , LaytonA . A randomized, single‐blind comparison of topical clindamycin + benzoyl peroxide (Duac) and erythromycin + zinc acetate (Zineryt) in the treatment of mild to moderate facial acne vulgaris. Journal of the European Academy of Dermatology &amp; Venereology2007;21(3):311‐9. [CENTRAL: CN‐00586947; MEDLINE: 17309451] ">Langner 2007</a>). </p> </section> <section id="CD011154-sec-0100"> <p><b>Withdrawal due to adverse events</b></p> <p>A total of 68 trials reported how many participants withdrew due to adverse events. This outcome was monitored throughout the whole course of the trials. </p> </section> </section> <section id="CD011154-sec-0101"> <h6 class="title">Secondary outcomes</h6> <section id="CD011154-sec-0102"> <p><b>Investigator‐assessed absolute or percentage change in lesion counts</b></p> <p>A majority of trials (97/120) provided the number of absolute or percentage change in lesion counts for at least one lesion type. All of these trials evaluated the change from baseline at the end of treatment duration (ranging from 3 weeks to 52 weeks), among which 91 trials repeatedly measured the outcome, with the intervals between two measurements ranging from one to four weeks. It was unclear whether repeated measurements were conducted in the other six studies, in which only the last measurement was reported (<a href="./references#CD011154-bbs2-0078" title="NCT01044264 . Clinical study between two 1% clindamycin/5% benzoyl peroxide topical gel formulations. https://clinicaltrials.gov/ct2/show/NCT01044264 (first received 4 January 2010). ">NCT01044264</a>; <a href="./references#CD011154-bbs2-0079" title="NCT01138514 . Clinical study between two clindamycin 1%/benzoyl peroxide 5% topical gels. clinicaltrials.gov/ct2/show/NCT01138514 (first received 4 June 2010). ">NCT01138514</a>; <a href="./references#CD011154-bbs2-0080" title="NCT01231334 . A study comparing Aczone® plus Differin® versus Duac® plus Differin® in patients with severe facial acne. clinicaltrials.gov/ct2/show/NCT01231334 (first received 28 October 2010). ">NCT01231334</a>; <a href="./references#CD011154-bbs2-0082" title="NCT02073461 . Efficacy and safety study of 2 different concentrations of CD1579 gels versus vehicle in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02073461 (first received 20 February 2014). ">NCT02073461</a>; <a href="./references#CD011154-bbs2-0083" title="NCT02465632 . To study generic clindamycin 1%/benzoyl peroxide 5% topical gel (Glenmark Generics, Ltd) in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02465632 (first received 4 June 2015). ">NCT02465632</a>; <a href="./references#CD011154-bbs2-0100" title="FDA , Center for Drug Evaluation and Research. Study 152. Medical Review of NDA 50‐741. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50‐741_duac%20topical%20gel_medr_p1.pdf. ">Study 152</a>). </p> </section> <section id="CD011154-sec-0103"> <p><b>Percentage of participants rated 'clear' or 'almost clear' on the Investigator Global Assessment (IGA) scale of acne severity</b></p> <p>A total of 25 trials assessed this outcome. The outcome was assessed at the end of treatment duration in all of the trials (ranging from 6 weeks to 24 weeks). Of 22 trials reporting repeat measurements of this outcome, 15 trials provided results for each measurement (<a href="./references#CD011154-bbs2-0025" title="DrenoB , KaufmannR , TalaricoS , Torres LozadaV , Rodriguez‐CastellanosMA , Gomez‐FloresM , et al. Combination therapy with adapalene‐benzoyl peroxide and oral lymecycline in the treatment of moderate to severe acne vulgaris: a multicentre, randomized, double‐blind controlled study. British Journal of Dermatology2011;165(2):383‐90. [CENTRAL: CN‐00800637; MEDLINE: 21495995] NCT01014689 . Efficacy and safety comparison of Epiduo gel associated with lymecycline 300 mg capsules versus Epiduo vehicle gel associated with lymecycline 300 mg capsules in the treatment of moderate to severe acne vulgaris (TEAM). clinicaltrials.gov/ct2/show/NCT01014689 (first received 17 November 2009). ">Dreno 2011</a>; <a href="./references#CD011154-bbs2-0027" title="DrénoB , BissonnetteR , Gagné‐HenleyA , BarankinB , LyndeC , KerroucheN , et al. Prevention and reduction of atrophic acne scars with adapalene 0.3%/benzoyl peroxide 2.5% gel in subjects with moderate or severe facial acne: results of a 6‐month randomized, vehicle‐controlled trial using intra‐individual comparison. American Journal of Clinical Dermatology2018;19(2):275‐86. [CENTRAL: CN‐01572577] NCT02735421 . Adapalene 0.3% ‐ Benzoyl Peroxide 2.5% Gel and Risk of Formation of Atrophic Acne Scars (OSCAR). clinicaltrials.gov/ct2/show/NCT02735421 (first received 7 April 2016). ">Dréno 2018</a>; <a href="./references#CD011154-bbs2-0035" title="EichenfieldL , HebertAA , LuckyAW , RudisillD , SugarmanJ , GoldLS , et al. Treatment of acne in children aged 9 to 11 with a fixed dose combination of adapalene‐benzoyl peroxide gel. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB19. [CENTRAL: CN‐01028500] EichenfieldLF , DraelosZ , LuckyAW , HebertAA , SugarmanJ , GoldLS , et al. Preadolescent moderate acne vulgaris: a randomized trial of the efficacy and safety of topical adapalene‐benzoyl peroxides. Journal of Drugs in Dermatology2013;12(6):611‐8. [CENTRAL: CN‐00914308; MEDLINE: 23839175] EichenfieldLF , DraelosZ , LuckyAW , HerbertAA , SugarmanJ , GoldS , et al. Treatment of acne in children 9‐11 with a fixed dose combination. Pediatric Dermatology2013;30(5):647. [CENTRAL: CN‐01025039] NCT01138735 . A multi‐center, randomized, vehicle‐controlled, double‐blind study to evaluate the safety and efficacy of Epiduo® (adapalene and benzoyl peroxide) gel 0.1%/2.5% administered once daily for the treatment of subjects 9 to 11 years of age with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT01138735 (first received 4 June 2010). ">Eichenfield 2013</a>; <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>; <a href="./references#CD011154-bbs2-0042" title="BrodellRT , SchlosserBJ , RafalE , TothD , TyringS , WertheimerA , et al. A fixed‐dose combination of adapalene 0.1%/BPO 2.5% allows an early and sustained improvement in quality of life and patient treatment satisfaction in severe acne. Journal of Dermatological Treatment2012;23(1):26‐34. [CENTRAL: CN‐00860557; MEDLINE: 22103674] BrodellRT , WertheimerA , TothD , BucherD , RafalE , KerroucheN , et al. Patient satisfaction with a fixed dose combination of adapalene‐benzoyl peroxide gel as part of a regimen and used alone as maintenance therapy. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB17. [CENTRAL: CN‐01028502] BrodellRT , WertheimerA , TothD , BucherD , RafalE , KerroucheN , et al. Treatment with adapalene‐benzoyl peroxide improves quality of life in patients with severe acne vulgaris. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB19. [CENTRAL: CN‐01028499] GoldLS , CruzA , EichenfieldL , TanJ , JorizzoJ , KerroucheN , et al. Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle‐controlled, double‐blind study of adapalene 0.1%‐benzoyl peroxide 2.5% fixed‐dose combination gel with doxycycline hyclate 100 mg. Cutis; Cutaneous Medicine for the Practitioner2010;85(2):94‐104. [CENTRAL: CN‐00743300; MEDLINE: 20349684] GoldLS , DhuinJC , TanJ , JorizzoJ . Adapalene 0.1%/benzoyl peroxide 2.5% gel with doxycycline hyclate 100 mg tablets compared to vehicle gel with doxycycline hyclate 100 mg tablets in the treatment of severe acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB13. [CENTRAL: CN‐00843733] JarrattM , BuckoAD , ZugajD , DhuinJC . Treatment with adapalene 0.1%‐BPO 2.5% and doxycycline 100 mg/day resulted in rapid and sustained decrease in Propionibacterium acnes (Poster P102). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB1. [CENTRAL: CN‐00843734] NCT00688064 . Adapalene‐BPO gel associated with doxycycline hyclate 100 mg in the treatment of severe acne vulgaris (ACCESS I). www.clinicaltrials.gov/ct2/show/NCT00688064 (first received 28 May 2008). TanJ , GoldLS , SchlessingerJ , BrodellR , JonesT , CruzA , et al. Short‐term combination therapy and long‐term relapse prevention in the treatment of severe acne vulgaris. Journal of Drugs in Dermatology2012;11(2):174‐80. [CENTRAL: CN‐00860272; MEDLINE: 22270198] TanJ , GoldLS , SchlessingerJ , BrodellR , JonesT , DhuinJC , et al. Combination of adapalene‐benzoyl peroxide and oral doxycycline is efficacious in short‐term therapy: maintenance with adapalene‐benzoyl peroxide prevents relapse in treatment of severe acne vulgaris. Pediatric Dermatology2012;29(5):688. TanJ , SchlessingerJ , GoldLS , BrodellR . Combination of adapalene‐benzoyl peroxide and oral doxycycline is efficacious in short‐term therapy: maintenance with adapalene‐benzoyl peroxide prevents relapse in treatment of severe acne vulgaris. Journal of the American Academy of Dermatology2012;66(4):AB15. [DOI: 10.1016/j.jaad.2011.11.072] ">Gold 2010</a>; <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>; <a href="./references#CD011154-bbs2-0048" title="2017‐001575‐23 . Clinical evaluation of efficacy at 2 weeks of Duac fixed dose combination gel in treatment of facial acne vulgaris in Japanese subjects. www.clinicaltrialsregister.eu/ctr‐search/trial/2017‐001575‐23/results (first received 21 September 2017). HayashiN , KurokawaI , SiakpereO , EndoA , HatanakaT , YamadaM , et al. Clindamycin phosphate 1.2%/benzoyl peroxide 3% fixed‐dose combination gel versus topical combination therapy of adapalene 0.1% gel and clindamycin phosphate 1.2% gel in the treatment of acne vulgaris in Japanese patients: a multicenter, randomized, investigator‐blind, parallel‐group study. Journal of Dermatology2018;45(8):951‐62. [CENTRAL: CN‐01629242] NCT02557399 . DUAC® early onset efficacy study in Japanese subjects. clinicaltrials.gov/ct2/show/NCT02557399 (first received 23 September 2015). ">Hayashi 2018</a>; <a href="./references#CD011154-bbs2-0053" title="JawadeSA , SaigaonkarVA , KondalkarAR . Efficacy and tolerability of adapalene 0.1%‐benzoyl peroxide 2.5% combination gel in treatment of acne vulgaris in Indian patients: a randomized investigator‐blind controlled trial. Iranian Journal of Dermatology2016;19(4):105‐12. [CENTRAL: CN‐01405922] ">Jawade 2016</a>; <a href="./references#CD011154-bbs2-0057" title="KaurJ , SehgalVK , GuptaAK , SinghSP . A comparative study to evaluate the efficacy and safety of combination topical preparations in acne vulgaris. International Journal of Applied &amp; Basic Medical Research2015;5(2):106‐10. [MEDLINE: 26097817] ">Kaur 2015</a>; <a href="./references#CD011154-bbs2-0058" title="KawashimaM , HashimotoH , Alio SaenzAB , OnoM , YamadaM . Is benzoyl peroxide 3% topical gel effective and safe in the treatment of acne vulgaris in Japanese patients? A multicenter, randomized, double‐blind, vehicle‐controlled, parallel‐group study. Journal of Dermatology2014;41(9):795‐801. [CENTRAL: CN‐01254201; MEDLINE: 25132461] NCT01400932 . Study STF115288, a clinical confirmation study of GI148512 in the treatment of acne vulgaris in Japanese subjects. www.clinicaltrials.gov/ct2/show/NCT01400932 (first received 21 July 2011). ">Kawashima 2014</a>; <a href="./references#CD011154-bbs2-0059" title="KawashimaM , HashimotoH , Alio SaenzAB , OnoM , YamadaM . Clindamycin phosphate 12%‐benzoyl peroxide 30% fixed‐dose combination gel has an effective and acceptable safety and tolerability profile for the treatment of acne vulgaris in Japanese patients: a phase III, multicentre, randomised, single‐blinded, active‐controlled, parallel‐group study. British Journal of Dermatology2015;172(2):494‐503. [CENTRAL: CN‐01115087] KawashimaM , YamadaM , ParishC . Clindamycin 1%/benzoyl peroxide 3% gel, a new topical combination product, is effective in Japanese patients with acne vulgaris. Journal of Investigative Dermatology2013;133:S160. [CENTRAL: CN‐01026775] ">Kawashima 2015</a>; <a href="./references#CD011154-bbs2-0091" title="ShafiqY , NaqviBS , RizwaniGH , UsmanM , ShahBA , AslamM , et al. Anti‐acne activity of Casuarina equisetifolia bark extract: a randomized clinical trial. Bangladesh Journal of Pharmacology2014;9(3):337‐41. [CENTRAL: CN‐00998392] ">Shafiq 2014</a>; <a href="./references#CD011154-bbs2-0105" title="ThiboutotD , JarrattM , RichP , RistT , RodriguezD , LevyS . A randomized, parallel, vehicle‐controlled comparison of two erythromycin/benzoyl peroxide preparations for acne vulgaris. Clinical Therapeutics2002;24(5):773‐85. [CENTRAL: CN‐00396107; MEDLINE: 12075945] ">Thiboutot 2002</a>; <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>; <a href="./references#CD011154-bbs2-0117" title="ZeichnerJA , WongV , LinknerRV , HaddicanM . Efficacy and safety of tretinoin 0.025%/clindamycin phosphate 1.2% gel in combination with benzoyl peroxide 6% cleansing cloths for the treatment of facial acne vulgaris. Journal of Drugs in Dermatology2013;12(3):277‐82. [CENTRAL: CN‐00876866; MEDLINE: 23545909] ">Zeichner 2013</a>), and the other seven only presented the results for the last measurement (<a href="./references#CD011154-bbs2-0007" title="BowmanS , GoldM , NasirA , VamvakiasG . Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and the combination of clindamycin/benzoyl peroxide and tretinoin plus clindamycin in the treatment of acne vulgaris: a randomized, blinded study. Journal of Drugs in Dermatology2005;4(5):611‐8. [CENTRAL: CN‐00530277; MEDLINE: 16167420] BowmanS , GoldMH , NasirA , VamvakiasG . Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and a combination of both regimens in the treatment of acne vulgaris: a randomized, blinded study. Abstract P147. American Academy of Dermatology, 64th Annual Meeting, March 3‐7, 2006. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB25. [CENTRAL: CN‐00602651] ">Bowman 2005</a>; <a href="./references#CD011154-bbs2-0038" title="FleischerAB , DraelosZD , AbramovitsW , PariserDM . Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4%, or vehicle gel for the treatment of acne vulgaris: a randomized, double‐blind study. Abstract P113. American Academy of Dermatology, 65th Annual Meeting, February 2‐6, 2007. Journal of the American Academy of Dermatology2007;56(2):AB16. [CENTRAL: CN‐00616000] FleischerAB , ShalitaA , EichenfieldLF , AbramovitsW , LuckyA , GarrettSCP . Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: a 12‐week, randomized, double‐blind study. Journal of Drugs in Dermatology2010;9(1):33‐40. [CENTRAL: CN‐00734828; MEDLINE: 20120423] NCT00151541 . A phase 3 study to compare the safety and efficacy of 5% dapsone topical gel (DTG) twice daily in combination with once daily vehicle control, adapalene gel 0.1% or benzoyl peroxide gel 4%. www.clinicaltrials.gov/ct2/show/NCT00151541 (first received 7 September 2005). ">Fleischer 2010</a>; <a href="./references#CD011154-bbs2-0051" title="JacksonJM , FuJJ , AlmekinderJL . A randomized, investigator‐blinded trial to assess the antimicrobial efficacy of a benzoyl peroxide 5%/clindamycin phosphate 1% gel compared with a clindamycin phosphate 1.2%/tretinoin 0.025% gel in the topical treatment of acne vulgaris. Journal of Drugs in Dermatology2010;9(2):131‐6. [CENTRAL: CN‐00743909; MEDLINE: 20214175] NCT00841776 . Comparative antimicrobial efficacy of two topical acne therapies for the treatment of facial acne. www.clinicaltrials.gov/ct2/show/NCT00841776 (first received 10 February 2009). ">Jackson 2010</a>; <a href="./references#CD011154-bbs2-0055" title="JonesT , MarkL , MonroeE , WeissJ , LevyS . A multicentre, double‐blind, parallel‐group study to evaluate 3% erythromycin/5% benzoyl peroxide dual‐pouch pack for acne vulgaris. Clinical Drug Investigation2002;22(7):455‐62. [CENTRAL: CN‐00405023] ">Jones 2002</a>; <a href="./references#CD011154-bbs2-0076" title="2015‐004900‐44 . A multi‐center randomized double blind vehicle‐controlled, phase 2 study of the safety and efficacy of benzoyl peroxide/clindamycin gel and tazarotene cream when used in combination in the treatment of acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2015‐004900‐44/results (results published 23 March 2017). NCT00713609 . Safety and efficacy study of clindamycin/benzoyl peroxide/tazarotene cream in subjects with acne. clinicaltrials.gov/ct2/show/NCT00713609 (first received 7 July 2008). ">NCT00713609</a>; <a href="./references#CD011154-bbs2-0087" title="AlexisAF , Cook‐BoldenF , LinT , BulleyB . Treatment of moderate‐to‐severe acne vulgaris in a Hispanic population: a post‐hoc analysis of the efficacy and tolerability of clindamycin 1.2%/benzoyl peroxide 3.75% gel. Journal of Clinical and Aesthetic Dermatology2017;10(6):36‐43. [CENTRAL: CN‐01471496; MEDLINE: 28979655] Cook‐BoldenFE . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate or severe adolescent acne vulgaris. Journal of Clinical &amp; Aesthetic Dermatology2015;8(5):28‐32. [CENTRAL: CN‐01074689; MEDLINE: 26029332] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015; Vol. 8, issue 12:22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] HarperJC . The efficacy and tolerability of a fixed combination clindamycin (1.2%) and benzoyl peroxide (3.75%) aqueous gel in patients with facial acne vulgaris: gender as a clinically relevant outcome variable. Journal of Drugs in Dermatology2015;14(4):381‐4. [CENTRAL: CN‐01070825; MEDLINE: 25844612] PariserDM , RichP , Cook‐BoldenFE , KorotzerA . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once daily treatment of moderate‐to‐severe acne vulgaris: assessment of safety in 498 patients. Journal of Clinical and Aesthetic Dermatology2015;8(5 Suppl 1):S6. PariserDM , RichP , Cook‐BoldenFE , KorotzerA . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once‐daily treatment of moderate to severe acne vulgaris. Journal of Drugs in Dermatology2014;13(9):1083‐9. [CENTRAL: CN‐01113744; MEDLINE: 25226009] Stein GoldL . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate and severe acne vulgaris subpopulations. Journal of Drugs in Dermatology2015; Vol. 14, issue 9:969‐74. [CENTRAL: CN‐01165932; MEDLINE: 26355615] ">Pariser 2014</a>; <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>). </p> </section> <section id="CD011154-sec-0104"> <p><b>Change in quality of life</b></p> <p>Only eight trials reported this outcome. Instruments used in these trials varied but included the following: Skindex‐29 (<a href="./references#CD011154-bbs2-0020" title="DhawanSS , GwazdauskasJ . Clindamycin phosphate 1.2%‐benzoyl peroxide (5% or 2.5%) plus tazarotene cream 0.1% for the treatment of acne. Cutis; Cutaneous Medicine for the Practitioner2013;91(2):99‐104. [CENTRAL: CN‐00869753; MEDLINE: 23513559] NCT01016977 . A phase 4, single‐blind, randomized study to compare the tolerability and efficacy of Tazorac cream when used in combination with either Duac gel or Acanya gel for the treatment of facial acne vulgaris. clinicaltrials.gov/ct2/show/NCT01016977 (first received 20 November 2009). ">Dhawan 2013</a>; <a href="./references#CD011154-bbs2-0046" title="Guerra‐TapiaA . Effects of benzoyl peroxide 5% clindamycin combination gel versus adapalene 0.1% on quality of life in patients with mild to moderate acne vulgaris: a randomized single‐blind study. Journal of Drugs in Dermatology2012;11(6):714‐22. [CENTRAL: CN‐00859793; MEDLINE: 22648218] NCT00807014 . Evaluation of quality of life, efficacy, and tolerance of Duac® gel compared to Differin® gel in the treatment of acne. www.clinicaltrials.gov/ct2/show/NCT00807014 (first received 10 December 2008). ">Guerra‐Tapia 2012</a>), Skindex‐16 (<a href="./references#CD011154-bbs2-0048" title="2017‐001575‐23 . Clinical evaluation of efficacy at 2 weeks of Duac fixed dose combination gel in treatment of facial acne vulgaris in Japanese subjects. www.clinicaltrialsregister.eu/ctr‐search/trial/2017‐001575‐23/results (first received 21 September 2017). HayashiN , KurokawaI , SiakpereO , EndoA , HatanakaT , YamadaM , et al. Clindamycin phosphate 1.2%/benzoyl peroxide 3% fixed‐dose combination gel versus topical combination therapy of adapalene 0.1% gel and clindamycin phosphate 1.2% gel in the treatment of acne vulgaris in Japanese patients: a multicenter, randomized, investigator‐blind, parallel‐group study. Journal of Dermatology2018;45(8):951‐62. [CENTRAL: CN‐01629242] NCT02557399 . DUAC® early onset efficacy study in Japanese subjects. clinicaltrials.gov/ct2/show/NCT02557399 (first received 23 September 2015). ">Hayashi 2018</a>), Children's Dermatology Life Quality Index (<a href="./references#CD011154-bbs2-0035" title="EichenfieldL , HebertAA , LuckyAW , RudisillD , SugarmanJ , GoldLS , et al. Treatment of acne in children aged 9 to 11 with a fixed dose combination of adapalene‐benzoyl peroxide gel. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB19. [CENTRAL: CN‐01028500] EichenfieldLF , DraelosZ , LuckyAW , HebertAA , SugarmanJ , GoldLS , et al. Preadolescent moderate acne vulgaris: a randomized trial of the efficacy and safety of topical adapalene‐benzoyl peroxides. Journal of Drugs in Dermatology2013;12(6):611‐8. [CENTRAL: CN‐00914308; MEDLINE: 23839175] EichenfieldLF , DraelosZ , LuckyAW , HerbertAA , SugarmanJ , GoldS , et al. Treatment of acne in children 9‐11 with a fixed dose combination. Pediatric Dermatology2013;30(5):647. [CENTRAL: CN‐01025039] NCT01138735 . A multi‐center, randomized, vehicle‐controlled, double‐blind study to evaluate the safety and efficacy of Epiduo® (adapalene and benzoyl peroxide) gel 0.1%/2.5% administered once daily for the treatment of subjects 9 to 11 years of age with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT01138735 (first received 4 June 2010). ">Eichenfield 2013</a>; <a href="./references#CD011154-bbs2-0089" title="2013‐004158‐81 . A multi‐centre, single‐blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1%/benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2013‐004158‐81/results (results published 15 March 2016). NCT02058628 . Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02058628 (first received 6 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single‐blind, parallel‐group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild‐to‐moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016; Vol. 30, issue 6:966‐73. [CENTRAL: CN‐01369030; MEDLINE: 26915831] ">Schaller 2016</a>), acne‐specific quality of life (<a href="./references#CD011154-bbs2-0013" title="ChantalatJ , LiuJC . Six‐week safety and efficacy evaluation of a synergistic microgel complex versus 10% benzoyl peroxide in the treatment of mild to moderate acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB14. [CENTRAL: CN‐00602658] ChantalatJ , LuedtkeK , WiegandB , LiuJC . Significant improvement in acne quality of life by a topical treatment containing a synergistic microgel complex and 2% salicylic acid. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN‐00602548] ChantalatJ , StamatasG , LiuJ C , ChenT . Treating emerging acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN‐00602574] ">Chantalat 2006</a>; <a href="./references#CD011154-bbs2-0087" title="AlexisAF , Cook‐BoldenF , LinT , BulleyB . Treatment of moderate‐to‐severe acne vulgaris in a Hispanic population: a post‐hoc analysis of the efficacy and tolerability of clindamycin 1.2%/benzoyl peroxide 3.75% gel. Journal of Clinical and Aesthetic Dermatology2017;10(6):36‐43. [CENTRAL: CN‐01471496; MEDLINE: 28979655] Cook‐BoldenFE . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate or severe adolescent acne vulgaris. Journal of Clinical &amp; Aesthetic Dermatology2015;8(5):28‐32. [CENTRAL: CN‐01074689; MEDLINE: 26029332] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015; Vol. 8, issue 12:22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] HarperJC . The efficacy and tolerability of a fixed combination clindamycin (1.2%) and benzoyl peroxide (3.75%) aqueous gel in patients with facial acne vulgaris: gender as a clinically relevant outcome variable. Journal of Drugs in Dermatology2015;14(4):381‐4. [CENTRAL: CN‐01070825; MEDLINE: 25844612] PariserDM , RichP , Cook‐BoldenFE , KorotzerA . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once daily treatment of moderate‐to‐severe acne vulgaris: assessment of safety in 498 patients. Journal of Clinical and Aesthetic Dermatology2015;8(5 Suppl 1):S6. PariserDM , RichP , Cook‐BoldenFE , KorotzerA . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once‐daily treatment of moderate to severe acne vulgaris. Journal of Drugs in Dermatology2014;13(9):1083‐9. [CENTRAL: CN‐01113744; MEDLINE: 25226009] Stein GoldL . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate and severe acne vulgaris subpopulations. Journal of Drugs in Dermatology2015; Vol. 14, issue 9:969‐74. [CENTRAL: CN‐01165932; MEDLINE: 26355615] ">Pariser 2014</a>), Dermatology Life Quality Index (<a href="./references#CD011154-bbs2-0089" title="2013‐004158‐81 . A multi‐centre, single‐blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1%/benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2013‐004158‐81/results (results published 15 March 2016). NCT02058628 . Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02058628 (first received 6 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single‐blind, parallel‐group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild‐to‐moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016; Vol. 30, issue 6:966‐73. [CENTRAL: CN‐01369030; MEDLINE: 26915831] ">Schaller 2016</a>), and Cardiff Acne Disability Index (<a href="./references#CD011154-bbs2-0103" title="TabasumH , AhmadT , AnjumF , RehmanH . The effect of Unani antiacne formulation (Zimade Muhasa) on acne vulgaris: a single blind, randomized, controlled clinical trial. Journal of Pakistan Association of Dermatologists2014;24(4):319‐26. [CENTRAL: CN‐01075653] ">Tabasum 2014</a>). All of these trials assessed this outcome at baseline and at the end of treatment duration (at 6 or 12 weeks). Two of these trials additionally measured the outcome after two‐week treatments (<a href="./references#CD011154-bbs2-0013" title="ChantalatJ , LiuJC . Six‐week safety and efficacy evaluation of a synergistic microgel complex versus 10% benzoyl peroxide in the treatment of mild to moderate acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB14. [CENTRAL: CN‐00602658] ChantalatJ , LuedtkeK , WiegandB , LiuJC . Significant improvement in acne quality of life by a topical treatment containing a synergistic microgel complex and 2% salicylic acid. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN‐00602548] ChantalatJ , StamatasG , LiuJ C , ChenT . Treating emerging acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN‐00602574] ">Chantalat 2006</a>; <a href="./references#CD011154-bbs2-0046" title="Guerra‐TapiaA . Effects of benzoyl peroxide 5% clindamycin combination gel versus adapalene 0.1% on quality of life in patients with mild to moderate acne vulgaris: a randomized single‐blind study. Journal of Drugs in Dermatology2012;11(6):714‐22. [CENTRAL: CN‐00859793; MEDLINE: 22648218] NCT00807014 . Evaluation of quality of life, efficacy, and tolerance of Duac® gel compared to Differin® gel in the treatment of acne. www.clinicaltrials.gov/ct2/show/NCT00807014 (first received 10 December 2008). ">Guerra‐Tapia 2012</a>), and one repeated measurements at weeks 1, 2, 4, 8, and 12 (<a href="./references#CD011154-bbs2-0048" title="2017‐001575‐23 . Clinical evaluation of efficacy at 2 weeks of Duac fixed dose combination gel in treatment of facial acne vulgaris in Japanese subjects. www.clinicaltrialsregister.eu/ctr‐search/trial/2017‐001575‐23/results (first received 21 September 2017). HayashiN , KurokawaI , SiakpereO , EndoA , HatanakaT , YamadaM , et al. Clindamycin phosphate 1.2%/benzoyl peroxide 3% fixed‐dose combination gel versus topical combination therapy of adapalene 0.1% gel and clindamycin phosphate 1.2% gel in the treatment of acne vulgaris in Japanese patients: a multicenter, randomized, investigator‐blind, parallel‐group study. Journal of Dermatology2018;45(8):951‐62. [CENTRAL: CN‐01629242] NCT02557399 . DUAC® early onset efficacy study in Japanese subjects. clinicaltrials.gov/ct2/show/NCT02557399 (first received 23 September 2015). ">Hayashi 2018</a>). </p> </section> <section id="CD011154-sec-0105"> <p><b>Reduction in <i>C acnes</i> strains</b></p> <p>This outcome was reported in eight trials, all of which assessed the change in total <i>C acnes</i> strains from baseline to the end of treatment (at week 12 or 16) (<a href="./references#CD011154-bbs2-0017" title="CunliffeW . A comparison of the clinical and antimicrobial efficacy of clinoxin AQ gel (1 % w/v clindamycin/5% w/v benzoyl peroxide) and 1% (w/v) clindamycin gel in the treatment of acne. British Journal of Dermatology2000;143(Suppl 57):72. [CENTRAL: CN‐00547635] CunliffeWJ , HollandKT , BojarR , LevySF . A randomized, double‐blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clinical Therapeutics2002;24(7):1117‐33. [CENTRAL: CN‐00404978; MEDLINE: 12182256] ">Cunliffe 2002</a>; <a href="./references#CD011154-bbs2-0032" title="EadyEA , BojarRA , JonesCE , CoveJH , HollandKT , CunliffeWJ . The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin‐resistant propionibacteria. British Journal of Dermatology1996;134(1):107‐13. [CENTRAL: CN‐00126809; MEDLINE: 8745894] EadyEA , BojarRA , JonesCE , CoveKT , CunliffeWJ . The effects of acne therapy with a combination of benzoyl peroxide and erythromycin on carriage of erythromycin resistant cutaneous propionibacteria. British Journal of Dermatology1994;131(3):437‐8. [CENTRAL: CN‐00318672] ">Eady 1996</a>; <a href="./references#CD011154-bbs2-0051" title="JacksonJM , FuJJ , AlmekinderJL . A randomized, investigator‐blinded trial to assess the antimicrobial efficacy of a benzoyl peroxide 5%/clindamycin phosphate 1% gel compared with a clindamycin phosphate 1.2%/tretinoin 0.025% gel in the topical treatment of acne vulgaris. Journal of Drugs in Dermatology2010;9(2):131‐6. [CENTRAL: CN‐00743909; MEDLINE: 20214175] NCT00841776 . Comparative antimicrobial efficacy of two topical acne therapies for the treatment of facial acne. www.clinicaltrials.gov/ct2/show/NCT00841776 (first received 10 February 2009). ">Jackson 2010</a>; <a href="./references#CD011154-bbs2-0059" title="KawashimaM , HashimotoH , Alio SaenzAB , OnoM , YamadaM . Clindamycin phosphate 12%‐benzoyl peroxide 30% fixed‐dose combination gel has an effective and acceptable safety and tolerability profile for the treatment of acne vulgaris in Japanese patients: a phase III, multicentre, randomised, single‐blinded, active‐controlled, parallel‐group study. British Journal of Dermatology2015;172(2):494‐503. [CENTRAL: CN‐01115087] KawashimaM , YamadaM , ParishC . Clindamycin 1%/benzoyl peroxide 3% gel, a new topical combination product, is effective in Japanese patients with acne vulgaris. Journal of Investigative Dermatology2013;133:S160. [CENTRAL: CN‐01026775] ">Kawashima 2015</a>; <a href="./references#CD011154-bbs2-0064" title="LangnerA , Sheehan‐DareR , LaytonA . A randomized, single‐blind comparison of topical clindamycin + benzoyl peroxide (Duac) and erythromycin + zinc acetate (Zineryt) in the treatment of mild to moderate facial acne vulgaris. Journal of the European Academy of Dermatology &amp; Venereology2007;21(3):311‐9. [CENTRAL: CN‐00586947; MEDLINE: 17309451] ">Langner 2007</a>; <a href="./references#CD011154-bbs2-0065" title="LangnerA , ChuA , GouldenV , AmbroziakM . A randomized, single‐blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris. British Journal of Dermatology2008;158(1):122‐9. [CENTRAL: CN‐00628563; MEDLINE: 18047518] ">Langner 2008</a>; <a href="./references#CD011154-bbs2-0067" title="LeydenJ , LevyS . The development of antibiotic resistance in Propionibacterium acnes. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):21‐4. [CENTRAL: CN‐00509691; MEDLINE: 11236211] ">Leyden 2001b1</a>; <a href="./references#CD011154-bbs2-0068" title="LeydenJ , LevyS . The development of antibiotic resistance in Propionibacterium acnes. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):21‐4. [CENTRAL: CN‐00509691; MEDLINE: 11236211] ">Leyden 2001b2</a>). The change in clindamycin‐ and erythromycin‐resistant <i>C acnes</i> strains was also measured in six (<a href="./references#CD011154-bbs2-0017" title="CunliffeW . A comparison of the clinical and antimicrobial efficacy of clinoxin AQ gel (1 % w/v clindamycin/5% w/v benzoyl peroxide) and 1% (w/v) clindamycin gel in the treatment of acne. British Journal of Dermatology2000;143(Suppl 57):72. [CENTRAL: CN‐00547635] CunliffeWJ , HollandKT , BojarR , LevySF . A randomized, double‐blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clinical Therapeutics2002;24(7):1117‐33. [CENTRAL: CN‐00404978; MEDLINE: 12182256] ">Cunliffe 2002</a>; <a href="./references#CD011154-bbs2-0051" title="JacksonJM , FuJJ , AlmekinderJL . A randomized, investigator‐blinded trial to assess the antimicrobial efficacy of a benzoyl peroxide 5%/clindamycin phosphate 1% gel compared with a clindamycin phosphate 1.2%/tretinoin 0.025% gel in the topical treatment of acne vulgaris. Journal of Drugs in Dermatology2010;9(2):131‐6. [CENTRAL: CN‐00743909; MEDLINE: 20214175] NCT00841776 . Comparative antimicrobial efficacy of two topical acne therapies for the treatment of facial acne. www.clinicaltrials.gov/ct2/show/NCT00841776 (first received 10 February 2009). ">Jackson 2010</a>; <a href="./references#CD011154-bbs2-0059" title="KawashimaM , HashimotoH , Alio SaenzAB , OnoM , YamadaM . Clindamycin phosphate 12%‐benzoyl peroxide 30% fixed‐dose combination gel has an effective and acceptable safety and tolerability profile for the treatment of acne vulgaris in Japanese patients: a phase III, multicentre, randomised, single‐blinded, active‐controlled, parallel‐group study. British Journal of Dermatology2015;172(2):494‐503. [CENTRAL: CN‐01115087] KawashimaM , YamadaM , ParishC . Clindamycin 1%/benzoyl peroxide 3% gel, a new topical combination product, is effective in Japanese patients with acne vulgaris. Journal of Investigative Dermatology2013;133:S160. [CENTRAL: CN‐01026775] ">Kawashima 2015</a>; <a href="./references#CD011154-bbs2-0064" title="LangnerA , Sheehan‐DareR , LaytonA . A randomized, single‐blind comparison of topical clindamycin + benzoyl peroxide (Duac) and erythromycin + zinc acetate (Zineryt) in the treatment of mild to moderate facial acne vulgaris. Journal of the European Academy of Dermatology &amp; Venereology2007;21(3):311‐9. [CENTRAL: CN‐00586947; MEDLINE: 17309451] ">Langner 2007</a>; <a href="./references#CD011154-bbs2-0065" title="LangnerA , ChuA , GouldenV , AmbroziakM . A randomized, single‐blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris. British Journal of Dermatology2008;158(1):122‐9. [CENTRAL: CN‐00628563; MEDLINE: 18047518] ">Langner 2008</a>; <a href="./references#CD011154-bbs2-0068" title="LeydenJ , LevyS . The development of antibiotic resistance in Propionibacterium acnes. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):21‐4. [CENTRAL: CN‐00509691; MEDLINE: 11236211] ">Leyden 2001b2</a>) and four (<a href="./references#CD011154-bbs2-0032" title="EadyEA , BojarRA , JonesCE , CoveJH , HollandKT , CunliffeWJ . The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin‐resistant propionibacteria. British Journal of Dermatology1996;134(1):107‐13. [CENTRAL: CN‐00126809; MEDLINE: 8745894] EadyEA , BojarRA , JonesCE , CoveKT , CunliffeWJ . The effects of acne therapy with a combination of benzoyl peroxide and erythromycin on carriage of erythromycin resistant cutaneous propionibacteria. British Journal of Dermatology1994;131(3):437‐8. [CENTRAL: CN‐00318672] ">Eady 1996</a>; <a href="./references#CD011154-bbs2-0051" title="JacksonJM , FuJJ , AlmekinderJL . A randomized, investigator‐blinded trial to assess the antimicrobial efficacy of a benzoyl peroxide 5%/clindamycin phosphate 1% gel compared with a clindamycin phosphate 1.2%/tretinoin 0.025% gel in the topical treatment of acne vulgaris. Journal of Drugs in Dermatology2010;9(2):131‐6. [CENTRAL: CN‐00743909; MEDLINE: 20214175] NCT00841776 . Comparative antimicrobial efficacy of two topical acne therapies for the treatment of facial acne. www.clinicaltrials.gov/ct2/show/NCT00841776 (first received 10 February 2009). ">Jackson 2010</a>; <a href="./references#CD011154-bbs2-0064" title="LangnerA , Sheehan‐DareR , LaytonA . A randomized, single‐blind comparison of topical clindamycin + benzoyl peroxide (Duac) and erythromycin + zinc acetate (Zineryt) in the treatment of mild to moderate facial acne vulgaris. Journal of the European Academy of Dermatology &amp; Venereology2007;21(3):311‐9. [CENTRAL: CN‐00586947; MEDLINE: 17309451] ">Langner 2007</a>; <a href="./references#CD011154-bbs2-0065" title="LangnerA , ChuA , GouldenV , AmbroziakM . A randomized, single‐blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris. British Journal of Dermatology2008;158(1):122‐9. [CENTRAL: CN‐00628563; MEDLINE: 18047518] ">Langner 2008</a>) of these trials respectively. Five trials conducted repeat measurements with an interval varying between one and eight weeks (<a href="./references#CD011154-bbs2-0017" title="CunliffeW . A comparison of the clinical and antimicrobial efficacy of clinoxin AQ gel (1 % w/v clindamycin/5% w/v benzoyl peroxide) and 1% (w/v) clindamycin gel in the treatment of acne. British Journal of Dermatology2000;143(Suppl 57):72. [CENTRAL: CN‐00547635] CunliffeWJ , HollandKT , BojarR , LevySF . A randomized, double‐blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clinical Therapeutics2002;24(7):1117‐33. [CENTRAL: CN‐00404978; MEDLINE: 12182256] ">Cunliffe 2002</a>; <a href="./references#CD011154-bbs2-0032" title="EadyEA , BojarRA , JonesCE , CoveJH , HollandKT , CunliffeWJ . The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin‐resistant propionibacteria. British Journal of Dermatology1996;134(1):107‐13. [CENTRAL: CN‐00126809; MEDLINE: 8745894] EadyEA , BojarRA , JonesCE , CoveKT , CunliffeWJ . The effects of acne therapy with a combination of benzoyl peroxide and erythromycin on carriage of erythromycin resistant cutaneous propionibacteria. British Journal of Dermatology1994;131(3):437‐8. [CENTRAL: CN‐00318672] ">Eady 1996</a>; <a href="./references#CD011154-bbs2-0051" title="JacksonJM , FuJJ , AlmekinderJL . A randomized, investigator‐blinded trial to assess the antimicrobial efficacy of a benzoyl peroxide 5%/clindamycin phosphate 1% gel compared with a clindamycin phosphate 1.2%/tretinoin 0.025% gel in the topical treatment of acne vulgaris. Journal of Drugs in Dermatology2010;9(2):131‐6. [CENTRAL: CN‐00743909; MEDLINE: 20214175] NCT00841776 . Comparative antimicrobial efficacy of two topical acne therapies for the treatment of facial acne. www.clinicaltrials.gov/ct2/show/NCT00841776 (first received 10 February 2009). ">Jackson 2010</a>; <a href="./references#CD011154-bbs2-0067" title="LeydenJ , LevyS . The development of antibiotic resistance in Propionibacterium acnes. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):21‐4. [CENTRAL: CN‐00509691; MEDLINE: 11236211] ">Leyden 2001b1</a>; <a href="./references#CD011154-bbs2-0068" title="LeydenJ , LevyS . The development of antibiotic resistance in Propionibacterium acnes. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):21‐4. [CENTRAL: CN‐00509691; MEDLINE: 11236211] ">Leyden 2001b2</a>). </p> </section> <section id="CD011154-sec-0106"> <p><b>Percentage of participants experiencing any adverse event</b></p> <p>A total of 96 trials provided the number of participants with any adverse events. This outcome was monitored throughout the whole course of the trials. </p> </section> </section> </section> <section id="CD011154-sec-0107"> <h5 class="title">Settings</h5> <p>Only 26 trials mentioned the setting of the studies. Among these trials, 14 included outpatients from clinics, medical departments, general practices, or student health centres. However, the other 12 trials reported only participants from hospitals, medical centres, or national medical institutes. A total of 54 studies were described as multi‐centre trials and 26 as single‐centre trials. Among 75 trials reporting the country settings, 33 studies involved at least a trial site in North America, 14 studies involved at least a European trial site, and 16 studies involved at least an east Asian trial site. </p> </section> <section id="CD011154-sec-0108"> <h5 class="title">Funding sources</h5> <p>Of the 120 trials, 50 were financially supported by industry, eight were supported by a non‐commercial organisation (e.g. university, government), and 63 did not report sources of funding. </p> </section> </section> <section id="CD011154-sec-0109"> <h4 class="title">Excluded studies</h4> <p>We excluded 119 trials described in 128 reports based on their full text. Reasons for exclusion are listed under <a href="./references#CD011154-sec-0599" title="">Characteristics of excluded studies</a>. We excluded 58 studies because BPO treatment served as a co‐intervention for all included participants to investigate other acne medications, and we excluded 21 studies because participants did not meet the inclusion criteria for this review. We excluded 23 studies because they were not RCTs. Treatment duration was less than two weeks in ten studies. Three RCTs compared multi‐step regimens involving multiple active ingredients in different formulations. Three RCTs re‐randomised participants upon completion of the first study phase. Seven RCTs did not involve any BPO treatment. Two trials involved oral treatment in the comparison, and one involved light treatment. </p> <section id="CD011154-sec-0110"> <h5 class="title">Studies awaiting classification</h5> <p>We identified 43 trials awaiting classification and summarised their features in the <a href="./references#CD011154-sec-0600" title="">Characteristics of studies awaiting classification</a> tables. A total of 27 studies were recorded in the trial registries as completed, but their results were not published (<a href="./references#CD011154-bbs2-0248" title="2004‐002272‐41 . A multi‐centre, single‐blind, parallel group, clinical evaluation of the efficacy and safety of Duac gel (a gel containing clindamycin phosphate [equivalent to 1% clindamycin] and 5% benzoyl peroxide) and Differin gel (a gel containing 0.1% adapalene) in the topical treatment of mild to moderate acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2004‐002272‐41/GB (first received 28 June 2005). ">2004‐002272‐41</a>; <a href="./references#CD011154-bbs2-0249" title="2006‐004278‐28/IT . Efficacy and safety of a fixed combination adapalene 0.1%/benzoyl peroxide 2.5% gel compared to clindamycin 1%/benzoyl peroxide 5% gel in the treatment of acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004278‐28/IT (first received 27 January 2009). ">2006‐004278‐28</a>; <a href="./references#CD011154-bbs2-0250" title="2008‐002359‐26 . A multi‐center, randomized, evaluator‐blind, parallel group study evaluation of the efficacy, safety, and tolerability of DUAC® Akne Gel and Epiduo® Gel in the topical treatment of facial acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐002359‐26 (first received 26 June 2008). ">2008‐002359‐26</a>; <a href="./references#CD011154-bbs2-0251" title="2008‐006792‐68 . Efficacy and safety comparison of adapalene 0.1%/benzoyl peroxide 2.5% gel associated with lymecycline 300mg capsules versus adapalene 0.1%/benzoyl peroxide 2.5% vehicle gel associated with lymecycline 300mg capsules in the treatment of moderate to severe acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2008‐006792‐68 (first received 12 May 2009). ">2008‐006792‐68</a>; <a href="./references#CD011154-bbs2-0252" title="2013‐001716‐30 . Exploratory, controlled, randomized, observer‐blind intrainidividual clinical trial to evaluate the efficacy and the tolerability of topically applied 0.1% tyrothricin (Tyrosur® Gel) in patients with mild to severe facial papulopustular acne. www.clinicaltrialsregister.eu/ctr‐search/trial/2013‐001716‐30 (first received 13 August 2013). ">2013‐001716‐30</a>; <a href="./references#CD011154-bbs2-0253" title="2016‐000063‐16/DE . Efficacy and safety of CD5024 1% in acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2016‐000063‐16/DE (first received 4 March 2016). ">2016‐000063‐16</a>; <a href="./references#CD011154-bbs2-0262" title="IRCT20181229042165N1 . Effectiveness of adapalene 0.1% with intense pulsed light versus benzoyl peroxide 5% with intense pulsed light in the treatment of acne vulgaris: a comparative study. apps.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20181229042165N1 (first received 8 January 2019). ">IRCT20181229042165N1</a>; <a href="./references#CD011154-bbs2-0266" title="DonaldAE , AtkinsonGE , LangnerA , ChuA , ClaytonT . Efficacy and safety of Duac Gel (a gel containing 1% clindamycin and 5% benzoyl peroxide) compared with Differin Gel (a gel containing 0.1% adapalene) in the topical treatment of mild to moderate acne vulgaris. Abstract P01.139. 14th Congress of the European Academy of Dermatology and Venereology, London, UK, 12‐15 October 2005. Journal of the European Academy of Dermatology and Venereology2005;19(Suppl 2):36. [CENTRAL: CN‐00602579] NCT00160394 . Comparison of Duac® gel and Differin® gel in mild to moderate acne vulgaris. clinicaltrials.gov/ct2/show/NCT00160394 (first received 12 September 2005). ">NCT00160394</a>; <a href="./references#CD011154-bbs2-0267" title="NCT00624676 . Efficacy and tolerance of a derivative of salicylic acid and 5% benzoyl peroxide in facial acne vulgaris. clinicaltrials.gov/ct2/show/NCT00624676 (first received 27 February 2008). ">NCT00624676</a>; <a href="./references#CD011154-bbs2-0268" title="NCT00663286 . A clinical trial evaluating the safety and efficacy of IDP‐110 in patients with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00663286 (first received 22 April 2008). NCT00664248 . A clinical study evaluating the safety and efficacy of IDP‐110 in patients with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00664248 (first received 22 April 2008). ">NCT00663286</a>; <a href="./references#CD011154-bbs2-0269" title="NCT01106807 . Exploratory study to evaluate the efficacy and safety of CD07223 gel in subjects with acne. clinicaltrials.gov/ct2/show/NCT01106807 (first received 20 April 2010). ">NCT01106807</a>; <a href="./references#CD011154-bbs2-0270" title="NCT01237821 . Comparing OTC acne treatment to prescription regimen. clinicaltrials.gov/ct2/show/NCT01237821 (first received 10 November 2010). ">NCT01237821</a>; <a href="./references#CD011154-bbs2-0271" title="NCT01445301 . Study STF115287, a clinical confirmation study of GSK2585823 in the treatment of acne vulgaris in Japanese subjects. clinicaltrials.gov/ct2/show/NCT01445301 (first received 3 October 2011). ">NCT01445301</a>; <a href="./references#CD011154-bbs2-0272" title="CTRI/2011/05/001762 . A clinical trial to compare adapalene and benzoyl peroxide combination local application gel to Epiduo of Galderma Laboratories, L.P., and both these to an inactive local application gel in patients with mild to severe pimple. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2011/05/001762 (first received 26 May 2011). NCT01501799 . A bioequivalence study with clinical endpoints comparing adapalene and benzoyl peroxide topical gel 0.1%/2.5% (Actavis Mid‐Atlantic LLC) to Epiduo™ (adapalene and benzoyl peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the treatment of mild to severe acne vulgaris. clinicaltrials.gov/ct2/show/NCT01501799 (first received 29 December 2011). ">NCT01501799</a>; <a href="./references#CD011154-bbs2-0273" title="NCT01742637 . Study comparing adapalene and benzoyl peroxide gel 0.1%/2.5% to Epiduo® and both to a placebo control in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT01742637 (first received 5 December 2012). ">NCT01742637</a>; <a href="./references#CD011154-bbs2-0274" title="NCT01769235 . Study comparing clindamycin phosphate and benzoyl peroxide gel to Acanya® Gel and both to a vehicle control in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT01769235 (first received 16 January 2013). ">NCT01769235</a>; <a href="./references#CD011154-bbs2-0275" title="NCT01769664 . A study comparing clindamycin 1%/benzoyl peroxide 5% topical gel to Duac® topical gel in the treatment of acne vulgaris. https://clinicaltrials.gov/ct2/show/NCT01769664 (first received 17 January 2013). ">NCT01769664</a>; <a href="./references#CD011154-bbs2-0276" title="NCT01788384 . Evaluate therapeutic equivalence and safety of two clindamycin phosphate and benzoyl peroxide gels in acne vulgaris. clinicaltrials.gov/ct2/show/NCT01788384 (first received 11 February 2013). ">NCT01788384</a>; <a href="./references#CD011154-bbs2-0277" title="NCT01796665 . A study to compare clindamycin phosphate and benzoyl peroxide topical gel 1.2%/2.5% to Acanya® topical gel in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT01796665 (first received 22 February 2013). ">NCT01796665</a>; <a href="./references#CD011154-bbs2-0278" title="NCT02515305 . Comparative safety and efficacy of two treatments in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02515305 (first received 4 August 2015). ">NCT02515305</a>; <a href="./references#CD011154-bbs2-0279" title="NCT02525549 . Comparative safety and bioequivalence of two treatments in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02525549 (first received 17 August 2015). ">NCT02525549</a>; <a href="./references#CD011154-bbs2-0280" title="NCT02578043 . A study comparing clindamycin and benzoyl peroxide gel 1.2%/3.75% to Onexton™ Gel in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02578043 (first received 14 October 2015). ">NCT02578043</a>; <a href="./references#CD011154-bbs2-0281" title="NCT02595034 . A study CLBG and benzoyl peroxide gel 1%/5% to BenzaClin® Gel in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02595034 (first received 1 November 2015). ">NCT02595034</a>; <a href="./references#CD011154-bbs2-0282" title="NCT02616614 . Double‐blind placebo‐controlled trial of generic clindamycin/benzoyl peroxide gel versus Onexton Gel in acne vulgaris. clinicaltrials.gov/ct2/show/NCT02616614 (first received 25 November 2015). ">NCT02616614</a>; <a href="./references#CD011154-bbs2-0283" title="NCT02651220 . Clinical end point study of generic adapalene and benzoyl peroxide gel versus Epiduo® Forte Gel in treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02651220 (first received 5 January 2016). ">NCT02651220</a>; <a href="./references#CD011154-bbs2-0284" title="NCT02709902 . Study comparing adapalene/BP gel to EPIDUO® FORTE and both to a placebo control in treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02709902 (first received 8 March 2016). ">NCT02709902</a>; <a href="./references#CD011154-bbs2-0285" title="NCT03393494 . Bioequivalence study of two treatments in the treatment of acne vulgaris on the face. clinicaltrials.gov/ct2/show/NCT03393494 (first received 8 January 2018). ">NCT03393494</a>). We found insufficient information to judge the eligibility of three conference proceedings (<a href="./references#CD011154-bbs2-0254" title="Ahmadi AshtianiH , Hooshange EhsaniA , BrikbinB , KrimlouZ , JavadiM . Evaluation of the effectiveness of formulation containing Cynara scolymus (Artichoke) leaf extract on epidermal growth factor (EGF) in older women with acne skin. Journal der Deutschen Dermatologischen Gesellschaft (Journal of the German Society of Dermatology)2014;12:20. ">Ahmadi 2014</a>; <a href="./references#CD011154-bbs2-0259" title="DahlA , OresajoC , BaumannL , YatskayerM . A split‐face clinical trial to compare the safety and efficacy of two topical acne treatments in subjects with mild to moderate acne vulgaris. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2011.11.101] ">Dahl 2012</a>; <a href="./references#CD011154-bbs2-0287" title="PerezE , FernandezJR , RouzardK , WebbC , VoronkovM , HealyJ , et al. SIG‐1459 and SIG‐1460: novel anti‐acne isoprenyl cysteine compounds. Journal of Investigative Dermatology2017;137(10 Suppl 2):S267. ">Perez 2017</a>); six paper abstracts also provided inadequate information (<a href="./references#CD011154-bbs2-0256" title="ChiouWL . Low intrinsic drug activity and dominant vehicle (placebo) effect in the topical treatment of acne vulgaris. International Journal of Clinical Pharmacology &amp; Therapeutics2012;50(6):434‐7. [CENTRAL: CN‐00969115; MEDLINE: 22677304] ">Chiou 2012</a>; <a href="./references#CD011154-bbs2-0261" title="FagundesDS , FraserJM , KlaudaHC . New therapy update ‐ A unique combination formulation in the treatment of inflammatory acne. Cutis; Cutaneous Medicine for the Practitioner2003;72(1 Suppl):16‐9. [CENTRAL: CN‐00450281; MEDLINE: 12887173] ">Fagundes 2003</a>; <a href="./references#CD011154-bbs2-0263" title="LassusA . Local treatment of acne. A clinical study and evaluation of the effect of different concentrations of benzoyl peroxide gel. Current Medical Research &amp; Opinion1981;7(6):370‐3. [CENTRAL: CN‐00025227; MEDLINE: 6453695] ">Lassus 1981</a>; <a href="./references#CD011154-bbs2-0264" title="LeydenJJ . Clindamycin 1%/benzoyl peroxide 5% is more effective than clindamycin alone in reducing Propionibacterium acnes (Abstract P1‐13). 11th Congress of the European Academy of Dermatology &amp; Venereology, Prague, October 2‐6, 2002. Journal of the European Academy of Dermatology and Venereology2002;16(Suppl 1):117. [CENTRAL: CN‐00416128] ">Leyden 2002</a>; <a href="./references#CD011154-bbs2-0289" title="StincoG , PiccirilloF , ValentF , ErrichettiE , MeoN , TrevisanG , et al. Efficacy, tolerability, impact on quality of life and sebostatic activity of three topical preparations for the treatment of mild to moderate facial acne vulgaris. Giornale Italiano di Dermatologia e Venereologia2016;151(3):230‐8. [CENTRAL: CN‐01158537; MEDLINE: 25236322] ">Stinco 2016</a>; <a href="./references#CD011154-bbs2-0290" title="WokalekH . Open, controlled multicenter trial of 2 benzoyl peroxide preparations in the treatment of acne vulgaris. Zeitschrift fur Hautkrankheiten1989;64(2):140‐4. [MEDLINE: 2524133] ">Wokalek 1989</a>). Neither abstracts nor full‐text articles were available for seven studies (<a href="./references#CD011154-bbs2-0255" title="Anonymous . Multicenter trial for aqueous gels with 5% and 10% benzoyl peroxide in treatment of acne vulgaris [Etude multicentrique d'eclaran (5 et 10) dans le traitement de l'acne vulgaire. A propos de 140 cas]. Comptes Rendus de Therapeutique et de Pharmacologie Clinique1985;3(31):11‐4. [CENTRAL: CN‐00365235] ">Anonymous 1985</a>; <a href="./references#CD011154-bbs2-0257" title="CunliffeWJ , DodmanB , EadR . Benzoyl peroxide in acne. Practitioner1978;220(1317):479‐82. [MEDLINE: 148043] ">Cunliffe 1978</a>; <a href="./references#CD011154-bbs2-0258" title="CunliffeWJ , BurkeB , DodmanB . Chloramphenicol and benzoyl peroxide in acne. A double‐blind clinical study. Practitioner1980;224(1347):952‐4. [CENTRAL: CN‐00024025; MEDLINE: 6449698] ">Cunliffe 1980</a>; <a href="./references#CD011154-bbs2-0260" title="DantoJL , MaddinWS , StewartWD , NelsonAJ . A controlled trial of benzoyl peroxide and precipitated sulfur cream in acne vulgaris. Applied Therapeutics1966;8(7):624‐5. [CENTRAL: CN‐00000721; MEDLINE: 4223595] ">Danto 1966</a>; <a href="./references#CD011154-bbs2-0265" title="Mallol MironJ , Hurtado ManzanoC , Parra OrtizI . Evaluation of the efficacy of benzoyl peroxide at high concentrations. Therapeutic and microbiological study. Medicina Clinica1984;83(17):705‐7. [CENTRAL: CN‐00268406; MEDLINE: 6240577] ">Mallol 1984</a>; <a href="./references#CD011154-bbs2-0286" title="Peereboom‐WyniaJDR , CornelissenPJG , BernsenR . A new alcohol free preparation of benzoyl peroxide gel (Basiron) for acne vulgaris. A double blind trial. Tijdschrift voor Therapie, Geneesmiddel en Onderzoek1984;9(10):519‐22. [CENTRAL: CN‐00334342] ">Peereboom‐Wynia 1984</a>; <a href="./references#CD011154-bbs2-0288" title="PrianoL , BorghiS , IsolaV , GrazioliI , MelziG , MassoneL . Topical spironolactone 5% versus benzoyl peroxide 5% + miconazole 2% in the therapy of acne: double‐blind, controlled study to evaluate the efficacy and the eventual systemic absorption [Spironolattone 5% verso benzoilperossido 5% + miconazolo 2%, per via topica nella terapia aell'acne: Studio controllato in doppio cieco per la valutazione di efficacia d non assorbimento transcutaneo]. Giornale Italiano di Dermatologia e Venereologia1993;128(4):XXVII‐XXX. [CENTRAL: CN‐00351889] ">Priano 1993</a>). We attempted to contact the responsible parties for these studies via available correspondence information but were unsuccessful in obtaining further details or results. </p> </section> <section id="CD011154-sec-0111"> <h5 class="title">Ongoing studies</h5> <p>We present the details of 22 ongoing trials under <a href="./references#CD011154-sec-0601" title="">Characteristics of ongoing studies</a> (<a href="./references#CD011154-bbs2-0291" title="2005‐004708‐35 . Multi‐centre, comparative, randomized, single‐blind, parallel group, clinical trial in phase IV for the evaluation of the subjects quality of life, the efficacy and the tolerance of Duac® gel (a gel containing clindamycin phosphate [equivalent to 1% clindamycin] and 5% benzoyl peroxide) and Differin® gel (a gel containing 0.1% adapalene) in the topical treatment of mild to moderate acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/search?query=2005‐004708‐35 (first received 22 June 2007). ">2005‐004708‐35</a>; <a href="./references#CD011154-bbs2-0292" title="2015‐002699‐26/DE . Pilot study of tolerability and effectivity following application of two combination topical acne products clindamycin 1% and 0.025% tretinoin gel (Acnatac® Gel), adapalen 0,1% and benzoyl peroxide 2,5% gel (Epiduo® Gel). www.clinicaltrialsregister.eu/ctr‐search/trial/2015‐002699‐26/DE (first received 13 August 2015). ">2015‐002699‐26</a>; <a href="./references#CD011154-bbs2-0293" title="ACTRN12609000443291 . Efficacy and safety comparison of adapalene 0.1%/benzoyl peroxide 2.5% gel associated with lymecycline 300mg capsules versus adapalene 0.1%/benzoyl peroxide 2.5% vehicle gel associated with lymecycline 300mg capsules in the treatment of moderate to severe acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12609000443291 (first received 12 June 2009). ">ACTRN12609000443291</a>; <a href="./references#CD011154-bbs2-0294" title="CTRI/2012/11/003127 . A randomized, open label, active controlled, parallel group trial to compare the safety and efficacy of adapalene, benzoyl peroxide, and benzoyl peroxide‐clindamycin combination in patients with acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2012/11/003127 (first received 21 November 2012). ">CTRI/2012/11/003127</a>; <a href="./references#CD011154-bbs2-0295" title="CTRI/2014/07/004734 . A multiple center, parallel group study to evaluate the bioequivalence of test drug clindamycin 1% and benzoyl peroxide 5% gel of Watson and reference drug BenzaclinÂ® (clindamycin 1% and benzoyl peroxide 5%) Gel of Dermik Labs, in treatment of subjects with acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2014/07/004734 (first received 14 July 2014). ">CTRI/2014/07/004734</a>; <a href="./references#CD011154-bbs2-0296" title="CTRI/2015/11/006379 . A randomized, double‐blind, multicentric, parallel‐group, active and placebo controlled, three arm clinical study to compare the efficacy and safety of clindamycin phosphate 1.2%/benzoyl peroxide 5% gel (of Cadila Healthcare Limited, India) versus DUACÂ® Gel (of Stiefel Laboratories, USA) versus placebo (vehicle gel) in the ratio of 2:2:1 respectively, in patients with acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2015/11/006379 (first received 26 November 2015). ">CTRI/2015/11/006379</a>; <a href="./references#CD011154-bbs2-0297" title="CTRI/2016/04/006875 . A comparative study of benzoyl peroxide 2.5% gel, adapalene 0.1% gel and their combination in treatment of acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2016/04/006875 (first received 27 April 2016). ">CTRI/2016/04/006875</a>; <a href="./references#CD011154-bbs2-0298" title="CTRI/2017/09/009884 . A multicenter, randomized, double blind, parallel, placebo controlled clinical endpoint study to determine the therapeutic equivalence of test product benzoyl peroxide 5% and clindamycin phosphate 1% gel and reference product BenzaClin Topical Gel in patients with acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2017/09/009884 (first received 22 September 2017). ">CTRI/2017/09/009884</a>; <a href="./references#CD011154-bbs2-0299" title="CTRI/2017/12/010974 . A clinical study to evaluate the efficacy and safety of Tila‐i Muhasa in the management of Busur Labaniyya (acne vulgaris). apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2017/12/010974 (first received 26 December 2017). ">CTRI/2017/12/010974</a>; <a href="./references#CD011154-bbs2-0300" title="CTRI/2018/05/013744 . Evaluation of safety and efficacy of hydrogen peroxide stabilized cream for treatment of mild to moderate acne vulgaris in comparison with benzoyl peroxide (BP) gel, double blinded randomized control study. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2018/05/013744 (first received 7 May 2018). ">CTRI/2018/05/013744</a>; <a href="./references#CD011154-bbs2-0301" title="CTRI/2018/05/013744 . A randomized, double blind, multicenter, three‐arm, parallel, placebo‐controlled clinical study to evaluate the bioequivalence using clinical endpoint of clindamycin phosphate 1.2% and benzoyl peroxide 5% gel (Encube Ethicals Private Limited, India) to DUACÂ® Gel (clindamycin phosphate 1.2% and benzoyl peroxide 5% gel) (Stiefel Laboratories, Inc., Research Triangle Park, NC 27709) in subjects with acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2018/06/014684 (first received 29 June 2018). ">CTRI/2018/06/014684</a>; <a href="./references#CD011154-bbs2-0302" title="IRCT2017072035195N1 . Comparison of the efficacy of dapsone 5% gel plus oral doxycycline versus benzoyl peroxide 5% gel plus oral doxycycline in patients with moderate acne vulgaris referred to Rasht Razi hospital during 2017‐2018. apps.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2017072035195N1 (first received 23 October 2017). ">IRCT2017072035195N1</a>; <a href="./references#CD011154-bbs2-0303" title="IRCT20170806035524N5 . Comparing efficacy of combination therapy with niosomal benzoyl peroxide 1% ‐ clindamycin 1% versus niosomal clindamycin 1% in acne vulgaris: a randomized clinical trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20170806035524N5 (first received 15 August 2018). ">IRCT20170806035524N5</a>; <a href="./references#CD011154-bbs2-0304" title="JPRN‐UMIN000019639 . Study of the utility of acute‐phase and remission maintenance therapy with 2.5% benzoyl peroxide gel for moderate or severe acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000019639 (first received 1 December 2015). ">JPRN‐UMIN000019639</a>; <a href="./references#CD011154-bbs2-0305" title="JPRN‐UMIN000024874 . Study of the utility of combination therapy 2.5% benzoyl peroxide gel and 2% ozenoxacin lotion for moderate or severe acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000024874 (first received 15 February 2017). ">JPRN‐UMIN000024874</a>; <a href="./references#CD011154-bbs2-0306" title="NCT00869492 . Comparison of nadifloxacin cream alone and with benzoyl peroxide solution in the treatment of acne. clinicaltrials.gov/ct2/show/NCT00869492 (first received 26 March 2009). ">NCT00869492</a>; <a href="./references#CD011154-bbs2-0307" title="NCT00877409 . A monocentric, single‐blind, randomized, placebo‐controlled study of the safety and efficacy of the topical drug Acnase creme in the treatment of acne vulgaris I and II. clinicaltrials.gov/ct2/show/NCT00877409 (first received 7 April 2009). ">NCT00877409</a>; <a href="./references#CD011154-bbs2-0308" title="NCT01422785 . A study comparing combination clindamycin phosphate/tretinoin gel alone versus with benzoyl peroxide foaming cloths for facial acne. clinicaltrials.gov/ct2/show/NCT01422785 (first received 24 August 2011). ">NCT01422785</a>; <a href="./references#CD011154-bbs2-0309" title="NCT02005666 . To compare the efficacy and safety of clindamycin phosphate 1.2%/benzoyl peroxide 5% gel of CHL versus DUAC® gel. clinicaltrials.gov/ct2/show/NCT02005666 (first received 9 December 2013). ">NCT02005666</a>; <a href="./references#CD011154-bbs2-0310" title="NCT02731105 . Pilot study of tolerability and effectivity of two combination topical acne products (PREFECT). clinicaltrials.gov/ct2/show/NCT02731105 (first received 29 March 2016). ">NCT02731105</a>; <a href="./references#CD011154-bbs2-0311" title="NCT03076320 . Pirfenidone plus M‐DDO gel in moderate and severe acne. clinicaltrials.gov/ct2/show/NCT03076320 (first received 6 March 2017). ">NCT03076320</a>; <a href="./references#CD011154-bbs2-0312" title="NCT03563365 . The functional and emotional benefits of Replenix Power of Three with Resveratrol. clinicaltrials.gov/ct2/show/NCT03563365 (first received 20 June 2018). ">NCT03563365</a>). Among these trials, 10 were initiated before 2015, with the earliest start date of 2007. These trials were probably unpublished studies, indicating risk of publication bias. All of these trials were parallel RCTs, and their comparisons involved BPO versus adapalene, BPO versus hydrogen peroxide, BPO/adapalene versus placebo, BPO/adapalene versus Replenix (green tea polyphenols) with resveratrol, BPO/clindamycin versus placebo, BPO/clindamycin versus clindamycin, BPO/sulphur versus placebo, BPO/clindamycin versus adapalene, BPO plus clindamycin/tretinoin versus clindamycin/tretinoin, and BPO plus nadifloxacin versus placebo plus nadifloxacin, and BPO/adapalene plus Replenix with resveratrol versus Replenix with resveratrol. Treatment duration was between 10 and 12 weeks in most trials (<a href="./references#CD011154-bbs2-0293" title="ACTRN12609000443291 . Efficacy and safety comparison of adapalene 0.1%/benzoyl peroxide 2.5% gel associated with lymecycline 300mg capsules versus adapalene 0.1%/benzoyl peroxide 2.5% vehicle gel associated with lymecycline 300mg capsules in the treatment of moderate to severe acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12609000443291 (first received 12 June 2009). ">ACTRN12609000443291</a>; <a href="./references#CD011154-bbs2-0294" title="CTRI/2012/11/003127 . A randomized, open label, active controlled, parallel group trial to compare the safety and efficacy of adapalene, benzoyl peroxide, and benzoyl peroxide‐clindamycin combination in patients with acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2012/11/003127 (first received 21 November 2012). ">CTRI/2012/11/003127</a>; <a href="./references#CD011154-bbs2-0295" title="CTRI/2014/07/004734 . A multiple center, parallel group study to evaluate the bioequivalence of test drug clindamycin 1% and benzoyl peroxide 5% gel of Watson and reference drug BenzaclinÂ® (clindamycin 1% and benzoyl peroxide 5%) Gel of Dermik Labs, in treatment of subjects with acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2014/07/004734 (first received 14 July 2014). ">CTRI/2014/07/004734</a>; <a href="./references#CD011154-bbs2-0296" title="CTRI/2015/11/006379 . A randomized, double‐blind, multicentric, parallel‐group, active and placebo controlled, three arm clinical study to compare the efficacy and safety of clindamycin phosphate 1.2%/benzoyl peroxide 5% gel (of Cadila Healthcare Limited, India) versus DUACÂ® Gel (of Stiefel Laboratories, USA) versus placebo (vehicle gel) in the ratio of 2:2:1 respectively, in patients with acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2015/11/006379 (first received 26 November 2015). ">CTRI/2015/11/006379</a>; <a href="./references#CD011154-bbs2-0297" title="CTRI/2016/04/006875 . A comparative study of benzoyl peroxide 2.5% gel, adapalene 0.1% gel and their combination in treatment of acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2016/04/006875 (first received 27 April 2016). ">CTRI/2016/04/006875</a>; <a href="./references#CD011154-bbs2-0298" title="CTRI/2017/09/009884 . A multicenter, randomized, double blind, parallel, placebo controlled clinical endpoint study to determine the therapeutic equivalence of test product benzoyl peroxide 5% and clindamycin phosphate 1% gel and reference product BenzaClin Topical Gel in patients with acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2017/09/009884 (first received 22 September 2017). ">CTRI/2017/09/009884</a>; <a href="./references#CD011154-bbs2-0301" title="CTRI/2018/05/013744 . A randomized, double blind, multicenter, three‐arm, parallel, placebo‐controlled clinical study to evaluate the bioequivalence using clinical endpoint of clindamycin phosphate 1.2% and benzoyl peroxide 5% gel (Encube Ethicals Private Limited, India) to DUACÂ® Gel (clindamycin phosphate 1.2% and benzoyl peroxide 5% gel) (Stiefel Laboratories, Inc., Research Triangle Park, NC 27709) in subjects with acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2018/06/014684 (first received 29 June 2018). ">CTRI/2018/06/014684</a>; <a href="./references#CD011154-bbs2-0302" title="IRCT2017072035195N1 . Comparison of the efficacy of dapsone 5% gel plus oral doxycycline versus benzoyl peroxide 5% gel plus oral doxycycline in patients with moderate acne vulgaris referred to Rasht Razi hospital during 2017‐2018. apps.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2017072035195N1 (first received 23 October 2017). ">IRCT2017072035195N1</a>; <a href="./references#CD011154-bbs2-0303" title="IRCT20170806035524N5 . Comparing efficacy of combination therapy with niosomal benzoyl peroxide 1% ‐ clindamycin 1% versus niosomal clindamycin 1% in acne vulgaris: a randomized clinical trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=IRCT20170806035524N5 (first received 15 August 2018). ">IRCT20170806035524N5</a>; <a href="./references#CD011154-bbs2-0304" title="JPRN‐UMIN000019639 . Study of the utility of acute‐phase and remission maintenance therapy with 2.5% benzoyl peroxide gel for moderate or severe acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000019639 (first received 1 December 2015). ">JPRN‐UMIN000019639</a>; <a href="./references#CD011154-bbs2-0305" title="JPRN‐UMIN000024874 . Study of the utility of combination therapy 2.5% benzoyl peroxide gel and 2% ozenoxacin lotion for moderate or severe acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐UMIN000024874 (first received 15 February 2017). ">JPRN‐UMIN000024874</a>; <a href="./references#CD011154-bbs2-0307" title="NCT00877409 . A monocentric, single‐blind, randomized, placebo‐controlled study of the safety and efficacy of the topical drug Acnase creme in the treatment of acne vulgaris I and II. clinicaltrials.gov/ct2/show/NCT00877409 (first received 7 April 2009). ">NCT00877409</a>; <a href="./references#CD011154-bbs2-0308" title="NCT01422785 . A study comparing combination clindamycin phosphate/tretinoin gel alone versus with benzoyl peroxide foaming cloths for facial acne. clinicaltrials.gov/ct2/show/NCT01422785 (first received 24 August 2011). ">NCT01422785</a>; <a href="./references#CD011154-bbs2-0309" title="NCT02005666 . To compare the efficacy and safety of clindamycin phosphate 1.2%/benzoyl peroxide 5% gel of CHL versus DUAC® gel. clinicaltrials.gov/ct2/show/NCT02005666 (first received 9 December 2013). ">NCT02005666</a>; <a href="./references#CD011154-bbs2-0311" title="NCT03076320 . Pirfenidone plus M‐DDO gel in moderate and severe acne. clinicaltrials.gov/ct2/show/NCT03076320 (first received 6 March 2017). ">NCT03076320</a>; <a href="./references#CD011154-bbs2-0312" title="NCT03563365 . The functional and emotional benefits of Replenix Power of Three with Resveratrol. clinicaltrials.gov/ct2/show/NCT03563365 (first received 20 June 2018). ">NCT03563365</a>). </p> </section> </section> </section> <section id="CD011154-sec-0112"> <h3 class="title">Risk of bias in included studies</h3> <p>Overall, none of the included studies were rated as having low risk of bias across all seven domains for assessment (<a href="./references#CD011154-sec-0598" title="">Characteristics of included studies</a>). We have presented each risk of bias item across all included studies in <a href="#CD011154-fig-0002">Figure 2</a> and a summary of risk of bias for each included study in <a href="#CD011154-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD011154-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011154-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD011154-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011154-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011154-sec-0113"> <h4 class="title">Allocation</h4> <section id="CD011154-sec-0114"> <h5 class="title">Random sequence generation</h5> <p>We judged the risk of bias as low in 39 studies in which an appropriate method (i.e. a random numbers table or computer software) was used to generate the random sequence. However, in the other 81 trials, study authors did not report how participants were randomly assigned to different treatment groups. We judged the risk of bias of these trials as unclear. </p> </section> <section id="CD011154-sec-0115"> <h5 class="title">Allocation concealment</h5> <p>Only nine trials were judged as having low risk in the domain of allocation concealment, which was ensured by central assignment of treatment or use of sequentially numbered, opaque, sealed envelopes. The remaining trials did not provide sufficient information for judgement about allocation concealment. </p> </section> </section> <section id="CD011154-sec-0116"> <h4 class="title">Blinding</h4> <section id="CD011154-sec-0117"> <h5 class="title">Blinding of participants and personnel</h5> <p>We decided the risk of bias as low in only six trials in which study authors specified that participants and personnel were blinded. Also complete blinding in these trials was possible as comparator preparations and usage of treatments were the same and the well‐known treatment‐related adverse events (such as dryness and erythema in BPO‐related treatments) were similar between groups. We classified 35 trials as having unclear risk, most of which were claimed to be double‐blind with no sufficient information on who was blinded when blinding was possible in these trials. We judged remaining trials (79/120) as high risk as study authors specified or indicated no blinding of participants or personnel, or treatment groups differed in comparator preparations, frequency of treatments, or well‐known treatment‐related adverse events. </p> </section> <section id="CD011154-sec-0118"> <h5 class="title">Blinding of outcome assessment</h5> <p>For only 19 trials, we judged the risk of bias as low given that study authors specified that outcome assessors were not aware of the treatment assignment, and the balance of specific treatment‐related adverse events between groups made complete blinding possible. We assessed 50 trials as having unclear risk because information needed for the judgement was insufficient. We considered the rest of the trials (51/120) to be at high risk of bias as study authors specified or indicated no blinding in the outcome assessment, or between‐group imbalance among treatment‐related adverse events may have compromised the blinding. </p> </section> </section> <section id="CD011154-sec-0119"> <h4 class="title">Incomplete outcome data</h4> <p>We considered 34 trials as having low risk of attrition bias when at least 90% of participants were followed up and the reasons for withdrawal were comparable between different treatment groups. We judged 34 trials as having high risk of bias because more than 10% of study participants did not provide complete outcome data, and some trials reported imbalance in the numbers and reasons for withdrawal between groups. We considered the remaining 52 trials as having unclear risk of bias. </p> </section> <section id="CD011154-sec-0120"> <h4 class="title">Selective reporting</h4> <p>With all outcomes planned on the trial registry reported, 26 trials were regarded as having low risk of reporting bias. We judged the risk of bias as high for 11 trials in which one or more outcomes planned in their published information on a trial registry or specified in the methods section were not reported in the results. Substantial uncertainty existed in this domain for 83 trials because no corresponding registered information or protocols were available to confirm whether all pre‐specified outcomes were reported, or because additional outcomes were reported besides those pre‐specified in a trial registry. </p> </section> <section id="CD011154-sec-0121"> <h4 class="title">Other potential sources of bias</h4> <p>In 25 trials, the baseline characteristics of participants were similar between different treatment groups and the washout periods of previous acne treatments were long enough. Risk of bias was high in 26 trials; the main issues involved imbalance in the demographics or in acne severity between groups or the unacceptably short washout periods. Insufficient information was available for this judgement on the remaining 69 trials. </p> </section> </section> <section id="CD011154-sec-0122"> <h3 class="title" id="CD011154-sec-0122">Effects of interventions</h3> <p>See: <a href="./full#CD011154-tbl-0001"><b>Summary of findings for the main comparison</b> Benzoyl peroxide compared to placebo or no treatment for acne</a>; <a href="./full#CD011154-tbl-0002"><b>Summary of findings 2</b> Benzoyl peroxide compared to adapalene for acne</a>; <a href="./full#CD011154-tbl-0003"><b>Summary of findings 3</b> Benzoyl peroxide compared to clindamycin for acne</a>; <a href="./full#CD011154-tbl-0004"><b>Summary of findings 4</b> Benzoyl peroxide compared to erythromycin for acne</a>; <a href="./full#CD011154-tbl-0005"><b>Summary of findings 5</b> Benzoyl peroxide compared to salicylic acid for acne</a> </p> <p>We reported pre‐defined outcomes under the following 47 pair‐wise comparisons that we identified from the included studies. In <a href="./references#CD011154-sec-0577" title="">Data and analyses</a>, we presented the results for five main comparisons, which included comparisons of BPO versus placebo/no treatment or four major topical active medications (adapalene, clindamycin, erythromycin, and salicylic acid). These comparisons were highlighted in our review because the treatments involved are now commonly used in clinical practice. For these comparisons, we rated the corresponding quality of evidence using GRADE. For the other 44 comparisons, we presented as many relevant details as we were able to obtain from the original reports. All comparisons involved only topical treatments and are summarised below. Results for the two primary outcomes (from studies included in and excluded from the main pooled analyses) are also presented in <a href="./appendices#CD011154-sec-0588">Appendix 9</a> and <a href="./appendices#CD011154-sec-0589">Appendix 10</a>. </p> <section id="CD011154-sec-0123"> <h4 class="title">Main comparisons</h4> <p> <ul id="CD011154-list-0012"> <li> <p>BPO versus placebo or no treatment</p> </li> <li> <p>BPO versus adapalene</p> </li> <li> <p>BPO versus clindamycin</p> </li> <li> <p>BPO versus erythromycin</p> </li> <li> <p>BPO versus salicylic acid</p> </li> </ul> </p> </section> <section id="CD011154-sec-0124"> <h4 class="title">Other comparisons</h4> <p> <ul id="CD011154-list-0013"> <li> <p>BPO versus tretinoin</p> </li> <li> <p>BPO versus isotretinoin</p> </li> <li> <p>BPO versus azelaic acid</p> </li> <li> <p>BPO versus retinoic acid</p> </li> <li> <p>BPO versus sulphur</p> </li> <li> <p>BPO versus hydrogen peroxide</p> </li> <li> <p>BPO versus superoxidised solution</p> </li> <li> <p>BPO versus <i>Casuarina equisetifolia</i> bark extract </p> </li> <li> <p>BPO versus Chinese medical mask</p> </li> <li> <p>BPO versus meclocycline sulfosalicylate</p> </li> <li> <p>BPO versus isolutrol</p> </li> <li> <p>BPO versus tea tree oil</p> </li> <li> <p>BPO versus Unani preparation (Zimade Muhasa)</p> </li> <li> <p>BPO versus glycerin</p> </li> <li> <p>BPO versus chloroxylenol/salicylic acid</p> </li> <li> <p>BPO versus chloroxylenol/zinc oxide</p> </li> <li> <p>BPO/adapalene versus placebo or no treatment</p> </li> <li> <p>BPO/adapalene versus tretinoin</p> </li> <li> <p>BPO/adapalene versus salicylic acid</p> </li> <li> <p>BPO/adapalene versus clindamycin/tretinoin</p> </li> <li> <p>BPO/clindamycin versus placebo or no treatment</p> </li> <li> <p>BPO/clindamycin versus adapalene</p> </li> <li> <p>BPO/clindamycin versus azelaic acid</p> </li> <li> <p>BPO/clindamycin versus erythromycin/zinc</p> </li> <li> <p>BPO/clindamycin versus dapsone</p> </li> <li> <p>BPO/erythromycin versus placebo or no treatment</p> </li> <li> <p>BPO/erythromycin versus clindamycin</p> </li> <li> <p>BPO/erythromycin versus azelaic acid</p> </li> <li> <p>BPO/erythromycin versus metronidazole</p> </li> <li> <p>BPO/erythromycin versus viaminate</p> </li> <li> <p>BPO/erythromycin versus zinc/erythromycin</p> </li> <li> <p>BPO/sulphur versus placebo</p> </li> <li> <p>BPO/glycolic acid/zinc lactate versus placebo</p> </li> <li> <p>BPO/potassium hydroxyquinoline sulphate versus placebo</p> </li> <li> <p>BPO (10%) versus BPO (5%)</p> </li> <li> <p>BPO (10%) versus BPO (2.5%)</p> </li> <li> <p>BPO (5%) versus BPO (2.5%)</p> </li> <li> <p>BPO (6%) versus BPO (5.5%)</p> </li> <li> <p>BPO (vehicle with 8% urea) versus BPO (vehicle with no urea)</p> </li> <li> <p>BPO (vehicle with acetone) versus BPO (vehicle with alcohol/detergent)</p> </li> <li> <p>BPO (formulation 1) versus BPO (formulation 2)</p> </li> <li> <p>Water‐based BPO versus alcohol‐based BPO</p> </li> </ul> </p> </section> <section id="CD011154-sec-0125"> <h4 class="title">Results for the main comparisons</h4> <section id="CD011154-sec-0126"> <h5 class="title">BPO versus placebo or no treatment</h5> <p>This comparison comprises 46 parallel trials and one split‐face trial. A total of 25 parallel trials (<a href="./references#CD011154-bbs2-0008" title="BurkeB , EadyEA , CunliffeWJ . Benzoyl peroxide versus topical erythromycin in the treatment of acne vulgaris. British Journal of Dermatology1983;108(2):199‐204. [CENTRAL: CN‐00568861; MEDLINE: 6218815] ">Burke 1983</a>; <a href="./references#CD011154-bbs2-0011" title="ChalkerDK , ShalitaA , SmithJG , SwannRW . A double‐blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. Journal of the American Academy of Dermatology1983;9(6):933‐6. [CENTRAL: CN‐00334175; MEDLINE: 6227643] ">Chalker 1983</a>; <a href="./references#CD011154-bbs2-0012" title="ChantalatJ , StamatasG , KolliasN , LiuJC . Comparative efficacy of target acne lesion resolution using a novel 2% salicylic acid composition versus 10% benzoyl peroxide. Journal of the European Academy of Dermatology and Venereology2005;19(Suppl 2):37. [CENTRAL: CN‐00602613] ">Chantalat 2005</a>; <a href="./references#CD011154-bbs2-0033" title="EdeM . A double blind, comparative study of benzoyl peroxide, benzoyl peroxide chlorhydroxyquinoline, benzoyl peroxide chlorhydroxyquinoline hydrocortisone, and placebo lotions in acne. Current Therapeutic Research ‐ Clinical and Experimental1973;15(9):624‐9. [CENTRAL: CN‐00009208; MEDLINE: 4270828] ">Ede 1973</a>; <a href="./references#CD011154-bbs2-0034" title="EichenfieldL , AlioA . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed dose combination gel for the treatment of acne vulgaris: a multicenter, double‐blind, parallel group, vehicle controlled study. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB10. [DOI: 10.1016/j.jaad.2011.11.049] EichenfieldLF , Alio SaenzAB . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed‐dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double‐blind, active‐ and vehicle‐controlled study. Journal of Drugs in Dermatology2011;10(12):1382‐96. [CENTRAL: CN‐00843726; MEDLINE: 22134562] NCT00776919 . A phase 3 multicenter, randomized, double‐blind, active and vehicle‐controlled study of the safety and efficacy of a clindamycin / benzoyl peroxide gel versus clindamycin gel versus benzoyl peroxide gel versus vehicle gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00776919 (first received 21 October 2008). ">Eichenfield 2011</a>; <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>; <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>; <a href="./references#CD011154-bbs2-0049" title="HughesBR . A double blind evaluation of topical isotretinoin, benzoyl peroxide and placebo in patients with acne. British Journal of Dermatology1989;121(s34):42. [DOI: 10.1111/j.1365‐2133.1989.tb05941.x] HughesBR , NorrisJF , CunliffeWJ . A double‐blind evaluation of topical isotretinoin 0.05%, benzoyl peroxide gel 5% and placebo in patients with acne. Clinical &amp; Experimental Dermatology1992;17(3):165‐8. [MEDLINE: 1451291] ">Hughes 1992</a>; <a href="./references#CD011154-bbs2-0052" title="JaffeGV , GrimshawJJ , ConstadD . Benzoyl peroxide in the treatment of acne vulgaris: a double‐blind, multi‐centre comparative study of 'Quinoderm' cream and 'Quinoderm' cream with hydrocortisone versus their base vehicle alone and a benzoyl peroxide only gel preparation. Current Medical Research &amp; Opinion1989;11(7):453‐62. [CENTRAL: CN‐00062342; MEDLINE: 2528439] ">Jaffe 1989</a>; <a href="./references#CD011154-bbs2-0056" title="KabirM , SadiqS , RazaA , KanwalS , TanvirT . Comparison of efficacy of adapalene (0.1% gel) monotherapy vs adapalene (0.1%) plus benzyl peroxide (2.5%) combination therapy for treatment of mild to moderate acne vulgaris. Pakistan Journal of Medical and Health Sciences2018;12(2):587‐9. ">Kabir 2018</a>; <a href="./references#CD011154-bbs2-0058" title="KawashimaM , HashimotoH , Alio SaenzAB , OnoM , YamadaM . Is benzoyl peroxide 3% topical gel effective and safe in the treatment of acne vulgaris in Japanese patients? A multicenter, randomized, double‐blind, vehicle‐controlled, parallel‐group study. Journal of Dermatology2014;41(9):795‐801. [CENTRAL: CN‐01254201; MEDLINE: 25132461] NCT01400932 . Study STF115288, a clinical confirmation study of GI148512 in the treatment of acne vulgaris in Japanese subjects. www.clinicaltrials.gov/ct2/show/NCT01400932 (first received 21 July 2011). ">Kawashima 2014</a>; <a href="./references#CD011154-bbs2-0061" title="KawashimaM , SatoS , FurukawaF , MatsunagaK , AkamatsuH , IgarashiA , et al. Twelve‐week, multicenter, placebo‐controlled, randomized, double‐blind, parallel‐group, comparative phase II/III study of benzoyl peroxide gel in patients with acne vulgaris: a secondary publication. Journal of Dermatology2017; Vol. 44, issue 7:774‐82. [CENTRAL: CN‐01458975] MorimotoH , KikukawaY , MurakamiN . Pharmacological profiles and clinical effects of benzoyl peroxide gel as treatments for acne vulgaris. Nippon Yakurigaku Zasshi ‐ Folia Pharmacologica Japonica2015;146(4):225‐32. [PUBMED: 26656967] ">Kawashima 2017b</a>; <a href="./references#CD011154-bbs2-0066" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM . Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] LeydenJ , et al. Treatment of acne vulgaris with a combination benzoyl peroxide/clindamycin topical gel Abstract P‐013. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S144. [CENTRAL: CN‐00478651] LeydenJJ , BergerRS , DunlapFE , EllisCN , ConnollyMA , LevySF . Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. American Journal of Clinical Dermatology2001;2(1):33‐9. [CENTRAL: CN‐00363426; MEDLINE: 11702619] ">Leyden 2001a</a>; <a href="./references#CD011154-bbs2-0069" title="LookingbillDP , ChalkerDK , LindholmJS , KatzHI , KempersSE , HuerterCJ , et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double‐blind investigations. Journal of the American Academy of Dermatology1997;37(4):590‐5. [CENTRAL: CN‐00144503; MEDLINE: 9344199] LookingbillDP , ChallenDK , LindholmJS . Treatment of acne with a combination of clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined result of two double blind investigations (Abstract no. 1). Indian Journal of Dermatology, Venerology and Leprology1995;61:398. ">Lookingbill 1997</a>; <a href="./references#CD011154-bbs2-0074" title="Mills JrOH , KligmanAM , PochiP , ComiteH . Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. International Journal of Dermatology1986;25(10):664‐7. [CENTRAL: CN‐00046261; MEDLINE: 2948929] ">Mills 1986</a>; <a href="./references#CD011154-bbs2-0082" title="NCT02073461 . Efficacy and safety study of 2 different concentrations of CD1579 gels versus vehicle in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02073461 (first received 20 February 2014). ">NCT02073461</a>; <a href="./references#CD011154-bbs2-0086" title="PapageorgiouPP , ChuAC . Chloroxylenol and zinc oxide containing cream (Nels cream) vs. 5% benzoyl peroxide cream in the treatment of acne vulgaris. A double‐blind, randomized, controlled trial. Clinical &amp; Experimental Dermatology2000;25(1):16‐20. [CENTRAL: CN‐00275100; MEDLINE: 10671963] ">Papageorgiou 2000</a>; <a href="./references#CD011154-bbs2-0097" title="SmithEB , PadillaRS , McCabeJM , BeckerLE . Benzoyl peroxide lotion (20 percent) in acne. Cutis; Cutaneous Medicine for the Practitioner1980;25(1):90‐2. [CENTRAL: CN‐00269336; MEDLINE: 6444379] ">Smith 1980</a>; <a href="./references#CD011154-bbs2-0100" title="FDA , Center for Drug Evaluation and Research. Study 152. Medical Review of NDA 50‐741. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50‐741_duac%20topical%20gel_medr_p1.pdf. ">Study 152</a>; <a href="./references#CD011154-bbs2-0101" title="FDA , Center for Drug Evaluation and Research. Study 156. Medical Review of NDA 50‐741. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50‐741_duac%20topical%20gel_medr_p1.pdf. ">Study 156</a>; <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>; <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>; <a href="./references#CD011154-bbs2-0108" title="Tirado‐SanchezA , Ponce‐OliveraRM . Efficacy and tolerance of superoxidized solution in the treatment of mild to moderate inflammatory acne. A double‐blinded, placebo‐ controlled, parallel‐group, randomized, clinical trial. Journal of Dermatological Treatment2009;20(5):289‐92. [CENTRAL: CN‐00743204; MEDLINE: 19459079] ">Tirado‐Sanchez 2009</a>; <a href="./references#CD011154-bbs2-0109" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM , et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] TschenE , et al. A combination benzoyl peroxide/clindamycin topical gel for the treatment of acne vulgaris. Abstract P‐029. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S150. [CENTRAL: CN‐00478786] TschenEH , KatzHI , JonesTM , MonroeEW , KrausSJ , ConnollyMA , et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2):165‐9. [CENTRAL: CN‐00346768; MEDLINE: 11236229] ">Tschen 2001</a>; <a href="./references#CD011154-bbs2-0112" title="VasarinshP . Benzoyl peroxide‐sulfur lotions in acne vulgaris ‐ a controlled study. Cutis; Cutaneous Medicine for the Practitioner1969;5(1):65‐9. [CENTRAL: CN‐00269401] ">Vasarinsh 1969</a>), as well as one split‐face trial (<a href="./references#CD011154-bbs2-0003" title="BikowskiJ , DelRossoJ , DesaiA , BenesV . Double‐blind, randomized, split‐face comparison of skin tolerability of benzoyl peroxide 4% wash vs a nonmedicated synthetic detergent skin cleanser. Abstract P151. American Academy of Dermatology, 64th Annual Meeting, March 3‐7, 2006. Journal of the American Academy of Dermatology2006;54:AB27. [CENTRAL: CN‐00602224] ">Bikowski 2006</a>), involved the comparison between BPO monotherapy and placebo or no treatment, with treatment duration varying from 2 weeks to 14 weeks. </p> <p>In all, 34 parallel trials treating participants for 2 to 24 weeks evaluated effects of BPO as an add‐on treatment (<a href="./references#CD011154-bbs2-0005" title="BorglundE , KristensenB , Larsson‐StymneB , StrandA , VeienNK , JakobsenHB . Topical meclocycline sulfosalicylate, benzoyl peroxide, and a combination of the two in the treatment of acne vulgaris. Acta Dermato‐Venereologica1991;71:175‐8. [CENTRAL: CN‐00075962; MEDLINE: 1675534] ">Borglund 1991</a>; <a href="./references#CD011154-bbs2-0010" title="CassanoN , AlessandriniG , CarrieriG , FaiD , GabbelloneM , GravanteM , et al. Treatment of mild to moderate acne vulgaris with adapalene alone or combined with other anti‐acne agents. A multicenter open trial. [Studio multicentrico in aperto sul trattamento dell'acne lieve/moderata con adapalene in monoterapia o in terapia combinata]. Giornale Italiano di Dermatologia e Venereologia2002;137(5):369‐75. [CENTRAL: CN‐00432115] ">Cassano 2002</a>; <a href="./references#CD011154-bbs2-0011" title="ChalkerDK , ShalitaA , SmithJG , SwannRW . A double‐blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. Journal of the American Academy of Dermatology1983;9(6):933‐6. [CENTRAL: CN‐00334175; MEDLINE: 6227643] ">Chalker 1983</a>; <a href="./references#CD011154-bbs2-0017" title="CunliffeW . A comparison of the clinical and antimicrobial efficacy of clinoxin AQ gel (1 % w/v clindamycin/5% w/v benzoyl peroxide) and 1% (w/v) clindamycin gel in the treatment of acne. British Journal of Dermatology2000;143(Suppl 57):72. [CENTRAL: CN‐00547635] CunliffeWJ , HollandKT , BojarR , LevySF . A randomized, double‐blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clinical Therapeutics2002;24(7):1117‐33. [CENTRAL: CN‐00404978; MEDLINE: 12182256] ">Cunliffe 2002</a>; <a href="./references#CD011154-bbs2-0019" title="DelRossoJ , KircikL . Comparison of the tolerability of benzoyl peroxide microsphere wash versus a gentle cleanser, when used in combination with a clindamycin and tretinoin gel: a multicenter, investigator‐blind, randomized study. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.100] ">Del 2009a</a>; <a href="./references#CD011154-bbs2-0023" title="DraelosZD , TanghettiEA . Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis; Cutaneous Medicine for the Practitioner2002;69(2 Suppl):20‐9. [CENTRAL: CN‐00409023; MEDLINE: 12095065] ">Draelos 2002</a>; <a href="./references#CD011154-bbs2-0024" title="DraelosZD , PottsA , Alio SaenzAB . Randomized tolerability analysis of clindamycin phosphate 1.2%‐tretinoin 0.025% gel used with benzoyl peroxide wash 4% for acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(6):310‐8. [CENTRAL: CN‐00770969; MEDLINE: 21284283] NCT00891982 . A phase 3, multicenter, assessor‐blinded study of the tolerability of a topical antibiotic and retinoid used in conjunction with benzoyl peroxide wash in subjects with mild‐to‐moderate facial acne vulgaris. clinicaltrials.gov/ct2/show/NCT00891982 (first received 29 April 2009). ">Draelos 2010</a>; <a href="./references#CD011154-bbs2-0032" title="EadyEA , BojarRA , JonesCE , CoveJH , HollandKT , CunliffeWJ . The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin‐resistant propionibacteria. British Journal of Dermatology1996;134(1):107‐13. [CENTRAL: CN‐00126809; MEDLINE: 8745894] EadyEA , BojarRA , JonesCE , CoveKT , CunliffeWJ . The effects of acne therapy with a combination of benzoyl peroxide and erythromycin on carriage of erythromycin resistant cutaneous propionibacteria. British Journal of Dermatology1994;131(3):437‐8. [CENTRAL: CN‐00318672] ">Eady 1996</a>; <a href="./references#CD011154-bbs2-0034" title="EichenfieldL , AlioA . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed dose combination gel for the treatment of acne vulgaris: a multicenter, double‐blind, parallel group, vehicle controlled study. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB10. [DOI: 10.1016/j.jaad.2011.11.049] EichenfieldLF , Alio SaenzAB . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed‐dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double‐blind, active‐ and vehicle‐controlled study. Journal of Drugs in Dermatology2011;10(12):1382‐96. [CENTRAL: CN‐00843726; MEDLINE: 22134562] NCT00776919 . A phase 3 multicenter, randomized, double‐blind, active and vehicle‐controlled study of the safety and efficacy of a clindamycin / benzoyl peroxide gel versus clindamycin gel versus benzoyl peroxide gel versus vehicle gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00776919 (first received 21 October 2008). ">Eichenfield 2011</a>; <a href="./references#CD011154-bbs2-0037" title="FangL , FuW , GuJ , SunJ , MaE . Efficacy and safety of benzoyl peroxide gel, 5% combined with adapalene gel, 0.1% in Chinese patients with acne vulgaris (Abstract). 20th World Congress of Dermatology, Paris, 1st to 5th July 2002. Annales de Dermatologie et de Venereologie2002;129(Suppl 1 Pt 2):P0020. [CENTRAL: CN‐00454223] ">Fang 2002</a>; <a href="./references#CD011154-bbs2-0038" title="FleischerAB , DraelosZD , AbramovitsW , PariserDM . Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4%, or vehicle gel for the treatment of acne vulgaris: a randomized, double‐blind study. Abstract P113. American Academy of Dermatology, 65th Annual Meeting, February 2‐6, 2007. Journal of the American Academy of Dermatology2007;56(2):AB16. [CENTRAL: CN‐00616000] FleischerAB , ShalitaA , EichenfieldLF , AbramovitsW , LuckyA , GarrettSCP . Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: a 12‐week, randomized, double‐blind study. Journal of Drugs in Dermatology2010;9(1):33‐40. [CENTRAL: CN‐00734828; MEDLINE: 20120423] NCT00151541 . A phase 3 study to compare the safety and efficacy of 5% dapsone topical gel (DTG) twice daily in combination with once daily vehicle control, adapalene gel 0.1% or benzoyl peroxide gel 4%. www.clinicaltrials.gov/ct2/show/NCT00151541 (first received 7 September 2005). ">Fleischer 2010</a>; <a href="./references#CD011154-bbs2-0039" title="FuWW , FangL , GuJ , ShunJF . Clinical efficacy and safety of 5% benzoyl peroxide gel combined with 0.1% adapalene gel in the treatment of acne vulgaris: a multicenter, randomized study. Chinese Journal of Dermatology2003;36(6):310‐2. [CENTRAL: CN‐00484027] ">Fu 2003</a>; <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>; <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>; <a href="./references#CD011154-bbs2-0053" title="JawadeSA , SaigaonkarVA , KondalkarAR . Efficacy and tolerability of adapalene 0.1%‐benzoyl peroxide 2.5% combination gel in treatment of acne vulgaris in Indian patients: a randomized investigator‐blind controlled trial. Iranian Journal of Dermatology2016;19(4):105‐12. [CENTRAL: CN‐01405922] ">Jawade 2016</a>; <a href="./references#CD011154-bbs2-0056" title="KabirM , SadiqS , RazaA , KanwalS , TanvirT . Comparison of efficacy of adapalene (0.1% gel) monotherapy vs adapalene (0.1%) plus benzyl peroxide (2.5%) combination therapy for treatment of mild to moderate acne vulgaris. Pakistan Journal of Medical and Health Sciences2018;12(2):587‐9. ">Kabir 2018</a>; <a href="./references#CD011154-bbs2-0059" title="KawashimaM , HashimotoH , Alio SaenzAB , OnoM , YamadaM . Clindamycin phosphate 12%‐benzoyl peroxide 30% fixed‐dose combination gel has an effective and acceptable safety and tolerability profile for the treatment of acne vulgaris in Japanese patients: a phase III, multicentre, randomised, single‐blinded, active‐controlled, parallel‐group study. British Journal of Dermatology2015;172(2):494‐503. [CENTRAL: CN‐01115087] KawashimaM , YamadaM , ParishC . Clindamycin 1%/benzoyl peroxide 3% gel, a new topical combination product, is effective in Japanese patients with acne vulgaris. Journal of Investigative Dermatology2013;133:S160. [CENTRAL: CN‐01026775] ">Kawashima 2015</a>; <a href="./references#CD011154-bbs2-0063" title="KorkutC , PiskinS . Benzoyl peroxide, adapalene, and their combination in the treatment of acne vulgaris. Journal of Dermatology2005;32(3):169‐73. [CENTRAL: CN‐00512006] ">Korkut 2005</a>; <a href="./references#CD011154-bbs2-0066" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM . Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] LeydenJ , et al. Treatment of acne vulgaris with a combination benzoyl peroxide/clindamycin topical gel Abstract P‐013. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S144. [CENTRAL: CN‐00478651] LeydenJJ , BergerRS , DunlapFE , EllisCN , ConnollyMA , LevySF . Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. American Journal of Clinical Dermatology2001;2(1):33‐9. [CENTRAL: CN‐00363426; MEDLINE: 11702619] ">Leyden 2001a</a>; <a href="./references#CD011154-bbs2-0067" title="LeydenJ , LevyS . The development of antibiotic resistance in Propionibacterium acnes. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):21‐4. [CENTRAL: CN‐00509691; MEDLINE: 11236211] ">Leyden 2001b1</a>; <a href="./references#CD011154-bbs2-0068" title="LeydenJ , LevyS . The development of antibiotic resistance in Propionibacterium acnes. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):21‐4. [CENTRAL: CN‐00509691; MEDLINE: 11236211] ">Leyden 2001b2</a>; <a href="./references#CD011154-bbs2-0069" title="LookingbillDP , ChalkerDK , LindholmJS , KatzHI , KempersSE , HuerterCJ , et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double‐blind investigations. Journal of the American Academy of Dermatology1997;37(4):590‐5. [CENTRAL: CN‐00144503; MEDLINE: 9344199] LookingbillDP , ChallenDK , LindholmJS . Treatment of acne with a combination of clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined result of two double blind investigations (Abstract no. 1). Indian Journal of Dermatology, Venerology and Leprology1995;61:398. ">Lookingbill 1997</a>; <a href="./references#CD011154-bbs2-0075" title="MiyachiY , MizziF , MitaT , BaiL , IkomaA . Efficacy and safety of a fixed dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% in Japanese patients with acne vulgaris ‐ a multicenter, randomized, double‐blinded, active‐controlled, parallel group phase III study. [Japanese]. Skin Research2016;15(4):278‐93. NCT02073448 . Efficacy and safety study of GK530G versus CD0271 0.1% gel and CD1579 2.5% gel in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02073448 (first received 20 February 2014). ">Miyachi 2016</a>; <a href="./references#CD011154-bbs2-0076" title="2015‐004900‐44 . A multi‐center randomized double blind vehicle‐controlled, phase 2 study of the safety and efficacy of benzoyl peroxide/clindamycin gel and tazarotene cream when used in combination in the treatment of acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2015‐004900‐44/results (results published 23 March 2017). NCT00713609 . Safety and efficacy study of clindamycin/benzoyl peroxide/tazarotene cream in subjects with acne. clinicaltrials.gov/ct2/show/NCT00713609 (first received 7 July 2008). ">NCT00713609</a>; <a href="./references#CD011154-bbs2-0084" title="OzgenZY , GurbuzO . A randomized, double‐blind comparison of nadifloxacin 1% cream alone and with benzoyl peroxide 5% lotion in the treatment of mild to moderate facial acne vulgaris. Marmara Medical Journal2013;26(1):243‐6. [CENTRAL: CN‐00912356] ">Ozgen 2013</a>; <a href="./references#CD011154-bbs2-0094" title="ShalitaAR , RafalES , AndersonDN , YavelR , LandowS , LeeWL . Compared efficacy and safety of tretinoin 0.1% microsphere gel alone and in combination with benzoyl peroxide 6% cleanser for the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2003;72(2):167‐72. [CENTRAL: CN‐00457639; MEDLINE: 12953944] ">Shalita 2003</a>; <a href="./references#CD011154-bbs2-0100" title="FDA , Center for Drug Evaluation and Research. Study 152. Medical Review of NDA 50‐741. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50‐741_duac%20topical%20gel_medr_p1.pdf. ">Study 152</a>; <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>; <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>; <a href="./references#CD011154-bbs2-0109" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM , et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] TschenE , et al. A combination benzoyl peroxide/clindamycin topical gel for the treatment of acne vulgaris. Abstract P‐029. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S150. [CENTRAL: CN‐00478786] TschenEH , KatzHI , JonesTM , MonroeEW , KrausSJ , ConnollyMA , et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2):165‐9. [CENTRAL: CN‐00346768; MEDLINE: 11236229] ">Tschen 2001</a>; <a href="./references#CD011154-bbs2-0110" title="TuckerSB , TausendR , CochranR , FlanniganSA . Comparison of topical clindamycin phosphate, benzoyl peroxide, and a combination of the two for the treatment of acne vulgaris. British Journal of Dermatology1984;110(4):487‐92. [CENTRAL: CN‐00568865; MEDLINE: 6231942] TuckerSB , TausendT , CochranR . Comparison of topical clindamycin phosphate, benzoyl peroxide and a combination of the two, for the treatment of acne vulgaris [abstract no:1]. Indian Journal of Dermatology, Venerology and Leprology1990;56:179. [CENTRAL: CN‐00692634] ">Tucker 1984</a>; <a href="./references#CD011154-bbs2-0112" title="VasarinshP . Benzoyl peroxide‐sulfur lotions in acne vulgaris ‐ a controlled study. Cutis; Cutaneous Medicine for the Practitioner1969;5(1):65‐9. [CENTRAL: CN‐00269401] ">Vasarinsh 1969</a>; <a href="./references#CD011154-bbs2-0115" title="2015‐004909‐16 . A multicentre, randomized, assessor‐blind, comparator‐controlled, parallel‐group clinical trial to establish the efficacy and safety of Duac™ (1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide) once daily gel compared with clindamycin phosphate gel (1% clindamycin as clindamycin phosphate) twice daily in the treatment of mild to moderate acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2015‐004909‐16/results (results published 29 December 2016). NCT01915732 . Efficacy and safety of Duac™ compared with clindamycin phosphate gel in the treatment of mild to moderate acne vulgaris. clinicaltrials.gov/ct2/show/NCT01915732 (first received 5 April 2013). XuJ , LuQ , HuangJ , SunQ , HaoF , GuJ , et al. A multicenter, randomized, single‐blind study of topical clindamycin 1%/benzoyl peroxide 5% once‐daily fixed dose combination gel (Duac) vs. clindamycin 1% twice‐daily gel in treatment of Chinese acne vulgaris patients. Journal of Investigative Dermatology2015;135(Suppl 2):S34, 192. [CENTRAL: CN‐01130701] XuJH , LuQJ , HuangJH , HaoF , SunQN , FangH , et al. A multicentre, randomized, single‐blind comparison of topical clindamycin 1%/benzoyl peroxide 5% once‐daily gel versus clindamycin 1% twice‐daily gel in the treatment of mild to moderate acne vulgaris in Chinese patients. Journal of the European Academy of Dermatology and Venereology2016;30(7):1176‐82. [CENTRAL: CN‐01178389; MEDLINE: 27075705] ">Xu 2016</a>; <a href="./references#CD011154-bbs2-0117" title="ZeichnerJA , WongV , LinknerRV , HaddicanM . Efficacy and safety of tretinoin 0.025%/clindamycin phosphate 1.2% gel in combination with benzoyl peroxide 6% cleansing cloths for the treatment of facial acne vulgaris. Journal of Drugs in Dermatology2013;12(3):277‐82. [CENTRAL: CN‐00876866; MEDLINE: 23545909] ">Zeichner 2013</a>). All outcomes of interest in this review were available except for change in quality of life. See <a href="./full#CD011154-tbl-0001">summary of findings Table for the main comparison</a>, where we rated the evidence for the two primary outcomes and the secondary safety outcome. </p> <section id="CD011154-sec-0127"> <h6 class="title">Primary outcome: participant global self‐assessment of acne improvement</h6> <p>Of 16 trials that reported this outcome, 13 treated participants for the long term (<a href="./references#CD011154-bbs2-0017" title="CunliffeW . A comparison of the clinical and antimicrobial efficacy of clinoxin AQ gel (1 % w/v clindamycin/5% w/v benzoyl peroxide) and 1% (w/v) clindamycin gel in the treatment of acne. British Journal of Dermatology2000;143(Suppl 57):72. [CENTRAL: CN‐00547635] CunliffeWJ , HollandKT , BojarR , LevySF . A randomized, double‐blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clinical Therapeutics2002;24(7):1117‐33. [CENTRAL: CN‐00404978; MEDLINE: 12182256] ">Cunliffe 2002</a>; <a href="./references#CD011154-bbs2-0023" title="DraelosZD , TanghettiEA . Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis; Cutaneous Medicine for the Practitioner2002;69(2 Suppl):20‐9. [CENTRAL: CN‐00409023; MEDLINE: 12095065] ">Draelos 2002</a>; <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>; <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>; <a href="./references#CD011154-bbs2-0053" title="JawadeSA , SaigaonkarVA , KondalkarAR . Efficacy and tolerability of adapalene 0.1%‐benzoyl peroxide 2.5% combination gel in treatment of acne vulgaris in Indian patients: a randomized investigator‐blind controlled trial. Iranian Journal of Dermatology2016;19(4):105‐12. [CENTRAL: CN‐01405922] ">Jawade 2016</a>; <a href="./references#CD011154-bbs2-0066" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM . Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] LeydenJ , et al. Treatment of acne vulgaris with a combination benzoyl peroxide/clindamycin topical gel Abstract P‐013. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S144. [CENTRAL: CN‐00478651] LeydenJJ , BergerRS , DunlapFE , EllisCN , ConnollyMA , LevySF . Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. American Journal of Clinical Dermatology2001;2(1):33‐9. [CENTRAL: CN‐00363426; MEDLINE: 11702619] ">Leyden 2001a</a>; <a href="./references#CD011154-bbs2-0075" title="MiyachiY , MizziF , MitaT , BaiL , IkomaA . Efficacy and safety of a fixed dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% in Japanese patients with acne vulgaris ‐ a multicenter, randomized, double‐blinded, active‐controlled, parallel group phase III study. [Japanese]. Skin Research2016;15(4):278‐93. NCT02073448 . Efficacy and safety study of GK530G versus CD0271 0.1% gel and CD1579 2.5% gel in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02073448 (first received 20 February 2014). ">Miyachi 2016</a>; <a href="./references#CD011154-bbs2-0094" title="ShalitaAR , RafalES , AndersonDN , YavelR , LandowS , LeeWL . Compared efficacy and safety of tretinoin 0.1% microsphere gel alone and in combination with benzoyl peroxide 6% cleanser for the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2003;72(2):167‐72. [CENTRAL: CN‐00457639; MEDLINE: 12953944] ">Shalita 2003</a>; <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>; <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>; <a href="./references#CD011154-bbs2-0109" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM , et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] TschenE , et al. A combination benzoyl peroxide/clindamycin topical gel for the treatment of acne vulgaris. Abstract P‐029. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S150. [CENTRAL: CN‐00478786] TschenEH , KatzHI , JonesTM , MonroeEW , KrausSJ , ConnollyMA , et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2):165‐9. [CENTRAL: CN‐00346768; MEDLINE: 11236229] ">Tschen 2001</a>; <a href="./references#CD011154-bbs2-0110" title="TuckerSB , TausendR , CochranR , FlanniganSA . Comparison of topical clindamycin phosphate, benzoyl peroxide, and a combination of the two for the treatment of acne vulgaris. British Journal of Dermatology1984;110(4):487‐92. [CENTRAL: CN‐00568865; MEDLINE: 6231942] TuckerSB , TausendT , CochranR . Comparison of topical clindamycin phosphate, benzoyl peroxide and a combination of the two, for the treatment of acne vulgaris [abstract no:1]. Indian Journal of Dermatology, Venerology and Leprology1990;56:179. [CENTRAL: CN‐00692634] ">Tucker 1984</a>; <a href="./references#CD011154-bbs2-0117" title="ZeichnerJA , WongV , LinknerRV , HaddicanM . Efficacy and safety of tretinoin 0.025%/clindamycin phosphate 1.2% gel in combination with benzoyl peroxide 6% cleansing cloths for the treatment of facial acne vulgaris. Journal of Drugs in Dermatology2013;12(3):277‐82. [CENTRAL: CN‐00876866; MEDLINE: 23545909] ">Zeichner 2013</a>), and two for the medium term (<a href="./references#CD011154-bbs2-0084" title="OzgenZY , GurbuzO . A randomized, double‐blind comparison of nadifloxacin 1% cream alone and with benzoyl peroxide 5% lotion in the treatment of mild to moderate facial acne vulgaris. Marmara Medical Journal2013;26(1):243‐6. [CENTRAL: CN‐00912356] ">Ozgen 2013</a>; <a href="./references#CD011154-bbs2-0086" title="PapageorgiouPP , ChuAC . Chloroxylenol and zinc oxide containing cream (Nels cream) vs. 5% benzoyl peroxide cream in the treatment of acne vulgaris. A double‐blind, randomized, controlled trial. Clinical &amp; Experimental Dermatology2000;25(1):16‐20. [CENTRAL: CN‐00275100; MEDLINE: 10671963] ">Papageorgiou 2000</a>). The treatment duration in <a href="./references#CD011154-bbs2-0112" title="VasarinshP . Benzoyl peroxide‐sulfur lotions in acne vulgaris ‐ a controlled study. Cutis; Cutaneous Medicine for the Practitioner1969;5(1):65‐9. [CENTRAL: CN‐00269401] ">Vasarinsh 1969</a> varied from 4 to 14 weeks. </p> <section id="CD011154-sec-0128"> <p><b>Main pooled analyses: BPO versus placebo or no treatment</b></p> <p>Overall, the data for long‐term outcomes from three trials were complete to be pooled (<a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>; <a href="./references#CD011154-bbs2-0053" title="JawadeSA , SaigaonkarVA , KondalkarAR . Efficacy and tolerability of adapalene 0.1%‐benzoyl peroxide 2.5% combination gel in treatment of acne vulgaris in Indian patients: a randomized investigator‐blind controlled trial. Iranian Journal of Dermatology2016;19(4):105‐12. [CENTRAL: CN‐01405922] ">Jawade 2016</a>; <a href="./references#CD011154-bbs2-0066" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM . Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] LeydenJ , et al. Treatment of acne vulgaris with a combination benzoyl peroxide/clindamycin topical gel Abstract P‐013. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S144. [CENTRAL: CN‐00478651] LeydenJJ , BergerRS , DunlapFE , EllisCN , ConnollyMA , LevySF . Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. American Journal of Clinical Dermatology2001;2(1):33‐9. [CENTRAL: CN‐00363426; MEDLINE: 11702619] ">Leyden 2001a</a>), and a total of 1111 participants in the BPO group and 1123 in the placebo group were included. The treatment duration was 10 weeks and 12 weeks in these trials. The outcome was assessed via a 6‐point or a 5‐point Likert‐like scale. The pooled risk ratio of treatment success was 1.27 (95% confidence interval (CI) 1.12 to 1.45; I² = 58%; <a href="./references#CD011154-fig-0007" title="">Analysis 1.1</a>), which shows some difference in this outcome between groups in favour of BPO treatment. </p> <p>The risk ratio of treatment success for the medium term was 2.70 (95% CI 1.68 to 4.34; I² = 0%; <a href="./references#CD011154-fig-0008" title="">Analysis 1.2</a>) from two trials (<a href="./references#CD011154-bbs2-0084" title="OzgenZY , GurbuzO . A randomized, double‐blind comparison of nadifloxacin 1% cream alone and with benzoyl peroxide 5% lotion in the treatment of mild to moderate facial acne vulgaris. Marmara Medical Journal2013;26(1):243‐6. [CENTRAL: CN‐00912356] ">Ozgen 2013</a>; <a href="./references#CD011154-bbs2-0086" title="PapageorgiouPP , ChuAC . Chloroxylenol and zinc oxide containing cream (Nels cream) vs. 5% benzoyl peroxide cream in the treatment of acne vulgaris. A double‐blind, randomized, controlled trial. Clinical &amp; Experimental Dermatology2000;25(1):16‐20. [CENTRAL: CN‐00275100; MEDLINE: 10671963] ">Papageorgiou 2000</a>). Study authors used two different 6‐point scales to assess the outcome. </p> </section> <section id="CD011154-sec-0129"> <p><b>Subgroup analyses: co‐intervention</b></p> <p>For <a href="./references#CD011154-fig-0007" title="">Analysis 1.1</a> and <a href="./references#CD011154-fig-0008" title="">Analysis 1.2</a>, the test for subgroup differences was not statistically significant, with P values of 0.42 and 0.71, respectively. This suggests that effects of BPO did not differ by the co‐intervention. </p> </section> <section id="CD011154-sec-0130"> <p><b>Studies not included in the meta‐analysis</b></p> <p>For the long‐term outcome, we did not include the other eight trials in the main analysis because the definitions of treatment success used were different from that in our review (<a href="./references#CD011154-bbs2-0005" title="BorglundE , KristensenB , Larsson‐StymneB , StrandA , VeienNK , JakobsenHB . Topical meclocycline sulfosalicylate, benzoyl peroxide, and a combination of the two in the treatment of acne vulgaris. Acta Dermato‐Venereologica1991;71:175‐8. [CENTRAL: CN‐00075962; MEDLINE: 1675534] ">Borglund 1991</a>; <a href="./references#CD011154-bbs2-0023" title="DraelosZD , TanghettiEA . Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis; Cutaneous Medicine for the Practitioner2002;69(2 Suppl):20‐9. [CENTRAL: CN‐00409023; MEDLINE: 12095065] ">Draelos 2002</a>; <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>; <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>; <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>; <a href="./references#CD011154-bbs2-0109" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM , et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] TschenE , et al. A combination benzoyl peroxide/clindamycin topical gel for the treatment of acne vulgaris. Abstract P‐029. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S150. [CENTRAL: CN‐00478786] TschenEH , KatzHI , JonesTM , MonroeEW , KrausSJ , ConnollyMA , et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2):165‐9. [CENTRAL: CN‐00346768; MEDLINE: 11236229] ">Tschen 2001</a>; <a href="./references#CD011154-bbs2-0110" title="TuckerSB , TausendR , CochranR , FlanniganSA . Comparison of topical clindamycin phosphate, benzoyl peroxide, and a combination of the two for the treatment of acne vulgaris. British Journal of Dermatology1984;110(4):487‐92. [CENTRAL: CN‐00568865; MEDLINE: 6231942] TuckerSB , TausendT , CochranR . Comparison of topical clindamycin phosphate, benzoyl peroxide and a combination of the two, for the treatment of acne vulgaris [abstract no:1]. Indian Journal of Dermatology, Venerology and Leprology1990;56:179. [CENTRAL: CN‐00692634] ">Tucker 1984</a>; <a href="./references#CD011154-bbs2-0117" title="ZeichnerJA , WongV , LinknerRV , HaddicanM . Efficacy and safety of tretinoin 0.025%/clindamycin phosphate 1.2% gel in combination with benzoyl peroxide 6% cleansing cloths for the treatment of facial acne vulgaris. Journal of Drugs in Dermatology2013;12(3):277‐82. [CENTRAL: CN‐00876866; MEDLINE: 23545909] ">Zeichner 2013</a>), but sensitivity analysis including these trials suggests similar results (risk ratio (RR) 1.32, 95% CI 1.20 to 1.45) to our main analysis in favour of BPO treatment (<a href="./appendices#CD011154-sec-0588">Appendix 9</a>). </p> <p>This outcome was assessed in the 10‐week trial comparing BPO plus meclocycline versus meclocycline monotherapy (<a href="./references#CD011154-bbs2-0005" title="BorglundE , KristensenB , Larsson‐StymneB , StrandA , VeienNK , JakobsenHB . Topical meclocycline sulfosalicylate, benzoyl peroxide, and a combination of the two in the treatment of acne vulgaris. Acta Dermato‐Venereologica1991;71:175‐8. [CENTRAL: CN‐00075962; MEDLINE: 1675534] ">Borglund 1991</a>), but it is unclear how the outcome was assessed. It was reported that participants rating treatments as "good to excellent" accounted for 55% and 49% in the two groups, respectively, with an RR of 1.13 (95% CI 0.70 to 1.80). </p> <p>This outcome was assessed via a 5‐point Likert‐like scale (from highly favourable to highly unfavourable) in one 12‐week parallel trial (<a href="./references#CD011154-bbs2-0023" title="DraelosZD , TanghettiEA . Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis; Cutaneous Medicine for the Practitioner2002;69(2 Suppl):20‐9. [CENTRAL: CN‐00409023; MEDLINE: 12095065] ">Draelos 2002</a>), with each group comprising 89 participants (BPO plus tazarotene versus tazarotene). At week 12, a significant difference was found in the proportion of participants rating the improvement as highly favourable or favourable (92% versus 73%; P &lt; 0.05) in favour of BPO treatment. </p> <p>In a 12‐week trial (<a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>), 415 participants in the BPO group, 418 in the placebo group, 419 in the BPO/adapalene group, and 418 in the adapalene group were assessed for this outcome via a 6‐point Likert‐like scale. The risk ratio for self‐reported complete or marked improvement was 1.16 (95% CI 1.01 to 1.34) in favour of BPO treatment. </p> <p>A similar 6‐point Likert‐like scale was used in another 12‐week trial in which 149 participants were treated with BPO, 71 with placebo, 149 with BPO/adapalene, and 148 with adapalene (<a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>). The risk ratio for self‐reported complete or marked improvement was 1.53 (95% CI 0.87 to 2.69) with no significant difference. </p> <p><a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>, with 809 participants in the BPO group, 395 in the placebo group, 797 in the BPO/clindamycin group, and 812 in the clindamycin group, assessed the outcome after 12 weeks using a 7‐point Likert‐like scale. The risk ratio for self‐reported clear or almost clear was 1.58 (95% CI 1.35 to 1.86) in favour of BPO treatment. </p> <p>In a 10‐week trial, a 7‐point Likert‐like scale (from 3 = much better to ‐3 = much worse) was used to assess the outcome (95 participants treated with BPO, 48 with placebo, 95 with BPO/clindamycin, and 49 with clindamycin) (<a href="./references#CD011154-bbs2-0109" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM , et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] TschenE , et al. A combination benzoyl peroxide/clindamycin topical gel for the treatment of acne vulgaris. Abstract P‐029. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S150. [CENTRAL: CN‐00478786] TschenEH , KatzHI , JonesTM , MonroeEW , KrausSJ , ConnollyMA , et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2):165‐9. [CENTRAL: CN‐00346768; MEDLINE: 11236229] ">Tschen 2001</a>). The risk ratio for being "much better" on this scale was 2.58 (95% CI 1.42 to 4.68) in favour of BPO treatment. </p> <p>In one 10‐week parallel trial with 24 participants on BPO plus clindamycin treatment and 29 on clindamycin alone, 96% and 95% of participants felt their acne had improved at week 10, respectively, with no statistical difference (<a href="./references#CD011154-bbs2-0110" title="TuckerSB , TausendR , CochranR , FlanniganSA . Comparison of topical clindamycin phosphate, benzoyl peroxide, and a combination of the two for the treatment of acne vulgaris. British Journal of Dermatology1984;110(4):487‐92. [CENTRAL: CN‐00568865; MEDLINE: 6231942] TuckerSB , TausendT , CochranR . Comparison of topical clindamycin phosphate, benzoyl peroxide and a combination of the two, for the treatment of acne vulgaris [abstract no:1]. Indian Journal of Dermatology, Venerology and Leprology1990;56:179. [CENTRAL: CN‐00692634] ">Tucker 1984</a>). However, it is unclear how this outcome was assessed. </p> <p><a href="./references#CD011154-bbs2-0117" title="ZeichnerJA , WongV , LinknerRV , HaddicanM . Efficacy and safety of tretinoin 0.025%/clindamycin phosphate 1.2% gel in combination with benzoyl peroxide 6% cleansing cloths for the treatment of facial acne vulgaris. Journal of Drugs in Dermatology2013;12(3):277‐82. [CENTRAL: CN‐00876866; MEDLINE: 23545909] ">Zeichner 2013</a> included 20 participants in each group (BPO plus tretinoin/clindamycin versus placebo plus tretinoin/clindamycin) and assessed this outcome using a 6‐point Likert‐like scale (0 = clear to 5 = severe). At week 12, no significant difference was found in the proportion of participants who scored 0 or 1 (5/20 versus 2/20; P = 0.24). </p> <p>The long‐term outcome was also assessed in a 12‐week parallel trial comparing BPO plus tretinoin versus placebo plus tretinoin, with completion of follow‐up in 56 of 87 participants (<a href="./references#CD011154-bbs2-0094" title="ShalitaAR , RafalES , AndersonDN , YavelR , LandowS , LeeWL . Compared efficacy and safety of tretinoin 0.1% microsphere gel alone and in combination with benzoyl peroxide 6% cleanser for the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2003;72(2):167‐72. [CENTRAL: CN‐00457639; MEDLINE: 12953944] ">Shalita 2003</a>). No information about the criteria for the measure was available. For this outcome, study authors reported that participants in both groups rated their improvement as mild. </p> <p><a href="./references#CD011154-bbs2-0112" title="VasarinshP . Benzoyl peroxide‐sulfur lotions in acne vulgaris ‐ a controlled study. Cutis; Cutaneous Medicine for the Practitioner1969;5(1):65‐9. [CENTRAL: CN‐00269401] ">Vasarinsh 1969</a>, with varied treatment duration, assessed the outcome using a 4‐point Likert‐like scale (from worse = ‐1 to greatly improved = 2). The average score was 0.66 and 0.53 for the BPO and placebo groups, respectively. This trial also compared BPO/sulphur with sulphur, and the average score was 1.15 and 0.75, respectively. </p> </section> </section> <section id="CD011154-sec-0131"> <h6 class="title">Primary outcome: withdrawal due to adverse effects</h6> <p>A total of 25 trials reported the long‐term outcome (<a href="./references#CD011154-bbs2-0005" title="BorglundE , KristensenB , Larsson‐StymneB , StrandA , VeienNK , JakobsenHB . Topical meclocycline sulfosalicylate, benzoyl peroxide, and a combination of the two in the treatment of acne vulgaris. Acta Dermato‐Venereologica1991;71:175‐8. [CENTRAL: CN‐00075962; MEDLINE: 1675534] ">Borglund 1991</a>; <a href="./references#CD011154-bbs2-0011" title="ChalkerDK , ShalitaA , SmithJG , SwannRW . A double‐blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. Journal of the American Academy of Dermatology1983;9(6):933‐6. [CENTRAL: CN‐00334175; MEDLINE: 6227643] ">Chalker 1983</a>; <a href="./references#CD011154-bbs2-0017" title="CunliffeW . A comparison of the clinical and antimicrobial efficacy of clinoxin AQ gel (1 % w/v clindamycin/5% w/v benzoyl peroxide) and 1% (w/v) clindamycin gel in the treatment of acne. British Journal of Dermatology2000;143(Suppl 57):72. [CENTRAL: CN‐00547635] CunliffeWJ , HollandKT , BojarR , LevySF . A randomized, double‐blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clinical Therapeutics2002;24(7):1117‐33. [CENTRAL: CN‐00404978; MEDLINE: 12182256] ">Cunliffe 2002</a>; <a href="./references#CD011154-bbs2-0023" title="DraelosZD , TanghettiEA . Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis; Cutaneous Medicine for the Practitioner2002;69(2 Suppl):20‐9. [CENTRAL: CN‐00409023; MEDLINE: 12095065] ">Draelos 2002</a>; <a href="./references#CD011154-bbs2-0034" title="EichenfieldL , AlioA . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed dose combination gel for the treatment of acne vulgaris: a multicenter, double‐blind, parallel group, vehicle controlled study. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB10. [DOI: 10.1016/j.jaad.2011.11.049] EichenfieldLF , Alio SaenzAB . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed‐dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double‐blind, active‐ and vehicle‐controlled study. Journal of Drugs in Dermatology2011;10(12):1382‐96. [CENTRAL: CN‐00843726; MEDLINE: 22134562] NCT00776919 . A phase 3 multicenter, randomized, double‐blind, active and vehicle‐controlled study of the safety and efficacy of a clindamycin / benzoyl peroxide gel versus clindamycin gel versus benzoyl peroxide gel versus vehicle gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00776919 (first received 21 October 2008). ">Eichenfield 2011</a>; <a href="./references#CD011154-bbs2-0038" title="FleischerAB , DraelosZD , AbramovitsW , PariserDM . Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4%, or vehicle gel for the treatment of acne vulgaris: a randomized, double‐blind study. Abstract P113. American Academy of Dermatology, 65th Annual Meeting, February 2‐6, 2007. Journal of the American Academy of Dermatology2007;56(2):AB16. [CENTRAL: CN‐00616000] FleischerAB , ShalitaA , EichenfieldLF , AbramovitsW , LuckyA , GarrettSCP . Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: a 12‐week, randomized, double‐blind study. Journal of Drugs in Dermatology2010;9(1):33‐40. [CENTRAL: CN‐00734828; MEDLINE: 20120423] NCT00151541 . A phase 3 study to compare the safety and efficacy of 5% dapsone topical gel (DTG) twice daily in combination with once daily vehicle control, adapalene gel 0.1% or benzoyl peroxide gel 4%. www.clinicaltrials.gov/ct2/show/NCT00151541 (first received 7 September 2005). ">Fleischer 2010</a>; <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>; <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>; <a href="./references#CD011154-bbs2-0049" title="HughesBR . A double blind evaluation of topical isotretinoin, benzoyl peroxide and placebo in patients with acne. British Journal of Dermatology1989;121(s34):42. [DOI: 10.1111/j.1365‐2133.1989.tb05941.x] HughesBR , NorrisJF , CunliffeWJ . A double‐blind evaluation of topical isotretinoin 0.05%, benzoyl peroxide gel 5% and placebo in patients with acne. Clinical &amp; Experimental Dermatology1992;17(3):165‐8. [MEDLINE: 1451291] ">Hughes 1992</a>; <a href="./references#CD011154-bbs2-0052" title="JaffeGV , GrimshawJJ , ConstadD . Benzoyl peroxide in the treatment of acne vulgaris: a double‐blind, multi‐centre comparative study of 'Quinoderm' cream and 'Quinoderm' cream with hydrocortisone versus their base vehicle alone and a benzoyl peroxide only gel preparation. Current Medical Research &amp; Opinion1989;11(7):453‐62. [CENTRAL: CN‐00062342; MEDLINE: 2528439] ">Jaffe 1989</a>; <a href="./references#CD011154-bbs2-0053" title="JawadeSA , SaigaonkarVA , KondalkarAR . Efficacy and tolerability of adapalene 0.1%‐benzoyl peroxide 2.5% combination gel in treatment of acne vulgaris in Indian patients: a randomized investigator‐blind controlled trial. Iranian Journal of Dermatology2016;19(4):105‐12. [CENTRAL: CN‐01405922] ">Jawade 2016</a>; <a href="./references#CD011154-bbs2-0058" title="KawashimaM , HashimotoH , Alio SaenzAB , OnoM , YamadaM . Is benzoyl peroxide 3% topical gel effective and safe in the treatment of acne vulgaris in Japanese patients? A multicenter, randomized, double‐blind, vehicle‐controlled, parallel‐group study. Journal of Dermatology2014;41(9):795‐801. [CENTRAL: CN‐01254201; MEDLINE: 25132461] NCT01400932 . Study STF115288, a clinical confirmation study of GI148512 in the treatment of acne vulgaris in Japanese subjects. www.clinicaltrials.gov/ct2/show/NCT01400932 (first received 21 July 2011). ">Kawashima 2014</a>; <a href="./references#CD011154-bbs2-0059" title="KawashimaM , HashimotoH , Alio SaenzAB , OnoM , YamadaM . Clindamycin phosphate 12%‐benzoyl peroxide 30% fixed‐dose combination gel has an effective and acceptable safety and tolerability profile for the treatment of acne vulgaris in Japanese patients: a phase III, multicentre, randomised, single‐blinded, active‐controlled, parallel‐group study. British Journal of Dermatology2015;172(2):494‐503. [CENTRAL: CN‐01115087] KawashimaM , YamadaM , ParishC . Clindamycin 1%/benzoyl peroxide 3% gel, a new topical combination product, is effective in Japanese patients with acne vulgaris. Journal of Investigative Dermatology2013;133:S160. [CENTRAL: CN‐01026775] ">Kawashima 2015</a>; <a href="./references#CD011154-bbs2-0061" title="KawashimaM , SatoS , FurukawaF , MatsunagaK , AkamatsuH , IgarashiA , et al. Twelve‐week, multicenter, placebo‐controlled, randomized, double‐blind, parallel‐group, comparative phase II/III study of benzoyl peroxide gel in patients with acne vulgaris: a secondary publication. Journal of Dermatology2017; Vol. 44, issue 7:774‐82. [CENTRAL: CN‐01458975] MorimotoH , KikukawaY , MurakamiN . Pharmacological profiles and clinical effects of benzoyl peroxide gel as treatments for acne vulgaris. Nippon Yakurigaku Zasshi ‐ Folia Pharmacologica Japonica2015;146(4):225‐32. [PUBMED: 26656967] ">Kawashima 2017b</a>; <a href="./references#CD011154-bbs2-0063" title="KorkutC , PiskinS . Benzoyl peroxide, adapalene, and their combination in the treatment of acne vulgaris. Journal of Dermatology2005;32(3):169‐73. [CENTRAL: CN‐00512006] ">Korkut 2005</a>; <a href="./references#CD011154-bbs2-0066" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM . Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] LeydenJ , et al. Treatment of acne vulgaris with a combination benzoyl peroxide/clindamycin topical gel Abstract P‐013. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S144. [CENTRAL: CN‐00478651] LeydenJJ , BergerRS , DunlapFE , EllisCN , ConnollyMA , LevySF . Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. American Journal of Clinical Dermatology2001;2(1):33‐9. [CENTRAL: CN‐00363426; MEDLINE: 11702619] ">Leyden 2001a</a>; <a href="./references#CD011154-bbs2-0069" title="LookingbillDP , ChalkerDK , LindholmJS , KatzHI , KempersSE , HuerterCJ , et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double‐blind investigations. Journal of the American Academy of Dermatology1997;37(4):590‐5. [CENTRAL: CN‐00144503; MEDLINE: 9344199] LookingbillDP , ChallenDK , LindholmJS . Treatment of acne with a combination of clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined result of two double blind investigations (Abstract no. 1). Indian Journal of Dermatology, Venerology and Leprology1995;61:398. ">Lookingbill 1997</a>; <a href="./references#CD011154-bbs2-0075" title="MiyachiY , MizziF , MitaT , BaiL , IkomaA . Efficacy and safety of a fixed dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% in Japanese patients with acne vulgaris ‐ a multicenter, randomized, double‐blinded, active‐controlled, parallel group phase III study. [Japanese]. Skin Research2016;15(4):278‐93. NCT02073448 . Efficacy and safety study of GK530G versus CD0271 0.1% gel and CD1579 2.5% gel in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02073448 (first received 20 February 2014). ">Miyachi 2016</a>; <a href="./references#CD011154-bbs2-0076" title="2015‐004900‐44 . A multi‐center randomized double blind vehicle‐controlled, phase 2 study of the safety and efficacy of benzoyl peroxide/clindamycin gel and tazarotene cream when used in combination in the treatment of acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2015‐004900‐44/results (results published 23 March 2017). NCT00713609 . Safety and efficacy study of clindamycin/benzoyl peroxide/tazarotene cream in subjects with acne. clinicaltrials.gov/ct2/show/NCT00713609 (first received 7 July 2008). ">NCT00713609</a>; <a href="./references#CD011154-bbs2-0101" title="FDA , Center for Drug Evaluation and Research. Study 156. Medical Review of NDA 50‐741. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50‐741_duac%20topical%20gel_medr_p1.pdf. ">Study 156</a>; <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>; <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>; <a href="./references#CD011154-bbs2-0108" title="Tirado‐SanchezA , Ponce‐OliveraRM . Efficacy and tolerance of superoxidized solution in the treatment of mild to moderate inflammatory acne. A double‐blinded, placebo‐ controlled, parallel‐group, randomized, clinical trial. Journal of Dermatological Treatment2009;20(5):289‐92. [CENTRAL: CN‐00743204; MEDLINE: 19459079] ">Tirado‐Sanchez 2009</a>; <a href="./references#CD011154-bbs2-0109" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM , et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] TschenE , et al. A combination benzoyl peroxide/clindamycin topical gel for the treatment of acne vulgaris. Abstract P‐029. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S150. [CENTRAL: CN‐00478786] TschenEH , KatzHI , JonesTM , MonroeEW , KrausSJ , ConnollyMA , et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2):165‐9. [CENTRAL: CN‐00346768; MEDLINE: 11236229] ">Tschen 2001</a>; <a href="./references#CD011154-bbs2-0115" title="2015‐004909‐16 . A multicentre, randomized, assessor‐blind, comparator‐controlled, parallel‐group clinical trial to establish the efficacy and safety of Duac™ (1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide) once daily gel compared with clindamycin phosphate gel (1% clindamycin as clindamycin phosphate) twice daily in the treatment of mild to moderate acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2015‐004909‐16/results (results published 29 December 2016). NCT01915732 . Efficacy and safety of Duac™ compared with clindamycin phosphate gel in the treatment of mild to moderate acne vulgaris. clinicaltrials.gov/ct2/show/NCT01915732 (first received 5 April 2013). XuJ , LuQ , HuangJ , SunQ , HaoF , GuJ , et al. A multicenter, randomized, single‐blind study of topical clindamycin 1%/benzoyl peroxide 5% once‐daily fixed dose combination gel (Duac) vs. clindamycin 1% twice‐daily gel in treatment of Chinese acne vulgaris patients. Journal of Investigative Dermatology2015;135(Suppl 2):S34, 192. [CENTRAL: CN‐01130701] XuJH , LuQJ , HuangJH , HaoF , SunQN , FangH , et al. A multicentre, randomized, single‐blind comparison of topical clindamycin 1%/benzoyl peroxide 5% once‐daily gel versus clindamycin 1% twice‐daily gel in the treatment of mild to moderate acne vulgaris in Chinese patients. Journal of the European Academy of Dermatology and Venereology2016;30(7):1176‐82. [CENTRAL: CN‐01178389; MEDLINE: 27075705] ">Xu 2016</a>), four reported the medium‐term outcome (<a href="./references#CD011154-bbs2-0008" title="BurkeB , EadyEA , CunliffeWJ . Benzoyl peroxide versus topical erythromycin in the treatment of acne vulgaris. British Journal of Dermatology1983;108(2):199‐204. [CENTRAL: CN‐00568861; MEDLINE: 6218815] ">Burke 1983</a>; <a href="./references#CD011154-bbs2-0074" title="Mills JrOH , KligmanAM , PochiP , ComiteH . Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. International Journal of Dermatology1986;25(10):664‐7. [CENTRAL: CN‐00046261; MEDLINE: 2948929] ">Mills 1986</a>; <a href="./references#CD011154-bbs2-0084" title="OzgenZY , GurbuzO . A randomized, double‐blind comparison of nadifloxacin 1% cream alone and with benzoyl peroxide 5% lotion in the treatment of mild to moderate facial acne vulgaris. Marmara Medical Journal2013;26(1):243‐6. [CENTRAL: CN‐00912356] ">Ozgen 2013</a>; <a href="./references#CD011154-bbs2-0086" title="PapageorgiouPP , ChuAC . Chloroxylenol and zinc oxide containing cream (Nels cream) vs. 5% benzoyl peroxide cream in the treatment of acne vulgaris. A double‐blind, randomized, controlled trial. Clinical &amp; Experimental Dermatology2000;25(1):16‐20. [CENTRAL: CN‐00275100; MEDLINE: 10671963] ">Papageorgiou 2000</a>), and one reported the short‐term outcome (<a href="./references#CD011154-bbs2-0024" title="DraelosZD , PottsA , Alio SaenzAB . Randomized tolerability analysis of clindamycin phosphate 1.2%‐tretinoin 0.025% gel used with benzoyl peroxide wash 4% for acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(6):310‐8. [CENTRAL: CN‐00770969; MEDLINE: 21284283] NCT00891982 . A phase 3, multicenter, assessor‐blinded study of the tolerability of a topical antibiotic and retinoid used in conjunction with benzoyl peroxide wash in subjects with mild‐to‐moderate facial acne vulgaris. clinicaltrials.gov/ct2/show/NCT00891982 (first received 29 April 2009). ">Draelos 2010</a>). </p> <section id="CD011154-sec-0132"> <p><b>Main pooled analyses: BPO versus placebo or no treatment</b></p> <p>For the long‐term period, risk of withdrawal due to adverse events was higher in the BPO group (RR 2.13, 95% CI 1.55 to 2.93; 13,744 participants; I² = 0%; <a href="./references#CD011154-fig-0009" title="">Analysis 1.3</a>). According to the funnel plot (<a href="#CD011154-fig-0004">Figure 4</a>) and Egger's test (P = 0.753), no evidence suggests potential publication bias. Erythema, pruritus, and skin burning were the most common causes of withdrawal. </p> <div class="figure" id="CD011154-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 BPO versus placebo or no treatment, outcome: 1.3 Withdrawal due to adverse effects (long‐term data)." data-id="CD011154-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 BPO versus placebo or no treatment, outcome: 1.3 Withdrawal due to adverse effects (long‐term data). </p> </div> </div> </div> <p>In terms of the medium‐term outcome, one trial found no withdrawals due to adverse effects (<a href="./references#CD011154-bbs2-0074" title="Mills JrOH , KligmanAM , PochiP , ComiteH . Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. International Journal of Dermatology1986;25(10):664‐7. [CENTRAL: CN‐00046261; MEDLINE: 2948929] ">Mills 1986</a>), another trial observed that only one participant discontinued BPO treatment (due to dermatitis) (<a href="./references#CD011154-bbs2-0008" title="BurkeB , EadyEA , CunliffeWJ . Benzoyl peroxide versus topical erythromycin in the treatment of acne vulgaris. British Journal of Dermatology1983;108(2):199‐204. [CENTRAL: CN‐00568861; MEDLINE: 6218815] ">Burke 1983</a>), and one trial reported that only one participant on BPO plus nadifloxacin withdrew because of a severe burning sensation (<a href="./references#CD011154-bbs2-0084" title="OzgenZY , GurbuzO . A randomized, double‐blind comparison of nadifloxacin 1% cream alone and with benzoyl peroxide 5% lotion in the treatment of mild to moderate facial acne vulgaris. Marmara Medical Journal2013;26(1):243‐6. [CENTRAL: CN‐00912356] ">Ozgen 2013</a>). These three trials suggested no clear differences between the two groups (RR 2.92, 95% CI 0.31 to 27.44; 202 participants; 3 studies; I² = 0%; <a href="./references#CD011154-fig-0010" title="">Analysis 1.4</a>). </p> </section> <section id="CD011154-sec-0133"> <p><b>Subgroup analyses: co‐intervention</b></p> <p>For long‐term data, the test for subgroup differences showed a borderline statistically significant difference when different co‐interventions were used (P = 0.05; <a href="./references#CD011154-fig-0009" title="">Analysis 1.3</a>). This potential difference came from the comparison between BPO plus tazarotene and tazarotene. In this comparison, BPO treatment was associated with non‐significantly decreased risk of withdrawal from the trial, but in other comparisons the association was opposite. </p> <p>For medium‐term data, we did not observe significant differences between subgroups (P = 1.00; <a href="./references#CD011154-fig-0010" title="">Analysis 1.4</a>). </p> <p><i>Studies not included in the meta‐analysis</i> </p> <p><a href="./references#CD011154-bbs2-0005" title="BorglundE , KristensenB , Larsson‐StymneB , StrandA , VeienNK , JakobsenHB . Topical meclocycline sulfosalicylate, benzoyl peroxide, and a combination of the two in the treatment of acne vulgaris. Acta Dermato‐Venereologica1991;71:175‐8. [CENTRAL: CN‐00075962; MEDLINE: 1675534] ">Borglund 1991</a>, the long‐term trial, reported that no participants discontinued BPO plus meclocycline or meclocycline monotherapy due to adverse events (<a href="./appendices#CD011154-sec-0589">Appendix 10</a>). </p> <p>Two studies, which assessed medium‐ and short‐term outcomes, respectively, were not included in the meta‐analysis. <a href="./references#CD011154-bbs2-0086" title="PapageorgiouPP , ChuAC . Chloroxylenol and zinc oxide containing cream (Nels cream) vs. 5% benzoyl peroxide cream in the treatment of acne vulgaris. A double‐blind, randomized, controlled trial. Clinical &amp; Experimental Dermatology2000;25(1):16‐20. [CENTRAL: CN‐00275100; MEDLINE: 10671963] ">Papageorgiou 2000</a> reported that two participants discontinued treatments because of flare‐up. However, it is unclear what treatments the participants received previously. </p> <p>The other trial was the only one that focused on the short‐term outcome. Of 61 participants enrolled (30 in the BPO plus tretinoin/clindamycin group and 31 in the placebo plus tretinoin/clindamycin group), no participants discontinued treatment because of adverse events during the four‐week period (<a href="./references#CD011154-bbs2-0024" title="DraelosZD , PottsA , Alio SaenzAB . Randomized tolerability analysis of clindamycin phosphate 1.2%‐tretinoin 0.025% gel used with benzoyl peroxide wash 4% for acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(6):310‐8. [CENTRAL: CN‐00770969; MEDLINE: 21284283] NCT00891982 . A phase 3, multicenter, assessor‐blinded study of the tolerability of a topical antibiotic and retinoid used in conjunction with benzoyl peroxide wash in subjects with mild‐to‐moderate facial acne vulgaris. clinicaltrials.gov/ct2/show/NCT00891982 (first received 29 April 2009). ">Draelos 2010</a>). </p> </section> </section> <section id="CD011154-sec-0134"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <p>Although 32 included trials assessed acne lesions (<a href="./references#CD011154-bbs2-0005" title="BorglundE , KristensenB , Larsson‐StymneB , StrandA , VeienNK , JakobsenHB . Topical meclocycline sulfosalicylate, benzoyl peroxide, and a combination of the two in the treatment of acne vulgaris. Acta Dermato‐Venereologica1991;71:175‐8. [CENTRAL: CN‐00075962; MEDLINE: 1675534] ">Borglund 1991</a>; <a href="./references#CD011154-bbs2-0008" title="BurkeB , EadyEA , CunliffeWJ . Benzoyl peroxide versus topical erythromycin in the treatment of acne vulgaris. British Journal of Dermatology1983;108(2):199‐204. [CENTRAL: CN‐00568861; MEDLINE: 6218815] ">Burke 1983</a>; <a href="./references#CD011154-bbs2-0010" title="CassanoN , AlessandriniG , CarrieriG , FaiD , GabbelloneM , GravanteM , et al. Treatment of mild to moderate acne vulgaris with adapalene alone or combined with other anti‐acne agents. A multicenter open trial. [Studio multicentrico in aperto sul trattamento dell'acne lieve/moderata con adapalene in monoterapia o in terapia combinata]. Giornale Italiano di Dermatologia e Venereologia2002;137(5):369‐75. [CENTRAL: CN‐00432115] ">Cassano 2002</a>; <a href="./references#CD011154-bbs2-0011" title="ChalkerDK , ShalitaA , SmithJG , SwannRW . A double‐blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. Journal of the American Academy of Dermatology1983;9(6):933‐6. [CENTRAL: CN‐00334175; MEDLINE: 6227643] ">Chalker 1983</a>; <a href="./references#CD011154-bbs2-0017" title="CunliffeW . A comparison of the clinical and antimicrobial efficacy of clinoxin AQ gel (1 % w/v clindamycin/5% w/v benzoyl peroxide) and 1% (w/v) clindamycin gel in the treatment of acne. British Journal of Dermatology2000;143(Suppl 57):72. [CENTRAL: CN‐00547635] CunliffeWJ , HollandKT , BojarR , LevySF . A randomized, double‐blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clinical Therapeutics2002;24(7):1117‐33. [CENTRAL: CN‐00404978; MEDLINE: 12182256] ">Cunliffe 2002</a>; <a href="./references#CD011154-bbs2-0023" title="DraelosZD , TanghettiEA . Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis; Cutaneous Medicine for the Practitioner2002;69(2 Suppl):20‐9. [CENTRAL: CN‐00409023; MEDLINE: 12095065] ">Draelos 2002</a>; <a href="./references#CD011154-bbs2-0033" title="EdeM . A double blind, comparative study of benzoyl peroxide, benzoyl peroxide chlorhydroxyquinoline, benzoyl peroxide chlorhydroxyquinoline hydrocortisone, and placebo lotions in acne. Current Therapeutic Research ‐ Clinical and Experimental1973;15(9):624‐9. [CENTRAL: CN‐00009208; MEDLINE: 4270828] ">Ede 1973</a>; <a href="./references#CD011154-bbs2-0034" title="EichenfieldL , AlioA . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed dose combination gel for the treatment of acne vulgaris: a multicenter, double‐blind, parallel group, vehicle controlled study. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB10. [DOI: 10.1016/j.jaad.2011.11.049] EichenfieldLF , Alio SaenzAB . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed‐dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double‐blind, active‐ and vehicle‐controlled study. Journal of Drugs in Dermatology2011;10(12):1382‐96. [CENTRAL: CN‐00843726; MEDLINE: 22134562] NCT00776919 . A phase 3 multicenter, randomized, double‐blind, active and vehicle‐controlled study of the safety and efficacy of a clindamycin / benzoyl peroxide gel versus clindamycin gel versus benzoyl peroxide gel versus vehicle gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00776919 (first received 21 October 2008). ">Eichenfield 2011</a>; <a href="./references#CD011154-bbs2-0037" title="FangL , FuW , GuJ , SunJ , MaE . Efficacy and safety of benzoyl peroxide gel, 5% combined with adapalene gel, 0.1% in Chinese patients with acne vulgaris (Abstract). 20th World Congress of Dermatology, Paris, 1st to 5th July 2002. Annales de Dermatologie et de Venereologie2002;129(Suppl 1 Pt 2):P0020. [CENTRAL: CN‐00454223] ">Fang 2002</a>; <a href="./references#CD011154-bbs2-0038" title="FleischerAB , DraelosZD , AbramovitsW , PariserDM . Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4%, or vehicle gel for the treatment of acne vulgaris: a randomized, double‐blind study. Abstract P113. American Academy of Dermatology, 65th Annual Meeting, February 2‐6, 2007. Journal of the American Academy of Dermatology2007;56(2):AB16. [CENTRAL: CN‐00616000] FleischerAB , ShalitaA , EichenfieldLF , AbramovitsW , LuckyA , GarrettSCP . Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: a 12‐week, randomized, double‐blind study. Journal of Drugs in Dermatology2010;9(1):33‐40. [CENTRAL: CN‐00734828; MEDLINE: 20120423] NCT00151541 . A phase 3 study to compare the safety and efficacy of 5% dapsone topical gel (DTG) twice daily in combination with once daily vehicle control, adapalene gel 0.1% or benzoyl peroxide gel 4%. www.clinicaltrials.gov/ct2/show/NCT00151541 (first received 7 September 2005). ">Fleischer 2010</a>; <a href="./references#CD011154-bbs2-0039" title="FuWW , FangL , GuJ , ShunJF . Clinical efficacy and safety of 5% benzoyl peroxide gel combined with 0.1% adapalene gel in the treatment of acne vulgaris: a multicenter, randomized study. Chinese Journal of Dermatology2003;36(6):310‐2. [CENTRAL: CN‐00484027] ">Fu 2003</a>; <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>; <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>; <a href="./references#CD011154-bbs2-0049" title="HughesBR . A double blind evaluation of topical isotretinoin, benzoyl peroxide and placebo in patients with acne. British Journal of Dermatology1989;121(s34):42. [DOI: 10.1111/j.1365‐2133.1989.tb05941.x] HughesBR , NorrisJF , CunliffeWJ . A double‐blind evaluation of topical isotretinoin 0.05%, benzoyl peroxide gel 5% and placebo in patients with acne. Clinical &amp; Experimental Dermatology1992;17(3):165‐8. [MEDLINE: 1451291] ">Hughes 1992</a>; <a href="./references#CD011154-bbs2-0058" title="KawashimaM , HashimotoH , Alio SaenzAB , OnoM , YamadaM . Is benzoyl peroxide 3% topical gel effective and safe in the treatment of acne vulgaris in Japanese patients? A multicenter, randomized, double‐blind, vehicle‐controlled, parallel‐group study. Journal of Dermatology2014;41(9):795‐801. [CENTRAL: CN‐01254201; MEDLINE: 25132461] NCT01400932 . Study STF115288, a clinical confirmation study of GI148512 in the treatment of acne vulgaris in Japanese subjects. www.clinicaltrials.gov/ct2/show/NCT01400932 (first received 21 July 2011). ">Kawashima 2014</a>; <a href="./references#CD011154-bbs2-0063" title="KorkutC , PiskinS . Benzoyl peroxide, adapalene, and their combination in the treatment of acne vulgaris. Journal of Dermatology2005;32(3):169‐73. [CENTRAL: CN‐00512006] ">Korkut 2005</a>; <a href="./references#CD011154-bbs2-0066" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM . Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] LeydenJ , et al. Treatment of acne vulgaris with a combination benzoyl peroxide/clindamycin topical gel Abstract P‐013. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S144. [CENTRAL: CN‐00478651] LeydenJJ , BergerRS , DunlapFE , EllisCN , ConnollyMA , LevySF . Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. American Journal of Clinical Dermatology2001;2(1):33‐9. [CENTRAL: CN‐00363426; MEDLINE: 11702619] ">Leyden 2001a</a>; <a href="./references#CD011154-bbs2-0069" title="LookingbillDP , ChalkerDK , LindholmJS , KatzHI , KempersSE , HuerterCJ , et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double‐blind investigations. Journal of the American Academy of Dermatology1997;37(4):590‐5. [CENTRAL: CN‐00144503; MEDLINE: 9344199] LookingbillDP , ChallenDK , LindholmJS . Treatment of acne with a combination of clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined result of two double blind investigations (Abstract no. 1). Indian Journal of Dermatology, Venerology and Leprology1995;61:398. ">Lookingbill 1997</a>; <a href="./references#CD011154-bbs2-0074" title="Mills JrOH , KligmanAM , PochiP , ComiteH . Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. International Journal of Dermatology1986;25(10):664‐7. [CENTRAL: CN‐00046261; MEDLINE: 2948929] ">Mills 1986</a>; <a href="./references#CD011154-bbs2-0075" title="MiyachiY , MizziF , MitaT , BaiL , IkomaA . Efficacy and safety of a fixed dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% in Japanese patients with acne vulgaris ‐ a multicenter, randomized, double‐blinded, active‐controlled, parallel group phase III study. [Japanese]. Skin Research2016;15(4):278‐93. NCT02073448 . Efficacy and safety study of GK530G versus CD0271 0.1% gel and CD1579 2.5% gel in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02073448 (first received 20 February 2014). ">Miyachi 2016</a>; <a href="./references#CD011154-bbs2-0082" title="NCT02073461 . Efficacy and safety study of 2 different concentrations of CD1579 gels versus vehicle in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02073461 (first received 20 February 2014). ">NCT02073461</a>; <a href="./references#CD011154-bbs2-0084" title="OzgenZY , GurbuzO . A randomized, double‐blind comparison of nadifloxacin 1% cream alone and with benzoyl peroxide 5% lotion in the treatment of mild to moderate facial acne vulgaris. Marmara Medical Journal2013;26(1):243‐6. [CENTRAL: CN‐00912356] ">Ozgen 2013</a>; <a href="./references#CD011154-bbs2-0086" title="PapageorgiouPP , ChuAC . Chloroxylenol and zinc oxide containing cream (Nels cream) vs. 5% benzoyl peroxide cream in the treatment of acne vulgaris. A double‐blind, randomized, controlled trial. Clinical &amp; Experimental Dermatology2000;25(1):16‐20. [CENTRAL: CN‐00275100; MEDLINE: 10671963] ">Papageorgiou 2000</a>; <a href="./references#CD011154-bbs2-0094" title="ShalitaAR , RafalES , AndersonDN , YavelR , LandowS , LeeWL . Compared efficacy and safety of tretinoin 0.1% microsphere gel alone and in combination with benzoyl peroxide 6% cleanser for the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2003;72(2):167‐72. [CENTRAL: CN‐00457639; MEDLINE: 12953944] ">Shalita 2003</a>; <a href="./references#CD011154-bbs2-0100" title="FDA , Center for Drug Evaluation and Research. Study 152. Medical Review of NDA 50‐741. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50‐741_duac%20topical%20gel_medr_p1.pdf. ">Study 152</a>; <a href="./references#CD011154-bbs2-0101" title="FDA , Center for Drug Evaluation and Research. Study 156. Medical Review of NDA 50‐741. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50‐741_duac%20topical%20gel_medr_p1.pdf. ">Study 156</a>; <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>; <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>; <a href="./references#CD011154-bbs2-0108" title="Tirado‐SanchezA , Ponce‐OliveraRM . Efficacy and tolerance of superoxidized solution in the treatment of mild to moderate inflammatory acne. A double‐blinded, placebo‐ controlled, parallel‐group, randomized, clinical trial. Journal of Dermatological Treatment2009;20(5):289‐92. [CENTRAL: CN‐00743204; MEDLINE: 19459079] ">Tirado‐Sanchez 2009</a>; <a href="./references#CD011154-bbs2-0109" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM , et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] TschenE , et al. A combination benzoyl peroxide/clindamycin topical gel for the treatment of acne vulgaris. Abstract P‐029. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S150. [CENTRAL: CN‐00478786] TschenEH , KatzHI , JonesTM , MonroeEW , KrausSJ , ConnollyMA , et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2):165‐9. [CENTRAL: CN‐00346768; MEDLINE: 11236229] ">Tschen 2001</a>; <a href="./references#CD011154-bbs2-0110" title="TuckerSB , TausendR , CochranR , FlanniganSA . Comparison of topical clindamycin phosphate, benzoyl peroxide, and a combination of the two for the treatment of acne vulgaris. British Journal of Dermatology1984;110(4):487‐92. [CENTRAL: CN‐00568865; MEDLINE: 6231942] TuckerSB , TausendT , CochranR . Comparison of topical clindamycin phosphate, benzoyl peroxide and a combination of the two, for the treatment of acne vulgaris [abstract no:1]. Indian Journal of Dermatology, Venerology and Leprology1990;56:179. [CENTRAL: CN‐00692634] ">Tucker 1984</a>; <a href="./references#CD011154-bbs2-0115" title="2015‐004909‐16 . A multicentre, randomized, assessor‐blind, comparator‐controlled, parallel‐group clinical trial to establish the efficacy and safety of Duac™ (1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide) once daily gel compared with clindamycin phosphate gel (1% clindamycin as clindamycin phosphate) twice daily in the treatment of mild to moderate acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2015‐004909‐16/results (results published 29 December 2016). NCT01915732 . Efficacy and safety of Duac™ compared with clindamycin phosphate gel in the treatment of mild to moderate acne vulgaris. clinicaltrials.gov/ct2/show/NCT01915732 (first received 5 April 2013). XuJ , LuQ , HuangJ , SunQ , HaoF , GuJ , et al. A multicenter, randomized, single‐blind study of topical clindamycin 1%/benzoyl peroxide 5% once‐daily fixed dose combination gel (Duac) vs. clindamycin 1% twice‐daily gel in treatment of Chinese acne vulgaris patients. Journal of Investigative Dermatology2015;135(Suppl 2):S34, 192. [CENTRAL: CN‐01130701] XuJH , LuQJ , HuangJH , HaoF , SunQN , FangH , et al. A multicentre, randomized, single‐blind comparison of topical clindamycin 1%/benzoyl peroxide 5% once‐daily gel versus clindamycin 1% twice‐daily gel in the treatment of mild to moderate acne vulgaris in Chinese patients. Journal of the European Academy of Dermatology and Venereology2016;30(7):1176‐82. [CENTRAL: CN‐01178389; MEDLINE: 27075705] ">Xu 2016</a>), only 10 trials provided sufficient data for our review to estimate effect size for the absolute or percentage change in total lesions (TLs), inflamed lesions (ILs), or non‐inflamed lesions (NILs) (<a href="./references#CD011154-bbs2-0008" title="BurkeB , EadyEA , CunliffeWJ . Benzoyl peroxide versus topical erythromycin in the treatment of acne vulgaris. British Journal of Dermatology1983;108(2):199‐204. [CENTRAL: CN‐00568861; MEDLINE: 6218815] ">Burke 1983</a>; <a href="./references#CD011154-bbs2-0017" title="CunliffeW . A comparison of the clinical and antimicrobial efficacy of clinoxin AQ gel (1 % w/v clindamycin/5% w/v benzoyl peroxide) and 1% (w/v) clindamycin gel in the treatment of acne. British Journal of Dermatology2000;143(Suppl 57):72. [CENTRAL: CN‐00547635] CunliffeWJ , HollandKT , BojarR , LevySF . A randomized, double‐blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clinical Therapeutics2002;24(7):1117‐33. [CENTRAL: CN‐00404978; MEDLINE: 12182256] ">Cunliffe 2002</a>; <a href="./references#CD011154-bbs2-0034" title="EichenfieldL , AlioA . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed dose combination gel for the treatment of acne vulgaris: a multicenter, double‐blind, parallel group, vehicle controlled study. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB10. [DOI: 10.1016/j.jaad.2011.11.049] EichenfieldLF , Alio SaenzAB . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed‐dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double‐blind, active‐ and vehicle‐controlled study. Journal of Drugs in Dermatology2011;10(12):1382‐96. [CENTRAL: CN‐00843726; MEDLINE: 22134562] NCT00776919 . A phase 3 multicenter, randomized, double‐blind, active and vehicle‐controlled study of the safety and efficacy of a clindamycin / benzoyl peroxide gel versus clindamycin gel versus benzoyl peroxide gel versus vehicle gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00776919 (first received 21 October 2008). ">Eichenfield 2011</a>; <a href="./references#CD011154-bbs2-0038" title="FleischerAB , DraelosZD , AbramovitsW , PariserDM . Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4%, or vehicle gel for the treatment of acne vulgaris: a randomized, double‐blind study. Abstract P113. American Academy of Dermatology, 65th Annual Meeting, February 2‐6, 2007. Journal of the American Academy of Dermatology2007;56(2):AB16. [CENTRAL: CN‐00616000] FleischerAB , ShalitaA , EichenfieldLF , AbramovitsW , LuckyA , GarrettSCP . Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: a 12‐week, randomized, double‐blind study. Journal of Drugs in Dermatology2010;9(1):33‐40. [CENTRAL: CN‐00734828; MEDLINE: 20120423] NCT00151541 . A phase 3 study to compare the safety and efficacy of 5% dapsone topical gel (DTG) twice daily in combination with once daily vehicle control, adapalene gel 0.1% or benzoyl peroxide gel 4%. www.clinicaltrials.gov/ct2/show/NCT00151541 (first received 7 September 2005). ">Fleischer 2010</a>; <a href="./references#CD011154-bbs2-0049" title="HughesBR . A double blind evaluation of topical isotretinoin, benzoyl peroxide and placebo in patients with acne. British Journal of Dermatology1989;121(s34):42. [DOI: 10.1111/j.1365‐2133.1989.tb05941.x] HughesBR , NorrisJF , CunliffeWJ . A double‐blind evaluation of topical isotretinoin 0.05%, benzoyl peroxide gel 5% and placebo in patients with acne. Clinical &amp; Experimental Dermatology1992;17(3):165‐8. [MEDLINE: 1451291] ">Hughes 1992</a>; <a href="./references#CD011154-bbs2-0058" title="KawashimaM , HashimotoH , Alio SaenzAB , OnoM , YamadaM . Is benzoyl peroxide 3% topical gel effective and safe in the treatment of acne vulgaris in Japanese patients? A multicenter, randomized, double‐blind, vehicle‐controlled, parallel‐group study. Journal of Dermatology2014;41(9):795‐801. [CENTRAL: CN‐01254201; MEDLINE: 25132461] NCT01400932 . Study STF115288, a clinical confirmation study of GI148512 in the treatment of acne vulgaris in Japanese subjects. www.clinicaltrials.gov/ct2/show/NCT01400932 (first received 21 July 2011). ">Kawashima 2014</a>; <a href="./references#CD011154-bbs2-0069" title="LookingbillDP , ChalkerDK , LindholmJS , KatzHI , KempersSE , HuerterCJ , et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double‐blind investigations. Journal of the American Academy of Dermatology1997;37(4):590‐5. [CENTRAL: CN‐00144503; MEDLINE: 9344199] LookingbillDP , ChallenDK , LindholmJS . Treatment of acne with a combination of clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined result of two double blind investigations (Abstract no. 1). Indian Journal of Dermatology, Venerology and Leprology1995;61:398. ">Lookingbill 1997</a>; <a href="./references#CD011154-bbs2-0074" title="Mills JrOH , KligmanAM , PochiP , ComiteH . Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. International Journal of Dermatology1986;25(10):664‐7. [CENTRAL: CN‐00046261; MEDLINE: 2948929] ">Mills 1986</a>; <a href="./references#CD011154-bbs2-0086" title="PapageorgiouPP , ChuAC . Chloroxylenol and zinc oxide containing cream (Nels cream) vs. 5% benzoyl peroxide cream in the treatment of acne vulgaris. A double‐blind, randomized, controlled trial. Clinical &amp; Experimental Dermatology2000;25(1):16‐20. [CENTRAL: CN‐00275100; MEDLINE: 10671963] ">Papageorgiou 2000</a>; <a href="./references#CD011154-bbs2-0115" title="2015‐004909‐16 . A multicentre, randomized, assessor‐blind, comparator‐controlled, parallel‐group clinical trial to establish the efficacy and safety of Duac™ (1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide) once daily gel compared with clindamycin phosphate gel (1% clindamycin as clindamycin phosphate) twice daily in the treatment of mild to moderate acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2015‐004909‐16/results (results published 29 December 2016). NCT01915732 . Efficacy and safety of Duac™ compared with clindamycin phosphate gel in the treatment of mild to moderate acne vulgaris. clinicaltrials.gov/ct2/show/NCT01915732 (first received 5 April 2013). XuJ , LuQ , HuangJ , SunQ , HaoF , GuJ , et al. A multicenter, randomized, single‐blind study of topical clindamycin 1%/benzoyl peroxide 5% once‐daily fixed dose combination gel (Duac) vs. clindamycin 1% twice‐daily gel in treatment of Chinese acne vulgaris patients. Journal of Investigative Dermatology2015;135(Suppl 2):S34, 192. [CENTRAL: CN‐01130701] XuJH , LuQJ , HuangJH , HaoF , SunQN , FangH , et al. A multicentre, randomized, single‐blind comparison of topical clindamycin 1%/benzoyl peroxide 5% once‐daily gel versus clindamycin 1% twice‐daily gel in the treatment of mild to moderate acne vulgaris in Chinese patients. Journal of the European Academy of Dermatology and Venereology2016;30(7):1176‐82. [CENTRAL: CN‐01178389; MEDLINE: 27075705] ">Xu 2016</a>). </p> <section id="CD011154-sec-0135"> <p><b>Main pooled analyses: BPO versus placebo or no treatment</b></p> <p>For long‐term treatment duration, the absolute change in TLs pooled from the three trials was ‐10.73 (95% CI ‐15.68 to ‐5.78; 3230 participants; I² = 84%; <a href="./references#CD011154-fig-0011" title="">Analysis 1.5</a>), in favour of both BPO monotherapy and add‐on treatment (<a href="./references#CD011154-bbs2-0034" title="EichenfieldL , AlioA . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed dose combination gel for the treatment of acne vulgaris: a multicenter, double‐blind, parallel group, vehicle controlled study. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB10. [DOI: 10.1016/j.jaad.2011.11.049] EichenfieldLF , Alio SaenzAB . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed‐dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double‐blind, active‐ and vehicle‐controlled study. Journal of Drugs in Dermatology2011;10(12):1382‐96. [CENTRAL: CN‐00843726; MEDLINE: 22134562] NCT00776919 . A phase 3 multicenter, randomized, double‐blind, active and vehicle‐controlled study of the safety and efficacy of a clindamycin / benzoyl peroxide gel versus clindamycin gel versus benzoyl peroxide gel versus vehicle gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00776919 (first received 21 October 2008). ">Eichenfield 2011</a>; <a href="./references#CD011154-bbs2-0058" title="KawashimaM , HashimotoH , Alio SaenzAB , OnoM , YamadaM . Is benzoyl peroxide 3% topical gel effective and safe in the treatment of acne vulgaris in Japanese patients? A multicenter, randomized, double‐blind, vehicle‐controlled, parallel‐group study. Journal of Dermatology2014;41(9):795‐801. [CENTRAL: CN‐01254201; MEDLINE: 25132461] NCT01400932 . Study STF115288, a clinical confirmation study of GI148512 in the treatment of acne vulgaris in Japanese subjects. www.clinicaltrials.gov/ct2/show/NCT01400932 (first received 21 July 2011). ">Kawashima 2014</a>; <a href="./references#CD011154-bbs2-0115" title="2015‐004909‐16 . A multicentre, randomized, assessor‐blind, comparator‐controlled, parallel‐group clinical trial to establish the efficacy and safety of Duac™ (1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide) once daily gel compared with clindamycin phosphate gel (1% clindamycin as clindamycin phosphate) twice daily in the treatment of mild to moderate acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2015‐004909‐16/results (results published 29 December 2016). NCT01915732 . Efficacy and safety of Duac™ compared with clindamycin phosphate gel in the treatment of mild to moderate acne vulgaris. clinicaltrials.gov/ct2/show/NCT01915732 (first received 5 April 2013). XuJ , LuQ , HuangJ , SunQ , HaoF , GuJ , et al. A multicenter, randomized, single‐blind study of topical clindamycin 1%/benzoyl peroxide 5% once‐daily fixed dose combination gel (Duac) vs. clindamycin 1% twice‐daily gel in treatment of Chinese acne vulgaris patients. Journal of Investigative Dermatology2015;135(Suppl 2):S34, 192. [CENTRAL: CN‐01130701] XuJH , LuQJ , HuangJH , HaoF , SunQN , FangH , et al. A multicentre, randomized, single‐blind comparison of topical clindamycin 1%/benzoyl peroxide 5% once‐daily gel versus clindamycin 1% twice‐daily gel in the treatment of mild to moderate acne vulgaris in Chinese patients. Journal of the European Academy of Dermatology and Venereology2016;30(7):1176‐82. [CENTRAL: CN‐01178389; MEDLINE: 27075705] ">Xu 2016</a>). The three trials also suggested significant absolute change in ILs and NILs among participants on BPO treatment, with pooled mean differences of ‐3.50 (95% CI ‐6.33 to ‐0.67; 2635 participants; I² = 92%; <a href="./references#CD011154-fig-0012" title="">Analysis 1.6</a>) and ‐6.53 (95% CI ‐9.74 to ‐3.32; 2635 participants; I² = 75%; <a href="./references#CD011154-fig-0013" title="">Analysis 1.7</a>), respectively. The two studies were conducted in western and Asian populations, respectively, which may lead to heterogeneity in the reduction in acne lesions. The difference in percentage change in TLs was 10.29% (95% CI 3.39% to 17.19%; 1567 participants; 4 studies; I² = 72%; <a href="./references#CD011154-fig-0014" title="">Analysis 1.8</a>), which was pooled from four trials (<a href="./references#CD011154-bbs2-0017" title="CunliffeW . A comparison of the clinical and antimicrobial efficacy of clinoxin AQ gel (1 % w/v clindamycin/5% w/v benzoyl peroxide) and 1% (w/v) clindamycin gel in the treatment of acne. British Journal of Dermatology2000;143(Suppl 57):72. [CENTRAL: CN‐00547635] CunliffeWJ , HollandKT , BojarR , LevySF . A randomized, double‐blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clinical Therapeutics2002;24(7):1117‐33. [CENTRAL: CN‐00404978; MEDLINE: 12182256] ">Cunliffe 2002</a>; <a href="./references#CD011154-bbs2-0038" title="FleischerAB , DraelosZD , AbramovitsW , PariserDM . Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4%, or vehicle gel for the treatment of acne vulgaris: a randomized, double‐blind study. Abstract P113. American Academy of Dermatology, 65th Annual Meeting, February 2‐6, 2007. Journal of the American Academy of Dermatology2007;56(2):AB16. [CENTRAL: CN‐00616000] FleischerAB , ShalitaA , EichenfieldLF , AbramovitsW , LuckyA , GarrettSCP . Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: a 12‐week, randomized, double‐blind study. Journal of Drugs in Dermatology2010;9(1):33‐40. [CENTRAL: CN‐00734828; MEDLINE: 20120423] NCT00151541 . A phase 3 study to compare the safety and efficacy of 5% dapsone topical gel (DTG) twice daily in combination with once daily vehicle control, adapalene gel 0.1% or benzoyl peroxide gel 4%. www.clinicaltrials.gov/ct2/show/NCT00151541 (first received 7 September 2005). ">Fleischer 2010</a>; <a href="./references#CD011154-bbs2-0075" title="MiyachiY , MizziF , MitaT , BaiL , IkomaA . Efficacy and safety of a fixed dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% in Japanese patients with acne vulgaris ‐ a multicenter, randomized, double‐blinded, active‐controlled, parallel group phase III study. [Japanese]. Skin Research2016;15(4):278‐93. NCT02073448 . Efficacy and safety study of GK530G versus CD0271 0.1% gel and CD1579 2.5% gel in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02073448 (first received 20 February 2014). ">Miyachi 2016</a>; <a href="./references#CD011154-bbs2-0115" title="2015‐004909‐16 . A multicentre, randomized, assessor‐blind, comparator‐controlled, parallel‐group clinical trial to establish the efficacy and safety of Duac™ (1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide) once daily gel compared with clindamycin phosphate gel (1% clindamycin as clindamycin phosphate) twice daily in the treatment of mild to moderate acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2015‐004909‐16/results (results published 29 December 2016). NCT01915732 . Efficacy and safety of Duac™ compared with clindamycin phosphate gel in the treatment of mild to moderate acne vulgaris. clinicaltrials.gov/ct2/show/NCT01915732 (first received 5 April 2013). XuJ , LuQ , HuangJ , SunQ , HaoF , GuJ , et al. A multicenter, randomized, single‐blind study of topical clindamycin 1%/benzoyl peroxide 5% once‐daily fixed dose combination gel (Duac) vs. clindamycin 1% twice‐daily gel in treatment of Chinese acne vulgaris patients. Journal of Investigative Dermatology2015;135(Suppl 2):S34, 192. [CENTRAL: CN‐01130701] XuJH , LuQJ , HuangJH , HaoF , SunQN , FangH , et al. A multicentre, randomized, single‐blind comparison of topical clindamycin 1%/benzoyl peroxide 5% once‐daily gel versus clindamycin 1% twice‐daily gel in the treatment of mild to moderate acne vulgaris in Chinese patients. Journal of the European Academy of Dermatology and Venereology2016;30(7):1176‐82. [CENTRAL: CN‐01178389; MEDLINE: 27075705] ">Xu 2016</a>). The counterpart in ILs and NILs from four trials was 17.22 (95% CI 4.98 to 29.45; 1588 participants; I² = 87%; <a href="./references#CD011154-fig-0015" title="">Analysis 1.9</a>) and 19.31 (95% CI 7.16 to 31.47; 1588 participants; I² = 80%; <a href="./references#CD011154-fig-0016" title="">Analysis 1.10</a>), respectively (<a href="./references#CD011154-bbs2-0017" title="CunliffeW . A comparison of the clinical and antimicrobial efficacy of clinoxin AQ gel (1 % w/v clindamycin/5% w/v benzoyl peroxide) and 1% (w/v) clindamycin gel in the treatment of acne. British Journal of Dermatology2000;143(Suppl 57):72. [CENTRAL: CN‐00547635] CunliffeWJ , HollandKT , BojarR , LevySF . A randomized, double‐blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clinical Therapeutics2002;24(7):1117‐33. [CENTRAL: CN‐00404978; MEDLINE: 12182256] ">Cunliffe 2002</a>; <a href="./references#CD011154-bbs2-0038" title="FleischerAB , DraelosZD , AbramovitsW , PariserDM . Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4%, or vehicle gel for the treatment of acne vulgaris: a randomized, double‐blind study. Abstract P113. American Academy of Dermatology, 65th Annual Meeting, February 2‐6, 2007. Journal of the American Academy of Dermatology2007;56(2):AB16. [CENTRAL: CN‐00616000] FleischerAB , ShalitaA , EichenfieldLF , AbramovitsW , LuckyA , GarrettSCP . Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: a 12‐week, randomized, double‐blind study. Journal of Drugs in Dermatology2010;9(1):33‐40. [CENTRAL: CN‐00734828; MEDLINE: 20120423] NCT00151541 . A phase 3 study to compare the safety and efficacy of 5% dapsone topical gel (DTG) twice daily in combination with once daily vehicle control, adapalene gel 0.1% or benzoyl peroxide gel 4%. www.clinicaltrials.gov/ct2/show/NCT00151541 (first received 7 September 2005). ">Fleischer 2010</a>; <a href="./references#CD011154-bbs2-0069" title="LookingbillDP , ChalkerDK , LindholmJS , KatzHI , KempersSE , HuerterCJ , et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double‐blind investigations. Journal of the American Academy of Dermatology1997;37(4):590‐5. [CENTRAL: CN‐00144503; MEDLINE: 9344199] LookingbillDP , ChallenDK , LindholmJS . Treatment of acne with a combination of clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined result of two double blind investigations (Abstract no. 1). Indian Journal of Dermatology, Venerology and Leprology1995;61:398. ">Lookingbill 1997</a>; <a href="./references#CD011154-bbs2-0115" title="2015‐004909‐16 . A multicentre, randomized, assessor‐blind, comparator‐controlled, parallel‐group clinical trial to establish the efficacy and safety of Duac™ (1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide) once daily gel compared with clindamycin phosphate gel (1% clindamycin as clindamycin phosphate) twice daily in the treatment of mild to moderate acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2015‐004909‐16/results (results published 29 December 2016). NCT01915732 . Efficacy and safety of Duac™ compared with clindamycin phosphate gel in the treatment of mild to moderate acne vulgaris. clinicaltrials.gov/ct2/show/NCT01915732 (first received 5 April 2013). XuJ , LuQ , HuangJ , SunQ , HaoF , GuJ , et al. A multicenter, randomized, single‐blind study of topical clindamycin 1%/benzoyl peroxide 5% once‐daily fixed dose combination gel (Duac) vs. clindamycin 1% twice‐daily gel in treatment of Chinese acne vulgaris patients. Journal of Investigative Dermatology2015;135(Suppl 2):S34, 192. [CENTRAL: CN‐01130701] XuJH , LuQJ , HuangJH , HaoF , SunQN , FangH , et al. A multicentre, randomized, single‐blind comparison of topical clindamycin 1%/benzoyl peroxide 5% once‐daily gel versus clindamycin 1% twice‐daily gel in the treatment of mild to moderate acne vulgaris in Chinese patients. Journal of the European Academy of Dermatology and Venereology2016;30(7):1176‐82. [CENTRAL: CN‐01178389; MEDLINE: 27075705] ">Xu 2016</a>). </p> <p>As for the medium‐term outcome, we found significant differences in percentage reduction in NILs (mean difference (MD) 18.42, 95% CI 1.39 to 35.45; 1212 participants; 3 studies; I² = 89%; <a href="./references#CD011154-fig-0019" title="">Analysis 1.13</a>) in favour of BPO treatment but not in TLs (MD 16.02, 95% CI ‐0.95 to 32.99; 252 participants; 2 studies; I² = 65%; <a href="./references#CD011154-fig-0017" title="">Analysis 1.11</a>) nor ILs (MD 13.83, 95% CI ‐0.22 to 27.88; 1212 participants; 3 studies; I² = 86%; <a href="./references#CD011154-fig-0018" title="">Analysis 1.12</a>). </p> <p>These trials also reported the short‐term outcome. We found significant differences in percentage reduction in TLs (MD 10.00, 95% CI 2.26 to 17.74; 201 participants; 1 study; <a href="./references#CD011154-fig-0020" title="">Analysis 1.14</a>) and NILs (MD 24.65, 95% CI 4.23 to 45.07; 229 participants; 2 studies; <a href="./references#CD011154-fig-0022" title="">Analysis 1.16</a>) in favour of BPO treatment but not in ILs (MD 14.02, 95% CI ‐0.60 to 28.63; 1212 participants; 3 studies; I² = 91%; <a href="./references#CD011154-fig-0021" title="">Analysis 1.15</a>). </p> </section> <section id="CD011154-sec-0136"> <p><b>Subgroup analyses: co‐intervention</b></p> <p>Most subgroup analyses suggested significant differences were common for BPO monotherapy and BPO combination (<a href="./references#CD011154-fig-0012" title="">Analysis 1.6</a>; <a href="./references#CD011154-fig-0013" title="">Analysis 1.7</a>; <a href="./references#CD011154-fig-0014" title="">Analysis 1.8</a>; <a href="./references#CD011154-fig-0015" title="">Analysis 1.9</a>; <a href="./references#CD011154-fig-0016" title="">Analysis 1.10</a>; <a href="./references#CD011154-fig-0018" title="">Analysis 1.12</a>; <a href="./references#CD011154-fig-0019" title="">Analysis 1.13</a>; <a href="./references#CD011154-fig-0021" title="">Analysis 1.15</a>). Reduction in acne lesions tended to be greater with BPO monotherapy than with BPO combination therapies. On the other hand, we did not observe the subgroup difference in absolute or percentage change in TLs regardless of treatment duration (<a href="./references#CD011154-fig-0011" title="">Analysis 1.5</a>; <a href="./references#CD011154-fig-0017" title="">Analysis 1.11</a>; <a href="./references#CD011154-fig-0020" title="">Analysis 1.14</a>). </p> </section> <section id="CD011154-sec-0137"> <p><b>Studies not included in the meta‐analysis</b></p> <p>In the other trials, data on the absolute or percentage change in acne lesions were insufficient to summarise the effect size. </p> <p>Three trials investigated BPO monotherapy. <a href="./references#CD011154-bbs2-0066" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM . Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] LeydenJ , et al. Treatment of acne vulgaris with a combination benzoyl peroxide/clindamycin topical gel Abstract P‐013. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S144. [CENTRAL: CN‐00478651] LeydenJJ , BergerRS , DunlapFE , EllisCN , ConnollyMA , LevySF . Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. American Journal of Clinical Dermatology2001;2(1):33‐9. [CENTRAL: CN‐00363426; MEDLINE: 11702619] ">Leyden 2001a</a> claimed that neither TLs (‐13.8 versus ‐1.3) nor ILs (‐5.9 versus 0.7) were significantly reduced in the BPO group when compared to the placebo group at week 10. However, another two trials did not show the difference. In <a href="./references#CD011154-bbs2-0100" title="FDA , Center for Drug Evaluation and Research. Study 152. Medical Review of NDA 50‐741. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50‐741_duac%20topical%20gel_medr_p1.pdf. ">Study 152</a>, the percentage reduction in TLs, ILs, and NILs was 25.5% versus 20.6% (P value not reported), 33.5% versus 28.6% (P = 0.54), and 18.8% versus 15.4% (P = 0.49) for the BPO group (n = 70) and the placebo group (n = 37). <a href="./references#CD011154-bbs2-0112" title="VasarinshP . Benzoyl peroxide‐sulfur lotions in acne vulgaris ‐ a controlled study. Cutis; Cutaneous Medicine for the Practitioner1969;5(1):65‐9. [CENTRAL: CN‐00269401] ">Vasarinsh 1969</a> assessed the change in lesion counts for superficial (comedones and pustules) and deep (papules and cysts) lesions, respectively, using a 11‐point scoring system (decrease in lesions by 100% = 5, 76% to 99% = 4, 51% to 75% = 3, 26% to 50% = 2, &lt; 25% = 1, no change = 0; increase by &lt; 25% = ‐1, 26% to 50% = ‐2, 51% to 75% = ‐3, 76% to 100% = ‐4, over 100% = ‐5). The average score for superficial lesions was 0.55 and 0 for the BPO and placebo groups, respectively, and the counterpart for deep lesions was 0.69 and 0.53. </p> <p>Four trials comparing BPO/adapalene with adapalene reported the percentage reduction in lesion counts (<a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>; <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>; <a href="./references#CD011154-bbs2-0075" title="MiyachiY , MizziF , MitaT , BaiL , IkomaA . Efficacy and safety of a fixed dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% in Japanese patients with acne vulgaris ‐ a multicenter, randomized, double‐blinded, active‐controlled, parallel group phase III study. [Japanese]. Skin Research2016;15(4):278‐93. NCT02073448 . Efficacy and safety study of GK530G versus CD0271 0.1% gel and CD1579 2.5% gel in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02073448 (first received 20 February 2014). ">Miyachi 2016</a>; <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>). <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a> found a significant difference in the percentage reduction in TLs (60.7% versus 49.8%), ILs (66.0% versus 52.1%), and NILs (58.9% versus 52.9%) between groups (all P values &lt; 0.05). In <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>, the percentage reduction in TLs, ILs, and NILs was significantly higher in the BPO/adapalene group (68.8% versus 55.7%, 72.4% versus 61.9%, and 66.4% versus 54.3%, respectively) (all P values &lt; 0.05). In <a href="./references#CD011154-bbs2-0075" title="MiyachiY , MizziF , MitaT , BaiL , IkomaA . Efficacy and safety of a fixed dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% in Japanese patients with acne vulgaris ‐ a multicenter, randomized, double‐blinded, active‐controlled, parallel group phase III study. [Japanese]. Skin Research2016;15(4):278‐93. NCT02073448 . Efficacy and safety study of GK530G versus CD0271 0.1% gel and CD1579 2.5% gel in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02073448 (first received 20 February 2014). ">Miyachi 2016</a>, which compared BPO/adapalene gel with adapalene in participants (212 versus 107 participants), the percentage reduction in TLs was 82.7% versus 68.6%, with a significant difference (MD 14.6%, 95% CI 8.3% to 20.8%). The average percentage reduction in ILs and NILs was 80.9% versus 66.2% (P &lt; 0.001) and 74.6% versus 61.1% (P &lt; 0.001), respectively. Another trial found 51.0% and 35.4% reduction in TLs, 62.9% and 45.7% in ILs, and 51.2% and 33.3% in NILs for BPO/adapalene and adapalene, respectively (all P values &lt; 0.001) (<a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>). </p> <p>Six trials compared BPO/clindamycin with clindamycin (<a href="./references#CD011154-bbs2-0066" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM . Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] LeydenJ , et al. Treatment of acne vulgaris with a combination benzoyl peroxide/clindamycin topical gel Abstract P‐013. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S144. [CENTRAL: CN‐00478651] LeydenJJ , BergerRS , DunlapFE , EllisCN , ConnollyMA , LevySF . Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. American Journal of Clinical Dermatology2001;2(1):33‐9. [CENTRAL: CN‐00363426; MEDLINE: 11702619] ">Leyden 2001a</a>; <a href="./references#CD011154-bbs2-0100" title="FDA , Center for Drug Evaluation and Research. Study 152. Medical Review of NDA 50‐741. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50‐741_duac%20topical%20gel_medr_p1.pdf. ">Study 152</a>; <a href="./references#CD011154-bbs2-0101" title="FDA , Center for Drug Evaluation and Research. Study 156. Medical Review of NDA 50‐741. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50‐741_duac%20topical%20gel_medr_p1.pdf. ">Study 156</a>; <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>; <a href="./references#CD011154-bbs2-0109" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM , et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] TschenE , et al. A combination benzoyl peroxide/clindamycin topical gel for the treatment of acne vulgaris. Abstract P‐029. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S150. [CENTRAL: CN‐00478786] TschenEH , KatzHI , JonesTM , MonroeEW , KrausSJ , ConnollyMA , et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2):165‐9. [CENTRAL: CN‐00346768; MEDLINE: 11236229] ">Tschen 2001</a>; <a href="./references#CD011154-bbs2-0110" title="TuckerSB , TausendR , CochranR , FlanniganSA . Comparison of topical clindamycin phosphate, benzoyl peroxide, and a combination of the two for the treatment of acne vulgaris. British Journal of Dermatology1984;110(4):487‐92. [CENTRAL: CN‐00568865; MEDLINE: 6231942] TuckerSB , TausendT , CochranR . Comparison of topical clindamycin phosphate, benzoyl peroxide and a combination of the two, for the treatment of acne vulgaris [abstract no:1]. Indian Journal of Dermatology, Venerology and Leprology1990;56:179. [CENTRAL: CN‐00692634] ">Tucker 1984</a>). For the absolute change in lesion counts, in another trial, investigators claimed that both TLs (‐18.4 versus ‐6.2; P &lt; 0.001) and ILs (‐10.1 versus ‐3.2; P &lt; 0.001) were significantly reduced in the BPO/clindamycin group when compared to the clindamycin group at week 10 (<a href="./references#CD011154-bbs2-0066" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM . Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] LeydenJ , et al. Treatment of acne vulgaris with a combination benzoyl peroxide/clindamycin topical gel Abstract P‐013. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S144. [CENTRAL: CN‐00478651] LeydenJJ , BergerRS , DunlapFE , EllisCN , ConnollyMA , LevySF . Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. American Journal of Clinical Dermatology2001;2(1):33‐9. [CENTRAL: CN‐00363426; MEDLINE: 11702619] ">Leyden 2001a</a>). <a href="./references#CD011154-bbs2-0109" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM , et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] TschenE , et al. A combination benzoyl peroxide/clindamycin topical gel for the treatment of acne vulgaris. Abstract P‐029. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S150. [CENTRAL: CN‐00478786] TschenEH , KatzHI , JonesTM , MonroeEW , KrausSJ , ConnollyMA , et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2):165‐9. [CENTRAL: CN‐00346768; MEDLINE: 11236229] ">Tschen 2001</a> found ‐16.6 versus ‐14.7 in ILs for BPO/clindamycin (95 participants) and clindamycin (49 participants) (P = 0.034). In <a href="./references#CD011154-bbs2-0110" title="TuckerSB , TausendR , CochranR , FlanniganSA . Comparison of topical clindamycin phosphate, benzoyl peroxide, and a combination of the two for the treatment of acne vulgaris. British Journal of Dermatology1984;110(4):487‐92. [CENTRAL: CN‐00568865; MEDLINE: 6231942] TuckerSB , TausendT , CochranR . Comparison of topical clindamycin phosphate, benzoyl peroxide and a combination of the two, for the treatment of acne vulgaris [abstract no:1]. Indian Journal of Dermatology, Venerology and Leprology1990;56:179. [CENTRAL: CN‐00692634] ">Tucker 1984</a>, trial authors reported the absolute change in comedone, papule, pustule, and cyst lesions at week 10 separately: corresponding results were ‐21.0 versus ‐7.3, ‐11.3 versus ‐9.7, ‐8.3 versus ‐3.4, and ‐1.4 versus ‐2.3. For the percentage change in lesion counts, in <a href="./references#CD011154-bbs2-0100" title="FDA , Center for Drug Evaluation and Research. Study 152. Medical Review of NDA 50‐741. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50‐741_duac%20topical%20gel_medr_p1.pdf. ">Study 152</a>, the percentage reduction in TLs, ILs, and NILs was 32.5% versus 23.5% (P = 0.002), 43.4% versus 39.8% (0.538), the 25.7% versus 11.2% (P &lt; 0.001) for the BPO/clindamycin group (n = 73 participants) and the clindamycin group (n = 70). In <a href="./references#CD011154-bbs2-0101" title="FDA , Center for Drug Evaluation and Research. Study 156. Medical Review of NDA 50‐741. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50‐741_duac%20topical%20gel_medr_p1.pdf. ">Study 156</a>, the percentage reduction in TLs, ILs, and NILs was 49.8% versus 33.3% (P &lt; 0.001), 57.3% versus 48.6% (0.03), and 39.0% versus 18.0% (P &lt; 0.001) for the BPO/clindamycin group (n = 96) and the clindamycin group (n = 96). For <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>, 797 participants were randomised to the BPO/clindamycin group and 812 participants to the clindamycin group. The percentage reduction was 47.9% versus 40.4% in TLs, 54.6% versus 46.2% in ILs, and 43.2% versus 36.2% in NILs at week 12 (all P values &lt; 0.001). </p> <p>Other comparisons for BPO as an add‐on treatment were limited. One 10‐week trial focusing on BPO/erythromycin versus erythromycin assessed the mean difference in the percentage reduction in lesion counts between two groups but reported only that the percentage reduction in comedone, pustule, papule, and inflammatory lesions seemed greater in the BPO/erythromycin group, with no significant difference (<a href="./references#CD011154-bbs2-0011" title="ChalkerDK , ShalitaA , SmithJG , SwannRW . A double‐blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. Journal of the American Academy of Dermatology1983;9(6):933‐6. [CENTRAL: CN‐00334175; MEDLINE: 6227643] ">Chalker 1983</a>). Two trials assessed the reduction in acne lesions for BPO plus adapalene versus adapalene (<a href="./references#CD011154-bbs2-0010" title="CassanoN , AlessandriniG , CarrieriG , FaiD , GabbelloneM , GravanteM , et al. Treatment of mild to moderate acne vulgaris with adapalene alone or combined with other anti‐acne agents. A multicenter open trial. [Studio multicentrico in aperto sul trattamento dell'acne lieve/moderata con adapalene in monoterapia o in terapia combinata]. Giornale Italiano di Dermatologia e Venereologia2002;137(5):369‐75. [CENTRAL: CN‐00432115] ">Cassano 2002</a>; <a href="./references#CD011154-bbs2-0037" title="FangL , FuW , GuJ , SunJ , MaE . Efficacy and safety of benzoyl peroxide gel, 5% combined with adapalene gel, 0.1% in Chinese patients with acne vulgaris (Abstract). 20th World Congress of Dermatology, Paris, 1st to 5th July 2002. Annales de Dermatologie et de Venereologie2002;129(Suppl 1 Pt 2):P0020. [CENTRAL: CN‐00454223] ">Fang 2002</a>). Only an abstract was available for <a href="./references#CD011154-bbs2-0010" title="CassanoN , AlessandriniG , CarrieriG , FaiD , GabbelloneM , GravanteM , et al. Treatment of mild to moderate acne vulgaris with adapalene alone or combined with other anti‐acne agents. A multicenter open trial. [Studio multicentrico in aperto sul trattamento dell'acne lieve/moderata con adapalene in monoterapia o in terapia combinata]. Giornale Italiano di Dermatologia e Venereologia2002;137(5):369‐75. [CENTRAL: CN‐00432115] ">Cassano 2002</a>, in which a total of 162 participants were randomised to one of the four groups: adapalene gel; adapalene gel; adapalene gel plus BPO gel 5%; and adapalene plus erythromycin gel 4%. With no information on the absolute or percentage reduction in lesion counts, trial authors claimed that all these treatments similarly led to a significant reduction in the numbers of papules, pustules, and comedones. The results of <a href="./references#CD011154-bbs2-0037" title="FangL , FuW , GuJ , SunJ , MaE . Efficacy and safety of benzoyl peroxide gel, 5% combined with adapalene gel, 0.1% in Chinese patients with acne vulgaris (Abstract). 20th World Congress of Dermatology, Paris, 1st to 5th July 2002. Annales de Dermatologie et de Venereologie2002;129(Suppl 1 Pt 2):P0020. [CENTRAL: CN‐00454223] ">Fang 2002</a> were also presented in an abstract. A total of 150 participants were randomised to one of the two groups. At week 12, there was no significant difference in the percentage reduction in TLs (81.3% versus 68.9%), despite higher reduction found in the BPO plus adapalene group. One 12‐week parallel trial comparing BPO plus tazarotene with tazarotene reported that the percentage reduction in both ILs (39.7% versus 43.7%, P &gt; 0.05) and NILs (42.7% versus 41.6%, P &gt; 0.05) was similar between two groups (<a href="./references#CD011154-bbs2-0023" title="DraelosZD , TanghettiEA . Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis; Cutaneous Medicine for the Practitioner2002;69(2 Suppl):20‐9. [CENTRAL: CN‐00409023; MEDLINE: 12095065] ">Draelos 2002</a>). For the medium‐ and short‐term periods, both treatments reduced NILs by about 40% and 30%, respectively, with no significant difference. Their effects on reducing ILs were also comparable (31% versus 31% for the medium‐term and 24% versus 17% for the short‐term period). In a 12‐week parallel trial (<a href="./references#CD011154-bbs2-0094" title="ShalitaAR , RafalES , AndersonDN , YavelR , LandowS , LeeWL . Compared efficacy and safety of tretinoin 0.1% microsphere gel alone and in combination with benzoyl peroxide 6% cleanser for the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2003;72(2):167‐72. [CENTRAL: CN‐00457639; MEDLINE: 12953944] ">Shalita 2003</a>), researchers investigating BPO plus tretinoin versus placebo plus tretinoin observed that the mean number of IL counts was reduced from 9.4 at baseline to 3.9 at week 12 among participants on BPO, and from 9.3 to 6.6 among participants on placebo (P &lt; 0.01). For NILs, there were no significant differences between treatment groups, although both groups had a significant reduction from baseline. One 10‐week parallel trial with 24 participants on BPO plus clindamycin and 29 participants on clindamycin alone reported the absolute reduction in comedone, pustule, papule, and cyst lesions from baseline to week 10 (‐20.4 versus ‐7.3, ‐5.4 versus ‐3.4, ‐11.4 versus ‐9.7, and ‐1.4 versus ‐2.4, respectively) (<a href="./references#CD011154-bbs2-0110" title="TuckerSB , TausendR , CochranR , FlanniganSA . Comparison of topical clindamycin phosphate, benzoyl peroxide, and a combination of the two for the treatment of acne vulgaris. British Journal of Dermatology1984;110(4):487‐92. [CENTRAL: CN‐00568865; MEDLINE: 6231942] TuckerSB , TausendT , CochranR . Comparison of topical clindamycin phosphate, benzoyl peroxide and a combination of the two, for the treatment of acne vulgaris [abstract no:1]. Indian Journal of Dermatology, Venerology and Leprology1990;56:179. [CENTRAL: CN‐00692634] ">Tucker 1984</a>). The significance of test results was not reported. As reported in one 10‐week parallel trial for BPO plus meclocycline sulfosalicylate versus meclocycline sulfosalicylate (<a href="./references#CD011154-bbs2-0005" title="BorglundE , KristensenB , Larsson‐StymneB , StrandA , VeienNK , JakobsenHB . Topical meclocycline sulfosalicylate, benzoyl peroxide, and a combination of the two in the treatment of acne vulgaris. Acta Dermato‐Venereologica1991;71:175‐8. [CENTRAL: CN‐00075962; MEDLINE: 1675534] ">Borglund 1991</a>), the difference in the absolute reduction in papules, pustules, and comedones was ‐2, ‐1.6, and ‐2.6, respectively, for long‐term data. For medium‐term outcomes, the counterpart was ‐2.9, ‐2.4, and ‐1, respectively. For short‐term outcomes, the counterpart was ‐4.8, ‐2.1, and 1.3, respectively. All results were not statistically significant (all P values &gt; 0.05). </p> <p>In an 8‐week parallel trial with 47 participants on BPO plus nadifloxacin and 46 participants on placebo plus nadifloxacin (<a href="./references#CD011154-bbs2-0084" title="OzgenZY , GurbuzO . A randomized, double‐blind comparison of nadifloxacin 1% cream alone and with benzoyl peroxide 5% lotion in the treatment of mild to moderate facial acne vulgaris. Marmara Medical Journal2013;26(1):243‐6. [CENTRAL: CN‐00912356] ">Ozgen 2013</a>), the mean percentage reduction in ILs and NILs was 53.5% versus 22.08% and 34.8% versus 7.6% (both P &lt; 0.001) at week 8. <a href="./references#CD011154-bbs2-0112" title="VasarinshP . Benzoyl peroxide‐sulfur lotions in acne vulgaris ‐ a controlled study. Cutis; Cutaneous Medicine for the Practitioner1969;5(1):65‐9. [CENTRAL: CN‐00269401] ">Vasarinsh 1969</a> compared BPO/sulphur with sulphur. The change in lesion counts in this trial was assessed for superficial (comedones and pustules) and deep (papules and cysts) lesions, respectively, using a 11‐point scoring system (decrease in lesions by 100% = 5, 76% to 99%=4, 51% to 75%=3, 26% to 50%=2, &lt; 25% = 1, and no change = 0; increase by &lt; 25% = ‐1, 26% to 50% = ‐2, 51% to 75% = ‐3, 76% to 100% = ‐4, over 100% = ‐5). The average score for superficial lesions was 0.81 and ‐0.70 for the BPO/sulphur and sulphur groups, respectively, and the counterpart for deep lesions was 0.91 and 0.30. </p> <p>We also found some trials that comparing only lesions between groups at end of treatment, rather than the absolute or percentage change in lesions. </p> <p>For BPO monotherapy, three trials reported long‐term data ‐ <a href="./references#CD011154-bbs2-0049" title="HughesBR . A double blind evaluation of topical isotretinoin, benzoyl peroxide and placebo in patients with acne. British Journal of Dermatology1989;121(s34):42. [DOI: 10.1111/j.1365‐2133.1989.tb05941.x] HughesBR , NorrisJF , CunliffeWJ . A double‐blind evaluation of topical isotretinoin 0.05%, benzoyl peroxide gel 5% and placebo in patients with acne. Clinical &amp; Experimental Dermatology1992;17(3):165‐8. [MEDLINE: 1451291] ">Hughes 1992</a> ‐ or medium‐term data (<a href="./references#CD011154-bbs2-0008" title="BurkeB , EadyEA , CunliffeWJ . Benzoyl peroxide versus topical erythromycin in the treatment of acne vulgaris. British Journal of Dermatology1983;108(2):199‐204. [CENTRAL: CN‐00568861; MEDLINE: 6218815] ">Burke 1983</a>; <a href="./references#CD011154-bbs2-0074" title="Mills JrOH , KligmanAM , PochiP , ComiteH . Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. International Journal of Dermatology1986;25(10):664‐7. [CENTRAL: CN‐00046261; MEDLINE: 2948929] ">Mills 1986</a>); all supported the benefits of BPO treatment. The mean difference was ‐27.50 (95% CI ‐46.77 to ‐8.23) in ILs, and ‐28.20 (95% CI ‐45.04 to ‐11.36) in NILs (<a href="./references#CD011154-bbs2-0049" title="HughesBR . A double blind evaluation of topical isotretinoin, benzoyl peroxide and placebo in patients with acne. British Journal of Dermatology1989;121(s34):42. [DOI: 10.1111/j.1365‐2133.1989.tb05941.x] HughesBR , NorrisJF , CunliffeWJ . A double‐blind evaluation of topical isotretinoin 0.05%, benzoyl peroxide gel 5% and placebo in patients with acne. Clinical &amp; Experimental Dermatology1992;17(3):165‐8. [MEDLINE: 1451291] ">Hughes 1992</a>). The mean difference was ‐16.00 (95% CI ‐18.25 to ‐13.75) in TLs, and ‐8.40 (95% CI ‐9.88 to ‐6.92) in NILs, as reported in <a href="./references#CD011154-bbs2-0008" title="BurkeB , EadyEA , CunliffeWJ . Benzoyl peroxide versus topical erythromycin in the treatment of acne vulgaris. British Journal of Dermatology1983;108(2):199‐204. [CENTRAL: CN‐00568861; MEDLINE: 6218815] ">Burke 1983</a>. The pooled mean difference in ILs was ‐4.40 (95% CI ‐5.47 to ‐3.33; I² = 0%). </p> <p>For BPO add‐on treatment, two trials presented long‐term data for BPO plus adapalene versus adapalene (<a href="./references#CD011154-bbs2-0039" title="FuWW , FangL , GuJ , ShunJF . Clinical efficacy and safety of 5% benzoyl peroxide gel combined with 0.1% adapalene gel in the treatment of acne vulgaris: a multicenter, randomized study. Chinese Journal of Dermatology2003;36(6):310‐2. [CENTRAL: CN‐00484027] ">Fu 2003</a>; <a href="./references#CD011154-bbs2-0063" title="KorkutC , PiskinS . Benzoyl peroxide, adapalene, and their combination in the treatment of acne vulgaris. Journal of Dermatology2005;32(3):169‐73. [CENTRAL: CN‐00512006] ">Korkut 2005</a>). No significant difference was found for TLs (MD 0.11, 95% CI ‐4.94 to 5.17; I² = 0%), ILs (MD ‐0.52, 95% CI ‐2.15 to 1.10; I² = 0%), and NILs (MD 0.87, 95% CI ‐2.15 to 3.88; I² = 0%). </p> </section> </section> <section id="CD011154-sec-0138"> <h6 class="title">Secondary outcome: percentage of participants rated 'clear' or 'almost clear' on the IGA scale of acne severity </h6> <p>Overall, BPO therapy was associated with higher proportions of participants rated 'clear' or 'almost clear' on the IGA scale, regardless of the length of treatment duration. </p> <section id="CD011154-sec-0139"> <p><b>Main pooled analyses: BPO versus placebo or no treatment</b></p> <p>The long‐term outcome was reported in 10 trials (<a href="./references#CD011154-bbs2-0034" title="EichenfieldL , AlioA . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed dose combination gel for the treatment of acne vulgaris: a multicenter, double‐blind, parallel group, vehicle controlled study. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB10. [DOI: 10.1016/j.jaad.2011.11.049] EichenfieldLF , Alio SaenzAB . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed‐dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double‐blind, active‐ and vehicle‐controlled study. Journal of Drugs in Dermatology2011;10(12):1382‐96. [CENTRAL: CN‐00843726; MEDLINE: 22134562] NCT00776919 . A phase 3 multicenter, randomized, double‐blind, active and vehicle‐controlled study of the safety and efficacy of a clindamycin / benzoyl peroxide gel versus clindamycin gel versus benzoyl peroxide gel versus vehicle gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00776919 (first received 21 October 2008). ">Eichenfield 2011</a>; <a href="./references#CD011154-bbs2-0038" title="FleischerAB , DraelosZD , AbramovitsW , PariserDM . Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4%, or vehicle gel for the treatment of acne vulgaris: a randomized, double‐blind study. Abstract P113. American Academy of Dermatology, 65th Annual Meeting, February 2‐6, 2007. Journal of the American Academy of Dermatology2007;56(2):AB16. [CENTRAL: CN‐00616000] FleischerAB , ShalitaA , EichenfieldLF , AbramovitsW , LuckyA , GarrettSCP . Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: a 12‐week, randomized, double‐blind study. Journal of Drugs in Dermatology2010;9(1):33‐40. [CENTRAL: CN‐00734828; MEDLINE: 20120423] NCT00151541 . A phase 3 study to compare the safety and efficacy of 5% dapsone topical gel (DTG) twice daily in combination with once daily vehicle control, adapalene gel 0.1% or benzoyl peroxide gel 4%. www.clinicaltrials.gov/ct2/show/NCT00151541 (first received 7 September 2005). ">Fleischer 2010</a>; <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>; <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>; <a href="./references#CD011154-bbs2-0058" title="KawashimaM , HashimotoH , Alio SaenzAB , OnoM , YamadaM . Is benzoyl peroxide 3% topical gel effective and safe in the treatment of acne vulgaris in Japanese patients? A multicenter, randomized, double‐blind, vehicle‐controlled, parallel‐group study. Journal of Dermatology2014;41(9):795‐801. [CENTRAL: CN‐01254201; MEDLINE: 25132461] NCT01400932 . Study STF115288, a clinical confirmation study of GI148512 in the treatment of acne vulgaris in Japanese subjects. www.clinicaltrials.gov/ct2/show/NCT01400932 (first received 21 July 2011). ">Kawashima 2014</a>; <a href="./references#CD011154-bbs2-0059" title="KawashimaM , HashimotoH , Alio SaenzAB , OnoM , YamadaM . Clindamycin phosphate 12%‐benzoyl peroxide 30% fixed‐dose combination gel has an effective and acceptable safety and tolerability profile for the treatment of acne vulgaris in Japanese patients: a phase III, multicentre, randomised, single‐blinded, active‐controlled, parallel‐group study. British Journal of Dermatology2015;172(2):494‐503. [CENTRAL: CN‐01115087] KawashimaM , YamadaM , ParishC . Clindamycin 1%/benzoyl peroxide 3% gel, a new topical combination product, is effective in Japanese patients with acne vulgaris. Journal of Investigative Dermatology2013;133:S160. [CENTRAL: CN‐01026775] ">Kawashima 2015</a>; <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>; <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>; <a href="./references#CD011154-bbs2-0115" title="2015‐004909‐16 . A multicentre, randomized, assessor‐blind, comparator‐controlled, parallel‐group clinical trial to establish the efficacy and safety of Duac™ (1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide) once daily gel compared with clindamycin phosphate gel (1% clindamycin as clindamycin phosphate) twice daily in the treatment of mild to moderate acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2015‐004909‐16/results (results published 29 December 2016). NCT01915732 . Efficacy and safety of Duac™ compared with clindamycin phosphate gel in the treatment of mild to moderate acne vulgaris. clinicaltrials.gov/ct2/show/NCT01915732 (first received 5 April 2013). XuJ , LuQ , HuangJ , SunQ , HaoF , GuJ , et al. A multicenter, randomized, single‐blind study of topical clindamycin 1%/benzoyl peroxide 5% once‐daily fixed dose combination gel (Duac) vs. clindamycin 1% twice‐daily gel in treatment of Chinese acne vulgaris patients. Journal of Investigative Dermatology2015;135(Suppl 2):S34, 192. [CENTRAL: CN‐01130701] XuJH , LuQJ , HuangJH , HaoF , SunQN , FangH , et al. A multicentre, randomized, single‐blind comparison of topical clindamycin 1%/benzoyl peroxide 5% once‐daily gel versus clindamycin 1% twice‐daily gel in the treatment of mild to moderate acne vulgaris in Chinese patients. Journal of the European Academy of Dermatology and Venereology2016;30(7):1176‐82. [CENTRAL: CN‐01178389; MEDLINE: 27075705] ">Xu 2016</a>; <a href="./references#CD011154-bbs2-0117" title="ZeichnerJA , WongV , LinknerRV , HaddicanM . Efficacy and safety of tretinoin 0.025%/clindamycin phosphate 1.2% gel in combination with benzoyl peroxide 6% cleansing cloths for the treatment of facial acne vulgaris. Journal of Drugs in Dermatology2013;12(3):277‐82. [CENTRAL: CN‐00876866; MEDLINE: 23545909] ">Zeichner 2013</a>), with an RR of 1.55 (95% CI 1.40 to 1.70; 10,399 participants; I² = 43%; <a href="./references#CD011154-fig-0023" title="">Analysis 1.17</a>). Counterparts for medium‐ and short‐term outcomes were reported in five studies (<a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>; <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>; <a href="./references#CD011154-bbs2-0058" title="KawashimaM , HashimotoH , Alio SaenzAB , OnoM , YamadaM . Is benzoyl peroxide 3% topical gel effective and safe in the treatment of acne vulgaris in Japanese patients? A multicenter, randomized, double‐blind, vehicle‐controlled, parallel‐group study. Journal of Dermatology2014;41(9):795‐801. [CENTRAL: CN‐01254201; MEDLINE: 25132461] NCT01400932 . Study STF115288, a clinical confirmation study of GI148512 in the treatment of acne vulgaris in Japanese subjects. www.clinicaltrials.gov/ct2/show/NCT01400932 (first received 21 July 2011). ">Kawashima 2014</a>; <a href="./references#CD011154-bbs2-0059" title="KawashimaM , HashimotoH , Alio SaenzAB , OnoM , YamadaM . Clindamycin phosphate 12%‐benzoyl peroxide 30% fixed‐dose combination gel has an effective and acceptable safety and tolerability profile for the treatment of acne vulgaris in Japanese patients: a phase III, multicentre, randomised, single‐blinded, active‐controlled, parallel‐group study. British Journal of Dermatology2015;172(2):494‐503. [CENTRAL: CN‐01115087] KawashimaM , YamadaM , ParishC . Clindamycin 1%/benzoyl peroxide 3% gel, a new topical combination product, is effective in Japanese patients with acne vulgaris. Journal of Investigative Dermatology2013;133:S160. [CENTRAL: CN‐01026775] ">Kawashima 2015</a>; <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>), with an RR of 1.96 (95% CI 1.58 to 2.44; 5014 participants; I² = 35%; <a href="./references#CD011154-fig-0024" title="">Analysis 1.18</a>) and 2.43 (95% CI 1.78 to 3.32; 5014 participants; I² = 19%; <a href="./references#CD011154-fig-0025" title="">Analysis 1.19</a>), respectively. </p> </section> <section id="CD011154-sec-0140"> <p><b>Subgroup analyses: co‐intervention</b></p> <p>In subgroup analysis, we did not observe that the effects of BPO can differ by co‐intervention, regardless of treatment duration (<a href="./references#CD011154-fig-0023" title="">Analysis 1.17</a>; <a href="./references#CD011154-fig-0024" title="">Analysis 1.18</a>; <a href="./references#CD011154-fig-0025" title="">Analysis 1.19</a>). </p> </section> </section> <section id="CD011154-sec-0141"> <h6 class="title">Secondary outcome: reduction in <i>C acnes</i> strains </h6> <section id="CD011154-sec-0142"> <p><b>Studies not included in the meta‐analysis</b></p> <p>This outcome was reported in only two trials (<a href="./references#CD011154-bbs2-0032" title="EadyEA , BojarRA , JonesCE , CoveJH , HollandKT , CunliffeWJ . The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin‐resistant propionibacteria. British Journal of Dermatology1996;134(1):107‐13. [CENTRAL: CN‐00126809; MEDLINE: 8745894] EadyEA , BojarRA , JonesCE , CoveKT , CunliffeWJ . The effects of acne therapy with a combination of benzoyl peroxide and erythromycin on carriage of erythromycin resistant cutaneous propionibacteria. British Journal of Dermatology1994;131(3):437‐8. [CENTRAL: CN‐00318672] ">Eady 1996</a>; <a href="./references#CD011154-bbs2-0059" title="KawashimaM , HashimotoH , Alio SaenzAB , OnoM , YamadaM . Clindamycin phosphate 12%‐benzoyl peroxide 30% fixed‐dose combination gel has an effective and acceptable safety and tolerability profile for the treatment of acne vulgaris in Japanese patients: a phase III, multicentre, randomised, single‐blinded, active‐controlled, parallel‐group study. British Journal of Dermatology2015;172(2):494‐503. [CENTRAL: CN‐01115087] KawashimaM , YamadaM , ParishC . Clindamycin 1%/benzoyl peroxide 3% gel, a new topical combination product, is effective in Japanese patients with acne vulgaris. Journal of Investigative Dermatology2013;133:S160. [CENTRAL: CN‐01026775] ">Kawashima 2015</a>). In <a href="./references#CD011154-bbs2-0059" title="KawashimaM , HashimotoH , Alio SaenzAB , OnoM , YamadaM . Clindamycin phosphate 12%‐benzoyl peroxide 30% fixed‐dose combination gel has an effective and acceptable safety and tolerability profile for the treatment of acne vulgaris in Japanese patients: a phase III, multicentre, randomised, single‐blinded, active‐controlled, parallel‐group study. British Journal of Dermatology2015;172(2):494‐503. [CENTRAL: CN‐01115087] KawashimaM , YamadaM , ParishC . Clindamycin 1%/benzoyl peroxide 3% gel, a new topical combination product, is effective in Japanese patients with acne vulgaris. Journal of Investigative Dermatology2013;133:S160. [CENTRAL: CN‐01026775] ">Kawashima 2015</a>, 34 (6.8%) in the BPO/clindamycin group and 59 (19 7%) in the clindamycin group had a sample of <i>C acnes</i> . Study authors reported that a small increase in the number of clindamycin‐resistant <i>C acnes</i> isolates was found across groups. <a href="./references#CD011154-bbs2-0032" title="EadyEA , BojarRA , JonesCE , CoveJH , HollandKT , CunliffeWJ . The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin‐resistant propionibacteria. British Journal of Dermatology1996;134(1):107‐13. [CENTRAL: CN‐00126809; MEDLINE: 8745894] EadyEA , BojarRA , JonesCE , CoveKT , CunliffeWJ . The effects of acne therapy with a combination of benzoyl peroxide and erythromycin on carriage of erythromycin resistant cutaneous propionibacteria. British Journal of Dermatology1994;131(3):437‐8. [CENTRAL: CN‐00318672] ">Eady 1996</a> randomised 20 participants into the combination treatment group and 17 into the erythromycin group. BPO/erythromycin treatment was more effective in reducing total propionibacterial numbers than was erythromycin alone at week 12. Meanwhile, erythromycin‐resistant propionibacteria were found in seven participants treated with combination formulation and in 10 participants treated with erythromycin alone. </p> </section> </section> <section id="CD011154-sec-0143"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <p>A total of 28 trials reported the outcome for long‐term treatment duration (<a href="./references#CD011154-bbs2-0005" title="BorglundE , KristensenB , Larsson‐StymneB , StrandA , VeienNK , JakobsenHB . Topical meclocycline sulfosalicylate, benzoyl peroxide, and a combination of the two in the treatment of acne vulgaris. Acta Dermato‐Venereologica1991;71:175‐8. [CENTRAL: CN‐00075962; MEDLINE: 1675534] ">Borglund 1991</a>; <a href="./references#CD011154-bbs2-0010" title="CassanoN , AlessandriniG , CarrieriG , FaiD , GabbelloneM , GravanteM , et al. Treatment of mild to moderate acne vulgaris with adapalene alone or combined with other anti‐acne agents. A multicenter open trial. [Studio multicentrico in aperto sul trattamento dell'acne lieve/moderata con adapalene in monoterapia o in terapia combinata]. Giornale Italiano di Dermatologia e Venereologia2002;137(5):369‐75. [CENTRAL: CN‐00432115] ">Cassano 2002</a>; <a href="./references#CD011154-bbs2-0011" title="ChalkerDK , ShalitaA , SmithJG , SwannRW . A double‐blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. Journal of the American Academy of Dermatology1983;9(6):933‐6. [CENTRAL: CN‐00334175; MEDLINE: 6227643] ">Chalker 1983</a>; <a href="./references#CD011154-bbs2-0017" title="CunliffeW . A comparison of the clinical and antimicrobial efficacy of clinoxin AQ gel (1 % w/v clindamycin/5% w/v benzoyl peroxide) and 1% (w/v) clindamycin gel in the treatment of acne. British Journal of Dermatology2000;143(Suppl 57):72. [CENTRAL: CN‐00547635] CunliffeWJ , HollandKT , BojarR , LevySF . A randomized, double‐blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clinical Therapeutics2002;24(7):1117‐33. [CENTRAL: CN‐00404978; MEDLINE: 12182256] ">Cunliffe 2002</a>; <a href="./references#CD011154-bbs2-0032" title="EadyEA , BojarRA , JonesCE , CoveJH , HollandKT , CunliffeWJ . The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin‐resistant propionibacteria. British Journal of Dermatology1996;134(1):107‐13. [CENTRAL: CN‐00126809; MEDLINE: 8745894] EadyEA , BojarRA , JonesCE , CoveKT , CunliffeWJ . The effects of acne therapy with a combination of benzoyl peroxide and erythromycin on carriage of erythromycin resistant cutaneous propionibacteria. British Journal of Dermatology1994;131(3):437‐8. [CENTRAL: CN‐00318672] ">Eady 1996</a>; <a href="./references#CD011154-bbs2-0034" title="EichenfieldL , AlioA . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed dose combination gel for the treatment of acne vulgaris: a multicenter, double‐blind, parallel group, vehicle controlled study. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB10. [DOI: 10.1016/j.jaad.2011.11.049] EichenfieldLF , Alio SaenzAB . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed‐dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double‐blind, active‐ and vehicle‐controlled study. Journal of Drugs in Dermatology2011;10(12):1382‐96. [CENTRAL: CN‐00843726; MEDLINE: 22134562] NCT00776919 . A phase 3 multicenter, randomized, double‐blind, active and vehicle‐controlled study of the safety and efficacy of a clindamycin / benzoyl peroxide gel versus clindamycin gel versus benzoyl peroxide gel versus vehicle gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00776919 (first received 21 October 2008). ">Eichenfield 2011</a>; <a href="./references#CD011154-bbs2-0037" title="FangL , FuW , GuJ , SunJ , MaE . Efficacy and safety of benzoyl peroxide gel, 5% combined with adapalene gel, 0.1% in Chinese patients with acne vulgaris (Abstract). 20th World Congress of Dermatology, Paris, 1st to 5th July 2002. Annales de Dermatologie et de Venereologie2002;129(Suppl 1 Pt 2):P0020. [CENTRAL: CN‐00454223] ">Fang 2002</a>; <a href="./references#CD011154-bbs2-0038" title="FleischerAB , DraelosZD , AbramovitsW , PariserDM . Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4%, or vehicle gel for the treatment of acne vulgaris: a randomized, double‐blind study. Abstract P113. American Academy of Dermatology, 65th Annual Meeting, February 2‐6, 2007. Journal of the American Academy of Dermatology2007;56(2):AB16. [CENTRAL: CN‐00616000] FleischerAB , ShalitaA , EichenfieldLF , AbramovitsW , LuckyA , GarrettSCP . Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: a 12‐week, randomized, double‐blind study. Journal of Drugs in Dermatology2010;9(1):33‐40. [CENTRAL: CN‐00734828; MEDLINE: 20120423] NCT00151541 . A phase 3 study to compare the safety and efficacy of 5% dapsone topical gel (DTG) twice daily in combination with once daily vehicle control, adapalene gel 0.1% or benzoyl peroxide gel 4%. www.clinicaltrials.gov/ct2/show/NCT00151541 (first received 7 September 2005). ">Fleischer 2010</a>; <a href="./references#CD011154-bbs2-0039" title="FuWW , FangL , GuJ , ShunJF . Clinical efficacy and safety of 5% benzoyl peroxide gel combined with 0.1% adapalene gel in the treatment of acne vulgaris: a multicenter, randomized study. Chinese Journal of Dermatology2003;36(6):310‐2. [CENTRAL: CN‐00484027] ">Fu 2003</a>; <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>; <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>; <a href="./references#CD011154-bbs2-0049" title="HughesBR . A double blind evaluation of topical isotretinoin, benzoyl peroxide and placebo in patients with acne. British Journal of Dermatology1989;121(s34):42. [DOI: 10.1111/j.1365‐2133.1989.tb05941.x] HughesBR , NorrisJF , CunliffeWJ . A double‐blind evaluation of topical isotretinoin 0.05%, benzoyl peroxide gel 5% and placebo in patients with acne. Clinical &amp; Experimental Dermatology1992;17(3):165‐8. [MEDLINE: 1451291] ">Hughes 1992</a>; <a href="./references#CD011154-bbs2-0052" title="JaffeGV , GrimshawJJ , ConstadD . Benzoyl peroxide in the treatment of acne vulgaris: a double‐blind, multi‐centre comparative study of 'Quinoderm' cream and 'Quinoderm' cream with hydrocortisone versus their base vehicle alone and a benzoyl peroxide only gel preparation. Current Medical Research &amp; Opinion1989;11(7):453‐62. [CENTRAL: CN‐00062342; MEDLINE: 2528439] ">Jaffe 1989</a>; <a href="./references#CD011154-bbs2-0058" title="KawashimaM , HashimotoH , Alio SaenzAB , OnoM , YamadaM . Is benzoyl peroxide 3% topical gel effective and safe in the treatment of acne vulgaris in Japanese patients? A multicenter, randomized, double‐blind, vehicle‐controlled, parallel‐group study. Journal of Dermatology2014;41(9):795‐801. [CENTRAL: CN‐01254201; MEDLINE: 25132461] NCT01400932 . Study STF115288, a clinical confirmation study of GI148512 in the treatment of acne vulgaris in Japanese subjects. www.clinicaltrials.gov/ct2/show/NCT01400932 (first received 21 July 2011). ">Kawashima 2014</a>; <a href="./references#CD011154-bbs2-0059" title="KawashimaM , HashimotoH , Alio SaenzAB , OnoM , YamadaM . Clindamycin phosphate 12%‐benzoyl peroxide 30% fixed‐dose combination gel has an effective and acceptable safety and tolerability profile for the treatment of acne vulgaris in Japanese patients: a phase III, multicentre, randomised, single‐blinded, active‐controlled, parallel‐group study. British Journal of Dermatology2015;172(2):494‐503. [CENTRAL: CN‐01115087] KawashimaM , YamadaM , ParishC . Clindamycin 1%/benzoyl peroxide 3% gel, a new topical combination product, is effective in Japanese patients with acne vulgaris. Journal of Investigative Dermatology2013;133:S160. [CENTRAL: CN‐01026775] ">Kawashima 2015</a>; <a href="./references#CD011154-bbs2-0063" title="KorkutC , PiskinS . Benzoyl peroxide, adapalene, and their combination in the treatment of acne vulgaris. Journal of Dermatology2005;32(3):169‐73. [CENTRAL: CN‐00512006] ">Korkut 2005</a>; <a href="./references#CD011154-bbs2-0066" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM . Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] LeydenJ , et al. Treatment of acne vulgaris with a combination benzoyl peroxide/clindamycin topical gel Abstract P‐013. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S144. [CENTRAL: CN‐00478651] LeydenJJ , BergerRS , DunlapFE , EllisCN , ConnollyMA , LevySF . Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. American Journal of Clinical Dermatology2001;2(1):33‐9. [CENTRAL: CN‐00363426; MEDLINE: 11702619] ">Leyden 2001a</a>; <a href="./references#CD011154-bbs2-0069" title="LookingbillDP , ChalkerDK , LindholmJS , KatzHI , KempersSE , HuerterCJ , et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double‐blind investigations. Journal of the American Academy of Dermatology1997;37(4):590‐5. [CENTRAL: CN‐00144503; MEDLINE: 9344199] LookingbillDP , ChallenDK , LindholmJS . Treatment of acne with a combination of clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined result of two double blind investigations (Abstract no. 1). Indian Journal of Dermatology, Venerology and Leprology1995;61:398. ">Lookingbill 1997</a>; <a href="./references#CD011154-bbs2-0075" title="MiyachiY , MizziF , MitaT , BaiL , IkomaA . Efficacy and safety of a fixed dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% in Japanese patients with acne vulgaris ‐ a multicenter, randomized, double‐blinded, active‐controlled, parallel group phase III study. [Japanese]. Skin Research2016;15(4):278‐93. NCT02073448 . Efficacy and safety study of GK530G versus CD0271 0.1% gel and CD1579 2.5% gel in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02073448 (first received 20 February 2014). ">Miyachi 2016</a>; <a href="./references#CD011154-bbs2-0082" title="NCT02073461 . Efficacy and safety study of 2 different concentrations of CD1579 gels versus vehicle in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02073461 (first received 20 February 2014). ">NCT02073461</a>; <a href="./references#CD011154-bbs2-0094" title="ShalitaAR , RafalES , AndersonDN , YavelR , LandowS , LeeWL . Compared efficacy and safety of tretinoin 0.1% microsphere gel alone and in combination with benzoyl peroxide 6% cleanser for the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2003;72(2):167‐72. [CENTRAL: CN‐00457639; MEDLINE: 12953944] ">Shalita 2003</a>; <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>; <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>; <a href="./references#CD011154-bbs2-0108" title="Tirado‐SanchezA , Ponce‐OliveraRM . Efficacy and tolerance of superoxidized solution in the treatment of mild to moderate inflammatory acne. A double‐blinded, placebo‐ controlled, parallel‐group, randomized, clinical trial. Journal of Dermatological Treatment2009;20(5):289‐92. [CENTRAL: CN‐00743204; MEDLINE: 19459079] ">Tirado‐Sanchez 2009</a>; <a href="./references#CD011154-bbs2-0109" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM , et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] TschenE , et al. A combination benzoyl peroxide/clindamycin topical gel for the treatment of acne vulgaris. Abstract P‐029. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S150. [CENTRAL: CN‐00478786] TschenEH , KatzHI , JonesTM , MonroeEW , KrausSJ , ConnollyMA , et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2):165‐9. [CENTRAL: CN‐00346768; MEDLINE: 11236229] ">Tschen 2001</a>; <a href="./references#CD011154-bbs2-0110" title="TuckerSB , TausendR , CochranR , FlanniganSA . Comparison of topical clindamycin phosphate, benzoyl peroxide, and a combination of the two for the treatment of acne vulgaris. British Journal of Dermatology1984;110(4):487‐92. [CENTRAL: CN‐00568865; MEDLINE: 6231942] TuckerSB , TausendT , CochranR . Comparison of topical clindamycin phosphate, benzoyl peroxide and a combination of the two, for the treatment of acne vulgaris [abstract no:1]. Indian Journal of Dermatology, Venerology and Leprology1990;56:179. [CENTRAL: CN‐00692634] ">Tucker 1984</a>; <a href="./references#CD011154-bbs2-0115" title="2015‐004909‐16 . A multicentre, randomized, assessor‐blind, comparator‐controlled, parallel‐group clinical trial to establish the efficacy and safety of Duac™ (1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide) once daily gel compared with clindamycin phosphate gel (1% clindamycin as clindamycin phosphate) twice daily in the treatment of mild to moderate acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2015‐004909‐16/results (results published 29 December 2016). NCT01915732 . Efficacy and safety of Duac™ compared with clindamycin phosphate gel in the treatment of mild to moderate acne vulgaris. clinicaltrials.gov/ct2/show/NCT01915732 (first received 5 April 2013). XuJ , LuQ , HuangJ , SunQ , HaoF , GuJ , et al. A multicenter, randomized, single‐blind study of topical clindamycin 1%/benzoyl peroxide 5% once‐daily fixed dose combination gel (Duac) vs. clindamycin 1% twice‐daily gel in treatment of Chinese acne vulgaris patients. Journal of Investigative Dermatology2015;135(Suppl 2):S34, 192. [CENTRAL: CN‐01130701] XuJH , LuQJ , HuangJH , HaoF , SunQN , FangH , et al. A multicentre, randomized, single‐blind comparison of topical clindamycin 1%/benzoyl peroxide 5% once‐daily gel versus clindamycin 1% twice‐daily gel in the treatment of mild to moderate acne vulgaris in Chinese patients. Journal of the European Academy of Dermatology and Venereology2016;30(7):1176‐82. [CENTRAL: CN‐01178389; MEDLINE: 27075705] ">Xu 2016;</a><a href="./references#CD011154-bbs2-0117" title="ZeichnerJA , WongV , LinknerRV , HaddicanM . Efficacy and safety of tretinoin 0.025%/clindamycin phosphate 1.2% gel in combination with benzoyl peroxide 6% cleansing cloths for the treatment of facial acne vulgaris. Journal of Drugs in Dermatology2013;12(3):277‐82. [CENTRAL: CN‐00876866; MEDLINE: 23545909] ">Zeichner 2013</a>), three trials for medium‐term duration (<a href="./references#CD011154-bbs2-0008" title="BurkeB , EadyEA , CunliffeWJ . Benzoyl peroxide versus topical erythromycin in the treatment of acne vulgaris. British Journal of Dermatology1983;108(2):199‐204. [CENTRAL: CN‐00568861; MEDLINE: 6218815] ">Burke 1983</a>; <a href="./references#CD011154-bbs2-0084" title="OzgenZY , GurbuzO . A randomized, double‐blind comparison of nadifloxacin 1% cream alone and with benzoyl peroxide 5% lotion in the treatment of mild to moderate facial acne vulgaris. Marmara Medical Journal2013;26(1):243‐6. [CENTRAL: CN‐00912356] ">Ozgen 2013</a>; <a href="./references#CD011154-bbs2-0086" title="PapageorgiouPP , ChuAC . Chloroxylenol and zinc oxide containing cream (Nels cream) vs. 5% benzoyl peroxide cream in the treatment of acne vulgaris. A double‐blind, randomized, controlled trial. Clinical &amp; Experimental Dermatology2000;25(1):16‐20. [CENTRAL: CN‐00275100; MEDLINE: 10671963] ">Papageorgiou 2000</a>), and two for short‐term duration (<a href="./references#CD011154-bbs2-0019" title="DelRossoJ , KircikL . Comparison of the tolerability of benzoyl peroxide microsphere wash versus a gentle cleanser, when used in combination with a clindamycin and tretinoin gel: a multicenter, investigator‐blind, randomized study. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.100] ">Del 2009a</a>; <a href="./references#CD011154-bbs2-0024" title="DraelosZD , PottsA , Alio SaenzAB . Randomized tolerability analysis of clindamycin phosphate 1.2%‐tretinoin 0.025% gel used with benzoyl peroxide wash 4% for acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(6):310‐8. [CENTRAL: CN‐00770969; MEDLINE: 21284283] NCT00891982 . A phase 3, multicenter, assessor‐blinded study of the tolerability of a topical antibiotic and retinoid used in conjunction with benzoyl peroxide wash in subjects with mild‐to‐moderate facial acne vulgaris. clinicaltrials.gov/ct2/show/NCT00891982 (first received 29 April 2009). ">Draelos 2010</a>); one assessed varying durations (<a href="./references#CD011154-bbs2-0112" title="VasarinshP . Benzoyl peroxide‐sulfur lotions in acne vulgaris ‐ a controlled study. Cutis; Cutaneous Medicine for the Practitioner1969;5(1):65‐9. [CENTRAL: CN‐00269401] ">Vasarinsh 1969</a>). </p> <section id="CD011154-sec-0144"> <p><b>Main pooled analyses: BPO versus placebo or no treatment</b></p> <p>Overall, we observed that BPO treatment can potentially result in higher risk of adverse events in the long‐term treatment period, with an RR of 1.40 (95% CI 1.15 to 1.70; 11,028 participants; I² = 72%; <a href="./references#CD011154-fig-0026" title="">Analysis 1.20</a>). According to the funnel plot (<a href="#CD011154-fig-0005">Figure 5</a>) and Egger's test (P = 0.881), no evidence suggests potential publication bias. Most adverse events were mild to moderate. The most common adverse events across trials included skin dryness, facial pain, pruritus, dermatitis, erythema, and irritation. </p> <div class="figure" id="CD011154-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 BPO versus placebo or no treatment, outcome: 1.20 Percentage of participants with any adverse events (long‐term data)." data-id="CD011154-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 BPO versus placebo or no treatment, outcome: 1.20 Percentage of participants with any adverse events (long‐term data). </p> </div> </div> </div> <p>Evidence for medium‐term or short‐term treatment duration was limited, with an RR of 1.67 (95% CI 1.08 to 2.59; 93 participants; 1 study; <a href="./references#CD011154-fig-0027" title="">Analysis 1.21</a>) and 0.13 (95% CI 0.02 to 0.94; 60 participants; 1 study; <a href="./references#CD011154-fig-0028" title="">Analysis 1.22</a>), respectively. </p> <p>In the trial with varying treatment durations, excessive erythema and dryness occurred in five participants on BPO and two on placebo. One participant developed severe allergic sensitisation after BPO treatment (<a href="./references#CD011154-bbs2-0112" title="VasarinshP . Benzoyl peroxide‐sulfur lotions in acne vulgaris ‐ a controlled study. Cutis; Cutaneous Medicine for the Practitioner1969;5(1):65‐9. [CENTRAL: CN‐00269401] ">Vasarinsh 1969</a>). </p> </section> <section id="CD011154-sec-0145"> <p><b>Subgroup analyses: co‐intervention</b></p> <p>We did not observe that the occurrence of adverse events differed by co‐intervention (P for subgroup differences = 0.32). </p> </section> <section id="CD011154-sec-0146"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Two trials did not present the number of participants experiencing at least one adverse event but reported that the number was similar across study treatments (<a href="./references#CD011154-bbs2-0005" title="BorglundE , KristensenB , Larsson‐StymneB , StrandA , VeienNK , JakobsenHB . Topical meclocycline sulfosalicylate, benzoyl peroxide, and a combination of the two in the treatment of acne vulgaris. Acta Dermato‐Venereologica1991;71:175‐8. [CENTRAL: CN‐00075962; MEDLINE: 1675534] ">Borglund 1991</a>; <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>). Although adverse events were assessed in four trials exploring effects of BPO plus adapalene versus adapalene (<a href="./references#CD011154-bbs2-0010" title="CassanoN , AlessandriniG , CarrieriG , FaiD , GabbelloneM , GravanteM , et al. Treatment of mild to moderate acne vulgaris with adapalene alone or combined with other anti‐acne agents. A multicenter open trial. [Studio multicentrico in aperto sul trattamento dell'acne lieve/moderata con adapalene in monoterapia o in terapia combinata]. Giornale Italiano di Dermatologia e Venereologia2002;137(5):369‐75. [CENTRAL: CN‐00432115] ">Cassano 2002</a>; <a href="./references#CD011154-bbs2-0037" title="FangL , FuW , GuJ , SunJ , MaE . Efficacy and safety of benzoyl peroxide gel, 5% combined with adapalene gel, 0.1% in Chinese patients with acne vulgaris (Abstract). 20th World Congress of Dermatology, Paris, 1st to 5th July 2002. Annales de Dermatologie et de Venereologie2002;129(Suppl 1 Pt 2):P0020. [CENTRAL: CN‐00454223] ">Fang 2002</a>; <a href="./references#CD011154-bbs2-0039" title="FuWW , FangL , GuJ , ShunJF . Clinical efficacy and safety of 5% benzoyl peroxide gel combined with 0.1% adapalene gel in the treatment of acne vulgaris: a multicenter, randomized study. Chinese Journal of Dermatology2003;36(6):310‐2. [CENTRAL: CN‐00484027] ">Fu 2003</a>; <a href="./references#CD011154-bbs2-0063" title="KorkutC , PiskinS . Benzoyl peroxide, adapalene, and their combination in the treatment of acne vulgaris. Journal of Dermatology2005;32(3):169‐73. [CENTRAL: CN‐00512006] ">Korkut 2005</a>), three of them did not present the outcomes of our review interest (<a href="./references#CD011154-bbs2-0010" title="CassanoN , AlessandriniG , CarrieriG , FaiD , GabbelloneM , GravanteM , et al. Treatment of mild to moderate acne vulgaris with adapalene alone or combined with other anti‐acne agents. A multicenter open trial. [Studio multicentrico in aperto sul trattamento dell'acne lieve/moderata con adapalene in monoterapia o in terapia combinata]. Giornale Italiano di Dermatologia e Venereologia2002;137(5):369‐75. [CENTRAL: CN‐00432115] ">Cassano 2002</a>; <a href="./references#CD011154-bbs2-0037" title="FangL , FuW , GuJ , SunJ , MaE . Efficacy and safety of benzoyl peroxide gel, 5% combined with adapalene gel, 0.1% in Chinese patients with acne vulgaris (Abstract). 20th World Congress of Dermatology, Paris, 1st to 5th July 2002. Annales de Dermatologie et de Venereologie2002;129(Suppl 1 Pt 2):P0020. [CENTRAL: CN‐00454223] ">Fang 2002</a>; <a href="./references#CD011154-bbs2-0063" title="KorkutC , PiskinS . Benzoyl peroxide, adapalene, and their combination in the treatment of acne vulgaris. Journal of Dermatology2005;32(3):169‐73. [CENTRAL: CN‐00512006] ">Korkut 2005</a>). We cannot calculate RR as the effect size for the comparison between BPO plus tretinoin and placebo plus tretinoin as investigated in one 12‐week parallel trial because the number of participants with at least one adverse event was not provided (<a href="./references#CD011154-bbs2-0094" title="ShalitaAR , RafalES , AndersonDN , YavelR , LandowS , LeeWL . Compared efficacy and safety of tretinoin 0.1% microsphere gel alone and in combination with benzoyl peroxide 6% cleanser for the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2003;72(2):167‐72. [CENTRAL: CN‐00457639; MEDLINE: 12953944] ">Shalita 2003</a>). <a href="./references#CD011154-bbs2-0112" title="VasarinshP . Benzoyl peroxide‐sulfur lotions in acne vulgaris ‐ a controlled study. Cutis; Cutaneous Medicine for the Practitioner1969;5(1):65‐9. [CENTRAL: CN‐00269401] ">Vasarinsh 1969</a> also assessed adverse events for the comparison between BPO/sulphur and sulphur, but the total number of participants with any adverse event was not reported. As mentioned in <a href="./references#CD011154-bbs2-0056" title="KabirM , SadiqS , RazaA , KanwalS , TanvirT . Comparison of efficacy of adapalene (0.1% gel) monotherapy vs adapalene (0.1%) plus benzyl peroxide (2.5%) combination therapy for treatment of mild to moderate acne vulgaris. Pakistan Journal of Medical and Health Sciences2018;12(2):587‐9. ">Kabir 2018</a>, adverse events were noted during the trial but were not reported. </p> </section> </section> </section> <section id="CD011154-sec-0147"> <h5 class="title">BPO versus adapalene</h5> <p>This comparison comprises 13 parallel trials (<a href="./references#CD011154-bbs2-0001" title="ACTRN12612001006831 . A randomized, double‐blind, clinical trial to compare the efficacy (lesion number), side effects, and patient's satisfaction rate of topical adapalene and benzoyl peroxide in the cases with mild acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12612001006831 (first received 18 September 2012). BabaeinejadSH , FouladiRF . The efficacy, safety and tolerability of adapalene versus benzoyl peroxide in the treatment of mild acne vulgaris; a randomized trial. Journal of Drugs in Dermatology2013;12(9):1033‐8. [CENTRAL: CN‐00917924; MEDLINE: 24002152] ">Babaeinejad 2013</a>; <a href="./references#CD011154-bbs2-0022" title="do NascimentoLV , GuedesAC , MagalhaesGM , deFariaFA , GuerraRM , deAlmeidaF . Single‐blind and comparative clinical study of the efficacy and safety of benzoyl peroxide 4% gel (BID) and adapalene 0.1% Gel (QD) in the treatment of acne vulgaris for 11 weeks. Journal of Dermatological Treatment2003;14(3):166‐71. [CENTRAL: CN‐00559227; MEDLINE: 14522627] ">do Nascimento 2003</a>; <a href="./references#CD011154-bbs2-0029" title="DudhiaS , ShahRB , AgrawalP , ShahA , DateS . Efficacy and safety of clindamycin gel plus either benzoyl peroxide gel or adapalene gel in the treatment of acne: a randomized open‐label study. Drugs and Therapy Perspectives2015;31(6):208‐12. [CENTRAL: CN‐01074309] ">Dudhia 2015</a>; <a href="./references#CD011154-bbs2-0038" title="FleischerAB , DraelosZD , AbramovitsW , PariserDM . Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4%, or vehicle gel for the treatment of acne vulgaris: a randomized, double‐blind study. Abstract P113. American Academy of Dermatology, 65th Annual Meeting, February 2‐6, 2007. Journal of the American Academy of Dermatology2007;56(2):AB16. [CENTRAL: CN‐00616000] FleischerAB , ShalitaA , EichenfieldLF , AbramovitsW , LuckyA , GarrettSCP . Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: a 12‐week, randomized, double‐blind study. Journal of Drugs in Dermatology2010;9(1):33‐40. [CENTRAL: CN‐00734828; MEDLINE: 20120423] NCT00151541 . A phase 3 study to compare the safety and efficacy of 5% dapsone topical gel (DTG) twice daily in combination with once daily vehicle control, adapalene gel 0.1% or benzoyl peroxide gel 4%. www.clinicaltrials.gov/ct2/show/NCT00151541 (first received 7 September 2005). ">Fleischer 2010</a>; <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>; <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>; <a href="./references#CD011154-bbs2-0048" title="2017‐001575‐23 . Clinical evaluation of efficacy at 2 weeks of Duac fixed dose combination gel in treatment of facial acne vulgaris in Japanese subjects. www.clinicaltrialsregister.eu/ctr‐search/trial/2017‐001575‐23/results (first received 21 September 2017). HayashiN , KurokawaI , SiakpereO , EndoA , HatanakaT , YamadaM , et al. Clindamycin phosphate 1.2%/benzoyl peroxide 3% fixed‐dose combination gel versus topical combination therapy of adapalene 0.1% gel and clindamycin phosphate 1.2% gel in the treatment of acne vulgaris in Japanese patients: a multicenter, randomized, investigator‐blind, parallel‐group study. Journal of Dermatology2018;45(8):951‐62. [CENTRAL: CN‐01629242] NCT02557399 . DUAC® early onset efficacy study in Japanese subjects. clinicaltrials.gov/ct2/show/NCT02557399 (first received 23 September 2015). ">Hayashi 2018</a>; <a href="./references#CD011154-bbs2-0050" title="IftikharU , AmanS , NadeemM , KazmiAH . A comparison of efficacy and safety of topical 0.1% adapalene and 4% benzoyl peroxide in the treatment of mild to moderate acne vulgaris. Journal of Pakistan Association of Dermatologists2009;19(3):141‐5. [www.jpad.com.pk/index.php/jpad/article/view/530] ">Iftikhar 2009</a>; <a href="./references#CD011154-bbs2-0053" title="JawadeSA , SaigaonkarVA , KondalkarAR . Efficacy and tolerability of adapalene 0.1%‐benzoyl peroxide 2.5% combination gel in treatment of acne vulgaris in Indian patients: a randomized investigator‐blind controlled trial. Iranian Journal of Dermatology2016;19(4):105‐12. [CENTRAL: CN‐01405922] ">Jawade 2016</a>; <a href="./references#CD011154-bbs2-0063" title="KorkutC , PiskinS . Benzoyl peroxide, adapalene, and their combination in the treatment of acne vulgaris. Journal of Dermatology2005;32(3):169‐73. [CENTRAL: CN‐00512006] ">Korkut 2005</a>; <a href="./references#CD011154-bbs2-0075" title="MiyachiY , MizziF , MitaT , BaiL , IkomaA . Efficacy and safety of a fixed dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% in Japanese patients with acne vulgaris ‐ a multicenter, randomized, double‐blinded, active‐controlled, parallel group phase III study. [Japanese]. Skin Research2016;15(4):278‐93. NCT02073448 . Efficacy and safety study of GK530G versus CD0271 0.1% gel and CD1579 2.5% gel in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02073448 (first received 20 February 2014). ">Miyachi 2016</a>; <a href="./references#CD011154-bbs2-0099" title="StincoG , BragadinG , TrotterD , PillonB , PatroneP . Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. Journal of the European Academy of Dermatology and Venereology2007;21(3):320‐5. [CENTRAL: CN‐00586948; MEDLINE: 17309452] ">Stinco 2007</a>; <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>). Participants in all trials except one were followed up for a long‐term period (<a href="./references#CD011154-bbs2-0099" title="StincoG , BragadinG , TrotterD , PillonB , PatroneP . Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. Journal of the European Academy of Dermatology and Venereology2007;21(3):320‐5. [CENTRAL: CN‐00586948; MEDLINE: 17309452] ">Stinco 2007</a>). All outcomes of interest in this review were available except the reduction in <i>C acnes</i> strains. See <a href="./full#CD011154-tbl-0002">summary of findings Table 2</a>, where we rated the evidence for the two primary outcomes and the secondary safety outcome. </p> <section id="CD011154-sec-0148"> <h6 class="title">Primary outcome: participant global self‐assessment of acne improvement</h6> <p>Eight trials presented long‐term data for this outcome (<a href="./references#CD011154-bbs2-0001" title="ACTRN12612001006831 . A randomized, double‐blind, clinical trial to compare the efficacy (lesion number), side effects, and patient's satisfaction rate of topical adapalene and benzoyl peroxide in the cases with mild acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12612001006831 (first received 18 September 2012). BabaeinejadSH , FouladiRF . The efficacy, safety and tolerability of adapalene versus benzoyl peroxide in the treatment of mild acne vulgaris; a randomized trial. Journal of Drugs in Dermatology2013;12(9):1033‐8. [CENTRAL: CN‐00917924; MEDLINE: 24002152] ">Babaeinejad 2013</a>; <a href="./references#CD011154-bbs2-0022" title="do NascimentoLV , GuedesAC , MagalhaesGM , deFariaFA , GuerraRM , deAlmeidaF . Single‐blind and comparative clinical study of the efficacy and safety of benzoyl peroxide 4% gel (BID) and adapalene 0.1% Gel (QD) in the treatment of acne vulgaris for 11 weeks. Journal of Dermatological Treatment2003;14(3):166‐71. [CENTRAL: CN‐00559227; MEDLINE: 14522627] ">do Nascimento 2003</a>; <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>; <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>; <a href="./references#CD011154-bbs2-0048" title="2017‐001575‐23 . Clinical evaluation of efficacy at 2 weeks of Duac fixed dose combination gel in treatment of facial acne vulgaris in Japanese subjects. www.clinicaltrialsregister.eu/ctr‐search/trial/2017‐001575‐23/results (first received 21 September 2017). HayashiN , KurokawaI , SiakpereO , EndoA , HatanakaT , YamadaM , et al. Clindamycin phosphate 1.2%/benzoyl peroxide 3% fixed‐dose combination gel versus topical combination therapy of adapalene 0.1% gel and clindamycin phosphate 1.2% gel in the treatment of acne vulgaris in Japanese patients: a multicenter, randomized, investigator‐blind, parallel‐group study. Journal of Dermatology2018;45(8):951‐62. [CENTRAL: CN‐01629242] NCT02557399 . DUAC® early onset efficacy study in Japanese subjects. clinicaltrials.gov/ct2/show/NCT02557399 (first received 23 September 2015). ">Hayashi 2018</a>; <a href="./references#CD011154-bbs2-0053" title="JawadeSA , SaigaonkarVA , KondalkarAR . Efficacy and tolerability of adapalene 0.1%‐benzoyl peroxide 2.5% combination gel in treatment of acne vulgaris in Indian patients: a randomized investigator‐blind controlled trial. Iranian Journal of Dermatology2016;19(4):105‐12. [CENTRAL: CN‐01405922] ">Jawade 2016</a>; <a href="./references#CD011154-bbs2-0075" title="MiyachiY , MizziF , MitaT , BaiL , IkomaA . Efficacy and safety of a fixed dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% in Japanese patients with acne vulgaris ‐ a multicenter, randomized, double‐blinded, active‐controlled, parallel group phase III study. [Japanese]. Skin Research2016;15(4):278‐93. NCT02073448 . Efficacy and safety study of GK530G versus CD0271 0.1% gel and CD1579 2.5% gel in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02073448 (first received 20 February 2014). ">Miyachi 2016</a>; <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>). Treatment duration was 12 weeks in all these trials except one (<a href="./references#CD011154-bbs2-0022" title="do NascimentoLV , GuedesAC , MagalhaesGM , deFariaFA , GuerraRM , deAlmeidaF . Single‐blind and comparative clinical study of the efficacy and safety of benzoyl peroxide 4% gel (BID) and adapalene 0.1% Gel (QD) in the treatment of acne vulgaris for 11 weeks. Journal of Dermatological Treatment2003;14(3):166‐71. [CENTRAL: CN‐00559227; MEDLINE: 14522627] ">do Nascimento 2003</a>), in which participants were treated for 11 weeks. </p> <section id="CD011154-sec-0149"> <p><b>Main pooled analyses: BPO versus adapalene</b></p> <p>Complete data for the long‐term outcome were available in five trials (<a href="./references#CD011154-bbs2-0001" title="ACTRN12612001006831 . A randomized, double‐blind, clinical trial to compare the efficacy (lesion number), side effects, and patient's satisfaction rate of topical adapalene and benzoyl peroxide in the cases with mild acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12612001006831 (first received 18 September 2012). BabaeinejadSH , FouladiRF . The efficacy, safety and tolerability of adapalene versus benzoyl peroxide in the treatment of mild acne vulgaris; a randomized trial. Journal of Drugs in Dermatology2013;12(9):1033‐8. [CENTRAL: CN‐00917924; MEDLINE: 24002152] ">Babaeinejad 2013</a>; <a href="./references#CD011154-bbs2-0022" title="do NascimentoLV , GuedesAC , MagalhaesGM , deFariaFA , GuerraRM , deAlmeidaF . Single‐blind and comparative clinical study of the efficacy and safety of benzoyl peroxide 4% gel (BID) and adapalene 0.1% Gel (QD) in the treatment of acne vulgaris for 11 weeks. Journal of Dermatological Treatment2003;14(3):166‐71. [CENTRAL: CN‐00559227; MEDLINE: 14522627] ">do Nascimento 2003</a>; <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>; <a href="./references#CD011154-bbs2-0048" title="2017‐001575‐23 . Clinical evaluation of efficacy at 2 weeks of Duac fixed dose combination gel in treatment of facial acne vulgaris in Japanese subjects. www.clinicaltrialsregister.eu/ctr‐search/trial/2017‐001575‐23/results (first received 21 September 2017). HayashiN , KurokawaI , SiakpereO , EndoA , HatanakaT , YamadaM , et al. Clindamycin phosphate 1.2%/benzoyl peroxide 3% fixed‐dose combination gel versus topical combination therapy of adapalene 0.1% gel and clindamycin phosphate 1.2% gel in the treatment of acne vulgaris in Japanese patients: a multicenter, randomized, investigator‐blind, parallel‐group study. Journal of Dermatology2018;45(8):951‐62. [CENTRAL: CN‐01629242] NCT02557399 . DUAC® early onset efficacy study in Japanese subjects. clinicaltrials.gov/ct2/show/NCT02557399 (first received 23 September 2015). ">Hayashi 2018</a>; <a href="./references#CD011154-bbs2-0053" title="JawadeSA , SaigaonkarVA , KondalkarAR . Efficacy and tolerability of adapalene 0.1%‐benzoyl peroxide 2.5% combination gel in treatment of acne vulgaris in Indian patients: a randomized investigator‐blind controlled trial. Iranian Journal of Dermatology2016;19(4):105‐12. [CENTRAL: CN‐01405922] ">Jawade 2016</a>), in which the outcome was assessed with a four‐category, a 5‐point, or a 6‐point Likert‐like scale. No difference in the probability of treatment success was found (RR 0.99, 95% CI 0.90 to 1.10; 1472 participants; 5 studies; I² = 55%; <a href="./references#CD011154-fig-0029" title="">Analysis 2.1</a>). </p> </section> <section id="CD011154-sec-0150"> <p><b>Subgroup analyses: co‐intervention</b></p> <p>We found that effects of BPO versus adapalene may be altered by co‐intervention with clindamycin, with a P value of 0.03 (<a href="./references#CD011154-fig-0029" title="">Analysis 2.1</a>). </p> </section> <section id="CD011154-sec-0151"> <p><b>Studies not included in the meta‐analysis</b></p> <p>We did not pool the results from the other three trials because data were insufficient to calculate the percentage of treatment success defined in our review (<a href="./appendices#CD011154-sec-0588">Appendix 9</a>) (<a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>; <a href="./references#CD011154-bbs2-0075" title="MiyachiY , MizziF , MitaT , BaiL , IkomaA . Efficacy and safety of a fixed dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% in Japanese patients with acne vulgaris ‐ a multicenter, randomized, double‐blinded, active‐controlled, parallel group phase III study. [Japanese]. Skin Research2016;15(4):278‐93. NCT02073448 . Efficacy and safety study of GK530G versus CD0271 0.1% gel and CD1579 2.5% gel in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02073448 (first received 20 February 2014). ">Miyachi 2016</a>; <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>). In <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>, 415 participants in the BPO group and 418 in the adapalene group were assessed for this outcome via a 6‐point Likert‐like scale. The risk ratio for self‐reported complete or marked improvement was 0.89 (95% CI 0.59 to 1.34). A similar 6‐point Likert‐like scale was used in another trial (<a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>), in which 149 participants were treated with BPO and 148 with placebo. The risk ratio for self‐reported complete or marked improvement was 0.88 (95% CI 0.63 to 1.22). Sensitivity analysis including both studies revealed similar results (RR 0.99, 95% CI 0.90 to 1.08). These results consistently suggested no difference in self‐assessed improvement between the two groups. In <a href="./references#CD011154-bbs2-0075" title="MiyachiY , MizziF , MitaT , BaiL , IkomaA . Efficacy and safety of a fixed dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% in Japanese patients with acne vulgaris ‐ a multicenter, randomized, double‐blinded, active‐controlled, parallel group phase III study. [Japanese]. Skin Research2016;15(4):278‐93. NCT02073448 . Efficacy and safety study of GK530G versus CD0271 0.1% gel and CD1579 2.5% gel in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02073448 (first received 20 February 2014). ">Miyachi 2016</a>, where self‐reported improvement was assessed via a 100‐mm visual analog scale (0 mm = not completely satisfactory, 100 mm = very satisfactory), the average (± standard deviation) score at 12 weeks was 79.6 ± 22.0 mm for BPO and 74.4 ± 19.7 mm for adapalene. </p> </section> </section> <section id="CD011154-sec-0152"> <h6 class="title">Primary outcome: withdrawal due to adverse effects</h6> <p>A total of 11 trials reported the long‐term outcome (<a href="./references#CD011154-bbs2-0001" title="ACTRN12612001006831 . A randomized, double‐blind, clinical trial to compare the efficacy (lesion number), side effects, and patient's satisfaction rate of topical adapalene and benzoyl peroxide in the cases with mild acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12612001006831 (first received 18 September 2012). BabaeinejadSH , FouladiRF . The efficacy, safety and tolerability of adapalene versus benzoyl peroxide in the treatment of mild acne vulgaris; a randomized trial. Journal of Drugs in Dermatology2013;12(9):1033‐8. [CENTRAL: CN‐00917924; MEDLINE: 24002152] ">Babaeinejad 2013</a>; <a href="./references#CD011154-bbs2-0022" title="do NascimentoLV , GuedesAC , MagalhaesGM , deFariaFA , GuerraRM , deAlmeidaF . Single‐blind and comparative clinical study of the efficacy and safety of benzoyl peroxide 4% gel (BID) and adapalene 0.1% Gel (QD) in the treatment of acne vulgaris for 11 weeks. Journal of Dermatological Treatment2003;14(3):166‐71. [CENTRAL: CN‐00559227; MEDLINE: 14522627] ">do Nascimento 2003</a>; <a href="./references#CD011154-bbs2-0038" title="FleischerAB , DraelosZD , AbramovitsW , PariserDM . Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4%, or vehicle gel for the treatment of acne vulgaris: a randomized, double‐blind study. Abstract P113. American Academy of Dermatology, 65th Annual Meeting, February 2‐6, 2007. Journal of the American Academy of Dermatology2007;56(2):AB16. [CENTRAL: CN‐00616000] FleischerAB , ShalitaA , EichenfieldLF , AbramovitsW , LuckyA , GarrettSCP . Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: a 12‐week, randomized, double‐blind study. Journal of Drugs in Dermatology2010;9(1):33‐40. [CENTRAL: CN‐00734828; MEDLINE: 20120423] NCT00151541 . A phase 3 study to compare the safety and efficacy of 5% dapsone topical gel (DTG) twice daily in combination with once daily vehicle control, adapalene gel 0.1% or benzoyl peroxide gel 4%. www.clinicaltrials.gov/ct2/show/NCT00151541 (first received 7 September 2005). ">Fleischer 2010</a>; <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>; <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>; <a href="./references#CD011154-bbs2-0048" title="2017‐001575‐23 . Clinical evaluation of efficacy at 2 weeks of Duac fixed dose combination gel in treatment of facial acne vulgaris in Japanese subjects. www.clinicaltrialsregister.eu/ctr‐search/trial/2017‐001575‐23/results (first received 21 September 2017). HayashiN , KurokawaI , SiakpereO , EndoA , HatanakaT , YamadaM , et al. Clindamycin phosphate 1.2%/benzoyl peroxide 3% fixed‐dose combination gel versus topical combination therapy of adapalene 0.1% gel and clindamycin phosphate 1.2% gel in the treatment of acne vulgaris in Japanese patients: a multicenter, randomized, investigator‐blind, parallel‐group study. Journal of Dermatology2018;45(8):951‐62. [CENTRAL: CN‐01629242] NCT02557399 . DUAC® early onset efficacy study in Japanese subjects. clinicaltrials.gov/ct2/show/NCT02557399 (first received 23 September 2015). ">Hayashi 2018</a>; <a href="./references#CD011154-bbs2-0050" title="IftikharU , AmanS , NadeemM , KazmiAH . A comparison of efficacy and safety of topical 0.1% adapalene and 4% benzoyl peroxide in the treatment of mild to moderate acne vulgaris. Journal of Pakistan Association of Dermatologists2009;19(3):141‐5. [www.jpad.com.pk/index.php/jpad/article/view/530] ">Iftikhar 2009</a>; <a href="./references#CD011154-bbs2-0053" title="JawadeSA , SaigaonkarVA , KondalkarAR . Efficacy and tolerability of adapalene 0.1%‐benzoyl peroxide 2.5% combination gel in treatment of acne vulgaris in Indian patients: a randomized investigator‐blind controlled trial. Iranian Journal of Dermatology2016;19(4):105‐12. [CENTRAL: CN‐01405922] ">Jawade 2016</a>; <a href="./references#CD011154-bbs2-0063" title="KorkutC , PiskinS . Benzoyl peroxide, adapalene, and their combination in the treatment of acne vulgaris. Journal of Dermatology2005;32(3):169‐73. [CENTRAL: CN‐00512006] ">Korkut 2005</a>; <a href="./references#CD011154-bbs2-0075" title="MiyachiY , MizziF , MitaT , BaiL , IkomaA . Efficacy and safety of a fixed dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% in Japanese patients with acne vulgaris ‐ a multicenter, randomized, double‐blinded, active‐controlled, parallel group phase III study. [Japanese]. Skin Research2016;15(4):278‐93. NCT02073448 . Efficacy and safety study of GK530G versus CD0271 0.1% gel and CD1579 2.5% gel in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02073448 (first received 20 February 2014). ">Miyachi 2016</a>; <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>), and one reported the medium‐term outcome (<a href="./references#CD011154-bbs2-0099" title="StincoG , BragadinG , TrotterD , PillonB , PatroneP . Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. Journal of the European Academy of Dermatology and Venereology2007;21(3):320‐5. [CENTRAL: CN‐00586948; MEDLINE: 17309452] ">Stinco 2007</a>). </p> <section id="CD011154-sec-0153"> <p><b>Main pooled analyses: BPO versus adapalene</b></p> <p>We did not observe significant differences in the long‐term withdrawal rate between BPO and adapalene, with an RR of 1.85 (95% CI 0.94 to 3.64; 3295 participants; 11 studies; I² = 0%; <a href="./references#CD011154-fig-0030" title="">Analysis 2.2</a>). As shown in the funnel plot (<a href="#CD011154-fig-0006">Figure 6</a>) and on Egger's test (P = 0.407), no evidence suggests potential publication bias. For medium‐term data, no participants discontinued treatment in <a href="./references#CD011154-bbs2-0099" title="StincoG , BragadinG , TrotterD , PillonB , PatroneP . Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. Journal of the European Academy of Dermatology and Venereology2007;21(3):320‐5. [CENTRAL: CN‐00586948; MEDLINE: 17309452] ">Stinco 2007</a>. </p> <div class="figure" id="CD011154-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 2 BPO versus adapalene, outcome: 2.2 Withdrawal due to adverse effects (long‐term data)." data-id="CD011154-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 2 BPO versus adapalene, outcome: 2.2 Withdrawal due to adverse effects (long‐term data). </p> </div> </div> </div> </section> <section id="CD011154-sec-0154"> <p><b>Subgroup analyses: co‐intervention</b></p> <p>No significant between‐group differences by co‐interventions were observed in subgroup analyses for the long‐term outcome (P = 0.60). </p> </section> </section> <section id="CD011154-sec-0155"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <p>Although lesion counts were assessed in nine included trials (<a href="./references#CD011154-bbs2-0001" title="ACTRN12612001006831 . A randomized, double‐blind, clinical trial to compare the efficacy (lesion number), side effects, and patient's satisfaction rate of topical adapalene and benzoyl peroxide in the cases with mild acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12612001006831 (first received 18 September 2012). BabaeinejadSH , FouladiRF . The efficacy, safety and tolerability of adapalene versus benzoyl peroxide in the treatment of mild acne vulgaris; a randomized trial. Journal of Drugs in Dermatology2013;12(9):1033‐8. [CENTRAL: CN‐00917924; MEDLINE: 24002152] ">Babaeinejad 2013</a>; <a href="./references#CD011154-bbs2-0022" title="do NascimentoLV , GuedesAC , MagalhaesGM , deFariaFA , GuerraRM , deAlmeidaF . Single‐blind and comparative clinical study of the efficacy and safety of benzoyl peroxide 4% gel (BID) and adapalene 0.1% Gel (QD) in the treatment of acne vulgaris for 11 weeks. Journal of Dermatological Treatment2003;14(3):166‐71. [CENTRAL: CN‐00559227; MEDLINE: 14522627] ">do Nascimento 2003</a>; <a href="./references#CD011154-bbs2-0038" title="FleischerAB , DraelosZD , AbramovitsW , PariserDM . Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4%, or vehicle gel for the treatment of acne vulgaris: a randomized, double‐blind study. Abstract P113. American Academy of Dermatology, 65th Annual Meeting, February 2‐6, 2007. Journal of the American Academy of Dermatology2007;56(2):AB16. [CENTRAL: CN‐00616000] FleischerAB , ShalitaA , EichenfieldLF , AbramovitsW , LuckyA , GarrettSCP . Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: a 12‐week, randomized, double‐blind study. Journal of Drugs in Dermatology2010;9(1):33‐40. [CENTRAL: CN‐00734828; MEDLINE: 20120423] NCT00151541 . A phase 3 study to compare the safety and efficacy of 5% dapsone topical gel (DTG) twice daily in combination with once daily vehicle control, adapalene gel 0.1% or benzoyl peroxide gel 4%. www.clinicaltrials.gov/ct2/show/NCT00151541 (first received 7 September 2005). ">Fleischer 2010</a>; <a href="./references#CD011154-bbs2-0048" title="2017‐001575‐23 . Clinical evaluation of efficacy at 2 weeks of Duac fixed dose combination gel in treatment of facial acne vulgaris in Japanese subjects. www.clinicaltrialsregister.eu/ctr‐search/trial/2017‐001575‐23/results (first received 21 September 2017). HayashiN , KurokawaI , SiakpereO , EndoA , HatanakaT , YamadaM , et al. Clindamycin phosphate 1.2%/benzoyl peroxide 3% fixed‐dose combination gel versus topical combination therapy of adapalene 0.1% gel and clindamycin phosphate 1.2% gel in the treatment of acne vulgaris in Japanese patients: a multicenter, randomized, investigator‐blind, parallel‐group study. Journal of Dermatology2018;45(8):951‐62. [CENTRAL: CN‐01629242] NCT02557399 . DUAC® early onset efficacy study in Japanese subjects. clinicaltrials.gov/ct2/show/NCT02557399 (first received 23 September 2015). ">Hayashi 2018</a>; <a href="./references#CD011154-bbs2-0050" title="IftikharU , AmanS , NadeemM , KazmiAH . A comparison of efficacy and safety of topical 0.1% adapalene and 4% benzoyl peroxide in the treatment of mild to moderate acne vulgaris. Journal of Pakistan Association of Dermatologists2009;19(3):141‐5. [www.jpad.com.pk/index.php/jpad/article/view/530] ">Iftikhar 2009</a>; <a href="./references#CD011154-bbs2-0063" title="KorkutC , PiskinS . Benzoyl peroxide, adapalene, and their combination in the treatment of acne vulgaris. Journal of Dermatology2005;32(3):169‐73. [CENTRAL: CN‐00512006] ">Korkut 2005</a>; <a href="./references#CD011154-bbs2-0075" title="MiyachiY , MizziF , MitaT , BaiL , IkomaA . Efficacy and safety of a fixed dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% in Japanese patients with acne vulgaris ‐ a multicenter, randomized, double‐blinded, active‐controlled, parallel group phase III study. [Japanese]. Skin Research2016;15(4):278‐93. NCT02073448 . Efficacy and safety study of GK530G versus CD0271 0.1% gel and CD1579 2.5% gel in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02073448 (first received 20 February 2014). ">Miyachi 2016</a>; <a href="./references#CD011154-bbs2-0095" title="ShwethaH , GeethaA . A comparative study of efficacy and safety of combination of topical 1% clindamycin and 0.1% adapalene with 1% clindamycin and 2.5% benzoyl peroxide in mild to moderate acne in a tertiary care hospital. Indian Journal of Pharmacology2013;45:S19. [CENTRAL: CN‐01057398] ShwethaH , GeethaA , RevathiTN . A comparative study of efficacy and safety of combination of topical 1% clindamycin and 0.1% adapalene with 1% clindamycin and 2.5% benzoyl peroxide in mild to moderate acne at a tertiary care hospital. Journal of Chemical and Pharmaceutical Research2014;6(2):736‐41. [CENTRAL: CN‐00986447] ">Shwetha 2014</a>; <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>), sufficient data were available from only four trials for our review to estimate the effect size for the absolute or percentage change in TLs, ILs, or NILs (<a href="./references#CD011154-bbs2-0048" title="2017‐001575‐23 . Clinical evaluation of efficacy at 2 weeks of Duac fixed dose combination gel in treatment of facial acne vulgaris in Japanese subjects. www.clinicaltrialsregister.eu/ctr‐search/trial/2017‐001575‐23/results (first received 21 September 2017). HayashiN , KurokawaI , SiakpereO , EndoA , HatanakaT , YamadaM , et al. Clindamycin phosphate 1.2%/benzoyl peroxide 3% fixed‐dose combination gel versus topical combination therapy of adapalene 0.1% gel and clindamycin phosphate 1.2% gel in the treatment of acne vulgaris in Japanese patients: a multicenter, randomized, investigator‐blind, parallel‐group study. Journal of Dermatology2018;45(8):951‐62. [CENTRAL: CN‐01629242] NCT02557399 . DUAC® early onset efficacy study in Japanese subjects. clinicaltrials.gov/ct2/show/NCT02557399 (first received 23 September 2015). ">Hayashi 2018</a>; <a href="./references#CD011154-bbs2-0022" title="do NascimentoLV , GuedesAC , MagalhaesGM , deFariaFA , GuerraRM , deAlmeidaF . Single‐blind and comparative clinical study of the efficacy and safety of benzoyl peroxide 4% gel (BID) and adapalene 0.1% Gel (QD) in the treatment of acne vulgaris for 11 weeks. Journal of Dermatological Treatment2003;14(3):166‐71. [CENTRAL: CN‐00559227; MEDLINE: 14522627] ">do Nascimento 2003</a>; <a href="./references#CD011154-bbs2-0038" title="FleischerAB , DraelosZD , AbramovitsW , PariserDM . Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4%, or vehicle gel for the treatment of acne vulgaris: a randomized, double‐blind study. Abstract P113. American Academy of Dermatology, 65th Annual Meeting, February 2‐6, 2007. Journal of the American Academy of Dermatology2007;56(2):AB16. [CENTRAL: CN‐00616000] FleischerAB , ShalitaA , EichenfieldLF , AbramovitsW , LuckyA , GarrettSCP . Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: a 12‐week, randomized, double‐blind study. Journal of Drugs in Dermatology2010;9(1):33‐40. [CENTRAL: CN‐00734828; MEDLINE: 20120423] NCT00151541 . A phase 3 study to compare the safety and efficacy of 5% dapsone topical gel (DTG) twice daily in combination with once daily vehicle control, adapalene gel 0.1% or benzoyl peroxide gel 4%. www.clinicaltrials.gov/ct2/show/NCT00151541 (first received 7 September 2005). ">Fleischer 2010</a>; <a href="./references#CD011154-bbs2-0095" title="ShwethaH , GeethaA . A comparative study of efficacy and safety of combination of topical 1% clindamycin and 0.1% adapalene with 1% clindamycin and 2.5% benzoyl peroxide in mild to moderate acne in a tertiary care hospital. Indian Journal of Pharmacology2013;45:S19. [CENTRAL: CN‐01057398] ShwethaH , GeethaA , RevathiTN . A comparative study of efficacy and safety of combination of topical 1% clindamycin and 0.1% adapalene with 1% clindamycin and 2.5% benzoyl peroxide in mild to moderate acne at a tertiary care hospital. Journal of Chemical and Pharmaceutical Research2014;6(2):736‐41. [CENTRAL: CN‐00986447] ">Shwetha 2014</a>). </p> <section id="CD011154-sec-0156"> <p><b>Main pooled analyses: BPO versus adapalene</b></p> <p>In the trial comparing BPO/clindamycin with adapalene plus clindamycin among 349 participants (<a href="./references#CD011154-bbs2-0048" title="2017‐001575‐23 . Clinical evaluation of efficacy at 2 weeks of Duac fixed dose combination gel in treatment of facial acne vulgaris in Japanese subjects. www.clinicaltrialsregister.eu/ctr‐search/trial/2017‐001575‐23/results (first received 21 September 2017). HayashiN , KurokawaI , SiakpereO , EndoA , HatanakaT , YamadaM , et al. Clindamycin phosphate 1.2%/benzoyl peroxide 3% fixed‐dose combination gel versus topical combination therapy of adapalene 0.1% gel and clindamycin phosphate 1.2% gel in the treatment of acne vulgaris in Japanese patients: a multicenter, randomized, investigator‐blind, parallel‐group study. Journal of Dermatology2018;45(8):951‐62. [CENTRAL: CN‐01629242] NCT02557399 . DUAC® early onset efficacy study in Japanese subjects. clinicaltrials.gov/ct2/show/NCT02557399 (first received 23 September 2015). ">Hayashi 2018</a>), the mean difference in absolute change in TLs, ILs, and NILs assessed after a long‐term treatment duration was ‐1.70 (95% CI ‐5.46 to 2.06; <a href="./references#CD011154-fig-0031" title="">Analysis 2.3</a>), ‐1.10 (95% CI ‐2.42 to 0.22; <a href="./references#CD011154-fig-0032" title="">Analysis 2.4</a>), and ‐0.60 (95% CI ‐3.65 to 2.45; <a href="./references#CD011154-fig-0033" title="">Analysis 2.5</a>), respectively, with no significant differences between the two groups. Counterparts reported in this trial were ‐0.70 (95% CI ‐5.09 to 3.69; <a href="./references#CD011154-fig-0034" title="">Analysis 2.6</a>), ‐1.90 (95% CI ‐3.44 to ‐0.36; <a href="./references#CD011154-fig-0035" title="">Analysis 2.7</a>), and 1.20 (95% CI ‐2.46 to 4.86; <a href="./references#CD011154-fig-0036" title="">Analysis 2.8</a>) for the medium‐term period and ‐4.70 (95% CI ‐9.39 to ‐0.01; <a href="./references#CD011154-fig-0037" title="">Analysis 2.9</a>), ‐2.60 (95% CI ‐4.29 to ‐0.91; <a href="./references#CD011154-fig-0038" title="">Analysis 2.10</a>), and ‐2.00 (95% CI ‐6.02 to 2.02; <a href="./references#CD011154-fig-0039" title="">Analysis 2.11</a>) for the short‐term period, respectively. </p> <p>For the percentage change in TLs, ILs, and NILs, the mean difference was ‐2.63 (95% CI ‐18.42 to 13.15; 869 participants; 4 studies; I² = 98%; <a href="./references#CD011154-fig-0040" title="">Analysis 2.12</a>), ‐5.70 (95% CI ‐21.14 to 9.74; 806 participants; 4 studies; I² = 98%; <a href="./references#CD011154-fig-0041" title="">Analysis 2.13</a>), and ‐7.09 (95% CI ‐21.39 to 7.21; 806 participants; 4 studies; I² = 97%; <a href="./references#CD011154-fig-0042" title="">Analysis 2.14</a>). Counterparts for the medium‐term period reported in this trial were 0.56 (95% CI ‐5.04 to 6.16; 547 participants; 2 studies; I² = 33%; <a href="./references#CD011154-fig-0043" title="">Analysis 2.15</a>), 5.55 (95% CI 1.58 to 9.52; 689 participants; 3 studies; I² = 0%; <a href="./references#CD011154-fig-0044" title="">Analysis 2.16</a>), and 0.89 (95% CI ‐8.35 to 10.12; 689 participants; 3 studies; I² = 71%; <a href="./references#CD011154-fig-0045" title="">Analysis 2.17</a>), and for the short‐term period, 4.50 (95% CI 0.22 to 8.78; 547 participants; 2 studies; I² = 10%; <a href="./references#CD011154-fig-0046" title="">Analysis 2.18</a>), 9.12 (95% CI 4.98 to 13.26; 689 participants; 3 studies; I² = 3%; <a href="./references#CD011154-fig-0047" title="">Analysis 2.19</a>), and 6.18 (95% CI ‐1.80 to 14.15; 689 participants; 3 studies; I² = 64%; <a href="./references#CD011154-fig-0048" title="">Analysis 2.20</a>), respectively. </p> </section> <section id="CD011154-sec-0157"> <p><b>Subgroup analyses: co‐intervention</b></p> <p>The percentage change in TLs, ILs, and NILs may differ by co‐interventions (<a href="./references#CD011154-fig-0040" title="">Analysis 2.12</a>; <a href="./references#CD011154-fig-0041" title="">Analysis 2.13</a>; <a href="./references#CD011154-fig-0042" title="">Analysis 2.14</a>; <a href="./references#CD011154-fig-0045" title="">Analysis 2.17</a>; <a href="./references#CD011154-fig-0048" title="">Analysis 2.20</a>). BPO monotherapy seemed to achieve greater reduction in TLs for the long term (<a href="./references#CD011154-fig-0040" title="">Analysis 2.12</a>) and in NILs for the medium (<a href="./references#CD011154-fig-0045" title="">Analysis 2.17</a>) and short term (<a href="./references#CD011154-fig-0048" title="">Analysis 2.20</a>) than adapalene monotherapy. On the other hand, greater reduction in ILs and NILs was observed with BPO/clindamycin versus adapalene plus clindamycin for the long term (<a href="./references#CD011154-fig-0041" title="">Analysis 2.13</a>; <a href="./references#CD011154-fig-0042" title="">Analysis 2.14</a>). We did not observe significant differences in the changes in any other acne lesions (<a href="./references#CD011154-fig-0043" title="">Analysis 2.15</a>; <a href="./references#CD011154-fig-0044" title="">Analysis 2.16</a>; <a href="./references#CD011154-fig-0046" title="">Analysis 2.18</a>; <a href="./references#CD011154-fig-0047" title="">Analysis 2.19</a>). </p> </section> <section id="CD011154-sec-0158"> <p><b>Studies not included in the meta‐analysis</b></p> <p>We also found some studies that assessed the change in acne lesions but did not provide sufficient data for meta‐analysis. For the comparison between BPO monotherapy versus adapalene monotherapy, we can compare the lesions between groups at end of treatment from only two trials (<a href="./references#CD011154-bbs2-0001" title="ACTRN12612001006831 . A randomized, double‐blind, clinical trial to compare the efficacy (lesion number), side effects, and patient's satisfaction rate of topical adapalene and benzoyl peroxide in the cases with mild acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12612001006831 (first received 18 September 2012). BabaeinejadSH , FouladiRF . The efficacy, safety and tolerability of adapalene versus benzoyl peroxide in the treatment of mild acne vulgaris; a randomized trial. Journal of Drugs in Dermatology2013;12(9):1033‐8. [CENTRAL: CN‐00917924; MEDLINE: 24002152] ">Babaeinejad 2013</a>; <a href="./references#CD011154-bbs2-0063" title="KorkutC , PiskinS . Benzoyl peroxide, adapalene, and their combination in the treatment of acne vulgaris. Journal of Dermatology2005;32(3):169‐73. [CENTRAL: CN‐00512006] ">Korkut 2005</a>): the mean difference was 3.62 (95% CI 2.02 to 5.22; I² = 0%) in TLs, ‐1.25 (95% CI ‐4.23 to 1.73; I² = 80%) in ILs, and 2.45 (95% CI 0.87 to 4.04; I² = 0%) in NILs. In <a href="./references#CD011154-bbs2-0050" title="IftikharU , AmanS , NadeemM , KazmiAH . A comparison of efficacy and safety of topical 0.1% adapalene and 4% benzoyl peroxide in the treatment of mild to moderate acne vulgaris. Journal of Pakistan Association of Dermatologists2009;19(3):141‐5. [www.jpad.com.pk/index.php/jpad/article/view/530] ">Iftikhar 2009</a>, no significant difference in the absolute reduction in TLs was found. The percentage reduction in TLs (35.6% versus 35.4%), ILs (43.6% versus 45.7%), and NILs (36.4% versus 33.3%) was similar between trial groups (<a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>). In <a href="./references#CD011154-bbs2-0075" title="MiyachiY , MizziF , MitaT , BaiL , IkomaA . Efficacy and safety of a fixed dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% in Japanese patients with acne vulgaris ‐ a multicenter, randomized, double‐blinded, active‐controlled, parallel group phase III study. [Japanese]. Skin Research2016;15(4):278‐93. NCT02073448 . Efficacy and safety study of GK530G versus CD0271 0.1% gel and CD1579 2.5% gel in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02073448 (first received 20 February 2014). ">Miyachi 2016</a>, which compared BPO with adapalene in participants (104 versus 101 participants), the percentage reduction in TLs was 73.5% versus 62.7%, with a significant difference (MD 10.80%, 95% CI 3.38 to 18.22%). The average percentage reduction in ILs and NILs was 78.9% versus 66.2% and 78.8% versus 61.1% (with no significance test results available), respectively. </p> </section> </section> <section id="CD011154-sec-0159"> <h6 class="title">Secondary outcome: percentage of participants rated 'clear' or 'almost clear' on the IGA scale of acne severity </h6> <p>This outcome was reported in five trials (<a href="./references#CD011154-bbs2-0048" title="2017‐001575‐23 . Clinical evaluation of efficacy at 2 weeks of Duac fixed dose combination gel in treatment of facial acne vulgaris in Japanese subjects. www.clinicaltrialsregister.eu/ctr‐search/trial/2017‐001575‐23/results (first received 21 September 2017). HayashiN , KurokawaI , SiakpereO , EndoA , HatanakaT , YamadaM , et al. Clindamycin phosphate 1.2%/benzoyl peroxide 3% fixed‐dose combination gel versus topical combination therapy of adapalene 0.1% gel and clindamycin phosphate 1.2% gel in the treatment of acne vulgaris in Japanese patients: a multicenter, randomized, investigator‐blind, parallel‐group study. Journal of Dermatology2018;45(8):951‐62. [CENTRAL: CN‐01629242] NCT02557399 . DUAC® early onset efficacy study in Japanese subjects. clinicaltrials.gov/ct2/show/NCT02557399 (first received 23 September 2015). ">Hayashi 2018</a>; <a href="./references#CD011154-bbs2-0038" title="FleischerAB , DraelosZD , AbramovitsW , PariserDM . Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4%, or vehicle gel for the treatment of acne vulgaris: a randomized, double‐blind study. Abstract P113. American Academy of Dermatology, 65th Annual Meeting, February 2‐6, 2007. Journal of the American Academy of Dermatology2007;56(2):AB16. [CENTRAL: CN‐00616000] FleischerAB , ShalitaA , EichenfieldLF , AbramovitsW , LuckyA , GarrettSCP . Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: a 12‐week, randomized, double‐blind study. Journal of Drugs in Dermatology2010;9(1):33‐40. [CENTRAL: CN‐00734828; MEDLINE: 20120423] NCT00151541 . A phase 3 study to compare the safety and efficacy of 5% dapsone topical gel (DTG) twice daily in combination with once daily vehicle control, adapalene gel 0.1% or benzoyl peroxide gel 4%. www.clinicaltrials.gov/ct2/show/NCT00151541 (first received 7 September 2005). ">Fleischer 2010</a>; <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>; <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>; <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>). </p> <section id="CD011154-sec-0160"> <p><b>Main pooled analyses: BPO versus adapalene</b></p> <p>Overall, there were no significant differences in this outcome after a long‐term treatment duration (RR 1.12, 95% CI 0.95 to 1.32; 2512 participants; 5 studies; I² = 20%; <a href="./references#CD011154-fig-0049" title="">Analysis 2.21</a>), regardless of BPO used as monotherapy or add‐on treatment. A shorter treatment period seemed to find the higher probability of achieving 'clear' or 'almost clear' in the BPO group, as shown by the risk ratio for the medium term (RR 1.36, 95% CI 1.07 to 1.74; 2314 participants; 4 studies; I² = 0%; <a href="./references#CD011154-fig-0050" title="">Analysis 2.22</a>) and for the short term (RR 2.14, 95% CI 1.41 to 3.27; 2314 participants; 4 studies; I² = 0%; <a href="./references#CD011154-fig-0051" title="">Analysis 2.23</a>). </p> </section> <section id="CD011154-sec-0161"> <p><b>Subgroup analyses: co‐intervention</b></p> <p>No evidence suggests that co‐intervention may alter the effects of BPO on this outcome for a long, medium, or short period (all P values for testing subgroup differences &gt; 0.05; <a href="./references#CD011154-fig-0049" title="">Analysis 2.21</a>; <a href="./references#CD011154-fig-0050" title="">Analysis 2.22</a>; <a href="./references#CD011154-fig-0051" title="">Analysis 2.23</a>). </p> </section> </section> <section id="CD011154-sec-0162"> <h6 class="title">Secondary outcome: change in quality of life</h6> <section id="CD011154-sec-0163"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Only one trial assessed the outcome using Skindex‐16 for the comparison between BPO/clindamycin versus adapalene plus clindamycin among 349 participants (<a href="./references#CD011154-bbs2-0048" title="2017‐001575‐23 . Clinical evaluation of efficacy at 2 weeks of Duac fixed dose combination gel in treatment of facial acne vulgaris in Japanese subjects. www.clinicaltrialsregister.eu/ctr‐search/trial/2017‐001575‐23/results (first received 21 September 2017). HayashiN , KurokawaI , SiakpereO , EndoA , HatanakaT , YamadaM , et al. Clindamycin phosphate 1.2%/benzoyl peroxide 3% fixed‐dose combination gel versus topical combination therapy of adapalene 0.1% gel and clindamycin phosphate 1.2% gel in the treatment of acne vulgaris in Japanese patients: a multicenter, randomized, investigator‐blind, parallel‐group study. Journal of Dermatology2018;45(8):951‐62. [CENTRAL: CN‐01629242] NCT02557399 . DUAC® early onset efficacy study in Japanese subjects. clinicaltrials.gov/ct2/show/NCT02557399 (first received 23 September 2015). ">Hayashi 2018</a>). Trial results suggest no significant differences between the two groups for the long‐term period, with an MD of ‐0.17 (95% CI ‐0.37 to 0.03; <a href="./references#CD011154-fig-0052" title="">Analysis 2.24</a>). For medium‐ and short‐term periods, more benefits were observed in the BPO add‐on treatment group, with an MD of ‐0.22 (95% CI ‐0.42 to ‐0.02; <a href="./references#CD011154-fig-0053" title="">Analysis 2.25</a>) and ‐0.22 (95% CI ‐0.41 to ‐0.03; <a href="./references#CD011154-fig-0054" title="">Analysis 2.26</a>), respectively. </p> </section> </section> <section id="CD011154-sec-0164"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <p>The outcome was reported in 10 trials for a long‐term treatment duration (<a href="./references#CD011154-bbs2-0001" title="ACTRN12612001006831 . A randomized, double‐blind, clinical trial to compare the efficacy (lesion number), side effects, and patient's satisfaction rate of topical adapalene and benzoyl peroxide in the cases with mild acne vulgaris. apps.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12612001006831 (first received 18 September 2012). BabaeinejadSH , FouladiRF . The efficacy, safety and tolerability of adapalene versus benzoyl peroxide in the treatment of mild acne vulgaris; a randomized trial. Journal of Drugs in Dermatology2013;12(9):1033‐8. [CENTRAL: CN‐00917924; MEDLINE: 24002152] ">Babaeinejad 2013</a>; <a href="./references#CD011154-bbs2-0022" title="do NascimentoLV , GuedesAC , MagalhaesGM , deFariaFA , GuerraRM , deAlmeidaF . Single‐blind and comparative clinical study of the efficacy and safety of benzoyl peroxide 4% gel (BID) and adapalene 0.1% Gel (QD) in the treatment of acne vulgaris for 11 weeks. Journal of Dermatological Treatment2003;14(3):166‐71. [CENTRAL: CN‐00559227; MEDLINE: 14522627] ">do Nascimento 2003</a>; <a href="./references#CD011154-bbs2-0038" title="FleischerAB , DraelosZD , AbramovitsW , PariserDM . Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4%, or vehicle gel for the treatment of acne vulgaris: a randomized, double‐blind study. Abstract P113. American Academy of Dermatology, 65th Annual Meeting, February 2‐6, 2007. Journal of the American Academy of Dermatology2007;56(2):AB16. [CENTRAL: CN‐00616000] FleischerAB , ShalitaA , EichenfieldLF , AbramovitsW , LuckyA , GarrettSCP . Dapsone gel 5% in combination with adapalene gel 0.1%, benzoyl peroxide gel 4% or moisturizer for the treatment of acne vulgaris: a 12‐week, randomized, double‐blind study. Journal of Drugs in Dermatology2010;9(1):33‐40. [CENTRAL: CN‐00734828; MEDLINE: 20120423] NCT00151541 . A phase 3 study to compare the safety and efficacy of 5% dapsone topical gel (DTG) twice daily in combination with once daily vehicle control, adapalene gel 0.1% or benzoyl peroxide gel 4%. www.clinicaltrials.gov/ct2/show/NCT00151541 (first received 7 September 2005). ">Fleischer 2010</a>; <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>; <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>; <a href="./references#CD011154-bbs2-0048" title="2017‐001575‐23 . Clinical evaluation of efficacy at 2 weeks of Duac fixed dose combination gel in treatment of facial acne vulgaris in Japanese subjects. www.clinicaltrialsregister.eu/ctr‐search/trial/2017‐001575‐23/results (first received 21 September 2017). HayashiN , KurokawaI , SiakpereO , EndoA , HatanakaT , YamadaM , et al. Clindamycin phosphate 1.2%/benzoyl peroxide 3% fixed‐dose combination gel versus topical combination therapy of adapalene 0.1% gel and clindamycin phosphate 1.2% gel in the treatment of acne vulgaris in Japanese patients: a multicenter, randomized, investigator‐blind, parallel‐group study. Journal of Dermatology2018;45(8):951‐62. [CENTRAL: CN‐01629242] NCT02557399 . DUAC® early onset efficacy study in Japanese subjects. clinicaltrials.gov/ct2/show/NCT02557399 (first received 23 September 2015). ">Hayashi 2018</a>; <a href="./references#CD011154-bbs2-0063" title="KorkutC , PiskinS . Benzoyl peroxide, adapalene, and their combination in the treatment of acne vulgaris. Journal of Dermatology2005;32(3):169‐73. [CENTRAL: CN‐00512006] ">Korkut 2005</a>; <a href="./references#CD011154-bbs2-0075" title="MiyachiY , MizziF , MitaT , BaiL , IkomaA . Efficacy and safety of a fixed dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% in Japanese patients with acne vulgaris ‐ a multicenter, randomized, double‐blinded, active‐controlled, parallel group phase III study. [Japanese]. Skin Research2016;15(4):278‐93. NCT02073448 . Efficacy and safety study of GK530G versus CD0271 0.1% gel and CD1579 2.5% gel in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02073448 (first received 20 February 2014). ">Miyachi 2016</a>; <a href="./references#CD011154-bbs2-0095" title="ShwethaH , GeethaA . A comparative study of efficacy and safety of combination of topical 1% clindamycin and 0.1% adapalene with 1% clindamycin and 2.5% benzoyl peroxide in mild to moderate acne in a tertiary care hospital. Indian Journal of Pharmacology2013;45:S19. [CENTRAL: CN‐01057398] ShwethaH , GeethaA , RevathiTN . A comparative study of efficacy and safety of combination of topical 1% clindamycin and 0.1% adapalene with 1% clindamycin and 2.5% benzoyl peroxide in mild to moderate acne at a tertiary care hospital. Journal of Chemical and Pharmaceutical Research2014;6(2):736‐41. [CENTRAL: CN‐00986447] ">Shwetha 2014</a>; <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>), and in two trials for a medium‐term treatment duration (<a href="./references#CD011154-bbs2-0029" title="DudhiaS , ShahRB , AgrawalP , ShahA , DateS . Efficacy and safety of clindamycin gel plus either benzoyl peroxide gel or adapalene gel in the treatment of acne: a randomized open‐label study. Drugs and Therapy Perspectives2015;31(6):208‐12. [CENTRAL: CN‐01074309] ">Dudhia 2015</a>; <a href="./references#CD011154-bbs2-0099" title="StincoG , BragadinG , TrotterD , PillonB , PatroneP . Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. Journal of the European Academy of Dermatology and Venereology2007;21(3):320‐5. [CENTRAL: CN‐00586948; MEDLINE: 17309452] ">Stinco 2007</a>). </p> <section id="CD011154-sec-0165"> <p><b>Main pooled analyses: BPO versus adapalene</b></p> <p>Of the ten trials, seven provided the number of participants with adverse events, and pooled results from these trials show no significant difference in the long‐term outcome between the two groups (RR 0.71, 95% CI 0.50 to 1.00; 2120 participants; I² = 70%; <a href="./references#CD011154-fig-0055" title="">Analysis 2.27</a>). One trial, conducted exclusively in Japanese people, increased the heterogeneity in this meta‐analysis (<a href="./references#CD011154-bbs2-0075" title="MiyachiY , MizziF , MitaT , BaiL , IkomaA . Efficacy and safety of a fixed dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% in Japanese patients with acne vulgaris ‐ a multicenter, randomized, double‐blinded, active‐controlled, parallel group phase III study. [Japanese]. Skin Research2016;15(4):278‐93. NCT02073448 . Efficacy and safety study of GK530G versus CD0271 0.1% gel and CD1579 2.5% gel in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02073448 (first received 20 February 2014). ">Miyachi 2016</a>). Most adverse events were mild to moderate and included skin dryness, peeling, burning, redness, nasopharyngitis, erythema, and application site pain. </p> <p>The risk of adverse events for the short‐term treatment duration was substantially uncertain, with an RR of 3.00 (95% CI 0.13 to 68.26; 70 participants; 2 studies; I² = 0%; <a href="./references#CD011154-fig-0056" title="">Analysis 2.28</a>). No adverse events for the medium‐term period were reported in the trial, which included 40 participants in total (<a href="./references#CD011154-bbs2-0099" title="StincoG , BragadinG , TrotterD , PillonB , PatroneP . Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. Journal of the European Academy of Dermatology and Venereology2007;21(3):320‐5. [CENTRAL: CN‐00586948; MEDLINE: 17309452] ">Stinco 2007</a>). After the four‐week treatment, one of 15 participants treated with BPO plus clindamycin had hyperpigmentation, and none of 15 participants treated with adapalene plus clindamycin reported an adverse event (<a href="./references#CD011154-bbs2-0029" title="DudhiaS , ShahRB , AgrawalP , ShahA , DateS . Efficacy and safety of clindamycin gel plus either benzoyl peroxide gel or adapalene gel in the treatment of acne: a randomized open‐label study. Drugs and Therapy Perspectives2015;31(6):208‐12. [CENTRAL: CN‐01074309] ">Dudhia 2015</a>). </p> </section> <section id="CD011154-sec-0166"> <p><b>Subgroup analyses: co‐intervention</b></p> <p>We did not observe that the long‐term outcome differed by co‐intervention (P value for subgroup differences = 0.44; <a href="./references#CD011154-fig-0055" title="">Analysis 2.27</a>). </p> </section> <section id="CD011154-sec-0167"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Another two trials mentioned only that no statistical differences in adverse events were found between the two groups (<a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>; <a href="./references#CD011154-bbs2-0063" title="KorkutC , PiskinS . Benzoyl peroxide, adapalene, and their combination in the treatment of acne vulgaris. Journal of Dermatology2005;32(3):169‐73. [CENTRAL: CN‐00512006] ">Korkut 2005</a>). </p> </section> </section> </section> <section id="CD011154-sec-0168"> <h5 class="title">BPO versus clindamycin</h5> <p>This comparison comprised eight parallel trials (<a href="./references#CD011154-bbs2-0034" title="EichenfieldL , AlioA . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed dose combination gel for the treatment of acne vulgaris: a multicenter, double‐blind, parallel group, vehicle controlled study. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB10. [DOI: 10.1016/j.jaad.2011.11.049] EichenfieldLF , Alio SaenzAB . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed‐dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double‐blind, active‐ and vehicle‐controlled study. Journal of Drugs in Dermatology2011;10(12):1382‐96. [CENTRAL: CN‐00843726; MEDLINE: 22134562] NCT00776919 . A phase 3 multicenter, randomized, double‐blind, active and vehicle‐controlled study of the safety and efficacy of a clindamycin / benzoyl peroxide gel versus clindamycin gel versus benzoyl peroxide gel versus vehicle gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00776919 (first received 21 October 2008). ">Eichenfield 2011</a>; <a href="./references#CD011154-bbs2-0066" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM . Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] LeydenJ , et al. Treatment of acne vulgaris with a combination benzoyl peroxide/clindamycin topical gel Abstract P‐013. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S144. [CENTRAL: CN‐00478651] LeydenJJ , BergerRS , DunlapFE , EllisCN , ConnollyMA , LevySF . Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. American Journal of Clinical Dermatology2001;2(1):33‐9. [CENTRAL: CN‐00363426; MEDLINE: 11702619] ">Leyden 2001a</a>; <a href="./references#CD011154-bbs2-0069" title="LookingbillDP , ChalkerDK , LindholmJS , KatzHI , KempersSE , HuerterCJ , et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double‐blind investigations. Journal of the American Academy of Dermatology1997;37(4):590‐5. [CENTRAL: CN‐00144503; MEDLINE: 9344199] LookingbillDP , ChallenDK , LindholmJS . Treatment of acne with a combination of clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined result of two double blind investigations (Abstract no. 1). Indian Journal of Dermatology, Venerology and Leprology1995;61:398. ">Lookingbill 1997</a>; <a href="./references#CD011154-bbs2-0090" title="SchmidtJB , NeumannR , FantaD , RaabW . 1 percent clindamycin phosphate solution versus 5 percent benzoyl peroxide gel in papulopustular acne. Zeitschrift fur Hautkrankheiten1988;63(5):374‐6. [PUBMED: 2970159] ">Schmidt 1988</a>; <a href="./references#CD011154-bbs2-0102" title="SwinyerLJ , BakerMD , SwinyerTA , MillsOHJr . A comparative study of benzoyl peroxide and clindamycin phosphate for treating acne vulgaris. British Journal of Dermatology1988;119(5):615‐22. [CENTRAL: CN‐00057230; MEDLINE: 2974719] ">Swinyer 1988</a>; <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>; <a href="./references#CD011154-bbs2-0109" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM , et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] TschenE , et al. A combination benzoyl peroxide/clindamycin topical gel for the treatment of acne vulgaris. Abstract P‐029. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S150. [CENTRAL: CN‐00478786] TschenEH , KatzHI , JonesTM , MonroeEW , KrausSJ , ConnollyMA , et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2):165‐9. [CENTRAL: CN‐00346768; MEDLINE: 11236229] ">Tschen 2001</a>; <a href="./references#CD011154-bbs2-0110" title="TuckerSB , TausendR , CochranR , FlanniganSA . Comparison of topical clindamycin phosphate, benzoyl peroxide, and a combination of the two for the treatment of acne vulgaris. British Journal of Dermatology1984;110(4):487‐92. [CENTRAL: CN‐00568865; MEDLINE: 6231942] TuckerSB , TausendT , CochranR . Comparison of topical clindamycin phosphate, benzoyl peroxide and a combination of the two, for the treatment of acne vulgaris [abstract no:1]. Indian Journal of Dermatology, Venerology and Leprology1990;56:179. [CENTRAL: CN‐00692634] ">Tucker 1984</a>). The treatment duration was long. All of the outcomes of interest in this review were available, except change in quality of life and reduction in <i>C acne</i> strains. See <a href="./full#CD011154-tbl-0003">summary of findings Table 3</a>, where we rated the evidence for the two primary outcomes and the secondary safety outcome. </p> <section id="CD011154-sec-0169"> <h6 class="title">Primary outcome: participant global self‐assessment of acne improvement</h6> <p>Trials assessing this outcome were all long‐term trials (<a href="./references#CD011154-bbs2-0023" title="DraelosZD , TanghettiEA . Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis; Cutaneous Medicine for the Practitioner2002;69(2 Suppl):20‐9. [CENTRAL: CN‐00409023; MEDLINE: 12095065] ">Draelos 2002</a>; <a href="./references#CD011154-bbs2-0066" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM . Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] LeydenJ , et al. Treatment of acne vulgaris with a combination benzoyl peroxide/clindamycin topical gel Abstract P‐013. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S144. [CENTRAL: CN‐00478651] LeydenJJ , BergerRS , DunlapFE , EllisCN , ConnollyMA , LevySF . Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. American Journal of Clinical Dermatology2001;2(1):33‐9. [CENTRAL: CN‐00363426; MEDLINE: 11702619] ">Leyden 2001a</a>; <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>; <a href="./references#CD011154-bbs2-0109" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM , et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] TschenE , et al. A combination benzoyl peroxide/clindamycin topical gel for the treatment of acne vulgaris. Abstract P‐029. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S150. [CENTRAL: CN‐00478786] TschenEH , KatzHI , JonesTM , MonroeEW , KrausSJ , ConnollyMA , et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2):165‐9. [CENTRAL: CN‐00346768; MEDLINE: 11236229] ">Tschen 2001</a>), one of which provided sufficient data to estimate the effect size (<a href="./references#CD011154-bbs2-0066" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM . Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] LeydenJ , et al. Treatment of acne vulgaris with a combination benzoyl peroxide/clindamycin topical gel Abstract P‐013. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S144. [CENTRAL: CN‐00478651] LeydenJJ , BergerRS , DunlapFE , EllisCN , ConnollyMA , LevySF . Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. American Journal of Clinical Dermatology2001;2(1):33‐9. [CENTRAL: CN‐00363426; MEDLINE: 11702619] ">Leyden 2001a</a>). </p> <section id="CD011154-sec-0170"> <p><b>Main pooled analyses: BPO versus clindamycin</b></p> <p>With 120 participants treated with BPO and 120 with clindamycin, the risk ratio of treatment success assessed via a 5‐point Likert‐like scale was 0.95 (95% CI 0.68 to 1.34; <a href="./references#CD011154-fig-0057" title="">Analysis 3.1</a>) (<a href="./references#CD011154-bbs2-0066" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM . Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] LeydenJ , et al. Treatment of acne vulgaris with a combination benzoyl peroxide/clindamycin topical gel Abstract P‐013. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S144. [CENTRAL: CN‐00478651] LeydenJJ , BergerRS , DunlapFE , EllisCN , ConnollyMA , LevySF . Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. American Journal of Clinical Dermatology2001;2(1):33‐9. [CENTRAL: CN‐00363426; MEDLINE: 11702619] ">Leyden 2001a</a>). </p> </section> <section id="CD011154-sec-0171"> <p><b>Studies not included in the meta‐analysis</b></p> <p>We did not pool the results with those from the other three trials (<a href="./references#CD011154-bbs2-0023" title="DraelosZD , TanghettiEA . Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis; Cutaneous Medicine for the Practitioner2002;69(2 Suppl):20‐9. [CENTRAL: CN‐00409023; MEDLINE: 12095065] ">Draelos 2002</a>; <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>; <a href="./references#CD011154-bbs2-0109" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM , et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] TschenE , et al. A combination benzoyl peroxide/clindamycin topical gel for the treatment of acne vulgaris. Abstract P‐029. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S150. [CENTRAL: CN‐00478786] TschenEH , KatzHI , JonesTM , MonroeEW , KrausSJ , ConnollyMA , et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2):165‐9. [CENTRAL: CN‐00346768; MEDLINE: 11236229] ">Tschen 2001</a>), given that the number of treatment successes defined in our review was not available (<a href="./appendices#CD011154-sec-0588">Appendix 9</a>). However, sensitivity analysis including these studies showed a similar result (RR 1.05, 95% CI 0.97 to 1.15) to the main analysis. </p> <p><a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a> randomly assigned 809 participants to the BPO group and 812 to the clindamycin group and assessed the outcome after 12 weeks using a 7‐point Likert‐like scale. The risk ratio for self‐reported clear or almost clear was 1.00 (95% CI 0.86 to 1.16). </p> <p>In another 10‐week trial (<a href="./references#CD011154-bbs2-0109" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM , et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] TschenE , et al. A combination benzoyl peroxide/clindamycin topical gel for the treatment of acne vulgaris. Abstract P‐029. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S150. [CENTRAL: CN‐00478786] TschenEH , KatzHI , JonesTM , MonroeEW , KrausSJ , ConnollyMA , et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2):165‐9. [CENTRAL: CN‐00346768; MEDLINE: 11236229] ">Tschen 2001</a>), a 7‐point Likert‐like scale (from 3 = much better to ‐3 = much worse) was used to assess the outcome for 95 participants treated with BPO and 49 participants treated with clindamycin. The risk ratio for achieving "much better" improvement on the scale was 1.77 (95% CI 0.82 to 3.81). These results consistently suggest similar effects of both treatments. </p> <p><a href="./references#CD011154-bbs2-0023" title="DraelosZD , TanghettiEA . Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis; Cutaneous Medicine for the Practitioner2002;69(2 Suppl):20‐9. [CENTRAL: CN‐00409023; MEDLINE: 12095065] ">Draelos 2002</a>, with 89 participants on BPO plus tazarotene and 87 participants on clindamycin plus tazarotene, assessed this outcome using a 5‐point Likert‐like scale (from highly favourable to highly unfavourable). At week 12, no significant difference was found in the proportion of participants rating improvement as highly favourable or favourable (92% versus 85%; P &gt; 0.05). We cannot estimate RR as the effect size because data were not sufficient to calculate the number of participants with treatment success defined in our review. </p> </section> </section> <section id="CD011154-sec-0172"> <h6 class="title">Primary outcome: withdrawal due to adverse effects</h6> <section id="CD011154-sec-0173"> <p><b>Main pooled analyses: BPO versus clindamycin</b></p> <p>Eight long‐term trials assessing this outcome suggest no clear differences in withdrawal due to adverse effects (<a href="./references#CD011154-bbs2-0023" title="DraelosZD , TanghettiEA . Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis; Cutaneous Medicine for the Practitioner2002;69(2 Suppl):20‐9. [CENTRAL: CN‐00409023; MEDLINE: 12095065] ">Draelos 2002</a>; <a href="./references#CD011154-bbs2-0034" title="EichenfieldL , AlioA . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed dose combination gel for the treatment of acne vulgaris: a multicenter, double‐blind, parallel group, vehicle controlled study. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB10. [DOI: 10.1016/j.jaad.2011.11.049] EichenfieldLF , Alio SaenzAB . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed‐dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double‐blind, active‐ and vehicle‐controlled study. Journal of Drugs in Dermatology2011;10(12):1382‐96. [CENTRAL: CN‐00843726; MEDLINE: 22134562] NCT00776919 . A phase 3 multicenter, randomized, double‐blind, active and vehicle‐controlled study of the safety and efficacy of a clindamycin / benzoyl peroxide gel versus clindamycin gel versus benzoyl peroxide gel versus vehicle gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00776919 (first received 21 October 2008). ">Eichenfield 2011</a>; <a href="./references#CD011154-bbs2-0066" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM . Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] LeydenJ , et al. Treatment of acne vulgaris with a combination benzoyl peroxide/clindamycin topical gel Abstract P‐013. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S144. [CENTRAL: CN‐00478651] LeydenJJ , BergerRS , DunlapFE , EllisCN , ConnollyMA , LevySF . Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. American Journal of Clinical Dermatology2001;2(1):33‐9. [CENTRAL: CN‐00363426; MEDLINE: 11702619] ">Leyden 2001a</a>; <a href="./references#CD011154-bbs2-0069" title="LookingbillDP , ChalkerDK , LindholmJS , KatzHI , KempersSE , HuerterCJ , et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double‐blind investigations. Journal of the American Academy of Dermatology1997;37(4):590‐5. [CENTRAL: CN‐00144503; MEDLINE: 9344199] LookingbillDP , ChallenDK , LindholmJS . Treatment of acne with a combination of clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined result of two double blind investigations (Abstract no. 1). Indian Journal of Dermatology, Venerology and Leprology1995;61:398. ">Lookingbill 1997</a>; <a href="./references#CD011154-bbs2-0101" title="FDA , Center for Drug Evaluation and Research. Study 156. Medical Review of NDA 50‐741. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50‐741_duac%20topical%20gel_medr_p1.pdf. ">Study 156</a>; <a href="./references#CD011154-bbs2-0102" title="SwinyerLJ , BakerMD , SwinyerTA , MillsOHJr . A comparative study of benzoyl peroxide and clindamycin phosphate for treating acne vulgaris. British Journal of Dermatology1988;119(5):615‐22. [CENTRAL: CN‐00057230; MEDLINE: 2974719] ">Swinyer 1988</a>; <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>; <a href="./references#CD011154-bbs2-0109" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM , et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] TschenE , et al. A combination benzoyl peroxide/clindamycin topical gel for the treatment of acne vulgaris. Abstract P‐029. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S150. [CENTRAL: CN‐00478786] TschenEH , KatzHI , JonesTM , MonroeEW , KrausSJ , ConnollyMA , et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2):165‐9. [CENTRAL: CN‐00346768; MEDLINE: 11236229] ">Tschen 2001</a>) (RR 1.93, 95% CI 0.90 to 4.11; 3330 participants; 8 studies; I² = 0%; <a href="./references#CD011154-fig-0058" title="">Analysis 3.2</a>). Reasons for withdrawal from these trials included application site hypersensitivity, pruritus, erythema, face oedema, rash, and skin burning. </p> </section> <section id="CD011154-sec-0174"> <p><b>Subgroup analyses: co‐intervention</b></p> <p>No evidence suggests that either BPO monotherapy or BPO add‐on treatment can increase the risk of withdrawal due to adverse events, with no significant differences between co‐intervention subgroups (P = 0.58). </p> </section> </section> <section id="CD011154-sec-0175"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <p>This outcome was assessed in 10 included trials (<a href="./references#CD011154-bbs2-0023" title="DraelosZD , TanghettiEA . Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis; Cutaneous Medicine for the Practitioner2002;69(2 Suppl):20‐9. [CENTRAL: CN‐00409023; MEDLINE: 12095065] ">Draelos 2002</a>; <a href="./references#CD011154-bbs2-0034" title="EichenfieldL , AlioA . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed dose combination gel for the treatment of acne vulgaris: a multicenter, double‐blind, parallel group, vehicle controlled study. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB10. [DOI: 10.1016/j.jaad.2011.11.049] EichenfieldLF , Alio SaenzAB . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed‐dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double‐blind, active‐ and vehicle‐controlled study. Journal of Drugs in Dermatology2011;10(12):1382‐96. [CENTRAL: CN‐00843726; MEDLINE: 22134562] NCT00776919 . A phase 3 multicenter, randomized, double‐blind, active and vehicle‐controlled study of the safety and efficacy of a clindamycin / benzoyl peroxide gel versus clindamycin gel versus benzoyl peroxide gel versus vehicle gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00776919 (first received 21 October 2008). ">Eichenfield 2011</a>; <a href="./references#CD011154-bbs2-0066" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM . Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] LeydenJ , et al. Treatment of acne vulgaris with a combination benzoyl peroxide/clindamycin topical gel Abstract P‐013. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S144. [CENTRAL: CN‐00478651] LeydenJJ , BergerRS , DunlapFE , EllisCN , ConnollyMA , LevySF . Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. American Journal of Clinical Dermatology2001;2(1):33‐9. [CENTRAL: CN‐00363426; MEDLINE: 11702619] ">Leyden 2001a</a>; <a href="./references#CD011154-bbs2-0069" title="LookingbillDP , ChalkerDK , LindholmJS , KatzHI , KempersSE , HuerterCJ , et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double‐blind investigations. Journal of the American Academy of Dermatology1997;37(4):590‐5. [CENTRAL: CN‐00144503; MEDLINE: 9344199] LookingbillDP , ChallenDK , LindholmJS . Treatment of acne with a combination of clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined result of two double blind investigations (Abstract no. 1). Indian Journal of Dermatology, Venerology and Leprology1995;61:398. ">Lookingbill 1997</a>; <a href="./references#CD011154-bbs2-0100" title="FDA , Center for Drug Evaluation and Research. Study 152. Medical Review of NDA 50‐741. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50‐741_duac%20topical%20gel_medr_p1.pdf. ">Study 152</a>; <a href="./references#CD011154-bbs2-0101" title="FDA , Center for Drug Evaluation and Research. Study 156. Medical Review of NDA 50‐741. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50‐741_duac%20topical%20gel_medr_p1.pdf. ">Study 156</a>; <a href="./references#CD011154-bbs2-0102" title="SwinyerLJ , BakerMD , SwinyerTA , MillsOHJr . A comparative study of benzoyl peroxide and clindamycin phosphate for treating acne vulgaris. British Journal of Dermatology1988;119(5):615‐22. [CENTRAL: CN‐00057230; MEDLINE: 2974719] ">Swinyer 1988</a>; <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>; <a href="./references#CD011154-bbs2-0109" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM , et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] TschenE , et al. A combination benzoyl peroxide/clindamycin topical gel for the treatment of acne vulgaris. Abstract P‐029. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S150. [CENTRAL: CN‐00478786] TschenEH , KatzHI , JonesTM , MonroeEW , KrausSJ , ConnollyMA , et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2):165‐9. [CENTRAL: CN‐00346768; MEDLINE: 11236229] ">Tschen 2001</a>; <a href="./references#CD011154-bbs2-0110" title="TuckerSB , TausendR , CochranR , FlanniganSA . Comparison of topical clindamycin phosphate, benzoyl peroxide, and a combination of the two for the treatment of acne vulgaris. British Journal of Dermatology1984;110(4):487‐92. [CENTRAL: CN‐00568865; MEDLINE: 6231942] TuckerSB , TausendT , CochranR . Comparison of topical clindamycin phosphate, benzoyl peroxide and a combination of the two, for the treatment of acne vulgaris [abstract no:1]. Indian Journal of Dermatology, Venerology and Leprology1990;56:179. [CENTRAL: CN‐00692634] ">Tucker 1984</a>). Two of these trials provided sufficient long‐term data to estimate effect size in our review (<a href="./references#CD011154-bbs2-0034" title="EichenfieldL , AlioA . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed dose combination gel for the treatment of acne vulgaris: a multicenter, double‐blind, parallel group, vehicle controlled study. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB10. [DOI: 10.1016/j.jaad.2011.11.049] EichenfieldLF , Alio SaenzAB . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed‐dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double‐blind, active‐ and vehicle‐controlled study. Journal of Drugs in Dermatology2011;10(12):1382‐96. [CENTRAL: CN‐00843726; MEDLINE: 22134562] NCT00776919 . A phase 3 multicenter, randomized, double‐blind, active and vehicle‐controlled study of the safety and efficacy of a clindamycin / benzoyl peroxide gel versus clindamycin gel versus benzoyl peroxide gel versus vehicle gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00776919 (first received 21 October 2008). ">Eichenfield 2011</a>; <a href="./references#CD011154-bbs2-0069" title="LookingbillDP , ChalkerDK , LindholmJS , KatzHI , KempersSE , HuerterCJ , et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double‐blind investigations. Journal of the American Academy of Dermatology1997;37(4):590‐5. [CENTRAL: CN‐00144503; MEDLINE: 9344199] LookingbillDP , ChallenDK , LindholmJS . Treatment of acne with a combination of clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined result of two double blind investigations (Abstract no. 1). Indian Journal of Dermatology, Venerology and Leprology1995;61:398. ">Lookingbill 1997</a>). </p> <section id="CD011154-sec-0176"> <p><b>Main pooled analyses: BPO versus clindamycin</b></p> <p>The absolute change in TLs was ‐3.50 (95% CI ‐7.54 to 0.54; <a href="./references#CD011154-fig-0059" title="">Analysis 3.3</a>), derived from a total of 323 participants treated with BPO and 318 participants treated with clindamycin (<a href="./references#CD011154-bbs2-0034" title="EichenfieldL , AlioA . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed dose combination gel for the treatment of acne vulgaris: a multicenter, double‐blind, parallel group, vehicle controlled study. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB10. [DOI: 10.1016/j.jaad.2011.11.049] EichenfieldLF , Alio SaenzAB . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed‐dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double‐blind, active‐ and vehicle‐controlled study. Journal of Drugs in Dermatology2011;10(12):1382‐96. [CENTRAL: CN‐00843726; MEDLINE: 22134562] NCT00776919 . A phase 3 multicenter, randomized, double‐blind, active and vehicle‐controlled study of the safety and efficacy of a clindamycin / benzoyl peroxide gel versus clindamycin gel versus benzoyl peroxide gel versus vehicle gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00776919 (first received 21 October 2008). ">Eichenfield 2011</a>). This trial also showed the absolute change in ILs (‐1.20, 95% CI ‐2.99 to 0.59; <a href="./references#CD011154-fig-0060" title="">Analysis 3.4</a>) and NILs (‐2.40, 95% CI ‐5.30 to 0.50; <a href="./references#CD011154-fig-0061" title="">Analysis 3.5</a>). These results did not show significant differences in absolute change for each lesion type. </p> <p>As for the percentage change, the mean difference reported in <a href="./references#CD011154-bbs2-0069" title="LookingbillDP , ChalkerDK , LindholmJS , KatzHI , KempersSE , HuerterCJ , et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double‐blind investigations. Journal of the American Academy of Dermatology1997;37(4):590‐5. [CENTRAL: CN‐00144503; MEDLINE: 9344199] LookingbillDP , ChallenDK , LindholmJS . Treatment of acne with a combination of clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined result of two double blind investigations (Abstract no. 1). Indian Journal of Dermatology, Venerology and Leprology1995;61:398. ">Lookingbill 1997</a> was in NILs (21.00, 95% CI 6.86 to 35.14; <a href="./references#CD011154-fig-0063" title="">Analysis 3.7</a>) but not in ILs (4.00, 95% CI ‐8.56 to 16.56; <a href="./references#CD011154-fig-0062" title="">Analysis 3.6</a>) (92 participants treated with BPO and 89 with clindamycin contributed to these two estimates). </p> </section> <section id="CD011154-sec-0177"> <p><b>Studies not included in the meta‐analysis</b></p> <p>For the absolute change, <a href="./references#CD011154-bbs2-0066" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM . Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] LeydenJ , et al. Treatment of acne vulgaris with a combination benzoyl peroxide/clindamycin topical gel Abstract P‐013. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S144. [CENTRAL: CN‐00478651] LeydenJJ , BergerRS , DunlapFE , EllisCN , ConnollyMA , LevySF . Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. American Journal of Clinical Dermatology2001;2(1):33‐9. [CENTRAL: CN‐00363426; MEDLINE: 11702619] ">Leyden 2001a</a> reported the absolute change in both TLs (‐13.8 versus ‐6.2) and ILs (‐5.9 versus ‐3.2) in the BPO group (120 participants) compared to the clindamycin group (120 participants) at week 10. <a href="./references#CD011154-bbs2-0109" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM , et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] TschenE , et al. A combination benzoyl peroxide/clindamycin topical gel for the treatment of acne vulgaris. Abstract P‐029. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S150. [CENTRAL: CN‐00478786] TschenEH , KatzHI , JonesTM , MonroeEW , KrausSJ , ConnollyMA , et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2):165‐9. [CENTRAL: CN‐00346768; MEDLINE: 11236229] ">Tschen 2001</a> found some difference (‐12.4 in ILs for BPO (95 participants) versus ‐14.7 for clindamycin (49 participants); P &lt; 0.034). In <a href="./references#CD011154-bbs2-0110" title="TuckerSB , TausendR , CochranR , FlanniganSA . Comparison of topical clindamycin phosphate, benzoyl peroxide, and a combination of the two for the treatment of acne vulgaris. British Journal of Dermatology1984;110(4):487‐92. [CENTRAL: CN‐00568865; MEDLINE: 6231942] TuckerSB , TausendT , CochranR . Comparison of topical clindamycin phosphate, benzoyl peroxide and a combination of the two, for the treatment of acne vulgaris [abstract no:1]. Indian Journal of Dermatology, Venerology and Leprology1990;56:179. [CENTRAL: CN‐00692634] ">Tucker 1984</a>, trial authors reported the absolute change in comedone, papule, pustule, and cyst lesions at week 10 separately: corresponding results were ‐6.8 versus ‐7.3, ‐9.5 versus ‐9.7, ‐5.7 versus ‐3.4, and ‐0.05 versus ‐2.3. </p> <p>The percentage reduction in TLs, ILs, and NILs was 25.5% versus 23.5%, 33.5% versus 29.8%, and 18.8% versus 11.2% for the BPO group (n = 70) and the clindamycin group (n = 70) in <a href="./references#CD011154-bbs2-0100" title="FDA , Center for Drug Evaluation and Research. Study 152. Medical Review of NDA 50‐741. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50‐741_duac%20topical%20gel_medr_p1.pdf. ">Study 152</a>. In <a href="./references#CD011154-bbs2-0101" title="FDA , Center for Drug Evaluation and Research. Study 156. Medical Review of NDA 50‐741. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50‐741_duac%20topical%20gel_medr_p1.pdf. ">Study 156</a>, the percentage reduction in TLs, ILs, and NILs was 43.3% versus 33.3% (P = 0.008), 56.7% versus 48.6% (0.048), and 28.7% versus 18.0% (0.037) for the BPO group (n = 96) versus the clindamycin group (n = 96). Another trial found a significant difference in the percentage reduction in NILs (62.9% (BPO, 30 participants) versus 37.1% (clindamycin, 30 participants); P &lt; 0.001) at week 12 (<a href="./references#CD011154-bbs2-0102" title="SwinyerLJ , BakerMD , SwinyerTA , MillsOHJr . A comparative study of benzoyl peroxide and clindamycin phosphate for treating acne vulgaris. British Journal of Dermatology1988;119(5):615‐22. [CENTRAL: CN‐00057230; MEDLINE: 2974719] ">Swinyer 1988</a>). For <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>, 809 participants were randomised to the BPO group and 812 to the clindamycin group. The percentage reduction was 41.6% versus 40.4% in TLs, 47.5% versus 46.2% in ILs, and 37.4% versus 36.2% in NILs at week 12. In <a href="./references#CD011154-bbs2-0023" title="DraelosZD , TanghettiEA . Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis; Cutaneous Medicine for the Practitioner2002;69(2 Suppl):20‐9. [CENTRAL: CN‐00409023; MEDLINE: 12095065] ">Draelos 2002</a>, the percentage reduction in both ILs (39.7% versus 40.2%; P &gt; 0.05) and NILs (42.7% versus 55.4%; P &gt; 0.05) at week 12 was similar between two groups. For the medium‐ and the short‐term period, both treatments reduced NILs by about 40% and 30%, respectively, with no significant differences. Similar effects on reducing ILs were also observed (31% versus 35% for the medium‐term period and 24% versus 22% for the short‐term period). We cannot estimate MD as the effect size because data were not sufficient to calculate standard deviation. </p> </section> </section> <section id="CD011154-sec-0178"> <h6 class="title">Secondary outcome: percentage of participants rated 'clear' or 'almost clear' on the IGA scale of acne severity </h6> <section id="CD011154-sec-0179"> <p><b>Main pooled analyses: BPO versus clindamycin</b></p> <p>The long‐term outcome was reported in two 12‐week trials (<a href="./references#CD011154-bbs2-0034" title="EichenfieldL , AlioA . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed dose combination gel for the treatment of acne vulgaris: a multicenter, double‐blind, parallel group, vehicle controlled study. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB10. [DOI: 10.1016/j.jaad.2011.11.049] EichenfieldLF , Alio SaenzAB . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed‐dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double‐blind, active‐ and vehicle‐controlled study. Journal of Drugs in Dermatology2011;10(12):1382‐96. [CENTRAL: CN‐00843726; MEDLINE: 22134562] NCT00776919 . A phase 3 multicenter, randomized, double‐blind, active and vehicle‐controlled study of the safety and efficacy of a clindamycin / benzoyl peroxide gel versus clindamycin gel versus benzoyl peroxide gel versus vehicle gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00776919 (first received 21 October 2008). ">Eichenfield 2011</a>; <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>). With a total of 1137 and 1140 participants treated with BPO and clindamycin, respectively, heterogeneity was substantial, with no significant difference in this outcome (RR 1.10, 95% CI 0.83 to 1.45; 2277 participants; 2 studies; I² = 72%; <a href="./references#CD011154-fig-0064" title="">Analysis 3.8</a>). </p> </section> </section> <section id="CD011154-sec-0180"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <p>The outcome was reported in five trials, all of which provided long‐term data (<a href="./references#CD011154-bbs2-0034" title="EichenfieldL , AlioA . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed dose combination gel for the treatment of acne vulgaris: a multicenter, double‐blind, parallel group, vehicle controlled study. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB10. [DOI: 10.1016/j.jaad.2011.11.049] EichenfieldLF , Alio SaenzAB . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed‐dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double‐blind, active‐ and vehicle‐controlled study. Journal of Drugs in Dermatology2011;10(12):1382‐96. [CENTRAL: CN‐00843726; MEDLINE: 22134562] NCT00776919 . A phase 3 multicenter, randomized, double‐blind, active and vehicle‐controlled study of the safety and efficacy of a clindamycin / benzoyl peroxide gel versus clindamycin gel versus benzoyl peroxide gel versus vehicle gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00776919 (first received 21 October 2008). ">Eichenfield 2011</a>; <a href="./references#CD011154-bbs2-0066" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM . Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] LeydenJ , et al. Treatment of acne vulgaris with a combination benzoyl peroxide/clindamycin topical gel Abstract P‐013. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S144. [CENTRAL: CN‐00478651] LeydenJJ , BergerRS , DunlapFE , EllisCN , ConnollyMA , LevySF . Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. American Journal of Clinical Dermatology2001;2(1):33‐9. [CENTRAL: CN‐00363426; MEDLINE: 11702619] ">Leyden 2001a</a>; <a href="./references#CD011154-bbs2-0069" title="LookingbillDP , ChalkerDK , LindholmJS , KatzHI , KempersSE , HuerterCJ , et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double‐blind investigations. Journal of the American Academy of Dermatology1997;37(4):590‐5. [CENTRAL: CN‐00144503; MEDLINE: 9344199] LookingbillDP , ChallenDK , LindholmJS . Treatment of acne with a combination of clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined result of two double blind investigations (Abstract no. 1). Indian Journal of Dermatology, Venerology and Leprology1995;61:398. ">Lookingbill 1997</a>; <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>; <a href="./references#CD011154-bbs2-0109" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM , et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] TschenE , et al. A combination benzoyl peroxide/clindamycin topical gel for the treatment of acne vulgaris. Abstract P‐029. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S150. [CENTRAL: CN‐00478786] TschenEH , KatzHI , JonesTM , MonroeEW , KrausSJ , ConnollyMA , et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2):165‐9. [CENTRAL: CN‐00346768; MEDLINE: 11236229] ">Tschen 2001</a>). </p> <section id="CD011154-sec-0181"> <p><b>Main pooled analyses: BPO versus clindamycin</b></p> <p>The risk of adverse events may be higher with BPO than with clindamycin (RR 1.24, 95% CI 0.97 to 1.58; 3018 participants; 6 studies; I² = 0%; <a href="./references#CD011154-fig-0065" title="">Analysis 3.9</a>). The most common adverse events reported in these trials included skin dryness, pruritus, burning, tingling, and headache. </p> </section> <section id="CD011154-sec-0182"> <p><b>Subgroup analyses: co‐intervention</b></p> <p>No evidence suggests that co‐intervention affected the association between BPO and adverse events (P value for subgroup differences = 0.43; <a href="./references#CD011154-fig-0065" title="">Analysis 3.9</a>). </p> </section> </section> </section> <section id="CD011154-sec-0183"> <h5 class="title">BPO versus erythromycin</h5> <p>The comparison was made in four trials (<a href="./references#CD011154-bbs2-0008" title="BurkeB , EadyEA , CunliffeWJ . Benzoyl peroxide versus topical erythromycin in the treatment of acne vulgaris. British Journal of Dermatology1983;108(2):199‐204. [CENTRAL: CN‐00568861; MEDLINE: 6218815] ">Burke 1983</a>; <a href="./references#CD011154-bbs2-0010" title="CassanoN , AlessandriniG , CarrieriG , FaiD , GabbelloneM , GravanteM , et al. Treatment of mild to moderate acne vulgaris with adapalene alone or combined with other anti‐acne agents. A multicenter open trial. [Studio multicentrico in aperto sul trattamento dell'acne lieve/moderata con adapalene in monoterapia o in terapia combinata]. Giornale Italiano di Dermatologia e Venereologia2002;137(5):369‐75. [CENTRAL: CN‐00432115] ">Cassano 2002</a>; <a href="./references#CD011154-bbs2-0011" title="ChalkerDK , ShalitaA , SmithJG , SwannRW . A double‐blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. Journal of the American Academy of Dermatology1983;9(6):933‐6. [CENTRAL: CN‐00334175; MEDLINE: 6227643] ">Chalker 1983</a>; <a href="./references#CD011154-bbs2-0021" title="DograA , SoodVK , MinochaYC . Comparative evaluation of retinoic acid, benzoyl peroxide and erythromycin lotion in acne vulgaris. Indian Journal of Dermatology, Venereology and Leprology1993;59(5):243‐6. [CENTRAL: CN‐01095331] ">Dogra 1993</a>), which provided data for withdrawal due to adverse effects, lesion counts, and adverse events. See <a href="./full#CD011154-tbl-0004">summary of findings Table 4</a>, where we rated evidence for the two primary outcomes and the secondary safety outcome. </p> <section id="CD011154-sec-0184"> <h6 class="title">Primary outcome: withdrawal due to adverse effects</h6> <section id="CD011154-sec-0185"> <p><b>Main pooled analyses: BPO versus erythromycin</b></p> <p>With 30 participants equally assigned to each group, an eight‐week trial reported that one participant in each group did not complete the trial due to adverse events (both had dermatitis) (<a href="./references#CD011154-bbs2-0008" title="BurkeB , EadyEA , CunliffeWJ . Benzoyl peroxide versus topical erythromycin in the treatment of acne vulgaris. British Journal of Dermatology1983;108(2):199‐204. [CENTRAL: CN‐00568861; MEDLINE: 6218815] ">Burke 1983</a>). Evidence suggests that the risk of withdrawal was not different between the two groups (RR 1.00, 95% CI 0.07 to 15.26; 30 participants; <a href="./references#CD011154-fig-0066" title="">Analysis 4.1</a>). </p> </section> <section id="CD011154-sec-0186"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Of 44 participants treated with BPO and 45 with erythromycin, none withdrew due to adverse events during a 10‐week trial (<a href="./references#CD011154-bbs2-0011" title="ChalkerDK , ShalitaA , SmithJG , SwannRW . A double‐blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. Journal of the American Academy of Dermatology1983;9(6):933‐6. [CENTRAL: CN‐00334175; MEDLINE: 6227643] ">Chalker 1983</a>). </p> </section> </section> <section id="CD011154-sec-0187"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0188"> <p><b>Studies not included in the meta‐analysis</b></p> <p>After a six‐week treatment duration, reduction of 34.8% in NILs and 73.6% in ILs was found in the erythromycin group, which consisted of 25 participants; the counterpart in NILs and ILs was 70.1% and 63.9%, respectively, in the BPO group of 24 participants (<a href="./references#CD011154-bbs2-0021" title="DograA , SoodVK , MinochaYC . Comparative evaluation of retinoic acid, benzoyl peroxide and erythromycin lotion in acne vulgaris. Indian Journal of Dermatology, Venereology and Leprology1993;59(5):243‐6. [CENTRAL: CN‐01095331] ">Dogra 1993</a>). </p> <p>Mean lesion counts at each follow‐up were reported in another trial (<a href="./references#CD011154-bbs2-0008" title="BurkeB , EadyEA , CunliffeWJ . Benzoyl peroxide versus topical erythromycin in the treatment of acne vulgaris. British Journal of Dermatology1983;108(2):199‐204. [CENTRAL: CN‐00568861; MEDLINE: 6218815] ">Burke 1983</a>). At the end of the trial, the mean difference in TLs, ILs, and NILs between BPO and erythromycin groups was ‐5.60 (95% CI ‐8.03 to ‐3.17), ‐0.90 (95% CI ‐1.72 to ‐0.08), and ‐8.40 (95% CI ‐9.87 to ‐6.93), respectively. </p> <p>In one 16‐week parallel trial involving BPO plus adapalene versus erythromycin plus adapalene (only abstract was available), it is unclear how many participants were randomised to each group (<a href="./references#CD011154-bbs2-0010" title="CassanoN , AlessandriniG , CarrieriG , FaiD , GabbelloneM , GravanteM , et al. Treatment of mild to moderate acne vulgaris with adapalene alone or combined with other anti‐acne agents. A multicenter open trial. [Studio multicentrico in aperto sul trattamento dell'acne lieve/moderata con adapalene in monoterapia o in terapia combinata]. Giornale Italiano di Dermatologia e Venereologia2002;137(5):369‐75. [CENTRAL: CN‐00432115] ">Cassano 2002</a>). With no details on the absolute or percentage reduction in lesion counts, study authors claimed that all these treatments similarly led to a significant reduction in the numbers of papules, pustules, and comedones. </p> </section> </section> <section id="CD011154-sec-0189"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0190"> <p><b>Studies not included in the meta‐analysis</b></p> <p>No adverse events were identified in one trial (<a href="./references#CD011154-bbs2-0011" title="ChalkerDK , ShalitaA , SmithJG , SwannRW . A double‐blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. Journal of the American Academy of Dermatology1983;9(6):933‐6. [CENTRAL: CN‐00334175; MEDLINE: 6227643] ">Chalker 1983</a>). In another trial, mild erythema and scaling were found in a small number of participants, but the exact number was not reported (<a href="./references#CD011154-bbs2-0008" title="BurkeB , EadyEA , CunliffeWJ . Benzoyl peroxide versus topical erythromycin in the treatment of acne vulgaris. British Journal of Dermatology1983;108(2):199‐204. [CENTRAL: CN‐00568861; MEDLINE: 6218815] ">Burke 1983</a>). In <a href="./references#CD011154-bbs2-0010" title="CassanoN , AlessandriniG , CarrieriG , FaiD , GabbelloneM , GravanteM , et al. Treatment of mild to moderate acne vulgaris with adapalene alone or combined with other anti‐acne agents. A multicenter open trial. [Studio multicentrico in aperto sul trattamento dell'acne lieve/moderata con adapalene in monoterapia o in terapia combinata]. Giornale Italiano di Dermatologia e Venereologia2002;137(5):369‐75. [CENTRAL: CN‐00432115] ">Cassano 2002</a>, tolerability was satisfactory in most cases in each treatment arm. Itching and burning occurred in the early phase in both groups, but the intensity of these symptoms was gradually decreased. We cannot calculate RR for these trials as the effect size because the number of participants with at least one adverse event was not provided. </p> </section> </section> </section> <section id="CD011154-sec-0191"> <h5 class="title">BPO versus salicylic acid</h5> <p>This comparison comprises three parallel trials (<a href="./references#CD011154-bbs2-0004" title="BissonnetteR , BolducC , SeiteS , NigenS , ProvostN , MaariC , et al. Randomized study comparing the efficacy and tolerance of a lipophillic hydroxy acid derivative of salicylic acid and 5% benzoyl peroxide in the treatment of facial acne vulgaris. Journal of Cosmetic Dermatology2009;8(1):19‐23. [CENTRAL: CN‐00698297; MEDLINE: 19250161] ">Bissonnette 2009</a>; <a href="./references#CD011154-bbs2-0012" title="ChantalatJ , StamatasG , KolliasN , LiuJC . Comparative efficacy of target acne lesion resolution using a novel 2% salicylic acid composition versus 10% benzoyl peroxide. Journal of the European Academy of Dermatology and Venereology2005;19(Suppl 2):37. [CENTRAL: CN‐00602613] ">Chantalat 2005</a>; <a href="./references#CD011154-bbs2-0013" title="ChantalatJ , LiuJC . Six‐week safety and efficacy evaluation of a synergistic microgel complex versus 10% benzoyl peroxide in the treatment of mild to moderate acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB14. [CENTRAL: CN‐00602658] ChantalatJ , LuedtkeK , WiegandB , LiuJC . Significant improvement in acne quality of life by a topical treatment containing a synergistic microgel complex and 2% salicylic acid. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN‐00602548] ChantalatJ , StamatasG , LiuJ C , ChenT . Treating emerging acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN‐00602574] ">Chantalat 2006</a>), along with one cross‐over trial (<a href="./references#CD011154-bbs2-0093" title="ShalitaAR . Comparison of a salicylic acid cleanser and a benzoyl peroxide wash in the treatment of acne vulgaris. Clinical Therapeutics1989;11(2):264‐7. [CENTRAL: CN‐00185376; MEDLINE: 2525420] ">Shalita 1989</a>). <a href="./references#CD011154-bbs2-0012" title="ChantalatJ , StamatasG , KolliasN , LiuJC . Comparative efficacy of target acne lesion resolution using a novel 2% salicylic acid composition versus 10% benzoyl peroxide. Journal of the European Academy of Dermatology and Venereology2005;19(Suppl 2):37. [CENTRAL: CN‐00602613] ">Chantalat 2005</a> did not present any outcomes of interest in this review in the abstract. For the other three trials, all outcomes of interest, except the percentage of participants rated 'clear' or 'almost clear' and the reduction in <i>C acnes</i> strains, were reported in at least one of these trials. See <a href="./full#CD011154-tbl-0005">summary of findings Table 5</a>, where we rated evidence for the two primary outcomes and the secondary safety outcome. </p> <section id="CD011154-sec-0192"> <h6 class="title">Primary outcome: participant global self‐assessment of acne improvement</h6> <section id="CD011154-sec-0193"> <p><b>Studies not included in the meta‐analysis</b></p> <p><a href="./references#CD011154-bbs2-0004" title="BissonnetteR , BolducC , SeiteS , NigenS , ProvostN , MaariC , et al. Randomized study comparing the efficacy and tolerance of a lipophillic hydroxy acid derivative of salicylic acid and 5% benzoyl peroxide in the treatment of facial acne vulgaris. Journal of Cosmetic Dermatology2009;8(1):19‐23. [CENTRAL: CN‐00698297; MEDLINE: 19250161] ">Bissonnette 2009</a>, a 12‐week trial, and <a href="./references#CD011154-bbs2-0013" title="ChantalatJ , LiuJC . Six‐week safety and efficacy evaluation of a synergistic microgel complex versus 10% benzoyl peroxide in the treatment of mild to moderate acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB14. [CENTRAL: CN‐00602658] ChantalatJ , LuedtkeK , WiegandB , LiuJC . Significant improvement in acne quality of life by a topical treatment containing a synergistic microgel complex and 2% salicylic acid. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN‐00602548] ChantalatJ , StamatasG , LiuJ C , ChenT . Treating emerging acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN‐00602574] ">Chantalat 2006</a>, a six‐week trial, assessed this outcome; neither provided sufficient data to estimate the effect size (<a href="./appendices#CD011154-sec-0588">Appendix 9</a>). </p> <p>A total of 80 participants with mild to moderate facial acne were randomised to either BPO or salicylic acid, and no significant difference was found (P = 0.81) (<a href="./references#CD011154-bbs2-0004" title="BissonnetteR , BolducC , SeiteS , NigenS , ProvostN , MaariC , et al. Randomized study comparing the efficacy and tolerance of a lipophillic hydroxy acid derivative of salicylic acid and 5% benzoyl peroxide in the treatment of facial acne vulgaris. Journal of Cosmetic Dermatology2009;8(1):19‐23. [CENTRAL: CN‐00698297; MEDLINE: 19250161] ">Bissonnette 2009</a>). According to the other trial, which included 21 participants treated with BPO and 20 with salicylic acid, self‐assessment results favoured salicylic acid in terms of improvements in tone and texture (<a href="./references#CD011154-bbs2-0013" title="ChantalatJ , LiuJC . Six‐week safety and efficacy evaluation of a synergistic microgel complex versus 10% benzoyl peroxide in the treatment of mild to moderate acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB14. [CENTRAL: CN‐00602658] ChantalatJ , LuedtkeK , WiegandB , LiuJC . Significant improvement in acne quality of life by a topical treatment containing a synergistic microgel complex and 2% salicylic acid. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN‐00602548] ChantalatJ , StamatasG , LiuJ C , ChenT . Treating emerging acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN‐00602574] ">Chantalat 2006</a>). </p> </section> </section> <section id="CD011154-sec-0194"> <h6 class="title">Primary outcome: withdrawal due to adverse effects</h6> <section id="CD011154-sec-0195"> <p><b>Studies not included in the meta‐analysis</b></p> <p>One trial reported that no participants terminated treatment due to adverse events (<a href="./appendices#CD011154-sec-0589">Appendix 10</a>) (<a href="./references#CD011154-bbs2-0004" title="BissonnetteR , BolducC , SeiteS , NigenS , ProvostN , MaariC , et al. Randomized study comparing the efficacy and tolerance of a lipophillic hydroxy acid derivative of salicylic acid and 5% benzoyl peroxide in the treatment of facial acne vulgaris. Journal of Cosmetic Dermatology2009;8(1):19‐23. [CENTRAL: CN‐00698297; MEDLINE: 19250161] ">Bissonnette 2009</a>). </p> </section> </section> <section id="CD011154-sec-0196"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0197"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Evidence in <a href="./references#CD011154-bbs2-0004" title="BissonnetteR , BolducC , SeiteS , NigenS , ProvostN , MaariC , et al. Randomized study comparing the efficacy and tolerance of a lipophillic hydroxy acid derivative of salicylic acid and 5% benzoyl peroxide in the treatment of facial acne vulgaris. Journal of Cosmetic Dermatology2009;8(1):19‐23. [CENTRAL: CN‐00698297; MEDLINE: 19250161] ">Bissonnette 2009</a> showed no difference in ILs (P = 0.748) or NILs (P = 0.445) between two groups. With 30 participants randomised in a four‐week cross‐over trial, a significant reduction in comedones was found in those treated with salicylic acid cleanser (<a href="./references#CD011154-bbs2-0093" title="ShalitaAR . Comparison of a salicylic acid cleanser and a benzoyl peroxide wash in the treatment of acne vulgaris. Clinical Therapeutics1989;11(2):264‐7. [CENTRAL: CN‐00185376; MEDLINE: 2525420] ">Shalita 1989</a>). However, neither of the trial reports provided sufficient data to estimate the effect size. </p> </section> </section> <section id="CD011154-sec-0198"> <h6 class="title">Secondary outcome: change in quality of life</h6> <section id="CD011154-sec-0199"> <p><b>Studies not included in the meta‐analysis</b></p> <p>As reported in <a href="./references#CD011154-bbs2-0013" title="ChantalatJ , LiuJC . Six‐week safety and efficacy evaluation of a synergistic microgel complex versus 10% benzoyl peroxide in the treatment of mild to moderate acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB14. [CENTRAL: CN‐00602658] ChantalatJ , LuedtkeK , WiegandB , LiuJC . Significant improvement in acne quality of life by a topical treatment containing a synergistic microgel complex and 2% salicylic acid. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN‐00602548] ChantalatJ , StamatasG , LiuJ C , ChenT . Treating emerging acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN‐00602574] ">Chantalat 2006</a>, participants treated with salicylic acid had a significant improvement in acne‐related quality of life (ARQL). This effect started at the second week and continued through the following four weeks. By contrast, such an effect was not found in the BPO group. Insufficient data were available from both trials to estimate the effect size. </p> </section> </section> <section id="CD011154-sec-0200"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0201"> <p><b>Main pooled analyses: BPO versus salicylic acid</b></p> <p>Although 16 of 80 participants in the trial had at least one adverse event during treatment (<a href="./references#CD011154-bbs2-0004" title="BissonnetteR , BolducC , SeiteS , NigenS , ProvostN , MaariC , et al. Randomized study comparing the efficacy and tolerance of a lipophillic hydroxy acid derivative of salicylic acid and 5% benzoyl peroxide in the treatment of facial acne vulgaris. Journal of Cosmetic Dermatology2009;8(1):19‐23. [CENTRAL: CN‐00698297; MEDLINE: 19250161] ">Bissonnette 2009</a>), the number of participants with adverse events was not reported for each group. In <a href="./references#CD011154-bbs2-0013" title="ChantalatJ , LiuJC . Six‐week safety and efficacy evaluation of a synergistic microgel complex versus 10% benzoyl peroxide in the treatment of mild to moderate acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB14. [CENTRAL: CN‐00602658] ChantalatJ , LuedtkeK , WiegandB , LiuJC . Significant improvement in acne quality of life by a topical treatment containing a synergistic microgel complex and 2% salicylic acid. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN‐00602548] ChantalatJ , StamatasG , LiuJ C , ChenT . Treating emerging acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN‐00602574] ">Chantalat 2006</a>, two of 21 participants treated with BPO experienced an adverse event, but no adverse events occurred among 20 participants in the salicylic acid group, with an RR of 4.77 (95% CI 0.24 to 93.67; <a href="./references#CD011154-fig-0067" title="">Analysis 5.1</a>). </p> </section> </section> </section> </section> <section id="CD011154-sec-0202"> <h4 class="title">Results for the other comparisons</h4> <section id="CD011154-sec-0203"> <h5 class="title">BPO versus tretinoin</h5> <p>Four long‐term trials ‐ <a href="./references#CD011154-bbs2-0007" title="BowmanS , GoldM , NasirA , VamvakiasG . Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and the combination of clindamycin/benzoyl peroxide and tretinoin plus clindamycin in the treatment of acne vulgaris: a randomized, blinded study. Journal of Drugs in Dermatology2005;4(5):611‐8. [CENTRAL: CN‐00530277; MEDLINE: 16167420] BowmanS , GoldMH , NasirA , VamvakiasG . Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and a combination of both regimens in the treatment of acne vulgaris: a randomized, blinded study. Abstract P147. American Academy of Dermatology, 64th Annual Meeting, March 3‐7, 2006. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB25. [CENTRAL: CN‐00602651] ">Bowman 2005</a>; <a href="./references#CD011154-bbs2-0047" title="GuptaAK , LyndeCW , KunynetzRA , AminS , ChoiK , GoldsteinE . A randomized, double‐blind, multicenter, parallel group study to compare relative efficacies of the topical gels 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/erythromycin 4% in the treatment of moderate acne vulgaris of the face. Journal of Cutaneous Medicine &amp; Surgery2003;7(1):31‐7. [CENTRAL: CN‐00435950; MEDLINE: 12362264] ">Gupta 2003</a>; <a href="./references#CD011154-bbs2-0051" title="JacksonJM , FuJJ , AlmekinderJL . A randomized, investigator‐blinded trial to assess the antimicrobial efficacy of a benzoyl peroxide 5%/clindamycin phosphate 1% gel compared with a clindamycin phosphate 1.2%/tretinoin 0.025% gel in the topical treatment of acne vulgaris. Journal of Drugs in Dermatology2010;9(2):131‐6. [CENTRAL: CN‐00743909; MEDLINE: 20214175] NCT00841776 . Comparative antimicrobial efficacy of two topical acne therapies for the treatment of facial acne. www.clinicaltrials.gov/ct2/show/NCT00841776 (first received 10 February 2009). ">Jackson 2010</a>; <a href="./references#CD011154-bbs2-0057" title="KaurJ , SehgalVK , GuptaAK , SinghSP . A comparative study to evaluate the efficacy and safety of combination topical preparations in acne vulgaris. International Journal of Applied &amp; Basic Medical Research2015;5(2):106‐10. [MEDLINE: 26097817] ">Kaur 2015</a> ‐ and two medium‐term trials with parallel design ‐ <a href="./references#CD011154-bbs2-0070" title="LyonsRE . Comparative effectiveness of benzoyl peroxide and tretinoin in acne vulgaris. International Journal of Dermatology1978;17(3):246‐51. [CENTRAL: CN‐00018160; MEDLINE: 148436] ">Lyons 1978</a>; <a href="./references#CD011154-bbs2-0092" title="ShahidJ , KamranT . Tretinoin cream versus benzoyl peroxide(10%) gel in the tropical treatment of mild acne vulgaris. Biomedica1996;12(1):22‐4. [CENTRAL: CN‐00777740] ">Shahid 1996</a> ‐ focused on this comparison. Outcomes of interest in this review were available in these trials. Another small‐scale trial including only eight participants did not cover any outcomes of interest in this review and focused merely on changes in the microbiome after topical treatment with BPO or tretinoin (<a href="./references#CD011154-bbs2-0015" title="CoughlinCC , SwinkSM , HorwinskiJ , SfyroeraG , BugayevJ , GriceEA , et al. The preadolescent acne microbiome: a prospective, randomized, pilot study investigating characterization and effects of acne therapy. Pediatric Dermatology2017;34(6):661‐4. [CENTRAL: CN‐01432160; MEDLINE: 29024079] ">Coughlin 2017</a>). </p> <section id="CD011154-sec-0204"> <h6 class="title">Primary outcome: participant global self‐assessment of acne improvement</h6> <section id="CD011154-sec-0205"> <p><b>Studies not included in the meta‐analysis</b></p> <p>This outcome was reported only in a 12‐week trial comparing BPO (5%)/erythromycin (3%) with tretinoin (0.025%)/erythromycin (4%) among 112 participants (<a href="./references#CD011154-bbs2-0047" title="GuptaAK , LyndeCW , KunynetzRA , AminS , ChoiK , GoldsteinE . A randomized, double‐blind, multicenter, parallel group study to compare relative efficacies of the topical gels 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/erythromycin 4% in the treatment of moderate acne vulgaris of the face. Journal of Cutaneous Medicine &amp; Surgery2003;7(1):31‐7. [CENTRAL: CN‐00435950; MEDLINE: 12362264] ">Gupta 2003</a>), but the data provided were not sufficient to calculate the effect size of treatment success defined in our review. Participants rated the overall change in their facial acne using a 7‐point scale (‐1 = exacerbation, 0 = no change, 1 = modest clearing, 2 = marked change, 3 = good, 4 = almost cleared, 5 = completely cleared). Trial authors claimed that scores rated in the BPO/erythromycin group were lower than those in the tretinoin/erythromycin group, with a significant difference as early as week 2. </p> </section> </section> <section id="CD011154-sec-0206"> <h6 class="title">Primary outcome: withdrawal due to adverse effects</h6> <section id="CD011154-sec-0207"> <p><b>Main pooled analyses: BPO versus tretinoin</b></p> <p>Three trials reported the long‐term outcome, with no statistical difference between BPO and tretinoin (RR 1.11, 95% CI 0.07 to 17.36; 200 participants; I² = 0%; <a href="./references#CD011154-fig-0068" title="">Analysis 6.1</a>) (<a href="./references#CD011154-bbs2-0007" title="BowmanS , GoldM , NasirA , VamvakiasG . Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and the combination of clindamycin/benzoyl peroxide and tretinoin plus clindamycin in the treatment of acne vulgaris: a randomized, blinded study. Journal of Drugs in Dermatology2005;4(5):611‐8. [CENTRAL: CN‐00530277; MEDLINE: 16167420] BowmanS , GoldMH , NasirA , VamvakiasG . Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and a combination of both regimens in the treatment of acne vulgaris: a randomized, blinded study. Abstract P147. American Academy of Dermatology, 64th Annual Meeting, March 3‐7, 2006. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB25. [CENTRAL: CN‐00602651] ">Bowman 2005</a>; <a href="./references#CD011154-bbs2-0047" title="GuptaAK , LyndeCW , KunynetzRA , AminS , ChoiK , GoldsteinE . A randomized, double‐blind, multicenter, parallel group study to compare relative efficacies of the topical gels 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/erythromycin 4% in the treatment of moderate acne vulgaris of the face. Journal of Cutaneous Medicine &amp; Surgery2003;7(1):31‐7. [CENTRAL: CN‐00435950; MEDLINE: 12362264] ">Gupta 2003</a>; <a href="./references#CD011154-bbs2-0051" title="JacksonJM , FuJJ , AlmekinderJL . A randomized, investigator‐blinded trial to assess the antimicrobial efficacy of a benzoyl peroxide 5%/clindamycin phosphate 1% gel compared with a clindamycin phosphate 1.2%/tretinoin 0.025% gel in the topical treatment of acne vulgaris. Journal of Drugs in Dermatology2010;9(2):131‐6. [CENTRAL: CN‐00743909; MEDLINE: 20214175] NCT00841776 . Comparative antimicrobial efficacy of two topical acne therapies for the treatment of facial acne. www.clinicaltrials.gov/ct2/show/NCT00841776 (first received 10 February 2009). ">Jackson 2010</a>). In one 10‐week trial (<a href="./references#CD011154-bbs2-0007" title="BowmanS , GoldM , NasirA , VamvakiasG . Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and the combination of clindamycin/benzoyl peroxide and tretinoin plus clindamycin in the treatment of acne vulgaris: a randomized, blinded study. Journal of Drugs in Dermatology2005;4(5):611‐8. [CENTRAL: CN‐00530277; MEDLINE: 16167420] BowmanS , GoldMH , NasirA , VamvakiasG . Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and a combination of both regimens in the treatment of acne vulgaris: a randomized, blinded study. Abstract P147. American Academy of Dermatology, 64th Annual Meeting, March 3‐7, 2006. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB25. [CENTRAL: CN‐00602651] ">Bowman 2005</a>), in which 43 were treated with BPO/clindamycin and 45 with tretinoin plus clindamycin, no participants in each group discontinued treatments due to adverse events during the trial. In one 16‐week trial (<a href="./references#CD011154-bbs2-0051" title="JacksonJM , FuJJ , AlmekinderJL . A randomized, investigator‐blinded trial to assess the antimicrobial efficacy of a benzoyl peroxide 5%/clindamycin phosphate 1% gel compared with a clindamycin phosphate 1.2%/tretinoin 0.025% gel in the topical treatment of acne vulgaris. Journal of Drugs in Dermatology2010;9(2):131‐6. [CENTRAL: CN‐00743909; MEDLINE: 20214175] NCT00841776 . Comparative antimicrobial efficacy of two topical acne therapies for the treatment of facial acne. www.clinicaltrials.gov/ct2/show/NCT00841776 (first received 10 February 2009). ">Jackson 2010</a>), which included 27 participants in each group (BPO/clindamycin versus tretinoin/clindamycin), no participants discontinued treatment because of adverse effects. Only two participants (2/112) in <a href="./references#CD011154-bbs2-0047" title="GuptaAK , LyndeCW , KunynetzRA , AminS , ChoiK , GoldsteinE . A randomized, double‐blind, multicenter, parallel group study to compare relative efficacies of the topical gels 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/erythromycin 4% in the treatment of moderate acne vulgaris of the face. Journal of Cutaneous Medicine &amp; Surgery2003;7(1):31‐7. [CENTRAL: CN‐00435950; MEDLINE: 12362264] ">Gupta 2003</a> did not complete the study due to severe burning or stinging, with one in each group. </p> </section> </section> <section id="CD011154-sec-0208"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0209"> <p><b>Studies not included in the meta‐analysis</b></p> <p>We cannot estimate MD as the effect size for this outcome because data were not sufficient to calculate standard deviation as reported in the included studies. In an eight‐week trial analysing 54 participants treated with BPO acetone gel (<a href="./references#CD011154-bbs2-0070" title="LyonsRE . Comparative effectiveness of benzoyl peroxide and tretinoin in acne vulgaris. International Journal of Dermatology1978;17(3):246‐51. [CENTRAL: CN‐00018160; MEDLINE: 148436] ">Lyons 1978</a>), 38 treated with BPO alcohol/detergent gel and 55 with tretinoin cream, trial authors reported that no statistical differences in the change in comedones, pustules, and total lesions were found between groups. However, both BPO gels reduced papules by 59% ‐ significantly higher than 29% with tretinoin cream. </p> <p>In one 12‐week parallel trial with 33 participants randomised to each group (BPO plus clindamycin versus tretinoin plus clindamycin) (<a href="./references#CD011154-bbs2-0057" title="KaurJ , SehgalVK , GuptaAK , SinghSP . A comparative study to evaluate the efficacy and safety of combination topical preparations in acne vulgaris. International Journal of Applied &amp; Basic Medical Research2015;5(2):106‐10. [MEDLINE: 26097817] ">Kaur 2015</a>), the mean number of ILs was reduced from 3.6 to 0 among participants on BPO plus clindamycin and from 4.9 to 0.3 among participants on tretinoin plus clindamycin. The mean number of NILs was reduced from 12.0 to 0 among participants on BPO plus clindamycin, and from 13.7 to 1.3 among participants on tretinoin plus clindamycin. It is unclear whether there was a significant difference between the two groups. </p> <p>In one 10‐week trial (<a href="./references#CD011154-bbs2-0007" title="BowmanS , GoldM , NasirA , VamvakiasG . Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and the combination of clindamycin/benzoyl peroxide and tretinoin plus clindamycin in the treatment of acne vulgaris: a randomized, blinded study. Journal of Drugs in Dermatology2005;4(5):611‐8. [CENTRAL: CN‐00530277; MEDLINE: 16167420] BowmanS , GoldMH , NasirA , VamvakiasG . Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and a combination of both regimens in the treatment of acne vulgaris: a randomized, blinded study. Abstract P147. American Academy of Dermatology, 64th Annual Meeting, March 3‐7, 2006. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB25. [CENTRAL: CN‐00602651] ">Bowman 2005</a>), the percentage reduction in TLs, ILs, and NILs at week 10 in the BPO/clindamycin group was 61.4%, 65.7%, and 57.2%, respectively, compared to 49.6%, 52.5%, and 46.2% in the other group. A significant difference was found in the percentage reduction in ILs (P = 0.02). For medium‐term and short‐term treatment durations, the percentage reduction in TLs (medium term: 51.2% versus 40.9%; short term: 42.1% versus 35.3%), ILs (61.0% versus 44.9%; 53.9% versus 45.7%), and NILs (42.8% versus 37.9%; 32.0% versus 21.9%) was consistently greater in the BPO/clindamycin treatment group, but it is unclear whether significant differences existed, as no relevant information was reported. </p> <p>The median percentage reduction reported in <a href="./references#CD011154-bbs2-0051" title="JacksonJM , FuJJ , AlmekinderJL . A randomized, investigator‐blinded trial to assess the antimicrobial efficacy of a benzoyl peroxide 5%/clindamycin phosphate 1% gel compared with a clindamycin phosphate 1.2%/tretinoin 0.025% gel in the topical treatment of acne vulgaris. Journal of Drugs in Dermatology2010;9(2):131‐6. [CENTRAL: CN‐00743909; MEDLINE: 20214175] NCT00841776 . Comparative antimicrobial efficacy of two topical acne therapies for the treatment of facial acne. www.clinicaltrials.gov/ct2/show/NCT00841776 (first received 10 February 2009). ">Jackson 2010</a> was 52.4% versus 54.3% in TLs, 74.1% versus 70.7% in ILs, and 53.3% versus 52.8% in NILs at week 16. The median percentage reduction in TLs was 52.4% versus 54.3%, 51.8% versus 44.5%, and 43.8% versus 31.3% for the long‐, medium‐, and short‐term periods. Trial authors claimed that the difference between groups was comparable, except that the short‐term period favoured BPO/clindamycin treatment. No significant difference was observed in the median percentage reduction in ILs and NILs at any time points (long term: 74.1% versus 70.7% in ILs, 53.3% versus 52.8% in NILs; medium term: 61.6% versus 46.7% in ILs, 30.9% versus 36.8% in NILs; short term: 53.7% versus 32.5% in ILs, 39.9% versus 25.1% in NILs). </p> <p>No significant difference was found in <a href="./references#CD011154-bbs2-0047" title="GuptaAK , LyndeCW , KunynetzRA , AminS , ChoiK , GoldsteinE . A randomized, double‐blind, multicenter, parallel group study to compare relative efficacies of the topical gels 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/erythromycin 4% in the treatment of moderate acne vulgaris of the face. Journal of Cutaneous Medicine &amp; Surgery2003;7(1):31‐7. [CENTRAL: CN‐00435950; MEDLINE: 12362264] ">Gupta 2003</a> for the absolute reduction in ILs or NILs at any time points between groups. The mean number of papules was reduced from 16.0 at baseline to 10 (short term), to 8 (medium term), and to 5.5 (long term) among participants on BPO/erythromycin The counterpart in participants on tretinoin/erythromycin was reduced from 17.7 to 12, to 8, and to 5.5, respectively. The number of pustules in BPO/erythromycin was reduced from 7.1 to 3.7, to 3, and to 2.3 for short‐, medium‐, and long‐term periods, respectively, and the counterpart in tretinoin/erythromycin was decreased from 8.3 to 3.7, to 2, and to 1.5. The mean number of comedones was reduced from 28.2 to 21.3, to 16.3, and to 9.3 in participants on BPO/erythromycin for short‐, medium‐, and long‐term periods, respectively. The counterpart was reduced from 35.5 to 21.3, to 13.1, to 11.7 in participants on tretinoin/erythromycin. </p> </section> </section> <section id="CD011154-sec-0210"> <h6 class="title">Secondary outcome: percentage of participants rated 'clear' or 'almost clear' on the IGA scale of acne severity </h6> <section id="CD011154-sec-0211"> <p><b>Main pooled analyses: BPO versus tretinoin</b></p> <p>At week 10, the percentage of participants rated 'clear' or 'almost clear' on the IGA scale of acne severity was not significantly different between the BPO/clindamycin group and the tretinoin plus clindamycin group (RR 2.09, 95% CI 0.86 to 5.08; 88 participants; <a href="./references#CD011154-fig-0069" title="">Analysis 6.2</a>). </p> </section> </section> <section id="CD011154-sec-0212"> <h6 class="title">Secondary outcome: reduction in <i>C acnes</i> strains (total and resistant) </h6> <section id="CD011154-sec-0213"> <p><b>Studies not included in the meta‐analysis</b></p> <p>This outcome was reported only in <a href="./references#CD011154-bbs2-0051" title="JacksonJM , FuJJ , AlmekinderJL . A randomized, investigator‐blinded trial to assess the antimicrobial efficacy of a benzoyl peroxide 5%/clindamycin phosphate 1% gel compared with a clindamycin phosphate 1.2%/tretinoin 0.025% gel in the topical treatment of acne vulgaris. Journal of Drugs in Dermatology2010;9(2):131‐6. [CENTRAL: CN‐00743909; MEDLINE: 20214175] NCT00841776 . Comparative antimicrobial efficacy of two topical acne therapies for the treatment of facial acne. www.clinicaltrials.gov/ct2/show/NCT00841776 (first received 10 February 2009). ">Jackson 2010</a> for this comparison. The reduction in total, erythromycin‐resistant, and clindamycin‐resistant <i>C acnes</i> strains at week 16 (log<sub>10</sub> CFU cm<sup>‐2</sup>) was ‐1.84 versus ‐0.78 (P &lt; 0.003), ‐0.83 versus 0.3 (P &lt; 0.002), and ‐0.73 versus 0.05 (P &lt; 0.002). </p> </section> </section> <section id="CD011154-sec-0214"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0215"> <p><b>Main pooled analyses: BPO versus tretinoin</b></p> <p>For the long‐term treatment duration, we did not observe significant differences between the two groups, with an RR of 0.58 (95% CI 0.31 to 1.07; 166 participants; 2 studies; I² = 29%; <a href="./references#CD011154-fig-0070" title="">Analysis 6.3</a>). Trial authors did not report further information regarding what adverse events were observed in <a href="./references#CD011154-bbs2-0051" title="JacksonJM , FuJJ , AlmekinderJL . A randomized, investigator‐blinded trial to assess the antimicrobial efficacy of a benzoyl peroxide 5%/clindamycin phosphate 1% gel compared with a clindamycin phosphate 1.2%/tretinoin 0.025% gel in the topical treatment of acne vulgaris. Journal of Drugs in Dermatology2010;9(2):131‐6. [CENTRAL: CN‐00743909; MEDLINE: 20214175] NCT00841776 . Comparative antimicrobial efficacy of two topical acne therapies for the treatment of facial acne. www.clinicaltrials.gov/ct2/show/NCT00841776 (first received 10 February 2009). ">Jackson 2010</a>. The most frequently reported adverse events in <a href="./references#CD011154-bbs2-0047" title="GuptaAK , LyndeCW , KunynetzRA , AminS , ChoiK , GoldsteinE . A randomized, double‐blind, multicenter, parallel group study to compare relative efficacies of the topical gels 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/erythromycin 4% in the treatment of moderate acne vulgaris of the face. Journal of Cutaneous Medicine &amp; Surgery2003;7(1):31‐7. [CENTRAL: CN‐00435950; MEDLINE: 12362264] ">Gupta 2003</a> were facial dryness, stinging/burning, erythema, pruritus, and peeling/scaling. No significant differences were found between groups for any individual adverse events, except erythema (6% versus 19%; P = 0.047). </p> <p>The outcome reported in trials for BPO monotherapy versus tretinoin was only for a medium‐term treatment duration (103 participants in BPO groups and 67 in the tretinoin group), with an RR of 0.03 (95% CI 0.00 to 0.48; 170 participants; 2 studies; I² = 0%; <a href="./references#CD011154-fig-0071" title="">Analysis 6.4</a>). <a href="./references#CD011154-bbs2-0092" title="ShahidJ , KamranT . Tretinoin cream versus benzoyl peroxide(10%) gel in the tropical treatment of mild acne vulgaris. Biomedica1996;12(1):22‐4. [CENTRAL: CN‐00777740] ">Shahid 1996</a> specified that no participants in both groups reported any adverse events. In <a href="./references#CD011154-bbs2-0070" title="LyonsRE . Comparative effectiveness of benzoyl peroxide and tretinoin in acne vulgaris. International Journal of Dermatology1978;17(3):246‐51. [CENTRAL: CN‐00018160; MEDLINE: 148436] ">Lyons 1978</a>, no adverse events were reported in either of the two BPO groups, but 18.2% (10/55) of participants treated with tretinoin cream experienced at least one adverse event, including burning, erythema, peeling, and soreness. </p> </section> <section id="CD011154-sec-0216"> <p><b>Subgroup analyses: co‐intervention</b></p> <p>No evidence suggests that this association may differ by co‐intervention (P value for subgroup differences = 0.24; <a href="./references#CD011154-fig-0070" title="">Analysis 6.3</a>). </p> </section> <section id="CD011154-sec-0217"> <p><b>Studies not included in the meta‐analysis</b></p> <p>We cannot calculate RR as the effect size for these trials because the number of participants with at least one adverse event was not provided (<a href="./references#CD011154-bbs2-0007" title="BowmanS , GoldM , NasirA , VamvakiasG . Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and the combination of clindamycin/benzoyl peroxide and tretinoin plus clindamycin in the treatment of acne vulgaris: a randomized, blinded study. Journal of Drugs in Dermatology2005;4(5):611‐8. [CENTRAL: CN‐00530277; MEDLINE: 16167420] BowmanS , GoldMH , NasirA , VamvakiasG . Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and a combination of both regimens in the treatment of acne vulgaris: a randomized, blinded study. Abstract P147. American Academy of Dermatology, 64th Annual Meeting, March 3‐7, 2006. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB25. [CENTRAL: CN‐00602651] ">Bowman 2005</a>; <a href="./references#CD011154-bbs2-0057" title="KaurJ , SehgalVK , GuptaAK , SinghSP . A comparative study to evaluate the efficacy and safety of combination topical preparations in acne vulgaris. International Journal of Applied &amp; Basic Medical Research2015;5(2):106‐10. [MEDLINE: 26097817] ">Kaur 2015</a>). </p> <p>Burning sensation and dryness were the only two adverse events that occurred during the <a href="./references#CD011154-bbs2-0057" title="KaurJ , SehgalVK , GuptaAK , SinghSP . A comparative study to evaluate the efficacy and safety of combination topical preparations in acne vulgaris. International Journal of Applied &amp; Basic Medical Research2015;5(2):106‐10. [MEDLINE: 26097817] ">Kaur 2015</a>. Burning sensation occurred in one participant on BPO plus clindamycin, and dryness occurred in four participants on tretinoin plus clindamycin. </p> <p>Although no significance test results were provided, <a href="./references#CD011154-bbs2-0007" title="BowmanS , GoldM , NasirA , VamvakiasG . Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and the combination of clindamycin/benzoyl peroxide and tretinoin plus clindamycin in the treatment of acne vulgaris: a randomized, blinded study. Journal of Drugs in Dermatology2005;4(5):611‐8. [CENTRAL: CN‐00530277; MEDLINE: 16167420] BowmanS , GoldMH , NasirA , VamvakiasG . Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and a combination of both regimens in the treatment of acne vulgaris: a randomized, blinded study. Abstract P147. American Academy of Dermatology, 64th Annual Meeting, March 3‐7, 2006. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB25. [CENTRAL: CN‐00602651] ">Bowman 2005</a> reported that adverse events were substantially more common among participants on BPO/clindamycin than among those on tretinoin and clindamycin. The most common adverse events were irritation (11.6% versus 17.9%), dryness (7.0% versus 15.6%), desquamation (7.0% versus 11.1%), and erythema (4.7% versus 8.9%). </p> </section> </section> </section> <section id="CD011154-sec-0218"> <h5 class="title">BPO versus isotretinoin</h5> <p>Three trials of parallel design focused on this comparison ‐ one for four weeks including 16 participants treated with BPO and 13 with isotretinoin (<a href="./references#CD011154-bbs2-0016" title="CunliffeWJ , GlassD , GoodeK , StablesGI , BoormanGC . A double‐blind investigation of the potential systemic absorption of isotretinoin, when combined with chemical sunscreens, following topical application to patients with widespread acne of the face and trunk. Acta Dermato‐Venereologica2001;81(1):14‐7. [CENTRAL: CN‐00373092; MEDLINE: 11411906] ">Cunliffe 2001</a>), one for 12 weeks including 26 participants treated with BPO and 25 with isotretinoin (<a href="./references#CD011154-bbs2-0049" title="HughesBR . A double blind evaluation of topical isotretinoin, benzoyl peroxide and placebo in patients with acne. British Journal of Dermatology1989;121(s34):42. [DOI: 10.1111/j.1365‐2133.1989.tb05941.x] HughesBR , NorrisJF , CunliffeWJ . A double‐blind evaluation of topical isotretinoin 0.05%, benzoyl peroxide gel 5% and placebo in patients with acne. Clinical &amp; Experimental Dermatology1992;17(3):165‐8. [MEDLINE: 1451291] ">Hughes 1992</a>), and another 12‐week trial (<a href="./references#CD011154-bbs2-0072" title="MarazziP , BoormanGC , DonaldAE , DaviesHD . Clinical evaluation of Double Strength Isotrexin versus Benzamycin in the topical treatment of mild to moderate acne vulgaris. Journal of Dermatological Treatment2002;13(3):111‐7. [CENTRAL: CN‐00409983; MEDLINE: 12227873] ">Marazzi 2002</a>), which included 93 participants treated with BPO/erythromycin and 95 participants with isotretinoin/erythromycin. The outcomes of interest in this review available for these trials were participant global self‐assessment, withdrawal due to adverse effects, lesion counts, and adverse events. </p> <section id="CD011154-sec-0219"> <h6 class="title">Primary outcome: participant global self‐assessment of acne improvement</h6> <section id="CD011154-sec-0220"> <p><b>Studies not included in the meta‐analysis</b></p> <p>In <a href="./references#CD011154-bbs2-0072" title="MarazziP , BoormanGC , DonaldAE , DaviesHD . Clinical evaluation of Double Strength Isotrexin versus Benzamycin in the topical treatment of mild to moderate acne vulgaris. Journal of Dermatological Treatment2002;13(3):111‐7. [CENTRAL: CN‐00409983; MEDLINE: 12227873] ">Marazzi 2002</a>, participants rated the overall change in their facial acne as improved, no change, or worse. There was no significant difference between the two groups in the proportion of participants rated as "improved" (P value = 0.26). </p> </section> </section> <section id="CD011154-sec-0221"> <h6 class="title">Primary outcome: withdrawal due to adverse effects</h6> <section id="CD011154-sec-0222"> <p><b>Main pooled analyses: BPO versus isotretinoin</b></p> <p>The risk of withdrawal due to adverse effects was not significantly different (RR 1.23, 95% CI 0.53 to 2.87; 239 participants; 2 studies; I² = 0%; <a href="./references#CD011154-fig-0072" title="">Analysis 7.1</a>) in <a href="./references#CD011154-bbs2-0049" title="HughesBR . A double blind evaluation of topical isotretinoin, benzoyl peroxide and placebo in patients with acne. British Journal of Dermatology1989;121(s34):42. [DOI: 10.1111/j.1365‐2133.1989.tb05941.x] HughesBR , NorrisJF , CunliffeWJ . A double‐blind evaluation of topical isotretinoin 0.05%, benzoyl peroxide gel 5% and placebo in patients with acne. Clinical &amp; Experimental Dermatology1992;17(3):165‐8. [MEDLINE: 1451291] ">Hughes 1992</a> and <a href="./references#CD011154-bbs2-0072" title="MarazziP , BoormanGC , DonaldAE , DaviesHD . Clinical evaluation of Double Strength Isotrexin versus Benzamycin in the topical treatment of mild to moderate acne vulgaris. Journal of Dermatological Treatment2002;13(3):111‐7. [CENTRAL: CN‐00409983; MEDLINE: 12227873] ">Marazzi 2002</a>). <a href="./references#CD011154-bbs2-0049" title="HughesBR . A double blind evaluation of topical isotretinoin, benzoyl peroxide and placebo in patients with acne. British Journal of Dermatology1989;121(s34):42. [DOI: 10.1111/j.1365‐2133.1989.tb05941.x] HughesBR , NorrisJF , CunliffeWJ . A double‐blind evaluation of topical isotretinoin 0.05%, benzoyl peroxide gel 5% and placebo in patients with acne. Clinical &amp; Experimental Dermatology1992;17(3):165‐8. [MEDLINE: 1451291] ">Hughes 1992</a> did not specify what adverse events led to their discontinuation. Nine participants on BPO/erythromycin and eight participants on isotretinoin/erythromycin withdrew due to adverse events, with no significant differences between the two groups (<a href="./references#CD011154-bbs2-0072" title="MarazziP , BoormanGC , DonaldAE , DaviesHD . Clinical evaluation of Double Strength Isotrexin versus Benzamycin in the topical treatment of mild to moderate acne vulgaris. Journal of Dermatological Treatment2002;13(3):111‐7. [CENTRAL: CN‐00409983; MEDLINE: 12227873] ">Marazzi 2002</a>). The major event leading to withdrawal was infection requiring antibiotic treatment. Besides, two participants on BPO/erythromycin and five on isotretinoin/erythromycin withdrew because of skin reactions to these products. </p> </section> <section id="CD011154-sec-0223"> <p><b>Subgroup analyses: co‐intervention</b></p> <p>No evidence suggests that this association may differ by co‐intervention (P value for subgroup differences = 0.24; <a href="./references#CD011154-fig-0072" title="">Analysis 7.1</a>). </p> </section> <section id="CD011154-sec-0224"> <p><b>Studies not included in the meta‐analysis</b></p> <p>No participants in <a href="./references#CD011154-bbs2-0016" title="CunliffeWJ , GlassD , GoodeK , StablesGI , BoormanGC . A double‐blind investigation of the potential systemic absorption of isotretinoin, when combined with chemical sunscreens, following topical application to patients with widespread acne of the face and trunk. Acta Dermato‐Venereologica2001;81(1):14‐7. [CENTRAL: CN‐00373092; MEDLINE: 11411906] ">Cunliffe 2001</a> withdrew as a result of any adverse events. </p> </section> </section> <section id="CD011154-sec-0225"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0226"> <p><b>Main pooled analyses: BPO versus isotretinoin</b></p> <p>For the comparison between BPO/erythromycin and isotretinoin/erythromycin, no significant difference was found in the absolute reduction in ILs (MD ‐4.00, 95% CI ‐9.89 to 1.89; <a href="./references#CD011154-fig-0073" title="">Analysis 7.2</a>) for the long‐term period. However, the counterpart for medium‐term and short‐term periods was significantly different, favouring BPO/erythromycin, with an MD of ‐6.10 (95% CI ‐11.27 to ‐0.93; <a href="./references#CD011154-fig-0075" title="">Analysis 7.4</a>) and ‐9.20 (95% CI ‐14.09 to ‐4.31; <a href="./references#CD011154-fig-0077" title="">Analysis 7.6</a>), respectively. In terms of the absolute change in NILs, no significant difference was observed for any time periods (long term: MD 2.30, 95% CI ‐6.07 to 10.67; <a href="./references#CD011154-fig-0074" title="">Analysis 7.3</a>; medium term: MD 4.90, 95% CI ‐1.66 to 11.46; <a href="./references#CD011154-fig-0076" title="">Analysis 7.5</a>; short‐term: MD 1.20, 95% CI ‐4.39 to 6.79; <a href="./references#CD011154-fig-0078" title="">Analysis 7.7</a>). </p> </section> <section id="CD011154-sec-0227"> <p><b>Studies not included in the meta‐analysis</b></p> <p>The outcome of lesion counts, rather than the change in lesion counts, was reported in <a href="./references#CD011154-bbs2-0049" title="HughesBR . A double blind evaluation of topical isotretinoin, benzoyl peroxide and placebo in patients with acne. British Journal of Dermatology1989;121(s34):42. [DOI: 10.1111/j.1365‐2133.1989.tb05941.x] HughesBR , NorrisJF , CunliffeWJ . A double‐blind evaluation of topical isotretinoin 0.05%, benzoyl peroxide gel 5% and placebo in patients with acne. Clinical &amp; Experimental Dermatology1992;17(3):165‐8. [MEDLINE: 1451291] ">Hughes 1992</a>. At the end of the trial (12 weeks), the mean difference between BPO and isotretinoin groups was ‐6.30 (95% CI ‐17.04 to 4.44). The mean difference for the medium‐term outcome (eight weeks) was ‐0.60 (95% CI ‐10.70 to 9.50). This outcome was not available for <a href="./references#CD011154-bbs2-0016" title="CunliffeWJ , GlassD , GoodeK , StablesGI , BoormanGC . A double‐blind investigation of the potential systemic absorption of isotretinoin, when combined with chemical sunscreens, following topical application to patients with widespread acne of the face and trunk. Acta Dermato‐Venereologica2001;81(1):14‐7. [CENTRAL: CN‐00373092; MEDLINE: 11411906] ">Cunliffe 2001</a>. </p> </section> </section> <section id="CD011154-sec-0228"> <h6 class="title">Percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0229"> <p><b>Main pooled analyses: BPO versus isotretinoin</b></p> <p>This outcome was reported in two trials (<a href="./references#CD011154-bbs2-0016" title="CunliffeWJ , GlassD , GoodeK , StablesGI , BoormanGC . A double‐blind investigation of the potential systemic absorption of isotretinoin, when combined with chemical sunscreens, following topical application to patients with widespread acne of the face and trunk. Acta Dermato‐Venereologica2001;81(1):14‐7. [CENTRAL: CN‐00373092; MEDLINE: 11411906] ">Cunliffe 2001</a>; <a href="./references#CD011154-bbs2-0072" title="MarazziP , BoormanGC , DonaldAE , DaviesHD . Clinical evaluation of Double Strength Isotrexin versus Benzamycin in the topical treatment of mild to moderate acne vulgaris. Journal of Dermatological Treatment2002;13(3):111‐7. [CENTRAL: CN‐00409983; MEDLINE: 12227873] ">Marazzi 2002</a>). </p> <p>In <a href="./references#CD011154-bbs2-0072" title="MarazziP , BoormanGC , DonaldAE , DaviesHD . Clinical evaluation of Double Strength Isotrexin versus Benzamycin in the topical treatment of mild to moderate acne vulgaris. Journal of Dermatological Treatment2002;13(3):111‐7. [CENTRAL: CN‐00409983; MEDLINE: 12227873] ">Marazzi 2002</a>, 53 participants in the BPO/erythromycin group and 64 participants in the isotretinoin/erythromycin group experienced at least one adverse event during the long‐term period, with no significant differences (RR 0.85, 95% CI 0.68 to 1.06; 188 participants; <a href="./references#CD011154-fig-0079" title="">Analysis 7.8</a>). The most common treatment‐related events were burning reported for three participants using BPO/erythromycin and five participants using isotretinoin/erythromycin, followed by itching or redness reported in three participants using BPO/erythromycin and four participants using isotretinoin/erythromycin. </p> <p>As reported in <a href="./references#CD011154-bbs2-0016" title="CunliffeWJ , GlassD , GoodeK , StablesGI , BoormanGC . A double‐blind investigation of the potential systemic absorption of isotretinoin, when combined with chemical sunscreens, following topical application to patients with widespread acne of the face and trunk. Acta Dermato‐Venereologica2001;81(1):14‐7. [CENTRAL: CN‐00373092; MEDLINE: 11411906] ">Cunliffe 2001</a>, the risk ratio for the short‐term outcome was 0.18 (95% CI 0.05 to 0.69; <a href="./references#CD011154-fig-0080" title="">Analysis 7.9</a>) in favour of BPO treatment. </p> </section> <section id="CD011154-sec-0230"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Instead of presenting the total number, authors of the <a href="./references#CD011154-bbs2-0049" title="HughesBR . A double blind evaluation of topical isotretinoin, benzoyl peroxide and placebo in patients with acne. British Journal of Dermatology1989;121(s34):42. [DOI: 10.1111/j.1365‐2133.1989.tb05941.x] HughesBR , NorrisJF , CunliffeWJ . A double‐blind evaluation of topical isotretinoin 0.05%, benzoyl peroxide gel 5% and placebo in patients with acne. Clinical &amp; Experimental Dermatology1992;17(3):165‐8. [MEDLINE: 1451291] ">Hughes 1992</a> trial described only the numbers of participants for individual adverse events. The most common adverse event for both groups was redness (10/26 for the BPO group and 10/25 for the isotretinoin group), followed by scaling (7/26 and 7/25, respectively). </p> </section> </section> </section> <section id="CD011154-sec-0231"> <h5 class="title">BPO versus azelaic acid</h5> <p>One trial of parallel design focused on this comparison, including 20 participants treated with BPO and 20 with azelaic acid for 8 weeks (<a href="./references#CD011154-bbs2-0099" title="StincoG , BragadinG , TrotterD , PillonB , PatroneP . Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. Journal of the European Academy of Dermatology and Venereology2007;21(3):320‐5. [CENTRAL: CN‐00586948; MEDLINE: 17309452] ">Stinco 2007</a>). Outcomes of interest in this review that were available in these trials were withdrawal due to adverse effects, lesion counts, and adverse events. </p> <section id="CD011154-sec-0232"> <h6 class="title">Primary outcome: withdrawal due to adverse effects</h6> <section id="CD011154-sec-0233"> <p><b>Studies not included in the meta‐analysis</b></p> <p>No withdrawal due to adverse events was reported in <a href="./references#CD011154-bbs2-0099" title="StincoG , BragadinG , TrotterD , PillonB , PatroneP . Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. Journal of the European Academy of Dermatology and Venereology2007;21(3):320‐5. [CENTRAL: CN‐00586948; MEDLINE: 17309452] ">Stinco 2007</a>. </p> </section> </section> <section id="CD011154-sec-0234"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0235"> <p><b>Studies not included in the meta‐analysis</b></p> <p>At the end of <a href="./references#CD011154-bbs2-0099" title="StincoG , BragadinG , TrotterD , PillonB , PatroneP . Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. Journal of the European Academy of Dermatology and Venereology2007;21(3):320‐5. [CENTRAL: CN‐00586948; MEDLINE: 17309452] ">Stinco 2007</a>, ILs were reduced by 45% in the azelaic acid group and 44% in the BPO group. NILs were reduced by 47% for azelaic acid and 38% for BPO. Trial authors reported no significant differences between treatments. </p> </section> </section> <section id="CD011154-sec-0236"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0237"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Although no data on the total number of participants experiencing an adverse event were provided in <a href="./references#CD011154-bbs2-0099" title="StincoG , BragadinG , TrotterD , PillonB , PatroneP . Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. Journal of the European Academy of Dermatology and Venereology2007;21(3):320‐5. [CENTRAL: CN‐00586948; MEDLINE: 17309452] ">Stinco 2007</a>, trial authors reported individual adverse events. For the BPO group, 12 participants reported itchiness (seven mild and five moderate) after two weeks of treatment. For the azelaic acid group, 20 participants reported itchiness (12 mild, five moderate, and three severe). Dryness occurred in 15 participants treated with BPO (one mild, nine moderate, and five severe) and in 14 treated with azelaic acid (nine mild, three moderate, and two severe). A total of 10 participants in the BPO group (eight mild and two moderate) and six in the azelaic acid group (five mild and one moderate) experienced erythema. </p> </section> </section> </section> <section id="CD011154-sec-0238"> <h5 class="title">BPO versus retinoic acid</h5> <p>One six‐week trial compared BPO with retinoic acid for treating acne and assessed only the outcome change in lesion counts (<a href="./references#CD011154-bbs2-0021" title="DograA , SoodVK , MinochaYC . Comparative evaluation of retinoic acid, benzoyl peroxide and erythromycin lotion in acne vulgaris. Indian Journal of Dermatology, Venereology and Leprology1993;59(5):243‐6. [CENTRAL: CN‐01095331] ">Dogra 1993</a>). A total of 24 participants in this trial were treated with BPO and 23 with retinoic acid. </p> <section id="CD011154-sec-0239"> <h6 class="title">Primary outcomes</h6> <p>No information on the primary outcomes was available.</p> </section> <section id="CD011154-sec-0240"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0241"> <p><b>Studies not included in the meta‐analysis</b></p> <p>After six‐week treatment duration, although reduction in NILs and ILs was 75.2% and 60.7%, respectively, in the retinoic acid group, the counterpart in the BPO group was 70.1% and 63.9% (<a href="./references#CD011154-bbs2-0021" title="DograA , SoodVK , MinochaYC . Comparative evaluation of retinoic acid, benzoyl peroxide and erythromycin lotion in acne vulgaris. Indian Journal of Dermatology, Venereology and Leprology1993;59(5):243‐6. [CENTRAL: CN‐01095331] ">Dogra 1993</a>). </p> </section> </section> </section> <section id="CD011154-sec-0242"> <h5 class="title">BPO versus sulphur</h5> <p>In one parallel trial compared BPO and sulphur (<a href="./references#CD011154-bbs2-0112" title="VasarinshP . Benzoyl peroxide‐sulfur lotions in acne vulgaris ‐ a controlled study. Cutis; Cutaneous Medicine for the Practitioner1969;5(1):65‐9. [CENTRAL: CN‐00269401] ">Vasarinsh 1969</a>), 16 participants were treated with BPO and 18 with sulphur for 4 to 14 weeks. The report of this trial covered the outcomes of participant self‐assessment of acne improvement, change in acne lesions, and adverse events. </p> <section id="CD011154-sec-0243"> <h6 class="title">Primary outcome: participant global self‐assessment of acne improvement</h6> <section id="CD011154-sec-0244"> <p><b>Studies not included in the meta‐analysis</b></p> <p>This trial assessed the outcome using a 4‐point Likert‐like scale (from worse = ‐1 to greatly improved = 2). The average score was 0.66 and 0.75 for the BPO and sulphur groups, respectively. </p> </section> </section> <section id="CD011154-sec-0245"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0246"> <p><b>Studies not included in the meta‐analysis</b></p> <p>The change in lesion counts was assessed for superficial (comedones and pustules) and deep (papules and cysts) lesions via an 11‐point scoring system (decrease in lesions by 100% = 5, 76% to 99% = 4, 51% to 75% = 3, 26% to 50% = 2, &lt; 25% = 1, no change = 0; increase by &lt; 25% = ‐1, 26% to 50% = ‐2, 51% to 75% = ‐3, 76% to 100% = ‐4, over 100% = ‐5). The average score for superficial lesions was 0.55 and ‐0.70 for BPO and sulphur groups, respectively, and the counterpart for deep lesions was 0.69 and 0.30. </p> </section> </section> <section id="CD011154-sec-0247"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0248"> <p><b>Studies not included in the meta‐analysis</b></p> <p>The study provided only information on individual adverse events. Excessive erythema and dryness occurred in five participants on BPO and four on sulphur. One participant developed severe allergic sensitisation after BPO treatment. We cannot calculate RR as the effect size because the number of participants with at least one adverse event was not provided. </p> </section> </section> </section> <section id="CD011154-sec-0249"> <h5 class="title">BPO versus hydrogen peroxide</h5> <p>Three eight‐week parallel trials contributed to this comparison (<a href="./references#CD011154-bbs2-0009" title="CapizziF , LandiF , MilaniM , AmerioP . Skin tolerability and efficacy of combination therapy with hydrogen peroxide stabilized cream and adapalene gel in comparison with benzoyl peroxide cream and adapalene gel in common acne. A randomized, investigator‐masked, controlled trial. British Journal of Dermatology2004;151(2):481‐4. [CENTRAL: CN‐00490924; MEDLINE: 15327558] ">Capizzi 2004</a>; <a href="./references#CD011154-bbs2-0073" title="MilaniM , BigardiA , ZavattarelliM . Efficacy and safety of stabilised hydrogen peroxide cream (Crystacide) in mild‐to‐moderate acne vulgaris: a randomised, controlled trial versus benzoyl peroxide gel. Current Medical Research &amp; Opinion2003;19(2):135‐8. [CENTRAL: CN‐00437298; MEDLINE: 12740158] ">Milani 2003</a>; <a href="./references#CD011154-bbs2-0111" title="TungR , BerardescaE , Dall'OglioF , MicaliG , SinagraJ , NodzenskiM , et al. Novel over‐the‐counter hydrogen peroxide based acne kit in treating acne: randomized, controlled, multicenter study of a hydrogen peroxide‐based acne system versus the benzoyl peroxide‐based acne system in the treatment of mild to moderate acne vulgaris. P8511. Journal of the American Academy of Dermatology2014;70(5 Suppl 1):AB9. [www.jaad.org/article/S0190‐9622(14)00039‐5/pdf] ">Tung 2014</a>). These trials covered the outcomes of our review interest including participant global self‐assessment, lesion counts, and total adverse events. </p> <section id="CD011154-sec-0250"> <h6 class="title">Primary outcome: participant global self‐assessment of acne improvement</h6> <section id="CD011154-sec-0251"> <p><b>Studies not included in the meta‐analysis</b></p> <p>One trial including a total of 120 participants assessed this outcome (<a href="./references#CD011154-bbs2-0111" title="TungR , BerardescaE , Dall'OglioF , MicaliG , SinagraJ , NodzenskiM , et al. Novel over‐the‐counter hydrogen peroxide based acne kit in treating acne: randomized, controlled, multicenter study of a hydrogen peroxide‐based acne system versus the benzoyl peroxide‐based acne system in the treatment of mild to moderate acne vulgaris. P8511. Journal of the American Academy of Dermatology2014;70(5 Suppl 1):AB9. [www.jaad.org/article/S0190‐9622(14)00039‐5/pdf] ">Tung 2014</a>). However, the data, which were available in an abstract, were not sufficient to estimate the effect size. Study authors reported that both acne regimens were effective but found no statistical difference across arms (P = 0.70). </p> </section> </section> <section id="CD011154-sec-0252"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0253"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Insufficient data were available to estimate the effect size of either absolute or percentage change. <a href="./references#CD011154-bbs2-0073" title="MilaniM , BigardiA , ZavattarelliM . Efficacy and safety of stabilised hydrogen peroxide cream (Crystacide) in mild‐to‐moderate acne vulgaris: a randomised, controlled trial versus benzoyl peroxide gel. Current Medical Research &amp; Opinion2003;19(2):135‐8. [CENTRAL: CN‐00437298; MEDLINE: 12740158] ">Milani 2003</a>, which included 30 participants treated with BPO and 30 with hydrogen peroxide, reported the mean counts of lesions at week 8. The mean difference in TLs, ILs, and NILs was ‐2.00 (95% CI ‐6.08 to 2.08), 0.00 (95% CI ‐1.52 to 1.52), and ‐2.00 (95% CI ‐4.09 to 0.09), respectively, with no significant difference. </p> <p><a href="./references#CD011154-bbs2-0009" title="CapizziF , LandiF , MilaniM , AmerioP . Skin tolerability and efficacy of combination therapy with hydrogen peroxide stabilized cream and adapalene gel in comparison with benzoyl peroxide cream and adapalene gel in common acne. A randomized, investigator‐masked, controlled trial. British Journal of Dermatology2004;151(2):481‐4. [CENTRAL: CN‐00490924; MEDLINE: 15327558] ">Capizzi 2004</a>, a parallel trial with 26 participants in each group (BPO plus adapalene versus hydrogen peroxide plus adapalene), suggested that BPO reduced the mean number of TLs from 40 to 5.4 and hydrogen peroxide from 44 to 3.2. ILs were decreased from 21 to 3.1 among participants on BPO, and from 25 to 2.5 among participants on hydrogen peroxide, with NILs decreasing from 19 to 2.3 and from 19 to 0.7 (P = 0.0025), respectively. </p> </section> </section> <section id="CD011154-sec-0254"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0255"> <p><b>Main pooled analyses: BPO versus isotretinoin</b></p> <p>The outcome was reported in both trials. In <a href="./references#CD011154-bbs2-0073" title="MilaniM , BigardiA , ZavattarelliM . Efficacy and safety of stabilised hydrogen peroxide cream (Crystacide) in mild‐to‐moderate acne vulgaris: a randomised, controlled trial versus benzoyl peroxide gel. Current Medical Research &amp; Opinion2003;19(2):135‐8. [CENTRAL: CN‐00437298; MEDLINE: 12740158] ">Milani 2003</a>, seven of 30 participants with BPO and two of 30 participants with hydrogen peroxide had at least one adverse event, with no significant difference between the two groups (RR 3.50, 95% CI 0.79 to 15.49; 60 participants; 1 study; <a href="./references#CD011154-fig-0081" title="">Analysis 8.1</a>). </p> </section> <section id="CD011154-sec-0256"> <p><b>Studies not included in the meta‐analysis</b></p> <p>No adverse events were found in each group in the other trial (<a href="./references#CD011154-bbs2-0111" title="TungR , BerardescaE , Dall'OglioF , MicaliG , SinagraJ , NodzenskiM , et al. Novel over‐the‐counter hydrogen peroxide based acne kit in treating acne: randomized, controlled, multicenter study of a hydrogen peroxide‐based acne system versus the benzoyl peroxide‐based acne system in the treatment of mild to moderate acne vulgaris. P8511. Journal of the American Academy of Dermatology2014;70(5 Suppl 1):AB9. [www.jaad.org/article/S0190‐9622(14)00039‐5/pdf] ">Tung 2014</a>), where the sample size for each group was not reported. We cannot calculate RR as the effect size for <a href="./references#CD011154-bbs2-0009" title="CapizziF , LandiF , MilaniM , AmerioP . Skin tolerability and efficacy of combination therapy with hydrogen peroxide stabilized cream and adapalene gel in comparison with benzoyl peroxide cream and adapalene gel in common acne. A randomized, investigator‐masked, controlled trial. British Journal of Dermatology2004;151(2):481‐4. [CENTRAL: CN‐00490924; MEDLINE: 15327558] ">Capizzi 2004</a> because the number of participants with at least one adverse event was not provided. Dryness, erythema, and burning were observed (19/26 versus 2/26, 5/26 versus 1/26, 4/26 versus 0/26 for BPO and hydrogen peroxide, respectively). A significant difference was found in the occurrence of dryness (P = 0.0025) and burning (P = 0.01). </p> </section> </section> </section> <section id="CD011154-sec-0257"> <h5 class="title">BPO versus superoxidised solution</h5> <p><a href="./references#CD011154-bbs2-0108" title="Tirado‐SanchezA , Ponce‐OliveraRM . Efficacy and tolerance of superoxidized solution in the treatment of mild to moderate inflammatory acne. A double‐blinded, placebo‐ controlled, parallel‐group, randomized, clinical trial. Journal of Dermatological Treatment2009;20(5):289‐92. [CENTRAL: CN‐00743204; MEDLINE: 19459079] ">Tirado‐Sanchez 2009</a>, a 12‐week parallel trial, focused on this comparison, in which 24 participants were randomly assigned to BPO treatment and 39 to superoxidised solution treatment. The outcomes of our review interest reported in this trial were withdrawal due to adverse effects, change in lesion counts, and occurrence of adverse events. </p> <section id="CD011154-sec-0258"> <h6 class="title">Primary outcome: withdrawal due to adverse effects</h6> <section id="CD011154-sec-0259"> <p><b>Studies not included in the meta‐analysis</b></p> <p>No withdrawal due to adverse events was reported in that trial.</p> </section> </section> <section id="CD011154-sec-0260"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0261"> <p><b>Studies not included in the meta‐analysis</b></p> <p>At the end of the trial, the mean number of ILs was reduced from 35 to 19 in the BPO group and from 34 to 12 in the superoxidised solution group. The proportion of participants with at least 50% reduction in ILs was 17 of 24 versus 30 of 39 with no significant difference. </p> </section> </section> <section id="CD011154-sec-0262"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0263"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Trial authors reported that no local adverse events were noted in each group. We cannot calculate RR as the effect size because the number of participants with at least one adverse event was not provided. </p> </section> </section> </section> <section id="CD011154-sec-0264"> <h5 class="title">BPO versus <i>Casuarina equisetifolia</i> bark extract </h5> <p><a href="./references#CD011154-bbs2-0091" title="ShafiqY , NaqviBS , RizwaniGH , UsmanM , ShahBA , AslamM , et al. Anti‐acne activity of Casuarina equisetifolia bark extract: a randomized clinical trial. Bangladesh Journal of Pharmacology2014;9(3):337‐41. [CENTRAL: CN‐00998392] ">Shafiq 2014</a>, a six‐week parallel trial, focused on this comparison with 25 participants in each group. No efficacy outcomes of interest in this review were reported. Clinical efficacy was assessed by Cook’s acne grading scale and trial authors claimed no significant differences between groups. The only outcome assessed in the trial and relevant to our review was the occurrence of adverse events. </p> <section id="CD011154-sec-0265"> <h6 class="title">Primary outcomes</h6> <p>No information was available on the primary outcomes.</p> </section> <section id="CD011154-sec-0266"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0267"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Although no severe adverse events were observed in the group receiving treatment with <i>Casuarina equisetifolia</i> bark extract, 17% of participants on BPO treatment complained of irritation, redness, and swelling. </p> </section> </section> </section> <section id="CD011154-sec-0268"> <h5 class="title">BPO versus Chinese herbal mask</h5> <p>One four‐week parallel trial compared BPO and Chinese medical mask (<a href="./references#CD011154-bbs2-0118" title="ZengX , LiuW L , ZhaoT . Effects of Chinese medical facial mask comprehensive therapy in treating acne vulgaris. Zhongguo Zhong Xi Yi Jie He za Zhi [Chinese Journal of Integrated Traditional and Western Medicine]2012;32(5):624‐7. [CENTRAL: CN‐00961274; MEDLINE: 22679722] ">Zeng 2012</a>). In all, 120 participants were assigned to the BPO group and 113 to the Chinese herbal mask. No efficacy outcomes of interest in this review were reported. The only outcome assessed in the trial and relevant to our review was the occurrence of adverse events. </p> <section id="CD011154-sec-0269"> <h6 class="title">Primary outcomes: participant global self‐assessment of acne improvement</h6> <section id="CD011154-sec-0270"> <p><b>Studies not included in the meta‐analysis</b></p> <p>This outcome was assessed using a questionnaire (no details about the questionnaire were specified) only for the Chinese herbal mask group and not for the BPO group. Of 111 respondents in the assessment, 104 (93.7%) were very satisfied or satisfied with the treatment. </p> </section> </section> <section id="CD011154-sec-0271"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0272"> <p><b>Studies not included in the meta‐analysis</b></p> <p>A total of 3 of 120 participants on BPO treatment and 2 of 112 participants on Chinese herbal mask complained of irritation and redness. We cannot calculate RR as the effect size because the number of participants with at least one adverse event was not provided. </p> </section> </section> </section> <section id="CD011154-sec-0273"> <h5 class="title">BPO versus meclocycline sulfosalicylate</h5> <p>One 10‐week parallel trial compared BPO and meclocycline sulfosalicylate (<a href="./references#CD011154-bbs2-0005" title="BorglundE , KristensenB , Larsson‐StymneB , StrandA , VeienNK , JakobsenHB . Topical meclocycline sulfosalicylate, benzoyl peroxide, and a combination of the two in the treatment of acne vulgaris. Acta Dermato‐Venereologica1991;71:175‐8. [CENTRAL: CN‐00075962; MEDLINE: 1675534] ">Borglund 1991</a>). A total of 36 participants treated with BPO and 33 with meclocycline were analysed. This study reported the outcomes of participant global self‐assessment of acne improvement, withdrawal due to adverse effects, change in lesion counts, and adverse events. </p> <section id="CD011154-sec-0274"> <h6 class="title">Primary outcomes: participant global self‐assessment of acne improvement</h6> <section id="CD011154-sec-0275"> <p><b>Studies not included in the meta‐analysis</b></p> <p>This outcome was assessed in the trial, but it is unclear how the outcome was assessed. It was reported that participants rating treatments as "good to excellent" accounted for 63% and 49% in the two groups, respectively, with an RR of 1.32 (95% CI 0.86 to 2.02). </p> <p><b>Primary outcomes: withdrawal due to adverse effects</b> </p> </section> <section id="CD011154-sec-0276"> <p><b>Main pooled analyses: BPO versus meclocycline</b></p> <p>It was reported that no participants discontinued meclocycline treatment due to adverse effects, but three discontinued BPO treatment for this reason, with an RR of 6.43 (95% CI 0.34 to 120.03; <a href="./references#CD011154-fig-0083" title="">Analysis 10.1</a>), Adverse events leading to withdrawal were not specified. </p> </section> </section> <section id="CD011154-sec-0277"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0278"> <p><b>Studies not included in the meta‐analysis</b></p> <p>For long‐term outcomes, the difference in absolute reduction in papules, pustules, and comedones was ‐5.3, 1.1, and ‐2.7, respectively. For medium‐term outcomes, the counterpart was ‐4.7, ‐0.1, and ‐3, respectively. For short‐term outcomes, the counterpart was ‐6.7, ‐0.6, and ‐1.9, respectively. All results were statistically significant (P &lt; 0.05) except for the reduction in pustules for long‐term data. </p> </section> </section> <section id="CD011154-sec-0279"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0280"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Trial authors reported that it was more common for BPO‐treated participants to have local side effects (including erythema, scaling, stinging/burning) than meclocycline‐treated participants. Yellowish decolouration was reported in one participant on BPO and in two participants on meclocycline. Allergic contact dermatitis was confirmed in one participant treated with BPO. We cannot calculate RR as the effect size because the number of participants with at least one adverse event was not provided. </p> </section> </section> </section> <section id="CD011154-sec-0281"> <h5 class="title">BPO versus isolutrol</h5> <p>This comparison was made in one 12‐week parallel trial with 35 participants in each group (<a href="./references#CD011154-bbs2-0031" title="DunlopKJ , BarnetsonRS . A comparative study of isolutrol versus benzoyl peroxide in the treatment of acne. Australasian Journal of Dermatology1995;36(1):13‐5. [CENTRAL: CN‐00114537; MEDLINE: 7763215] ">Dunlop 1995</a>). Change in lesion counts and adverse events were reported. </p> <section id="CD011154-sec-0282"> <h6 class="title">Primary outcomes</h6> <p>No information was available on the primary outcomes.</p> </section> <section id="CD011154-sec-0283"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0284"> <p><b>Studies not included in the meta‐analysis</b></p> <p>At week 12, BPO reduced the mean number of ILs from 33.3 to 12.7, and isolutrol from 23.9 to 15.7. NILs were decreased from 25.5 to 11.9 among participants on BPO and from 23.4 to 16.4 among participants on isolutrol. Trial authors presented significance test results for before‐and‐after lesion counts in each group rather than differences between the two groups. </p> </section> </section> <section id="CD011154-sec-0285"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0286"> <p><b>Main pooled analyses: BPO versus isolutrol</b></p> <p>Overall, adverse events occurred in 94% of BPO‐treated participants, whereas only 34% of isolutrol‐treated participants reported such problems, with higher risk in the BPO group (RR 2.75, 95% CI 1.73 to 4.38; 70 participants; <a href="./references#CD011154-fig-0082" title="">Analysis 9.1</a>). The most common event reported in the BPO group was dryness (83%), followed by erythema (49%). Dryness (31%) and pruritus (14%) were the most common events in the isolutrol group. </p> </section> </section> </section> <section id="CD011154-sec-0287"> <h5 class="title">BPO versus tea tree oil</h5> <p>One 10‐week parallel trial compared BPO and tea tree oil (<a href="./references#CD011154-bbs2-0002" title="BassettIB , PannowitzDL , BarnetsonRS . A comparative study of tea‐tree oil versus benzoyl peroxide in the treatment of acne. Medical Journal of Australia1990;153(8):455‐8. [CENTRAL: CN‐00070530; MEDLINE: 2145499] ">Bassett 1990</a>). A total of 124 participants were included in the trial, where 63 participants assigned to the BPO group and 61 to the tea tree oil group were followed up for three months. Outcomes covered in the study included change in lesion counts and adverse events. </p> <section id="CD011154-sec-0288"> <h6 class="title">Primary outcomes</h6> <p>No information was available on the primary outcomes.</p> </section> <section id="CD011154-sec-0289"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0290"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Insufficient data were available in this trial to estimate the effect size of absolute or percentage change. It was reported that the mean difference in absolute reduction in ILs was ‐10.4 (P &lt; 0.001), ‐10.8 (P &lt; 0.001), and ‐10.2 (P &lt; 0.05) for the long, medium, and short term, respectively. The counterpart in NILs was ‐1.2, ‐1.0, and ‐2.3, respectively (all P values &gt; 0.05). </p> </section> </section> <section id="CD011154-sec-0291"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0292"> <p><b>Main pooled analyses: BPO versus tea tree oil</b></p> <p>Overall, 79% (50/63) of BPO‐treated participants and 44% (27/61) of tea tree oil‐treated participants reported adverse events during the trial, with an RR of 1.79 (95% CI 1.32 to 2.44; <a href="./references#CD011154-fig-0084" title="">Analysis 11.1</a>). The most common adverse events reported included skin dryness, pruritus, stinging, burning, and redness. </p> </section> </section> </section> <section id="CD011154-sec-0293"> <h5 class="title">BPO versus Unani preparation (Zimade Muhasa)</h5> <p>This comparison was made in one six‐week parallel trial with 24 participants in each group (<a href="./references#CD011154-bbs2-0103" title="TabasumH , AhmadT , AnjumF , RehmanH . The effect of Unani antiacne formulation (Zimade Muhasa) on acne vulgaris: a single blind, randomized, controlled clinical trial. Journal of Pakistan Association of Dermatologists2014;24(4):319‐26. [CENTRAL: CN‐01075653] ">Tabasum 2014</a>). This trial reported outcomes of our review interest including withdrawal due to adverse effects, lesion counts, and adverse events. </p> <section id="CD011154-sec-0294"> <h6 class="title">Primary outcome: withdrawal due to adverse effects</h6> <section id="CD011154-sec-0295"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Four participants in each group did not complete the study; however, none of these participants withdrew from the trial due to adverse effects. </p> </section> </section> <section id="CD011154-sec-0296"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0297"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Trial authors presented significance test results for before‐and‐after lesion counts in each group rather than the difference between the two groups based on the Global Acne Severity Scale (<a href="./references#CD011154-bbs2-0103" title="TabasumH , AhmadT , AnjumF , RehmanH . The effect of Unani antiacne formulation (Zimade Muhasa) on acne vulgaris: a single blind, randomized, controlled clinical trial. Journal of Pakistan Association of Dermatologists2014;24(4):319‐26. [CENTRAL: CN‐01075653] ">Tabasum 2014</a>). At week 6, grading scores for comedones and papules were significantly different before and after both treatments (both P values &lt; 0.001). Although significant results were found for the grading scores for pustules (P &lt; 0.001) and nodules (P = 0.02) in the Unani preparation group, scores in the BPO group were not significantly reduced from baseline. </p> </section> </section> <section id="CD011154-sec-0298"> <h6 class="title">Secondary outcome: change in quality of life</h6> <section id="CD011154-sec-0299"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Similar to the outcome mentioned above, trial authors presented significance test results for before‐and‐after quality of life in each group rather than the difference between two groups. The mean score of the Cardiff Acne Disability Index was reduced from 12.00 to 5.80 in the BPO group (P &lt; 0.001) and from 12.25 to 4.95 in the Unani preparation group (P &lt; 0.001). </p> </section> </section> <section id="CD011154-sec-0300"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0301"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Trial authors claimed that the difference between two groups regarding adverse events was not significant. The most common events reported in both groups were itching (9/20 versus 13/20) and dryness (9/20 versus 7/20). We cannot calculate RR as the effect size because the number of participants with at least one adverse event was not provided. </p> </section> </section> </section> <section id="CD011154-sec-0302"> <h5 class="title">BPO versus glycerin in methylated spirit</h5> <p>One six‐week trial made this comparison, in which the only outcome assessed was change in lesion counts (<a href="./references#CD011154-bbs2-0021" title="DograA , SoodVK , MinochaYC . Comparative evaluation of retinoic acid, benzoyl peroxide and erythromycin lotion in acne vulgaris. Indian Journal of Dermatology, Venereology and Leprology1993;59(5):243‐6. [CENTRAL: CN‐01095331] ">Dogra 1993</a>). </p> <section id="CD011154-sec-0303"> <h6 class="title">Primary outcomes</h6> <p>No information on the primary outcomes was available.</p> </section> <section id="CD011154-sec-0304"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0305"> <p><b>Studies not included in the meta‐analysis</b></p> <p>After a six‐week treatment duration, although a reduction in NILs and 1ILs was 7.4% and 11.9% in the glycerin group of 21 participants, respectively, the counterpart was 70.1% and 63.9% in the BPO group of 24 participants (<a href="./references#CD011154-bbs2-0021" title="DograA , SoodVK , MinochaYC . Comparative evaluation of retinoic acid, benzoyl peroxide and erythromycin lotion in acne vulgaris. Indian Journal of Dermatology, Venereology and Leprology1993;59(5):243‐6. [CENTRAL: CN‐01095331] ">Dogra 1993</a>). </p> </section> </section> </section> <section id="CD011154-sec-0306"> <h5 class="title">BPO versus chloroxylenol/salicylic acid</h5> <p>One 12‐week parallel trial compared BPO and chloroxylenol/salicylic acid (<a href="./references#CD011154-bbs2-0006" title="BoutliF , ZiogaM , KoussidouT , IoannidesD , MourellouO . Comparison of chloroxylenol 0.5% plus salicylic acid 2% cream and benzoyl peroxide 5% gel in the treatment of acne vulgaris: a randomized double‐blind study. Drugs under Experimental and Clinical Research2003;29(3):101‐5. [CENTRAL: CN‐00464160; MEDLINE: 14708455] ">Boutli 2003</a>). Only an abstract was available for this trial. Nineteen participants on BPO and 18 on chloroxylenol/salicylic acid were assessed for the outcomes of change in lesion counts and adverse events. Limited information on these outcomes was available in the abstract. </p> <section id="CD011154-sec-0307"> <h6 class="title">Primary outcomes</h6> <p>No information was available on the primary outcomes.</p> </section> <section id="CD011154-sec-0308"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0309"> <p><b>Studies not included in the meta‐analysis</b></p> <p>At week 12, both groups showed marked improvement in both ILs (60% versus 62%) and NILs (54% versus 56%). With no statistically significant difference in such reduction between groups, trial authors concluded that both treatments were similarly effective in reducing lesions. </p> </section> </section> <section id="CD011154-sec-0310"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0311"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Trial authors mentioned that erythema and photosensitivity were significantly less in the chloroxylenol/salicylic acid group at week 12 than in the BPO group (P = 0.0002 and P = 0.05, respectively). We cannot calculate RR as the effect size because the number of participants with at least one adverse event was not provided. </p> </section> </section> </section> <section id="CD011154-sec-0312"> <h5 class="title">BPO versus chloroxylenol/zinc oxide</h5> <p>One eight‐week parallel trial compared BPO and chloroxylenol/zinc oxide (<a href="./references#CD011154-bbs2-0086" title="PapageorgiouPP , ChuAC . Chloroxylenol and zinc oxide containing cream (Nels cream) vs. 5% benzoyl peroxide cream in the treatment of acne vulgaris. A double‐blind, randomized, controlled trial. Clinical &amp; Experimental Dermatology2000;25(1):16‐20. [CENTRAL: CN‐00275100; MEDLINE: 10671963] ">Papageorgiou 2000</a>). Thirteen participants in each group were assessed for the outcomes of change in lesion counts and adverse events. </p> <section id="CD011154-sec-0313"> <h6 class="title">Primary outcome: participant global self‐assessment of acne improvement</h6> <section id="CD011154-sec-0314"> <p><b>Main pooled analyses: BPO versus chloroxylenol/zinc oxide</b></p> <p>The medium‐term outcome was assessed according to the percentage of improvement (as worse, no change (0 to 9%), mild improvement (10% to 39%), moderate improvement (40% to 69%), marked improvement (70% to 89%), and clearance (&gt; 90%)), with no significant difference in treatment success (RR 0.89, 95% CI 0.51 to 1.56; 26 participants; <a href="./references#CD011154-fig-0085" title="">Analysis 12.1</a>). </p> </section> </section> <section id="CD011154-sec-0315"> <h6 class="title">Primary outcome: withdrawal due to adverse effects</h6> <section id="CD011154-sec-0316"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Two participants discontinued treatment due to flare‐ups. However, it is unclear what treatments they received before the flare‐ups. </p> </section> </section> <section id="CD011154-sec-0317"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0318"> <p><b>Main pooled analyses: BPO versus chloroxylenol/zinc oxide</b></p> <p>This trial reported the percentage change in ILs and NILs. Compared with the chloroxylenol/zinc oxide group, mean differences in the percentage change were ‐7.70% (95% CI ‐19.36% to 3.96%) and ‐5.60% (95% CI ‐14.74% to 3.54%), respectively. </p> </section> </section> <section id="CD011154-sec-0319"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0320"> <p><b>Studies not included in the meta‐analysis</b></p> <p>No significant difference in the number of flare‐ups was found (2/13 on BPO versus 1/13 on chloroxylenol/zinc oxide). Dryness and/or peeling of the skin was reported by four participants on BPO and one participant on chloroxylenol/zinc oxide (P &lt; 0.01). We cannot calculate RR as the effect size because the number of participants with at least one adverse event was not provided. </p> </section> </section> </section> <section id="CD011154-sec-0321"> <h5 class="title">BPO/adapalene versus placebo or no treatment</h5> <p>This comparison comprised eight parallel trials (<a href="./references#CD011154-bbs2-0025" title="DrenoB , KaufmannR , TalaricoS , Torres LozadaV , Rodriguez‐CastellanosMA , Gomez‐FloresM , et al. Combination therapy with adapalene‐benzoyl peroxide and oral lymecycline in the treatment of moderate to severe acne vulgaris: a multicentre, randomized, double‐blind controlled study. British Journal of Dermatology2011;165(2):383‐90. [CENTRAL: CN‐00800637; MEDLINE: 21495995] NCT01014689 . Efficacy and safety comparison of Epiduo gel associated with lymecycline 300 mg capsules versus Epiduo vehicle gel associated with lymecycline 300 mg capsules in the treatment of moderate to severe acne vulgaris (TEAM). clinicaltrials.gov/ct2/show/NCT01014689 (first received 17 November 2009). ">Dreno 2011</a>; <a href="./references#CD011154-bbs2-0035" title="EichenfieldL , HebertAA , LuckyAW , RudisillD , SugarmanJ , GoldLS , et al. Treatment of acne in children aged 9 to 11 with a fixed dose combination of adapalene‐benzoyl peroxide gel. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB19. [CENTRAL: CN‐01028500] EichenfieldLF , DraelosZ , LuckyAW , HebertAA , SugarmanJ , GoldLS , et al. Preadolescent moderate acne vulgaris: a randomized trial of the efficacy and safety of topical adapalene‐benzoyl peroxides. Journal of Drugs in Dermatology2013;12(6):611‐8. [CENTRAL: CN‐00914308; MEDLINE: 23839175] EichenfieldLF , DraelosZ , LuckyAW , HerbertAA , SugarmanJ , GoldS , et al. Treatment of acne in children 9‐11 with a fixed dose combination. Pediatric Dermatology2013;30(5):647. [CENTRAL: CN‐01025039] NCT01138735 . A multi‐center, randomized, vehicle‐controlled, double‐blind study to evaluate the safety and efficacy of Epiduo® (adapalene and benzoyl peroxide) gel 0.1%/2.5% administered once daily for the treatment of subjects 9 to 11 years of age with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT01138735 (first received 4 June 2010). ">Eichenfield 2013</a>; <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>; <a href="./references#CD011154-bbs2-0042" title="BrodellRT , SchlosserBJ , RafalE , TothD , TyringS , WertheimerA , et al. A fixed‐dose combination of adapalene 0.1%/BPO 2.5% allows an early and sustained improvement in quality of life and patient treatment satisfaction in severe acne. Journal of Dermatological Treatment2012;23(1):26‐34. [CENTRAL: CN‐00860557; MEDLINE: 22103674] BrodellRT , WertheimerA , TothD , BucherD , RafalE , KerroucheN , et al. Patient satisfaction with a fixed dose combination of adapalene‐benzoyl peroxide gel as part of a regimen and used alone as maintenance therapy. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB17. [CENTRAL: CN‐01028502] BrodellRT , WertheimerA , TothD , BucherD , RafalE , KerroucheN , et al. Treatment with adapalene‐benzoyl peroxide improves quality of life in patients with severe acne vulgaris. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB19. [CENTRAL: CN‐01028499] GoldLS , CruzA , EichenfieldL , TanJ , JorizzoJ , KerroucheN , et al. Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle‐controlled, double‐blind study of adapalene 0.1%‐benzoyl peroxide 2.5% fixed‐dose combination gel with doxycycline hyclate 100 mg. Cutis; Cutaneous Medicine for the Practitioner2010;85(2):94‐104. [CENTRAL: CN‐00743300; MEDLINE: 20349684] GoldLS , DhuinJC , TanJ , JorizzoJ . Adapalene 0.1%/benzoyl peroxide 2.5% gel with doxycycline hyclate 100 mg tablets compared to vehicle gel with doxycycline hyclate 100 mg tablets in the treatment of severe acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB13. [CENTRAL: CN‐00843733] JarrattM , BuckoAD , ZugajD , DhuinJC . Treatment with adapalene 0.1%‐BPO 2.5% and doxycycline 100 mg/day resulted in rapid and sustained decrease in Propionibacterium acnes (Poster P102). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB1. [CENTRAL: CN‐00843734] NCT00688064 . Adapalene‐BPO gel associated with doxycycline hyclate 100 mg in the treatment of severe acne vulgaris (ACCESS I). www.clinicaltrials.gov/ct2/show/NCT00688064 (first received 28 May 2008). TanJ , GoldLS , SchlessingerJ , BrodellR , JonesT , CruzA , et al. Short‐term combination therapy and long‐term relapse prevention in the treatment of severe acne vulgaris. Journal of Drugs in Dermatology2012;11(2):174‐80. [CENTRAL: CN‐00860272; MEDLINE: 22270198] TanJ , GoldLS , SchlessingerJ , BrodellR , JonesT , DhuinJC , et al. Combination of adapalene‐benzoyl peroxide and oral doxycycline is efficacious in short‐term therapy: maintenance with adapalene‐benzoyl peroxide prevents relapse in treatment of severe acne vulgaris. Pediatric Dermatology2012;29(5):688. TanJ , SchlessingerJ , GoldLS , BrodellR . Combination of adapalene‐benzoyl peroxide and oral doxycycline is efficacious in short‐term therapy: maintenance with adapalene‐benzoyl peroxide prevents relapse in treatment of severe acne vulgaris. Journal of the American Academy of Dermatology2012;66(4):AB15. [DOI: 10.1016/j.jaad.2011.11.072] ">Gold 2010</a>; <a href="./references#CD011154-bbs2-0043" title="AlexisAF , Cook‐BoldenFE , YorkJP . Adapalene/benzoyl peroxide gel 0.3%/2.5%: a safe and effective acne therapy in all skin phototypes. Journal of Drugs in Dermatology2017;16(6):574‐81. [CENTRAL: CN‐01416574; MEDLINE: 28686775] GoldLS , WeissJ , RuedaMJ , LiuH , TanghettiE . Moderate and severe inflammatory acne vulgaris effectively treated with single‐agent therapy by a new fixed‐dose combination adapalene 0.3 %/benzoyl peroxide 2.5 % gel: a randomized, double‐blind, parallel‐group, controlled study. American Journal of Clinical Dermatology2016;17(3):293‐303. [CENTRAL: CN‐01264220; MEDLINE: 26945741] ">Gold 2016</a>; <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>; <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>; <a href="./references#CD011154-bbs2-0114" title="Stein GoldL , WerschlerWP , MohawkJ . Adapalene/benzoyl peroxide gel 0.3%/2.5%: effective acne therapy regardless of age or gender. Journal of Drugs in Dermatology2017;16(6):582‐9. [CENTRAL: CN‐01458199; MEDLINE: 28686776] WeissJ , GoldLS , RuedaMJ , TanghettiE . Adapalene 0.3%/benzoyl peroxide 2.5% gel for the treatment of severe inflammatory acne: a randomized, double‐blind, parallel‐group, controlled study. Pediatric Dermatology2017;34:S103. [CENTRAL: CN‐01399571] WeissJ , GoldLS , TanghettiE , BouvresseS , YaoM , DujolsC , et al. Efficacy and safety of adapalene 0.3%/benzoyl peroxide 2.5% topical gel in moderate and severe acne vulgaris. Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB7. [CENTRAL: CN‐01088984] WeissJ , GoldLS , TanghettiE , DujolsC , RuedaMJ . Efficacy and safety of adapalene 0.3%/benzoyl peroxide 2.5% topical gel in moderate and severe acne vulgaris. Journal of the American Academy of Dermatology2017; Vol. 34:S31. [CENTRAL: CN‐01399572] WeissJ , Stein GoldL , LeoniM , RuedaMj , LiuH , TanghettiE . Customized single‐agent therapy management of severe inflammatory acne: a randomized, double‐blind, parallel‐group controlled study of a new treatment ‐ adapalene 0.3%‐benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2015;14(12):1427‐35. [CENTRAL: CN‐01200535; MEDLINE: 26659936] WeissJ , Stein‐GoldL , TanghettiE , DujolsC , LeoniM , DownsT . Adapalene 0.3%/benzoyl peroxide 2.5% topical gel: efficacy and safety in moderate and severe acne vulgaris. British Journal of Dermatology2015;173:66. [CENTRAL: CN‐01108071] WeissJS , Stein GoldLS , TanghettiEA , LeoniMJ , LiuH , RuedaMJ . Adapalene 0.3%/benzoyl peroxide 2.5% gel for the treatment of severe inflammatory acne: a randomized, double‐blind, parallel‐group, controlled study. 3544. Journal of the American Academy of Dermatology2016;74(5 Suppl 1):AB1. [www.jaad.org/article/S0190‐9622(16)00135‐3/pdf] ">Weiss 2015</a>), as well as two split‐face trials (<a href="./references#CD011154-bbs2-0026" title="DrenoB , TanJ , RivierM , MartelP , BissonnetteR . Adapalene 0.1%/benzoyl peroxide 2.5% gel reduces the risk of atrophic scar formation in moderate inflammatory acne: a split‐face randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2017;31(4):737‐42. [CENTRAL: CN‐01424729; MEDLINE: 27790756] ">Dreno 2016</a>; <a href="./references#CD011154-bbs2-0027" title="DrénoB , BissonnetteR , Gagné‐HenleyA , BarankinB , LyndeC , KerroucheN , et al. Prevention and reduction of atrophic acne scars with adapalene 0.3%/benzoyl peroxide 2.5% gel in subjects with moderate or severe facial acne: results of a 6‐month randomized, vehicle‐controlled trial using intra‐individual comparison. American Journal of Clinical Dermatology2018;19(2):275‐86. [CENTRAL: CN‐01572577] NCT02735421 . Adapalene 0.3% ‐ Benzoyl Peroxide 2.5% Gel and Risk of Formation of Atrophic Acne Scars (OSCAR). clinicaltrials.gov/ct2/show/NCT02735421 (first received 7 April 2016). ">Dréno 2018</a>), in which all participants were followed up for at least 12 weeks. All outcomes of interest in this review were available except reduction in <i>C acnes</i> strains. </p> <section id="CD011154-sec-0322"> <h6 class="title">Primary outcome: participant global self‐assessment of acne improvement</h6> <p>Of seven trials that reported this outcome (<a href="./references#CD011154-bbs2-0025" title="DrenoB , KaufmannR , TalaricoS , Torres LozadaV , Rodriguez‐CastellanosMA , Gomez‐FloresM , et al. Combination therapy with adapalene‐benzoyl peroxide and oral lymecycline in the treatment of moderate to severe acne vulgaris: a multicentre, randomized, double‐blind controlled study. British Journal of Dermatology2011;165(2):383‐90. [CENTRAL: CN‐00800637; MEDLINE: 21495995] NCT01014689 . Efficacy and safety comparison of Epiduo gel associated with lymecycline 300 mg capsules versus Epiduo vehicle gel associated with lymecycline 300 mg capsules in the treatment of moderate to severe acne vulgaris (TEAM). clinicaltrials.gov/ct2/show/NCT01014689 (first received 17 November 2009). ">Dreno 2011</a>; <a href="./references#CD011154-bbs2-0035" title="EichenfieldL , HebertAA , LuckyAW , RudisillD , SugarmanJ , GoldLS , et al. Treatment of acne in children aged 9 to 11 with a fixed dose combination of adapalene‐benzoyl peroxide gel. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB19. [CENTRAL: CN‐01028500] EichenfieldLF , DraelosZ , LuckyAW , HebertAA , SugarmanJ , GoldLS , et al. Preadolescent moderate acne vulgaris: a randomized trial of the efficacy and safety of topical adapalene‐benzoyl peroxides. Journal of Drugs in Dermatology2013;12(6):611‐8. [CENTRAL: CN‐00914308; MEDLINE: 23839175] EichenfieldLF , DraelosZ , LuckyAW , HerbertAA , SugarmanJ , GoldS , et al. Treatment of acne in children 9‐11 with a fixed dose combination. Pediatric Dermatology2013;30(5):647. [CENTRAL: CN‐01025039] NCT01138735 . A multi‐center, randomized, vehicle‐controlled, double‐blind study to evaluate the safety and efficacy of Epiduo® (adapalene and benzoyl peroxide) gel 0.1%/2.5% administered once daily for the treatment of subjects 9 to 11 years of age with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT01138735 (first received 4 June 2010). ">Eichenfield 2013</a>; <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>; <a href="./references#CD011154-bbs2-0042" title="BrodellRT , SchlosserBJ , RafalE , TothD , TyringS , WertheimerA , et al. A fixed‐dose combination of adapalene 0.1%/BPO 2.5% allows an early and sustained improvement in quality of life and patient treatment satisfaction in severe acne. Journal of Dermatological Treatment2012;23(1):26‐34. [CENTRAL: CN‐00860557; MEDLINE: 22103674] BrodellRT , WertheimerA , TothD , BucherD , RafalE , KerroucheN , et al. Patient satisfaction with a fixed dose combination of adapalene‐benzoyl peroxide gel as part of a regimen and used alone as maintenance therapy. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB17. [CENTRAL: CN‐01028502] BrodellRT , WertheimerA , TothD , BucherD , RafalE , KerroucheN , et al. Treatment with adapalene‐benzoyl peroxide improves quality of life in patients with severe acne vulgaris. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB19. [CENTRAL: CN‐01028499] GoldLS , CruzA , EichenfieldL , TanJ , JorizzoJ , KerroucheN , et al. Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle‐controlled, double‐blind study of adapalene 0.1%‐benzoyl peroxide 2.5% fixed‐dose combination gel with doxycycline hyclate 100 mg. Cutis; Cutaneous Medicine for the Practitioner2010;85(2):94‐104. [CENTRAL: CN‐00743300; MEDLINE: 20349684] GoldLS , DhuinJC , TanJ , JorizzoJ . Adapalene 0.1%/benzoyl peroxide 2.5% gel with doxycycline hyclate 100 mg tablets compared to vehicle gel with doxycycline hyclate 100 mg tablets in the treatment of severe acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB13. [CENTRAL: CN‐00843733] JarrattM , BuckoAD , ZugajD , DhuinJC . Treatment with adapalene 0.1%‐BPO 2.5% and doxycycline 100 mg/day resulted in rapid and sustained decrease in Propionibacterium acnes (Poster P102). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB1. [CENTRAL: CN‐00843734] NCT00688064 . Adapalene‐BPO gel associated with doxycycline hyclate 100 mg in the treatment of severe acne vulgaris (ACCESS I). www.clinicaltrials.gov/ct2/show/NCT00688064 (first received 28 May 2008). TanJ , GoldLS , SchlessingerJ , BrodellR , JonesT , CruzA , et al. Short‐term combination therapy and long‐term relapse prevention in the treatment of severe acne vulgaris. Journal of Drugs in Dermatology2012;11(2):174‐80. [CENTRAL: CN‐00860272; MEDLINE: 22270198] TanJ , GoldLS , SchlessingerJ , BrodellR , JonesT , DhuinJC , et al. Combination of adapalene‐benzoyl peroxide and oral doxycycline is efficacious in short‐term therapy: maintenance with adapalene‐benzoyl peroxide prevents relapse in treatment of severe acne vulgaris. Pediatric Dermatology2012;29(5):688. TanJ , SchlessingerJ , GoldLS , BrodellR . Combination of adapalene‐benzoyl peroxide and oral doxycycline is efficacious in short‐term therapy: maintenance with adapalene‐benzoyl peroxide prevents relapse in treatment of severe acne vulgaris. Journal of the American Academy of Dermatology2012;66(4):AB15. [DOI: 10.1016/j.jaad.2011.11.072] ">Gold 2010</a>; <a href="./references#CD011154-bbs2-0043" title="AlexisAF , Cook‐BoldenFE , YorkJP . Adapalene/benzoyl peroxide gel 0.3%/2.5%: a safe and effective acne therapy in all skin phototypes. Journal of Drugs in Dermatology2017;16(6):574‐81. [CENTRAL: CN‐01416574; MEDLINE: 28686775] GoldLS , WeissJ , RuedaMJ , LiuH , TanghettiE . Moderate and severe inflammatory acne vulgaris effectively treated with single‐agent therapy by a new fixed‐dose combination adapalene 0.3 %/benzoyl peroxide 2.5 % gel: a randomized, double‐blind, parallel‐group, controlled study. American Journal of Clinical Dermatology2016;17(3):293‐303. [CENTRAL: CN‐01264220; MEDLINE: 26945741] ">Gold 2016</a>; <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>; <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>), three trials presented data in accordance with the definition of treatment success in our review (<a href="./references#CD011154-bbs2-0025" title="DrenoB , KaufmannR , TalaricoS , Torres LozadaV , Rodriguez‐CastellanosMA , Gomez‐FloresM , et al. Combination therapy with adapalene‐benzoyl peroxide and oral lymecycline in the treatment of moderate to severe acne vulgaris: a multicentre, randomized, double‐blind controlled study. British Journal of Dermatology2011;165(2):383‐90. [CENTRAL: CN‐00800637; MEDLINE: 21495995] NCT01014689 . Efficacy and safety comparison of Epiduo gel associated with lymecycline 300 mg capsules versus Epiduo vehicle gel associated with lymecycline 300 mg capsules in the treatment of moderate to severe acne vulgaris (TEAM). clinicaltrials.gov/ct2/show/NCT01014689 (first received 17 November 2009). ">Dreno 2011</a>; <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>; <a href="./references#CD011154-bbs2-0043" title="AlexisAF , Cook‐BoldenFE , YorkJP . Adapalene/benzoyl peroxide gel 0.3%/2.5%: a safe and effective acne therapy in all skin phototypes. Journal of Drugs in Dermatology2017;16(6):574‐81. [CENTRAL: CN‐01416574; MEDLINE: 28686775] GoldLS , WeissJ , RuedaMJ , LiuH , TanghettiE . Moderate and severe inflammatory acne vulgaris effectively treated with single‐agent therapy by a new fixed‐dose combination adapalene 0.3 %/benzoyl peroxide 2.5 % gel: a randomized, double‐blind, parallel‐group, controlled study. American Journal of Clinical Dermatology2016;17(3):293‐303. [CENTRAL: CN‐01264220; MEDLINE: 26945741] ">Gold 2016</a>). </p> <section id="CD011154-sec-0323"> <p><b>Main pooled analyses: BPO/adapalene versus placebo or no treatment</b></p> <p>Overall, there was no significant difference in long‐term treatment success between the two groups (RR 1.16, 95% CI 0.97 to 1.38; 1480 participants; 3 studies; I² = 84%; <a href="./references#CD011154-fig-0086" title="">Analysis 13.1</a>). </p> </section> <section id="CD011154-sec-0324"> <p><b>Subgroup analyses: co‐intervention</b></p> <p>Effects differed by the co‐intervention (P value for subgroup differences = 0.02), with a larger effect size in the BPO/adapalene versus the placebo or no treatment group (RR 1.25, 95% CI 1.09 to 1.44) than with the co‐intervention of lymecycline (RR 0.99, 95% CI 0.87 to 1.13) (<a href="./references#CD011154-fig-0086" title="">Analysis 13.1</a>). </p> </section> <section id="CD011154-sec-0325"> <p><b>Studies not included in the meta‐analysis</b></p> <p>We did not pool results from the other four trials assessing this outcome because the number of treatment successes defined in our review was not available (<a href="./references#CD011154-bbs2-0035" title="EichenfieldL , HebertAA , LuckyAW , RudisillD , SugarmanJ , GoldLS , et al. Treatment of acne in children aged 9 to 11 with a fixed dose combination of adapalene‐benzoyl peroxide gel. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB19. [CENTRAL: CN‐01028500] EichenfieldLF , DraelosZ , LuckyAW , HebertAA , SugarmanJ , GoldLS , et al. Preadolescent moderate acne vulgaris: a randomized trial of the efficacy and safety of topical adapalene‐benzoyl peroxides. Journal of Drugs in Dermatology2013;12(6):611‐8. [CENTRAL: CN‐00914308; MEDLINE: 23839175] EichenfieldLF , DraelosZ , LuckyAW , HerbertAA , SugarmanJ , GoldS , et al. Treatment of acne in children 9‐11 with a fixed dose combination. Pediatric Dermatology2013;30(5):647. [CENTRAL: CN‐01025039] NCT01138735 . A multi‐center, randomized, vehicle‐controlled, double‐blind study to evaluate the safety and efficacy of Epiduo® (adapalene and benzoyl peroxide) gel 0.1%/2.5% administered once daily for the treatment of subjects 9 to 11 years of age with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT01138735 (first received 4 June 2010). ">Eichenfield 2013</a>; <a href="./references#CD011154-bbs2-0042" title="BrodellRT , SchlosserBJ , RafalE , TothD , TyringS , WertheimerA , et al. A fixed‐dose combination of adapalene 0.1%/BPO 2.5% allows an early and sustained improvement in quality of life and patient treatment satisfaction in severe acne. Journal of Dermatological Treatment2012;23(1):26‐34. [CENTRAL: CN‐00860557; MEDLINE: 22103674] BrodellRT , WertheimerA , TothD , BucherD , RafalE , KerroucheN , et al. Patient satisfaction with a fixed dose combination of adapalene‐benzoyl peroxide gel as part of a regimen and used alone as maintenance therapy. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB17. [CENTRAL: CN‐01028502] BrodellRT , WertheimerA , TothD , BucherD , RafalE , KerroucheN , et al. Treatment with adapalene‐benzoyl peroxide improves quality of life in patients with severe acne vulgaris. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB19. [CENTRAL: CN‐01028499] GoldLS , CruzA , EichenfieldL , TanJ , JorizzoJ , KerroucheN , et al. Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle‐controlled, double‐blind study of adapalene 0.1%‐benzoyl peroxide 2.5% fixed‐dose combination gel with doxycycline hyclate 100 mg. Cutis; Cutaneous Medicine for the Practitioner2010;85(2):94‐104. [CENTRAL: CN‐00743300; MEDLINE: 20349684] GoldLS , DhuinJC , TanJ , JorizzoJ . Adapalene 0.1%/benzoyl peroxide 2.5% gel with doxycycline hyclate 100 mg tablets compared to vehicle gel with doxycycline hyclate 100 mg tablets in the treatment of severe acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB13. [CENTRAL: CN‐00843733] JarrattM , BuckoAD , ZugajD , DhuinJC . Treatment with adapalene 0.1%‐BPO 2.5% and doxycycline 100 mg/day resulted in rapid and sustained decrease in Propionibacterium acnes (Poster P102). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB1. [CENTRAL: CN‐00843734] NCT00688064 . Adapalene‐BPO gel associated with doxycycline hyclate 100 mg in the treatment of severe acne vulgaris (ACCESS I). www.clinicaltrials.gov/ct2/show/NCT00688064 (first received 28 May 2008). TanJ , GoldLS , SchlessingerJ , BrodellR , JonesT , CruzA , et al. Short‐term combination therapy and long‐term relapse prevention in the treatment of severe acne vulgaris. Journal of Drugs in Dermatology2012;11(2):174‐80. [CENTRAL: CN‐00860272; MEDLINE: 22270198] TanJ , GoldLS , SchlessingerJ , BrodellR , JonesT , DhuinJC , et al. Combination of adapalene‐benzoyl peroxide and oral doxycycline is efficacious in short‐term therapy: maintenance with adapalene‐benzoyl peroxide prevents relapse in treatment of severe acne vulgaris. Pediatric Dermatology2012;29(5):688. TanJ , SchlessingerJ , GoldLS , BrodellR . Combination of adapalene‐benzoyl peroxide and oral doxycycline is efficacious in short‐term therapy: maintenance with adapalene‐benzoyl peroxide prevents relapse in treatment of severe acne vulgaris. Journal of the American Academy of Dermatology2012;66(4):AB15. [DOI: 10.1016/j.jaad.2011.11.072] ">Gold 2010</a>; <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>; <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>). </p> <p><a href="./references#CD011154-bbs2-0035" title="EichenfieldL , HebertAA , LuckyAW , RudisillD , SugarmanJ , GoldLS , et al. Treatment of acne in children aged 9 to 11 with a fixed dose combination of adapalene‐benzoyl peroxide gel. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB19. [CENTRAL: CN‐01028500] EichenfieldLF , DraelosZ , LuckyAW , HebertAA , SugarmanJ , GoldLS , et al. Preadolescent moderate acne vulgaris: a randomized trial of the efficacy and safety of topical adapalene‐benzoyl peroxides. Journal of Drugs in Dermatology2013;12(6):611‐8. [CENTRAL: CN‐00914308; MEDLINE: 23839175] EichenfieldLF , DraelosZ , LuckyAW , HerbertAA , SugarmanJ , GoldS , et al. Treatment of acne in children 9‐11 with a fixed dose combination. Pediatric Dermatology2013;30(5):647. [CENTRAL: CN‐01025039] NCT01138735 . A multi‐center, randomized, vehicle‐controlled, double‐blind study to evaluate the safety and efficacy of Epiduo® (adapalene and benzoyl peroxide) gel 0.1%/2.5% administered once daily for the treatment of subjects 9 to 11 years of age with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT01138735 (first received 4 June 2010). ">Eichenfield 2013</a> randomised 142 participants to the BPO/adapalene group and 143 to the placebo group and assessed the outcome using a 6‐point Likert‐like scale. The risk ratio for self‐reported complete or marked improvement was 2.93 (95% CI 2.14 to 4.01). </p> <p>In <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>, 419 participants in the BPO/adapalene group and 418 in the placebo group were assessed via a 6‐point Likert‐like scale. The risk ratio for self‐reported complete or marked improvement was 1.75 (95% CI 1.46 to 2.09). </p> <p>A similar 6‐point Likert‐like scale was used in another trial (<a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>), in which 149 participants were treated with BPO/adapalene and 71 participants with placebo. The risk ratio for self‐reported complete or marked improvement was 3.00 (95% CI 1.64 to 5.49). </p> <p><a href="./references#CD011154-bbs2-0042" title="BrodellRT , SchlosserBJ , RafalE , TothD , TyringS , WertheimerA , et al. A fixed‐dose combination of adapalene 0.1%/BPO 2.5% allows an early and sustained improvement in quality of life and patient treatment satisfaction in severe acne. Journal of Dermatological Treatment2012;23(1):26‐34. [CENTRAL: CN‐00860557; MEDLINE: 22103674] BrodellRT , WertheimerA , TothD , BucherD , RafalE , KerroucheN , et al. Patient satisfaction with a fixed dose combination of adapalene‐benzoyl peroxide gel as part of a regimen and used alone as maintenance therapy. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB17. [CENTRAL: CN‐01028502] BrodellRT , WertheimerA , TothD , BucherD , RafalE , KerroucheN , et al. Treatment with adapalene‐benzoyl peroxide improves quality of life in patients with severe acne vulgaris. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB19. [CENTRAL: CN‐01028499] GoldLS , CruzA , EichenfieldL , TanJ , JorizzoJ , KerroucheN , et al. Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle‐controlled, double‐blind study of adapalene 0.1%‐benzoyl peroxide 2.5% fixed‐dose combination gel with doxycycline hyclate 100 mg. Cutis; Cutaneous Medicine for the Practitioner2010;85(2):94‐104. [CENTRAL: CN‐00743300; MEDLINE: 20349684] GoldLS , DhuinJC , TanJ , JorizzoJ . Adapalene 0.1%/benzoyl peroxide 2.5% gel with doxycycline hyclate 100 mg tablets compared to vehicle gel with doxycycline hyclate 100 mg tablets in the treatment of severe acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB13. [CENTRAL: CN‐00843733] JarrattM , BuckoAD , ZugajD , DhuinJC . Treatment with adapalene 0.1%‐BPO 2.5% and doxycycline 100 mg/day resulted in rapid and sustained decrease in Propionibacterium acnes (Poster P102). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB1. [CENTRAL: CN‐00843734] NCT00688064 . Adapalene‐BPO gel associated with doxycycline hyclate 100 mg in the treatment of severe acne vulgaris (ACCESS I). www.clinicaltrials.gov/ct2/show/NCT00688064 (first received 28 May 2008). TanJ , GoldLS , SchlessingerJ , BrodellR , JonesT , CruzA , et al. Short‐term combination therapy and long‐term relapse prevention in the treatment of severe acne vulgaris. Journal of Drugs in Dermatology2012;11(2):174‐80. [CENTRAL: CN‐00860272; MEDLINE: 22270198] TanJ , GoldLS , SchlessingerJ , BrodellR , JonesT , DhuinJC , et al. Combination of adapalene‐benzoyl peroxide and oral doxycycline is efficacious in short‐term therapy: maintenance with adapalene‐benzoyl peroxide prevents relapse in treatment of severe acne vulgaris. Pediatric Dermatology2012;29(5):688. TanJ , SchlessingerJ , GoldLS , BrodellR . Combination of adapalene‐benzoyl peroxide and oral doxycycline is efficacious in short‐term therapy: maintenance with adapalene‐benzoyl peroxide prevents relapse in treatment of severe acne vulgaris. Journal of the American Academy of Dermatology2012;66(4):AB15. [DOI: 10.1016/j.jaad.2011.11.072] ">Gold 2010</a>, a 12‐week trial including 232 participants in the BPO/adapalene plus doxycycline group and 227 in the placebo plus doxycycline group, assessed participant satisfaction at week 12 and found significant differences in the proportion of participants reporting "very satisfied" or "satisfied" (scale used for the assessment was not specified) in favour of the BPO/adapalene add‐on treatment group (76.3% versus 50.3%; P &lt; 0.001). </p> <p>These results consistently suggested a significant difference between the two groups in favour of BPO/adapalene. Sensitivity analysis additionally including these four trials suggests a higher probability of self‐assessed improvement in the BPO/adapalene group, with an RR of 1.55 (95% CI 1.25 to 1.91). </p> </section> </section> <section id="CD011154-sec-0326"> <h6 class="title">Primary outcome: withdrawal due to adverse effects</h6> <p>Ten trials reported the long‐term outcome (<a href="./references#CD011154-bbs2-0025" title="DrenoB , KaufmannR , TalaricoS , Torres LozadaV , Rodriguez‐CastellanosMA , Gomez‐FloresM , et al. Combination therapy with adapalene‐benzoyl peroxide and oral lymecycline in the treatment of moderate to severe acne vulgaris: a multicentre, randomized, double‐blind controlled study. British Journal of Dermatology2011;165(2):383‐90. [CENTRAL: CN‐00800637; MEDLINE: 21495995] NCT01014689 . Efficacy and safety comparison of Epiduo gel associated with lymecycline 300 mg capsules versus Epiduo vehicle gel associated with lymecycline 300 mg capsules in the treatment of moderate to severe acne vulgaris (TEAM). clinicaltrials.gov/ct2/show/NCT01014689 (first received 17 November 2009). ">Dreno 2011</a>; <a href="./references#CD011154-bbs2-0026" title="DrenoB , TanJ , RivierM , MartelP , BissonnetteR . Adapalene 0.1%/benzoyl peroxide 2.5% gel reduces the risk of atrophic scar formation in moderate inflammatory acne: a split‐face randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2017;31(4):737‐42. [CENTRAL: CN‐01424729; MEDLINE: 27790756] ">Dreno 2016</a>; <a href="./references#CD011154-bbs2-0027" title="DrénoB , BissonnetteR , Gagné‐HenleyA , BarankinB , LyndeC , KerroucheN , et al. Prevention and reduction of atrophic acne scars with adapalene 0.3%/benzoyl peroxide 2.5% gel in subjects with moderate or severe facial acne: results of a 6‐month randomized, vehicle‐controlled trial using intra‐individual comparison. American Journal of Clinical Dermatology2018;19(2):275‐86. [CENTRAL: CN‐01572577] NCT02735421 . Adapalene 0.3% ‐ Benzoyl Peroxide 2.5% Gel and Risk of Formation of Atrophic Acne Scars (OSCAR). clinicaltrials.gov/ct2/show/NCT02735421 (first received 7 April 2016). ">Dréno 2018</a>; <a href="./references#CD011154-bbs2-0035" title="EichenfieldL , HebertAA , LuckyAW , RudisillD , SugarmanJ , GoldLS , et al. Treatment of acne in children aged 9 to 11 with a fixed dose combination of adapalene‐benzoyl peroxide gel. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB19. [CENTRAL: CN‐01028500] EichenfieldLF , DraelosZ , LuckyAW , HebertAA , SugarmanJ , GoldLS , et al. Preadolescent moderate acne vulgaris: a randomized trial of the efficacy and safety of topical adapalene‐benzoyl peroxides. Journal of Drugs in Dermatology2013;12(6):611‐8. [CENTRAL: CN‐00914308; MEDLINE: 23839175] EichenfieldLF , DraelosZ , LuckyAW , HerbertAA , SugarmanJ , GoldS , et al. Treatment of acne in children 9‐11 with a fixed dose combination. Pediatric Dermatology2013;30(5):647. [CENTRAL: CN‐01025039] NCT01138735 . A multi‐center, randomized, vehicle‐controlled, double‐blind study to evaluate the safety and efficacy of Epiduo® (adapalene and benzoyl peroxide) gel 0.1%/2.5% administered once daily for the treatment of subjects 9 to 11 years of age with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT01138735 (first received 4 June 2010). ">Eichenfield 2013</a>; <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>; <a href="./references#CD011154-bbs2-0042" title="BrodellRT , SchlosserBJ , RafalE , TothD , TyringS , WertheimerA , et al. A fixed‐dose combination of adapalene 0.1%/BPO 2.5% allows an early and sustained improvement in quality of life and patient treatment satisfaction in severe acne. Journal of Dermatological Treatment2012;23(1):26‐34. [CENTRAL: CN‐00860557; MEDLINE: 22103674] BrodellRT , WertheimerA , TothD , BucherD , RafalE , KerroucheN , et al. Patient satisfaction with a fixed dose combination of adapalene‐benzoyl peroxide gel as part of a regimen and used alone as maintenance therapy. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB17. [CENTRAL: CN‐01028502] BrodellRT , WertheimerA , TothD , BucherD , RafalE , KerroucheN , et al. Treatment with adapalene‐benzoyl peroxide improves quality of life in patients with severe acne vulgaris. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB19. [CENTRAL: CN‐01028499] GoldLS , CruzA , EichenfieldL , TanJ , JorizzoJ , KerroucheN , et al. Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle‐controlled, double‐blind study of adapalene 0.1%‐benzoyl peroxide 2.5% fixed‐dose combination gel with doxycycline hyclate 100 mg. Cutis; Cutaneous Medicine for the Practitioner2010;85(2):94‐104. [CENTRAL: CN‐00743300; MEDLINE: 20349684] GoldLS , DhuinJC , TanJ , JorizzoJ . Adapalene 0.1%/benzoyl peroxide 2.5% gel with doxycycline hyclate 100 mg tablets compared to vehicle gel with doxycycline hyclate 100 mg tablets in the treatment of severe acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB13. [CENTRAL: CN‐00843733] JarrattM , BuckoAD , ZugajD , DhuinJC . Treatment with adapalene 0.1%‐BPO 2.5% and doxycycline 100 mg/day resulted in rapid and sustained decrease in Propionibacterium acnes (Poster P102). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB1. [CENTRAL: CN‐00843734] NCT00688064 . Adapalene‐BPO gel associated with doxycycline hyclate 100 mg in the treatment of severe acne vulgaris (ACCESS I). www.clinicaltrials.gov/ct2/show/NCT00688064 (first received 28 May 2008). TanJ , GoldLS , SchlessingerJ , BrodellR , JonesT , CruzA , et al. Short‐term combination therapy and long‐term relapse prevention in the treatment of severe acne vulgaris. Journal of Drugs in Dermatology2012;11(2):174‐80. [CENTRAL: CN‐00860272; MEDLINE: 22270198] TanJ , GoldLS , SchlessingerJ , BrodellR , JonesT , DhuinJC , et al. Combination of adapalene‐benzoyl peroxide and oral doxycycline is efficacious in short‐term therapy: maintenance with adapalene‐benzoyl peroxide prevents relapse in treatment of severe acne vulgaris. Pediatric Dermatology2012;29(5):688. TanJ , SchlessingerJ , GoldLS , BrodellR . Combination of adapalene‐benzoyl peroxide and oral doxycycline is efficacious in short‐term therapy: maintenance with adapalene‐benzoyl peroxide prevents relapse in treatment of severe acne vulgaris. Journal of the American Academy of Dermatology2012;66(4):AB15. [DOI: 10.1016/j.jaad.2011.11.072] ">Gold 2010</a>; <a href="./references#CD011154-bbs2-0043" title="AlexisAF , Cook‐BoldenFE , YorkJP . Adapalene/benzoyl peroxide gel 0.3%/2.5%: a safe and effective acne therapy in all skin phototypes. Journal of Drugs in Dermatology2017;16(6):574‐81. [CENTRAL: CN‐01416574; MEDLINE: 28686775] GoldLS , WeissJ , RuedaMJ , LiuH , TanghettiE . Moderate and severe inflammatory acne vulgaris effectively treated with single‐agent therapy by a new fixed‐dose combination adapalene 0.3 %/benzoyl peroxide 2.5 % gel: a randomized, double‐blind, parallel‐group, controlled study. American Journal of Clinical Dermatology2016;17(3):293‐303. [CENTRAL: CN‐01264220; MEDLINE: 26945741] ">Gold 2016</a>; <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>; <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>; <a href="./references#CD011154-bbs2-0114" title="Stein GoldL , WerschlerWP , MohawkJ . Adapalene/benzoyl peroxide gel 0.3%/2.5%: effective acne therapy regardless of age or gender. Journal of Drugs in Dermatology2017;16(6):582‐9. [CENTRAL: CN‐01458199; MEDLINE: 28686776] WeissJ , GoldLS , RuedaMJ , TanghettiE . Adapalene 0.3%/benzoyl peroxide 2.5% gel for the treatment of severe inflammatory acne: a randomized, double‐blind, parallel‐group, controlled study. Pediatric Dermatology2017;34:S103. [CENTRAL: CN‐01399571] WeissJ , GoldLS , TanghettiE , BouvresseS , YaoM , DujolsC , et al. Efficacy and safety of adapalene 0.3%/benzoyl peroxide 2.5% topical gel in moderate and severe acne vulgaris. Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB7. [CENTRAL: CN‐01088984] WeissJ , GoldLS , TanghettiE , DujolsC , RuedaMJ . Efficacy and safety of adapalene 0.3%/benzoyl peroxide 2.5% topical gel in moderate and severe acne vulgaris. Journal of the American Academy of Dermatology2017; Vol. 34:S31. [CENTRAL: CN‐01399572] WeissJ , Stein GoldL , LeoniM , RuedaMj , LiuH , TanghettiE . Customized single‐agent therapy management of severe inflammatory acne: a randomized, double‐blind, parallel‐group controlled study of a new treatment ‐ adapalene 0.3%‐benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2015;14(12):1427‐35. [CENTRAL: CN‐01200535; MEDLINE: 26659936] WeissJ , Stein‐GoldL , TanghettiE , DujolsC , LeoniM , DownsT . Adapalene 0.3%/benzoyl peroxide 2.5% topical gel: efficacy and safety in moderate and severe acne vulgaris. British Journal of Dermatology2015;173:66. [CENTRAL: CN‐01108071] WeissJS , Stein GoldLS , TanghettiEA , LeoniMJ , LiuH , RuedaMJ . Adapalene 0.3%/benzoyl peroxide 2.5% gel for the treatment of severe inflammatory acne: a randomized, double‐blind, parallel‐group, controlled study. 3544. Journal of the American Academy of Dermatology2016;74(5 Suppl 1):AB1. [www.jaad.org/article/S0190‐9622(16)00135‐3/pdf] ">Weiss 2015</a>). </p> <section id="CD011154-sec-0327"> <p><b>Main pooled analyses: BPO/adapalene versus placebo or no treatment</b></p> <p>The risk ratio of withdrawal due to adverse effects was 2.28 (95% CI 1.10 to 4.71; 3801 participants; I² = 3%; <a href="./references#CD011154-fig-0087" title="">Analysis 13.2</a>), pooled from the eight parallel‐group trials with a total of 2199 participants on BPO/adapalene and 1602 on placebo (<a href="./references#CD011154-bbs2-0025" title="DrenoB , KaufmannR , TalaricoS , Torres LozadaV , Rodriguez‐CastellanosMA , Gomez‐FloresM , et al. Combination therapy with adapalene‐benzoyl peroxide and oral lymecycline in the treatment of moderate to severe acne vulgaris: a multicentre, randomized, double‐blind controlled study. British Journal of Dermatology2011;165(2):383‐90. [CENTRAL: CN‐00800637; MEDLINE: 21495995] NCT01014689 . Efficacy and safety comparison of Epiduo gel associated with lymecycline 300 mg capsules versus Epiduo vehicle gel associated with lymecycline 300 mg capsules in the treatment of moderate to severe acne vulgaris (TEAM). clinicaltrials.gov/ct2/show/NCT01014689 (first received 17 November 2009). ">Dreno 2011</a>; <a href="./references#CD011154-bbs2-0035" title="EichenfieldL , HebertAA , LuckyAW , RudisillD , SugarmanJ , GoldLS , et al. Treatment of acne in children aged 9 to 11 with a fixed dose combination of adapalene‐benzoyl peroxide gel. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB19. [CENTRAL: CN‐01028500] EichenfieldLF , DraelosZ , LuckyAW , HebertAA , SugarmanJ , GoldLS , et al. Preadolescent moderate acne vulgaris: a randomized trial of the efficacy and safety of topical adapalene‐benzoyl peroxides. Journal of Drugs in Dermatology2013;12(6):611‐8. [CENTRAL: CN‐00914308; MEDLINE: 23839175] EichenfieldLF , DraelosZ , LuckyAW , HerbertAA , SugarmanJ , GoldS , et al. Treatment of acne in children 9‐11 with a fixed dose combination. Pediatric Dermatology2013;30(5):647. [CENTRAL: CN‐01025039] NCT01138735 . A multi‐center, randomized, vehicle‐controlled, double‐blind study to evaluate the safety and efficacy of Epiduo® (adapalene and benzoyl peroxide) gel 0.1%/2.5% administered once daily for the treatment of subjects 9 to 11 years of age with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT01138735 (first received 4 June 2010). ">Eichenfield 2013</a>; <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>; <a href="./references#CD011154-bbs2-0042" title="BrodellRT , SchlosserBJ , RafalE , TothD , TyringS , WertheimerA , et al. A fixed‐dose combination of adapalene 0.1%/BPO 2.5% allows an early and sustained improvement in quality of life and patient treatment satisfaction in severe acne. Journal of Dermatological Treatment2012;23(1):26‐34. [CENTRAL: CN‐00860557; MEDLINE: 22103674] BrodellRT , WertheimerA , TothD , BucherD , RafalE , KerroucheN , et al. Patient satisfaction with a fixed dose combination of adapalene‐benzoyl peroxide gel as part of a regimen and used alone as maintenance therapy. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB17. [CENTRAL: CN‐01028502] BrodellRT , WertheimerA , TothD , BucherD , RafalE , KerroucheN , et al. Treatment with adapalene‐benzoyl peroxide improves quality of life in patients with severe acne vulgaris. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB19. [CENTRAL: CN‐01028499] GoldLS , CruzA , EichenfieldL , TanJ , JorizzoJ , KerroucheN , et al. Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle‐controlled, double‐blind study of adapalene 0.1%‐benzoyl peroxide 2.5% fixed‐dose combination gel with doxycycline hyclate 100 mg. Cutis; Cutaneous Medicine for the Practitioner2010;85(2):94‐104. [CENTRAL: CN‐00743300; MEDLINE: 20349684] GoldLS , DhuinJC , TanJ , JorizzoJ . Adapalene 0.1%/benzoyl peroxide 2.5% gel with doxycycline hyclate 100 mg tablets compared to vehicle gel with doxycycline hyclate 100 mg tablets in the treatment of severe acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB13. [CENTRAL: CN‐00843733] JarrattM , BuckoAD , ZugajD , DhuinJC . Treatment with adapalene 0.1%‐BPO 2.5% and doxycycline 100 mg/day resulted in rapid and sustained decrease in Propionibacterium acnes (Poster P102). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB1. [CENTRAL: CN‐00843734] NCT00688064 . Adapalene‐BPO gel associated with doxycycline hyclate 100 mg in the treatment of severe acne vulgaris (ACCESS I). www.clinicaltrials.gov/ct2/show/NCT00688064 (first received 28 May 2008). TanJ , GoldLS , SchlessingerJ , BrodellR , JonesT , CruzA , et al. Short‐term combination therapy and long‐term relapse prevention in the treatment of severe acne vulgaris. Journal of Drugs in Dermatology2012;11(2):174‐80. [CENTRAL: CN‐00860272; MEDLINE: 22270198] TanJ , GoldLS , SchlessingerJ , BrodellR , JonesT , DhuinJC , et al. Combination of adapalene‐benzoyl peroxide and oral doxycycline is efficacious in short‐term therapy: maintenance with adapalene‐benzoyl peroxide prevents relapse in treatment of severe acne vulgaris. Pediatric Dermatology2012;29(5):688. TanJ , SchlessingerJ , GoldLS , BrodellR . Combination of adapalene‐benzoyl peroxide and oral doxycycline is efficacious in short‐term therapy: maintenance with adapalene‐benzoyl peroxide prevents relapse in treatment of severe acne vulgaris. Journal of the American Academy of Dermatology2012;66(4):AB15. [DOI: 10.1016/j.jaad.2011.11.072] ">Gold 2010</a>; <a href="./references#CD011154-bbs2-0043" title="AlexisAF , Cook‐BoldenFE , YorkJP . Adapalene/benzoyl peroxide gel 0.3%/2.5%: a safe and effective acne therapy in all skin phototypes. Journal of Drugs in Dermatology2017;16(6):574‐81. [CENTRAL: CN‐01416574; MEDLINE: 28686775] GoldLS , WeissJ , RuedaMJ , LiuH , TanghettiE . Moderate and severe inflammatory acne vulgaris effectively treated with single‐agent therapy by a new fixed‐dose combination adapalene 0.3 %/benzoyl peroxide 2.5 % gel: a randomized, double‐blind, parallel‐group, controlled study. American Journal of Clinical Dermatology2016;17(3):293‐303. [CENTRAL: CN‐01264220; MEDLINE: 26945741] ">Gold 2016</a>; <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>; <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>; <a href="./references#CD011154-bbs2-0114" title="Stein GoldL , WerschlerWP , MohawkJ . Adapalene/benzoyl peroxide gel 0.3%/2.5%: effective acne therapy regardless of age or gender. Journal of Drugs in Dermatology2017;16(6):582‐9. [CENTRAL: CN‐01458199; MEDLINE: 28686776] WeissJ , GoldLS , RuedaMJ , TanghettiE . Adapalene 0.3%/benzoyl peroxide 2.5% gel for the treatment of severe inflammatory acne: a randomized, double‐blind, parallel‐group, controlled study. Pediatric Dermatology2017;34:S103. [CENTRAL: CN‐01399571] WeissJ , GoldLS , TanghettiE , BouvresseS , YaoM , DujolsC , et al. Efficacy and safety of adapalene 0.3%/benzoyl peroxide 2.5% topical gel in moderate and severe acne vulgaris. Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB7. [CENTRAL: CN‐01088984] WeissJ , GoldLS , TanghettiE , DujolsC , RuedaMJ . Efficacy and safety of adapalene 0.3%/benzoyl peroxide 2.5% topical gel in moderate and severe acne vulgaris. Journal of the American Academy of Dermatology2017; Vol. 34:S31. [CENTRAL: CN‐01399572] WeissJ , Stein GoldL , LeoniM , RuedaMj , LiuH , TanghettiE . Customized single‐agent therapy management of severe inflammatory acne: a randomized, double‐blind, parallel‐group controlled study of a new treatment ‐ adapalene 0.3%‐benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2015;14(12):1427‐35. [CENTRAL: CN‐01200535; MEDLINE: 26659936] WeissJ , Stein‐GoldL , TanghettiE , DujolsC , LeoniM , DownsT . Adapalene 0.3%/benzoyl peroxide 2.5% topical gel: efficacy and safety in moderate and severe acne vulgaris. British Journal of Dermatology2015;173:66. [CENTRAL: CN‐01108071] WeissJS , Stein GoldLS , TanghettiEA , LeoniMJ , LiuH , RuedaMJ . Adapalene 0.3%/benzoyl peroxide 2.5% gel for the treatment of severe inflammatory acne: a randomized, double‐blind, parallel‐group, controlled study. 3544. Journal of the American Academy of Dermatology2016;74(5 Suppl 1):AB1. [www.jaad.org/article/S0190‐9622(16)00135‐3/pdf] ">Weiss 2015</a>), suggesting higher risk of discontinuation in the BPO/adapalene group. The adverse events reported leading to withdrawal included erythema, irritation, and atopic dermatitis flare. </p> </section> <section id="CD011154-sec-0328"> <p><b>Subgroup analyses: co‐intervention</b></p> <p>No evidence suggests that the association may differ by co‐intervention (P value for subgroup differences = 0.12) (<a href="./references#CD011154-fig-0087" title="">Analysis 13.2</a>). </p> </section> <section id="CD011154-sec-0329"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Two split‐face design trials reported that one of 38 participants discontinued BPO/adapalene because of moderate skin irritation (<a href="./references#CD011154-bbs2-0026" title="DrenoB , TanJ , RivierM , MartelP , BissonnetteR . Adapalene 0.1%/benzoyl peroxide 2.5% gel reduces the risk of atrophic scar formation in moderate inflammatory acne: a split‐face randomized controlled trial. Journal of the European Academy of Dermatology and Venereology2017;31(4):737‐42. [CENTRAL: CN‐01424729; MEDLINE: 27790756] ">Dreno 2016</a>), and that two of 67 participants had treatment‐related adverse events on the BPO/adapalene side (one with moderate pain of skin and one with mild skin irritation) that led to study discontinuation (<a href="./references#CD011154-bbs2-0027" title="DrénoB , BissonnetteR , Gagné‐HenleyA , BarankinB , LyndeC , KerroucheN , et al. Prevention and reduction of atrophic acne scars with adapalene 0.3%/benzoyl peroxide 2.5% gel in subjects with moderate or severe facial acne: results of a 6‐month randomized, vehicle‐controlled trial using intra‐individual comparison. American Journal of Clinical Dermatology2018;19(2):275‐86. [CENTRAL: CN‐01572577] NCT02735421 . Adapalene 0.3% ‐ Benzoyl Peroxide 2.5% Gel and Risk of Formation of Atrophic Acne Scars (OSCAR). clinicaltrials.gov/ct2/show/NCT02735421 (first received 7 April 2016). ">Dréno 2018</a>), respectively. </p> </section> </section> <section id="CD011154-sec-0330"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <p>Six trials reported the percentage reduction in lesion counts, none of which provided sufficient data to estimate effect size (<a href="./references#CD011154-bbs2-0027" title="DrénoB , BissonnetteR , Gagné‐HenleyA , BarankinB , LyndeC , KerroucheN , et al. Prevention and reduction of atrophic acne scars with adapalene 0.3%/benzoyl peroxide 2.5% gel in subjects with moderate or severe facial acne: results of a 6‐month randomized, vehicle‐controlled trial using intra‐individual comparison. American Journal of Clinical Dermatology2018;19(2):275‐86. [CENTRAL: CN‐01572577] NCT02735421 . Adapalene 0.3% ‐ Benzoyl Peroxide 2.5% Gel and Risk of Formation of Atrophic Acne Scars (OSCAR). clinicaltrials.gov/ct2/show/NCT02735421 (first received 7 April 2016). ">Dréno 2018</a>; <a href="./references#CD011154-bbs2-0035" title="EichenfieldL , HebertAA , LuckyAW , RudisillD , SugarmanJ , GoldLS , et al. Treatment of acne in children aged 9 to 11 with a fixed dose combination of adapalene‐benzoyl peroxide gel. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB19. [CENTRAL: CN‐01028500] EichenfieldLF , DraelosZ , LuckyAW , HebertAA , SugarmanJ , GoldLS , et al. Preadolescent moderate acne vulgaris: a randomized trial of the efficacy and safety of topical adapalene‐benzoyl peroxides. Journal of Drugs in Dermatology2013;12(6):611‐8. [CENTRAL: CN‐00914308; MEDLINE: 23839175] EichenfieldLF , DraelosZ , LuckyAW , HerbertAA , SugarmanJ , GoldS , et al. Treatment of acne in children 9‐11 with a fixed dose combination. Pediatric Dermatology2013;30(5):647. [CENTRAL: CN‐01025039] NCT01138735 . A multi‐center, randomized, vehicle‐controlled, double‐blind study to evaluate the safety and efficacy of Epiduo® (adapalene and benzoyl peroxide) gel 0.1%/2.5% administered once daily for the treatment of subjects 9 to 11 years of age with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT01138735 (first received 4 June 2010). ">Eichenfield 2013</a>; <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>; <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>; <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>; <a href="./references#CD011154-bbs2-0114" title="Stein GoldL , WerschlerWP , MohawkJ . Adapalene/benzoyl peroxide gel 0.3%/2.5%: effective acne therapy regardless of age or gender. Journal of Drugs in Dermatology2017;16(6):582‐9. [CENTRAL: CN‐01458199; MEDLINE: 28686776] WeissJ , GoldLS , RuedaMJ , TanghettiE . Adapalene 0.3%/benzoyl peroxide 2.5% gel for the treatment of severe inflammatory acne: a randomized, double‐blind, parallel‐group, controlled study. Pediatric Dermatology2017;34:S103. [CENTRAL: CN‐01399571] WeissJ , GoldLS , TanghettiE , BouvresseS , YaoM , DujolsC , et al. Efficacy and safety of adapalene 0.3%/benzoyl peroxide 2.5% topical gel in moderate and severe acne vulgaris. Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB7. [CENTRAL: CN‐01088984] WeissJ , GoldLS , TanghettiE , DujolsC , RuedaMJ . Efficacy and safety of adapalene 0.3%/benzoyl peroxide 2.5% topical gel in moderate and severe acne vulgaris. Journal of the American Academy of Dermatology2017; Vol. 34:S31. [CENTRAL: CN‐01399572] WeissJ , Stein GoldL , LeoniM , RuedaMj , LiuH , TanghettiE . Customized single‐agent therapy management of severe inflammatory acne: a randomized, double‐blind, parallel‐group controlled study of a new treatment ‐ adapalene 0.3%‐benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2015;14(12):1427‐35. [CENTRAL: CN‐01200535; MEDLINE: 26659936] WeissJ , Stein‐GoldL , TanghettiE , DujolsC , LeoniM , DownsT . Adapalene 0.3%/benzoyl peroxide 2.5% topical gel: efficacy and safety in moderate and severe acne vulgaris. British Journal of Dermatology2015;173:66. [CENTRAL: CN‐01108071] WeissJS , Stein GoldLS , TanghettiEA , LeoniMJ , LiuH , RuedaMJ . Adapalene 0.3%/benzoyl peroxide 2.5% gel for the treatment of severe inflammatory acne: a randomized, double‐blind, parallel‐group, controlled study. 3544. Journal of the American Academy of Dermatology2016;74(5 Suppl 1):AB1. [www.jaad.org/article/S0190‐9622(16)00135‐3/pdf] ">Weiss 2015</a>). The results of these trials were consistently significant across studies. </p> <section id="CD011154-sec-0331"> <p><b>Studies not included in the meta‐analysis</b></p> <p>In the split‐face trial (<a href="./references#CD011154-bbs2-0027" title="DrénoB , BissonnetteR , Gagné‐HenleyA , BarankinB , LyndeC , KerroucheN , et al. Prevention and reduction of atrophic acne scars with adapalene 0.3%/benzoyl peroxide 2.5% gel in subjects with moderate or severe facial acne: results of a 6‐month randomized, vehicle‐controlled trial using intra‐individual comparison. American Journal of Clinical Dermatology2018;19(2):275‐86. [CENTRAL: CN‐01572577] NCT02735421 . Adapalene 0.3% ‐ Benzoyl Peroxide 2.5% Gel and Risk of Formation of Atrophic Acne Scars (OSCAR). clinicaltrials.gov/ct2/show/NCT02735421 (first received 7 April 2016). ">Dréno 2018</a>), the percentage reduction in acne lesion counts at week 24 was greater for the BPO/adapalene side than for the placebo side, with differences of 22.4% (73.3 versus 50.9%), 28.8% (86.7 versus 57.9%), and 18.1% (59.5 versus 41.4%) for total, inflammatory, and non‐inflammatory lesions, respectively. </p> <p><a href="./references#CD011154-bbs2-0035" title="EichenfieldL , HebertAA , LuckyAW , RudisillD , SugarmanJ , GoldLS , et al. Treatment of acne in children aged 9 to 11 with a fixed dose combination of adapalene‐benzoyl peroxide gel. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB19. [CENTRAL: CN‐01028500] EichenfieldLF , DraelosZ , LuckyAW , HebertAA , SugarmanJ , GoldLS , et al. Preadolescent moderate acne vulgaris: a randomized trial of the efficacy and safety of topical adapalene‐benzoyl peroxides. Journal of Drugs in Dermatology2013;12(6):611‐8. [CENTRAL: CN‐00914308; MEDLINE: 23839175] EichenfieldLF , DraelosZ , LuckyAW , HerbertAA , SugarmanJ , GoldS , et al. Treatment of acne in children 9‐11 with a fixed dose combination. Pediatric Dermatology2013;30(5):647. [CENTRAL: CN‐01025039] NCT01138735 . A multi‐center, randomized, vehicle‐controlled, double‐blind study to evaluate the safety and efficacy of Epiduo® (adapalene and benzoyl peroxide) gel 0.1%/2.5% administered once daily for the treatment of subjects 9 to 11 years of age with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT01138735 (first received 4 June 2010). ">Eichenfield 2013</a> found a significant difference in percentage reduction in TLs (68.6% versus 19.3%), ILs (63.2% versus 14.3%), and NILs (70.7% versus 14.6%) (all P values &lt; 0.001). </p> <p>Similar results were found in <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>, showing a significant difference in percentage reduction in TLs (60.7% versus 31.7%), ILs (66.0% versus 36.9%), and NILs (58.9% versus 32.9%) between groups (all P values &lt; 0.05). </p> <p>In <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>, compared with placebo groups, the percentage reductions in TLs, ILs, and NILs were significantly higher in the BPO/adapalene group (68.8% versus 41.1%, 72.4% versus 49.8%, and 66.4% versus 41.9%, respectively) (all P values &lt; 0.05). </p> <p><a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a> found 51.0% and 31% reduction in TLs, 62.9% and 37.8% in ILs, and 51.2% and 37.5% in NILs for BPO/adapalene and adapalene, respectively (all P values &lt; 0.001). </p> <p>In <a href="./references#CD011154-bbs2-0114" title="Stein GoldL , WerschlerWP , MohawkJ . Adapalene/benzoyl peroxide gel 0.3%/2.5%: effective acne therapy regardless of age or gender. Journal of Drugs in Dermatology2017;16(6):582‐9. [CENTRAL: CN‐01458199; MEDLINE: 28686776] WeissJ , GoldLS , RuedaMJ , TanghettiE . Adapalene 0.3%/benzoyl peroxide 2.5% gel for the treatment of severe inflammatory acne: a randomized, double‐blind, parallel‐group, controlled study. Pediatric Dermatology2017;34:S103. [CENTRAL: CN‐01399571] WeissJ , GoldLS , TanghettiE , BouvresseS , YaoM , DujolsC , et al. Efficacy and safety of adapalene 0.3%/benzoyl peroxide 2.5% topical gel in moderate and severe acne vulgaris. Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB7. [CENTRAL: CN‐01088984] WeissJ , GoldLS , TanghettiE , DujolsC , RuedaMJ . Efficacy and safety of adapalene 0.3%/benzoyl peroxide 2.5% topical gel in moderate and severe acne vulgaris. Journal of the American Academy of Dermatology2017; Vol. 34:S31. [CENTRAL: CN‐01399572] WeissJ , Stein GoldL , LeoniM , RuedaMj , LiuH , TanghettiE . Customized single‐agent therapy management of severe inflammatory acne: a randomized, double‐blind, parallel‐group controlled study of a new treatment ‐ adapalene 0.3%‐benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2015;14(12):1427‐35. [CENTRAL: CN‐01200535; MEDLINE: 26659936] WeissJ , Stein‐GoldL , TanghettiE , DujolsC , LeoniM , DownsT . Adapalene 0.3%/benzoyl peroxide 2.5% topical gel: efficacy and safety in moderate and severe acne vulgaris. British Journal of Dermatology2015;173:66. [CENTRAL: CN‐01108071] WeissJS , Stein GoldLS , TanghettiEA , LeoniMJ , LiuH , RuedaMJ . Adapalene 0.3%/benzoyl peroxide 2.5% gel for the treatment of severe inflammatory acne: a randomized, double‐blind, parallel‐group, controlled study. 3544. Journal of the American Academy of Dermatology2016;74(5 Suppl 1):AB1. [www.jaad.org/article/S0190‐9622(16)00135‐3/pdf] ">Weiss 2015</a>, which compared BPO/adapalene gel with placebo among participants with moderate and severe acne (217 versus 69 participants), the absolute changes in ILs for each group were ‐27.0 and ‐14.4, respectively. The absolute changes in NILs were ‐40.1 and ‐18.4, respectively. This trial also reported percentage changes in ILs (‐68.7% vs. ‐39.2%) and NILs (‐68.3% vs. ‐37.3%, respectively). Trial authors claimed the P values for all changes to be less than 0.001. </p> <p>As reported in <a href="./references#CD011154-bbs2-0025" title="DrenoB , KaufmannR , TalaricoS , Torres LozadaV , Rodriguez‐CastellanosMA , Gomez‐FloresM , et al. Combination therapy with adapalene‐benzoyl peroxide and oral lymecycline in the treatment of moderate to severe acne vulgaris: a multicentre, randomized, double‐blind controlled study. British Journal of Dermatology2011;165(2):383‐90. [CENTRAL: CN‐00800637; MEDLINE: 21495995] NCT01014689 . Efficacy and safety comparison of Epiduo gel associated with lymecycline 300 mg capsules versus Epiduo vehicle gel associated with lymecycline 300 mg capsules in the treatment of moderate to severe acne vulgaris (TEAM). clinicaltrials.gov/ct2/show/NCT01014689 (first received 17 November 2009). ">Dreno 2011</a>, a significant difference was found in the percentage reduction in TLs (74.1% versus 56.8%; P &lt; 0.001), ILs (81.7% versus 71.0%; P &lt; 0.001), and NILs (71.7% versus 52.5%; P &lt; 0.001) between the BPO/adapalene group and the placebo group. </p> </section> </section> <section id="CD011154-sec-0332"> <h6 class="title">Secondary outcome: percentage of participants rated 'clear' or 'almost clear' on the IGA scale of acne severity </h6> <section id="CD011154-sec-0333"> <p><b>Main pooled analyses: BPO/adapalene versus placebo or no treatment</b></p> <p>Pooled results for the long‐term outcome support the use of BPO/adapalene (RR 2.43, 95% CI 1.80 to 3.28; 3012 participants; 6 studies; I² = 77%; <a href="./references#CD011154-fig-0088" title="">Analysis 13.3</a>). Three studies focusing on BPO/adapalene used alone reported medium‐ and short‐term outcomes, with an RR of 2.56 (95% CI 1.88 to 3.47; 2175 participants; I² = 31%; <a href="./references#CD011154-fig-0089" title="">Analysis 13.4</a>) and an RR of 2.76 (95% CI 1.84 to 4.16; 2175 participants; I² = 0%; <a href="./references#CD011154-fig-0090" title="">Analysis 13.5</a>), respectively. </p> </section> <section id="CD011154-sec-0334"> <p><b>Subgroup analyses: co‐intervention</b></p> <p>For the long‐term outcome, effects of BPO differed by the co‐intervention (P value for subgroup differences &lt; 0.0001; <a href="./references#CD011154-fig-0088" title="">Analysis 13.3</a>). For BPO/adapalene used alone, the pooled risk ratio for the long‐term outcome was 2.45 (95% CI 2.07 to 2.90; I² = 1%) (<a href="./references#CD011154-bbs2-0035" title="EichenfieldL , HebertAA , LuckyAW , RudisillD , SugarmanJ , GoldLS , et al. Treatment of acne in children aged 9 to 11 with a fixed dose combination of adapalene‐benzoyl peroxide gel. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB19. [CENTRAL: CN‐01028500] EichenfieldLF , DraelosZ , LuckyAW , HebertAA , SugarmanJ , GoldLS , et al. Preadolescent moderate acne vulgaris: a randomized trial of the efficacy and safety of topical adapalene‐benzoyl peroxides. Journal of Drugs in Dermatology2013;12(6):611‐8. [CENTRAL: CN‐00914308; MEDLINE: 23839175] EichenfieldLF , DraelosZ , LuckyAW , HerbertAA , SugarmanJ , GoldS , et al. Treatment of acne in children 9‐11 with a fixed dose combination. Pediatric Dermatology2013;30(5):647. [CENTRAL: CN‐01025039] NCT01138735 . A multi‐center, randomized, vehicle‐controlled, double‐blind study to evaluate the safety and efficacy of Epiduo® (adapalene and benzoyl peroxide) gel 0.1%/2.5% administered once daily for the treatment of subjects 9 to 11 years of age with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT01138735 (first received 4 June 2010). ">Eichenfield 2013</a>; <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>; <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>; <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>). A significant difference was found for this outcome (74/232 versus 19/227) favouring BPO/adapalene plus doxycycline treatment (RR 3.81, 95% CI 2.38 to 6.10) in <a href="./references#CD011154-bbs2-0042" title="BrodellRT , SchlosserBJ , RafalE , TothD , TyringS , WertheimerA , et al. A fixed‐dose combination of adapalene 0.1%/BPO 2.5% allows an early and sustained improvement in quality of life and patient treatment satisfaction in severe acne. Journal of Dermatological Treatment2012;23(1):26‐34. [CENTRAL: CN‐00860557; MEDLINE: 22103674] BrodellRT , WertheimerA , TothD , BucherD , RafalE , KerroucheN , et al. Patient satisfaction with a fixed dose combination of adapalene‐benzoyl peroxide gel as part of a regimen and used alone as maintenance therapy. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB17. [CENTRAL: CN‐01028502] BrodellRT , WertheimerA , TothD , BucherD , RafalE , KerroucheN , et al. Treatment with adapalene‐benzoyl peroxide improves quality of life in patients with severe acne vulgaris. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB19. [CENTRAL: CN‐01028499] GoldLS , CruzA , EichenfieldL , TanJ , JorizzoJ , KerroucheN , et al. Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle‐controlled, double‐blind study of adapalene 0.1%‐benzoyl peroxide 2.5% fixed‐dose combination gel with doxycycline hyclate 100 mg. Cutis; Cutaneous Medicine for the Practitioner2010;85(2):94‐104. [CENTRAL: CN‐00743300; MEDLINE: 20349684] GoldLS , DhuinJC , TanJ , JorizzoJ . Adapalene 0.1%/benzoyl peroxide 2.5% gel with doxycycline hyclate 100 mg tablets compared to vehicle gel with doxycycline hyclate 100 mg tablets in the treatment of severe acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB13. [CENTRAL: CN‐00843733] JarrattM , BuckoAD , ZugajD , DhuinJC . Treatment with adapalene 0.1%‐BPO 2.5% and doxycycline 100 mg/day resulted in rapid and sustained decrease in Propionibacterium acnes (Poster P102). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB1. [CENTRAL: CN‐00843734] NCT00688064 . Adapalene‐BPO gel associated with doxycycline hyclate 100 mg in the treatment of severe acne vulgaris (ACCESS I). www.clinicaltrials.gov/ct2/show/NCT00688064 (first received 28 May 2008). TanJ , GoldLS , SchlessingerJ , BrodellR , JonesT , CruzA , et al. Short‐term combination therapy and long‐term relapse prevention in the treatment of severe acne vulgaris. Journal of Drugs in Dermatology2012;11(2):174‐80. [CENTRAL: CN‐00860272; MEDLINE: 22270198] TanJ , GoldLS , SchlessingerJ , BrodellR , JonesT , DhuinJC , et al. Combination of adapalene‐benzoyl peroxide and oral doxycycline is efficacious in short‐term therapy: maintenance with adapalene‐benzoyl peroxide prevents relapse in treatment of severe acne vulgaris. Pediatric Dermatology2012;29(5):688. TanJ , SchlessingerJ , GoldLS , BrodellR . Combination of adapalene‐benzoyl peroxide and oral doxycycline is efficacious in short‐term therapy: maintenance with adapalene‐benzoyl peroxide prevents relapse in treatment of severe acne vulgaris. Journal of the American Academy of Dermatology2012;66(4):AB15. [DOI: 10.1016/j.jaad.2011.11.072] ">Gold 2010</a>. <a href="./references#CD011154-bbs2-0025" title="DrenoB , KaufmannR , TalaricoS , Torres LozadaV , Rodriguez‐CastellanosMA , Gomez‐FloresM , et al. Combination therapy with adapalene‐benzoyl peroxide and oral lymecycline in the treatment of moderate to severe acne vulgaris: a multicentre, randomized, double‐blind controlled study. British Journal of Dermatology2011;165(2):383‐90. [CENTRAL: CN‐00800637; MEDLINE: 21495995] NCT01014689 . Efficacy and safety comparison of Epiduo gel associated with lymecycline 300 mg capsules versus Epiduo vehicle gel associated with lymecycline 300 mg capsules in the treatment of moderate to severe acne vulgaris (TEAM). clinicaltrials.gov/ct2/show/NCT01014689 (first received 17 November 2009). ">Dreno 2011</a> showed a significant difference in this outcome (91/191 versus 63/187), with an RR of 1.41 (95% CI 1.10 to 1.82). </p> </section> <section id="CD011154-sec-0335"> <p><b>Studies not included in the meta‐analysis</b></p> <p>In a split‐face trial (<a href="./references#CD011154-bbs2-0027" title="DrénoB , BissonnetteR , Gagné‐HenleyA , BarankinB , LyndeC , KerroucheN , et al. Prevention and reduction of atrophic acne scars with adapalene 0.3%/benzoyl peroxide 2.5% gel in subjects with moderate or severe facial acne: results of a 6‐month randomized, vehicle‐controlled trial using intra‐individual comparison. American Journal of Clinical Dermatology2018;19(2):275‐86. [CENTRAL: CN‐01572577] NCT02735421 . Adapalene 0.3% ‐ Benzoyl Peroxide 2.5% Gel and Risk of Formation of Atrophic Acne Scars (OSCAR). clinicaltrials.gov/ct2/show/NCT02735421 (first received 7 April 2016). ">Dréno 2018</a>), 'clear' or 'almost clear' was 45% more likely to occur with BPO/adapalene than with placebo (64.2 versus 19.4%). </p> </section> </section> <section id="CD011154-sec-0336"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0337"> <p><b>Main pooled analyses: BPO/adapalene versus placebo or no treatment</b></p> <p>Overall, BPO/adapalene tended to increase the long‐term risk of adverse events (RR 2.67, 95% CI 1.15 to 6.19; 2465 participants; 6 studies; I² = 86%; <a href="./references#CD011154-fig-0091" title="">Analysis 13.6</a>). The most common adverse events reported in these trials included burning sensation, skin irritation, dryness, and headache. </p> </section> <section id="CD011154-sec-0338"> <p><b>Subgroup analyses: co‐intervention</b></p> <p>Substantial heterogeneity may be due to the co‐interventions (test for subgroup differences: P = 0.0002; <a href="./references#CD011154-fig-0091" title="">Analysis 13.6</a>). For BPO/adapalene used alone, adverse events were assessed in all five trials, four of which presented sufficient data for pooling, including 927 participants in the BPO/adapalene group and 701 in the placebo group (<a href="./references#CD011154-bbs2-0035" title="EichenfieldL , HebertAA , LuckyAW , RudisillD , SugarmanJ , GoldLS , et al. Treatment of acne in children aged 9 to 11 with a fixed dose combination of adapalene‐benzoyl peroxide gel. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB19. [CENTRAL: CN‐01028500] EichenfieldLF , DraelosZ , LuckyAW , HebertAA , SugarmanJ , GoldLS , et al. Preadolescent moderate acne vulgaris: a randomized trial of the efficacy and safety of topical adapalene‐benzoyl peroxides. Journal of Drugs in Dermatology2013;12(6):611‐8. [CENTRAL: CN‐00914308; MEDLINE: 23839175] EichenfieldLF , DraelosZ , LuckyAW , HerbertAA , SugarmanJ , GoldS , et al. Treatment of acne in children 9‐11 with a fixed dose combination. Pediatric Dermatology2013;30(5):647. [CENTRAL: CN‐01025039] NCT01138735 . A multi‐center, randomized, vehicle‐controlled, double‐blind study to evaluate the safety and efficacy of Epiduo® (adapalene and benzoyl peroxide) gel 0.1%/2.5% administered once daily for the treatment of subjects 9 to 11 years of age with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT01138735 (first received 4 June 2010). ">Eichenfield 2013</a>; <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>; <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>; <a href="./references#CD011154-bbs2-0114" title="Stein GoldL , WerschlerWP , MohawkJ . Adapalene/benzoyl peroxide gel 0.3%/2.5%: effective acne therapy regardless of age or gender. Journal of Drugs in Dermatology2017;16(6):582‐9. [CENTRAL: CN‐01458199; MEDLINE: 28686776] WeissJ , GoldLS , RuedaMJ , TanghettiE . Adapalene 0.3%/benzoyl peroxide 2.5% gel for the treatment of severe inflammatory acne: a randomized, double‐blind, parallel‐group, controlled study. Pediatric Dermatology2017;34:S103. [CENTRAL: CN‐01399571] WeissJ , GoldLS , TanghettiE , BouvresseS , YaoM , DujolsC , et al. Efficacy and safety of adapalene 0.3%/benzoyl peroxide 2.5% topical gel in moderate and severe acne vulgaris. Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB7. [CENTRAL: CN‐01088984] WeissJ , GoldLS , TanghettiE , DujolsC , RuedaMJ . Efficacy and safety of adapalene 0.3%/benzoyl peroxide 2.5% topical gel in moderate and severe acne vulgaris. Journal of the American Academy of Dermatology2017; Vol. 34:S31. [CENTRAL: CN‐01399572] WeissJ , Stein GoldL , LeoniM , RuedaMj , LiuH , TanghettiE . Customized single‐agent therapy management of severe inflammatory acne: a randomized, double‐blind, parallel‐group controlled study of a new treatment ‐ adapalene 0.3%‐benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2015;14(12):1427‐35. [CENTRAL: CN‐01200535; MEDLINE: 26659936] WeissJ , Stein‐GoldL , TanghettiE , DujolsC , LeoniM , DownsT . Adapalene 0.3%/benzoyl peroxide 2.5% topical gel: efficacy and safety in moderate and severe acne vulgaris. British Journal of Dermatology2015;173:66. [CENTRAL: CN‐01108071] WeissJS , Stein GoldLS , TanghettiEA , LeoniMJ , LiuH , RuedaMJ . Adapalene 0.3%/benzoyl peroxide 2.5% gel for the treatment of severe inflammatory acne: a randomized, double‐blind, parallel‐group, controlled study. 3544. Journal of the American Academy of Dermatology2016;74(5 Suppl 1):AB1. [www.jaad.org/article/S0190‐9622(16)00135‐3/pdf] ">Weiss 2015</a>). The pooled RR was 4.71 (95% CI 2.36 to 9.37; I² = 36%; <a href="./references#CD011154-fig-0091" title="">Analysis 13.6</a>), suggesting the risk of adverse events was significantly higher in the BPO/adapalene treatment group. As for BPO/adapalene add‐on treatment, however, we did not find increased risk (<a href="./references#CD011154-bbs2-0025" title="DrenoB , KaufmannR , TalaricoS , Torres LozadaV , Rodriguez‐CastellanosMA , Gomez‐FloresM , et al. Combination therapy with adapalene‐benzoyl peroxide and oral lymecycline in the treatment of moderate to severe acne vulgaris: a multicentre, randomized, double‐blind controlled study. British Journal of Dermatology2011;165(2):383‐90. [CENTRAL: CN‐00800637; MEDLINE: 21495995] NCT01014689 . Efficacy and safety comparison of Epiduo gel associated with lymecycline 300 mg capsules versus Epiduo vehicle gel associated with lymecycline 300 mg capsules in the treatment of moderate to severe acne vulgaris (TEAM). clinicaltrials.gov/ct2/show/NCT01014689 (first received 17 November 2009). ">Dreno 2011</a>; <a href="./references#CD011154-bbs2-0042" title="BrodellRT , SchlosserBJ , RafalE , TothD , TyringS , WertheimerA , et al. A fixed‐dose combination of adapalene 0.1%/BPO 2.5% allows an early and sustained improvement in quality of life and patient treatment satisfaction in severe acne. Journal of Dermatological Treatment2012;23(1):26‐34. [CENTRAL: CN‐00860557; MEDLINE: 22103674] BrodellRT , WertheimerA , TothD , BucherD , RafalE , KerroucheN , et al. Patient satisfaction with a fixed dose combination of adapalene‐benzoyl peroxide gel as part of a regimen and used alone as maintenance therapy. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB17. [CENTRAL: CN‐01028502] BrodellRT , WertheimerA , TothD , BucherD , RafalE , KerroucheN , et al. Treatment with adapalene‐benzoyl peroxide improves quality of life in patients with severe acne vulgaris. Journal of the American Academy of Dermatology2013;68(4 Suppl 1):AB19. [CENTRAL: CN‐01028499] GoldLS , CruzA , EichenfieldL , TanJ , JorizzoJ , KerroucheN , et al. Effective and safe combination therapy for severe acne vulgaris: a randomized, vehicle‐controlled, double‐blind study of adapalene 0.1%‐benzoyl peroxide 2.5% fixed‐dose combination gel with doxycycline hyclate 100 mg. Cutis; Cutaneous Medicine for the Practitioner2010;85(2):94‐104. [CENTRAL: CN‐00743300; MEDLINE: 20349684] GoldLS , DhuinJC , TanJ , JorizzoJ . Adapalene 0.1%/benzoyl peroxide 2.5% gel with doxycycline hyclate 100 mg tablets compared to vehicle gel with doxycycline hyclate 100 mg tablets in the treatment of severe acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB13. [CENTRAL: CN‐00843733] JarrattM , BuckoAD , ZugajD , DhuinJC . Treatment with adapalene 0.1%‐BPO 2.5% and doxycycline 100 mg/day resulted in rapid and sustained decrease in Propionibacterium acnes (Poster P102). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB1. [CENTRAL: CN‐00843734] NCT00688064 . Adapalene‐BPO gel associated with doxycycline hyclate 100 mg in the treatment of severe acne vulgaris (ACCESS I). www.clinicaltrials.gov/ct2/show/NCT00688064 (first received 28 May 2008). TanJ , GoldLS , SchlessingerJ , BrodellR , JonesT , CruzA , et al. Short‐term combination therapy and long‐term relapse prevention in the treatment of severe acne vulgaris. Journal of Drugs in Dermatology2012;11(2):174‐80. [CENTRAL: CN‐00860272; MEDLINE: 22270198] TanJ , GoldLS , SchlessingerJ , BrodellR , JonesT , DhuinJC , et al. Combination of adapalene‐benzoyl peroxide and oral doxycycline is efficacious in short‐term therapy: maintenance with adapalene‐benzoyl peroxide prevents relapse in treatment of severe acne vulgaris. Pediatric Dermatology2012;29(5):688. TanJ , SchlessingerJ , GoldLS , BrodellR . Combination of adapalene‐benzoyl peroxide and oral doxycycline is efficacious in short‐term therapy: maintenance with adapalene‐benzoyl peroxide prevents relapse in treatment of severe acne vulgaris. Journal of the American Academy of Dermatology2012;66(4):AB15. [DOI: 10.1016/j.jaad.2011.11.072] ">Gold 2010</a>). </p> </section> <section id="CD011154-sec-0339"> <p><b><i>Studies not included in the meta‐analysis</i> </b></p> <p><a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a> did not present the number of participants experiencing at least one adverse event but reported that the number was similar across study treatments. <a href="./references#CD011154-bbs2-0027" title="DrénoB , BissonnetteR , Gagné‐HenleyA , BarankinB , LyndeC , KerroucheN , et al. Prevention and reduction of atrophic acne scars with adapalene 0.3%/benzoyl peroxide 2.5% gel in subjects with moderate or severe facial acne: results of a 6‐month randomized, vehicle‐controlled trial using intra‐individual comparison. American Journal of Clinical Dermatology2018;19(2):275‐86. [CENTRAL: CN‐01572577] NCT02735421 . Adapalene 0.3% ‐ Benzoyl Peroxide 2.5% Gel and Risk of Formation of Atrophic Acne Scars (OSCAR). clinicaltrials.gov/ct2/show/NCT02735421 (first received 7 April 2016). ">Dréno 2018</a>, a split‐face trial, showed that treatment‐related adverse events were reported in 25.4% of participants, with 20.9% on the BPO/adapalene side versus 9.0% on the placebo side. The most common were skin irritation (14.9% versus 6.0%) and skin pain (3.0% versus 1.5%). </p> </section> </section> </section> <section id="CD011154-sec-0340"> <h5 class="title">BPO/adapalene versus tretinoin</h5> <p>One three‐week split‐face trial including 73 participants made this comparison (<a href="./references#CD011154-bbs2-0081" title="NCT01522456 . Split‐face tolerability comparison between adapalene‐benzoyl peroxide gel versus tretinoin gel. www.clinicaltrials.gov/ct2/show/NCT01522456 (first received 23 January 2012). ">NCT01522456</a>). Results about adverse events were published on the trial registry. No information regarding other outcomes was available. </p> <section id="CD011154-sec-0341"> <h6 class="title">Primary outcomes</h6> <p>No information was available on the primary outcomes.</p> </section> <section id="CD011154-sec-0342"> <h6 class="title">Secondary outcomes: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0343"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Rather than summarising the number of adverse events, trial authors reported local side effects individually during the three‐week period. The number of participants experiencing erythema, scaling, dryness, and stinging/burning was 25 versus 28, 25 versus 18, 34 versus 28, and 51 versus 57, respectively. We cannot calculate RR as the effect size because the number of participants with at least one adverse event was not provided. </p> </section> </section> </section> <section id="CD011154-sec-0344"> <h5 class="title">BPO/adapalene versus salicylic acid</h5> <p>One 12‐week parallel trial compared BPO/adapalene and salicylic acid (<a href="./references#CD011154-bbs2-0071" title="MakinoE , MehtaR . A nondrying acne regimen provides rapid reduction in erythema and efficacy comparable to adapalene/benzoyl peroxide 0.1%/2.5% combination. Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB4. [CENTRAL: CN‐01088986] ">Makino 2015</a>). Only a conference abstract was available for this trial. The abstract reported limited information on characteristics of the trial and on outcomes, including the Investigator Global Assessment of acne severity and change in lesion counts. A four‐week split‐face trial comparing BPO plus adapalene with salicylic acid reported participant global self‐assessment of acne improvement, withdrawal due to adverse effects, change in lesion counts, and adverse events (<a href="./references#CD011154-bbs2-0120" title="ZhengY , YinS , XiaY , ChenJ , YeC , ZengQ , et al. Efficacy and safety of 2% supramolecular salicylic acid compared with 5% benzoyl peroxide/0.1% adapalene in the acne treatment: a randomized, split‐face, open‐label, single‐center study. Cutaneous &amp; Ocular Toxicology2019;38(1):48‐54. [CENTRAL: CN‐01741062] ">Zheng 2019</a>). </p> <section id="CD011154-sec-0345"> <h6 class="title">Primary outcome: participant global self‐assessment of acne improvement</h6> <section id="CD011154-sec-0346"> <p><b>Studies not included in the meta‐analysis</b></p> <p>The proportion of participants rating BPO plus adapalene as better, similar, or worse than salicylic acid was 25.8%, 41.9%, and 32.2%, respectively (<a href="./references#CD011154-bbs2-0120" title="ZhengY , YinS , XiaY , ChenJ , YeC , ZengQ , et al. Efficacy and safety of 2% supramolecular salicylic acid compared with 5% benzoyl peroxide/0.1% adapalene in the acne treatment: a randomized, split‐face, open‐label, single‐center study. Cutaneous &amp; Ocular Toxicology2019;38(1):48‐54. [CENTRAL: CN‐01741062] ">Zheng 2019</a>). </p> </section> </section> <section id="CD011154-sec-0347"> <h6 class="title">Primary outcome: withdrawal due to adverse effects</h6> <section id="CD011154-sec-0348"> <p><b>Studies not included in the meta‐analysis</b></p> <p>During the trial, 3 out of 34 participants developed irritant contact dermatitis on BPO treatment and withdrew from the study (<a href="./references#CD011154-bbs2-0120" title="ZhengY , YinS , XiaY , ChenJ , YeC , ZengQ , et al. Efficacy and safety of 2% supramolecular salicylic acid compared with 5% benzoyl peroxide/0.1% adapalene in the acne treatment: a randomized, split‐face, open‐label, single‐center study. Cutaneous &amp; Ocular Toxicology2019;38(1):48‐54. [CENTRAL: CN‐01741062] ">Zheng 2019</a>). </p> </section> </section> <section id="CD011154-sec-0349"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0350"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Trial authors reported no significant difference in reducing ILs and NILs between groups (<a href="./references#CD011154-bbs2-0071" title="MakinoE , MehtaR . A nondrying acne regimen provides rapid reduction in erythema and efficacy comparable to adapalene/benzoyl peroxide 0.1%/2.5% combination. Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB4. [CENTRAL: CN‐01088986] ">Makino 2015</a>). After four weeks, BPO plus adapalene showed similar reduction in papules/pustules (49.8% versus 47.9%), non‐inflammatory lesions (42.7% versus 43.1%), and total lesions (45.6% versus 44.1%) (<a href="./references#CD011154-bbs2-0120" title="ZhengY , YinS , XiaY , ChenJ , YeC , ZengQ , et al. Efficacy and safety of 2% supramolecular salicylic acid compared with 5% benzoyl peroxide/0.1% adapalene in the acne treatment: a randomized, split‐face, open‐label, single‐center study. Cutaneous &amp; Ocular Toxicology2019;38(1):48‐54. [CENTRAL: CN‐01741062] ">Zheng 2019</a>). </p> </section> </section> <section id="CD011154-sec-0351"> <h6 class="title">Secondary outcome: percentage of participants rated 'clear' or 'almost clear' on the IGA scale of acne severity </h6> <section id="CD011154-sec-0352"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Trial authors reported no significant difference in the mean scores of IGA between groups (<a href="./references#CD011154-bbs2-0071" title="MakinoE , MehtaR . A nondrying acne regimen provides rapid reduction in erythema and efficacy comparable to adapalene/benzoyl peroxide 0.1%/2.5% combination. Journal of the American Academy of Dermatology2015;72(5 Suppl 1):AB4. [CENTRAL: CN‐01088986] ">Makino 2015</a>). </p> </section> </section> <section id="CD011154-sec-0353"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0354"> <p><b>Studies not included in the meta‐analysis</b></p> <p>No participants developed adverse events, except for three, who discontinued treatment due to irritant contact dermatitis at the BPO treatment site (<a href="./references#CD011154-bbs2-0120" title="ZhengY , YinS , XiaY , ChenJ , YeC , ZengQ , et al. Efficacy and safety of 2% supramolecular salicylic acid compared with 5% benzoyl peroxide/0.1% adapalene in the acne treatment: a randomized, split‐face, open‐label, single‐center study. Cutaneous &amp; Ocular Toxicology2019;38(1):48‐54. [CENTRAL: CN‐01741062] ">Zheng 2019</a>). </p> </section> </section> </section> <section id="CD011154-sec-0355"> <h5 class="title">BPO/adapalene versus clindamycin/tretinoin</h5> <p>This comparison was made in one three‐week split‐face trial (<a href="./references#CD011154-bbs2-0045" title="GoreshiR , SamraoA , EhstBD . A double‐blind, randomized, bilateral comparison of skin irritancy following application of the combination acne products clindamycin/tretinoin and benzoyl peroxide/adapalene. Journal of Drugs in Dermatology2012;11(12):1422‐6. [CENTRAL: CN‐00877482; MEDLINE: 23377511] GoreshiR , SamraoA , EhstBD . Double‐blind, randomized, bilateral comparison of skin irritancy following application of the combination acne products clindamycin/tretinoin and benzoyl peroxide/adapalene. Journal of Investigative Dermatology2012;132:S86. ">Goreshi 2012</a>), which included 24 participants, all of whom applied BPO/adapalene to one side of the face and clindamycin/tretinoin to the other side. The main purpose of this trial was to assess tolerance of treatments. This trial reported change in lesion counts and adverse events. </p> <section id="CD011154-sec-0356"> <h6 class="title">Primary outcomes</h6> <p>No information regarding the primary outcomes was reported.</p> </section> <section id="CD011154-sec-0357"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0358"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Trial authors claimed no significant change in lesion counts between groups. However, no relevant data were presented. </p> </section> </section> <section id="CD011154-sec-0359"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0360"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Trial authors did not present the number of adverse events but the mean score of erythema, dryness/scaling, itching, and burning/stinging on a 4‐point scale (from 0 = none to 3 = severe). Mean differences were 0.4 (P &lt; 0.001), 0.201 (P &lt; 0.001), 0.01 (P = 0.162), and 0.076 (P = 0.401), respectively. We cannot calculate RR as the effect size because the number of participants with at least one adverse event was not provided. </p> </section> </section> </section> <section id="CD011154-sec-0361"> <h5 class="title">BPO/clindamycin versus placebo or no treatment</h5> <p>We included 12 parallel trials for this comparison (<a href="./references#CD011154-bbs2-0007" title="BowmanS , GoldM , NasirA , VamvakiasG . Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and the combination of clindamycin/benzoyl peroxide and tretinoin plus clindamycin in the treatment of acne vulgaris: a randomized, blinded study. Journal of Drugs in Dermatology2005;4(5):611‐8. [CENTRAL: CN‐00530277; MEDLINE: 16167420] BowmanS , GoldMH , NasirA , VamvakiasG . Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and a combination of both regimens in the treatment of acne vulgaris: a randomized, blinded study. Abstract P147. American Academy of Dermatology, 64th Annual Meeting, March 3‐7, 2006. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB25. [CENTRAL: CN‐00602651] ">Bowman 2005</a>; <a href="./references#CD011154-bbs2-0018" title="DelRossoJ , GreenL , KempersS , TanghettiE . A comparison of initiating treatment for acne vulgaris with 5% benzoyl peroxide/1% clindamycin gel, 0.1% adapalene gel, or both for 4 weeks then combination therapy or 0.1% adapalene gel for 8 weeks. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB22. [CENTRAL: CN‐00602643] DelRossoJQ . Study results of benzoyl peroxide 5%/clindamycin 1% topical gel, adapalene 0.1% gel, and use in combination for acne vulgaris. Journal of Drugs in Dermatology2007;6(6):616‐22. [CENTRAL: CN‐00611006; MEDLINE: 17668527] ">Del 2007</a>; <a href="./references#CD011154-bbs2-0034" title="EichenfieldL , AlioA . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed dose combination gel for the treatment of acne vulgaris: a multicenter, double‐blind, parallel group, vehicle controlled study. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB10. [DOI: 10.1016/j.jaad.2011.11.049] EichenfieldLF , Alio SaenzAB . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed‐dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double‐blind, active‐ and vehicle‐controlled study. Journal of Drugs in Dermatology2011;10(12):1382‐96. [CENTRAL: CN‐00843726; MEDLINE: 22134562] NCT00776919 . A phase 3 multicenter, randomized, double‐blind, active and vehicle‐controlled study of the safety and efficacy of a clindamycin / benzoyl peroxide gel versus clindamycin gel versus benzoyl peroxide gel versus vehicle gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00776919 (first received 21 October 2008). ">Eichenfield 2011</a>; <a href="./references#CD011154-bbs2-0066" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM . Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] LeydenJ , et al. Treatment of acne vulgaris with a combination benzoyl peroxide/clindamycin topical gel Abstract P‐013. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S144. [CENTRAL: CN‐00478651] LeydenJJ , BergerRS , DunlapFE , EllisCN , ConnollyMA , LevySF . Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. American Journal of Clinical Dermatology2001;2(1):33‐9. [CENTRAL: CN‐00363426; MEDLINE: 11702619] ">Leyden 2001a</a>; <a href="./references#CD011154-bbs2-0069" title="LookingbillDP , ChalkerDK , LindholmJS , KatzHI , KempersSE , HuerterCJ , et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double‐blind investigations. Journal of the American Academy of Dermatology1997;37(4):590‐5. [CENTRAL: CN‐00144503; MEDLINE: 9344199] LookingbillDP , ChallenDK , LindholmJS . Treatment of acne with a combination of clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined result of two double blind investigations (Abstract no. 1). Indian Journal of Dermatology, Venerology and Leprology1995;61:398. ">Lookingbill 1997</a>; <a href="./references#CD011154-bbs2-0078" title="NCT01044264 . Clinical study between two 1% clindamycin/5% benzoyl peroxide topical gel formulations. https://clinicaltrials.gov/ct2/show/NCT01044264 (first received 4 January 2010). ">NCT01044264</a>; <a href="./references#CD011154-bbs2-0079" title="NCT01138514 . Clinical study between two clindamycin 1%/benzoyl peroxide 5% topical gels. clinicaltrials.gov/ct2/show/NCT01138514 (first received 4 June 2010). ">NCT01138514</a>; <a href="./references#CD011154-bbs2-0087" title="AlexisAF , Cook‐BoldenF , LinT , BulleyB . Treatment of moderate‐to‐severe acne vulgaris in a Hispanic population: a post‐hoc analysis of the efficacy and tolerability of clindamycin 1.2%/benzoyl peroxide 3.75% gel. Journal of Clinical and Aesthetic Dermatology2017;10(6):36‐43. [CENTRAL: CN‐01471496; MEDLINE: 28979655] Cook‐BoldenFE . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate or severe adolescent acne vulgaris. Journal of Clinical &amp; Aesthetic Dermatology2015;8(5):28‐32. [CENTRAL: CN‐01074689; MEDLINE: 26029332] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015; Vol. 8, issue 12:22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] HarperJC . The efficacy and tolerability of a fixed combination clindamycin (1.2%) and benzoyl peroxide (3.75%) aqueous gel in patients with facial acne vulgaris: gender as a clinically relevant outcome variable. Journal of Drugs in Dermatology2015;14(4):381‐4. [CENTRAL: CN‐01070825; MEDLINE: 25844612] PariserDM , RichP , Cook‐BoldenFE , KorotzerA . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once daily treatment of moderate‐to‐severe acne vulgaris: assessment of safety in 498 patients. Journal of Clinical and Aesthetic Dermatology2015;8(5 Suppl 1):S6. PariserDM , RichP , Cook‐BoldenFE , KorotzerA . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once‐daily treatment of moderate to severe acne vulgaris. Journal of Drugs in Dermatology2014;13(9):1083‐9. [CENTRAL: CN‐01113744; MEDLINE: 25226009] Stein GoldL . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate and severe acne vulgaris subpopulations. Journal of Drugs in Dermatology2015; Vol. 14, issue 9:969‐74. [CENTRAL: CN‐01165932; MEDLINE: 26355615] ">Pariser 2014</a>; <a href="./references#CD011154-bbs2-0100" title="FDA , Center for Drug Evaluation and Research. Study 152. Medical Review of NDA 50‐741. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50‐741_duac%20topical%20gel_medr_p1.pdf. ">Study 152</a>; <a href="./references#CD011154-bbs2-0104" title="TanghettiE , AbramovitsW , SolomonB , LovenK , ShalitaA . Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double‐blind, randomized parallel‐group trial. Journal of Drugs in Dermatology2006;5(3):256‐61. [CENTRAL: CN‐00563788; MEDLINE: 16573259] ">Tanghetti 2006</a>; <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>; <a href="./references#CD011154-bbs2-0109" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM , et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] TschenE , et al. A combination benzoyl peroxide/clindamycin topical gel for the treatment of acne vulgaris. Abstract P‐029. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S150. [CENTRAL: CN‐00478786] TschenEH , KatzHI , JonesTM , MonroeEW , KrausSJ , ConnollyMA , et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2):165‐9. [CENTRAL: CN‐00346768; MEDLINE: 11236229] ">Tschen 2001</a>). All trials followed up on participants for 10 to 12 weeks. All outcomes of interest in this review were available for these trials except reduction in <i>C acnes</i> strains. </p> <section id="CD011154-sec-0362"> <h6 class="title">Primary outcome: participant global self‐assessment of acne improvement</h6> <section id="CD011154-sec-0363"> <p><b>Main pooled analyses: BPO/clindamycin versus placebo or no treatment</b></p> <p>This outcome was assessed in five trials (<a href="./references#CD011154-bbs2-0066" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM . Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] LeydenJ , et al. Treatment of acne vulgaris with a combination benzoyl peroxide/clindamycin topical gel Abstract P‐013. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S144. [CENTRAL: CN‐00478651] LeydenJJ , BergerRS , DunlapFE , EllisCN , ConnollyMA , LevySF . Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. American Journal of Clinical Dermatology2001;2(1):33‐9. [CENTRAL: CN‐00363426; MEDLINE: 11702619] ">Leyden 2001a</a>; <a href="./references#CD011154-bbs2-0087" title="AlexisAF , Cook‐BoldenF , LinT , BulleyB . Treatment of moderate‐to‐severe acne vulgaris in a Hispanic population: a post‐hoc analysis of the efficacy and tolerability of clindamycin 1.2%/benzoyl peroxide 3.75% gel. Journal of Clinical and Aesthetic Dermatology2017;10(6):36‐43. [CENTRAL: CN‐01471496; MEDLINE: 28979655] Cook‐BoldenFE . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate or severe adolescent acne vulgaris. Journal of Clinical &amp; Aesthetic Dermatology2015;8(5):28‐32. [CENTRAL: CN‐01074689; MEDLINE: 26029332] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015; Vol. 8, issue 12:22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] HarperJC . The efficacy and tolerability of a fixed combination clindamycin (1.2%) and benzoyl peroxide (3.75%) aqueous gel in patients with facial acne vulgaris: gender as a clinically relevant outcome variable. Journal of Drugs in Dermatology2015;14(4):381‐4. [CENTRAL: CN‐01070825; MEDLINE: 25844612] PariserDM , RichP , Cook‐BoldenFE , KorotzerA . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once daily treatment of moderate‐to‐severe acne vulgaris: assessment of safety in 498 patients. Journal of Clinical and Aesthetic Dermatology2015;8(5 Suppl 1):S6. PariserDM , RichP , Cook‐BoldenFE , KorotzerA . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once‐daily treatment of moderate to severe acne vulgaris. Journal of Drugs in Dermatology2014;13(9):1083‐9. [CENTRAL: CN‐01113744; MEDLINE: 25226009] Stein GoldL . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate and severe acne vulgaris subpopulations. Journal of Drugs in Dermatology2015; Vol. 14, issue 9:969‐74. [CENTRAL: CN‐01165932; MEDLINE: 26355615] ">Pariser 2014</a>; <a href="./references#CD011154-bbs2-0104" title="TanghettiE , AbramovitsW , SolomonB , LovenK , ShalitaA . Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double‐blind, randomized parallel‐group trial. Journal of Drugs in Dermatology2006;5(3):256‐61. [CENTRAL: CN‐00563788; MEDLINE: 16573259] ">Tanghetti 2006</a>; <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>; <a href="./references#CD011154-bbs2-0109" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM , et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] TschenE , et al. A combination benzoyl peroxide/clindamycin topical gel for the treatment of acne vulgaris. Abstract P‐029. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S150. [CENTRAL: CN‐00478786] TschenEH , KatzHI , JonesTM , MonroeEW , KrausSJ , ConnollyMA , et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2):165‐9. [CENTRAL: CN‐00346768; MEDLINE: 11236229] ">Tschen 2001</a>), only one of which presented data in accordance with the definition of the outcome in our review (<a href="./references#CD011154-bbs2-0066" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM . Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] LeydenJ , et al. Treatment of acne vulgaris with a combination benzoyl peroxide/clindamycin topical gel Abstract P‐013. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S144. [CENTRAL: CN‐00478651] LeydenJJ , BergerRS , DunlapFE , EllisCN , ConnollyMA , LevySF . Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. American Journal of Clinical Dermatology2001;2(1):33‐9. [CENTRAL: CN‐00363426; MEDLINE: 11702619] ">Leyden 2001a</a>). Results from these trials consistently showed significant difference between the two groups. </p> <p><a href="./references#CD011154-bbs2-0066" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM . Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] LeydenJ , et al. Treatment of acne vulgaris with a combination benzoyl peroxide/clindamycin topical gel Abstract P‐013. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S144. [CENTRAL: CN‐00478651] LeydenJJ , BergerRS , DunlapFE , EllisCN , ConnollyMA , LevySF . Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. American Journal of Clinical Dermatology2001;2(1):33‐9. [CENTRAL: CN‐00363426; MEDLINE: 11702619] ">Leyden 2001a</a> included 120 participants in the BPO/clindamycin group and 120 in the placebo group. The outcome was assessed with a 5‐point Likert‐like scale. The risk ratio for treatment success was 2.95 (95% CI 1.96 to 4.46; <a href="./references#CD011154-fig-0092" title="">Analysis 14.1</a>) with significant differences between the two groups. </p> </section> <section id="CD011154-sec-0364"> <p><b>Studies not included in the meta‐analysis</b></p> <p>We cannot pool this result with those from the other four trials because they did not present the number of treatment successes as defined in our review (<a href="./references#CD011154-bbs2-0087" title="AlexisAF , Cook‐BoldenF , LinT , BulleyB . Treatment of moderate‐to‐severe acne vulgaris in a Hispanic population: a post‐hoc analysis of the efficacy and tolerability of clindamycin 1.2%/benzoyl peroxide 3.75% gel. Journal of Clinical and Aesthetic Dermatology2017;10(6):36‐43. [CENTRAL: CN‐01471496; MEDLINE: 28979655] Cook‐BoldenFE . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate or severe adolescent acne vulgaris. Journal of Clinical &amp; Aesthetic Dermatology2015;8(5):28‐32. [CENTRAL: CN‐01074689; MEDLINE: 26029332] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015; Vol. 8, issue 12:22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] HarperJC . The efficacy and tolerability of a fixed combination clindamycin (1.2%) and benzoyl peroxide (3.75%) aqueous gel in patients with facial acne vulgaris: gender as a clinically relevant outcome variable. Journal of Drugs in Dermatology2015;14(4):381‐4. [CENTRAL: CN‐01070825; MEDLINE: 25844612] PariserDM , RichP , Cook‐BoldenFE , KorotzerA . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once daily treatment of moderate‐to‐severe acne vulgaris: assessment of safety in 498 patients. Journal of Clinical and Aesthetic Dermatology2015;8(5 Suppl 1):S6. PariserDM , RichP , Cook‐BoldenFE , KorotzerA . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once‐daily treatment of moderate to severe acne vulgaris. Journal of Drugs in Dermatology2014;13(9):1083‐9. [CENTRAL: CN‐01113744; MEDLINE: 25226009] Stein GoldL . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate and severe acne vulgaris subpopulations. Journal of Drugs in Dermatology2015; Vol. 14, issue 9:969‐74. [CENTRAL: CN‐01165932; MEDLINE: 26355615] ">Pariser 2014</a>; <a href="./references#CD011154-bbs2-0104" title="TanghettiE , AbramovitsW , SolomonB , LovenK , ShalitaA . Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double‐blind, randomized parallel‐group trial. Journal of Drugs in Dermatology2006;5(3):256‐61. [CENTRAL: CN‐00563788; MEDLINE: 16573259] ">Tanghetti 2006</a>; <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>; <a href="./references#CD011154-bbs2-0109" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM , et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] TschenE , et al. A combination benzoyl peroxide/clindamycin topical gel for the treatment of acne vulgaris. Abstract P‐029. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S150. [CENTRAL: CN‐00478786] TschenEH , KatzHI , JonesTM , MonroeEW , KrausSJ , ConnollyMA , et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2):165‐9. [CENTRAL: CN‐00346768; MEDLINE: 11236229] ">Tschen 2001</a>). <a href="./references#CD011154-bbs2-0087" title="AlexisAF , Cook‐BoldenF , LinT , BulleyB . Treatment of moderate‐to‐severe acne vulgaris in a Hispanic population: a post‐hoc analysis of the efficacy and tolerability of clindamycin 1.2%/benzoyl peroxide 3.75% gel. Journal of Clinical and Aesthetic Dermatology2017;10(6):36‐43. [CENTRAL: CN‐01471496; MEDLINE: 28979655] Cook‐BoldenFE . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate or severe adolescent acne vulgaris. Journal of Clinical &amp; Aesthetic Dermatology2015;8(5):28‐32. [CENTRAL: CN‐01074689; MEDLINE: 26029332] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015; Vol. 8, issue 12:22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] HarperJC . The efficacy and tolerability of a fixed combination clindamycin (1.2%) and benzoyl peroxide (3.75%) aqueous gel in patients with facial acne vulgaris: gender as a clinically relevant outcome variable. Journal of Drugs in Dermatology2015;14(4):381‐4. [CENTRAL: CN‐01070825; MEDLINE: 25844612] PariserDM , RichP , Cook‐BoldenFE , KorotzerA . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once daily treatment of moderate‐to‐severe acne vulgaris: assessment of safety in 498 patients. Journal of Clinical and Aesthetic Dermatology2015;8(5 Suppl 1):S6. PariserDM , RichP , Cook‐BoldenFE , KorotzerA . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once‐daily treatment of moderate to severe acne vulgaris. Journal of Drugs in Dermatology2014;13(9):1083‐9. [CENTRAL: CN‐01113744; MEDLINE: 25226009] Stein GoldL . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate and severe acne vulgaris subpopulations. Journal of Drugs in Dermatology2015; Vol. 14, issue 9:969‐74. [CENTRAL: CN‐01165932; MEDLINE: 26355615] ">Pariser 2014</a> randomised 253 participants to the BPO/clindamycin group and 245 to the placebo group and assessed the outcome using a 7‐point Likert‐like scale. At week 12, the risk ratio for self‐reported ‘clear’ or ‘almost clear’ was 1.98 (95% CI 1.44 to 2.73). A similar 7‐point Likert‐like scale was used in <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>, in which 797 participants in the BPO/clindamycin group and 395 participants in the placebo group were assessed. The risk ratio for self‐reported ‘clear’ or ‘almost clear’ was 2.34 (95% CI 1.85 to 2.97). Another 7‐point Likert‐like scale was used in <a href="./references#CD011154-bbs2-0109" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM , et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] TschenE , et al. A combination benzoyl peroxide/clindamycin topical gel for the treatment of acne vulgaris. Abstract P‐029. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S150. [CENTRAL: CN‐00478786] TschenEH , KatzHI , JonesTM , MonroeEW , KrausSJ , ConnollyMA , et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2):165‐9. [CENTRAL: CN‐00346768; MEDLINE: 11236229] ">Tschen 2001</a>, in which 95 participants were treated with BPO/clindamycin and 48 with placebo. The risk ratio for self‐reported ‘much better’ was 4.04 (95% CI 1.52 to 10.77). In one 12‐week trial including 60 participants on BPO/clindamycin and 61 on placebo (<a href="./references#CD011154-bbs2-0104" title="TanghettiE , AbramovitsW , SolomonB , LovenK , ShalitaA . Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double‐blind, randomized parallel‐group trial. Journal of Drugs in Dermatology2006;5(3):256‐61. [CENTRAL: CN‐00563788; MEDLINE: 16573259] ">Tanghetti 2006</a>), all of whom received tazarotene as a co‐intervention, participants rated their overall impression of their treatment as highly favourable, favourable, unfavourable, or highly unfavourable. There was no significant difference in the proportion of participants rating improvement as highly favourable or favourable between the two groups (94% versus 90%) at week 12. Sensitivity analysis including these trials showed an RR of 2.10 (95% CI 1.25 to 3.52). </p> </section> </section> <section id="CD011154-sec-0365"> <h6 class="title">Primary outcome: withdrawal due to adverse effects</h6> <p>The long‐term outcome was reported in eight trials (<a href="./references#CD011154-bbs2-0007" title="BowmanS , GoldM , NasirA , VamvakiasG . Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and the combination of clindamycin/benzoyl peroxide and tretinoin plus clindamycin in the treatment of acne vulgaris: a randomized, blinded study. Journal of Drugs in Dermatology2005;4(5):611‐8. [CENTRAL: CN‐00530277; MEDLINE: 16167420] BowmanS , GoldMH , NasirA , VamvakiasG . Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and a combination of both regimens in the treatment of acne vulgaris: a randomized, blinded study. Abstract P147. American Academy of Dermatology, 64th Annual Meeting, March 3‐7, 2006. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB25. [CENTRAL: CN‐00602651] ">Bowman 2005</a>; <a href="./references#CD011154-bbs2-0034" title="EichenfieldL , AlioA . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed dose combination gel for the treatment of acne vulgaris: a multicenter, double‐blind, parallel group, vehicle controlled study. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB10. [DOI: 10.1016/j.jaad.2011.11.049] EichenfieldLF , Alio SaenzAB . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed‐dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double‐blind, active‐ and vehicle‐controlled study. Journal of Drugs in Dermatology2011;10(12):1382‐96. [CENTRAL: CN‐00843726; MEDLINE: 22134562] NCT00776919 . A phase 3 multicenter, randomized, double‐blind, active and vehicle‐controlled study of the safety and efficacy of a clindamycin / benzoyl peroxide gel versus clindamycin gel versus benzoyl peroxide gel versus vehicle gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00776919 (first received 21 October 2008). ">Eichenfield 2011</a>; <a href="./references#CD011154-bbs2-0066" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM . Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] LeydenJ , et al. Treatment of acne vulgaris with a combination benzoyl peroxide/clindamycin topical gel Abstract P‐013. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S144. [CENTRAL: CN‐00478651] LeydenJJ , BergerRS , DunlapFE , EllisCN , ConnollyMA , LevySF . Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. American Journal of Clinical Dermatology2001;2(1):33‐9. [CENTRAL: CN‐00363426; MEDLINE: 11702619] ">Leyden 2001a</a>; <a href="./references#CD011154-bbs2-0069" title="LookingbillDP , ChalkerDK , LindholmJS , KatzHI , KempersSE , HuerterCJ , et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double‐blind investigations. Journal of the American Academy of Dermatology1997;37(4):590‐5. [CENTRAL: CN‐00144503; MEDLINE: 9344199] LookingbillDP , ChallenDK , LindholmJS . Treatment of acne with a combination of clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined result of two double blind investigations (Abstract no. 1). Indian Journal of Dermatology, Venerology and Leprology1995;61:398. ">Lookingbill 1997</a>; <a href="./references#CD011154-bbs2-0087" title="AlexisAF , Cook‐BoldenF , LinT , BulleyB . Treatment of moderate‐to‐severe acne vulgaris in a Hispanic population: a post‐hoc analysis of the efficacy and tolerability of clindamycin 1.2%/benzoyl peroxide 3.75% gel. Journal of Clinical and Aesthetic Dermatology2017;10(6):36‐43. [CENTRAL: CN‐01471496; MEDLINE: 28979655] Cook‐BoldenFE . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate or severe adolescent acne vulgaris. Journal of Clinical &amp; Aesthetic Dermatology2015;8(5):28‐32. [CENTRAL: CN‐01074689; MEDLINE: 26029332] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015; Vol. 8, issue 12:22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] HarperJC . The efficacy and tolerability of a fixed combination clindamycin (1.2%) and benzoyl peroxide (3.75%) aqueous gel in patients with facial acne vulgaris: gender as a clinically relevant outcome variable. Journal of Drugs in Dermatology2015;14(4):381‐4. [CENTRAL: CN‐01070825; MEDLINE: 25844612] PariserDM , RichP , Cook‐BoldenFE , KorotzerA . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once daily treatment of moderate‐to‐severe acne vulgaris: assessment of safety in 498 patients. Journal of Clinical and Aesthetic Dermatology2015;8(5 Suppl 1):S6. PariserDM , RichP , Cook‐BoldenFE , KorotzerA . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once‐daily treatment of moderate to severe acne vulgaris. Journal of Drugs in Dermatology2014;13(9):1083‐9. [CENTRAL: CN‐01113744; MEDLINE: 25226009] Stein GoldL . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate and severe acne vulgaris subpopulations. Journal of Drugs in Dermatology2015; Vol. 14, issue 9:969‐74. [CENTRAL: CN‐01165932; MEDLINE: 26355615] ">Pariser 2014</a>; <a href="./references#CD011154-bbs2-0104" title="TanghettiE , AbramovitsW , SolomonB , LovenK , ShalitaA . Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double‐blind, randomized parallel‐group trial. Journal of Drugs in Dermatology2006;5(3):256‐61. [CENTRAL: CN‐00563788; MEDLINE: 16573259] ">Tanghetti 2006</a>; <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>; <a href="./references#CD011154-bbs2-0109" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM , et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] TschenE , et al. A combination benzoyl peroxide/clindamycin topical gel for the treatment of acne vulgaris. Abstract P‐029. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S150. [CENTRAL: CN‐00478786] TschenEH , KatzHI , JonesTM , MonroeEW , KrausSJ , ConnollyMA , et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2):165‐9. [CENTRAL: CN‐00346768; MEDLINE: 11236229] ">Tschen 2001</a>), which included a total of 1791 participants treated with BPO/clindamycin and 1304 treated with placebo. </p> <section id="CD011154-sec-0366"> <p><b>Main pooled analyses: BPO/clindamycin versus placebo or no treatment</b></p> <p>No evidence suggests that participants treated with BPO/clindamycin had a higher risk of withdrawal due to adverse effects, with an RR of 1.07 (95% CI 0.38 to 3.00; 3095 participants; 8 studies; I² = 0%; <a href="./references#CD011154-fig-0093" title="">Analysis 14.2</a>). The most common adverse events leading to withdrawal included erythema, face oedema, rash, pruritus, and skin burning. </p> </section> <section id="CD011154-sec-0367"> <p><b>Subgroup analyses: co‐intervention</b></p> <p>We did not observe significant differences between different co‐intervention subgroups (test for subgroup differences: P = 0.28; <a href="./references#CD011154-fig-0093" title="">Analysis 14.2</a>). </p> </section> </section> <section id="CD011154-sec-0368"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <p>All 12 trials reported the mean or percentage reduction in lesions counts (<a href="./references#CD011154-bbs2-0007" title="BowmanS , GoldM , NasirA , VamvakiasG . Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and the combination of clindamycin/benzoyl peroxide and tretinoin plus clindamycin in the treatment of acne vulgaris: a randomized, blinded study. Journal of Drugs in Dermatology2005;4(5):611‐8. [CENTRAL: CN‐00530277; MEDLINE: 16167420] BowmanS , GoldMH , NasirA , VamvakiasG . Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and a combination of both regimens in the treatment of acne vulgaris: a randomized, blinded study. Abstract P147. American Academy of Dermatology, 64th Annual Meeting, March 3‐7, 2006. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB25. [CENTRAL: CN‐00602651] ">Bowman 2005</a>; <a href="./references#CD011154-bbs2-0018" title="DelRossoJ , GreenL , KempersS , TanghettiE . A comparison of initiating treatment for acne vulgaris with 5% benzoyl peroxide/1% clindamycin gel, 0.1% adapalene gel, or both for 4 weeks then combination therapy or 0.1% adapalene gel for 8 weeks. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB22. [CENTRAL: CN‐00602643] DelRossoJQ . Study results of benzoyl peroxide 5%/clindamycin 1% topical gel, adapalene 0.1% gel, and use in combination for acne vulgaris. Journal of Drugs in Dermatology2007;6(6):616‐22. [CENTRAL: CN‐00611006; MEDLINE: 17668527] ">Del 2007</a>; <a href="./references#CD011154-bbs2-0034" title="EichenfieldL , AlioA . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed dose combination gel for the treatment of acne vulgaris: a multicenter, double‐blind, parallel group, vehicle controlled study. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB10. [DOI: 10.1016/j.jaad.2011.11.049] EichenfieldLF , Alio SaenzAB . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed‐dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double‐blind, active‐ and vehicle‐controlled study. Journal of Drugs in Dermatology2011;10(12):1382‐96. [CENTRAL: CN‐00843726; MEDLINE: 22134562] NCT00776919 . A phase 3 multicenter, randomized, double‐blind, active and vehicle‐controlled study of the safety and efficacy of a clindamycin / benzoyl peroxide gel versus clindamycin gel versus benzoyl peroxide gel versus vehicle gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00776919 (first received 21 October 2008). ">Eichenfield 2011</a>; <a href="./references#CD011154-bbs2-0066" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM . Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] LeydenJ , et al. Treatment of acne vulgaris with a combination benzoyl peroxide/clindamycin topical gel Abstract P‐013. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S144. [CENTRAL: CN‐00478651] LeydenJJ , BergerRS , DunlapFE , EllisCN , ConnollyMA , LevySF . Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. American Journal of Clinical Dermatology2001;2(1):33‐9. [CENTRAL: CN‐00363426; MEDLINE: 11702619] ">Leyden 2001a</a>; <a href="./references#CD011154-bbs2-0069" title="LookingbillDP , ChalkerDK , LindholmJS , KatzHI , KempersSE , HuerterCJ , et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double‐blind investigations. Journal of the American Academy of Dermatology1997;37(4):590‐5. [CENTRAL: CN‐00144503; MEDLINE: 9344199] LookingbillDP , ChallenDK , LindholmJS . Treatment of acne with a combination of clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined result of two double blind investigations (Abstract no. 1). Indian Journal of Dermatology, Venerology and Leprology1995;61:398. ">Lookingbill 1997</a>; <a href="./references#CD011154-bbs2-0078" title="NCT01044264 . Clinical study between two 1% clindamycin/5% benzoyl peroxide topical gel formulations. https://clinicaltrials.gov/ct2/show/NCT01044264 (first received 4 January 2010). ">NCT01044264</a>; <a href="./references#CD011154-bbs2-0079" title="NCT01138514 . Clinical study between two clindamycin 1%/benzoyl peroxide 5% topical gels. clinicaltrials.gov/ct2/show/NCT01138514 (first received 4 June 2010). ">NCT01138514</a>; <a href="./references#CD011154-bbs2-0087" title="AlexisAF , Cook‐BoldenF , LinT , BulleyB . Treatment of moderate‐to‐severe acne vulgaris in a Hispanic population: a post‐hoc analysis of the efficacy and tolerability of clindamycin 1.2%/benzoyl peroxide 3.75% gel. Journal of Clinical and Aesthetic Dermatology2017;10(6):36‐43. [CENTRAL: CN‐01471496; MEDLINE: 28979655] Cook‐BoldenFE . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate or severe adolescent acne vulgaris. Journal of Clinical &amp; Aesthetic Dermatology2015;8(5):28‐32. [CENTRAL: CN‐01074689; MEDLINE: 26029332] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015; Vol. 8, issue 12:22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] HarperJC . The efficacy and tolerability of a fixed combination clindamycin (1.2%) and benzoyl peroxide (3.75%) aqueous gel in patients with facial acne vulgaris: gender as a clinically relevant outcome variable. Journal of Drugs in Dermatology2015;14(4):381‐4. [CENTRAL: CN‐01070825; MEDLINE: 25844612] PariserDM , RichP , Cook‐BoldenFE , KorotzerA . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once daily treatment of moderate‐to‐severe acne vulgaris: assessment of safety in 498 patients. Journal of Clinical and Aesthetic Dermatology2015;8(5 Suppl 1):S6. PariserDM , RichP , Cook‐BoldenFE , KorotzerA . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once‐daily treatment of moderate to severe acne vulgaris. Journal of Drugs in Dermatology2014;13(9):1083‐9. [CENTRAL: CN‐01113744; MEDLINE: 25226009] Stein GoldL . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate and severe acne vulgaris subpopulations. Journal of Drugs in Dermatology2015; Vol. 14, issue 9:969‐74. [CENTRAL: CN‐01165932; MEDLINE: 26355615] ">Pariser 2014</a>; <a href="./references#CD011154-bbs2-0100" title="FDA , Center for Drug Evaluation and Research. Study 152. Medical Review of NDA 50‐741. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50‐741_duac%20topical%20gel_medr_p1.pdf. ">Study 152</a>; <a href="./references#CD011154-bbs2-0104" title="TanghettiE , AbramovitsW , SolomonB , LovenK , ShalitaA . Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double‐blind, randomized parallel‐group trial. Journal of Drugs in Dermatology2006;5(3):256‐61. [CENTRAL: CN‐00563788; MEDLINE: 16573259] ">Tanghetti 2006</a>; <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>; <a href="./references#CD011154-bbs2-0109" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM , et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] TschenE , et al. A combination benzoyl peroxide/clindamycin topical gel for the treatment of acne vulgaris. Abstract P‐029. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S150. [CENTRAL: CN‐00478786] TschenEH , KatzHI , JonesTM , MonroeEW , KrausSJ , ConnollyMA , et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2):165‐9. [CENTRAL: CN‐00346768; MEDLINE: 11236229] ">Tschen 2001</a>). Three of them provided sufficient data to estimate effect size (<a href="./references#CD011154-bbs2-0034" title="EichenfieldL , AlioA . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed dose combination gel for the treatment of acne vulgaris: a multicenter, double‐blind, parallel group, vehicle controlled study. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB10. [DOI: 10.1016/j.jaad.2011.11.049] EichenfieldLF , Alio SaenzAB . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed‐dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double‐blind, active‐ and vehicle‐controlled study. Journal of Drugs in Dermatology2011;10(12):1382‐96. [CENTRAL: CN‐00843726; MEDLINE: 22134562] NCT00776919 . A phase 3 multicenter, randomized, double‐blind, active and vehicle‐controlled study of the safety and efficacy of a clindamycin / benzoyl peroxide gel versus clindamycin gel versus benzoyl peroxide gel versus vehicle gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00776919 (first received 21 October 2008). ">Eichenfield 2011</a>; <a href="./references#CD011154-bbs2-0069" title="LookingbillDP , ChalkerDK , LindholmJS , KatzHI , KempersSE , HuerterCJ , et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double‐blind investigations. Journal of the American Academy of Dermatology1997;37(4):590‐5. [CENTRAL: CN‐00144503; MEDLINE: 9344199] LookingbillDP , ChallenDK , LindholmJS . Treatment of acne with a combination of clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined result of two double blind investigations (Abstract no. 1). Indian Journal of Dermatology, Venerology and Leprology1995;61:398. ">Lookingbill 1997</a>; <a href="./references#CD011154-bbs2-0079" title="NCT01138514 . Clinical study between two clindamycin 1%/benzoyl peroxide 5% topical gels. clinicaltrials.gov/ct2/show/NCT01138514 (first received 4 June 2010). ">NCT01138514</a>). Results were consistently significant across studies. </p> <section id="CD011154-sec-0369"> <p><b>Main pooled analyses: BPO/clindamycin versus placebo or no treatment</b></p> <p>For the mean change in lesion counts, <a href="./references#CD011154-bbs2-0034" title="EichenfieldL , AlioA . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed dose combination gel for the treatment of acne vulgaris: a multicenter, double‐blind, parallel group, vehicle controlled study. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB10. [DOI: 10.1016/j.jaad.2011.11.049] EichenfieldLF , Alio SaenzAB . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed‐dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double‐blind, active‐ and vehicle‐controlled study. Journal of Drugs in Dermatology2011;10(12):1382‐96. [CENTRAL: CN‐00843726; MEDLINE: 22134562] NCT00776919 . A phase 3 multicenter, randomized, double‐blind, active and vehicle‐controlled study of the safety and efficacy of a clindamycin / benzoyl peroxide gel versus clindamycin gel versus benzoyl peroxide gel versus vehicle gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00776919 (first received 21 October 2008). ">Eichenfield 2011</a>, which included 322 participants treated with BPO/clindamycin and 329 treated with placebo, found significant differences in the reduction in TLs (MD ‐15.20; 95% CI ‐19.57 to ‐10.83; <a href="./references#CD011154-fig-0094" title="">Analysis 14.3</a>), ILs (MD ‐5.10; 95% CI ‐6.83 to ‐3.37; <a href="./references#CD011154-fig-0095" title="">Analysis 14.4</a>), and NILs (MD ‐10.00; 95% CI ‐13.20 to ‐6.80; <a href="./references#CD011154-fig-0096" title="">Analysis 14.5</a>). </p> <p>For the percentage change in lesion counts, we pooled two trials including 944 and 485 participants treated with BPO/clindamycin and placebo, respectively (<a href="./references#CD011154-bbs2-0069" title="LookingbillDP , ChalkerDK , LindholmJS , KatzHI , KempersSE , HuerterCJ , et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double‐blind investigations. Journal of the American Academy of Dermatology1997;37(4):590‐5. [CENTRAL: CN‐00144503; MEDLINE: 9344199] LookingbillDP , ChallenDK , LindholmJS . Treatment of acne with a combination of clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined result of two double blind investigations (Abstract no. 1). Indian Journal of Dermatology, Venerology and Leprology1995;61:398. ">Lookingbill 1997</a>; <a href="./references#CD011154-bbs2-0079" title="NCT01138514 . Clinical study between two clindamycin 1%/benzoyl peroxide 5% topical gels. clinicaltrials.gov/ct2/show/NCT01138514 (first received 4 June 2010). ">NCT01138514</a>). The mean difference in percentage reduction in ILs and NILs was 44.16% (95% CI 23.53 to 64.79%; 2 studies; I² = 86%; <a href="./references#CD011154-fig-0097" title="">Analysis 14.6</a>) and 37.65% (95% CI 26.04 to 49.25%; 2 studies; I² = 50%; <a href="./references#CD011154-fig-0098" title="">Analysis 14.7</a>), respectively, with substantial heterogeneity. The two trials were different in acne severity (<a href="./references#CD011154-bbs2-0069" title="LookingbillDP , ChalkerDK , LindholmJS , KatzHI , KempersSE , HuerterCJ , et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double‐blind investigations. Journal of the American Academy of Dermatology1997;37(4):590‐5. [CENTRAL: CN‐00144503; MEDLINE: 9344199] LookingbillDP , ChallenDK , LindholmJS . Treatment of acne with a combination of clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined result of two double blind investigations (Abstract no. 1). Indian Journal of Dermatology, Venerology and Leprology1995;61:398. ">Lookingbill 1997</a> covered mild acne, but <a href="./references#CD011154-bbs2-0079" title="NCT01138514 . Clinical study between two clindamycin 1%/benzoyl peroxide 5% topical gels. clinicaltrials.gov/ct2/show/NCT01138514 (first received 4 June 2010). ">NCT01138514</a> exclusively focused on moderate to severe acne). </p> </section> <section id="CD011154-sec-0370"> <p><b>Studies not included in the meta‐analysis</b></p> <p>For the following trials, we cannot estimate MD as the effect size for this outcome because data were not sufficient to calculate standard deviation. </p> <p>Regarding the mean change in lesion counts, <a href="./references#CD011154-bbs2-0066" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM . Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] LeydenJ , et al. Treatment of acne vulgaris with a combination benzoyl peroxide/clindamycin topical gel Abstract P‐013. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S144. [CENTRAL: CN‐00478651] LeydenJJ , BergerRS , DunlapFE , EllisCN , ConnollyMA , LevySF . Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. American Journal of Clinical Dermatology2001;2(1):33‐9. [CENTRAL: CN‐00363426; MEDLINE: 11702619] ">Leyden 2001a</a> claimed that both TLs (‐18.4 versus ‐1.3) and ILs (‐10.1 versus 0.7) were significantly reduced in the BPO/clindamycin group when compared to the placebo group at week 10. <a href="./references#CD011154-bbs2-0109" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM , et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] TschenE , et al. A combination benzoyl peroxide/clindamycin topical gel for the treatment of acne vulgaris. Abstract P‐029. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S150. [CENTRAL: CN‐00478786] TschenEH , KatzHI , JonesTM , MonroeEW , KrausSJ , ConnollyMA , et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2):165‐9. [CENTRAL: CN‐00346768; MEDLINE: 11236229] ">Tschen 2001</a> found ‐16.6 versus ‐11.3 in ILs for BPO/clindamycin (95 participants) and placebo (48 participants) (P &lt; 0.034). </p> <p>As for the percentage change in lesion counts, trial data published on the registry show 63.8% reduction in ILs among 218 participants treated with BPO/clindamycin and 49.9% among 185 participants treated with placebo (<a href="./references#CD011154-bbs2-0078" title="NCT01044264 . Clinical study between two 1% clindamycin/5% benzoyl peroxide topical gel formulations. https://clinicaltrials.gov/ct2/show/NCT01044264 (first received 4 January 2010). ">NCT01044264</a>). </p> <p>In <a href="./references#CD011154-bbs2-0087" title="AlexisAF , Cook‐BoldenF , LinT , BulleyB . Treatment of moderate‐to‐severe acne vulgaris in a Hispanic population: a post‐hoc analysis of the efficacy and tolerability of clindamycin 1.2%/benzoyl peroxide 3.75% gel. Journal of Clinical and Aesthetic Dermatology2017;10(6):36‐43. [CENTRAL: CN‐01471496; MEDLINE: 28979655] Cook‐BoldenFE . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate or severe adolescent acne vulgaris. Journal of Clinical &amp; Aesthetic Dermatology2015;8(5):28‐32. [CENTRAL: CN‐01074689; MEDLINE: 26029332] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015; Vol. 8, issue 12:22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] HarperJC . The efficacy and tolerability of a fixed combination clindamycin (1.2%) and benzoyl peroxide (3.75%) aqueous gel in patients with facial acne vulgaris: gender as a clinically relevant outcome variable. Journal of Drugs in Dermatology2015;14(4):381‐4. [CENTRAL: CN‐01070825; MEDLINE: 25844612] PariserDM , RichP , Cook‐BoldenFE , KorotzerA . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once daily treatment of moderate‐to‐severe acne vulgaris: assessment of safety in 498 patients. Journal of Clinical and Aesthetic Dermatology2015;8(5 Suppl 1):S6. PariserDM , RichP , Cook‐BoldenFE , KorotzerA . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once‐daily treatment of moderate to severe acne vulgaris. Journal of Drugs in Dermatology2014;13(9):1083‐9. [CENTRAL: CN‐01113744; MEDLINE: 25226009] Stein GoldL . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate and severe acne vulgaris subpopulations. Journal of Drugs in Dermatology2015; Vol. 14, issue 9:969‐74. [CENTRAL: CN‐01165932; MEDLINE: 26355615] ">Pariser 2014</a>, BPO/clindamycin was statistically superior to placebo in terms of lesion percentage reduction in both ILs and NILs. The percent change in ILs from baseline to week 12 was 60.6% with BPO/clindamycin versus 31.4% with placebo, and 51.6% versus 27.4% in NILs (both P values &lt; 0.001). </p> <p>Similar results were found in <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008,</a> in which 797 participants were randomised to the BPO/clindamycin group and 395 to the placebo group. The percentage reduction was 47.9% versus 26.2% in TLs, 54.6% versus 29.0% in ILs, and 43.2% versus 24.0% in NILs at week 12 (all P values &lt; 0.001). </p> <p>In <a href="./references#CD011154-bbs2-0100" title="FDA , Center for Drug Evaluation and Research. Study 152. Medical Review of NDA 50‐741. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/50‐741_duac%20topical%20gel_medr_p1.pdf. ">Study 152</a>, the percentage reduction in TLs, ILs, and NILs was 32.5% versus 20.6% (P = 0.003), 43.4% versus 28.6% (0.046), and 25.7% versus 15.4% (0.008) for the BPO/clindamycin group (n = 73) and the placebo group (n = 37). </p> <p><a href="./references#CD011154-bbs2-0018" title="DelRossoJ , GreenL , KempersS , TanghettiE . A comparison of initiating treatment for acne vulgaris with 5% benzoyl peroxide/1% clindamycin gel, 0.1% adapalene gel, or both for 4 weeks then combination therapy or 0.1% adapalene gel for 8 weeks. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB22. [CENTRAL: CN‐00602643] DelRossoJQ . Study results of benzoyl peroxide 5%/clindamycin 1% topical gel, adapalene 0.1% gel, and use in combination for acne vulgaris. Journal of Drugs in Dermatology2007;6(6):616‐22. [CENTRAL: CN‐00611006; MEDLINE: 17668527] ">Del 2007</a>, a 12‐week parallel trial including 37 participants on BPO/clindamycin plus adapalene and 37 participants on adapalene, showed that there was a statistically greater percentage reduction in TLs among participants on BPO/clindamycin plus adapalene than on adapalene (71% versus 52%; P &lt; 0.05) at week 12. A statistically greater reduction was also found in NILs (71% versus 51%; P &lt; 0.05). Despite no significant difference, BPO/clindamycin plus adapalene led to a greater reduction in ILs (71% versus 58%). </p> <p>For the comparison between BPO/clindamycin plus tazarotene versus placebo plus tazarotene (<a href="./references#CD011154-bbs2-0104" title="TanghettiE , AbramovitsW , SolomonB , LovenK , ShalitaA . Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double‐blind, randomized parallel‐group trial. Journal of Drugs in Dermatology2006;5(3):256‐61. [CENTRAL: CN‐00563788; MEDLINE: 16573259] ">Tanghetti 2006</a>), the number of papules and pustules was reduced by 63% among participants on BPO/clindamycin and by 58% among participants on placebo at week 12, but no significant difference was found. The percentage reduction in open and closed comedones was 70% and 60% (P &lt; 0.01). </p> <p><a href="./references#CD011154-bbs2-0007" title="BowmanS , GoldM , NasirA , VamvakiasG . Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and the combination of clindamycin/benzoyl peroxide and tretinoin plus clindamycin in the treatment of acne vulgaris: a randomized, blinded study. Journal of Drugs in Dermatology2005;4(5):611‐8. [CENTRAL: CN‐00530277; MEDLINE: 16167420] BowmanS , GoldMH , NasirA , VamvakiasG . Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and a combination of both regimens in the treatment of acne vulgaris: a randomized, blinded study. Abstract P147. American Academy of Dermatology, 64th Annual Meeting, March 3‐7, 2006. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB25. [CENTRAL: CN‐00602651] ">Bowman 2005</a> reported that at week 10, the percentage reduction in TLs, ILs, and NILs in the BPO/clindamycin plus tretinoin and clindamycin treatment groups was 62.6%, 69.3%, and 61.0%, respectively, compared to 49.6%, 52.5%, and 46.2% in the other group. A significant difference was found in the percentage reduction in ILs (P = 0.02). For medium‐term and short‐term treatment duration, the percentage reduction in TLs (medium‐term: 55.8% versus 40.9%; short‐term: 49.8% versus 35.3%), ILs (53.7% versus 44.9%; 52% versus 45.7%), and NILs (59.6% versus 37.9%; 48.6% versus 21.9%) was consistently greater in the BPO/clindamycin add‐on treatment group, but it is unclear whether significant differences existed, as no information about this was reported. </p> </section> </section> <section id="CD011154-sec-0371"> <h6 class="title">Secondary outcome: percentage of participants rated 'clear' or 'almost clear' on the IGA scale of acne severity </h6> <section id="CD011154-sec-0372"> <p><b>Main pooled analyses: BPO/clindamycin versus placebo or no treatment</b></p> <p>This outcome for the long term was reported in five trials (<a href="./references#CD011154-bbs2-0007" title="BowmanS , GoldM , NasirA , VamvakiasG . Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and the combination of clindamycin/benzoyl peroxide and tretinoin plus clindamycin in the treatment of acne vulgaris: a randomized, blinded study. Journal of Drugs in Dermatology2005;4(5):611‐8. [CENTRAL: CN‐00530277; MEDLINE: 16167420] BowmanS , GoldMH , NasirA , VamvakiasG . Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and a combination of both regimens in the treatment of acne vulgaris: a randomized, blinded study. Abstract P147. American Academy of Dermatology, 64th Annual Meeting, March 3‐7, 2006. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB25. [CENTRAL: CN‐00602651] ">Bowman 2005</a>; <a href="./references#CD011154-bbs2-0034" title="EichenfieldL , AlioA . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed dose combination gel for the treatment of acne vulgaris: a multicenter, double‐blind, parallel group, vehicle controlled study. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB10. [DOI: 10.1016/j.jaad.2011.11.049] EichenfieldLF , Alio SaenzAB . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed‐dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double‐blind, active‐ and vehicle‐controlled study. Journal of Drugs in Dermatology2011;10(12):1382‐96. [CENTRAL: CN‐00843726; MEDLINE: 22134562] NCT00776919 . A phase 3 multicenter, randomized, double‐blind, active and vehicle‐controlled study of the safety and efficacy of a clindamycin / benzoyl peroxide gel versus clindamycin gel versus benzoyl peroxide gel versus vehicle gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00776919 (first received 21 October 2008). ">Eichenfield 2011</a>; <a href="./references#CD011154-bbs2-0079" title="NCT01138514 . Clinical study between two clindamycin 1%/benzoyl peroxide 5% topical gels. clinicaltrials.gov/ct2/show/NCT01138514 (first received 4 June 2010). ">NCT01138514</a>; <a href="./references#CD011154-bbs2-0087" title="AlexisAF , Cook‐BoldenF , LinT , BulleyB . Treatment of moderate‐to‐severe acne vulgaris in a Hispanic population: a post‐hoc analysis of the efficacy and tolerability of clindamycin 1.2%/benzoyl peroxide 3.75% gel. Journal of Clinical and Aesthetic Dermatology2017;10(6):36‐43. [CENTRAL: CN‐01471496; MEDLINE: 28979655] Cook‐BoldenFE . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate or severe adolescent acne vulgaris. Journal of Clinical &amp; Aesthetic Dermatology2015;8(5):28‐32. [CENTRAL: CN‐01074689; MEDLINE: 26029332] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015; Vol. 8, issue 12:22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] HarperJC . The efficacy and tolerability of a fixed combination clindamycin (1.2%) and benzoyl peroxide (3.75%) aqueous gel in patients with facial acne vulgaris: gender as a clinically relevant outcome variable. Journal of Drugs in Dermatology2015;14(4):381‐4. [CENTRAL: CN‐01070825; MEDLINE: 25844612] PariserDM , RichP , Cook‐BoldenFE , KorotzerA . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once daily treatment of moderate‐to‐severe acne vulgaris: assessment of safety in 498 patients. Journal of Clinical and Aesthetic Dermatology2015;8(5 Suppl 1):S6. PariserDM , RichP , Cook‐BoldenFE , KorotzerA . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once‐daily treatment of moderate to severe acne vulgaris. Journal of Drugs in Dermatology2014;13(9):1083‐9. [CENTRAL: CN‐01113744; MEDLINE: 25226009] Stein GoldL . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate and severe acne vulgaris subpopulations. Journal of Drugs in Dermatology2015; Vol. 14, issue 9:969‐74. [CENTRAL: CN‐01165932; MEDLINE: 26355615] ">Pariser 2014</a>; <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>), in which 2226 participants were included in the BPO/clindamycin group and 1399 in the placebo group. The pooled risk ratio showed clear differences in the outcome (RR 2.37, 95% CI 1.87 to 3.01; 3993 participants; 5 studies; I² = 65%; <a href="./references#CD011154-fig-0099" title="">Analysis 14.8</a>), with substantial heterogeneity probably induced by the <a href="./references#CD011154-bbs2-0007" title="BowmanS , GoldM , NasirA , VamvakiasG . Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and the combination of clindamycin/benzoyl peroxide and tretinoin plus clindamycin in the treatment of acne vulgaris: a randomized, blinded study. Journal of Drugs in Dermatology2005;4(5):611‐8. [CENTRAL: CN‐00530277; MEDLINE: 16167420] BowmanS , GoldMH , NasirA , VamvakiasG . Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and a combination of both regimens in the treatment of acne vulgaris: a randomized, blinded study. Abstract P147. American Academy of Dermatology, 64th Annual Meeting, March 3‐7, 2006. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB25. [CENTRAL: CN‐00602651] ">Bowman 2005</a> and <a href="./references#CD011154-bbs2-0079" title="NCT01138514 . Clinical study between two clindamycin 1%/benzoyl peroxide 5% topical gels. clinicaltrials.gov/ct2/show/NCT01138514 (first received 4 June 2010). ">NCT01138514</a> trials, in which the concentration of BPO was higher (5%) than in the others (2.5% or 3%). </p> </section> <section id="CD011154-sec-0373"> <p><b>Subgroup analyses: co‐intervention</b></p> <p>We did not find that the effects of BPO on this outcome can differ by co‐intervention, with a P value of 0.25 (<a href="./references#CD011154-fig-0099" title="">Analysis 14.8</a>). </p> </section> </section> <section id="CD011154-sec-0374"> <h6 class="title">Secondary outcome: change in quality of life</h6> <section id="CD011154-sec-0375"> <p><b>Studies not included in the meta‐analysis</b></p> <p><a href="./references#CD011154-bbs2-0087" title="AlexisAF , Cook‐BoldenF , LinT , BulleyB . Treatment of moderate‐to‐severe acne vulgaris in a Hispanic population: a post‐hoc analysis of the efficacy and tolerability of clindamycin 1.2%/benzoyl peroxide 3.75% gel. Journal of Clinical and Aesthetic Dermatology2017;10(6):36‐43. [CENTRAL: CN‐01471496; MEDLINE: 28979655] Cook‐BoldenFE . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate or severe adolescent acne vulgaris. Journal of Clinical &amp; Aesthetic Dermatology2015;8(5):28‐32. [CENTRAL: CN‐01074689; MEDLINE: 26029332] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015; Vol. 8, issue 12:22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] HarperJC . The efficacy and tolerability of a fixed combination clindamycin (1.2%) and benzoyl peroxide (3.75%) aqueous gel in patients with facial acne vulgaris: gender as a clinically relevant outcome variable. Journal of Drugs in Dermatology2015;14(4):381‐4. [CENTRAL: CN‐01070825; MEDLINE: 25844612] PariserDM , RichP , Cook‐BoldenFE , KorotzerA . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once daily treatment of moderate‐to‐severe acne vulgaris: assessment of safety in 498 patients. Journal of Clinical and Aesthetic Dermatology2015;8(5 Suppl 1):S6. PariserDM , RichP , Cook‐BoldenFE , KorotzerA . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once‐daily treatment of moderate to severe acne vulgaris. Journal of Drugs in Dermatology2014;13(9):1083‐9. [CENTRAL: CN‐01113744; MEDLINE: 25226009] Stein GoldL . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate and severe acne vulgaris subpopulations. Journal of Drugs in Dermatology2015; Vol. 14, issue 9:969‐74. [CENTRAL: CN‐01165932; MEDLINE: 26355615] ">Pariser 2014</a> reported this outcome as assessed by the acne‐specific quality of life (Acne‐QoL) questionnaire. There was no significant difference in the mean score for each domain at week 12, although each domain was scored higher in the BPO/clindamycin group (7.6 versus 5.9 in self‐perception, 5.5 versus 4.5 in role‐emotional, 4.7 versus 3.7 in role‐social, and 6.5 versus 4.3 in acne symptoms). </p> </section> </section> <section id="CD011154-sec-0376"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <p>Ten trials reported adverse events (<a href="./references#CD011154-bbs2-0007" title="BowmanS , GoldM , NasirA , VamvakiasG . Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and the combination of clindamycin/benzoyl peroxide and tretinoin plus clindamycin in the treatment of acne vulgaris: a randomized, blinded study. Journal of Drugs in Dermatology2005;4(5):611‐8. [CENTRAL: CN‐00530277; MEDLINE: 16167420] BowmanS , GoldMH , NasirA , VamvakiasG . Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and a combination of both regimens in the treatment of acne vulgaris: a randomized, blinded study. Abstract P147. American Academy of Dermatology, 64th Annual Meeting, March 3‐7, 2006. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB25. [CENTRAL: CN‐00602651] ">Bowman 2005</a>; <a href="./references#CD011154-bbs2-0018" title="DelRossoJ , GreenL , KempersS , TanghettiE . A comparison of initiating treatment for acne vulgaris with 5% benzoyl peroxide/1% clindamycin gel, 0.1% adapalene gel, or both for 4 weeks then combination therapy or 0.1% adapalene gel for 8 weeks. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB22. [CENTRAL: CN‐00602643] DelRossoJQ . Study results of benzoyl peroxide 5%/clindamycin 1% topical gel, adapalene 0.1% gel, and use in combination for acne vulgaris. Journal of Drugs in Dermatology2007;6(6):616‐22. [CENTRAL: CN‐00611006; MEDLINE: 17668527] ">Del 2007</a>; <a href="./references#CD011154-bbs2-0034" title="EichenfieldL , AlioA . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed dose combination gel for the treatment of acne vulgaris: a multicenter, double‐blind, parallel group, vehicle controlled study. Journal of the American Academy of Dermatology2012;66(4 Suppl 1):AB10. [DOI: 10.1016/j.jaad.2011.11.049] EichenfieldLF , Alio SaenzAB . Safety and efficacy of clindamycin phosphate 1.2%‐benzoyl peroxide 3% fixed‐dose combination gel for the treatment of acne vulgaris: a phase 3, multicenter, randomized, double‐blind, active‐ and vehicle‐controlled study. Journal of Drugs in Dermatology2011;10(12):1382‐96. [CENTRAL: CN‐00843726; MEDLINE: 22134562] NCT00776919 . A phase 3 multicenter, randomized, double‐blind, active and vehicle‐controlled study of the safety and efficacy of a clindamycin / benzoyl peroxide gel versus clindamycin gel versus benzoyl peroxide gel versus vehicle gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00776919 (first received 21 October 2008). ">Eichenfield 2011</a>; <a href="./references#CD011154-bbs2-0066" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM . Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] LeydenJ , et al. Treatment of acne vulgaris with a combination benzoyl peroxide/clindamycin topical gel Abstract P‐013. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S144. [CENTRAL: CN‐00478651] LeydenJJ , BergerRS , DunlapFE , EllisCN , ConnollyMA , LevySF . Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. American Journal of Clinical Dermatology2001;2(1):33‐9. [CENTRAL: CN‐00363426; MEDLINE: 11702619] ">Leyden 2001a</a>; <a href="./references#CD011154-bbs2-0069" title="LookingbillDP , ChalkerDK , LindholmJS , KatzHI , KempersSE , HuerterCJ , et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double‐blind investigations. Journal of the American Academy of Dermatology1997;37(4):590‐5. [CENTRAL: CN‐00144503; MEDLINE: 9344199] LookingbillDP , ChallenDK , LindholmJS . Treatment of acne with a combination of clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined result of two double blind investigations (Abstract no. 1). Indian Journal of Dermatology, Venerology and Leprology1995;61:398. ">Lookingbill 1997</a>; <a href="./references#CD011154-bbs2-0078" title="NCT01044264 . Clinical study between two 1% clindamycin/5% benzoyl peroxide topical gel formulations. https://clinicaltrials.gov/ct2/show/NCT01044264 (first received 4 January 2010). ">NCT01044264</a>; <a href="./references#CD011154-bbs2-0079" title="NCT01138514 . Clinical study between two clindamycin 1%/benzoyl peroxide 5% topical gels. clinicaltrials.gov/ct2/show/NCT01138514 (first received 4 June 2010). ">NCT01138514</a>; <a href="./references#CD011154-bbs2-0087" title="AlexisAF , Cook‐BoldenF , LinT , BulleyB . Treatment of moderate‐to‐severe acne vulgaris in a Hispanic population: a post‐hoc analysis of the efficacy and tolerability of clindamycin 1.2%/benzoyl peroxide 3.75% gel. Journal of Clinical and Aesthetic Dermatology2017;10(6):36‐43. [CENTRAL: CN‐01471496; MEDLINE: 28979655] Cook‐BoldenFE . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate or severe adolescent acne vulgaris. Journal of Clinical &amp; Aesthetic Dermatology2015;8(5):28‐32. [CENTRAL: CN‐01074689; MEDLINE: 26029332] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015; Vol. 8, issue 12:22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] HarperJC . The efficacy and tolerability of a fixed combination clindamycin (1.2%) and benzoyl peroxide (3.75%) aqueous gel in patients with facial acne vulgaris: gender as a clinically relevant outcome variable. Journal of Drugs in Dermatology2015;14(4):381‐4. [CENTRAL: CN‐01070825; MEDLINE: 25844612] PariserDM , RichP , Cook‐BoldenFE , KorotzerA . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once daily treatment of moderate‐to‐severe acne vulgaris: assessment of safety in 498 patients. Journal of Clinical and Aesthetic Dermatology2015;8(5 Suppl 1):S6. PariserDM , RichP , Cook‐BoldenFE , KorotzerA . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once‐daily treatment of moderate to severe acne vulgaris. Journal of Drugs in Dermatology2014;13(9):1083‐9. [CENTRAL: CN‐01113744; MEDLINE: 25226009] Stein GoldL . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and benzoyl peroxide (3.75%) aqueous gel in moderate and severe acne vulgaris subpopulations. Journal of Drugs in Dermatology2015; Vol. 14, issue 9:969‐74. [CENTRAL: CN‐01165932; MEDLINE: 26355615] ">Pariser 2014</a>; <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>; <a href="./references#CD011154-bbs2-0109" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM , et al. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] TschenE , et al. A combination benzoyl peroxide/clindamycin topical gel for the treatment of acne vulgaris. Abstract P‐029. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S150. [CENTRAL: CN‐00478786] TschenEH , KatzHI , JonesTM , MonroeEW , KrausSJ , ConnollyMA , et al. A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2):165‐9. [CENTRAL: CN‐00346768; MEDLINE: 11236229] ">Tschen 2001</a>), all of which investigated BPO/clindamycin versus placebo or no treatment, with no additional co‐interventions. </p> <section id="CD011154-sec-0377"> <p><b>Main pooled analyses: BPO/clindamycin versus placebo or no treatment</b></p> <p>With sufficient data for the meta‐analysis in eight trials, the pooled risk ratio was 0.91 (95% CI 0.78 to 1.07; 5042 participants; I² = 24%; <a href="./references#CD011154-fig-0100" title="">Analysis 14.9</a>). The most common adverse events observed across included trials were skin dryness, irritation, desquamation, and erythema. </p> </section> <section id="CD011154-sec-0378"> <p><b>Studies not included in the meta‐analysis</b></p> <p>We cannot calculate RR as the effect size because the number of participants with at least one adverse event was not provided in the <a href="./references#CD011154-bbs2-0018" title="DelRossoJ , GreenL , KempersS , TanghettiE . A comparison of initiating treatment for acne vulgaris with 5% benzoyl peroxide/1% clindamycin gel, 0.1% adapalene gel, or both for 4 weeks then combination therapy or 0.1% adapalene gel for 8 weeks. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB22. [CENTRAL: CN‐00602643] DelRossoJQ . Study results of benzoyl peroxide 5%/clindamycin 1% topical gel, adapalene 0.1% gel, and use in combination for acne vulgaris. Journal of Drugs in Dermatology2007;6(6):616‐22. [CENTRAL: CN‐00611006; MEDLINE: 17668527] ">Del 2007</a> and <a href="./references#CD011154-bbs2-0104" title="TanghettiE , AbramovitsW , SolomonB , LovenK , ShalitaA . Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double‐blind, randomized parallel‐group trial. Journal of Drugs in Dermatology2006;5(3):256‐61. [CENTRAL: CN‐00563788; MEDLINE: 16573259] ">Tanghetti 2006</a> trials. In <a href="./references#CD011154-bbs2-0018" title="DelRossoJ , GreenL , KempersS , TanghettiE . A comparison of initiating treatment for acne vulgaris with 5% benzoyl peroxide/1% clindamycin gel, 0.1% adapalene gel, or both for 4 weeks then combination therapy or 0.1% adapalene gel for 8 weeks. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB22. [CENTRAL: CN‐00602643] DelRossoJQ . Study results of benzoyl peroxide 5%/clindamycin 1% topical gel, adapalene 0.1% gel, and use in combination for acne vulgaris. Journal of Drugs in Dermatology2007;6(6):616‐22. [CENTRAL: CN‐00611006; MEDLINE: 17668527] ">Del 2007</a>, the proportion of participants experiencing erythema, dryness, burning, and pruritus was 14.8% versus 24.3%, 51.6% versus 56.8%, 11.2% versus 12.6%, and 8.5% versus 15.5%. A significant difference was found in erythema (P &lt; 0.05). <a href="./references#CD011154-bbs2-0104" title="TanghettiE , AbramovitsW , SolomonB , LovenK , ShalitaA . Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double‐blind, randomized parallel‐group trial. Journal of Drugs in Dermatology2006;5(3):256‐61. [CENTRAL: CN‐00563788; MEDLINE: 16573259] ">Tanghetti 2006</a>, the other trial, found no significant difference in the incidence of peeling and dryness between groups (10% versus 18% and 8% versus 12%, respectively). Trial authors reported no significant differences in grading for erythema, burning, dryness, or pruritus. </p> </section> </section> </section> <section id="CD011154-sec-0379"> <h5 class="title">BPO/clindamycin versus adapalene</h5> <p>The comparison was made in four parallel trials (<a href="./references#CD011154-bbs2-0028" title="DubeyA , AmaneH . Comparison of efficacy and safety of adapalene and benzoyl peroxide‐clindamycin combination in the topical treatment of acne vulgaris. International Journal of Basic &amp; Clinical Pharmacology2016;5(5):1727‐32. [DOI: 10.18203/2319‐2003.ijbcp20163207] ">Dubey 2016</a>; <a href="./references#CD011154-bbs2-0046" title="Guerra‐TapiaA . Effects of benzoyl peroxide 5% clindamycin combination gel versus adapalene 0.1% on quality of life in patients with mild to moderate acne vulgaris: a randomized single‐blind study. Journal of Drugs in Dermatology2012;11(6):714‐22. [CENTRAL: CN‐00859793; MEDLINE: 22648218] NCT00807014 . Evaluation of quality of life, efficacy, and tolerance of Duac® gel compared to Differin® gel in the treatment of acne. www.clinicaltrials.gov/ct2/show/NCT00807014 (first received 10 December 2008). ">Guerra‐Tapia 2012</a>; <a href="./references#CD011154-bbs2-0062" title="KoHC , SongM , SeoSH , OhCK , KwonKS , KimMB . Prospective, open‐label, comparative study of clindamycin 1%/benzoyl peroxide 5% gel with adapalene 0.1% gel in Asian acne patients: efficacy and tolerability. Journal of the European Academy of Dermatology &amp; Venereology2009;23(3):245‐50. [CENTRAL: CN‐00697965; MEDLINE: 19438817] ">Ko 2009</a>; <a href="./references#CD011154-bbs2-0065" title="LangnerA , ChuA , GouldenV , AmbroziakM . A randomized, single‐blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris. British Journal of Dermatology2008;158(1):122‐9. [CENTRAL: CN‐00628563; MEDLINE: 18047518] ">Langner 2008</a>), which provided data for all outcomes of interest in this review except the Investigator Global Assessment. Participants were followed up to 12 weeks in these trials. </p> <section id="CD011154-sec-0380"> <h6 class="title">Primary outcome: participant global self‐assessment of acne improvement</h6> <p>This outcome was assessed in two trials (<a href="./references#CD011154-bbs2-0046" title="Guerra‐TapiaA . Effects of benzoyl peroxide 5% clindamycin combination gel versus adapalene 0.1% on quality of life in patients with mild to moderate acne vulgaris: a randomized single‐blind study. Journal of Drugs in Dermatology2012;11(6):714‐22. [CENTRAL: CN‐00859793; MEDLINE: 22648218] NCT00807014 . Evaluation of quality of life, efficacy, and tolerance of Duac® gel compared to Differin® gel in the treatment of acne. www.clinicaltrials.gov/ct2/show/NCT00807014 (first received 10 December 2008). ">Guerra‐Tapia 2012</a>; <a href="./references#CD011154-bbs2-0065" title="LangnerA , ChuA , GouldenV , AmbroziakM . A randomized, single‐blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris. British Journal of Dermatology2008;158(1):122‐9. [CENTRAL: CN‐00628563; MEDLINE: 18047518] ">Langner 2008</a>), one of which presented data in accordance with the definition of the outcome in our review (<a href="./references#CD011154-bbs2-0046" title="Guerra‐TapiaA . Effects of benzoyl peroxide 5% clindamycin combination gel versus adapalene 0.1% on quality of life in patients with mild to moderate acne vulgaris: a randomized single‐blind study. Journal of Drugs in Dermatology2012;11(6):714‐22. [CENTRAL: CN‐00859793; MEDLINE: 22648218] NCT00807014 . Evaluation of quality of life, efficacy, and tolerance of Duac® gel compared to Differin® gel in the treatment of acne. www.clinicaltrials.gov/ct2/show/NCT00807014 (first received 10 December 2008). ">Guerra‐Tapia 2012</a>). </p> <section id="CD011154-sec-0381"> <p><b>Main pooled analyses: BPO/clindamycin versus adapalene</b></p> <p><a href="./references#CD011154-bbs2-0046" title="Guerra‐TapiaA . Effects of benzoyl peroxide 5% clindamycin combination gel versus adapalene 0.1% on quality of life in patients with mild to moderate acne vulgaris: a randomized single‐blind study. Journal of Drugs in Dermatology2012;11(6):714‐22. [CENTRAL: CN‐00859793; MEDLINE: 22648218] NCT00807014 . Evaluation of quality of life, efficacy, and tolerance of Duac® gel compared to Differin® gel in the treatment of acne. www.clinicaltrials.gov/ct2/show/NCT00807014 (first received 10 December 2008). ">Guerra‐Tapia 2012</a> included 83 participants in the BPO/clindamycin group and 85 participants in the adapalene group. The outcome was assessed with a 12‐grade system. The risk ratio of self‐rated improvement was 1.12 (95% CI 0.96 to 1.31) (83% versus 74%) at week 12 (<a href="./references#CD011154-fig-0101" title="">Analysis 15.1</a>). </p> </section> <section id="CD011154-sec-0382"> <p><b>Studies not included in the meta‐analysis</b></p> <p>We cannot pool this result with those from the other trial ‐ <a href="./references#CD011154-bbs2-0065" title="LangnerA , ChuA , GouldenV , AmbroziakM . A randomized, single‐blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris. British Journal of Dermatology2008;158(1):122‐9. [CENTRAL: CN‐00628563; MEDLINE: 18047518] ">Langner 2008</a> ‐ because the outcome was assessed on a different definition. In <a href="./references#CD011154-bbs2-0065" title="LangnerA , ChuA , GouldenV , AmbroziakM . A randomized, single‐blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris. British Journal of Dermatology2008;158(1):122‐9. [CENTRAL: CN‐00628563; MEDLINE: 18047518] ">Langner 2008</a>, 65 participants randomised to the BPO/clindamycin group and 65 to the adapalene group rated their condition as improved, no change, or worse. Trial authors reported that the percentage of improvement increased over time to about 90% at week 12 for both treatment groups. Although the proportion of improvement was greater early in treatment with BPO/clindamycin (weeks 1, 2, 4, and 8), no significant difference was found at week 12. </p> </section> </section> <section id="CD011154-sec-0383"> <h6 class="title">Primary outcome: withdrawal due to adverse effects</h6> <section id="CD011154-sec-0384"> <p><b>Main pooled analyses: BPO/clindamycin versus adapalene</b></p> <p>The outcome was reported in three trials (<a href="./references#CD011154-bbs2-0028" title="DubeyA , AmaneH . Comparison of efficacy and safety of adapalene and benzoyl peroxide‐clindamycin combination in the topical treatment of acne vulgaris. International Journal of Basic &amp; Clinical Pharmacology2016;5(5):1727‐32. [DOI: 10.18203/2319‐2003.ijbcp20163207] ">Dubey 2016</a>; <a href="./references#CD011154-bbs2-0046" title="Guerra‐TapiaA . Effects of benzoyl peroxide 5% clindamycin combination gel versus adapalene 0.1% on quality of life in patients with mild to moderate acne vulgaris: a randomized single‐blind study. Journal of Drugs in Dermatology2012;11(6):714‐22. [CENTRAL: CN‐00859793; MEDLINE: 22648218] NCT00807014 . Evaluation of quality of life, efficacy, and tolerance of Duac® gel compared to Differin® gel in the treatment of acne. www.clinicaltrials.gov/ct2/show/NCT00807014 (first received 10 December 2008). ">Guerra‐Tapia 2012</a>; <a href="./references#CD011154-bbs2-0065" title="LangnerA , ChuA , GouldenV , AmbroziakM . A randomized, single‐blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris. British Journal of Dermatology2008;158(1):122‐9. [CENTRAL: CN‐00628563; MEDLINE: 18047518] ">Langner 2008</a>). No evidence suggests that participants treated with BPO/clindamycin had higher risk of withdrawal due to adverse effects. The risk ratio was 0.41 (95% CI 0.05 to 3.05; 398 participants; 3 studies; I² = 0%; <a href="./references#CD011154-fig-0102" title="">Analysis 15.2</a>). <a href="./references#CD011154-bbs2-0046" title="Guerra‐TapiaA . Effects of benzoyl peroxide 5% clindamycin combination gel versus adapalene 0.1% on quality of life in patients with mild to moderate acne vulgaris: a randomized single‐blind study. Journal of Drugs in Dermatology2012;11(6):714‐22. [CENTRAL: CN‐00859793; MEDLINE: 22648218] NCT00807014 . Evaluation of quality of life, efficacy, and tolerance of Duac® gel compared to Differin® gel in the treatment of acne. www.clinicaltrials.gov/ct2/show/NCT00807014 (first received 10 December 2008). ">Guerra‐Tapia 2012</a> did not specify any adverse events leading to treatment discontinuation. In <a href="./references#CD011154-bbs2-0065" title="LangnerA , ChuA , GouldenV , AmbroziakM . A randomized, single‐blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris. British Journal of Dermatology2008;158(1):122‐9. [CENTRAL: CN‐00628563; MEDLINE: 18047518] ">Langner 2008</a>, one participant in each group experienced adverse events leading to withdrawal from the study (BPO/clindamycin: erythema, burning, and pruritus; adapalene: dermatitis). No participants discontinued treatment due to adverse events in <a href="./references#CD011154-bbs2-0028" title="DubeyA , AmaneH . Comparison of efficacy and safety of adapalene and benzoyl peroxide‐clindamycin combination in the topical treatment of acne vulgaris. International Journal of Basic &amp; Clinical Pharmacology2016;5(5):1727‐32. [DOI: 10.18203/2319‐2003.ijbcp20163207] ">Dubey 2016</a>. </p> </section> </section> <section id="CD011154-sec-0385"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <p>All the four trials assessed the mean or percentage reduction in lesion counts, none of which, however, provided sufficient data to estimate effect size (<a href="./references#CD011154-bbs2-0028" title="DubeyA , AmaneH . Comparison of efficacy and safety of adapalene and benzoyl peroxide‐clindamycin combination in the topical treatment of acne vulgaris. International Journal of Basic &amp; Clinical Pharmacology2016;5(5):1727‐32. [DOI: 10.18203/2319‐2003.ijbcp20163207] ">Dubey 2016</a>; <a href="./references#CD011154-bbs2-0046" title="Guerra‐TapiaA . Effects of benzoyl peroxide 5% clindamycin combination gel versus adapalene 0.1% on quality of life in patients with mild to moderate acne vulgaris: a randomized single‐blind study. Journal of Drugs in Dermatology2012;11(6):714‐22. [CENTRAL: CN‐00859793; MEDLINE: 22648218] NCT00807014 . Evaluation of quality of life, efficacy, and tolerance of Duac® gel compared to Differin® gel in the treatment of acne. www.clinicaltrials.gov/ct2/show/NCT00807014 (first received 10 December 2008). ">Guerra‐Tapia 2012</a>; <a href="./references#CD011154-bbs2-0062" title="KoHC , SongM , SeoSH , OhCK , KwonKS , KimMB . Prospective, open‐label, comparative study of clindamycin 1%/benzoyl peroxide 5% gel with adapalene 0.1% gel in Asian acne patients: efficacy and tolerability. Journal of the European Academy of Dermatology &amp; Venereology2009;23(3):245‐50. [CENTRAL: CN‐00697965; MEDLINE: 19438817] ">Ko 2009</a>; <a href="./references#CD011154-bbs2-0065" title="LangnerA , ChuA , GouldenV , AmbroziakM . A randomized, single‐blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris. British Journal of Dermatology2008;158(1):122‐9. [CENTRAL: CN‐00628563; MEDLINE: 18047518] ">Langner 2008</a>). </p> <section id="CD011154-sec-0386"> <p><b>Studies not included in the meta‐analysis</b></p> <p>In <a href="./references#CD011154-bbs2-0028" title="DubeyA , AmaneH . Comparison of efficacy and safety of adapalene and benzoyl peroxide‐clindamycin combination in the topical treatment of acne vulgaris. International Journal of Basic &amp; Clinical Pharmacology2016;5(5):1727‐32. [DOI: 10.18203/2319‐2003.ijbcp20163207] ">Dubey 2016</a>, trial authors found that mean NIL, IL, and total counts were reduced from 24.74 at baseline to 5.23 at week 12, from 16.38 to 2.12 and from 27.53 to 5.59, respectively, in the BPO/clindamycin group. Counterparts in the clindamycin group were from 25.91 to 3.95, from 16.25 to 2.00, and from 28.68 to 4.29, respectively. Trial authors stated that no statistical difference was found between two groups for any type of lesion count. <a href="./references#CD011154-bbs2-0046" title="Guerra‐TapiaA . Effects of benzoyl peroxide 5% clindamycin combination gel versus adapalene 0.1% on quality of life in patients with mild to moderate acne vulgaris: a randomized single‐blind study. Journal of Drugs in Dermatology2012;11(6):714‐22. [CENTRAL: CN‐00859793; MEDLINE: 22648218] NCT00807014 . Evaluation of quality of life, efficacy, and tolerance of Duac® gel compared to Differin® gel in the treatment of acne. www.clinicaltrials.gov/ct2/show/NCT00807014 (first received 10 December 2008). ">Guerra‐Tapia 2012</a> found a significant difference in the reduction in TLs (‐33.9 versus ‐27.1; P &lt; 0.05), ILs (‐17.0 versus ‐15.1; P &lt; 0.05), and NILs (‐20.1 versus ‐18.0; non‐significance) at week 12. In another trial ‐ <a href="./references#CD011154-bbs2-0062" title="KoHC , SongM , SeoSH , OhCK , KwonKS , KimMB . Prospective, open‐label, comparative study of clindamycin 1%/benzoyl peroxide 5% gel with adapalene 0.1% gel in Asian acne patients: efficacy and tolerability. Journal of the European Academy of Dermatology &amp; Venereology2009;23(3):245‐50. [CENTRAL: CN‐00697965; MEDLINE: 19438817] ">Ko 2009</a> ‐ investigators claimed that TLs (‐44.9 versus ‐34.1; P = 0.017) and ILs (‐29.7 versus ‐19.2; P = 0.026) were significantly reduced in 31 participants in the BPO/clindamycin group at week 12 compared to 38 participants in the adapalene group; however, this significant difference was not found in NILs (‐14.8 versus ‐15.0). <a href="./references#CD011154-bbs2-0065" title="LangnerA , ChuA , GouldenV , AmbroziakM . A randomized, single‐blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris. British Journal of Dermatology2008;158(1):122‐9. [CENTRAL: CN‐00628563; MEDLINE: 18047518] ">Langner 2008</a> found that percentage reduction at week 12 was 70.4% versus 53.1% in TLs (P &lt; 0.005), 81.5% versus 58.2% in ILs (P &lt; 0.001), and 61.9% versus 50.0% in NILs (P &lt; 0.005). </p> </section> </section> <section id="CD011154-sec-0387"> <h6 class="title">Secondary outcome: change in quality of life</h6> <section id="CD011154-sec-0388"> <p><b>Main pooled analyses: BPO/clindamycin versus adapalene</b></p> <p><a href="./references#CD011154-bbs2-0046" title="Guerra‐TapiaA . Effects of benzoyl peroxide 5% clindamycin combination gel versus adapalene 0.1% on quality of life in patients with mild to moderate acne vulgaris: a randomized single‐blind study. Journal of Drugs in Dermatology2012;11(6):714‐22. [CENTRAL: CN‐00859793; MEDLINE: 22648218] NCT00807014 . Evaluation of quality of life, efficacy, and tolerance of Duac® gel compared to Differin® gel in the treatment of acne. www.clinicaltrials.gov/ct2/show/NCT00807014 (first received 10 December 2008). ">Guerra‐Tapia 2012</a> reported this outcome as assessed with Skindex‐29. A significant difference was found for the long‐term (MD ‐4.20, 95% CI ‐7.06 to ‐1.34; 168 participants; <a href="./references#CD011154-fig-0103" title="">Analysis 15.3</a>) and short‐term periods (MD ‐3.80, 95% CI ‐6.16 to ‐1.44; 168 participants; <a href="./references#CD011154-fig-0104" title="">Analysis 15.4</a>) in favour of BPO/clindamycin. </p> </section> </section> <section id="CD011154-sec-0389"> <h6 class="title">Secondary outcome: reduction in <i>C acnes</i> strains </h6> <section id="CD011154-sec-0390"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Twenty samples were collected from each group (BPO/clindamycin and adapalene groups) (<a href="./references#CD011154-bbs2-0065" title="LangnerA , ChuA , GouldenV , AmbroziakM . A randomized, single‐blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris. British Journal of Dermatology2008;158(1):122‐9. [CENTRAL: CN‐00628563; MEDLINE: 18047518] ">Langner 2008</a>). The reduction in total, erythromycin‐resistant, and clindamycin‐resistant <i>C acnes</i> strains at week 12 was ‐1.24 versus 0.50 versus ‐0.91 versus 0.13 and ‐0.80 versus 0.09 log<sub>10</sub> CFU cm<sup>‐2</sup>. It is unclear whether the difference was significant. </p> </section> </section> <section id="CD011154-sec-0391"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <p>All four trials reported adverse events (<a href="./references#CD011154-bbs2-0028" title="DubeyA , AmaneH . Comparison of efficacy and safety of adapalene and benzoyl peroxide‐clindamycin combination in the topical treatment of acne vulgaris. International Journal of Basic &amp; Clinical Pharmacology2016;5(5):1727‐32. [DOI: 10.18203/2319‐2003.ijbcp20163207] ">Dubey 2016</a>; <a href="./references#CD011154-bbs2-0046" title="Guerra‐TapiaA . Effects of benzoyl peroxide 5% clindamycin combination gel versus adapalene 0.1% on quality of life in patients with mild to moderate acne vulgaris: a randomized single‐blind study. Journal of Drugs in Dermatology2012;11(6):714‐22. [CENTRAL: CN‐00859793; MEDLINE: 22648218] NCT00807014 . Evaluation of quality of life, efficacy, and tolerance of Duac® gel compared to Differin® gel in the treatment of acne. www.clinicaltrials.gov/ct2/show/NCT00807014 (first received 10 December 2008). ">Guerra‐Tapia 2012</a>; <a href="./references#CD011154-bbs2-0062" title="KoHC , SongM , SeoSH , OhCK , KwonKS , KimMB . Prospective, open‐label, comparative study of clindamycin 1%/benzoyl peroxide 5% gel with adapalene 0.1% gel in Asian acne patients: efficacy and tolerability. Journal of the European Academy of Dermatology &amp; Venereology2009;23(3):245‐50. [CENTRAL: CN‐00697965; MEDLINE: 19438817] ">Ko 2009</a>; <a href="./references#CD011154-bbs2-0065" title="LangnerA , ChuA , GouldenV , AmbroziakM . A randomized, single‐blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris. British Journal of Dermatology2008;158(1):122‐9. [CENTRAL: CN‐00628563; MEDLINE: 18047518] ">Langner 2008</a>), two of which presented sufficient data for the meta‐analysis (<a href="./references#CD011154-bbs2-0046" title="Guerra‐TapiaA . Effects of benzoyl peroxide 5% clindamycin combination gel versus adapalene 0.1% on quality of life in patients with mild to moderate acne vulgaris: a randomized single‐blind study. Journal of Drugs in Dermatology2012;11(6):714‐22. [CENTRAL: CN‐00859793; MEDLINE: 22648218] NCT00807014 . Evaluation of quality of life, efficacy, and tolerance of Duac® gel compared to Differin® gel in the treatment of acne. www.clinicaltrials.gov/ct2/show/NCT00807014 (first received 10 December 2008). ">Guerra‐Tapia 2012</a>; <a href="./references#CD011154-bbs2-0065" title="LangnerA , ChuA , GouldenV , AmbroziakM . A randomized, single‐blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris. British Journal of Dermatology2008;158(1):122‐9. [CENTRAL: CN‐00628563; MEDLINE: 18047518] ">Langner 2008</a>). </p> <section id="CD011154-sec-0392"> <p><b>Main pooled analyses: BPO/clindamycin versus adapalene</b></p> <p>With a total of 148 participants in the BPO/clindamycin group and 150 in the adapalene group, the pooled risk ratio was 0.60 (95% CI 0.36 to 1.01; 298 participants; 2 studies; I² = 0%; <a href="./references#CD011154-fig-0105" title="">Analysis 15.5</a>), and the difference between groups was not statistically significant. In <a href="./references#CD011154-bbs2-0046" title="Guerra‐TapiaA . Effects of benzoyl peroxide 5% clindamycin combination gel versus adapalene 0.1% on quality of life in patients with mild to moderate acne vulgaris: a randomized single‐blind study. Journal of Drugs in Dermatology2012;11(6):714‐22. [CENTRAL: CN‐00859793; MEDLINE: 22648218] NCT00807014 . Evaluation of quality of life, efficacy, and tolerance of Duac® gel compared to Differin® gel in the treatment of acne. www.clinicaltrials.gov/ct2/show/NCT00807014 (first received 10 December 2008). ">Guerra‐Tapia 2012</a>, among 83 participants treated with BPO/clindamycin, site reactions, nasopharyngitis, and nervous system disorders occurred in five, eight, and five participants, respectively. In the adapalene group of 85 participants, counterparts were 14, 27, and 8, respectively. In <a href="./references#CD011154-bbs2-0065" title="LangnerA , ChuA , GouldenV , AmbroziakM . A randomized, single‐blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of mild to moderate facial acne vulgaris. British Journal of Dermatology2008;158(1):122‐9. [CENTRAL: CN‐00628563; MEDLINE: 18047518] ">Langner 2008</a>, only one (1.5%) participant in the BPO/clindamycin group was considered to have treatment‐related adverse events (burning, erythema, and dryness). In the adapalene group, seven (10.8%) participants had adverse events (application site burning, dermatitis, desquamation, dryness, erythema, pain, and pruritus). </p> </section> <section id="CD011154-sec-0393"> <p><b>Studies not included in the meta‐analysis</b></p> <p>In <a href="./references#CD011154-bbs2-0028" title="DubeyA , AmaneH . Comparison of efficacy and safety of adapalene and benzoyl peroxide‐clindamycin combination in the topical treatment of acne vulgaris. International Journal of Basic &amp; Clinical Pharmacology2016;5(5):1727‐32. [DOI: 10.18203/2319‐2003.ijbcp20163207] ">Dubey 2016</a>, dryness was the only adverse event reported, which was observed in 2.1% of participants treated with adapalene, but dryness (2.2%) and itching (2.2%) were found in the BPO/clindamycin group. <a href="./references#CD011154-bbs2-0062" title="KoHC , SongM , SeoSH , OhCK , KwonKS , KimMB . Prospective, open‐label, comparative study of clindamycin 1%/benzoyl peroxide 5% gel with adapalene 0.1% gel in Asian acne patients: efficacy and tolerability. Journal of the European Academy of Dermatology &amp; Venereology2009;23(3):245‐50. [CENTRAL: CN‐00697965; MEDLINE: 19438817] ">Ko 2009</a> reported that both drugs were well tolerated, with most mild adverse events observed within one month of treatments, such as erythema, desquamation, stinging/burning sensation, dry skin, and pruritus. </p> </section> </section> </section> <section id="CD011154-sec-0394"> <h5 class="title">BPO/clindamycin versus azelaic acid</h5> <p>The comparison was made in one parallel trial (<a href="./references#CD011154-bbs2-0089" title="2013‐004158‐81 . A multi‐centre, single‐blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1%/benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2013‐004158‐81/results (results published 15 March 2016). NCT02058628 . Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02058628 (first received 6 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single‐blind, parallel‐group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild‐to‐moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016; Vol. 30, issue 6:966‐73. [CENTRAL: CN‐01369030; MEDLINE: 26915831] ">Schaller 2016</a>), which provided data for all outcomes of our review interest except the Investigator Global Assessment and reduction in <i>C acnes</i> strains. Participants were followed up to 12 weeks in this trial. </p> <section id="CD011154-sec-0395"> <h6 class="title">Primary outcome: participant global self‐assessment of acne improvement</h6> <section id="CD011154-sec-0396"> <p><b>Main pooled analyses: BPO/clindamycin versus azelaic acid</b></p> <p><a href="./references#CD011154-bbs2-0089" title="2013‐004158‐81 . A multi‐centre, single‐blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1%/benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2013‐004158‐81/results (results published 15 March 2016). NCT02058628 . Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02058628 (first received 6 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single‐blind, parallel‐group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild‐to‐moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016; Vol. 30, issue 6:966‐73. [CENTRAL: CN‐01369030; MEDLINE: 26915831] ">Schaller 2016</a> included 108 participants in the BPO/clindamycin group and 109 in the azelaic acid group. The outcome was assessed via a 7‐point scale. Participants treated with BPO/clindamycin were more likely to achieve treatment success (rated as "very much improved" or "much improved") throughout the trial, with an RR of 1.38 (95% CI 1.05 to 1.81; <a href="./references#CD011154-fig-0106" title="">Analysis 16.1</a>), 1.44 (95% CI 1.09 to 1.89; <a href="./references#CD011154-fig-0107" title="">Analysis 16.2</a>), and 1.37 (95% CI 1.00 to 1.88; <a href="./references#CD011154-fig-0108" title="">Analysis 16.3</a>) for long‐, medium‐, and short‐term periods, respectively. </p> </section> </section> <section id="CD011154-sec-0397"> <h6 class="title">Primary outcome: withdrawal due to adverse effects</h6> <section id="CD011154-sec-0398"> <p><b>Main pooled analyses: BPO/clindamycin versus azelaic acid</b></p> <p>One participant in each group discontinued treatment due to adverse effects (application site erythema, dryness, pruritus and pain, and left and right eyelid oedema occurred in the participant on BPO/clindamycin, and application site pruritus and pain occurred in the participant on azelaic acid) (<a href="./references#CD011154-bbs2-0089" title="2013‐004158‐81 . A multi‐centre, single‐blind, parallel group, clinical evaluation of the efficacy and safety of clindamycin 1%/benzoyl peroxide 3% and azelaic acid 20% in the topical treatment of mild to moderate acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2013‐004158‐81/results (results published 15 March 2016). NCT02058628 . Comparison of the efficacy and safety of clindamycin + benzoyl peroxide formulation with azelaic acid formulation in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02058628 (first received 6 February 2014). SchallerM , SebastianM , RessC , SeidelD , HennigM . A multicentre, randomized, single‐blind, parallel‐group study comparing the efficacy and tolerability of benzoyl peroxide 3%/clindamycin 1% with azelaic acid 20% in the topical treatment of mild‐to‐moderate acne vulgaris. Journal of the European Academy of Dermatology and Venereology2016; Vol. 30, issue 6:966‐73. [CENTRAL: CN‐01369030; MEDLINE: 26915831] ">Schaller 2016</a>). No significant difference was observed between the two groups, with an RR of 1.01 (95% CI 0.06 to 15.93; 217 participants; <a href="./references#CD011154-fig-0109" title="">Analysis 16.4</a>). </p> </section> </section> <section id="CD011154-sec-0399"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <p>The percentage reduction in each type of lesion was significantly different between the two groups at three time points, consistently supporting the benefits of BPO/clindamycin. </p> <section id="CD011154-sec-0400"> <p><b>Main pooled analyses: BPO/clindamycin versus azelaic acid</b></p> <p>For the long‐term period, the mean difference was 18.50% (95% CI 10.54 to 26.46%; 211 participants; <a href="./references#CD011154-fig-0110" title="">Analysis 16.5</a>), 17.30% (95% CI 9.87 to 24.73%; 211 participants; <a href="./references#CD011154-fig-0111" title="">Analysis 16.6</a>), and 18.50% (95% CI 8.67 to 28.33%; 211 participants; <a href="./references#CD011154-fig-0112" title="">Analysis 16.7</a>) for TLs, ILs, and NILs, respectively. </p> <p>For the medium‐term period, the counterpart was 15.10% (95% CI 7.19 to 23.01%; 206 participants; <a href="./references#CD011154-fig-0113" title="">Analysis 16.8</a>), 15.90% (95% CI 8.06 to 23.74%; 206 participants; <a href="./references#CD011154-fig-0114" title="">Analysis 16.9</a>), and 13.00% (95% CI 3.24 to 22.76%; 206 participants; <a href="./references#CD011154-fig-0115" title="">Analysis 16.10</a>). </p> <p>The short‐term mean difference was 13.00% (95% CI 6.77 to 19.23%; 212 participants; <a href="./references#CD011154-fig-0116" title="">Analysis 16.11</a>), 14.10% (95% CI 6.18 to 22.02%; 212 participants; <a href="./references#CD011154-fig-0117" title="">Analysis 16.12</a>), and 11.10% (95% CI 3.56 to 18.64%; 212 participants; <a href="./references#CD011154-fig-0118" title="">Analysis 16.13</a>). </p> </section> </section> <section id="CD011154-sec-0401"> <h6 class="title">Secondary outcome: percentage of participants rated 'clear' or 'almost clear' on the IGA scale of acne severity </h6> <section id="CD011154-sec-0402"> <p><b>Main pooled analyses: BPO/clindamycin versus azelaic acid</b></p> <p>This outcome was significantly different between the two groups for long‐ and medium‐term periods, with an RR of 1.91 (95% CI 1.17 to 3.11; <a href="./references#CD011154-fig-0119" title="">Analysis 16.14</a>) and 1.88 (95% CI 1.07 to 3.32; <a href="./references#CD011154-fig-0120" title="">Analysis 16.15</a>), respectively, in favour of BPO/clindamycin treatment. We cannot observe significant differences for the short‐term period (RR 1.74, 95% CI 0.87 to 3.49; <a href="./references#CD011154-fig-0121" title="">Analysis 16.16</a>). </p> </section> </section> <section id="CD011154-sec-0403"> <h6 class="title">Secondary outcome: change in quality of life</h6> <section id="CD011154-sec-0404"> <p><b>Studies not included in the meta‐analysis</b></p> <p>A greater percentage change in quality of life was reported at week 12 in the Children's Dermatology Life Quality Index (CDLQI) score (60.5% versus 36.8%) and the Dermatology Life Quality Index (DLQI) score (73.4% versus 31.9%) for BPO/clindamycin versus azelaic acid. </p> </section> </section> <section id="CD011154-sec-0405"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0406"> <p><b>Main pooled analyses: BPO/clindamycin versus azelaic acid</b></p> <p>Treatment‐related adverse events were reported in 13.9% and 33.0% of participants with BPO/clindamycin and azelaic acid treatment, respectively, with significantly lower risk in the BPO/clindamycin group (RR 0.42, 95% CI 0.24 to 0.72; 217 participants; <a href="./references#CD011154-fig-0122" title="">Analysis 16.17</a>). Local reactions occurred in 15.7% of participants treated with BPO/clindamycin (24 events in 17 participants) and 35.8% of participants with azelaic acid (60 events in 39 participants), including pruritus (7.4% versus 22.9%), pain (6.5% versus 20.2%), erythema (2.8% versus 4.6%), and dryness (1.9% versus 2.8%). </p> </section> </section> </section> <section id="CD011154-sec-0407"> <h5 class="title">BPO/clindamycin versus erythromycin/zinc</h5> <p>This comparison was made in one 12‐week trial (<a href="./references#CD011154-bbs2-0064" title="LangnerA , Sheehan‐DareR , LaytonA . A randomized, single‐blind comparison of topical clindamycin + benzoyl peroxide (Duac) and erythromycin + zinc acetate (Zineryt) in the treatment of mild to moderate facial acne vulgaris. Journal of the European Academy of Dermatology &amp; Venereology2007;21(3):311‐9. [CENTRAL: CN‐00586947; MEDLINE: 17309451] ">Langner 2007</a>), which included 73 participants on BPO/clindamycin and 75 on erythromycin/zinc. This trial reported the following outcomes of our review interest: participant global self‐assessment, withdrawal due to adverse effects, change in lesion counts, reduction in <i>C acnes</i> strains, and adverse events. </p> <section id="CD011154-sec-0408"> <h6 class="title">Primary outcome: participant global self‐assessment of acne improvement</h6> <section id="CD011154-sec-0409"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Participants rated their improvement as improved, no change, or worse. There was no significant difference in the proportion of "improved" between the two groups (91.9% versus 89.3%) at week 12. </p> </section> </section> <section id="CD011154-sec-0410"> <h6 class="title">Primary outcome: withdrawal due to adverse effects</h6> <section id="CD011154-sec-0411"> <p><b>Main pooled analyses: BPO/clindamycin versus erythromycin/zinc</b></p> <p>Two participants withdrew, with no significant differences between the two groups (RR 1.03, 95% CI 0.07 to 16.12; 148 participants; <a href="./references#CD011154-fig-0123" title="">Analysis 17.1</a>): one participant on BPO/clindamycin treatment due to rash and skin tightness and one on erythromycin/zinc treatment due to exacerbation of acne. </p> </section> </section> <section id="CD011154-sec-0412"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <p>The absolute change in each type of lesion reported from the ITT analysis was not significantly different between the two groups at the three time points. </p> <section id="CD011154-sec-0413"> <p><b>Main pooled analyses: BPO/clindamycin versus erythromycin/zinc</b></p> <p>For the long‐term period, the mean difference was 6.10 (95% CI ‐4.65 to 16.85; <a href="./references#CD011154-fig-0124" title="">Analysis 17.2</a>), 0.10 (95% CI ‐3.85 to 4.05; <a href="./references#CD011154-fig-0125" title="">Analysis 17.3</a>), and 6.40 (95% CI ‐2.16 to 14.96; <a href="./references#CD011154-fig-0126" title="">Analysis 17.4</a>) for TLs, ILs, and NILs, respectively. </p> <p>For the medium‐term period, the counterpart was 5.60 (95% CI ‐5.61 to 16.81; <a href="./references#CD011154-fig-0127" title="">Analysis 17.5</a>), ‐0.20 (95% CI ‐4.33 to 3.93; <a href="./references#CD011154-fig-0128" title="">Analysis 17.6</a>), and 6.20 (95% CI ‐2.66 to 15.06; <a href="./references#CD011154-fig-0129" title="">Analysis 17.7</a>). </p> <p>The short‐term mean difference was 5.80 (95% CI ‐5.96 to 17.56; <a href="./references#CD011154-fig-0130" title="">Analysis 17.8</a>), 0.10 (95% CI ‐3.91 to 4.11; <a href="./references#CD011154-fig-0131" title="">Analysis 17.9</a>), and 6.20 (95% CI ‐3.60 to 16.00; <a href="./references#CD011154-fig-0132" title="">Analysis 17.10</a>). </p> </section> </section> <section id="CD011154-sec-0414"> <h6 class="title">Secondary outcome: reduction in <i>C acnes</i> strains </h6> <section id="CD011154-sec-0415"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Only 14 participants treated with BPO/clindamycin and 15 treated with erythromycin/zinc contributed to the bacteriology data. At week 12, the total number of <i>C acnes</i> strains (log<sub>10</sub> CFU cm<sup>‐2</sup>) was reduced from 5.38 (standard deviation (SD), 0.82) to 3.67 (SD, 1.30) and from 4.35 (SD, 1.19) to 3.49 (SD, 2.18) for BPO/clindamycin and erythromycin/zinc groups, respectively. In the BPO/clindamycin group, the number of erythromycin‐ and clindamycin‐resistant <i>C acnes</i> strains was reduced from 2.71 (SD, 2.35) to 1.45 (SD, 1.86) and from 2.48 (SD, 2.30) to 1.14 (SD, 1.75), respectively. In the erythromycin/zinc group, however, there was an increase in the number of erythromycin‐ and clindamycin‐resistant <i>C acnes</i> strains: from 0.76 (1.64) to 2.53 (SD, 2.05) and from 0.78 (SD, 1.56) to 2.19 (SD, 2.21), respectively. With no significance test results reported, trial authors claimed that the level of resistance appeared to decline with BPO/clindamycin but appeared to increase with erythromycin/zinc. We cannot estimate MD as the effect size because data were not sufficient to calculate the standard deviation of the change in <i>C acnes</i> strains from baseline. </p> </section> </section> <section id="CD011154-sec-0416"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0417"> <p><b>Main pooled analyses: BPO/clindamycin versus erythromycin/zinc</b></p> <p>A total of 20.5% of participants on BPO/clindamycin and 30.7% of participants on erythromycin/zinc reported at least one adverse event, with no significant difference detected (RR 0.67, 95% CI 0.38 to 1.18; 148 participants; <a href="./references#CD011154-fig-0133" title="">Analysis 17.11</a>). Common adverse events that occurred in each group were similar, including dryness (4.1% versus 5.3%), desquamation (4.1% versus 2.7%), burning (2.7% versus 2.7%), and erythema (2.7 versus 2.7%). There were no differences between treatments. </p> </section> </section> </section> <section id="CD011154-sec-0418"> <h5 class="title">BPO/clindamycin versus dapsone</h5> <p>One 12‐week parallel trial made this comparison (<a href="./references#CD011154-bbs2-0080" title="NCT01231334 . A study comparing Aczone® plus Differin® versus Duac® plus Differin® in patients with severe facial acne. clinicaltrials.gov/ct2/show/NCT01231334 (first received 28 October 2010). ">NCT01231334</a>), including 141 participants on BPO/clindamycin plus adapalene and 145 on dapsone plus adapalene. Results about change in lesion reduction and adverse events were published on the trial registry. No information regarding other outcomes was available. </p> <section id="CD011154-sec-0419"> <h6 class="title">Primary outcomes</h6> <p>No information was available on the primary outcomes.</p> </section> <section id="CD011154-sec-0420"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0421"> <p><b>Studies not included in the meta‐analysis</b></p> <p>The median percentage reduction was 65.0% versus 62.7% in TLs, 75.9% versus 70.7% in ILs, and 60.7% versus 55.3% in NILs at week 12. No significance test results were presented. </p> </section> </section> <section id="CD011154-sec-0422"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0423"> <p><b>Main pooled analyses: BPO/clindamycin plus adapalene versus dapsone plus adapalene</b></p> <p>No serious adverse events were found in both groups. During the 12‐week period, adverse events occurred in 15 participants on BPO/clindamycin plus adapalene (7 participants with nasopharyngitis and 8 with headache) and 23 participants on dapsone plus adapalene (15 participants with nasopharyngitis and 8 with headache), with no significant differences between the two groups (RR 0.67, 95% CI 0.37 to 1.23; <a href="./references#CD011154-fig-0134" title="">Analysis 18.1</a>). </p> </section> </section> </section> <section id="CD011154-sec-0424"> <h5 class="title">BPO/erythromycin versus placebo or no treatment</h5> <p>The comparison was made in five parallel trials (<a href="./references#CD011154-bbs2-0011" title="ChalkerDK , ShalitaA , SmithJG , SwannRW . A double‐blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. Journal of the American Academy of Dermatology1983;9(6):933‐6. [CENTRAL: CN‐00334175; MEDLINE: 6227643] ">Chalker 1983</a>; <a href="./references#CD011154-bbs2-0023" title="DraelosZD , TanghettiEA . Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis; Cutaneous Medicine for the Practitioner2002;69(2 Suppl):20‐9. [CENTRAL: CN‐00409023; MEDLINE: 12095065] ">Draelos 2002</a>; <a href="./references#CD011154-bbs2-0055" title="JonesT , MarkL , MonroeE , WeissJ , LevyS . A multicentre, double‐blind, parallel‐group study to evaluate 3% erythromycin/5% benzoyl peroxide dual‐pouch pack for acne vulgaris. Clinical Drug Investigation2002;22(7):455‐62. [CENTRAL: CN‐00405023] ">Jones 2002</a>; <a href="./references#CD011154-bbs2-0096" title="SklarJL , JacobsonC , RizerR , GansEH . Evaluation of triaz 10% gel and benzamycin in acne vulgaris. Journal of Dermatological Treatment1996;7(3):147‐52. [CENTRAL: CN‐00173449] ">Sklar 1996</a>; <a href="./references#CD011154-bbs2-0105" title="ThiboutotD , JarrattM , RichP , RistT , RodriguezD , LevyS . A randomized, parallel, vehicle‐controlled comparison of two erythromycin/benzoyl peroxide preparations for acne vulgaris. Clinical Therapeutics2002;24(5):773‐85. [CENTRAL: CN‐00396107; MEDLINE: 12075945] ">Thiboutot 2002</a>), which provided data for all the outcomes of interest in this review except quality of life and reduction in <i>C. acnes</i> strains. </p> <section id="CD011154-sec-0425"> <h6 class="title">Primary outcome: participant global self‐assessment of acne improvement</h6> <p>For BPO/erythromycin used alone, two 8‐week trials reported this outcome (<a href="./references#CD011154-bbs2-0055" title="JonesT , MarkL , MonroeE , WeissJ , LevyS . A multicentre, double‐blind, parallel‐group study to evaluate 3% erythromycin/5% benzoyl peroxide dual‐pouch pack for acne vulgaris. Clinical Drug Investigation2002;22(7):455‐62. [CENTRAL: CN‐00405023] ">Jones 2002</a>; <a href="./references#CD011154-bbs2-0105" title="ThiboutotD , JarrattM , RichP , RistT , RodriguezD , LevyS . A randomized, parallel, vehicle‐controlled comparison of two erythromycin/benzoyl peroxide preparations for acne vulgaris. Clinical Therapeutics2002;24(5):773‐85. [CENTRAL: CN‐00396107; MEDLINE: 12075945] ">Thiboutot 2002</a>). </p> <section id="CD011154-sec-0426"> <p><b>Main pooled analyses: BPO/erythromycin versus placebo or no treatment</b></p> <p><a href="./references#CD011154-bbs2-0055" title="JonesT , MarkL , MonroeE , WeissJ , LevyS . A multicentre, double‐blind, parallel‐group study to evaluate 3% erythromycin/5% benzoyl peroxide dual‐pouch pack for acne vulgaris. Clinical Drug Investigation2002;22(7):455‐62. [CENTRAL: CN‐00405023] ">Jones 2002</a> presented data in accordance with the definition of treatment success in our review. The trial included 112 participants in the BPO/erythromycin group and 111 in the placebo group. The outcome was assessed with a 4‐point Likert‐like scale. The risk ratio of treatment success was 1.28 (95% CI 1.04 to 1.57; <a href="./references#CD011154-fig-0135" title="">Analysis 19.1</a>), supporting the benefits of BPO/erythromycin treatment. </p> </section> <section id="CD011154-sec-0427"> <p><b>Studies not included in the meta‐analysis</b></p> <p>A similar scale was used in the other trial (<a href="./references#CD011154-bbs2-0105" title="ThiboutotD , JarrattM , RichP , RistT , RodriguezD , LevyS . A randomized, parallel, vehicle‐controlled comparison of two erythromycin/benzoyl peroxide preparations for acne vulgaris. Clinical Therapeutics2002;24(5):773‐85. [CENTRAL: CN‐00396107; MEDLINE: 12075945] ">Thiboutot 2002</a>), but the proportion of treatment success defined in our review cannot be calculated based on data provided in the original report of this trial. With 245 participants treated with BPO/erythromycin and 82 with placebo, the trial found that participants receiving BPO/erythromycin had significantly greater scores at the end of treatment compared with participants receiving placebo (P &lt; 0.001). </p> <p>Another 12‐week parallel trial included 90 participants on BPO/erythromycin plus tazarotene and 89 participants on tazarotene alone (<a href="./references#CD011154-bbs2-0023" title="DraelosZD , TanghettiEA . Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis; Cutaneous Medicine for the Practitioner2002;69(2 Suppl):20‐9. [CENTRAL: CN‐00409023; MEDLINE: 12095065] ">Draelos 2002</a>). This outcome was assessed using a 5‐point Likert‐like scale (from highly favourable to highly unfavourable). At week 12, no significant difference was found in the proportion of participants rating the improvement as "highly favourable" or "favourable" (86% versus 73%). </p> </section> </section> <section id="CD011154-sec-0428"> <h6 class="title">Primary outcome: withdrawal due to adverse effects</h6> <section id="CD011154-sec-0429"> <p><b>Main pooled analyses: BPO/erythromycin versus placebo or no treatment</b></p> <p>The long‐term trial reported that 6% of participants on BPO/erythromycin versus 11% on placebo discontinued treatments because of adverse events during the 12‐week period (<a href="./references#CD011154-bbs2-0023" title="DraelosZD , TanghettiEA . Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis; Cutaneous Medicine for the Practitioner2002;69(2 Suppl):20‐9. [CENTRAL: CN‐00409023; MEDLINE: 12095065] ">Draelos 2002</a>), with no clear differences detected (RR 0.49, 95% CI 0.18 to 1.39; 179 participants; <a href="./references#CD011154-fig-0136" title="">Analysis 19.2</a>). The trial did not specify which adverse events led to withdrawal. </p> <p>For the other two medium‐term trials (<a href="./references#CD011154-bbs2-0055" title="JonesT , MarkL , MonroeE , WeissJ , LevyS . A multicentre, double‐blind, parallel‐group study to evaluate 3% erythromycin/5% benzoyl peroxide dual‐pouch pack for acne vulgaris. Clinical Drug Investigation2002;22(7):455‐62. [CENTRAL: CN‐00405023] ">Jones 2002</a>; <a href="./references#CD011154-bbs2-0105" title="ThiboutotD , JarrattM , RichP , RistT , RodriguezD , LevyS . A randomized, parallel, vehicle‐controlled comparison of two erythromycin/benzoyl peroxide preparations for acne vulgaris. Clinical Therapeutics2002;24(5):773‐85. [CENTRAL: CN‐00396107; MEDLINE: 12075945] ">Thiboutot 2002</a>), only one of 193 participants receiving placebo withdrew because of dryness and itching, and none withdrew from the BPO/erythromycin group consisting of 357 participants, with an RR of 0.33 (95% CI 0.01 to 8.02; 550 participants; 2 studies; I² = 0%; <a href="./references#CD011154-fig-0137" title="">Analysis 19.3</a>). </p> </section> <section id="CD011154-sec-0430"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Two trials provided long‐term data for this outcome (<a href="./references#CD011154-bbs2-0011" title="ChalkerDK , ShalitaA , SmithJG , SwannRW . A double‐blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. Journal of the American Academy of Dermatology1983;9(6):933‐6. [CENTRAL: CN‐00334175; MEDLINE: 6227643] ">Chalker 1983</a>; <a href="./references#CD011154-bbs2-0096" title="SklarJL , JacobsonC , RizerR , GansEH . Evaluation of triaz 10% gel and benzamycin in acne vulgaris. Journal of Dermatological Treatment1996;7(3):147‐52. [CENTRAL: CN‐00173449] ">Sklar 1996</a>). They included an equal number of participants in each group (76 participants in each) and found that no participants discontinued treatments because of adverse effects. </p> </section> </section> <section id="CD011154-sec-0431"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <p>All four trials reported the mean or percentage reduction in lesion counts (<a href="./references#CD011154-bbs2-0011" title="ChalkerDK , ShalitaA , SmithJG , SwannRW . A double‐blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. Journal of the American Academy of Dermatology1983;9(6):933‐6. [CENTRAL: CN‐00334175; MEDLINE: 6227643] ">Chalker 1983</a>; <a href="./references#CD011154-bbs2-0055" title="JonesT , MarkL , MonroeE , WeissJ , LevyS . A multicentre, double‐blind, parallel‐group study to evaluate 3% erythromycin/5% benzoyl peroxide dual‐pouch pack for acne vulgaris. Clinical Drug Investigation2002;22(7):455‐62. [CENTRAL: CN‐00405023] ">Jones 2002</a>; <a href="./references#CD011154-bbs2-0096" title="SklarJL , JacobsonC , RizerR , GansEH . Evaluation of triaz 10% gel and benzamycin in acne vulgaris. Journal of Dermatological Treatment1996;7(3):147‐52. [CENTRAL: CN‐00173449] ">Sklar 1996</a>; <a href="./references#CD011154-bbs2-0105" title="ThiboutotD , JarrattM , RichP , RistT , RodriguezD , LevyS . A randomized, parallel, vehicle‐controlled comparison of two erythromycin/benzoyl peroxide preparations for acne vulgaris. Clinical Therapeutics2002;24(5):773‐85. [CENTRAL: CN‐00396107; MEDLINE: 12075945] ">Thiboutot 2002</a>). Two of them provided sufficient data to estimate the effect size (<a href="./references#CD011154-bbs2-0055" title="JonesT , MarkL , MonroeE , WeissJ , LevyS . A multicentre, double‐blind, parallel‐group study to evaluate 3% erythromycin/5% benzoyl peroxide dual‐pouch pack for acne vulgaris. Clinical Drug Investigation2002;22(7):455‐62. [CENTRAL: CN‐00405023] ">Jones 2002</a>; <a href="./references#CD011154-bbs2-0096" title="SklarJL , JacobsonC , RizerR , GansEH . Evaluation of triaz 10% gel and benzamycin in acne vulgaris. Journal of Dermatological Treatment1996;7(3):147‐52. [CENTRAL: CN‐00173449] ">Sklar 1996</a>). </p> <section id="CD011154-sec-0432"> <p><b>Main pooled analyses: BPO/erythromycin versus placebo or no treatment</b></p> <p>For the long‐term change in lesion counts, the mean difference in the absolute change was ‐5.20 (95% CI ‐11.74 to 1.34; <a href="./references#CD011154-fig-0138" title="">Analysis 19.4</a>), ‐6.93 (95% CI ‐11.55 to ‐2.31; <a href="./references#CD011154-fig-0139" title="">Analysis 19.5</a>), and 1.80 (95% CI ‐1.96 to 5.56; <a href="./references#CD011154-fig-0140" title="">Analysis 19.6</a>) for TLs, ILs, and NILs, respectively (<a href="./references#CD011154-bbs2-0096" title="SklarJL , JacobsonC , RizerR , GansEH . Evaluation of triaz 10% gel and benzamycin in acne vulgaris. Journal of Dermatological Treatment1996;7(3):147‐52. [CENTRAL: CN‐00173449] ">Sklar 1996</a>). </p> <p>For the medium‐term change in lesion counts, the mean difference in the absolute change pooled from two trials was ‐4.59 (95% CI ‐12.63 to 3.44; 281 participants; 2 studies; I² = 75%; <a href="./references#CD011154-fig-0141" title="">Analysis 19.7</a>), ‐3.90 (95% CI ‐8.07 to 0.27; 58 participants; 1 study; <a href="./references#CD011154-fig-0142" title="">Analysis 19.8</a>), and 0.80 (95% CI ‐4.30 to 5.89; 281 participants; 2 studies; I² = 73%; <a href="./references#CD011154-fig-0143" title="">Analysis 19.9</a>) for TLs, ILs, and NILs respectively, with no significant differences but high heterogeneity (<a href="./references#CD011154-bbs2-0055" title="JonesT , MarkL , MonroeE , WeissJ , LevyS . A multicentre, double‐blind, parallel‐group study to evaluate 3% erythromycin/5% benzoyl peroxide dual‐pouch pack for acne vulgaris. Clinical Drug Investigation2002;22(7):455‐62. [CENTRAL: CN‐00405023] ">Jones 2002</a>; <a href="./references#CD011154-bbs2-0096" title="SklarJL , JacobsonC , RizerR , GansEH . Evaluation of triaz 10% gel and benzamycin in acne vulgaris. Journal of Dermatological Treatment1996;7(3):147‐52. [CENTRAL: CN‐00173449] ">Sklar 1996</a>). </p> <p><a href="./references#CD011154-bbs2-0096" title="SklarJL , JacobsonC , RizerR , GansEH . Evaluation of triaz 10% gel and benzamycin in acne vulgaris. Journal of Dermatological Treatment1996;7(3):147‐52. [CENTRAL: CN‐00173449] ">Sklar 1996</a> also reported the short‐term outcome. It found no significant differences between the two groups in the absolute change in TLs (MD ‐3.60, 95% CI ‐7.92 to 0.72; <a href="./references#CD011154-fig-0144" title="">Analysis 19.10</a>) and in NILs (MD 2.40, 95% CI ‐0.71 to 5.51; <a href="./references#CD011154-fig-0146" title="">Analysis 19.12</a>). However, the change in ILs differed between groups, favouring the BPO/erythromycin group (MD ‐6.10, 95% CI ‐9.39 to ‐2.81; <a href="./references#CD011154-fig-0145" title="">Analysis 19.11</a>). </p> </section> <section id="CD011154-sec-0433"> <p><b>Studies not included in the meta‐analysis</b></p> <p>The other long‐term trial mentioned only whether the significant difference was found (<a href="./references#CD011154-bbs2-0011" title="ChalkerDK , ShalitaA , SmithJG , SwannRW . A double‐blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. Journal of the American Academy of Dermatology1983;9(6):933‐6. [CENTRAL: CN‐00334175; MEDLINE: 6227643] ">Chalker 1983</a>). As reported, BPO/erythromycin was significantly superior to placebo at week 10 in the percentage reduction in comedone, pustule, papule, and inflammatory lesions. </p> <p>We cannot obtain mean difference from another medium‐term trial (<a href="./references#CD011154-bbs2-0105" title="ThiboutotD , JarrattM , RichP , RistT , RodriguezD , LevyS . A randomized, parallel, vehicle‐controlled comparison of two erythromycin/benzoyl peroxide preparations for acne vulgaris. Clinical Therapeutics2002;24(5):773‐85. [CENTRAL: CN‐00396107; MEDLINE: 12075945] ">Thiboutot 2002</a>). Trial authors claimed that significant differences in the percentage reduction in TLs, ILs, and NILs were found at week 8. In the BPO/erythromycin group, TLs were reduced by 58.5%, ILs by 62.6%, and NILs by 59%, compared to 27.5%, 34.1%, and 28.0% in the placebo group. </p> <p>For the comparison between BPO/erythromycin plus tazarotene and tazarotene, the percentage reduction in ILs was significantly different (65.2% versus 43.7%; P &lt; 0.05) between two groups at week 12 but not the reduction in NILs (48.4% versus 41.6%; P &gt; 0.05). For the medium‐ and short‐term periods, both treatments reduced NILs by about 40% and 30%, respectively, with no significant differences. On the other hand, BPO/erythromycin plus tazarotene was more effective for reducing ILs (58% versus 31% for the medium‐term period and 44% versus 17% for the short‐term period). We cannot estimate MD as the effect size because data were not sufficient to calculate standard deviation. </p> </section> </section> <section id="CD011154-sec-0434"> <h6 class="title">Secondary outcome: percentage of participants rated 'clear' or 'almost clear' on the IGA scale of acne severity </h6> <section id="CD011154-sec-0435"> <p><b>Main pooled analyses: BPO/erythromycin versus placebo or no treatment</b></p> <p>This outcome was reported in two medium‐term trials (<a href="./references#CD011154-bbs2-0055" title="JonesT , MarkL , MonroeE , WeissJ , LevyS . A multicentre, double‐blind, parallel‐group study to evaluate 3% erythromycin/5% benzoyl peroxide dual‐pouch pack for acne vulgaris. Clinical Drug Investigation2002;22(7):455‐62. [CENTRAL: CN‐00405023] ">Jones 2002</a>; <a href="./references#CD011154-bbs2-0105" title="ThiboutotD , JarrattM , RichP , RistT , RodriguezD , LevyS . A randomized, parallel, vehicle‐controlled comparison of two erythromycin/benzoyl peroxide preparations for acne vulgaris. Clinical Therapeutics2002;24(5):773‐85. [CENTRAL: CN‐00396107; MEDLINE: 12075945] ">Thiboutot 2002</a>), in which 357 and 193 participants were randomised to BPO/adapalene and placebo groups, respectively. The pooled risk ratio was 2.84 (95% CI 1.79 to 4.52; I² = 9%; <a href="./references#CD011154-fig-0147" title="">Analysis 19.13</a>). For the short‐term outcome, <a href="./references#CD011154-bbs2-0105" title="ThiboutotD , JarrattM , RichP , RistT , RodriguezD , LevyS . A randomized, parallel, vehicle‐controlled comparison of two erythromycin/benzoyl peroxide preparations for acne vulgaris. Clinical Therapeutics2002;24(5):773‐85. [CENTRAL: CN‐00396107; MEDLINE: 12075945] ">Thiboutot 2002</a> reported the risk ratio of 6.69 (95% CI 0.91 to 49.10; <a href="./references#CD011154-fig-0148" title="">Analysis 19.14</a>), and <a href="./references#CD011154-bbs2-0055" title="JonesT , MarkL , MonroeE , WeissJ , LevyS . A multicentre, double‐blind, parallel‐group study to evaluate 3% erythromycin/5% benzoyl peroxide dual‐pouch pack for acne vulgaris. Clinical Drug Investigation2002;22(7):455‐62. [CENTRAL: CN‐00405023] ">Jones 2002</a> mentioned significant differences (P &lt; 0.021). </p> </section> </section> <section id="CD011154-sec-0436"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0437"> <p><b>Main pooled analyses: BPO/erythromycin versus placebo or no treatment</b></p> <p>For the long‐term outcome, with no significant differences between two groups, 15 of 90 versus 14 of 89 participants had at least one treatment‐related adverse event (RR 1.06, 95% CI 0.54 to 2.06; 179 participants; <a href="./references#CD011154-fig-0149" title="">Analysis 19.15</a>). The distribution of adverse events in each group is unclear. <a href="./references#CD011154-bbs2-0011" title="ChalkerDK , ShalitaA , SmithJG , SwannRW . A double‐blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. Journal of the American Academy of Dermatology1983;9(6):933‐6. [CENTRAL: CN‐00334175; MEDLINE: 6227643] ">Chalker 1983</a> reported no adverse events observed during a 10‐week period. The other long‐term trial did not present the total number of participants with at least one adverse event but claimed that the incidence of scaling and tightness in the BPO/erythromycin group was significantly higher (P &lt; 0.05) than in the placebo group. </p> <p>In the two medium‐term trials (<a href="./references#CD011154-bbs2-0055" title="JonesT , MarkL , MonroeE , WeissJ , LevyS . A multicentre, double‐blind, parallel‐group study to evaluate 3% erythromycin/5% benzoyl peroxide dual‐pouch pack for acne vulgaris. Clinical Drug Investigation2002;22(7):455‐62. [CENTRAL: CN‐00405023] ">Jones 2002</a>; <a href="./references#CD011154-bbs2-0105" title="ThiboutotD , JarrattM , RichP , RistT , RodriguezD , LevyS . A randomized, parallel, vehicle‐controlled comparison of two erythromycin/benzoyl peroxide preparations for acne vulgaris. Clinical Therapeutics2002;24(5):773‐85. [CENTRAL: CN‐00396107; MEDLINE: 12075945] ">Thiboutot 2002</a>), the risk ratio was 1.88 (95% CI 0.92 to 3.87; <a href="./references#CD011154-fig-0150" title="">Analysis 19.16</a>). </p> </section> </section> </section> <section id="CD011154-sec-0438"> <h5 class="title">BPO/erythromycin versus clindamycin</h5> <p>One 10‐week parallel trial compared BPO/erythromycin and clindamycin (<a href="./references#CD011154-bbs2-0085" title="PackmanA . A controlled, randomized study comparing the efficacy of a 3% erythromycin and 5% benzoyl peroxide combination gel with clindamycin phosphate lotion for the treatment of acne vulgaris. Abstract P138. Journal of the European Academy of Dermatology and Venereology1995;5:S152. [CENTRAL: CN‐00602580] PackmanAM , BrownRH , DunlapFE , KrausSJ , WebsterGF . Treatment of acne vulgaris: combination of 3% erythromycin and 5% benzoyl peroxide in a gel compared to clindamycin phosphate lotion. International Journal of Dermatology1996;35(3):209‐11. [CENTRAL: CN‐00125217; MEDLINE: 8655242] ">Packman 1996</a>), in which 99 participants received BPO/erythromycin and 100 received clindamycin. One 12‐week parallel trial included 90 participants on BPO/erythromycin and 87 on clindamycin, all of whom received tazarotene as a co‐intervention (<a href="./references#CD011154-bbs2-0023" title="DraelosZD , TanghettiEA . Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis; Cutaneous Medicine for the Practitioner2002;69(2 Suppl):20‐9. [CENTRAL: CN‐00409023; MEDLINE: 12095065] ">Draelos 2002</a>). This trial reported the following outcomes of our review interest: participant global self‐assessment, withdrawal due to adverse effects, change in lesion counts, and adverse events. </p> <section id="CD011154-sec-0439"> <h6 class="title">Primary outcome: participant global self‐assessment of acne improvement</h6> <section id="CD011154-sec-0440"> <p><b>Studies not included in the meta‐analysis</b></p> <p>This outcome was assessed in <a href="./references#CD011154-bbs2-0023" title="DraelosZD , TanghettiEA . Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis; Cutaneous Medicine for the Practitioner2002;69(2 Suppl):20‐9. [CENTRAL: CN‐00409023; MEDLINE: 12095065] ">Draelos 2002</a> via a 5‐point Likert‐like scale (from highly favourable to highly unfavourable). At week 12, no significant difference was found in the proportion of participants rating improvement as highly favourable or favourable (86% versus 85%). We cannot estimate RR as the effect size because data were not sufficient to calculate the number of participants with treatment success defined in our review. </p> </section> </section> <section id="CD011154-sec-0441"> <h6 class="title">Primary outcome: withdrawal due to adverse effects</h6> <section id="CD011154-sec-0442"> <p><b>Main pooled analyses: BPO/erythromycin versus clindamycin</b></p> <p>Participants on BPO/erythromycin tended to discontinue treatments because of adverse events, with no significant differences between the two groups (RR 1.51, 95% CI 0.50 to 4.61; 376 participants; 2 studies; I² = 0%; <a href="./references#CD011154-fig-0151" title="">Analysis 20.1</a>). Both trials did not report which adverse events led to their withdrawal. </p> </section> <section id="CD011154-sec-0443"> <p><b>Subgroup analyses: co‐intervention</b></p> <p>No evidence suggests the co‐intervention may affect the effect, with a P value of 0.49 (<a href="./references#CD011154-fig-0151" title="">Analysis 20.1</a>). </p> </section> </section> <section id="CD011154-sec-0444"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0445"> <p><b>Studies not included in the meta‐analysis</b></p> <p>We cannot estimate MD as the effect size because data in both trials were not sufficient to calculate standard deviation. </p> <p>In <a href="./references#CD011154-bbs2-0085" title="PackmanA . A controlled, randomized study comparing the efficacy of a 3% erythromycin and 5% benzoyl peroxide combination gel with clindamycin phosphate lotion for the treatment of acne vulgaris. Abstract P138. Journal of the European Academy of Dermatology and Venereology1995;5:S152. [CENTRAL: CN‐00602580] PackmanAM , BrownRH , DunlapFE , KrausSJ , WebsterGF . Treatment of acne vulgaris: combination of 3% erythromycin and 5% benzoyl peroxide in a gel compared to clindamycin phosphate lotion. International Journal of Dermatology1996;35(3):209‐11. [CENTRAL: CN‐00125217; MEDLINE: 8655242] ">Packman 1996</a>, the absolute change in ILs and NILs was significantly different between the two groups at any time point, in favour of BPO/erythromycin. The mean number of ILs decreased from 18.2 at baseline to 11.5 (short term), 9.0 (medium term), and 8.4 (long term) in participants on BPO/erythromycin, and the counterpart decreased from 17.4 to 12.7, 12.0, and 12.3 in participants on clindamycin. The mean number of NILs decreased from 25.6 at baseline to 15.4, 14.7, and 13.6 in participants on BPO/erythromycin, but there was almost no change in participants on clindamycin (from 23.6 to 25.5, 22.6, and 23.2). </p> <p>In <a href="./references#CD011154-bbs2-0023" title="DraelosZD , TanghettiEA . Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis; Cutaneous Medicine for the Practitioner2002;69(2 Suppl):20‐9. [CENTRAL: CN‐00409023; MEDLINE: 12095065] ">Draelos 2002</a>, the percentage reduction in ILs at week 12 was significantly different (65.2% versus 40.1%; P &lt; 0.05) but not in NILs (48.4% versus 55.7%; P &gt; 0.05). For the medium‐ and short‐term periods, both treatments reduced NILs by about 40% and 30%, respectively, with no significant differences. On the other hand, BPO/erythromycin plus tazarotene seemed more effective for reducing ILs (58% versus 35% for the medium‐term period and 44% versus 22% for the short‐term period). </p> </section> </section> <section id="CD011154-sec-0446"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0447"> <p><b>Main pooled analyses: BPO/erythromycin versus clindamycin</b></p> <p>Non‐significantly increased risk of adverse event occurrence was observed between the two groups (RR 2.16, 95% CI 0.77 to 6.08; 378 participants; 2 studies; I² = 23%; <a href="./references#CD011154-fig-0152" title="">Analysis 20.2</a>). Adverse events reported in the trials included dryness, erythema, pruritus, stinging, burning, and unusual taste and smell. </p> </section> <section id="CD011154-sec-0448"> <p><b>Subgroup analyses: co‐intervention</b></p> <p>No evidence suggests that the co‐intervention may affect the effect, with a P value of 0.25 (<a href="./references#CD011154-fig-0152" title="">Analysis 20.2</a>). </p> </section> </section> </section> <section id="CD011154-sec-0449"> <h5 class="title">BPO/erythromycin versus azelaic acid</h5> <p>One eight‐week parallel trial compared BPO/erythromycin and azelaic acid (<a href="./references#CD011154-bbs2-0030" title="DunlapFE . An investigator blinded randomized study comparing a 3% erythromycin/5% benzoyl peroxide combination in gel versus 20% azelaic acid cream in the treatment of acne vulgaris. Abstract 126. Journal of Investigative Dermatology1997;108(3):392. [CENTRAL: CN‐00355137] ">Dunlap 1997</a>). Only an abstract was available for this trial. A total of 150 participants were included in the trial, but it is unclear how many participants were in each group. The abstract reported limited information on the change in lesion counts. </p> <section id="CD011154-sec-0450"> <h6 class="title">Primary outcomes</h6> <p>No information was available on the primary outcomes.</p> </section> <section id="CD011154-sec-0451"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0452"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Trial authors reported that BPO/erythromycin was superior to azelaic acid in reducing ILs at week 8, but they were not significantly different in reducing NILs. We cannot estimate RR as the effect size because insufficient data were reported in the abstract. </p> </section> </section> </section> <section id="CD011154-sec-0453"> <h5 class="title">BPO/erythromycin versus metronidazole</h5> <p>One four‐week parallel trial made this comparison (<a href="./references#CD011154-bbs2-0036" title="FanLH , XuCR . A randomised controlled trial of Bimaisen (compound erythromycin and benzoyl peroxide) versus metronidazole in the treatment of acne. Journal of Clinical Dermatology1998;27(6):385‐6. [CENTRAL: CN‐00454221] ">Fan 1998</a>), in which 56 participants received BPO/erythromycin and 54 received metronidazole. Trial authors reported the change in lesion counts. </p> <section id="CD011154-sec-0454"> <h6 class="title">Primary outcomes</h6> <p>No information was available on the primary outcomes.</p> </section> <section id="CD011154-sec-0455"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0456"> <p><b>Studies not included in the meta‐analysis</b></p> <p>At week 4, the difference in TLs between the two treatment groups was not significant. The mean number of TLs decreased from of 18.1 at baseline to 3.7 in participants on BPO/erythromycin and from 17.8 to 4.2 in participants on metronidazole. We cannot estimate MD as the effect size because data were not sufficient to calculate standard deviation. </p> </section> </section> </section> <section id="CD011154-sec-0457"> <h5 class="title">BPO/erythromycin versus viaminate</h5> <p>One four‐week parallel trial made this comparison (<a href="./references#CD011154-bbs2-0119" title="ZhaoXJ . The curative effect comparison of erythromycin‐benzoyl peroxide and Cuo Chuang Wang in treating acne vulgaris. Chinese Journal of Dermatovenereology2001;15(4):288. [CENTRAL: CN‐00454983] ">Zhao 2001</a>), in which 100 participants received BPO/erythromycin and 87 received viaminate. The trial reported withdrawal due to adverse effects and adverse events. </p> <section id="CD011154-sec-0458"> <h6 class="title">Primary outcome: withdrawal due to adverse effects</h6> <section id="CD011154-sec-0459"> <p><b>Studies not included in the meta‐analysis</b></p> <p>No participants discontinued treatments due to adverse effects.</p> </section> </section> <section id="CD011154-sec-0460"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0461"> <p><b>Main pooled analyses: BPO/erythromycin versus viaminate</b></p> <p>No adverse events occurred in the viaminate group, but 13 participants in the BPO/erythromycin group had dryness and mild peeling and redness, with significantly higher risk in the BPO/erythromycin group (RR 23.52, 95% CI 1.42 to 390.03; 187 participants; <a href="./references#CD011154-fig-0153" title="">Analysis 21.1</a>). </p> </section> </section> </section> <section id="CD011154-sec-0462"> <h5 class="title">BPO/erythromycin versus zinc/erythromycin</h5> <p>One 10‐week trial compared BPO (5%)/erythromycin (3%) and zinc (1.2%)/erythromycin (4%) (<a href="./references#CD011154-bbs2-0014" title="ChuA . The comparative safety and efficacy of benzoyl peroxide 5%/erythromycin 3% gel and erythromycin 4%/zinc 1.2% solution in the treatment of acne vulgaris. British Journal of Dermatology1996;135(Suppl 47):30. [CENTRAL: CN‐00415429] ChuA , HuberFJ , PlottRT . The comparative efficacy of benzoyl peroxide 5%/erythromycin 3% gel and erythromycin 4%/zinc 1.2% solution in the treatment of acne vulgaris. British Journal of Dermatology1997;136(2):235‐8. [CENTRAL: CN‐00137636; MEDLINE: 9068739] ChuA , HuberFJ , PlottRT . The comparative safety and efficacy of benzoyl peroxide 5%/erythromycin 3% gel and erythromycin 4%/zinc 1% solution in the treatment of acne vulgaris. Journal of Investigative Dermatology1997;108(3):392. [CENTRAL: CN‐00352565] ">Chu 1997</a>): a total of 72 participants were included. It is unclear how many participants were randomised to each group, so we cannot calculate the effect size for any outcomes. Trial authors reported the following outcomes of our review interest: participant global self‐assessment, withdrawal due to adverse effects, change in lesion counts, and adverse events. </p> <section id="CD011154-sec-0463"> <h6 class="title">Primary outcome: participant global self‐assessment of acne improvement</h6> <section id="CD011154-sec-0464"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Participants rated overall acne improvement using a 6‐point scale (0 = worse, 1 = no change, 2 = slight improvement, 3 = mild improvement, 4 = moderate improvement, 5 = excellent improvement). For this outcome, trial authors reported only that participant self‐assessment was strongly in favour of BPO/erythromycin (P &lt; 0.001). </p> </section> </section> <section id="CD011154-sec-0465"> <h6 class="title">Primary outcome: withdrawal due to adverse effects</h6> <section id="CD011154-sec-0466"> <p><b>Studies not included in the meta‐analysis</b></p> <p>No participants on BPO/erythromycin and three participants on zinc/erythromycin discontinued treatment due to adverse events. It is unclear what adverse events occurred in these three participants. </p> </section> </section> <section id="CD011154-sec-0467"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0468"> <p><b>Studies not included in the meta‐analysis</b></p> <p>A significant difference between groups was found in the percentage reduction in both ILs (86.6% versus 60.3%) and NILs (53.1% versus 26.8%) for the long‐term period (week 10) (both P values &lt; 0.005). For the medium‐term period, significant differences were observed in both ILs (80% versus 52%) and NILs (49% versus 25%). However, the percentage reduction in ILs was significantly different for the short‐term period (69% versus 44%), but not the percentage reduction in NILs (26% versus 14%). </p> </section> </section> <section id="CD011154-sec-0469"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0470"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Only one participant on BPO/erythromycin reported adverse events (dryness and irritation). In the zinc/erythromycin group, four participants reported nine adverse events, including irritation, itching, dryness, redness, scratching, scaling, and soreness. </p> </section> </section> </section> <section id="CD011154-sec-0471"> <h5 class="title">BPO/sulphur versus placebo</h5> <p>One parallel trial compared BPO/sulphur and placebo (<a href="./references#CD011154-bbs2-0112" title="VasarinshP . Benzoyl peroxide‐sulfur lotions in acne vulgaris ‐ a controlled study. Cutis; Cutaneous Medicine for the Practitioner1969;5(1):65‐9. [CENTRAL: CN‐00269401] ">Vasarinsh 1969</a>); 19 participants were treated with BPO and 19 with placebo for 4 to 14 weeks. This trial report covered the outcomes of participant self‐assessment of acne improvement, change in acne lesions, and adverse events. </p> <section id="CD011154-sec-0472"> <h6 class="title">Primary outcome: participant global self‐assessment of acne improvement</h6> <section id="CD011154-sec-0473"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Researchers assessed the outcome using a 4‐point Likert‐like scale (from worse = ‐1 to greatly improved = 2). The average score was 1.15 and 0.53 for the BPO/sulphur and placebo groups, respectively. We cannot estimate RR as the effect size because data were not sufficient to calculate the number of participants with treatment success as defined in our review. </p> </section> </section> <section id="CD011154-sec-0474"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0475"> <p><b>Studies not included in the meta‐analysis</b></p> <p>The change in lesion counts was assessed for superficial (comedones and pustules) and deep (papules and cysts) lesions, respectively, via an 11‐point scoring system (decrease in lesions by 100% = 5, 76% to 99% = 4, 51% to 75% = 3, 26% to 50% = 2, &lt; 25% = 1, and no change = 0; increase by &lt; 25% = ‐1, 26% to 50% = ‐2, 51% to 75% = ‐3, 76% to 100% = ‐4, and over 100% = ‐5). The average score for superficial lesions was 0.81 and 0 for the BPO/sulphur and placebo groups, respectively, and the counterpart for deep lesions was 0.91 and 0.53. We cannot estimate MD as the effect size because data were not sufficient to calculate standard deviation. </p> </section> </section> <section id="CD011154-sec-0476"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0477"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Individual adverse events were reported, but the total number of participants with any adverse event was not reported. Excessive erythema and dryness occurred in two participants on placebo and in four participants taking BPO/sulphur treatment. </p> </section> </section> </section> <section id="CD011154-sec-0478"> <h5 class="title">BPO/glycolic acid/zinc lactate versus placebo</h5> <p><a href="./references#CD011154-bbs2-0096" title="SklarJL , JacobsonC , RizerR , GansEH . Evaluation of triaz 10% gel and benzamycin in acne vulgaris. Journal of Dermatological Treatment1996;7(3):147‐52. [CENTRAL: CN‐00173449] ">Sklar 1996</a>, a 12‐week trial that made this comparison, included 30 participants on BPO/glycolic acid/zinc lactate gel and 32 on placebo. Trial authors reported the following outcomes of our review interest: withdrawal due to adverse effects, change in lesion counts, and adverse events. </p> <section id="CD011154-sec-0479"> <h6 class="title">Primary outcome: withdrawal due to adverse effects</h6> <section id="CD011154-sec-0480"> <p><b>Studies not included in the meta‐analysis</b></p> <p>No participants discontinued treatment because of any adverse events.</p> </section> </section> <section id="CD011154-sec-0481"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0482"> <p><b>Main pooled analyses: BPO/glycolic acid/zinc lactate versus placebo</b></p> <p>For the long‐term change in lesion counts, the absolute change in TLs and ILs was significantly different, with an MD of ‐6.50 (95% CI ‐12.56 to ‐0.44; 56 participants; <a href="./references#CD011154-fig-0154" title="">Analysis 22.1</a>) and ‐5.60 (95% CI ‐10.38 to ‐0.82; 56 participants; <a href="./references#CD011154-fig-0155" title="">Analysis 22.2</a>), respectively. No clear difference in NILs was found (MD ‐0.90, 95% CI ‐4.74 to 2.94; 56 participants; <a href="./references#CD011154-fig-0156" title="">Analysis 22.3</a>). </p> <p>For the medium‐term absolute change in lesion counts, no significant difference was observed for any types of lesions, with an MD of ‐0.90 (95% CI ‐5.26 to 3.46; 56 participants; <a href="./references#CD011154-fig-0157" title="">Analysis 22.4</a>), ‐2.60 (95% CI ‐6.59 to 1.39; 56 participants; <a href="./references#CD011154-fig-0158" title="">Analysis 22.5</a>), and 1.70 (95% CI ‐1.95 to 5.35; 56 participants; <a href="./references#CD011154-fig-0159" title="">Analysis 22.6</a>) for TLs, ILs, and NILs, respectively. </p> <p>Trial authors also reported the short‐term outcome, noting no significant differences between the two groups in the absolute change in TLs (MD ‐4.20, 95% CI ‐9.29 to 0.89; 58 participants; <a href="./references#CD011154-fig-0160" title="">Analysis 22.7</a>) nor in NILs (MD 0.50, 95% CI ‐3.41 to 4.41; 58 participants; <a href="./references#CD011154-fig-0162" title="">Analysis 22.9</a>). However, the change in ILs differed, favouring the BPO/erythromycin group (MD ‐4.80, 95% CI ‐8.66 to ‐0.94; 58 participants; <a href="./references#CD011154-fig-0161" title="">Analysis 22.8</a>). </p> </section> </section> <section id="CD011154-sec-0483"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0484"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Trial authors reported that adverse events including mild erythema, scaling, tightness, burning, stinging, itching, or tingling were observed in both groups. However, the number of participants with any event in each group was not reported. </p> </section> </section> </section> <section id="CD011154-sec-0485"> <h5 class="title">BPO/potassium hydroxyquinoline sulphate versus placebo</h5> <p>One 12‐week trial made this comparison (<a href="./references#CD011154-bbs2-0052" title="JaffeGV , GrimshawJJ , ConstadD . Benzoyl peroxide in the treatment of acne vulgaris: a double‐blind, multi‐centre comparative study of 'Quinoderm' cream and 'Quinoderm' cream with hydrocortisone versus their base vehicle alone and a benzoyl peroxide only gel preparation. Current Medical Research &amp; Opinion1989;11(7):453‐62. [CENTRAL: CN‐00062342; MEDLINE: 2528439] ">Jaffe 1989</a>); 25 participants on BPO/potassium hydroxyquinoline sulphate cream and 28 on placebo were included. Trial authors reported the following outcomes of our review interest: withdrawal due to adverse effects and adverse events. </p> <section id="CD011154-sec-0486"> <h6 class="title">Primary outcome: withdrawal due to adverse effects</h6> <section id="CD011154-sec-0487"> <p><b>Main pooled analyses: BPO/potassium hydroxyquinoline sulphate versus placebo</b></p> <p>Three participants on BPO/potassium hydroxyquinoline sulphate discontinued treatment because of stinging or skin irritation, with no significant differences between the two groups (RR 7.81, 95% CI 0.42 to 144.12; 53 participants; <a href="./references#CD011154-fig-0163" title="">Analysis 23.1</a>). </p> </section> </section> <section id="CD011154-sec-0488"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0489"> <p><b>Studies not included in the meta‐analysis</b></p> </section> <section id="CD011154-sec-0490"> <p><b>Trial authors mentioned that adverse events were recorded; however, no information on specific adverse events was available in the results section, except that three participants withdrew due to adverse events.</b></p> </section> </section> </section> <section id="CD011154-sec-0491"> <h5 class="title">BPO (10%) versus BPO (5%)</h5> <p>Two trials compared 10% BPO with 5% BPO for treating acne (<a href="./references#CD011154-bbs2-0054" title="JiS , TuP , LiGQ , LiuLL , ChenXX , ZhuXJ . A comparison of 10% benzoyl peroxide cream and 5% benzoyl peroxide gel in the treatment of acne vulgaris. Chinese Journal of Clinical Pharmacology2000;16(1):15‐7. [CENTRAL: CN‐00602357] ">Ji 2000</a>; <a href="./references#CD011154-bbs2-0113" title="WangAP , TuP , JiS Z , WuY , ShenY , ZhuXJ . Clinical efficacy of benzoyl peroxide gel with different concentrations in acne vulgaris. Chinese Journal of Dermatology2003;36(6):313‐5. [CENTRAL: CN‐00486355] ">Wang 2003</a>); length of treatment in both was six weeks. Both trials assessed the following outcomes: withdrawal, lesion counts, and adverse events. </p> <section id="CD011154-sec-0492"> <h6 class="title">Primary outcome: withdrawal due to adverse effects</h6> <section id="CD011154-sec-0493"> <p><b>Main pooled analyses: BPO (10%) versus BPO (5%)</b></p> <p>One of 93 participants treated with 10% BPO discontinued treatment due to adverse effects, and five of 164 participants in the 5% BPO group withdrew (<a href="./references#CD011154-bbs2-0054" title="JiS , TuP , LiGQ , LiuLL , ChenXX , ZhuXJ . A comparison of 10% benzoyl peroxide cream and 5% benzoyl peroxide gel in the treatment of acne vulgaris. Chinese Journal of Clinical Pharmacology2000;16(1):15‐7. [CENTRAL: CN‐00602357] ">Ji 2000</a>; <a href="./references#CD011154-bbs2-0113" title="WangAP , TuP , JiS Z , WuY , ShenY , ZhuXJ . Clinical efficacy of benzoyl peroxide gel with different concentrations in acne vulgaris. Chinese Journal of Dermatology2003;36(6):313‐5. [CENTRAL: CN‐00486355] ">Wang 2003</a>). Such differences were not significant, with an RR of 0.40 (95% CI 0.06 to 2.52; I² = 0%; <a href="./references#CD011154-fig-0164" title="">Analysis 24.1</a>). It is unclear which adverse events resulted in their withdrawal. </p> </section> </section> <section id="CD011154-sec-0494"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0495"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Neither of the trials reported the change in lesion counts from baseline, but trial authors reported lesion counts at the end of the study. Compared with 5% BPO, the mean difference in IL counts at week 6 was ‐0.62 (95% CI ‐1.97 to 0.73; I² = 19%), and the counterpart in NIL counts was ‐7.56 (95% CI ‐12.04 to ‐3.07; I² = 65%). </p> </section> </section> <section id="CD011154-sec-0496"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0497"> <p><b>Main pooled analyses: BPO (10%) versus BPO (5%)</b></p> <p>No evidence suggests a significant difference in the occurrence of adverse events. The risk ratio was 0.72 (95% CI 0.40 to 1.31; I² = 65%; <a href="./references#CD011154-fig-0165" title="">Analysis 24.2</a>). </p> </section> </section> </section> <section id="CD011154-sec-0498"> <h5 class="title">BPO (10%) versus BPO (2.5%)</h5> <p>Two trials compared 10% BPO with 2.5% BPO for treating acne (<a href="./references#CD011154-bbs2-0074" title="Mills JrOH , KligmanAM , PochiP , ComiteH . Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. International Journal of Dermatology1986;25(10):664‐7. [CENTRAL: CN‐00046261; MEDLINE: 2948929] ">Mills 1986</a>; <a href="./references#CD011154-bbs2-0113" title="WangAP , TuP , JiS Z , WuY , ShenY , ZhuXJ . Clinical efficacy of benzoyl peroxide gel with different concentrations in acne vulgaris. Chinese Journal of Dermatology2003;36(6):313‐5. [CENTRAL: CN‐00486355] ">Wang 2003</a>); length of treatment was six or eight weeks. Researchers assessed the following outcomes: withdrawal, lesion counts, and adverse events. </p> <section id="CD011154-sec-0499"> <h6 class="title">Primary outcome: withdrawal due to adverse effects</h6> <section id="CD011154-sec-0500"> <p><b>Studies not included in the meta‐analysis</b></p> <p>In total, the two trials included 58 participants treated with 10% BPO and 56 treated with 2.5% BPO. None in both groups discontinued treatment due to adverse effects. </p> </section> </section> <section id="CD011154-sec-0501"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0502"> <p><b>Studies not included in the meta‐analysis</b></p> <p>With 24 participants treated with 10% BPO and an equal number of participants with 2.5% BPO, <a href="./references#CD011154-bbs2-0074" title="Mills JrOH , KligmanAM , PochiP , ComiteH . Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. International Journal of Dermatology1986;25(10):664‐7. [CENTRAL: CN‐00046261; MEDLINE: 2948929] ">Mills 1986</a> found similar percentage reduction in ILs (44.7% versus 46.7%) at week 8. </p> <p>In <a href="./references#CD011154-bbs2-0113" title="WangAP , TuP , JiS Z , WuY , ShenY , ZhuXJ . Clinical efficacy of benzoyl peroxide gel with different concentrations in acne vulgaris. Chinese Journal of Dermatology2003;36(6):313‐5. [CENTRAL: CN‐00486355] ">Wang 2003</a>, 33 participants were included in the 10% BPO group and 124 in the 2.5% BPO group. Trial authors presented lesion counts at week 6, rather than the change in lesion counts from baseline, suggesting that both IL and NIL counts were fewer in the 10% BPO group (MD for ILs ‐3.80, 95% CI ‐5.99 to ‐1.61; MD for NILs ‐3.70, 95% CI ‐6.66 to ‐0.74). </p> </section> </section> <section id="CD011154-sec-0503"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0504"> <p><b>Main pooled analyses: BPO (10%) versus BPO (2.5%)</b></p> <p>In <a href="./references#CD011154-bbs2-0113" title="WangAP , TuP , JiS Z , WuY , ShenY , ZhuXJ . Clinical efficacy of benzoyl peroxide gel with different concentrations in acne vulgaris. Chinese Journal of Dermatology2003;36(6):313‐5. [CENTRAL: CN‐00486355] ">Wang 2003</a>, more participants in the 10% BPO group were experiencing adverse events (20/33 versus 11/31; RR 1.71, 95% CI 0.99 to 2.96; <a href="./references#CD011154-fig-0166" title="">Analysis 25.1</a>). <a href="./references#CD011154-bbs2-0074" title="Mills JrOH , KligmanAM , PochiP , ComiteH . Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. International Journal of Dermatology1986;25(10):664‐7. [CENTRAL: CN‐00046261; MEDLINE: 2948929] ">Mills 1986</a> reported a significant difference in the frequency and severity of erythema, peeling, and burning between those receiving 10% BPO and those receiving 2.5% BPO at all follow‐up visits. </p> </section> </section> </section> <section id="CD011154-sec-0505"> <h5 class="title">BPO (5%) versus BPO (2.5%)</h5> <p>This comparison consisted of six trials assessing BPO (5%) versus BPO (2.5%) with no co‐intervention (<a href="./references#CD011154-bbs2-0060" title="KawashimaM , NagareT , KatsuramakiT . Open‐label, randomized, multicenter, phase III study to evaluate the safety and efficacy of benzoyl peroxide gel in long‐term use in patients with acne vulgaris: a secondary publication. Journal of Dermatology2017; Vol. 44, issue 6:635‐43. [CENTRAL: CN‐01459134; MEDLINE: 28150367] MorimotoH , KikukawaY , MurakamiN . Pharmacological profiles and clinical effects of benzoyl peroxide gel as treatments for acne vulgaris. Nippon Yakurigaku Zasshi ‐ Folia Pharmacologica Japonica2015;146(4):225‐32. [PUBMED: 26656967] ">Kawashima 2017a</a>; <a href="./references#CD011154-bbs2-0061" title="KawashimaM , SatoS , FurukawaF , MatsunagaK , AkamatsuH , IgarashiA , et al. Twelve‐week, multicenter, placebo‐controlled, randomized, double‐blind, parallel‐group, comparative phase II/III study of benzoyl peroxide gel in patients with acne vulgaris: a secondary publication. Journal of Dermatology2017; Vol. 44, issue 7:774‐82. [CENTRAL: CN‐01458975] MorimotoH , KikukawaY , MurakamiN . Pharmacological profiles and clinical effects of benzoyl peroxide gel as treatments for acne vulgaris. Nippon Yakurigaku Zasshi ‐ Folia Pharmacologica Japonica2015;146(4):225‐32. [PUBMED: 26656967] ">Kawashima 2017b</a>; <a href="./references#CD011154-bbs2-0074" title="Mills JrOH , KligmanAM , PochiP , ComiteH . Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. International Journal of Dermatology1986;25(10):664‐7. [CENTRAL: CN‐00046261; MEDLINE: 2948929] ">Mills 1986</a>; <a href="./references#CD011154-bbs2-0082" title="NCT02073461 . Efficacy and safety study of 2 different concentrations of CD1579 gels versus vehicle in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02073461 (first received 20 February 2014). ">NCT02073461</a>; <a href="./references#CD011154-bbs2-0113" title="WangAP , TuP , JiS Z , WuY , ShenY , ZhuXJ . Clinical efficacy of benzoyl peroxide gel with different concentrations in acne vulgaris. Chinese Journal of Dermatology2003;36(6):313‐5. [CENTRAL: CN‐00486355] ">Wang 2003</a>; <a href="./references#CD011154-bbs2-0116" title="YongCC . Benzoyl peroxide gel therapy in acne in Singapore. International Journal of Dermatology1979;18(6):485‐8. [CENTRAL: CN‐00560673; MEDLINE: 158569] ">Yong 1979</a>), along with one trial using clindamycin and tazarotene as co‐interventions in each group (<a href="./references#CD011154-bbs2-0020" title="DhawanSS , GwazdauskasJ . Clindamycin phosphate 1.2%‐benzoyl peroxide (5% or 2.5%) plus tazarotene cream 0.1% for the treatment of acne. Cutis; Cutaneous Medicine for the Practitioner2013;91(2):99‐104. [CENTRAL: CN‐00869753; MEDLINE: 23513559] NCT01016977 . A phase 4, single‐blind, randomized study to compare the tolerability and efficacy of Tazorac cream when used in combination with either Duac gel or Acanya gel for the treatment of facial acne vulgaris. clinicaltrials.gov/ct2/show/NCT01016977 (first received 20 November 2009). ">Dhawan 2013</a>). Researchers assessed the following outcomes: participant global self‐assessment, withdrawal due to adverse effects, change in lesion counts, change in quality of life, and adverse events. </p> <section id="CD011154-sec-0506"> <h6 class="title">Primary outcome: participant global self‐assessment of acne improvement</h6> <section id="CD011154-sec-0507"> <p><b>Studies not included in the meta‐analysis</b></p> <p>The outcome was assessed in <a href="./references#CD011154-bbs2-0020" title="DhawanSS , GwazdauskasJ . Clindamycin phosphate 1.2%‐benzoyl peroxide (5% or 2.5%) plus tazarotene cream 0.1% for the treatment of acne. Cutis; Cutaneous Medicine for the Practitioner2013;91(2):99‐104. [CENTRAL: CN‐00869753; MEDLINE: 23513559] NCT01016977 . A phase 4, single‐blind, randomized study to compare the tolerability and efficacy of Tazorac cream when used in combination with either Duac gel or Acanya gel for the treatment of facial acne vulgaris. clinicaltrials.gov/ct2/show/NCT01016977 (first received 20 November 2009). ">Dhawan 2013</a> (including 20 participants in each group) via a 5‐point scale (1 = very satisfied, 2 = satisfied, 3 = neutral, 4 = unsatisfied, 5 = very unsatisfied). There was no significant difference between the two groups in the proportion of participants rating the improvement as "very satisfied" or "satisfied" (88.2% versus 85.0%) at week 12. We cannot estimate RR as the effect size because data were not sufficient to calculate the number of participants with treatment success defined in our review. </p> </section> </section> <section id="CD011154-sec-0508"> <h6 class="title">Primary outcome: withdrawal due to adverse effects</h6> <section id="CD011154-sec-0509"> <p><b>Main pooled analyses: BPO (5%) versus BPO (2.5%)</b></p> <p>In the long‐term trials (<a href="./references#CD011154-bbs2-0020" title="DhawanSS , GwazdauskasJ . Clindamycin phosphate 1.2%‐benzoyl peroxide (5% or 2.5%) plus tazarotene cream 0.1% for the treatment of acne. Cutis; Cutaneous Medicine for the Practitioner2013;91(2):99‐104. [CENTRAL: CN‐00869753; MEDLINE: 23513559] NCT01016977 . A phase 4, single‐blind, randomized study to compare the tolerability and efficacy of Tazorac cream when used in combination with either Duac gel or Acanya gel for the treatment of facial acne vulgaris. clinicaltrials.gov/ct2/show/NCT01016977 (first received 20 November 2009). ">Dhawan 2013</a>; <a href="./references#CD011154-bbs2-0060" title="KawashimaM , NagareT , KatsuramakiT . Open‐label, randomized, multicenter, phase III study to evaluate the safety and efficacy of benzoyl peroxide gel in long‐term use in patients with acne vulgaris: a secondary publication. Journal of Dermatology2017; Vol. 44, issue 6:635‐43. [CENTRAL: CN‐01459134; MEDLINE: 28150367] MorimotoH , KikukawaY , MurakamiN . Pharmacological profiles and clinical effects of benzoyl peroxide gel as treatments for acne vulgaris. Nippon Yakurigaku Zasshi ‐ Folia Pharmacologica Japonica2015;146(4):225‐32. [PUBMED: 26656967] ">Kawashima 2017a</a>; <a href="./references#CD011154-bbs2-0061" title="KawashimaM , SatoS , FurukawaF , MatsunagaK , AkamatsuH , IgarashiA , et al. Twelve‐week, multicenter, placebo‐controlled, randomized, double‐blind, parallel‐group, comparative phase II/III study of benzoyl peroxide gel in patients with acne vulgaris: a secondary publication. Journal of Dermatology2017; Vol. 44, issue 7:774‐82. [CENTRAL: CN‐01458975] MorimotoH , KikukawaY , MurakamiN . Pharmacological profiles and clinical effects of benzoyl peroxide gel as treatments for acne vulgaris. Nippon Yakurigaku Zasshi ‐ Folia Pharmacologica Japonica2015;146(4):225‐32. [PUBMED: 26656967] ">Kawashima 2017b</a>), the pooled RR of this outcome was 1.28 (95% CI 0.65 to 2.54; 906 participants; I² = 0%; <a href="./references#CD011154-fig-0167" title="">Analysis 26.1</a>). Adverse events leading to withdrawal included application site erythema and irritation. </p> <p><a href="./references#CD011154-bbs2-0113" title="WangAP , TuP , JiS Z , WuY , ShenY , ZhuXJ . Clinical efficacy of benzoyl peroxide gel with different concentrations in acne vulgaris. Chinese Journal of Dermatology2003;36(6):313‐5. [CENTRAL: CN‐00486355] ">Wang 2003</a>, a six‐week trial, and <a href="./references#CD011154-bbs2-0074" title="Mills JrOH , KligmanAM , PochiP , ComiteH . Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. International Journal of Dermatology1986;25(10):664‐7. [CENTRAL: CN‐00046261; MEDLINE: 2948929] ">Mills 1986</a>, an eight‐week trial, reported medium‐term outcomes. Among a total of 151 participants treated with 5% BPO and 57 participants treated with 2.5% BPO, only three participants on 5% BPO treatment discontinued treatment due to adverse effects (<a href="./references#CD011154-bbs2-0074" title="Mills JrOH , KligmanAM , PochiP , ComiteH . Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. International Journal of Dermatology1986;25(10):664‐7. [CENTRAL: CN‐00046261; MEDLINE: 2948929] ">Mills 1986</a>; <a href="./references#CD011154-bbs2-0113" title="WangAP , TuP , JiS Z , WuY , ShenY , ZhuXJ . Clinical efficacy of benzoyl peroxide gel with different concentrations in acne vulgaris. Chinese Journal of Dermatology2003;36(6):313‐5. [CENTRAL: CN‐00486355] ">Wang 2003</a>), with an RR of 1.79 (95% CI 0.09 to 33.82; <a href="./references#CD011154-fig-0168" title="">Analysis 26.2</a>). Trial authors did not specify which adverse events led to their withdrawal. </p> </section> <section id="CD011154-sec-0510"> <p><b>Subgroup analyses: co‐intervention</b></p> <p>For the long‐term outcome, no evidence suggests that the effect may be affected by the co‐intervention (P = 0.59; <a href="./references#CD011154-fig-0167" title="">Analysis 26.1</a>). </p> </section> <section id="CD011154-sec-0511"> <p><b>Studies not included in the meta‐analysis</b></p> <p>In <a href="./references#CD011154-bbs2-0116" title="YongCC . Benzoyl peroxide gel therapy in acne in Singapore. International Journal of Dermatology1979;18(6):485‐8. [CENTRAL: CN‐00560673; MEDLINE: 158569] ">Yong 1979</a>, in which participants were treated for 4 to 18 weeks, 11 participants did not complete the trial because of desquamation and erythema, and four participants with pustulation and exacerbation of acne lesions were withdrawn. In this trial, however, it is unclear how many participants in each group withdrew. </p> </section> </section> <section id="CD011154-sec-0512"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0513"> <p><b>Studies not included in the meta‐analysis</b></p> <p>With 25 participants on 5% BPO and 26 on 2.5% BPO, <a href="./references#CD011154-bbs2-0074" title="Mills JrOH , KligmanAM , PochiP , ComiteH . Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. International Journal of Dermatology1986;25(10):664‐7. [CENTRAL: CN‐00046261; MEDLINE: 2948929] ">Mills 1986</a> found similar percentage reduction in ILs (57.7% versus 55.9%) at week 8. A total of 124 participants were included in the 5% BPO group and 31 in the 2.5% BPO group (<a href="./references#CD011154-bbs2-0113" title="WangAP , TuP , JiS Z , WuY , ShenY , ZhuXJ . Clinical efficacy of benzoyl peroxide gel with different concentrations in acne vulgaris. Chinese Journal of Dermatology2003;36(6):313‐5. [CENTRAL: CN‐00486355] ">Wang 2003</a>). Trial authors presented lesion counts at week 6, rather than the change in lesion counts from baseline, suggesting that IL but not NIL counts were lower in the 5% BPO group (MD for ILs ‐4.00, 95% CI ‐6.42 to ‐1.58; MD for NILs 1.80, 95% CI ‐1.69 to 5.29). In a 12‐week trial including 78 participants on 5% BPO and 79 on 2.5% BPO (<a href="./references#CD011154-bbs2-0082" title="NCT02073461 . Efficacy and safety study of 2 different concentrations of CD1579 gels versus vehicle in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02073461 (first received 20 February 2014). ">NCT02073461</a>), the reduction in TLs was 65.9% and 58.3%, respectively, with no significance test results presented. In <a href="./references#CD011154-bbs2-0116" title="YongCC . Benzoyl peroxide gel therapy in acne in Singapore. International Journal of Dermatology1979;18(6):485‐8. [CENTRAL: CN‐00560673; MEDLINE: 158569] ">Yong 1979</a>, 98 participants on 5% BPO and 96 on 2.5% BPO were assessed for treatment improvement based on the percentage reduction in lesion counts. At least 50% reduction was found in 74 versus 64 participants. <a href="./references#CD011154-bbs2-0020" title="DhawanSS , GwazdauskasJ . Clindamycin phosphate 1.2%‐benzoyl peroxide (5% or 2.5%) plus tazarotene cream 0.1% for the treatment of acne. Cutis; Cutaneous Medicine for the Practitioner2013;91(2):99‐104. [CENTRAL: CN‐00869753; MEDLINE: 23513559] NCT01016977 . A phase 4, single‐blind, randomized study to compare the tolerability and efficacy of Tazorac cream when used in combination with either Duac gel or Acanya gel for the treatment of facial acne vulgaris. clinicaltrials.gov/ct2/show/NCT01016977 (first received 20 November 2009). ">Dhawan 2013</a> suggested no significant difference in the percentage reduction in TLs, ILs, and NILs at week 12 (67.7% versus 67.9%, 66.1% versus 53.8%, and 67.8% versus 75.0%, respectively). We cannot estimate MD as the effect size because data were not sufficient to calculate standard deviation. </p> </section> </section> <section id="CD011154-sec-0514"> <h6 class="title">Secondary outcome: change in quality of life</h6> <section id="CD011154-sec-0515"> <p><b>Main pooled analyses: BPO (5%) versus BPO (2.5%)</b></p> <p>In <a href="./references#CD011154-bbs2-0020" title="DhawanSS , GwazdauskasJ . Clindamycin phosphate 1.2%‐benzoyl peroxide (5% or 2.5%) plus tazarotene cream 0.1% for the treatment of acne. Cutis; Cutaneous Medicine for the Practitioner2013;91(2):99‐104. [CENTRAL: CN‐00869753; MEDLINE: 23513559] NCT01016977 . A phase 4, single‐blind, randomized study to compare the tolerability and efficacy of Tazorac cream when used in combination with either Duac gel or Acanya gel for the treatment of facial acne vulgaris. clinicaltrials.gov/ct2/show/NCT01016977 (first received 20 November 2009). ">Dhawan 2013</a>, no significant difference was found in the mean change in Skindex‐29 global scores from baseline at week 12 (MD ‐2.40, 95% CI ‐8.68 to 3.88; 40 participants; <a href="./references#CD011154-fig-0169" title="">Analysis 26.3</a>). </p> </section> </section> <section id="CD011154-sec-0516"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0517"> <p><b>Main pooled analyses: BPO (5%) versus BPO (2.5%)</b></p> <p>Three studies provided long‐term data for this outcome in a total of 1063 participants (529 in the 5% group and 534 in the 2.5% group), with no clear differences between groups (RR 1.06, 95% CI 0.95 to 1.19; <a href="./references#CD011154-fig-0170" title="">Analysis 26.4</a>) (<a href="./references#CD011154-bbs2-0020" title="DhawanSS , GwazdauskasJ . Clindamycin phosphate 1.2%‐benzoyl peroxide (5% or 2.5%) plus tazarotene cream 0.1% for the treatment of acne. Cutis; Cutaneous Medicine for the Practitioner2013;91(2):99‐104. [CENTRAL: CN‐00869753; MEDLINE: 23513559] NCT01016977 . A phase 4, single‐blind, randomized study to compare the tolerability and efficacy of Tazorac cream when used in combination with either Duac gel or Acanya gel for the treatment of facial acne vulgaris. clinicaltrials.gov/ct2/show/NCT01016977 (first received 20 November 2009). ">Dhawan 2013</a>, <a href="./references#CD011154-bbs2-0060" title="KawashimaM , NagareT , KatsuramakiT . Open‐label, randomized, multicenter, phase III study to evaluate the safety and efficacy of benzoyl peroxide gel in long‐term use in patients with acne vulgaris: a secondary publication. Journal of Dermatology2017; Vol. 44, issue 6:635‐43. [CENTRAL: CN‐01459134; MEDLINE: 28150367] MorimotoH , KikukawaY , MurakamiN . Pharmacological profiles and clinical effects of benzoyl peroxide gel as treatments for acne vulgaris. Nippon Yakurigaku Zasshi ‐ Folia Pharmacologica Japonica2015;146(4):225‐32. [PUBMED: 26656967] ">Kawashima 2017a</a>; <a href="./references#CD011154-bbs2-0061" title="KawashimaM , SatoS , FurukawaF , MatsunagaK , AkamatsuH , IgarashiA , et al. Twelve‐week, multicenter, placebo‐controlled, randomized, double‐blind, parallel‐group, comparative phase II/III study of benzoyl peroxide gel in patients with acne vulgaris: a secondary publication. Journal of Dermatology2017; Vol. 44, issue 7:774‐82. [CENTRAL: CN‐01458975] MorimotoH , KikukawaY , MurakamiN . Pharmacological profiles and clinical effects of benzoyl peroxide gel as treatments for acne vulgaris. Nippon Yakurigaku Zasshi ‐ Folia Pharmacologica Japonica2015;146(4):225‐32. [PUBMED: 26656967] ">Kawashima 2017b</a>; <a href="./references#CD011154-bbs2-0082" title="NCT02073461 . Efficacy and safety study of 2 different concentrations of CD1579 gels versus vehicle in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02073461 (first received 20 February 2014). ">NCT02073461</a>). </p> <p><a href="./references#CD011154-bbs2-0060" title="KawashimaM , NagareT , KatsuramakiT . Open‐label, randomized, multicenter, phase III study to evaluate the safety and efficacy of benzoyl peroxide gel in long‐term use in patients with acne vulgaris: a secondary publication. Journal of Dermatology2017; Vol. 44, issue 6:635‐43. [CENTRAL: CN‐01459134; MEDLINE: 28150367] MorimotoH , KikukawaY , MurakamiN . Pharmacological profiles and clinical effects of benzoyl peroxide gel as treatments for acne vulgaris. Nippon Yakurigaku Zasshi ‐ Folia Pharmacologica Japonica2015;146(4):225‐32. [PUBMED: 26656967] ">Kawashima 2017a</a> reported that the top three adverse events were skin exfoliation (52/227 versus 42/231), application site irritation (46/227 versus 44/231), and application site erythema (41/227 versus 32/231). Similarly, the most common adverse event in <a href="./references#CD011154-bbs2-0061" title="KawashimaM , SatoS , FurukawaF , MatsunagaK , AkamatsuH , IgarashiA , et al. Twelve‐week, multicenter, placebo‐controlled, randomized, double‐blind, parallel‐group, comparative phase II/III study of benzoyl peroxide gel in patients with acne vulgaris: a secondary publication. Journal of Dermatology2017; Vol. 44, issue 7:774‐82. [CENTRAL: CN‐01458975] MorimotoH , KikukawaY , MurakamiN . Pharmacological profiles and clinical effects of benzoyl peroxide gel as treatments for acne vulgaris. Nippon Yakurigaku Zasshi ‐ Folia Pharmacologica Japonica2015;146(4):225‐32. [PUBMED: 26656967] ">Kawashima 2017b</a> was skin exfoliation (48/204 versus 39/204), followed by erythema (22/204 versus 28/204) and irritation (25/204 versus 17/204). Skin irritation (1/78 versus 3/79) was the most frequent skin or cutaneous adverse event reported in <a href="./references#CD011154-bbs2-0082" title="NCT02073461 . Efficacy and safety study of 2 different concentrations of CD1579 gels versus vehicle in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02073461 (first received 20 February 2014). ">NCT02073461</a>. <a href="./references#CD011154-bbs2-0020" title="DhawanSS , GwazdauskasJ . Clindamycin phosphate 1.2%‐benzoyl peroxide (5% or 2.5%) plus tazarotene cream 0.1% for the treatment of acne. Cutis; Cutaneous Medicine for the Practitioner2013;91(2):99‐104. [CENTRAL: CN‐00869753; MEDLINE: 23513559] NCT01016977 . A phase 4, single‐blind, randomized study to compare the tolerability and efficacy of Tazorac cream when used in combination with either Duac gel or Acanya gel for the treatment of facial acne vulgaris. clinicaltrials.gov/ct2/show/NCT01016977 (first received 20 November 2009). ">Dhawan 2013</a> reported that 11 participants on BPO (5%)/clindamycin and seven participants on BPO (2.5%)/clindamycin had at least one adverse event, most of which were related to infections and infestations with nasopharyngitis. </p> <p>Three trials reported the medium‐term outcome (<a href="./references#CD011154-bbs2-0074" title="Mills JrOH , KligmanAM , PochiP , ComiteH . Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. International Journal of Dermatology1986;25(10):664‐7. [CENTRAL: CN‐00046261; MEDLINE: 2948929] ">Mills 1986</a>; <a href="./references#CD011154-bbs2-0113" title="WangAP , TuP , JiS Z , WuY , ShenY , ZhuXJ . Clinical efficacy of benzoyl peroxide gel with different concentrations in acne vulgaris. Chinese Journal of Dermatology2003;36(6):313‐5. [CENTRAL: CN‐00486355] ">Wang 2003</a>; <a href="./references#CD011154-bbs2-0116" title="YongCC . Benzoyl peroxide gel therapy in acne in Singapore. International Journal of Dermatology1979;18(6):485‐8. [CENTRAL: CN‐00560673; MEDLINE: 158569] ">Yong 1979</a>); of these, only <a href="./references#CD011154-bbs2-0113" title="WangAP , TuP , JiS Z , WuY , ShenY , ZhuXJ . Clinical efficacy of benzoyl peroxide gel with different concentrations in acne vulgaris. Chinese Journal of Dermatology2003;36(6):313‐5. [CENTRAL: CN‐00486355] ">Wang 2003</a> provided sufficient data for an effect estimate. More participants in the 5% BPO group experienced adverse events (82/124 versus 11/31; RR 1.86, 95% CI 1.14 to 3.05; <a href="./references#CD011154-fig-0171" title="">Analysis 26.5</a>). </p> </section> <section id="CD011154-sec-0518"> <p><b>Subgroup analyses: co‐intervention</b></p> <p>For the long‐term outcome, we did not find evidence suggesting this effect may differ by co‐intervention, with a P value of 0.86 (<a href="./references#CD011154-fig-0170" title="">Analysis 26.4</a>). </p> </section> <section id="CD011154-sec-0519"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Two medium‐term trials did not provide sufficient data for the meta‐analysis. <a href="./references#CD011154-bbs2-0074" title="Mills JrOH , KligmanAM , PochiP , ComiteH . Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. International Journal of Dermatology1986;25(10):664‐7. [CENTRAL: CN‐00046261; MEDLINE: 2948929] ">Mills 1986</a> reported no significant differences in the frequency and severity of erythema, peeling, and burning between those receiving 5% BPO and those given 2.5% BPO. Adverse events were reported individually in <a href="./references#CD011154-bbs2-0116" title="YongCC . Benzoyl peroxide gel therapy in acne in Singapore. International Journal of Dermatology1979;18(6):485‐8. [CENTRAL: CN‐00560673; MEDLINE: 158569] ">Yong 1979</a>, with erythema the most common event (50/98 versus 45/96), followed by desquamation (28/98 versus 22/96). </p> </section> </section> </section> <section id="CD011154-sec-0520"> <h5 class="title">BPO gel (6%) versus BPO cream (5.5%)</h5> <p>One 12‐week trial, which included 24 participants in each group, compared the two concentrations of BPO (<a href="./references#CD011154-bbs2-0098" title="SmithS , KempersS . Multicenter, randomized, evaluator‐blinded, parallel group comparison study of the safety and efficacy of microentrapped benzoyl peroxide cream versus benzoyl peroxide gel in mild to moderate acne vulgaris. Abstract P165. American Academy of Dermatology 64th Annual Meeting, March 3‐7, 2006. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB30. [CENTRAL: CN‐00602161] SmithSR , KempersS . A study of 5.5% benzoyl peroxide microsphere cream versus 6% benzoyl peroxide gel in the treatment of acne vulgaris. Cosmetic Dermatology2006;19(8):537‐42. [CENTRAL: CN‐00641810] ">Smith 2006</a>). Trial authors reported the following outcomes of our review interest: participant global self‐assessment, withdrawal due to adverse effects, change in lesion counts, and adverse events. </p> <section id="CD011154-sec-0521"> <h6 class="title">Primary outcome: participant global self‐assessment of acne improvement</h6> <section id="CD011154-sec-0522"> <p><b>Studies not included in the meta‐analysis</b></p> <p>The outcome was assessed via a 5‐point scale (from 0 = no improvement or worsening to 4 = complete clearing). With no significance test results reported, trial authors claimed that more participants on 5.5% BPO cream rated the improvement as "marked" or "better" than those on 6% BPO gel (38% versus 32%). We cannot estimate the RR because data were not sufficient to calculate the number of participants with treatment success defined in our review. </p> </section> </section> <section id="CD011154-sec-0523"> <h6 class="title">Primary outcome: withdrawal due to adverse effects</h6> <section id="CD011154-sec-0524"> <p><b>Main pooled analyses: BPO gel (6%) versus BPO cream (5.5%)</b></p> <p>One participant on 6% BPO gel discontinued treatment due to application site irritation, with no significant differences between the two groups (RR 3.00, 95% CI 0.13 to 70.16; 48 participants; <a href="./references#CD011154-fig-0172" title="">Analysis 27.1</a>). </p> </section> </section> <section id="CD011154-sec-0525"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0526"> <p><b>Studies not included in the meta‐analysis</b></p> <p>No significant difference was found in the percentage reduction in TLs, ILs, and NILs at week 12 (21.2% versus 35.6%, 25.1% versus 39.3%, and 19.5% versus 33.0%, respectively). We cannot estimate MD as the effect size because data were not sufficient to calculate standard deviation. </p> </section> </section> <section id="CD011154-sec-0527"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0528"> <p><b>Studies not included in the meta‐analysis</b></p> <p>As reported by trial authors, 46 adverse events were reported in 48% of participants and were more frequently observed in participants on 6% BPO. However, the number of adverse events for each group is unclear. The most common events were dryness, erythema, scaling, itching, stinging, and burning. </p> </section> </section> </section> <section id="CD011154-sec-0529"> <h5 class="title">BPO (vehicle with 8% urea) versus BPO (vehicle with no urea)</h5> <p>One eight‐week split‐face trial made this comparison (<a href="./references#CD011154-bbs2-0088" title="PrinceRA , HarrisJM , MarocJA . Comparative trial of benzoyl peroxide versus benzoyl peroxide with urea in inflammatory acne. Cutis; Cutaneous Medicine for the Practitioner1982;29(6):638‐40, 644‐5. [CENTRAL: CN‐00028602; MEDLINE: 6213380] ">Prince 1982</a>), including 39 participants. Only an abstract was available for this trial. The abstract reported limited information on trial characteristics and on the outcome of change in lesion counts. </p> <section id="CD011154-sec-0530"> <h6 class="title">Primary outcomes</h6> <p>No information was available on the primary outcomes.</p> </section> <section id="CD011154-sec-0531"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0532"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Trial authors found no significant differences in the reduction in TLs and ILs between groups during the eight weeks. We cannot estimate MD as the effect size because data were not sufficient to calculate standard deviation. </p> </section> </section> </section> <section id="CD011154-sec-0533"> <h5 class="title">BPO (vehicle with acetone) versus BPO (vehicle with alcohol/detergent)</h5> <p>This comparison was made in one 8‐week parallel trial (<a href="./references#CD011154-bbs2-0070" title="LyonsRE . Comparative effectiveness of benzoyl peroxide and tretinoin in acne vulgaris. International Journal of Dermatology1978;17(3):246‐51. [CENTRAL: CN‐00018160; MEDLINE: 148436] ">Lyons 1978</a>), which included 54 participants treated with BPO acetone gel and 38 treated with BPO alcohol/detergent gel. Trial authors reported the following outcomes of our review interest: withdrawal due to adverse effects, change in lesion counts, and adverse events. </p> <section id="CD011154-sec-0534"> <h6 class="title">Primary outcomes</h6> <p>No primary outcomes of this review were reported in the trials.</p> </section> <section id="CD011154-sec-0535"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0536"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Trial authors reported that no statistical differences in the percentage change in comedones (62% versus 57%), papules (56% versus 56%), pustules (80% versus 79%), and total lesions (62% versus 59%) were found between groups at week 8. We cannot estimate MD as the effect size because data were not sufficient to calculate standard deviation. </p> </section> </section> <section id="CD011154-sec-0537"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0538"> <p><b>Studies not included in the meta‐analysis</b></p> <p>No adverse events were reported in either of the BPO gel groups.</p> </section> </section> </section> <section id="CD011154-sec-0539"> <h5 class="title">BPO (formulation 1) versus BPO (formulation 2)</h5> <p>One four‐week split‐face trial made this comparison (<a href="./references#CD011154-bbs2-0077" title="NCT00787943 . Study of two different 10.0% benzoyl peroxide creams for mild to moderate acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00787943 (first received 6 November 2008). ">NCT00787943</a>), including 10 participants receiving each formulation on each face side. No information was provided regarding differences between the two formulations. Results about the change in lesion reduction and about adverse events were published on the trial registry. No information regarding other outcomes was available. </p> <section id="CD011154-sec-0540"> <h6 class="title">Primary outcomes</h6> <p>No information was available on the primary outcomes.</p> </section> <section id="CD011154-sec-0541"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0542"> <p><b>Studies not included in the meta‐analysis</b></p> <p>The trial registry published papule and pustule counts for each individual at any time point, with no statistical results available. </p> </section> </section> <section id="CD011154-sec-0543"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0544"> <p><b>Studies not included in the meta‐analysis</b></p> <p>No serious adverse events were found in the 10 participants. During the four‐week period, adverse events occurred in eight participants. All experienced burning/stinging. </p> </section> </section> </section> <section id="CD011154-sec-0545"> <h5 class="title">Water‐based BPO versus alcohol‐based BPO</h5> <p>This comparison was made in one 8‐week split‐face trial (<a href="./references#CD011154-bbs2-0040" title="FyrandO , JakobsenHB . Water‐based versus alcohol‐based benzoyl peroxide preparations in the treatment of acne vulgaris. Dermatologica1986;172(5):263‐7. [CENTRAL: CN‐00044206; MEDLINE: 2943613] ">Fyrand 1986</a>), which included 45 participants treated with water‐based BPO on one side of the face and with alcohol‐based BPO on the other side. Trial authors reported the following outcomes of our review interest: withdrawal due to adverse effects, change in lesion counts, and adverse events. </p> <section id="CD011154-sec-0546"> <h6 class="title">Primary outcome: withdrawal due to adverse effects</h6> <section id="CD011154-sec-0547"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Six participants discontinued treatment due to local side effects. Two participants had severe dermatitis on both sides. Side effects occurred on both sides in another two participants but were worse on the side treated with alcohol‐based BPO: one participant had erythema, itching, and stinging, and the other had erythema and scaling. Another two participants stopped alcohol‐based BPO because of severe stinging. </p> </section> </section> <section id="CD011154-sec-0548"> <h6 class="title">Secondary outcome: investigator‐assessed change in lesion counts</h6> <section id="CD011154-sec-0549"> <p><b>Studies not included in the meta‐analysis</b></p> <p>Trial authors reported no significant differences (mean difference was null) at each time point (four weeks and eight weeks) for any types of lesions including open comedones, closed comedones, pustules, papules, and cysts. We cannot estimate MD as the effect size because data were not sufficient to calculate standard deviation. </p> </section> </section> <section id="CD011154-sec-0550"> <h6 class="title">Secondary outcome: percentage of participants experiencing any adverse event</h6> <section id="CD011154-sec-0551"> <p><b>Studies not included in the meta‐analysis</b></p> <p>No significant difference in the incidence of peeling and dryness was found between groups (10% versus 18% and 8% versus 12%, respectively). Trial authors reported no significant differences in grading for erythema, burning, dryness, or pruritus. </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011154-sec-0552" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011154-sec-0552">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011154-sec-0639">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011154-sec-0552"></div> <section id="CD011154-sec-0553"> <h3 class="title" id="CD011154-sec-0553">Summary of main results</h3> <p>We included 120 randomised controlled trials (RCTs) (188 reports) in this systematic review, which consisted of 47 pair‐wise comparisons involving topical treatments. Most of the evidence centred around BPO (as monotherapy or as add‐on treatment) and benzoyl peroxide (BPO) fixed combination treatments (BPO/adapalene, BPO/clindamycin, or BPO/erythromycin). Treatment duration in most of these trials was longer than eight weeks (a long‐term period as defined in our review); we found that our included studies rarely assessed short‐term treatment. Evaluation of our outcomes was limited, with many of our included studies assessing different outcomes from those we had pre‐specified as of interest. Application vehicle and BPO concentration were treatment aspects that were under‐reviewed by our studies. </p> <p>We summarise here the key results for our key treatment comparisons.</p> <p> <ul id="CD011154-list-0014"> <li> <p>BPO versus placebo or no treatment (<a href="./full#CD011154-tbl-0001">summary of findings Table for the main comparison</a>). </p> </li> <li> <p>BPO versus adapalene (<a href="./full#CD011154-tbl-0002">summary of findings Table 2</a>). </p> </li> <li> <p>BPO versus clindamycin (<a href="./full#CD011154-tbl-0003">summary of findings Table 3</a>). </p> </li> <li> <p>BPO versus erythromycin (<a href="./full#CD011154-tbl-0004">summary of findings Table 4</a>). </p> </li> <li> <p>BPO versus salicylic acid (<a href="./full#CD011154-tbl-0005">summary of findings Table 5</a>). </p> </li> </ul> </p> <section id="CD011154-sec-0554"> <h4 class="title">Clinical efficacy</h4> <section id="CD011154-sec-0555"> <h5 class="title">Primary efficacy outcome: participant global self‐assessment of acne improvement</h5> <p>Our review suggests that BPO as monotherapy or as add‐on treatment may be more effective than placebo or no treatment in achieving self‐reported treatment success (low‐certainty evidence). </p> <p>Low‐certainty evidence suggests there may be little to no difference in achieving treatment success when BPO is compared to adapalene or to clindamycin. In studies using their own definitions of self‐reported improvement, a neutral comparative effect was observed for BPO when compared with adapalene, clindamycin, or salicylic acid. </p> <p>No studies evaluating BPO compared to erythromycin or salicylic acid assessed self‐reported acne improvement. </p> </section> </section> <section id="CD011154-sec-0556"> <h4 class="title">Adverse effects</h4> <section id="CD011154-sec-0557"> <h5 class="title">Primary safety outcome: withdrawal due to adverse effects</h5> <p>Withdrawal from the trial due to adverse effects was generally rare in the included trials. However, low‐certainty evidence suggests that participants on BPO may be more likely than participants on placebo or no treatment to discontinue treatment. Skin burning, erythema, and pruritus were the main adverse events leading to withdrawal for this comparison. </p> <p>We found very low‐certainty evidence for risk of withdrawal due to adverse events when BPO was compared to clindamycin, erythromycin, adapalene, or salicylic acid: there may be little to no difference between groups in these comparisons in terms of withdrawal; however, we are unsure of the results due to the very low certainty of the evidence. When stated, reasons given for withdrawal may be associated with tolerability and included local hypersensitivity, pruritus, dermatitis, erythema, face oedema, rash, and skin burning. </p> </section> <section id="CD011154-sec-0558"> <h5 class="title">Secondary safety outcome: percentage of participants experiencing any adverse event</h5> <p>Adverse events were usually short term, mild to moderate, and well tolerated. The most commonly reported adverse events included skin dryness, pruritus, dermatitis, erythema, pain at the site of application, and irritation. </p> <p>For BPO compared with placebo or no treatment, adapalene, erythromycin, or salicylic acid, we found only very low‐certainty evidence underlying risk of adverse events, so we are uncertain whether there was a difference between these groups. </p> <p>Moderate‐certainty evidence indicates that BPO may increase risk of adverse events when compared with clindamycin; however, the 95% confidence interval (CI) indicates that BPO might make little to no difference. </p> </section> </section> </section> <section id="CD011154-sec-0559"> <h3 class="title" id="CD011154-sec-0559">Overall completeness and applicability of evidence</h3> <p>Evidence from our included studies was insufficient to fully address the objectives of this review: minimal assessment of key outcomes, variation in how reported outcomes were measured, and lack of evidence for key comparisons, limiting our conclusions. </p> <p>Most of the participants in the included trials suffered mild to moderate facial acne. Nearly 22% had severe acne, and 18% of studies did not report acne severity. We had planned to conduct subgroup analysis of severity, but none of the comparisons met our prerequisite (each subgroup included at least three studies). The mean age of participants ranged from 18 to 30, which is a relevant target population, as 64% of people aged 20 to 29 years may still have acne. Women who were pregnant, breastfeeding, or planning pregnancy were excluded from the trials. Therefore, the results of this review might not apply to these excluded participants. Approximately 7% of the included studies assessed acne on the trunk, meaning that our evidence pertains mainly to facial acne. </p> <p>Although we assessed the outcomes for different treatment duration, most evidence was derived from studies (80/120 trials) with a long‐term treatment duration (&gt; 8 weeks). This might also restrict the results reported in this review, in that they cannot be generalised to people treated for a shorter time. However, evidence from a longer treatment duration (at least 24 weeks) was rare, with only four included trials having participants treated for at least 24 weeks. Although long‐term treatment was our primary end point of interest, we aimed to report shorter treatment periods as an indicator of early improvement; however, short‐term treatment was given in only 10% of the studies. </p> <p>Despite a large number of trials included in this review, the number of trials for most outcomes of interest for a specific comparison was usually limited. This hindered investigation of heterogeneity sources (e.g. subgroup analysis), assessment of publication bias, and evaluation of the certainty of evidence. In terms of treatment, application vehicle and concentration are considered key treatment factors, but only four comparisons assessed BPO given in different vehicles, and different concentrations of BPO (10%, 6%, 5.5%, 5%, 2.5%) were assessed by only 10 studies in total, with low numbers eligible for pooling in a meta‐analysis. Combination treatment was also evaluated in relatively few trials. </p> <p>The primary efficacy outcome (self‐reported improvement) was reported in only 38 trials. Moreover, assessment scales varied substantially in these studies, and data for this outcome were heterogeneous. Evidence synthesis for this outcome was thus impossible for most comparisons. </p> <p>For secondary efficacy outcomes, most trials (97/120) presented results related to acne lesions (mostly as the primary outcome). However, reporting was not consistent across these trials, which was reflected in three aspects. First, different types of lesions were reported. Most trials reported only one or two types of lesions (total, inflamed, or non‐inflamed lesions). Second, different measures were used across trials, including absolute change in lesions, percentage change in lesions, and change in lesion counts. One or two measures were usually reported in a trial. Third, results were not completely reported. Most trials reported only point estimates, without standard errors, 95% confidence intervals, or specified P values. The problems with inconsistent and incomplete reporting not only hindered evidence synthesis but also implied the probability of selective reporting. The Investigator Global Assessment (IGA) scale of acne severity was used in a small portion of trials (25/120), in which the proportion or the number of participants rated as 'clear' or 'almost clear' was presented. Limited data were available on the change in quality of life and reduction in <i>Cutibacterium acnes (C acnes)</i> strains, neither of which could be assessed for most comparisons in this review. </p> <p>Regarding safety outcomes, only 68 of the 120 trials reported withdrawal due to adverse effects, but most trials (96/120) mentioned the number of participants with any adverse events. </p> </section> <section id="CD011154-sec-0560"> <h3 class="title" id="CD011154-sec-0560">Quality of the evidence</h3> <p>We summarised the certainty of evidence for five main comparisons. Certainty of the evidence was moderate in a limited number of outcomes, but most varied from low to very low certainty, depending on the outcomes and comparisons. The most common reasons for downgrading the certainty level were risk of bias, imprecision, and inconsistency of results. </p> <section id="CD011154-sec-0561"> <h4 class="title">Limitations in study design or execution</h4> <p>We considered most of the included studies as having high or unclear risk of bias in all seven risk of bias domains. We classified 65% of the included studies as having high risk of performance bias due to no blinding of participants and personnel, and nearly half as having high risk of detection bias for no blinding of outcome assessment. Blinding is likely to affect the measurement of outcomes for acne improvement, especially for the subjective measure, for the participant's self‐reported acne improvement. Even though blinding was conducted in some trials, success in blinding was difficult because treatment comparators differed in their appearance, properties, or known adverse effects (<a href="./references#CD011154-bbs2-0342" title="IngramJR , GrindlayDJ , WilliamsHC . Problems in the reporting of acne clinical trials: a spot check from the 2009 Annual Evidence Update on Acne Vulgaris. Trials2010;11:77. [MEDLINE: 20624287] ">Ingram 2010</a>). Lack of successful blinding could lead to biased results in favour of an experimental intervention due to lack of expectations in a control group, especially in placebo‐controlled trials. Because of incomplete outcome data, we judged more than a quarter of studies as having high risk of attrition bias. Most of the included studies did not provide sufficient information to determine the risk of bias in the domain of allocation concealment. Failure to conduct allocation concealment may lead investigators to include participants on the basis of their prognostic factors (such as severity and duration of acne) or to deliberately direct participants to the treatment from which they were considered to benefit more. Due to high and unclear risk of bias, we downgraded the certainty of evidence for risk of bias by one or more levels for most of the outcomes that we evaluated. </p> </section> <section id="CD011154-sec-0562"> <h4 class="title">Inconsistency of results</h4> <p>The small number of included studies confined assessment of inconsistency for most comparisons. When inconsistency was identified, however, we downgraded the certainty of evidence by one level. </p> <p>For the primary efficacy outcome, heterogeneity probably resulted from differences in the scales used to assess participant‐reported acne improvement. Heterogeneity was also common in the safety outcome probably due to different criteria used to determine adverse events. In the subgroup analysis, we found that effects of BPO may differ by co‐interventions. Acne severity, BPO concentrations, and countries in which trials were conducted (western and Asian) were also potential sources of heterogeneity. </p> </section> <section id="CD011154-sec-0563"> <h4 class="title">Indirectness</h4> <p>We included studies that met the eligibility criteria regarding study population, intervention, comparison, and outcomes. We assessed only the two primary outcomes and adverse events related to treatment. We did not downgrade the certainty of evidence for any outcomes for indirectness. </p> </section> <section id="CD011154-sec-0564"> <h4 class="title">Imprecision</h4> <p>The numbers of studies included were small for most comparisons. Events were rare in some outcomes, for example, withdrawal due to adverse effects and occurrence of adverse events. Consequently, imprecision was one major reason for which we downgraded the certainty of evidence. </p> </section> <section id="CD011154-sec-0565"> <h4 class="title">Publication bias</h4> <p>In the systematic review process, we conducted a comprehensive search to minimise the risk of publication bias. For <a href="./references#CD011154-fig-0009" title="">Analysis 1.3</a>, <a href="./references#CD011154-fig-0026" title="">Analysis 1.20</a>, and <a href="./references#CD011154-fig-0030" title="">Analysis 2.2</a>, when the number of included trials met the prerequisites as pre‐defined for publication bias analysis, funnel plots suggested low risk of publication bias (<a href="#CD011154-fig-0004">Figure 4</a>; <a href="#CD011154-fig-0005">Figure 5</a>; <a href="#CD011154-fig-0006">Figure 6</a>). On the other hand, we identified risk of publication bias for some comparisons (BPO versus placebo or no treatment, BPO versus adapalene, BPO/adapalene versus placebo, BPO/clindamycin versus placebo, BPO/clindamycin versus adapalene, and BPO/sulphur versus placebo) that were involved in 10 trials starting before 2015 but still "ongoing" as shown in the trial registries. </p> </section> <section id="CD011154-sec-0566"> <h4 class="title">Upgrading of certainty of evidence</h4> <p>We included only randomised trials; thus, the certainty of evidence would be high if we did not rate down due to any of the GRADE downgrading domains (risk of bias, inconsistency, indirectness, imprecision, and publication bias). If we had any concerns for rating down, we would not be confident to upgrade the certainty of evidence. </p> </section> </section> <section id="CD011154-sec-0567"> <h3 class="title" id="CD011154-sec-0567">Potential biases in the review process</h3> <p>We made every effort to minimise potential bias in the review process. We comprehensively searched and included studies with no limits on language or publication year, so that the risk of missing eligible studies was low. Two review authors independently determined the eligibility of studies, extracted data, and assessed risk of bias, with a third review author acting as an arbiter to minimise potential bias in the review process. None of the review authors had a conflict of interest regarding any of the medications involved in this review. </p> <p>However, several limitations of our review should be acknowledged. First, some potentially relevant trials were not included in our full assessment, as we could not confirm eligibility for those that were not reported in full text (listed in <a href="./references#CD011154-sec-0600" title="">Characteristics of studies awaiting classification</a>). Second, all amendments were made to the original protocol before data extraction and were based on consideration of clinical relevance, the purpose of this review, and consistency in definitions with other acne‐related Cochrane Reviews. Third, poor reporting was very common in the included trials and may introduce some bias or incompleteness in our assessment and analysis. To clarify any ambiguity due to such poor reporting, we contacted study authors for additional data (mainly about primary outcomes and the availability of full text) but seldom received a response to our request. </p> </section> <section id="CD011154-sec-0568"> <h3 class="title" id="CD011154-sec-0568">Agreements and disagreements with other studies or reviews</h3> <p>Several relevant systematic reviews (or meta‐analyses) have been conducted for BPO versus placebo (<a href="./references#CD011154-bbs2-0351" title="LamelSA , SivamaniRK , RahvarM , MaibachHI . Evaluating clinical trial design: systematic review of randomized vehicle‐controlled trials for determining efficacy of benzoyl peroxide topical therapy for acne. Archives of Dermatological Research2015;307:757‐66. ">Lamel 2015</a>; <a href="./references#CD011154-bbs2-0375" title="SeidlerEM ,  KimballAB . Meta‐analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne. Journal of the American Academy of Dermatology2010;63(1):52‐62. [MEDLINE: 20488582] ">Seidler 2010</a>), BPO versus adapalene (<a href="./references#CD011154-bbs2-0348" title="KolliSS , PeconeD , PonaA , ClineA , FeldmanSR . Topical retinoids in acne vulgaris: a systematic review. American Journal of Clinical Dermatology2019;20(3):345‐65. [PUBMED: 30674002] ">Kolli 2019</a>), BPO versus clindamycin (<a href="./references#CD011154-bbs2-0375" title="SeidlerEM ,  KimballAB . Meta‐analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne. Journal of the American Academy of Dermatology2010;63(1):52‐62. [MEDLINE: 20488582] ">Seidler 2010</a>), BPO/adapalene versus placebo (<a href="./references#CD011154-bbs2-0329" title="DresslerC , RosumeckS , NastA . How much do we know about maintaining treatment response after successful acne therapy? Systematic review on the efficacy and safety of acne maintenance therapy. Dermatology2016;232:371‐80. [MEDLINE: 27220773] ">Dressler 2016</a>; <a href="./references#CD011154-bbs2-0337" title="GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] ">Gold 2016a</a>; <a href="./references#CD011154-bbs2-0348" title="KolliSS , PeconeD , PonaA , ClineA , FeldmanSR . Topical retinoids in acne vulgaris: a systematic review. American Journal of Clinical Dermatology2019;20(3):345‐65. [PUBMED: 30674002] ">Kolli 2019</a>; <a href="./references#CD011154-bbs2-0391" title="ZhouR , JiangX . Effects of adapalene‐benzoyl peroxide combination gel in treatment or maintenance therapy of moderate or severe acne vulgaris: a meta‐analysis. Annals of Dermatology2014;26(1):43‐52. [MEDLINE: 24648685] ">Zhou 2014</a>), BPO/adapalene versus adapalene (<a href="./references#CD011154-bbs2-0348" title="KolliSS , PeconeD , PonaA , ClineA , FeldmanSR . Topical retinoids in acne vulgaris: a systematic review. American Journal of Clinical Dermatology2019;20(3):345‐65. [PUBMED: 30674002] ">Kolli 2019</a>), BPO/clindamycin versus placebo (<a href="./references#CD011154-bbs2-0375" title="SeidlerEM ,  KimballAB . Meta‐analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne. Journal of the American Academy of Dermatology2010;63(1):52‐62. [MEDLINE: 20488582] ">Seidler 2010</a>), BPO/clindamycin versus adapalene (<a href="./references#CD011154-bbs2-0348" title="KolliSS , PeconeD , PonaA , ClineA , FeldmanSR . Topical retinoids in acne vulgaris: a systematic review. American Journal of Clinical Dermatology2019;20(3):345‐65. [PUBMED: 30674002] ">Kolli 2019</a>), BPO plus salicylic acid versus placebo (<a href="./references#CD011154-bbs2-0375" title="SeidlerEM ,  KimballAB . Meta‐analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne. Journal of the American Academy of Dermatology2010;63(1):52‐62. [MEDLINE: 20488582] ">Seidler 2010</a>), BPO plus salicylic acid versus clindamycin (<a href="./references#CD011154-bbs2-0375" title="SeidlerEM ,  KimballAB . Meta‐analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne. Journal of the American Academy of Dermatology2010;63(1):52‐62. [MEDLINE: 20488582] ">Seidler 2010</a>), and BPO 10% versus 5% versus 2.5% (<a href="./references#CD011154-bbs2-0333" title="FakhouriT , YentzerBA , FeldmanSR . Advancement in benzoyl peroxide‐based acne treatment: methods to increase both efficacy and tolerability. Journal of Drugs in Dermatology2009;8(7):657‐61. [MEDLINE: 19588642] ">Fakhouri 2009</a>). The main difference between these reviews and ours was the choice of primary efficacy outcome: those reviews assessed changes in acne lesions or used IGA as the primary outcome, but our review focused primarily on participant self‐assessment. </p> <p>In the systematic review of randomised placebo‐controlled trials that aimed to assess the impact of study design and implementation on the efficacy of BPO, when compared with placebo, for treating acne (<a href="./references#CD011154-bbs2-0351" title="LamelSA , SivamaniRK , RahvarM , MaibachHI . Evaluating clinical trial design: systematic review of randomized vehicle‐controlled trials for determining efficacy of benzoyl peroxide topical therapy for acne. Archives of Dermatological Research2015;307:757‐66. ">Lamel 2015</a>), the percentage reductions in total, inflamed, and non‐inflamed lesions were inappropriately pooled for the active BPO monotherapy and placebo groups separately. The average percentage reduction in total, inflamed, and non‐inflamed lesions was 44.3 (standard deviation (SD), 9.2) versus 27.8 (SD, 21.0), 52.1 (SD, 10.4) versus 34.7 (SD, 22.7), and 41.5 (SD, 9.4) versus 27.0 (SD, 20.9) for BPO monotherapy and placebo groups, respectively. These results favouring BPO were consistent with our long‐term results. However, <a href="./references#CD011154-bbs2-0351" title="LamelSA , SivamaniRK , RahvarM , MaibachHI . Evaluating clinical trial design: systematic review of randomized vehicle‐controlled trials for determining efficacy of benzoyl peroxide topical therapy for acne. Archives of Dermatological Research2015;307:757‐66. ">Lamel 2015</a> did not estimate the mean difference in percentage reduction in lesions but pooled the data for each arm separately, with no consideration of the difference in treatment duration between studies. Risk of bias for each included trial was not assessed. </p> <p>For the comparison between BPO/adapalene and placebo, one review identified only one eligible trial supporting the use of BPO/adapalene maintenance treatment for reducing inflamed and non‐inflamed lesions (<a href="./references#CD011154-bbs2-0329" title="DresslerC , RosumeckS , NastA . How much do we know about maintaining treatment response after successful acne therapy? Systematic review on the efficacy and safety of acne maintenance therapy. Dermatology2016;232:371‐80. [MEDLINE: 27220773] ">Dressler 2016</a>). Participants on 24‐week treatment with BPO/adapalene were more likely to achieve 'clear' or 'almost clear' on the IGA scale (45.7% versus 25.6%), which was in line with our results. One meta‐analysis pooled individual participant data from three 12‐week trials, all of which were included in our review (<a href="./references#CD011154-bbs2-0337" title="GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] ">Gold 2016a</a>). Results on achieving 'clear' or 'almost clear' on the IGA scale were similar to ours: review authors conducted analyses for adult females and teenage females separately and concluded that once‐daily fixed‐dose BPO/adapalene was an efficacious and well‐tolerated anti‐acne treatment for both. Another systematic review including six trials supported the benefits of BPO/adapalene in terms of achieving 'clear' or 'almost clear' on the IGA and participant self‐reported improvement. These review authors also expressed some concerns about withdrawal due to BPO/adapalene‐related adverse effects (<a href="./references#CD011154-bbs2-0391" title="ZhouR , JiangX . Effects of adapalene‐benzoyl peroxide combination gel in treatment or maintenance therapy of moderate or severe acne vulgaris: a meta‐analysis. Annals of Dermatology2014;26(1):43‐52. [MEDLINE: 24648685] ">Zhou 2014</a>). Similar results were shown in our review for the IGA outcome, but for participant‐reported improvement, we found no significant differences after long‐term treatment. </p> <p>A meta‐analysis involving 23 trials tried to compare five topical treatments (<a href="./references#CD011154-bbs2-0375" title="SeidlerEM ,  KimballAB . Meta‐analysis comparing efficacy of benzoyl peroxide, clindamycin, benzoyl peroxide with salicylic acid, and combination benzoyl peroxide/clindamycin in acne. Journal of the American Academy of Dermatology2010;63(1):52‐62. [MEDLINE: 20488582] ">Seidler 2010</a>), including 5% BPO, clindamycin, BPO (5%)/clindamycin, BPO (5%) plus salicylic acid, and placebo. Absolute and percentage reductions in inflamed and non‐inflamed lesions were the main outcomes assessed in the review. BPO monotherapy, BPO/clindamycin, and BPO plus salicylic acid were all superior to placebo for any outcome regardless of lesion type and treatment duration. Our review found similar results for long‐term assessment of BPO monotherapy and BPO/clindamycin but did not include any studies assessing BPO plus salicylic acid. Both BPO/clindamycin and BPO plus salicylic acid seemed superior to clindamycin monotherapy for all outcomes except the absolute reduction in inflamed lesions at 10 to 12 weeks. However, these results are questionable because they were obtained from naive comparisons based on overlaps in 95% CIs estimated from the data syntheses for each arm separately. In addition, information regarding assessment of risk of bias was lacking. Our review did not include any studies assessing these comparisons. </p> <p>A systematic review comparing BPO concentrations suggested that 10%, 5%, and 2.5% were equally effective in reducing inflammatory acne, but a higher concentration seemed to increase the risk of adverse effects (<a href="./references#CD011154-bbs2-0333" title="FakhouriT , YentzerBA , FeldmanSR . Advancement in benzoyl peroxide‐based acne treatment: methods to increase both efficacy and tolerability. Journal of Drugs in Dermatology2009;8(7):657‐61. [MEDLINE: 19588642] ">Fakhouri 2009</a>). However, these results were not convincing due to the poor quality of the review: unclear inclusion criteria for studies, no assessment of risk of bias, and no attempt to combine studies (<a href="./references#CD011154-bbs2-0377" title="SmithE V , GrindlayDJ , WilliamsHC . What's new in acne? An analysis of systematic reviews published in 2009‐2010. Clinical &amp; Experimental Dermatology2010;36(2):119‐22. [MEDLINE: 20738323] ">Smith 2010</a>). </p> <p>A systematic review focusing on topical retinoids in acne vulgaris included some studies involving BPO treatment (<a href="./references#CD011154-bbs2-0348" title="KolliSS , PeconeD , PonaA , ClineA , FeldmanSR . Topical retinoids in acne vulgaris: a systematic review. American Journal of Clinical Dermatology2019;20(3):345‐65. [PUBMED: 30674002] ">Kolli 2019</a>), all of which were covered in our review. That review summarised individual studies on acne lesion reduction and Investigator Global Assessment success rate. Its findings were similar to ours for these comparisons: BPO versus adapalene, BPO/adapalene versus placebo, BPO/adapalene versus adapalene, and BPO/clindamycin versus adapalene. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011154-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011154-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/full#CD011154-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011154-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/full#CD011154-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011154-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/full#CD011154-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 BPO versus placebo or no treatment, outcome: 1.3 Withdrawal due to adverse effects (long‐term data)." data-id="CD011154-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 BPO versus placebo or no treatment, outcome: 1.3 Withdrawal due to adverse effects (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/full#CD011154-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 BPO versus placebo or no treatment, outcome: 1.20 Percentage of participants with any adverse events (long‐term data)." data-id="CD011154-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 BPO versus placebo or no treatment, outcome: 1.20 Percentage of participants with any adverse events (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/full#CD011154-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 2 BPO versus adapalene, outcome: 2.2 Withdrawal due to adverse effects (long‐term data)." data-id="CD011154-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 2 BPO versus adapalene, outcome: 2.2 Withdrawal due to adverse effects (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/full#CD011154-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 BPO versus placebo or no treatment, Outcome 1 Participant's global self‐assessment of improvement (long‐term data)." data-id="CD011154-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 BPO versus placebo or no treatment, Outcome 1 Participant's global self‐assessment of improvement (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 BPO versus placebo or no treatment, Outcome 2 Participant's global self‐assessment of improvement (medium‐term data)." data-id="CD011154-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 BPO versus placebo or no treatment, Outcome 2 Participant's global self‐assessment of improvement (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 BPO versus placebo or no treatment, Outcome 3 Withdrawal due to adverse effects (long‐term data)." data-id="CD011154-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 BPO versus placebo or no treatment, Outcome 3 Withdrawal due to adverse effects (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 BPO versus placebo or no treatment, Outcome 4 Withdrawal due to adverse effects (medium‐term data)." data-id="CD011154-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 BPO versus placebo or no treatment, Outcome 4 Withdrawal due to adverse effects (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 BPO versus placebo or no treatment, Outcome 5 Investigator‐assessed absolute change in total lesions (long‐term data)." data-id="CD011154-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 BPO versus placebo or no treatment, Outcome 5 Investigator‐assessed absolute change in total lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 BPO versus placebo or no treatment, Outcome 6 Investigator‐assessed absolute change in inflammatory lesions (long‐term data)." data-id="CD011154-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 BPO versus placebo or no treatment, Outcome 6 Investigator‐assessed absolute change in inflammatory lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 BPO versus placebo or no treatment, Outcome 7 Investigator‐assessed absolute change in non‐inflammatory lesions (long‐term data)." data-id="CD011154-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 BPO versus placebo or no treatment, Outcome 7 Investigator‐assessed absolute change in non‐inflammatory lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 BPO versus placebo or no treatment, Outcome 8 Investigator‐assessed percentage change in total lesions (long‐term data)." data-id="CD011154-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 BPO versus placebo or no treatment, Outcome 8 Investigator‐assessed percentage change in total lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 BPO versus placebo or no treatment, Outcome 9 Investigator‐assessed percentage change in inflammatory lesions (long‐term data)." data-id="CD011154-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 BPO versus placebo or no treatment, Outcome 9 Investigator‐assessed percentage change in inflammatory lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 BPO versus placebo or no treatment, Outcome 10 Investigator‐assessed percentage change in non‐inflammatory lesions (long‐term data)." data-id="CD011154-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 BPO versus placebo or no treatment, Outcome 10 Investigator‐assessed percentage change in non‐inflammatory lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 BPO versus placebo or no treatment, Outcome 11 Investigator‐assessed percentage change in total lesions (medium‐term data)." data-id="CD011154-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 BPO versus placebo or no treatment, Outcome 11 Investigator‐assessed percentage change in total lesions (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 BPO versus placebo or no treatment, Outcome 12 Investigator‐assessed percentage change in inflammatory lesions (medium‐term data)." data-id="CD011154-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 BPO versus placebo or no treatment, Outcome 12 Investigator‐assessed percentage change in inflammatory lesions (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 BPO versus placebo or no treatment, Outcome 13 Investigator‐assessed percentage change in non‐inflammatory lesions (medium‐term data)." data-id="CD011154-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 BPO versus placebo or no treatment, Outcome 13 Investigator‐assessed percentage change in non‐inflammatory lesions (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 BPO versus placebo or no treatment, Outcome 14 Investigator‐assessed percentage change in total lesions (short‐term data)." data-id="CD011154-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 BPO versus placebo or no treatment, Outcome 14 Investigator‐assessed percentage change in total lesions (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 BPO versus placebo or no treatment, Outcome 15 Investigator‐assessed percentage change in inflammatory lesions (short‐term data)." data-id="CD011154-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 BPO versus placebo or no treatment, Outcome 15 Investigator‐assessed percentage change in inflammatory lesions (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 BPO versus placebo or no treatment, Outcome 16 Investigator‐assessed percentage change in non‐inflammatory lesions (short‐term data)." data-id="CD011154-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 BPO versus placebo or no treatment, Outcome 16 Investigator‐assessed percentage change in non‐inflammatory lesions (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 BPO versus placebo or no treatment, Outcome 17 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (long‐term data)." data-id="CD011154-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 BPO versus placebo or no treatment, Outcome 17 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 BPO versus placebo or no treatment, Outcome 18 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (medium‐term data)." data-id="CD011154-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 BPO versus placebo or no treatment, Outcome 18 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 BPO versus placebo or no treatment, Outcome 19 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (short‐term data)." data-id="CD011154-fig-0025" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 BPO versus placebo or no treatment, Outcome 19 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-001-20.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 BPO versus placebo or no treatment, Outcome 20 Percentage of participants with any adverse events (long‐term data)." data-id="CD011154-fig-0026" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 BPO versus placebo or no treatment, Outcome 20 Percentage of participants with any adverse events (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 BPO versus placebo or no treatment, Outcome 21 Percentage of participants with any adverse events (medium‐term data)." data-id="CD011154-fig-0027" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 BPO versus placebo or no treatment, Outcome 21 Percentage of participants with any adverse events (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 BPO versus placebo or no treatment, Outcome 22 Percentage of participants with any adverse events (short‐term data)." data-id="CD011154-fig-0028" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 BPO versus placebo or no treatment, Outcome 22 Percentage of participants with any adverse events (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BPO versus adapalene, Outcome 1 Participant's global self‐assessment of improvement (long‐term data)." data-id="CD011154-fig-0029" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 BPO versus adapalene, Outcome 1 Participant's global self‐assessment of improvement (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-002-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BPO versus adapalene, Outcome 2 Withdrawal due to adverse effects (long‐term data)." data-id="CD011154-fig-0030" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 BPO versus adapalene, Outcome 2 Withdrawal due to adverse effects (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BPO versus adapalene, Outcome 3 Investigator‐assessed absolute change in total lesions (long‐term data)." data-id="CD011154-fig-0031" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 BPO versus adapalene, Outcome 3 Investigator‐assessed absolute change in total lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BPO versus adapalene, Outcome 4 Investigator‐assessed absolute change in inflammatory lesions (long‐term data)." data-id="CD011154-fig-0032" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 BPO versus adapalene, Outcome 4 Investigator‐assessed absolute change in inflammatory lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BPO versus adapalene, Outcome 5 Investigator‐assessed absolute change in non‐inflammatory lesions (long‐term data)." data-id="CD011154-fig-0033" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 BPO versus adapalene, Outcome 5 Investigator‐assessed absolute change in non‐inflammatory lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BPO versus adapalene, Outcome 6 Investigator‐assessed absolute change in total lesions (medium‐term data)." data-id="CD011154-fig-0034" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 BPO versus adapalene, Outcome 6 Investigator‐assessed absolute change in total lesions (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BPO versus adapalene, Outcome 7 Investigator‐assessed absolute change in inflammatory lesions (medium‐term data)." data-id="CD011154-fig-0035" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 BPO versus adapalene, Outcome 7 Investigator‐assessed absolute change in inflammatory lesions (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BPO versus adapalene, Outcome 8 Investigator‐assessed absolute change in non‐inflammatory lesions (medium‐term data)." data-id="CD011154-fig-0036" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 BPO versus adapalene, Outcome 8 Investigator‐assessed absolute change in non‐inflammatory lesions (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BPO versus adapalene, Outcome 9 Investigator‐assessed absolute change in total lesions (short‐term data)." data-id="CD011154-fig-0037" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 BPO versus adapalene, Outcome 9 Investigator‐assessed absolute change in total lesions (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BPO versus adapalene, Outcome 10 Investigator‐assessed absolute change in inflammatory lesions (short‐term data)." data-id="CD011154-fig-0038" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 BPO versus adapalene, Outcome 10 Investigator‐assessed absolute change in inflammatory lesions (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BPO versus adapalene, Outcome 11 Investigator‐assessed absolute change in non‐inflammatory lesions (short‐term data)." data-id="CD011154-fig-0039" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 BPO versus adapalene, Outcome 11 Investigator‐assessed absolute change in non‐inflammatory lesions (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BPO versus adapalene, Outcome 12 Investigator‐assessed percentage change in total lesions (long‐term data)." data-id="CD011154-fig-0040" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 BPO versus adapalene, Outcome 12 Investigator‐assessed percentage change in total lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BPO versus adapalene, Outcome 13 Investigator‐assessed percentage change in inflammatory lesions (long‐term data)." data-id="CD011154-fig-0041" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 BPO versus adapalene, Outcome 13 Investigator‐assessed percentage change in inflammatory lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BPO versus adapalene, Outcome 14 Investigator‐assessed percentage change in non‐inflammatory lesions (long‐term data)." data-id="CD011154-fig-0042" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 BPO versus adapalene, Outcome 14 Investigator‐assessed percentage change in non‐inflammatory lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BPO versus adapalene, Outcome 15 Investigator‐assessed percentage change in total lesions (medium‐term data)." data-id="CD011154-fig-0043" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 BPO versus adapalene, Outcome 15 Investigator‐assessed percentage change in total lesions (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BPO versus adapalene, Outcome 16 Investigator‐assessed percentage change in inflammatory lesions (medium‐term data)." data-id="CD011154-fig-0044" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 BPO versus adapalene, Outcome 16 Investigator‐assessed percentage change in inflammatory lesions (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BPO versus adapalene, Outcome 17 Investigator‐assessed percentage change in non‐inflammatory lesions (medium‐term data)." data-id="CD011154-fig-0045" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 BPO versus adapalene, Outcome 17 Investigator‐assessed percentage change in non‐inflammatory lesions (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-002-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-002-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BPO versus adapalene, Outcome 18 Investigator‐assessed percentage change in total lesions (short‐term data)." data-id="CD011154-fig-0046" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2 BPO versus adapalene, Outcome 18 Investigator‐assessed percentage change in total lesions (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-002-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-002-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BPO versus adapalene, Outcome 19 Investigator‐assessed percentage change in inflammatory lesions (short‐term data)." data-id="CD011154-fig-0047" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2 BPO versus adapalene, Outcome 19 Investigator‐assessed percentage change in inflammatory lesions (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-002-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-002-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BPO versus adapalene, Outcome 20 Investigator‐assessed percentage change in non‐inflammatory lesions (short‐term data)." data-id="CD011154-fig-0048" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2 BPO versus adapalene, Outcome 20 Investigator‐assessed percentage change in non‐inflammatory lesions (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-002-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-002-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BPO versus adapalene, Outcome 21 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (long‐term data)." data-id="CD011154-fig-0049" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2 BPO versus adapalene, Outcome 21 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-002-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-002-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BPO versus adapalene, Outcome 22 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (medium‐term data)." data-id="CD011154-fig-0050" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.22</div> <div class="figure-caption"> <p>Comparison 2 BPO versus adapalene, Outcome 22 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-002-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-002-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BPO versus adapalene, Outcome 23 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (short‐term data)." data-id="CD011154-fig-0051" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.23</div> <div class="figure-caption"> <p>Comparison 2 BPO versus adapalene, Outcome 23 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-002-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-002-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BPO versus adapalene, Outcome 24 Change in quality of life (long‐term data)." data-id="CD011154-fig-0052" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.24</div> <div class="figure-caption"> <p>Comparison 2 BPO versus adapalene, Outcome 24 Change in quality of life (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-002-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-002-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BPO versus adapalene, Outcome 25 Change in quality of life (medium‐term data)." data-id="CD011154-fig-0053" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.25</div> <div class="figure-caption"> <p>Comparison 2 BPO versus adapalene, Outcome 25 Change in quality of life (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-002-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-002-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BPO versus adapalene, Outcome 26 Change in quality of life (short‐term data)." data-id="CD011154-fig-0054" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.26</div> <div class="figure-caption"> <p>Comparison 2 BPO versus adapalene, Outcome 26 Change in quality of life (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-002-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-002-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BPO versus adapalene, Outcome 27 Percentage of participants with any adverse events (long‐term data)." data-id="CD011154-fig-0055" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.27</div> <div class="figure-caption"> <p>Comparison 2 BPO versus adapalene, Outcome 27 Percentage of participants with any adverse events (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-002-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-002-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 BPO versus adapalene, Outcome 28 Percentage of participants with any adverse events (short‐term data)." data-id="CD011154-fig-0056" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.28</div> <div class="figure-caption"> <p>Comparison 2 BPO versus adapalene, Outcome 28 Percentage of participants with any adverse events (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-002-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 BPO versus clindamycin, Outcome 1 Participant's global self‐assessment of improvement (long‐term data)." data-id="CD011154-fig-0057" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 BPO versus clindamycin, Outcome 1 Participant's global self‐assessment of improvement (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 BPO versus clindamycin, Outcome 2 Withdrawal due to adverse effects (long‐term data)." data-id="CD011154-fig-0058" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 BPO versus clindamycin, Outcome 2 Withdrawal due to adverse effects (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 BPO versus clindamycin, Outcome 3 Investigator‐assessed absolute change in total lesions (long‐term data)." data-id="CD011154-fig-0059" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 BPO versus clindamycin, Outcome 3 Investigator‐assessed absolute change in total lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 BPO versus clindamycin, Outcome 4 Investigator‐assessed absolute change in inflammatory lesions (long‐term data)." data-id="CD011154-fig-0060" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 BPO versus clindamycin, Outcome 4 Investigator‐assessed absolute change in inflammatory lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 BPO versus clindamycin, Outcome 5 Investigator‐assessed absolute change in non‐inflammatory lesions (long‐term data)." data-id="CD011154-fig-0061" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 BPO versus clindamycin, Outcome 5 Investigator‐assessed absolute change in non‐inflammatory lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 BPO versus clindamycin, Outcome 6 Investigator‐assessed percentage change in inflammatory lesions (long‐term data)." data-id="CD011154-fig-0062" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 BPO versus clindamycin, Outcome 6 Investigator‐assessed percentage change in inflammatory lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 BPO versus clindamycin, Outcome 7 Investigator‐assessed percentage change in non‐inflammatory lesions (long‐term data)." data-id="CD011154-fig-0063" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 BPO versus clindamycin, Outcome 7 Investigator‐assessed percentage change in non‐inflammatory lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 BPO versus clindamycin, Outcome 8 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (long‐term data)." data-id="CD011154-fig-0064" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 BPO versus clindamycin, Outcome 8 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 BPO versus clindamycin, Outcome 9 Percentage of participants with any adverse events (long‐term data)." data-id="CD011154-fig-0065" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 BPO versus clindamycin, Outcome 9 Percentage of participants with any adverse events (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 BPO versus erythromycin, Outcome 1 Withdrawal due to adverse effects (medium‐term data)." data-id="CD011154-fig-0066" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 BPO versus erythromycin, Outcome 1 Withdrawal due to adverse effects (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 BPO versus salicylic acid, Outcome 1 Percentage of participants with any adverse events (medium‐term data)." data-id="CD011154-fig-0067" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 BPO versus salicylic acid, Outcome 1 Percentage of participants with any adverse events (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 BPO versus tretinoin, Outcome 1 Withdrawal due to adverse effects (long‐term data)." data-id="CD011154-fig-0068" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 BPO versus tretinoin, Outcome 1 Withdrawal due to adverse effects (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 BPO versus tretinoin, Outcome 2 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (long‐term data)." data-id="CD011154-fig-0069" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 BPO versus tretinoin, Outcome 2 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 BPO versus tretinoin, Outcome 3 Percentage of participants with any adverse events (long‐term data)." data-id="CD011154-fig-0070" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 BPO versus tretinoin, Outcome 3 Percentage of participants with any adverse events (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 BPO versus tretinoin, Outcome 4 Percentage of participants with any adverse events (medium‐term data)." data-id="CD011154-fig-0071" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 BPO versus tretinoin, Outcome 4 Percentage of participants with any adverse events (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 BPO versus isotretinoin, Outcome 1 Withdrawal due to adverse effects (long‐term data)." data-id="CD011154-fig-0072" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 BPO versus isotretinoin, Outcome 1 Withdrawal due to adverse effects (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 BPO versus isotretinoin, Outcome 2 Investigator‐assessed absolute change in inflammatory lesions (long‐term data)." data-id="CD011154-fig-0073" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 BPO versus isotretinoin, Outcome 2 Investigator‐assessed absolute change in inflammatory lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 BPO versus isotretinoin, Outcome 3 Investigator‐assessed absolute change in non‐inflammatory lesions (long‐term data)." data-id="CD011154-fig-0074" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 BPO versus isotretinoin, Outcome 3 Investigator‐assessed absolute change in non‐inflammatory lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 BPO versus isotretinoin, Outcome 4 Investigator‐assessed absolute change in inflammatory lesions (medium‐term data)." data-id="CD011154-fig-0075" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 BPO versus isotretinoin, Outcome 4 Investigator‐assessed absolute change in inflammatory lesions (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-007-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-007-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 BPO versus isotretinoin, Outcome 5 Investigator‐assessed absolute change in non‐inflammatory lesions (medium‐term data)." data-id="CD011154-fig-0076" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-007-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 BPO versus isotretinoin, Outcome 5 Investigator‐assessed absolute change in non‐inflammatory lesions (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-007-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-007-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-007-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 BPO versus isotretinoin, Outcome 6 Investigator‐assessed absolute change in inflammatory lesions (short‐term data)." data-id="CD011154-fig-0077" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-007-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7 BPO versus isotretinoin, Outcome 6 Investigator‐assessed absolute change in inflammatory lesions (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-007-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-007-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-007-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 BPO versus isotretinoin, Outcome 7 Investigator‐assessed absolute change in non‐inflammatory lesions (short‐term data)." data-id="CD011154-fig-0078" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-007-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7 BPO versus isotretinoin, Outcome 7 Investigator‐assessed absolute change in non‐inflammatory lesions (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-007-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-007-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-007-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 BPO versus isotretinoin, Outcome 8 Percentage of participants with any adverse events (long‐term data)." data-id="CD011154-fig-0079" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-007-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7 BPO versus isotretinoin, Outcome 8 Percentage of participants with any adverse events (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-007-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-007-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-007-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 BPO versus isotretinoin, Outcome 9 Percentage of participants with any adverse events (short‐term data)." data-id="CD011154-fig-0080" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-007-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.9</div> <div class="figure-caption"> <p>Comparison 7 BPO versus isotretinoin, Outcome 9 Percentage of participants with any adverse events (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-007-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 BPO versus hydrogen peroxide, Outcome 1 Percentage of participants with any adverse events (medium‐term data)." data-id="CD011154-fig-0081" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 BPO versus hydrogen peroxide, Outcome 1 Percentage of participants with any adverse events (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 BPO versus isolutrol, Outcome 1 Percentage of participants with any adverse events (long‐term data)." data-id="CD011154-fig-0082" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 BPO versus isolutrol, Outcome 1 Percentage of participants with any adverse events (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 BPO versus meclocycline, Outcome 1 Withdrawal due to adverse effects (long‐term data)." data-id="CD011154-fig-0083" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 BPO versus meclocycline, Outcome 1 Withdrawal due to adverse effects (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 BPO versus tea tree oil, Outcome 1 Percentage of participants with any adverse events (long‐term data)." data-id="CD011154-fig-0084" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 BPO versus tea tree oil, Outcome 1 Percentage of participants with any adverse events (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 BPO versus chloroxylenol/zinc oxide, Outcome 1 Participant's global self‐assessment of improvement (medium‐term data)." data-id="CD011154-fig-0085" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 BPO versus chloroxylenol/zinc oxide, Outcome 1 Participant's global self‐assessment of improvement (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-013-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-013-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 BPO/adapalene versus placebo or no treatment, Outcome 1 Participant's global self‐assessment of improvement (long‐term data)." data-id="CD011154-fig-0086" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-013-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13 BPO/adapalene versus placebo or no treatment, Outcome 1 Participant's global self‐assessment of improvement (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-013-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-013-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-013-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 BPO/adapalene versus placebo or no treatment, Outcome 2 Withdrawal due to adverse effects (long‐term data)." data-id="CD011154-fig-0087" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-013-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13 BPO/adapalene versus placebo or no treatment, Outcome 2 Withdrawal due to adverse effects (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-013-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-013-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-013-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 BPO/adapalene versus placebo or no treatment, Outcome 3 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (long‐term data)." data-id="CD011154-fig-0088" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-013-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13 BPO/adapalene versus placebo or no treatment, Outcome 3 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-013-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-013-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-013-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 BPO/adapalene versus placebo or no treatment, Outcome 4 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (medium‐term data)." data-id="CD011154-fig-0089" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-013-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.4</div> <div class="figure-caption"> <p>Comparison 13 BPO/adapalene versus placebo or no treatment, Outcome 4 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-013-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-013-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-013-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 BPO/adapalene versus placebo or no treatment, Outcome 5 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (short‐term data)." data-id="CD011154-fig-0090" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-013-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.5</div> <div class="figure-caption"> <p>Comparison 13 BPO/adapalene versus placebo or no treatment, Outcome 5 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-013-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-013-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-013-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 BPO/adapalene versus placebo or no treatment, Outcome 6 Percentage of participants with any adverse events (long‐term data)." data-id="CD011154-fig-0091" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-013-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.6</div> <div class="figure-caption"> <p>Comparison 13 BPO/adapalene versus placebo or no treatment, Outcome 6 Percentage of participants with any adverse events (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-013-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-014-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-014-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 BPO/clindamycin versus placebo or no treatment, Outcome 1 Participant's global self‐assessment of improvement (long‐term data)." data-id="CD011154-fig-0092" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-014-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14 BPO/clindamycin versus placebo or no treatment, Outcome 1 Participant's global self‐assessment of improvement (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-014-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-014-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-014-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 BPO/clindamycin versus placebo or no treatment, Outcome 2 Withdrawal due to adverse effects (long‐term data)." data-id="CD011154-fig-0093" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-014-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14 BPO/clindamycin versus placebo or no treatment, Outcome 2 Withdrawal due to adverse effects (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-014-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-014-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-014-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 BPO/clindamycin versus placebo or no treatment, Outcome 3 Investigator‐assessed absolute change in total lesions (long‐term data)." data-id="CD011154-fig-0094" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-014-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14 BPO/clindamycin versus placebo or no treatment, Outcome 3 Investigator‐assessed absolute change in total lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-014-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-014-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-014-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 BPO/clindamycin versus placebo or no treatment, Outcome 4 Investigator‐assessed absolute change in inflammatory lesions (long‐term data)." data-id="CD011154-fig-0095" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-014-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.4</div> <div class="figure-caption"> <p>Comparison 14 BPO/clindamycin versus placebo or no treatment, Outcome 4 Investigator‐assessed absolute change in inflammatory lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-014-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-014-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-014-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 BPO/clindamycin versus placebo or no treatment, Outcome 5 Investigator‐assessed absolute change in non‐inflammatory lesions (long‐term data)." data-id="CD011154-fig-0096" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-014-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.5</div> <div class="figure-caption"> <p>Comparison 14 BPO/clindamycin versus placebo or no treatment, Outcome 5 Investigator‐assessed absolute change in non‐inflammatory lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-014-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-014-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-014-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 BPO/clindamycin versus placebo or no treatment, Outcome 6 Investigator‐assessed percentage change in inflammatory lesions (long‐term data)." data-id="CD011154-fig-0097" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-014-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.6</div> <div class="figure-caption"> <p>Comparison 14 BPO/clindamycin versus placebo or no treatment, Outcome 6 Investigator‐assessed percentage change in inflammatory lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-014-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-014-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-014-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 BPO/clindamycin versus placebo or no treatment, Outcome 7 Investigator‐assessed percentage change in non‐inflammatory lesions (long‐term data)." data-id="CD011154-fig-0098" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-014-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.7</div> <div class="figure-caption"> <p>Comparison 14 BPO/clindamycin versus placebo or no treatment, Outcome 7 Investigator‐assessed percentage change in non‐inflammatory lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-014-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-014-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-014-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 BPO/clindamycin versus placebo or no treatment, Outcome 8 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (long‐term data)." data-id="CD011154-fig-0099" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-014-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.8</div> <div class="figure-caption"> <p>Comparison 14 BPO/clindamycin versus placebo or no treatment, Outcome 8 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-014-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-014-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-014-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 BPO/clindamycin versus placebo or no treatment, Outcome 9 Percentage of participants with any adverse events (long‐term data)." data-id="CD011154-fig-0100" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-014-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.9</div> <div class="figure-caption"> <p>Comparison 14 BPO/clindamycin versus placebo or no treatment, Outcome 9 Percentage of participants with any adverse events (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-014-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-015-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-015-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 BPO/clindamycin versus adapalene, Outcome 1 Participant's global self‐assessment of improvement (long‐term data)." data-id="CD011154-fig-0101" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-015-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15 BPO/clindamycin versus adapalene, Outcome 1 Participant's global self‐assessment of improvement (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-015-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-015-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-015-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 BPO/clindamycin versus adapalene, Outcome 2 Withdrawal due to adverse effects (long‐term data)." data-id="CD011154-fig-0102" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-015-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.2</div> <div class="figure-caption"> <p>Comparison 15 BPO/clindamycin versus adapalene, Outcome 2 Withdrawal due to adverse effects (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-015-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-015-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-015-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 BPO/clindamycin versus adapalene, Outcome 3 Change in quality of life (long‐term data)." data-id="CD011154-fig-0103" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-015-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.3</div> <div class="figure-caption"> <p>Comparison 15 BPO/clindamycin versus adapalene, Outcome 3 Change in quality of life (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-015-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-015-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-015-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 BPO/clindamycin versus adapalene, Outcome 4 Change in quality of life (short‐term data)." data-id="CD011154-fig-0104" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-015-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.4</div> <div class="figure-caption"> <p>Comparison 15 BPO/clindamycin versus adapalene, Outcome 4 Change in quality of life (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-015-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-015-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-015-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 BPO/clindamycin versus adapalene, Outcome 5 Percentage of participants with any adverse events (long‐term data)." data-id="CD011154-fig-0105" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-015-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.5</div> <div class="figure-caption"> <p>Comparison 15 BPO/clindamycin versus adapalene, Outcome 5 Percentage of participants with any adverse events (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-015-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-016-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-016-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 1 Participant's global self‐assessment of improvement (long‐term data)." data-id="CD011154-fig-0106" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 1 Participant's global self‐assessment of improvement (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-016-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-016-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 2 Participant's global self‐assessment of improvement (medium‐term data)." data-id="CD011154-fig-0107" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.2</div> <div class="figure-caption"> <p>Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 2 Participant's global self‐assessment of improvement (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-016-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-016-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 3 Participant's global self‐assessment of improvement (short‐term data)." data-id="CD011154-fig-0108" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.3</div> <div class="figure-caption"> <p>Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 3 Participant's global self‐assessment of improvement (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-016-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-016-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 4 Withdrawal due to adverse effects (long‐term data)." data-id="CD011154-fig-0109" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.4</div> <div class="figure-caption"> <p>Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 4 Withdrawal due to adverse effects (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-016-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-016-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 5 Investigator‐assessed percentage change in total lesions (long‐term data)." data-id="CD011154-fig-0110" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.5</div> <div class="figure-caption"> <p>Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 5 Investigator‐assessed percentage change in total lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-016-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-016-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 6 Investigator‐assessed percentage change in inflammatory lesions (long‐term data)." data-id="CD011154-fig-0111" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.6</div> <div class="figure-caption"> <p>Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 6 Investigator‐assessed percentage change in inflammatory lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-016-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-016-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 7 Investigator‐assessed percentage change in non‐inflammatory lesions (long‐term data)." data-id="CD011154-fig-0112" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.7</div> <div class="figure-caption"> <p>Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 7 Investigator‐assessed percentage change in non‐inflammatory lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-016-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-016-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 8 Investigator‐assessed percentage change in total lesions (medium‐term data)." data-id="CD011154-fig-0113" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.8</div> <div class="figure-caption"> <p>Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 8 Investigator‐assessed percentage change in total lesions (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-016-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-016-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 9 Investigator‐assessed percentage change in inflammatory lesions (medium‐term data)." data-id="CD011154-fig-0114" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.9</div> <div class="figure-caption"> <p>Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 9 Investigator‐assessed percentage change in inflammatory lesions (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-016-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-016-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 10 Investigator‐assessed percentage change in non‐inflammatory lesions (medium‐term data)." data-id="CD011154-fig-0115" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.10</div> <div class="figure-caption"> <p>Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 10 Investigator‐assessed percentage change in non‐inflammatory lesions (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-016-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-016-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 11 Investigator‐assessed percentage change in total lesions (short‐term data)." data-id="CD011154-fig-0116" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.11</div> <div class="figure-caption"> <p>Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 11 Investigator‐assessed percentage change in total lesions (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0117"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-016-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-016-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 12 Investigator‐assessed percentage change in inflammatory lesions (short‐term data)." data-id="CD011154-fig-0117" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.12</div> <div class="figure-caption"> <p>Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 12 Investigator‐assessed percentage change in inflammatory lesions (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0117">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0118"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-016-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-016-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 13 Investigator‐assessed percentage change in non‐inflammatory lesions (short‐term data)." data-id="CD011154-fig-0118" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.13</div> <div class="figure-caption"> <p>Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 13 Investigator‐assessed percentage change in non‐inflammatory lesions (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0118">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0119"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-016-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-016-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 14 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (long‐term data)." data-id="CD011154-fig-0119" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.14</div> <div class="figure-caption"> <p>Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 14 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0119">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0120"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-016-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-016-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 15 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (medium‐term data)." data-id="CD011154-fig-0120" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.15</div> <div class="figure-caption"> <p>Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 15 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0120">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0121"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-016-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-016-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 16 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (short‐term data)." data-id="CD011154-fig-0121" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.16</div> <div class="figure-caption"> <p>Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 16 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0121">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0122"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-016-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-016-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 17 Percentage of participants with any adverse events (long‐term data)." data-id="CD011154-fig-0122" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.17</div> <div class="figure-caption"> <p>Comparison 16 BPO/clindamycin versus azelaic acid, Outcome 17 Percentage of participants with any adverse events (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0122">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-016-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0123"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-017-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-017-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 BPO/clindamycin versus erythromycin/zinc, Outcome 1 Withdrawal due to adverse effects (long‐term data)." data-id="CD011154-fig-0123" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-017-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17 BPO/clindamycin versus erythromycin/zinc, Outcome 1 Withdrawal due to adverse effects (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0123">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-017-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0124"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-017-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-017-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 BPO/clindamycin versus erythromycin/zinc, Outcome 2 Investigator‐assessed absolute change in total lesions (long‐term data)." data-id="CD011154-fig-0124" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-017-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.2</div> <div class="figure-caption"> <p>Comparison 17 BPO/clindamycin versus erythromycin/zinc, Outcome 2 Investigator‐assessed absolute change in total lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0124">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-017-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0125"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-017-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-017-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 BPO/clindamycin versus erythromycin/zinc, Outcome 3 Investigator‐assessed absolute change in inflammatory lesions (long‐term data)." data-id="CD011154-fig-0125" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-017-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.3</div> <div class="figure-caption"> <p>Comparison 17 BPO/clindamycin versus erythromycin/zinc, Outcome 3 Investigator‐assessed absolute change in inflammatory lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0125">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-017-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0126"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-017-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-017-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 BPO/clindamycin versus erythromycin/zinc, Outcome 4 Investigator‐assessed absolute change in non‐inflammatory lesions (long‐term data)." data-id="CD011154-fig-0126" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-017-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.4</div> <div class="figure-caption"> <p>Comparison 17 BPO/clindamycin versus erythromycin/zinc, Outcome 4 Investigator‐assessed absolute change in non‐inflammatory lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0126">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-017-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0127"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-017-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-017-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 BPO/clindamycin versus erythromycin/zinc, Outcome 5 Investigator‐assessed absolute change in total lesions (medium‐term data)." data-id="CD011154-fig-0127" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-017-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.5</div> <div class="figure-caption"> <p>Comparison 17 BPO/clindamycin versus erythromycin/zinc, Outcome 5 Investigator‐assessed absolute change in total lesions (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0127">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-017-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0128"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-017-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-017-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 BPO/clindamycin versus erythromycin/zinc, Outcome 6 Investigator‐assessed absolute change in inflammatory lesions (medium‐term data)." data-id="CD011154-fig-0128" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-017-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.6</div> <div class="figure-caption"> <p>Comparison 17 BPO/clindamycin versus erythromycin/zinc, Outcome 6 Investigator‐assessed absolute change in inflammatory lesions (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0128">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-017-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0129"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-017-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-017-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 BPO/clindamycin versus erythromycin/zinc, Outcome 7 Investigator‐assessed absolute change in non‐inflammatory lesions (medium‐term data)." data-id="CD011154-fig-0129" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-017-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.7</div> <div class="figure-caption"> <p>Comparison 17 BPO/clindamycin versus erythromycin/zinc, Outcome 7 Investigator‐assessed absolute change in non‐inflammatory lesions (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0129">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-017-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0130"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-017-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-017-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 BPO/clindamycin versus erythromycin/zinc, Outcome 8 Investigator‐assessed absolute change in total lesions (short‐term data)." data-id="CD011154-fig-0130" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-017-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.8</div> <div class="figure-caption"> <p>Comparison 17 BPO/clindamycin versus erythromycin/zinc, Outcome 8 Investigator‐assessed absolute change in total lesions (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0130">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-017-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0131"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-017-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-017-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 BPO/clindamycin versus erythromycin/zinc, Outcome 9 Investigator‐assessed absolute change in inflammatory lesions (short‐term data)." data-id="CD011154-fig-0131" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-017-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.9</div> <div class="figure-caption"> <p>Comparison 17 BPO/clindamycin versus erythromycin/zinc, Outcome 9 Investigator‐assessed absolute change in inflammatory lesions (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0131">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-017-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0132"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-017-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-017-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 BPO/clindamycin versus erythromycin/zinc, Outcome 10 Investigator‐assessed absolute change in non‐inflammatory lesions (short‐term data)." data-id="CD011154-fig-0132" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-017-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.10</div> <div class="figure-caption"> <p>Comparison 17 BPO/clindamycin versus erythromycin/zinc, Outcome 10 Investigator‐assessed absolute change in non‐inflammatory lesions (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0132">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-017-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0133"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-017-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-017-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 BPO/clindamycin versus erythromycin/zinc, Outcome 11 Percentage of participants with any adverse events (long‐term data)." data-id="CD011154-fig-0133" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-017-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.11</div> <div class="figure-caption"> <p>Comparison 17 BPO/clindamycin versus erythromycin/zinc, Outcome 11 Percentage of participants with any adverse events (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0133">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-017-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0134"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-018-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-018-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 BPO/clindamycin versus dapsone, Outcome 1 Percentage of participants with any adverse events (long‐term data)." data-id="CD011154-fig-0134" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-018-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.1</div> <div class="figure-caption"> <p>Comparison 18 BPO/clindamycin versus dapsone, Outcome 1 Percentage of participants with any adverse events (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0134">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-018-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0135"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-019-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-019-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 1 Participant's global self‐assessment of improvement (medium‐term data)." data-id="CD011154-fig-0135" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.1</div> <div class="figure-caption"> <p>Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 1 Participant's global self‐assessment of improvement (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0135">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0136"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-019-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-019-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 2 Withdrawal due to adverse effects (long‐term data)." data-id="CD011154-fig-0136" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.2</div> <div class="figure-caption"> <p>Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 2 Withdrawal due to adverse effects (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0136">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0137"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-019-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-019-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 3 Withdrawal due to adverse effects (medium‐term data)." data-id="CD011154-fig-0137" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.3</div> <div class="figure-caption"> <p>Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 3 Withdrawal due to adverse effects (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0137">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0138"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-019-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-019-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 4 Investigator‐assessed absolute change in total lesions (long‐term data)." data-id="CD011154-fig-0138" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.4</div> <div class="figure-caption"> <p>Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 4 Investigator‐assessed absolute change in total lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0138">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0139"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-019-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-019-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 5 Investigator‐assessed absolute change in inflammatory lesions (long‐term data)." data-id="CD011154-fig-0139" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.5</div> <div class="figure-caption"> <p>Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 5 Investigator‐assessed absolute change in inflammatory lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0139">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0140"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-019-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-019-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 6 Investigator‐assessed absolute change in non‐inflammatory lesions (long‐term data)." data-id="CD011154-fig-0140" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.6</div> <div class="figure-caption"> <p>Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 6 Investigator‐assessed absolute change in non‐inflammatory lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0140">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0141"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-019-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-019-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 7 Investigator‐assessed absolute change in total lesions (medium‐term data)." data-id="CD011154-fig-0141" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.7</div> <div class="figure-caption"> <p>Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 7 Investigator‐assessed absolute change in total lesions (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0141">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0142"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-019-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-019-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 8 Investigator‐assessed absolute change in inflammatory lesions (medium‐term data)." data-id="CD011154-fig-0142" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.8</div> <div class="figure-caption"> <p>Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 8 Investigator‐assessed absolute change in inflammatory lesions (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0142">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0143"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-019-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-019-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 9 Investigator‐assessed absolute change in non‐inflammatory lesions (medium‐term data)." data-id="CD011154-fig-0143" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.9</div> <div class="figure-caption"> <p>Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 9 Investigator‐assessed absolute change in non‐inflammatory lesions (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0143">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0144"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-019-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-019-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 10 Investigator‐assessed absolute change in total lesions (short‐term data)." data-id="CD011154-fig-0144" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.10</div> <div class="figure-caption"> <p>Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 10 Investigator‐assessed absolute change in total lesions (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0144">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0145"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-019-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-019-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 11 Investigator‐assessed absolute change in inflammatory lesions (short‐term data)." data-id="CD011154-fig-0145" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.11</div> <div class="figure-caption"> <p>Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 11 Investigator‐assessed absolute change in inflammatory lesions (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0145">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0146"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-019-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-019-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 12 Investigator‐assessed absolute change in non‐inflammatory lesions (short‐term data)." data-id="CD011154-fig-0146" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.12</div> <div class="figure-caption"> <p>Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 12 Investigator‐assessed absolute change in non‐inflammatory lesions (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0146">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0147"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-019-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-019-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 13 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (medium‐term data)." data-id="CD011154-fig-0147" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.13</div> <div class="figure-caption"> <p>Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 13 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0147">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0148"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-019-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-019-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 14 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (short‐term data)." data-id="CD011154-fig-0148" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.14</div> <div class="figure-caption"> <p>Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 14 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0148">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0149"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-019-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-019-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 15 Percentage of participants with any adverse events (long‐term data)." data-id="CD011154-fig-0149" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.15</div> <div class="figure-caption"> <p>Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 15 Percentage of participants with any adverse events (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0149">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0150"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-019-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-019-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 16 Percentage of participants with any adverse events (medium‐term data)." data-id="CD011154-fig-0150" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.16</div> <div class="figure-caption"> <p>Comparison 19 BPO/erythromycin versus placebo or no treatment, Outcome 16 Percentage of participants with any adverse events (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0150">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-019-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0151"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-020-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-020-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 20 BPO/erythromycin versus clindamycin, Outcome 1 Withdrawal due to adverse effects (long‐term data)." data-id="CD011154-fig-0151" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-020-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.1</div> <div class="figure-caption"> <p>Comparison 20 BPO/erythromycin versus clindamycin, Outcome 1 Withdrawal due to adverse effects (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0151">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-020-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0152"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-020-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-020-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 20 BPO/erythromycin versus clindamycin, Outcome 2 Percentage of participants with any adverse events (long‐term data)." data-id="CD011154-fig-0152" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-020-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.2</div> <div class="figure-caption"> <p>Comparison 20 BPO/erythromycin versus clindamycin, Outcome 2 Percentage of participants with any adverse events (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0152">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-020-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0153"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-021-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-021-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 21 BPO/erythromycin versus viaminate, Outcome 1 Percentage of participants with any adverse events (short‐term data)." data-id="CD011154-fig-0153" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-021-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.1</div> <div class="figure-caption"> <p>Comparison 21 BPO/erythromycin versus viaminate, Outcome 1 Percentage of participants with any adverse events (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0153">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-021-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0154"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-022-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-022-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 BPO/glycolic acid/zinc lactate versus placebo, Outcome 1 Investigator‐assessed absolute change in total lesions (long‐term data)." data-id="CD011154-fig-0154" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-022-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.1</div> <div class="figure-caption"> <p>Comparison 22 BPO/glycolic acid/zinc lactate versus placebo, Outcome 1 Investigator‐assessed absolute change in total lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0154">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-022-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0155"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-022-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-022-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 BPO/glycolic acid/zinc lactate versus placebo, Outcome 2 Investigator‐assessed absolute change in inflammatory lesions (long‐term data)." data-id="CD011154-fig-0155" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-022-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.2</div> <div class="figure-caption"> <p>Comparison 22 BPO/glycolic acid/zinc lactate versus placebo, Outcome 2 Investigator‐assessed absolute change in inflammatory lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0155">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-022-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0156"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-022-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-022-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 BPO/glycolic acid/zinc lactate versus placebo, Outcome 3 Investigator‐assessed absolute change in non‐inflammatory lesions (long‐term data)." data-id="CD011154-fig-0156" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-022-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.3</div> <div class="figure-caption"> <p>Comparison 22 BPO/glycolic acid/zinc lactate versus placebo, Outcome 3 Investigator‐assessed absolute change in non‐inflammatory lesions (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0156">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-022-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0157"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-022-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-022-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 BPO/glycolic acid/zinc lactate versus placebo, Outcome 4 Investigator‐assessed absolute change in total lesions (medium‐term data)." data-id="CD011154-fig-0157" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-022-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.4</div> <div class="figure-caption"> <p>Comparison 22 BPO/glycolic acid/zinc lactate versus placebo, Outcome 4 Investigator‐assessed absolute change in total lesions (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0157">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-022-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0158"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-022-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-022-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 BPO/glycolic acid/zinc lactate versus placebo, Outcome 5 Investigator‐assessed absolute change in inflammatory lesions (medium‐term data)." data-id="CD011154-fig-0158" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-022-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.5</div> <div class="figure-caption"> <p>Comparison 22 BPO/glycolic acid/zinc lactate versus placebo, Outcome 5 Investigator‐assessed absolute change in inflammatory lesions (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0158">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-022-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0159"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-022-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-022-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 BPO/glycolic acid/zinc lactate versus placebo, Outcome 6 Investigator‐assessed absolute change in non‐inflammatory lesions (medium‐term data)." data-id="CD011154-fig-0159" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-022-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.6</div> <div class="figure-caption"> <p>Comparison 22 BPO/glycolic acid/zinc lactate versus placebo, Outcome 6 Investigator‐assessed absolute change in non‐inflammatory lesions (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0159">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-022-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0160"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-022-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-022-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 BPO/glycolic acid/zinc lactate versus placebo, Outcome 7 Investigator‐assessed absolute change in total lesions (short‐term data)." data-id="CD011154-fig-0160" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-022-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.7</div> <div class="figure-caption"> <p>Comparison 22 BPO/glycolic acid/zinc lactate versus placebo, Outcome 7 Investigator‐assessed absolute change in total lesions (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0160">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-022-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0161"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-022-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-022-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 BPO/glycolic acid/zinc lactate versus placebo, Outcome 8 Investigator‐assessed absolute change in inflammatory lesions (short‐term data)." data-id="CD011154-fig-0161" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-022-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.8</div> <div class="figure-caption"> <p>Comparison 22 BPO/glycolic acid/zinc lactate versus placebo, Outcome 8 Investigator‐assessed absolute change in inflammatory lesions (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0161">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-022-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0162"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-022-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-022-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 BPO/glycolic acid/zinc lactate versus placebo, Outcome 9 Investigator‐assessed absolute change in non‐inflammatory lesions (short‐term data)." data-id="CD011154-fig-0162" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-022-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.9</div> <div class="figure-caption"> <p>Comparison 22 BPO/glycolic acid/zinc lactate versus placebo, Outcome 9 Investigator‐assessed absolute change in non‐inflammatory lesions (short‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0162">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-022-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0163"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-023-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-023-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 23 BPO/potassium hydroxyquinoline sulphate versus placebo, Outcome 1 Withdrawal due to adverse effects (long‐term data)." data-id="CD011154-fig-0163" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-023-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.1</div> <div class="figure-caption"> <p>Comparison 23 BPO/potassium hydroxyquinoline sulphate versus placebo, Outcome 1 Withdrawal due to adverse effects (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0163">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-023-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0164"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-024-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-024-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 24 BPO 10% versus BPO 5%, Outcome 1 Withdrawal due to adverse effects (medium‐term data)." data-id="CD011154-fig-0164" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-024-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.1</div> <div class="figure-caption"> <p>Comparison 24 BPO 10% versus BPO 5%, Outcome 1 Withdrawal due to adverse effects (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0164">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-024-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0165"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-024-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-024-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 24 BPO 10% versus BPO 5%, Outcome 2 Percentage of participants with any adverse events (medium‐term data)." data-id="CD011154-fig-0165" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-024-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.2</div> <div class="figure-caption"> <p>Comparison 24 BPO 10% versus BPO 5%, Outcome 2 Percentage of participants with any adverse events (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0165">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-024-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0166"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-025-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-025-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 25 BPO 10% versus BPO 2.5%, Outcome 1 Percentage of participants with any adverse events (medium‐term data)." data-id="CD011154-fig-0166" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-025-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 25.1</div> <div class="figure-caption"> <p>Comparison 25 BPO 10% versus BPO 2.5%, Outcome 1 Percentage of participants with any adverse events (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0166">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-025-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0167"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-026-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-026-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 26 BPO 5% versus BPO 2.5%, Outcome 1 Withdrawal due to adverse effects (long‐term data)." data-id="CD011154-fig-0167" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-026-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.1</div> <div class="figure-caption"> <p>Comparison 26 BPO 5% versus BPO 2.5%, Outcome 1 Withdrawal due to adverse effects (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0167">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-026-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0168"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-026-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-026-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 26 BPO 5% versus BPO 2.5%, Outcome 2 Withdrawal due to adverse effects (medium‐term data)." data-id="CD011154-fig-0168" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-026-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.2</div> <div class="figure-caption"> <p>Comparison 26 BPO 5% versus BPO 2.5%, Outcome 2 Withdrawal due to adverse effects (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0168">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-026-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0169"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-026-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-026-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 26 BPO 5% versus BPO 2.5%, Outcome 3 Change in quality of life (long‐term data)." data-id="CD011154-fig-0169" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-026-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.3</div> <div class="figure-caption"> <p>Comparison 26 BPO 5% versus BPO 2.5%, Outcome 3 Change in quality of life (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0169">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-026-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0170"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-026-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-026-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 26 BPO 5% versus BPO 2.5%, Outcome 4 Percentage of participants with any adverse events (long‐term data)." data-id="CD011154-fig-0170" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-026-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.4</div> <div class="figure-caption"> <p>Comparison 26 BPO 5% versus BPO 2.5%, Outcome 4 Percentage of participants with any adverse events (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0170">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-026-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0171"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-026-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-026-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 26 BPO 5% versus BPO 2.5%, Outcome 5 Percentage of participants with any adverse events (medium‐term data)." data-id="CD011154-fig-0171" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-026-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.5</div> <div class="figure-caption"> <p>Comparison 26 BPO 5% versus BPO 2.5%, Outcome 5 Percentage of participants with any adverse events (medium‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0171">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-026-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011154-fig-0172"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/urn:x-wiley:14651858:media:CD011154:CD011154-CMP-027-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_t/tCD011154-CMP-027-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 27 BPO gel (6%) versus BPO cream (5.5%), Outcome 1 Withdrawal due to adverse effects (long‐term data)." data-id="CD011154-fig-0172" src="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-027-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 27.1</div> <div class="figure-caption"> <p>Comparison 27 BPO gel (6%) versus BPO cream (5.5%), Outcome 1 Withdrawal due to adverse effects (long‐term data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-fig-0172">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/media/CDSR/CD011154/image_n/nCD011154-CMP-027-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011154-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Benzoyl peroxide compared to placebo or no treatment for acne</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Benzoyl peroxide compared to placebo or no treatment for acne</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> acne vulgaris<br/> <b>Setting:</b> unspecified (probably outpatient)<br/> <b>Intervention:</b> benzoyl peroxide<br/> <b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo or no treatment<sup>a</sup> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with benzoyl peroxide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant's global self‐assessment of improvement (long‐term data)<br/> assessed with any greater improvement above the first category of improvement on a Likert or Likert‐like scale<br/> Treatment duration: range 10 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>550 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>699 per 1000<br/> (616 to 798) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.27<br/> (1.12 to 1.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2234<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse effects (long‐term data)<br/> Treatment duration: range 10 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8 per 1000<br/> (6 to 11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.13<br/> (1.55 to 2.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,744<br/> (24 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of participants with any adverse events (long‐term data)<br/> Treatment duration: range 10 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>79 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>111 per 1000<br/> (91 to 135) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.40<br/> (1.15 to 1.70) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11,028<br/> (21 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝ ⊝<br/> Very low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The control group risk estimate is the median control group risk across studies. </p> <p><sup>b</sup>Downgraded by two levels to low‐quality evidence due to study limitations (risk of bias) and publication bias. <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a> was classified as high risk of bias due to "incomplete outcome data". Although ITT strategy was taken, 14.3% of participants discontinued and withdrawal due to adverse events was higher in the adapalene‐BPO combination gel group. Both <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a> and <a href="./references#CD011154-bbs2-0066" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM . Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] LeydenJ , et al. Treatment of acne vulgaris with a combination benzoyl peroxide/clindamycin topical gel Abstract P‐013. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S144. [CENTRAL: CN‐00478651] LeydenJJ , BergerRS , DunlapFE , EllisCN , ConnollyMA , LevySF . Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. American Journal of Clinical Dermatology2001;2(1):33‐9. [CENTRAL: CN‐00363426; MEDLINE: 11702619] ">Leyden 2001a</a> were classified as "unclear risk of bias" for randomisation, allocation concealment, and blinding of participants and outcome assessors. In <a href="./references#CD011154-bbs2-0053" title="JawadeSA , SaigaonkarVA , KondalkarAR . Efficacy and tolerability of adapalene 0.1%‐benzoyl peroxide 2.5% combination gel in treatment of acne vulgaris in Indian patients: a randomized investigator‐blind controlled trial. Iranian Journal of Dermatology2016;19(4):105‐12. [CENTRAL: CN‐01405922] ">Jawade 2016</a>, the proportion of withdrawals was high and participants were excluded from analysis because of non‐compliance with the treatment regimen or duration and protocol violation. In addition, all studies were judged to be unclear for at least one risk of bias domain. There was potential risk of publication bias because we identified trials starting before 2015 but still "ongoing" as shown in the trial registries. </p> <p><sup>c</sup>Downgraded by two levels to low‐quality evidence due to study limitations (risk of bias). Ten studies were classified as “high risk of bias” for at least one risk of bias domain, including <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>, <a href="./references#CD011154-bbs2-0059" title="KawashimaM , HashimotoH , Alio SaenzAB , OnoM , YamadaM . Clindamycin phosphate 12%‐benzoyl peroxide 30% fixed‐dose combination gel has an effective and acceptable safety and tolerability profile for the treatment of acne vulgaris in Japanese patients: a phase III, multicentre, randomised, single‐blinded, active‐controlled, parallel‐group study. British Journal of Dermatology2015;172(2):494‐503. [CENTRAL: CN‐01115087] KawashimaM , YamadaM , ParishC . Clindamycin 1%/benzoyl peroxide 3% gel, a new topical combination product, is effective in Japanese patients with acne vulgaris. Journal of Investigative Dermatology2013;133:S160. [CENTRAL: CN‐01026775] ">Kawashima 2015</a>, and <a href="./references#CD011154-bbs2-0115" title="2015‐004909‐16 . A multicentre, randomized, assessor‐blind, comparator‐controlled, parallel‐group clinical trial to establish the efficacy and safety of Duac™ (1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide) once daily gel compared with clindamycin phosphate gel (1% clindamycin as clindamycin phosphate) twice daily in the treatment of mild to moderate acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2015‐004909‐16/results (results published 29 December 2016). NCT01915732 . Efficacy and safety of Duac™ compared with clindamycin phosphate gel in the treatment of mild to moderate acne vulgaris. clinicaltrials.gov/ct2/show/NCT01915732 (first received 5 April 2013). XuJ , LuQ , HuangJ , SunQ , HaoF , GuJ , et al. A multicenter, randomized, single‐blind study of topical clindamycin 1%/benzoyl peroxide 5% once‐daily fixed dose combination gel (Duac) vs. clindamycin 1% twice‐daily gel in treatment of Chinese acne vulgaris patients. Journal of Investigative Dermatology2015;135(Suppl 2):S34, 192. [CENTRAL: CN‐01130701] XuJH , LuQJ , HuangJH , HaoF , SunQN , FangH , et al. A multicentre, randomized, single‐blind comparison of topical clindamycin 1%/benzoyl peroxide 5% once‐daily gel versus clindamycin 1% twice‐daily gel in the treatment of mild to moderate acne vulgaris in Chinese patients. Journal of the European Academy of Dermatology and Venereology2016;30(7):1176‐82. [CENTRAL: CN‐01178389; MEDLINE: 27075705] ">Xu 2016</a>, for blinding of participants and healthcare providers; <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>, <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>, <a href="./references#CD011154-bbs2-0052" title="JaffeGV , GrimshawJJ , ConstadD . Benzoyl peroxide in the treatment of acne vulgaris: a double‐blind, multi‐centre comparative study of 'Quinoderm' cream and 'Quinoderm' cream with hydrocortisone versus their base vehicle alone and a benzoyl peroxide only gel preparation. Current Medical Research &amp; Opinion1989;11(7):453‐62. [CENTRAL: CN‐00062342; MEDLINE: 2528439] ">Jaffe 1989</a>, <a href="./references#CD011154-bbs2-0053" title="JawadeSA , SaigaonkarVA , KondalkarAR . Efficacy and tolerability of adapalene 0.1%‐benzoyl peroxide 2.5% combination gel in treatment of acne vulgaris in Indian patients: a randomized investigator‐blind controlled trial. Iranian Journal of Dermatology2016;19(4):105‐12. [CENTRAL: CN‐01405922] ">Jawade 2016</a>, <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>, <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>, and <a href="./references#CD011154-bbs2-0115" title="2015‐004909‐16 . A multicentre, randomized, assessor‐blind, comparator‐controlled, parallel‐group clinical trial to establish the efficacy and safety of Duac™ (1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide) once daily gel compared with clindamycin phosphate gel (1% clindamycin as clindamycin phosphate) twice daily in the treatment of mild to moderate acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2015‐004909‐16/results (results published 29 December 2016). NCT01915732 . Efficacy and safety of Duac™ compared with clindamycin phosphate gel in the treatment of mild to moderate acne vulgaris. clinicaltrials.gov/ct2/show/NCT01915732 (first received 5 April 2013). XuJ , LuQ , HuangJ , SunQ , HaoF , GuJ , et al. A multicenter, randomized, single‐blind study of topical clindamycin 1%/benzoyl peroxide 5% once‐daily fixed dose combination gel (Duac) vs. clindamycin 1% twice‐daily gel in treatment of Chinese acne vulgaris patients. Journal of Investigative Dermatology2015;135(Suppl 2):S34, 192. [CENTRAL: CN‐01130701] XuJH , LuQJ , HuangJH , HaoF , SunQN , FangH , et al. A multicentre, randomized, single‐blind comparison of topical clindamycin 1%/benzoyl peroxide 5% once‐daily gel versus clindamycin 1% twice‐daily gel in the treatment of mild to moderate acne vulgaris in Chinese patients. Journal of the European Academy of Dermatology and Venereology2016;30(7):1176‐82. [CENTRAL: CN‐01178389; MEDLINE: 27075705] ">Xu 2016</a> for incomplete outcome data; and <a href="./references#CD011154-bbs2-0011" title="ChalkerDK , ShalitaA , SmithJG , SwannRW . A double‐blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. Journal of the American Academy of Dermatology1983;9(6):933‐6. [CENTRAL: CN‐00334175; MEDLINE: 6227643] ">Chalker 1983</a> and <a href="./references#CD011154-bbs2-0052" title="JaffeGV , GrimshawJJ , ConstadD . Benzoyl peroxide in the treatment of acne vulgaris: a double‐blind, multi‐centre comparative study of 'Quinoderm' cream and 'Quinoderm' cream with hydrocortisone versus their base vehicle alone and a benzoyl peroxide only gel preparation. Current Medical Research &amp; Opinion1989;11(7):453‐62. [CENTRAL: CN‐00062342; MEDLINE: 2528439] ">Jaffe 1989</a> for selective reporting of outcomes. In addition, all studies were judged to be unclear for at least one risk of bias domain. There was potential risk of publication bias because we identified trials starting before 2015 but still "ongoing" as shown in the trial registries. </p> <p><sup>d</sup>Downgraded by three levels to very low‐quality evidence due to study limitations (risk of bias) and inconsistency. Ten studies were classified as “high risk of bias” for at least one risk of bias domain, including <a href="./references#CD011154-bbs2-0023" title="DraelosZD , TanghettiEA . Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis; Cutaneous Medicine for the Practitioner2002;69(2 Suppl):20‐9. [CENTRAL: CN‐00409023; MEDLINE: 12095065] ">Draelos 2002</a>, <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>, <a href="./references#CD011154-bbs2-0059" title="KawashimaM , HashimotoH , Alio SaenzAB , OnoM , YamadaM . Clindamycin phosphate 12%‐benzoyl peroxide 30% fixed‐dose combination gel has an effective and acceptable safety and tolerability profile for the treatment of acne vulgaris in Japanese patients: a phase III, multicentre, randomised, single‐blinded, active‐controlled, parallel‐group study. British Journal of Dermatology2015;172(2):494‐503. [CENTRAL: CN‐01115087] KawashimaM , YamadaM , ParishC . Clindamycin 1%/benzoyl peroxide 3% gel, a new topical combination product, is effective in Japanese patients with acne vulgaris. Journal of Investigative Dermatology2013;133:S160. [CENTRAL: CN‐01026775] ">Kawashima 2015</a>, <a href="./references#CD011154-bbs2-0082" title="NCT02073461 . Efficacy and safety study of 2 different concentrations of CD1579 gels versus vehicle in the treatment of acne vulgaris. clinicaltrials.gov/ct2/show/NCT02073461 (first received 20 February 2014). ">NCT02073461</a>, <a href="./references#CD011154-bbs2-0115" title="2015‐004909‐16 . A multicentre, randomized, assessor‐blind, comparator‐controlled, parallel‐group clinical trial to establish the efficacy and safety of Duac™ (1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide) once daily gel compared with clindamycin phosphate gel (1% clindamycin as clindamycin phosphate) twice daily in the treatment of mild to moderate acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2015‐004909‐16/results (results published 29 December 2016). NCT01915732 . Efficacy and safety of Duac™ compared with clindamycin phosphate gel in the treatment of mild to moderate acne vulgaris. clinicaltrials.gov/ct2/show/NCT01915732 (first received 5 April 2013). XuJ , LuQ , HuangJ , SunQ , HaoF , GuJ , et al. A multicenter, randomized, single‐blind study of topical clindamycin 1%/benzoyl peroxide 5% once‐daily fixed dose combination gel (Duac) vs. clindamycin 1% twice‐daily gel in treatment of Chinese acne vulgaris patients. Journal of Investigative Dermatology2015;135(Suppl 2):S34, 192. [CENTRAL: CN‐01130701] XuJH , LuQJ , HuangJH , HaoF , SunQN , FangH , et al. A multicentre, randomized, single‐blind comparison of topical clindamycin 1%/benzoyl peroxide 5% once‐daily gel versus clindamycin 1% twice‐daily gel in the treatment of mild to moderate acne vulgaris in Chinese patients. Journal of the European Academy of Dermatology and Venereology2016;30(7):1176‐82. [CENTRAL: CN‐01178389; MEDLINE: 27075705] ">Xu 2016</a>, and <a href="./references#CD011154-bbs2-0117" title="ZeichnerJA , WongV , LinknerRV , HaddicanM . Efficacy and safety of tretinoin 0.025%/clindamycin phosphate 1.2% gel in combination with benzoyl peroxide 6% cleansing cloths for the treatment of facial acne vulgaris. Journal of Drugs in Dermatology2013;12(3):277‐82. [CENTRAL: CN‐00876866; MEDLINE: 23545909] ">Zeichner 2013</a> for blinding of participants and healthcare providers; <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>, <a href="./references#CD011154-bbs2-0052" title="JaffeGV , GrimshawJJ , ConstadD . Benzoyl peroxide in the treatment of acne vulgaris: a double‐blind, multi‐centre comparative study of 'Quinoderm' cream and 'Quinoderm' cream with hydrocortisone versus their base vehicle alone and a benzoyl peroxide only gel preparation. Current Medical Research &amp; Opinion1989;11(7):453‐62. [CENTRAL: CN‐00062342; MEDLINE: 2528439] ">Jaffe 1989</a>, <a href="./references#CD011154-bbs2-0059" title="KawashimaM , HashimotoH , Alio SaenzAB , OnoM , YamadaM . Clindamycin phosphate 12%‐benzoyl peroxide 30% fixed‐dose combination gel has an effective and acceptable safety and tolerability profile for the treatment of acne vulgaris in Japanese patients: a phase III, multicentre, randomised, single‐blinded, active‐controlled, parallel‐group study. British Journal of Dermatology2015;172(2):494‐503. [CENTRAL: CN‐01115087] KawashimaM , YamadaM , ParishC . Clindamycin 1%/benzoyl peroxide 3% gel, a new topical combination product, is effective in Japanese patients with acne vulgaris. Journal of Investigative Dermatology2013;133:S160. [CENTRAL: CN‐01026775] ">Kawashima 2015</a>, <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a>, <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>, and <a href="./references#CD011154-bbs2-0115" title="2015‐004909‐16 . A multicentre, randomized, assessor‐blind, comparator‐controlled, parallel‐group clinical trial to establish the efficacy and safety of Duac™ (1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide) once daily gel compared with clindamycin phosphate gel (1% clindamycin as clindamycin phosphate) twice daily in the treatment of mild to moderate acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2015‐004909‐16/results (results published 29 December 2016). NCT01915732 . Efficacy and safety of Duac™ compared with clindamycin phosphate gel in the treatment of mild to moderate acne vulgaris. clinicaltrials.gov/ct2/show/NCT01915732 (first received 5 April 2013). XuJ , LuQ , HuangJ , SunQ , HaoF , GuJ , et al. A multicenter, randomized, single‐blind study of topical clindamycin 1%/benzoyl peroxide 5% once‐daily fixed dose combination gel (Duac) vs. clindamycin 1% twice‐daily gel in treatment of Chinese acne vulgaris patients. Journal of Investigative Dermatology2015;135(Suppl 2):S34, 192. [CENTRAL: CN‐01130701] XuJH , LuQJ , HuangJH , HaoF , SunQN , FangH , et al. A multicentre, randomized, single‐blind comparison of topical clindamycin 1%/benzoyl peroxide 5% once‐daily gel versus clindamycin 1% twice‐daily gel in the treatment of mild to moderate acne vulgaris in Chinese patients. Journal of the European Academy of Dermatology and Venereology2016;30(7):1176‐82. [CENTRAL: CN‐01178389; MEDLINE: 27075705] ">Xu 2016</a> for incomplete outcome data; and <a href="./references#CD011154-bbs2-0011" title="ChalkerDK , ShalitaA , SmithJG , SwannRW . A double‐blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. Journal of the American Academy of Dermatology1983;9(6):933‐6. [CENTRAL: CN‐00334175; MEDLINE: 6227643] ">Chalker 1983</a> and <a href="./references#CD011154-bbs2-0052" title="JaffeGV , GrimshawJJ , ConstadD . Benzoyl peroxide in the treatment of acne vulgaris: a double‐blind, multi‐centre comparative study of 'Quinoderm' cream and 'Quinoderm' cream with hydrocortisone versus their base vehicle alone and a benzoyl peroxide only gel preparation. Current Medical Research &amp; Opinion1989;11(7):453‐62. [CENTRAL: CN‐00062342; MEDLINE: 2528439] ">Jaffe 1989</a> for selective reporting of outcomes. All were classified as “unclear risk of bias” for at least one risk of bias domain. We further downgraded the evidence by one level because of inconsistency: point estimates varied, and I² was 72%. There was potential risk of publication bias because we identified trials starting before 2015 but still "ongoing" as shown in the trial registries. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Benzoyl peroxide compared to placebo or no treatment for acne</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/full#CD011154-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011154-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Benzoyl peroxide compared to adapalene for acne</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Benzoyl peroxide compared to adapalene for acne</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> acne vulgaris<br/> <b>Setting:</b> unspecified (probably outpatient)<br/> <b>Intervention:</b> benzoyl peroxide<br/> <b>Comparison:</b> adapalene </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with adapalene</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with benzoyl peroxide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant's global self‐assessment of improvement (long‐term data)<br/> assessed with any greater improvement above the first category of improvement on a Likert or Likert‐like scale<br/> Treatment duration: range 11 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>785 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>777 per 1000<br/> (707 to 864) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.99<br/> (0.90 to 1.10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1472<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse effects (long‐term data)<br/> Treatment duration: range 11 weeks to 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000<br/> (2 to 5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.85<br/> (0.94 to 3.64) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3295<br/> (11 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of participants with any adverse events (long‐term data)<br/> Treatment duration: range 11 weeks to 24 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>203 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>144 per 1000<br/> (101 to 203) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.71<br/> (0.50 to 1.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2120<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The control group risk estimate is the median control group risk across studies. </p> <p><sup>b</sup>Downgraded by two levels to low‐quality evidence due to study limitations (risk of bias) as three studies were classified as "high risk of bias" for incomplete outcome data and one study for blinding of participants. In <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>, although ITT strategy was taken, 14.3% of participants discontinued and withdrawal due to adverse events was higher in the adapalene‐BPO combination gel group. In <a href="./references#CD011154-bbs2-0022" title="do NascimentoLV , GuedesAC , MagalhaesGM , deFariaFA , GuerraRM , deAlmeidaF . Single‐blind and comparative clinical study of the efficacy and safety of benzoyl peroxide 4% gel (BID) and adapalene 0.1% Gel (QD) in the treatment of acne vulgaris for 11 weeks. Journal of Dermatological Treatment2003;14(3):166‐71. [CENTRAL: CN‐00559227; MEDLINE: 14522627] ">do Nascimento 2003</a>, comparing dropout rates between groups revealed that the adapalene group showed the higher rate of participants who withdrew from the study before completion of treatment. In <a href="./references#CD011154-bbs2-0053" title="JawadeSA , SaigaonkarVA , KondalkarAR . Efficacy and tolerability of adapalene 0.1%‐benzoyl peroxide 2.5% combination gel in treatment of acne vulgaris in Indian patients: a randomized investigator‐blind controlled trial. Iranian Journal of Dermatology2016;19(4):105‐12. [CENTRAL: CN‐01405922] ">Jawade 2016</a>, the proportion of withdrawal was high and participants were excluded from analysis because of non‐compliance with the treatment regimen or duration schedule and protocol violation. In <a href="./references#CD011154-bbs2-0048" title="2017‐001575‐23 . Clinical evaluation of efficacy at 2 weeks of Duac fixed dose combination gel in treatment of facial acne vulgaris in Japanese subjects. www.clinicaltrialsregister.eu/ctr‐search/trial/2017‐001575‐23/results (first received 21 September 2017). HayashiN , KurokawaI , SiakpereO , EndoA , HatanakaT , YamadaM , et al. Clindamycin phosphate 1.2%/benzoyl peroxide 3% fixed‐dose combination gel versus topical combination therapy of adapalene 0.1% gel and clindamycin phosphate 1.2% gel in the treatment of acne vulgaris in Japanese patients: a multicenter, randomized, investigator‐blind, parallel‐group study. Journal of Dermatology2018;45(8):951‐62. [CENTRAL: CN‐01629242] NCT02557399 . DUAC® early onset efficacy study in Japanese subjects. clinicaltrials.gov/ct2/show/NCT02557399 (first received 23 September 2015). ">Hayashi 2018</a>, only investigators, not participants, were blinded. There was potential risk of publication bias because we identified trials starting before 2015 but still "ongoing" as shown in the trial registries. </p> <p><sup>c</sup>Downgraded by three levels to very low‐quality evidence: one level due to study limitations (risk of bias) as eight included studies were classified as “high risk of bias” in at least one risk of bias domain. <a href="./references#CD011154-bbs2-0048" title="2017‐001575‐23 . Clinical evaluation of efficacy at 2 weeks of Duac fixed dose combination gel in treatment of facial acne vulgaris in Japanese subjects. www.clinicaltrialsregister.eu/ctr‐search/trial/2017‐001575‐23/results (first received 21 September 2017). HayashiN , KurokawaI , SiakpereO , EndoA , HatanakaT , YamadaM , et al. Clindamycin phosphate 1.2%/benzoyl peroxide 3% fixed‐dose combination gel versus topical combination therapy of adapalene 0.1% gel and clindamycin phosphate 1.2% gel in the treatment of acne vulgaris in Japanese patients: a multicenter, randomized, investigator‐blind, parallel‐group study. Journal of Dermatology2018;45(8):951‐62. [CENTRAL: CN‐01629242] NCT02557399 . DUAC® early onset efficacy study in Japanese subjects. clinicaltrials.gov/ct2/show/NCT02557399 (first received 23 September 2015). ">Hayashi 2018</a>, <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>, <a href="./references#CD011154-bbs2-0050" title="IftikharU , AmanS , NadeemM , KazmiAH . A comparison of efficacy and safety of topical 0.1% adapalene and 4% benzoyl peroxide in the treatment of mild to moderate acne vulgaris. Journal of Pakistan Association of Dermatologists2009;19(3):141‐5. [www.jpad.com.pk/index.php/jpad/article/view/530] ">Iftikhar 2009</a>, and <a href="./references#CD011154-bbs2-0063" title="KorkutC , PiskinS . Benzoyl peroxide, adapalene, and their combination in the treatment of acne vulgaris. Journal of Dermatology2005;32(3):169‐73. [CENTRAL: CN‐00512006] ">Korkut 2005</a> were at high risk of bias due to unblinded or partially blinded design. <a href="./references#CD011154-bbs2-0022" title="do NascimentoLV , GuedesAC , MagalhaesGM , deFariaFA , GuerraRM , deAlmeidaF . Single‐blind and comparative clinical study of the efficacy and safety of benzoyl peroxide 4% gel (BID) and adapalene 0.1% Gel (QD) in the treatment of acne vulgaris for 11 weeks. Journal of Dermatological Treatment2003;14(3):166‐71. [CENTRAL: CN‐00559227; MEDLINE: 14522627] ">do Nascimento 2003</a>, <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>, <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a>, <a href="./references#CD011154-bbs2-0053" title="JawadeSA , SaigaonkarVA , KondalkarAR . Efficacy and tolerability of adapalene 0.1%‐benzoyl peroxide 2.5% combination gel in treatment of acne vulgaris in Indian patients: a randomized investigator‐blind controlled trial. Iranian Journal of Dermatology2016;19(4):105‐12. [CENTRAL: CN‐01405922] ">Jawade 2016</a>, and <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a> were classified as high risk of bias for incomplete participant data. All included studies were classified as unclear for at least one risk of bias domain. Evidence was downgraded by a further one level due to imprecision as the confidence interval includes 1; could not exclude the possibility of no effect compared with adapalene. The estimate was based on a small number of events. There was potential risk of publication bias because we identified trials starting before 2015 but still "ongoing" as shown in the trial registries. </p> <p><sup>d</sup>Downgraded by three levels to very low‐quality evidence: one level due to study limitations (risk of bias) as four included studies were classified as “high risk of bias” in at least one risk of bias domain. <a href="./references#CD011154-bbs2-0048" title="2017‐001575‐23 . Clinical evaluation of efficacy at 2 weeks of Duac fixed dose combination gel in treatment of facial acne vulgaris in Japanese subjects. www.clinicaltrialsregister.eu/ctr‐search/trial/2017‐001575‐23/results (first received 21 September 2017). HayashiN , KurokawaI , SiakpereO , EndoA , HatanakaT , YamadaM , et al. Clindamycin phosphate 1.2%/benzoyl peroxide 3% fixed‐dose combination gel versus topical combination therapy of adapalene 0.1% gel and clindamycin phosphate 1.2% gel in the treatment of acne vulgaris in Japanese patients: a multicenter, randomized, investigator‐blind, parallel‐group study. Journal of Dermatology2018;45(8):951‐62. [CENTRAL: CN‐01629242] NCT02557399 . DUAC® early onset efficacy study in Japanese subjects. clinicaltrials.gov/ct2/show/NCT02557399 (first received 23 September 2015). ">Hayashi 2018</a> and <a href="./references#CD011154-bbs2-0044" title="2006‐004215‐21 . A multi‐center, randomized, double‐blind, parallel‐group study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel compared with adapalene topical gel, 0.1%; benzoyl peroxide topical gel, 2.5% and topical gel vehicle in subjects with acne vulgaris. www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐004215‐21/DE (first received 31 October 2006). AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [MEDLINE: 28331557] GollnickHP , DraelosZ , GlennMJ , RosophLA , KaszubaA , CornelisonR , et al. Adapalene‐benzoyl peroxide, a unique fixed‐dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double‐blind, controlled study in 1670 patients. British Journal of Dermatology2009;161(5):1180‐9. [CENTRAL: CN‐00731000; MEDLINE: 19466959] GollnickHPM , KaszubaA , RosophL , DraelosZ . Adapalene‐benzoyl peroxide: a trans‐Atlantic, randomized, double‐blind, controlled study in 1670 acne vulgaris patients (Poster P712). 68th Annual Meeting of the American Academy of Dermatology, AAD Miami, FL, United States. Journal of the American Academy of Dermatology2010;62(3 Suppl 1):AB16. [CENTRAL: CN‐00843731] NCT00421993 . A study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. www.clinicaltrials.gov/ct2/show/NCT00421993 (first received 11 January 2007). ">Gollnick 2009</a> were at high risk of bias due to unblinded or partially blinded design. Three trials ‐ <a href="./references#CD011154-bbs2-0022" title="do NascimentoLV , GuedesAC , MagalhaesGM , deFariaFA , GuerraRM , deAlmeidaF . Single‐blind and comparative clinical study of the efficacy and safety of benzoyl peroxide 4% gel (BID) and adapalene 0.1% Gel (QD) in the treatment of acne vulgaris for 11 weeks. Journal of Dermatological Treatment2003;14(3):166‐71. [CENTRAL: CN‐00559227; MEDLINE: 14522627] ">do Nascimento 2003</a>, <a href="./references#CD011154-bbs2-0041" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9:23‐9. [MEDLINE: 28331557] GoldLS , TanJ , Cruz‐SantanaA , PappK , PoulinY , SchlessingerJ , et al. A North American study of adapalene‐benzoyl peroxide combination gel in the treatment of acne. Cutis2009;84:110‐6. [MEDLINE: 19746769] GoldLS , TanJ , PappK , PoulinY . A pivotal study comparing the efficacy and safety of the adapalene‐benzoyl peroxide fixed‐dose combination gel with each component and the vehicle in 1668 patients with acne vulgaris. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB16. [CENTRAL: CN‐00843732] NCT00422240 . Study to demonstrate the efficacy and safety of adapalene/benzoyl peroxide topical gel in subjects with acne vulgaris. clinicaltrials.gov/ct2/show/NCT00422240 (first received 11 January 2007). ">Gold 2009</a>, and <a href="./references#CD011154-bbs2-0106" title="AlexisAF , JohnsonLA , KerroucheN , CallenderVD . A subgroup analysis to evaluate the efficacy and safety of adapalene‐benzoyl peroxide topical gel in black subjects with moderate acne. Journal of Drugs in Dermatology2014;13(2):170‐4. [CENTRAL: CN‐00985276; MEDLINE: 24509968] EichenfieldLE , JorizzoJL , DirschkaT , TaubAF , LyndeC , GraeberM , et al. Treatment of 2,453 acne vulgaris patients aged 12‐17 years with the fixed‐dose adapalene‐benzoyl peroxide combination topical gel: efficacy and safety. Journal of Drugs in Dermatology2010;9(11):1395‐401. [CENTRAL: CN‐00888969; MEDLINE: 21061762] GoldLS , BaldwinH , RuedaMJ , KerroucheN , DrenoB . Adapalene‐benzoyl peroxide gel is efficacious and safe in adult female acne, with a profile comparable to that seen in teen‐aged females. Journal of Clinical and Aesthetic Dermatology2016;9(7):23‐9. [CENTRAL: CN‐01197640; MEDLINE: 28331557] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] ThiboutotDM , WeissJ , BuckoA , EichenfieldL , JonesT , ClarkS , et al. Adapalene‐benzoyl peroxide, a fixed‐dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double‐blind, controlled study. Journal of the American Academy of Dermatology2007;57(5):791‐9. [CENTRAL: CN‐00610848; MEDLINE: 17655969] ">Thiboutot 2007</a> ‐ were classified as high risk of bias for incomplete participant data. All included studies were classified as unclear for at least one risk of bias domain. Evidence was also downgraded by one level due to inconsistency as I² = 70% and point estimates were not similar. There was potential risk of publication bias because we identified trials starting before 2015 but still "ongoing" as shown in the trial registries. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Benzoyl peroxide compared to adapalene for acne</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/full#CD011154-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011154-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Benzoyl peroxide compared to clindamycin for acne</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Benzoyl peroxide compared to clindamycin for acne</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> acne vulgaris<br/> <b>Setting:</b> unspecified (probably outpatient)<br/> <b>Intervention:</b> benzoyl peroxide<br/> <b>Comparison:</b> clindamycin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with clindamycin</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with benzoyl peroxide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant's global self‐assessment of improvement (long‐term data)<br/> assessed with any greater improvement above the first category of improvement on a Likert or Likert‐like scale<br/> Treatment duration: 10 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>367 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>348 per 1000<br/> (249 to 491) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.95<br/> (0.68 to 1.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Withdrawal due to adverse effects (long‐term data)<br/> Treatment duration: range 10 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Low risk: 0 per 1000<sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000<br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.93<br/> (0.90 to 4.11) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>3330<br/> (8 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>High risk: 46 per 1000<sup>c</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>89 per 1000 (41 to 189)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of participants with any adverse events (long‐term data)<br/> Treatment duration: range 10 weeks to 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>73 per 1000<sup>a</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>91 per 1000<br/> (71 to 116) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.24<br/> (0.97 to 1.58) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3018<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The control group risk estimate is the median control group risk across studies. </p> <p><sup>b</sup>Downgraded by two levels to low‐quality evidence: one level due to imprecision as the confidence interval is wide and includes 1; could not exclude the possibility of no effect compared with clindamycin. The estimate was based on a small number of events. One further level due to study limitations (risk of bias), as <a href="./references#CD011154-bbs2-0066" title="EllisCN , LeydenJ , KatzHI , GoldfarbMT , HickmanJ , JonesTM . Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2001;67(2 Suppl):13‐20. [CENTRAL: CN‐00520424; MEDLINE: 11236210] LeydenJ , et al. Treatment of acne vulgaris with a combination benzoyl peroxide/clindamycin topical gel Abstract P‐013. 8th Congress of the European Academy of Dermatology and Venereology. Amsterdam, The Netherlands, 29 Sept‐3 October 1999. Journal of the European Academy of Dermatology and Venereology1999;12(Suppl 2):S144. [CENTRAL: CN‐00478651] LeydenJJ , BergerRS , DunlapFE , EllisCN , ConnollyMA , LevySF . Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. American Journal of Clinical Dermatology2001;2(1):33‐9. [CENTRAL: CN‐00363426; MEDLINE: 11702619] ">Leyden 2001a</a> was classified as “unclear risk of bias” for most risk of bias domains because the report did not provide sufficient information to allow judgement. </p> <p><sup>c</sup>We assume a range of risks according to risks in the control groups of included studies, where we expect different populations to experience different risks of events of interest. In this case, the lower limit of the risk is 0, and the upper limit is the highest control group risk in the included studies. </p> <p><sup>d</sup>Downgraded by three levels to very low‐quality evidence: two levels due to very serious imprecision as the confidence interval includes 1; could not exclude the possibility of no effect compared with clindamycin, and there were very few events. One further level due to study limitations (risk of bias) as seven of the included studies were classified as “unclear risk of bias” for most risk of bias domains because reports did not provide sufficient information to allow judgement. In addition, in <a href="./references#CD011154-bbs2-0023" title="DraelosZD , TanghettiEA . Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis; Cutaneous Medicine for the Practitioner2002;69(2 Suppl):20‐9. [CENTRAL: CN‐00409023; MEDLINE: 12095065] ">Draelos 2002</a>, the nurse may be aware of erythromycin/benzoyl peroxide treatment after randomisation. This study has a high proportion of withdrawal, and it is unclear whether numbers of withdrawals and corresponding reasons were balanced between groups. In addition, ITT analysis was not conducted. In <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>, 10% of participants did not complete the treatment duration within each group and reasons were not balanced across groups. Besides, trial authors did not compare characteristics between participants who completed and discontinued treatment. </p> <p><sup>e</sup>Downgraded by one level to moderate‐quality evidence due to risk of bias as five included studies were classified as “unclear risk of bias” for most risk of bias domains because reports did not provide sufficient information to allow judgement. In addition, in <a href="./references#CD011154-bbs2-0023" title="DraelosZD , TanghettiEA . Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis; Cutaneous Medicine for the Practitioner2002;69(2 Suppl):20‐9. [CENTRAL: CN‐00409023; MEDLINE: 12095065] ">Draelos 2002</a>, the nurse may be aware of the erythromycin/benzoyl peroxide treatment after randomisation. This study has a high proportion of withdrawal, and it is unclear whether numbers of withdrawals and corresponding reasons were balanced between groups. In addition, ITT analysis was not conducted. In <a href="./references#CD011154-bbs2-0107" title="Cook‐BoldenF , ChenD , EichenfieldL , Stein‐GoldL . Managing moderate to severe acne in adolescents: benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1755 subjects. P740. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [DOI: 10.1016/j.jaad.2008.11.121] Cook‐BoldenFE . Treatment of moderate to severe acne vulgaris in a Hispanic population: a post‐hoc analysis of efficacy and tolerability of clindamycin phosphate 1.2%/benzoyl peroxide 2.5% gel. Journal of Drugs in Dermatology2012;11(4):455‐9. [CENTRAL: CN‐00880750; MEDLINE: 22453581] EichenfieldLF , KrakowskiAC . Moderate to severe acne in adolescents with skin of color: benefits of a fixed combination clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel. Journal of Drugs in Dermatology2012;11(7):818‐24. [CENTRAL: CN‐00879677; MEDLINE: 22777222] GoldMH , KorotzerA . Sub‐group analyses from a trial of a fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% gel for the treatment of moderate‐to‐severe acne vulgaris. Journal of Clinical and Aesthetic Dermatology2015;8(12):22‐6. [CENTRAL: CN‐01162058; MEDLINE: 26705445] Stein‐GoldL , ChenD , Cook‐BoldenF , BaldwinH . Efficacy of a once‐daily fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel across a broad patient population with moderate to severe acne. Journal of the American Academy of Dermatology2010;62(3 Suppl):AB15. [CENTRAL: CN‐00843902] ThiboutotD , ShalitaA , ZaengleinA , CalvareseB . Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne. P738. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ShalitaA , ZaengleinA , CortesR . Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once‐daily treatment of moderate to severe acne. P739. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB22. [CENTRAL: CN‐01574645; DOI: 10.1016/j.jaad.2008.11.120] ThiboutotD , ZaengleinA , WeissJ , WebsterG , CalvareseB , ChenD . An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once‐daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. Journal of the American Academy of Dermatology2008;59(5):792‐800. [CENTRAL: CN‐00667399; MEDLINE: 18805603] WebsterG , GoldM , RichP , MrazS . Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne. P718. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB17. [DOI: 10.1016/j.jaad.2008.11.099] WebsterG , RichP , GoldMH , MrazS , CalvareseB , ChenD . Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. Journal of Drugs in Dermatology2009;8(8):736‐43. [CENTRAL: CN‐00720449; MEDLINE: 19663111] WebsterG , ThiboutotDM , ChenDM , MerikleE . Impact of a fixed combination of clindamycin phosphate 1.2%‐benzoyl peroxide 2.5% aqueous gel on health‐related quality of life in moderate to severe acne vulgaris. Cutis; Cutaneous Medicine for the Practitioner2010;86(5):263‐7. [CENTRAL: CN‐00771267; MEDLINE: 21214129] WeissJ , FowlerJ , YuK , SwinyerL . Patient‐reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2813 subjects. P274. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB18. [DOI: 10.1016/j.jaad.2008.11.105] ">Thiboutot 2008</a>, 10% of participants did not complete the treatment duration within each group and reasons were not balanced across groups. Besides, trial authors did not compare characteristics between participants who completed and discontinued treatment. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Benzoyl peroxide compared to clindamycin for acne</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/full#CD011154-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011154-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Benzoyl peroxide compared to erythromycin for acne</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Benzoyl peroxide compared to erythromycin for acne</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> acne vulgaris<br/> <b>Setting:</b> unspecified (probably outpatient)<br/> <b>Intervention:</b> benzoyl peroxide<br/> <b>Comparison:</b> erythromycin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with erythromycin<sup>a</sup> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with benzoyl peroxide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant's global self‐assessment of improvement (long‐term data) ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neither long‐ nor medium‐term data for this outcome were reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse effects (medium‐term data)<br/> Treatment duration: 8 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.00 (0.07 to 15.26)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of participants with any adverse events (long‐term data)<br/> Treatment duration: 10 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were zero events in either group, so absolute risks and relative effect could not be calculated </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The control group risk estimate is the median control group risk across studies. </p> <p><sup>b</sup>Downgraded by three levels due to serious risk of bias and very serious imprecision. We downgraded by one level due to risk of bias because <a href="./references#CD011154-bbs2-0008" title="BurkeB , EadyEA , CunliffeWJ . Benzoyl peroxide versus topical erythromycin in the treatment of acne vulgaris. British Journal of Dermatology1983;108(2):199‐204. [CENTRAL: CN‐00568861; MEDLINE: 6218815] ">Burke 1983</a> was a study without sufficient information in the report to allow judgement about risk of bias. In <a href="./references#CD011154-bbs2-0011" title="ChalkerDK , ShalitaA , SmithJG , SwannRW . A double‐blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. Journal of the American Academy of Dermatology1983;9(6):933‐6. [CENTRAL: CN‐00334175; MEDLINE: 6227643] ">Chalker 1983</a>, trial authors did not provide sufficient information on randomisation and blinding, although they described this study as "randomised" and "double‐blind". We further downgraded by two levels due to very serious imprecision because of a very small number of events. </p> <p><sup>c</sup>Downgraded by three levels due to serious risk of bias and very serious imprecision. We downgraded by one level due to risk of bias because in <a href="./references#CD011154-bbs2-0011" title="ChalkerDK , ShalitaA , SmithJG , SwannRW . A double‐blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide combination in the treatment of acne vulgaris. Journal of the American Academy of Dermatology1983;9(6):933‐6. [CENTRAL: CN‐00334175; MEDLINE: 6227643] ">Chalker 1983</a>, trial authors did not provide sufficient information on randomisation and blinding, although they described this study as "randomised" and "double‐blind". We further downgraded by two levels due to very serious imprecision because there were zero events in either group and the effect was not estimable. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Benzoyl peroxide compared to erythromycin for acne</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/full#CD011154-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011154-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Benzoyl peroxide compared to salicylic acid for acne</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Benzoyl peroxide compared to salicylic acid for acne</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> acne vulgaris<br/> <b>Setting:</b> unspecified (probably outpatient)<br/> <b>Intervention:</b> benzoyl peroxide<br/> <b>Comparison:</b> salicylic acid </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with salicylic acid<sup>a</sup> </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with benzoyl peroxide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant's global self‐assessment of improvement (long‐term data) ‐ not measured</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neither long‐ nor medium‐term data for this outcome were reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to adverse effects (long‐term data)<br/> Treatment duration: 12 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No withdrawals in either group, so absolute risks and relative effect could not be calculated </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of participants with any adverse events (medium‐term data)</p> <p>Treatment duration: 6 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 4.77 (0.24 to 93.67)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were zero events in the salicylic acid group and 2 events in the BPO group​, so absolute risks could not be calculated </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The control group risk estimate is the median control group risk across studies. </p> <p><sup>b</sup>Downgraded by three levels due to serious risk of bias and very serious imprecision. We downgraded by one level due to risk of bias because in <a href="./references#CD011154-bbs2-0004" title="BissonnetteR , BolducC , SeiteS , NigenS , ProvostN , MaariC , et al. Randomized study comparing the efficacy and tolerance of a lipophillic hydroxy acid derivative of salicylic acid and 5% benzoyl peroxide in the treatment of facial acne vulgaris. Journal of Cosmetic Dermatology2009;8(1):19‐23. [CENTRAL: CN‐00698297; MEDLINE: 19250161] ">Bissonnette 2009</a>, a high proportion (21/80) of participants withdrew from the trial. No information on comparisons of reasons for withdrawal between groups was available, with no ITT analysis being conducted. We further downgraded by two levels due to very serious imprecision because there were zero events in either group and the effect was not estimable. </p> <p><sup>c</sup>Downgraded by three levels due to serious risk of bias and very serious imprecision. We downgraded by one level due to risk of bias because the included study, <a href="./references#CD011154-bbs2-0013" title="ChantalatJ , LiuJC . Six‐week safety and efficacy evaluation of a synergistic microgel complex versus 10% benzoyl peroxide in the treatment of mild to moderate acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB14. [CENTRAL: CN‐00602658] ChantalatJ , LuedtkeK , WiegandB , LiuJC . Significant improvement in acne quality of life by a topical treatment containing a synergistic microgel complex and 2% salicylic acid. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN‐00602548] ChantalatJ , StamatasG , LiuJ C , ChenT . Treating emerging acne. Journal of the American Academy of Dermatology2006;54(3 Suppl):AB21. [CENTRAL: CN‐00602574] ">Chantalat 2006</a>, was classified as “unclear risk of bias” for most risk of bias domains because the report did not provide sufficient information to allow judgement. We further downgraded by two levels due to very serious imprecision because of the very small number of events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Benzoyl peroxide compared to salicylic acid for acne</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/full#CD011154-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011154-tbl-0006"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of unfamiliar terms</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Term</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Definition</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne inversa</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A chronic disease of the apocrine glands occurring mainly in the axillae and in groin regions. It is caused by poral occlusion with secondary bacterial infection, evolving into abscesses that eventually rupture. The chronic phase is characterised by ulcers, sinus tracts, fistulas, fibrosis, and scarring </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne vulgaris</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic acne involving mainly the face, chest, and shoulders, which is common among adolescents, and characterised by the intermittent formation of discrete papular and/or pustular lesions, sometimes resulting in scarring </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alpha‐hydroxy acids</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Organic acids, such as glycolic, lactic, citric, and mandelic acids, containing a hydroxyl group bonded to the carbon atom adjacent to the carboxylic acid group. They are used in skin care preparations for their exfoliating properties </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Androgen</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A steroid hormone, such as testosterone or androsterone, that controls the development and maintenance of masculine characteristics. Androgens stimulate sebaceous glands to grow and produce sebum, and therefore cause acne </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Azelaic acid</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A natural material that kills bacteria in the skin and decreases the production of keratin. It is used to treat and prevent mild and moderate acne that is caused by bacteria </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacterial resistance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The ability of bacteria to resist the effects of an antibiotic</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Benzoyl peroxide</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An organic compound in the peroxide family used for acne treatment. It works as a peeling agent. It increases skin turnover, clearing pores and reducing the bacterial count (specifically <i>C acnes</i>) as well as acting directly as an anti‐microbial agent </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chloracne</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An acneiform eruption due to exposure to chlorine compounds</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clindamycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A lincosamide antibiotic, commonly used for topical treatment of acne</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Colonisation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The presence of bacteria on a body surface (like on the skin, mouth, intestines or airway) without causing disease in the person </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Comedolytic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The term used to describe a product or medication that inhibits the formation of comedones. Comedolytic products work by helping the skin to shed more effectively, keeping the pores from becoming plugged </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comedone</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A blocked pore in the form of a yellow or black bump or plug on the skin</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Corticosteroids</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any of a class of steroid hormones formed in the cortex of the adrenal gland or chemically similar synthesised hormones that have anti‐inflammatory properties </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cyst</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A closed sac having a distinct membrane compared to nearby tissue, which may contain air, fluids, or semi‐solid material </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cytokines</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A diverse group of soluble molecules important for cell signalling in the generation of an immune response, where they act as intercellular mediators or signalling molecules </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Differentiation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The process by which a less specialised cell becomes a more specialised cell.</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drug‐induced acne</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne caused or exacerbated by several types of drugs, such as anti‐epileptics, halogens, and steroids </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Eczema</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An acute or chronic non‐contagious inflammation of the skin, often caused by allergy and characterised by itching, scaling, and blistering </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythema</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blanching reddening of the skin due to local vasodilatation</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Erythromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A macrolide antibiotic, commonly used for topical treatment of acne</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypercolonisation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abnormal increase in the number of bacteria otherwise normally present on a body surface without causing disease in the person </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Infantile acne</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne that presents at the age of 2 to 6 months and persists until the age of 3 to 4 years </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Keratinisation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The process of keratin production that forms an epidermal barrier in stratified squamous epithelial tissue </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Microcomedones</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Microscopic comedones, not visible to the naked eye</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nodule</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A deep skin‐seated dome‐shaped solid lump</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Occupational acne</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acne caused by exposure to extraneous agents or adverse conditions in a working environment. The agents and conditions that most commonly cause problems are oils, tars, and excessive humidity </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Papule</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Small, solid, raised lesion, usually dome‐shaped</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pilosebaceous unit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The hair follicle and sebaceous gland</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Polycystic ovarian syndrome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A condition caused by the imbalance of female sex hormones. It is associated with absence of ovulation resulting in irregular menstrual cycles and infertility, insulin resistance causing obesity, and high levels of masculinising hormones causing excessive hair growth and acne </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pustule</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A visible collection of pus</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reactive oxygen species</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chemically reactive molecules containing oxygen. Increased levels of reactive oxygen species may result in significant damage to cell structures, which is called <i>oxidative stress</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Resorcinol</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A dihydroxy benzene compound used in many acne treatment products. It helps prevent comedones by removing buildup of dead skin cells </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retinoids</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A class of chemical compound related chemically to vitamin A, topically used for acne treatment due to the way they regulate epithelial cell growth </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rosacea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A chronic dermatitis of the face, especially of the nose and cheeks, characterised by a red or rosy colouration, caused by dilation of capillaries, and the appearance of acne‐like pimples </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sebaceous glands</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Glands that produce sebum and deliver it to the surface of the skin. They are larger and greater in number on the face and upper parts of the trunk, which makes these the acne‐prone areas </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sebum</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An oily substance produced by the sebaceous glands of the skin. Its main function is to protect and waterproof the hair and skin. Oily skin and acne are the result of excessive sebum production </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Scar</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The fibrous tissue replacing normal tissues destroyed by injury, disease, or surgery</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sodium sulphacetamide</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A sulphonamid antibiotic used topically for fighting bacteria on the skin in the treatment of acne, dandruff, and seborrhoeic dermatitis </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tetracycline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A broad‐spectrum antibiotic synthesised from chlortetracycline or derived from certain micro‐organisms of the genus <i>Streptomyces</i> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical therapy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A medication in the form of a cream, foam, gel, lotion, or ointment that is applied to body surfaces to treat ailments </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Glossary of unfamiliar terms</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/full#CD011154-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011154-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">BPO versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participant's global self‐assessment of improvement (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [1.12, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 BPO monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1073</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [0.94, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 BPO/adapalene versus adapalene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>921</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [0.98, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 BPO/clindamycin versus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.11, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Participant's global self‐assessment of improvement (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.70 [1.68, 4.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 BPO monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.31 [0.90, 5.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 BPO plus nadifloxacin versus placebo plus nadifloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.85 [1.64, 4.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Withdrawal due to adverse effects (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>13744</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.13 [1.55, 2.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 BPO monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5493</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.10 [1.22, 3.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 BPO/adapalene versus adapalene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.45 [1.47, 8.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 BPO/clindamycin versus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4918</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.91 [1.68, 5.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 BPO/erythromycin versus erythromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 BPO plus adapalene versus adapalene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.25, 100.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 BPO plus tazarotene versus tazarotene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.26, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7 BPO/clindamycin plus tazarotene versus clindamycin plus tazarotene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>214</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.15, 7.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8 BPO plus dapsone versus placebo plus dapsone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.45 [0.52, 173.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Withdrawal due to adverse effects (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.92 [0.31, 27.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 BPO monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.90 [0.12, 68.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 BPO plus nadifloxacin versus placebo plus nadifloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.94 [0.12, 70.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Investigator‐assessed absolute change in total lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.73 [‐15.68, ‐5.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 BPO monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐16.14 [‐26.51, ‐5.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 BPO/clindmycin versus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.25 [‐11.05, ‐3.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Investigator‐assessed absolute change in inflammatory lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.50 [‐6.33, ‐0.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 BPO monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.12 [‐11.02, ‐1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 BPO/clindamycin versus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.03 [‐1.88, ‐0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Investigator‐assessed absolute change in non‐inflammatory lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.53 [‐9.74, ‐3.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 BPO monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.69 [‐15.08, ‐4.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 BPO/clindamycin versus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.97 [‐5.81, ‐2.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Investigator‐assessed percentage change in total lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1567</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.29 [3.39, 17.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 BPO/adapalene versus adapalene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.60 [8.35, 20.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 BPO/clindamycin versus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1053</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.74 [‐6.51, 31.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 BPO plus dapsone versus placebo plus dapsone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.00 [‐2.06, 16.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Investigator‐assessed percentage change in inflammatory lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1588</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>17.22 [4.98, 29.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 BPO monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>34.0 [18.20, 49.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 BPO/clindamycin versus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.51 [‐2.02, 33.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 BPO plus dapsone versus placebo plus dapsone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.0 [‐0.82, 18.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Investigator‐assessed percentage change in non‐inflammatory lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1588</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>19.31 [7.16, 31.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 BPO monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>41.0 [23.47, 58.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 BPO/clindamycin versus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1237</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>17.07 [2.15, 32.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 BPO plus dapsone versus placebo plus dapsone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.0 [‐3.24, 19.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Investigator‐assessed percentage change in total lesions (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>16.02 [‐0.95, 32.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 BPO/clindamycin versus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>26.70 [8.33, 45.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 BPO plus dapsone versus placebo plus dapsone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.0 [‐0.43, 18.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Investigator‐assessed percentage change in inflammatory lesions (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.83 [‐0.22, 27.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 BPO monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>33.80 [19.68, 47.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 BPO/clindamycin versus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.82, 9.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 BPO plus dapsone versus placebo plus dapsone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.00 [‐2.86, 16.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Investigator‐assessed percentage change in non‐inflammatory lesions (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>18.42 [1.39, 35.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 BPO monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>40.2 [26.10, 54.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 BPO/clindamycin versus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.0 [2.56, 13.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 BPO plus dapsone versus placebo plus dapsone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.0 [‐1.18, 21.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Investigator‐assessed percentage change in total lesions (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.0 [2.26, 17.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 BPO plus dapsone versus placebo plus dapsone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.0 [2.26, 17.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Investigator‐assessed percentage change in inflammatory lesions (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.02 [‐0.60, 28.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 BPO monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>32.9 [22.22, 43.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 BPO/clindamycin versus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.00 [1.65, 10.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 BPO plus dapsone versus placebo plus dapsone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [‐3.57, 13.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Investigator‐assessed percentage change in non‐inflammatory lesions (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>229</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>24.65 [4.23, 45.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 BPO monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>35.90 [21.00, 50.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 BPO plus dapsone versus placebo plus dapsone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.0 [5.32, 24.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10399</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [1.40, 1.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 BPO monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.37, 2.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 BPO/adapalene versus adapalene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1969</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [1.42, 1.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 BPO/clindamycin versus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4079</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [1.31, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.4 BPO plus tretinoin/clindamycin versus placebo plus tretinoin/clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.67, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.5 BPO plus dapsone versus placebo plus dapsone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.82, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.96 [1.58, 2.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 BPO monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [1.22, 3.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 BPO/adapalene versus adapalene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1969</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.98 [1.43, 2.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 BPO/clindamycin versus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>799</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.30 [1.55, 3.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.43 [1.78, 3.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 BPO monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.57 [1.28, 5.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 BPO/adapalene versus adapalene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1969</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.16 [2.05, 4.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3 BPO/clindamycin versus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>799</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [1.08, 2.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Percentage of participants with any adverse events (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>11028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.15, 1.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 BPO monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [1.01, 2.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 BPO/adapalene versus adapalene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1447</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.98, 1.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.3 BPO/clindamycin versus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.48 [1.02, 2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.4 BPO plus adapalene versus adapalene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>149</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.67, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.5 BPO plus tazarotene versus tazarotene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.25, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.6 BPO plus tretinoin/clindamycin versus placebo plus tretinoin/clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.34, 26.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.7 BPO plus dapsone versus placebo plus dapsone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>201</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.36 [0.75, 7.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Percentage of participants with any adverse events (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [1.08, 2.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 BPO plus nadifloxacin versus placebo plus nadifloxacin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [1.08, 2.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Percentage of participants with any adverse events (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.02, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 BPO plus tretinoin/clindamycin versus placebo plus tretinoin/clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.02, 0.94]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">BPO versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011154-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">BPO versus adapalene</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participant's global self‐assessment of improvement (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1472</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.90, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 BPO monotherapy versus adapalene monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1123</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.86, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 BPO/clindamycin versus adapalene plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [1.01, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Withdrawal due to adverse effects (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.85 [0.94, 3.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 BPO monotherapy versus adapalene monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2748</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.05 [0.83, 5.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 BPO plus dapsone versus adapalene plus dapsone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.08 [0.46, 35.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 BPO/clindamycin versus adapalene plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.38, 3.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Investigator‐assessed absolute change in total lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.70 [‐5.46, 2.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 BPO/clindamycin versus adapalene plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.70 [‐5.46, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Investigator‐assessed absolute change in inflammatory lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.10 [‐2.42, 0.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 BPO/clindamycin versus adapalene plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.10 [‐2.42, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Investigator‐assessed absolute change in non‐inflammatory lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐3.65, 2.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 BPO/clindamycin versus adapalene plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐3.65, 2.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Investigator‐assessed absolute change in total lesions (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐5.09, 3.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 BPO/clindamycin versus adapalene plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐5.09, 3.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Investigator‐assessed absolute change in inflammatory lesions (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.90 [‐3.44, ‐0.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 BPO/clindamycin versus adapalene plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.90 [‐3.44, ‐0.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Investigator‐assessed absolute change in non‐inflammatory lesions (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [‐2.46, 4.86]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 BPO/clindamycin versus adapalene plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [‐2.46, 4.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Investigator‐assessed absolute change in total lesions (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.70 [‐9.39, ‐0.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 BPO/clindamycin versus adapalene plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.70 [‐9.39, ‐0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Investigator‐assessed absolute change in inflammatory lesions (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.60 [‐4.29, ‐0.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 BPO/clindamycin versus adapalene plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.60 [‐4.29, ‐0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Investigator‐assessed absolute change in non‐inflammatory lesions (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.0 [‐6.02, 2.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 BPO/clindamycin versus adapalene plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.0 [‐6.02, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Investigator‐assessed percentage change in total lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>869</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.63 [‐18.42, 13.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 BPO monotherapy versus adapalene monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>205</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.80 [3.38, 18.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 BPO plus clindamycin versus adapalene plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐19.0 [‐20.49, ‐17.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 BPO plus dapsone versus adapalene plus dapsone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.0 [‐14.37, 4.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.4 BPO/clindamycin versus adapalene plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.24 [‐0.36, 6.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Investigator‐assessed percentage change in inflammatory lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>806</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.70 [‐21.14, 9.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 BPO monotherapy versus adapalene monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.70 [‐16.46, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 BPO plus clindamycin versus adapalene plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐20.0 [‐22.17, ‐17.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 BPO plus dapsone versus adapalene plus dapsone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [‐9.03, 11.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.4 BPO/clindamycin versus adapalene plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.49 [0.64, 8.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Investigator‐assessed percentage change in non‐inflammatory lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>806</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.09 [‐21.39, 7.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 BPO monotherapy versus adapalene monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.90 [‐13.31, 5.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 BPO plus clindamycin versus adapalene plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐19.0 [‐20.95, ‐17.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 BPO plus dapsone versus adapalene plus dapsone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.0 [‐20.31, 2.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.4 BPO/clindamycin versus adapalene plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.81 [‐0.59, 8.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Investigator‐assessed percentage change in total lesions (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [‐5.04, 6.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 BPO plus dapsone versus adapalene plus dapsone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.0 [‐13.25, 5.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 BPO/clindamycin versus adapalene plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.35 [‐1.89, 6.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Investigator‐assessed percentage change in inflammatory lesions (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>689</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.55 [1.58, 9.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 BPO monotherapy versus adapalene monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.40 [‐9.01, 13.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 BPO plus dapsone versus adapalene plus dapsone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [‐6.67, 12.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 BPO/clindamycin versus adapalene plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.69 [1.98, 11.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Investigator‐assessed percentage change in non‐inflammatory lesions (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>689</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [‐8.35, 10.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 BPO monotherapy versus adapalene monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.90 [0.52, 21.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 BPO plus dapsone versus adapalene plus dapsone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.0 [‐19.78, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 BPO/clindamycin versus adapalene plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [‐4.65, 5.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Investigator‐assessed percentage change in total lesions (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>547</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.50 [0.22, 8.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 BPO plus dapsone versus adapalene plus dapsone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [‐6.80, 8.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 BPO/clindamycin versus adapalene plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.86 [1.28, 10.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Investigator‐assessed percentage change in inflammatory lesions (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>689</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.12 [4.98, 13.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 BPO monotherapy versus adapalene monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.60 [4.28, 24.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 BPO plus dapsone versus adapalene plus dapsone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [‐3.22, 13.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3 BPO/clindamycin versus adapalene plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.38 [4.17, 14.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Investigator‐assessed percentage change in non‐inflammatory lesions (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>689</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.18 [‐1.80, 14.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 BPO monotherapy versus adapalene monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.30 [5.71, 24.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 BPO plus dapsone versus adapalene plus dapsone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐9.75, 9.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.3 BPO/clindamycin versus adapalene plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.94 [‐2.02, 9.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.95, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 BPO monotherapy versus adapalene monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1965</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.98, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 BPO plus dapsone versus adapalene plus dapsone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.59, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3 BPO/clindamycin versus adapalene plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.95, 2.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [1.07, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 BPO monotherapy versus adapalene monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1965</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [1.01, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.2 BPO/clindamycin versus adapalene plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [0.87, 3.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.14 [1.41, 3.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 BPO monotherapy versus adapalene monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1965</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.14 [1.30, 3.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.2 BPO/clindamycin versus adapalene plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.23 [0.87, 5.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Change in quality of life (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.37, 0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 BPO/clindamycin versus adapalene plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.17 [‐0.37, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Change in quality of life (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐0.42, ‐0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 BPO/clindamycin versus adapalene plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐0.42, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Change in quality of life (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐0.41, ‐0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 BPO/clindamycin versus adapalene plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.22 [‐0.41, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Percentage of participants with any adverse events (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.50, 1.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 BPO monotherapy versus adapalene monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1573</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.48, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.2 BPO plus dapsone versus adapalene plus dapsone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>198</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.30, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.3 BPO/clindamycin versus adapalene plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.42, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Percentage of participants with any adverse events (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 68.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1 BPO monotherapy versus adapalene monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.2 BPO plus clindamycin versus adapalene plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 68.26]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">BPO versus adapalene</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011154-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">BPO versus clindamycin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participant's global self‐assessment of improvement (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.68, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 BPO monotherapy versus clindamycin monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.68, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Withdrawal due to adverse effects (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [0.90, 4.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 BPO monotherapy versus clindamycin monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.27 [0.87, 5.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 BPO plus tazarotene versus clindamycin plus tazarotene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [0.43, 5.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Investigator‐assessed absolute change in total lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>641</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.5 [‐7.54, 0.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 BPO monotherapy versus clindamycin monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>641</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.5 [‐7.54, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Investigator‐assessed absolute change in inflammatory lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>641</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.20 [‐2.99, 0.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 BPO monotherapy versus clindamycin monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>641</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.20 [‐2.99, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Investigator‐assessed absolute change in non‐inflammatory lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>641</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.40 [‐5.30, 0.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 BPO monotherapy versus clindamycin monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>641</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.40 [‐5.30, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Investigator‐assessed percentage change in inflammatory lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.0 [‐8.56, 16.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 BPO monotherapy versus clindamycin monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.0 [‐8.56, 16.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Investigator‐assessed percentage change in non‐inflammatory lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>21.0 [6.86, 35.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 BPO monotherapy versus clindamycin monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>181</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>21.0 [6.86, 35.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.83, 1.45]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 BPO monotherapy versus clindamycin monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2277</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.83, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Percentage of participants with any adverse events (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3018</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.97, 1.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 BPO monotherapy versus clindamycin monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2842</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.98, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 BPO plus tazarotene versus clindamycin plus tazarotene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.35, 2.15]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">BPO versus clindamycin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011154-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">BPO versus erythromycin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Withdrawal due to adverse effects (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.07, 15.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 BPO monotherapy versus erythromycin monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.07, 15.26]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">BPO versus erythromycin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011154-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">BPO versus salicylic acid</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Percentage of participants with any adverse events (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.77 [0.24, 93.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 BPO monotherapy versus salicylic acid monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.77 [0.24, 93.67]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">BPO versus salicylic acid</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011154-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">BPO versus tretinoin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Withdrawal due to adverse effects (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.07, 17.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 BPO/clindamycin versus tretinoin plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 BPO/clindamycin versus tretinoin/clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 BPO/erythromycin versus tretinoin/erythromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.07, 17.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [0.86, 5.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 BPO/clindamycin versus tretinoin plus clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.09 [0.86, 5.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Percentage of participants with any adverse events (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.31, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 BPO/clindamycin versus tretinoin/clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.33, 3.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 BPO/erythromycin versus tretinoin/erythromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.31, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Percentage of participants with any adverse events (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [0.00, 0.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 BPO monotherapy versus tretinoin monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [0.00, 0.48]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">BPO versus tretinoin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011154-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">BPO versus isotretinoin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Withdrawal due to adverse effects (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.53, 2.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 BPO monotherapy versus isotretinoin monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.92 [0.19, 19.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 BPO/erythromycin versus isotretinoin/erythromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.46, 2.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Investigator‐assessed absolute change in inflammatory lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.0 [‐9.89, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 BPO/erythromycin versus isotretinoin/erythromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.0 [‐9.89, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Investigator‐assessed absolute change in non‐inflammatory lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.30 [‐6.07, 10.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 BPO/erythromycin versus isotretinoin/erythromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.30 [‐6.07, 10.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Investigator‐assessed absolute change in inflammatory lesions (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.10 [‐11.27, ‐0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 BPO/erythromycin versus isotretinoin/erythromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.10 [‐11.27, ‐0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Investigator‐assessed absolute change in non‐inflammatory lesions (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.90 [‐1.66, 11.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 BPO/erythromycin versus isotretinoin/erythromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.90 [‐1.66, 11.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Investigator‐assessed absolute change in inflammatory lesions (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.20 [‐14.09, ‐4.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 BPO/erythromycin versus isotretinoin/erythromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.20 [‐14.09, ‐4.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Investigator‐assessed absolute change in non‐inflammatory lesions (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [‐4.39, 6.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 BPO/erythromycin versus isotretinoin/erythromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [‐4.39, 6.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Percentage of participants with any adverse events (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.68, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 BPO/erythromycin versus isotretinoin/erythromycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.68, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Percentage of participants with any adverse events (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.05, 0.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 BPO monotherapy versus isotretinoin monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.05, 0.69]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">BPO versus isotretinoin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011154-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">BPO versus hydrogen peroxide</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Percentage of participants with any adverse events (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.5 [0.79, 15.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 BPO monotherapy versus hydrogen peroxide monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.5 [0.79, 15.49]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">BPO versus hydrogen peroxide</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011154-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">BPO versus isolutrol</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Percentage of participants with any adverse events (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.75 [1.73, 4.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">BPO versus isolutrol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011154-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">BPO versus meclocycline</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Withdrawal due to adverse effects (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.43 [0.34, 120.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 BPO monotherapy versus meclocycline monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.43 [0.34, 120.03]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">BPO versus meclocycline</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011154-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">BPO versus tea tree oil</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Percentage of participants with any adverse events (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.79 [1.32, 2.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 BPO monotherapy versus tea tree oil monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.79 [1.32, 2.44]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">BPO versus tea tree oil</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011154-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">BPO versus chloroxylenol/zinc oxide</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participant's global self‐assessment of improvement (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.51, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 BPO monotherapy versus chloroxylenol/salicylic acid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.51, 1.56]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">BPO versus chloroxylenol/zinc oxide</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011154-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">BPO/adapalene versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participant's global self‐assessment of improvement (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.97, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 BPO/adapalene monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [1.09, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 BPO/adapalene plus lymecycline versus placebo plus lymecycline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.87, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Withdrawal due to adverse effects (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3801</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.28 [1.10, 4.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 BPO/adapalene monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2964</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.01 [1.34, 6.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 BPO/adapalene plus doxycycline versus placebo plus doxycycline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.09, 2.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 BPO/adapalene plus lymecycline versus placebo plus lymecycline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.85 [0.36, 131.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.43 [1.80, 3.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 BPO/adapalene monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.45 [2.07, 2.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 BPO/adapalene plus doxycycline versus placebo plus doxycycline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.81 [2.38, 6.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 BPO/adapalene plus lymecycline versus placebo plus lymecycline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.41 [1.10, 1.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.56 [1.88, 3.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 BPO/adapalene monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.56 [1.88, 3.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.76 [1.84, 4.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 BPO/adapalene monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.76 [1.84, 4.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Percentage of participants with any adverse events (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2465</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.67 [1.15, 6.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 BPO/adapalene monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1628</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.60 [2.42, 8.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 BPO/adapalene plus doxycycline versus placebo plus doxycycline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>459</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.55, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 BPO/adapalene plus lymecycline versus placebo plus lymecycline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.53, 2.05]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">BPO/adapalene versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011154-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">BPO/clindamycin versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participant's global self‐assessment of improvement (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.95 [1.96, 4.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 BPO/clindamycin monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>240</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.95 [1.96, 4.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Withdrawal due to adverse effects (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3095</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.38, 3.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 BPO/clindamycin monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2885</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.29, 2.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 BPO/clindamycin plus tretinoin and clindamycin versus tretinoin and clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.11 [0.25, 103.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 BPO/clindamycin plus tazarotene versus placebo plus tazarotene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>121</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Investigator‐assessed absolute change in total lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.2 [‐19.57, ‐10.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 BPO/clindamycin monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.2 [‐19.57, ‐10.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Investigator‐assessed absolute change in inflammatory lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.1 [‐6.83, ‐3.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 BPO/clindamycin monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.1 [‐6.83, ‐3.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Investigator‐assessed absolute change in non‐inflammatory lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.0 [‐13.20, ‐6.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 BPO/clindamycin monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.0 [‐13.20, ‐6.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Investigator‐assessed percentage change in inflammatory lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>44.16 [23.53, 64.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 BPO/clindamycin monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>44.16 [23.53, 64.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Investigator‐assessed percentage change in non‐inflammatory lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>37.65 [26.04, 49.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 BPO/clindamycin monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>37.65 [26.04, 49.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3993</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.37 [1.87, 3.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 BPO/clindamycin monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.29 [1.79, 2.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 BPO/clindamycin plus tretinoin and clindamycin versus tretinoin and clindamycin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.75 [1.68, 8.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Percentage of participants with any adverse events (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5042</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.78, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 BPO/clindamycin monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5042</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.78, 1.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">BPO/clindamycin versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011154-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">BPO/clindamycin versus adapalene</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participant's global self‐assessment of improvement (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.96, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 BPO/clindamycin versus adapalene monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.96, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Withdrawal due to adverse effects (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.05, 3.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 BPO/clindamycin versus adapalene monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.05, 3.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Change in quality of life (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.20 [‐7.06, ‐1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 BPO/clindamycin versus adapalene monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.20 [‐7.06, ‐1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Change in quality of life (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.8 [‐6.16, ‐1.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 BPO/clindamycin versus adapalene monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.8 [‐6.16, ‐1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Percentage of participants with any adverse events (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.36, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 BPO/clindamycin versus adapalene monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.36, 1.01]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">BPO/clindamycin versus adapalene</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011154-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">BPO/clindamycin versus azelaic acid</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participant's global self‐assessment of improvement (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [1.05, 1.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 BPO/clindamycin versus azelaic acid monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [1.05, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Participant's global self‐assessment of improvement (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [1.09, 1.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 BPO/clindamycin versus azelaic acid monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.44 [1.09, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participant's global self‐assessment of improvement (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [1.00, 1.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 BPO/clindamycin versus azelaic acid monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [1.00, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Withdrawal due to adverse effects (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.06, 15.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 BPO/clindamycin versus azelaic acid monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.06, 15.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Investigator‐assessed percentage change in total lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>18.50 [10.54, 26.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 BPO/clindamycin versus azelaic acid monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>18.50 [10.54, 26.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Investigator‐assessed percentage change in inflammatory lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>17.30 [9.87, 24.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 BPO/clindamycin versus azelaic acid monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>17.30 [9.87, 24.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Investigator‐assessed percentage change in non‐inflammatory lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>18.5 [8.67, 28.33]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 BPO/clindamycin versus azelaic acid monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>18.5 [8.67, 28.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Investigator‐assessed percentage change in total lesions (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.10 [7.19, 23.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 BPO/clindamycin versus azelaic acid monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.10 [7.19, 23.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Investigator‐assessed percentage change in inflammatory lesions (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.90 [8.06, 23.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 BPO/clindamycin versus azelaic acid monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.90 [8.06, 23.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Investigator‐assessed percentage change in non‐inflammatory lesions (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.00 [3.24, 22.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 BPO/clindamycin versus azelaic acid monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.00 [3.24, 22.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Investigator‐assessed percentage change in total lesions (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.00 [6.77, 19.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 BPO/clindamycin versus azelaic acid monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.00 [6.77, 19.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Investigator‐assessed percentage change in inflammatory lesions (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.10 [6.18, 22.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 BPO/clindamycin versus azelaic acid monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.10 [6.18, 22.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Investigator‐assessed percentage change in non‐inflammatory lesions (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.10 [3.56, 18.64]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 BPO/clindamycin versus azelaic acid monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.10 [3.56, 18.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [1.17, 3.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 BPO/clindamycin versus azelaic acid monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.91 [1.17, 3.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [1.07, 3.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 BPO/clindamycin versus azelaic acid monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [1.07, 3.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [0.87, 3.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 BPO/clindamycin versus azelaic acid monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [0.87, 3.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Percentage of participants with any adverse events (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.24, 0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 BPO/clindamycin versus azelaic acid monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.24, 0.72]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">BPO/clindamycin versus azelaic acid</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011154-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">BPO/clindamycin versus erythromycin/zinc</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Withdrawal due to adverse effects (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.07, 16.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 BPO/clindamycin monotherapy versus erythromycin/zinc monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.07, 16.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Investigator‐assessed absolute change in total lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.10 [‐4.65, 16.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 BPO/clindamycin monotherapy versus erythromycin/zinc monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.10 [‐4.65, 16.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Investigator‐assessed absolute change in inflammatory lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐3.85, 4.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 BPO/clindamycin monotherapy versus erythromycin/zinc monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐3.85, 4.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Investigator‐assessed absolute change in non‐inflammatory lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.40 [‐2.16, 14.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 BPO/clindamycin monotherapy versus erythromycin/zinc monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.40 [‐2.16, 14.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Investigator‐assessed absolute change in total lesions (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.60 [‐5.61, 16.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 BPO/clindamycin monotherapy versus erythromycin/zinc monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.60 [‐5.61, 16.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Investigator‐assessed absolute change in inflammatory lesions (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐4.33, 3.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 BPO/clindamycin monotherapy versus erythromycin/zinc monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐4.33, 3.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Investigator‐assessed absolute change in non‐inflammatory lesions (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.20 [‐2.66, 15.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 BPO/clindamycin monotherapy versus erythromycin/zinc monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.20 [‐2.66, 15.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Investigator‐assessed absolute change in total lesions (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.80 [‐5.96, 17.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 BPO/clindamycin monotherapy versus erythromycin/zinc monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.80 [‐5.96, 17.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Investigator‐assessed absolute change in inflammatory lesions (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐3.91, 4.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 BPO/clindamycin monotherapy versus erythromycin/zinc monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐3.91, 4.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Investigator‐assessed absolute change in non‐inflammatory lesions (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.20 [‐3.60, 16.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 BPO/clindamycin monotherapy versus erythromycin/zinc monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.20 [‐3.60, 16.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Percentage of participants with any adverse events (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.38, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 BPO/clindamycin monotherapy versus erythromycin/zinc monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.38, 1.18]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">BPO/clindamycin versus erythromycin/zinc</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011154-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">BPO/clindamycin versus dapsone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Percentage of participants with any adverse events (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.37, 1.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 BPO/clindamycin plus adapalene versus dapsone plus adapalene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.37, 1.23]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">BPO/clindamycin versus dapsone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011154-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">BPO/erythromycin versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participant's global self‐assessment of improvement (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [1.04, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 BPO/erythromycin monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [1.04, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Withdrawal due to adverse effects (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.18, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 BPO/erythromycin plus tazarotene versus tazarotene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.18, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Withdrawal due to adverse effects (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 BPO/erythromycin monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 8.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Investigator‐assessed absolute change in total lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.20 [‐11.74, 1.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 BPO/erythromycin monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.20 [‐11.74, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Investigator‐assessed absolute change in inflammatory lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.9 [‐11.52, ‐2.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 BPO/erythromycin monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.9 [‐11.52, ‐2.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Investigator‐assessed absolute change in non‐inflammatory lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [‐1.96, 5.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 BPO/erythromycin monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [‐1.96, 5.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Investigator‐assessed absolute change in total lesions (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.59 [‐12.63, 3.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 BPO/erythromycin monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.59 [‐12.63, 3.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Investigator‐assessed absolute change in inflammatory lesions (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.90 [‐8.07, 0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 BPO/erythromycin monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.90 [‐8.07, 0.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Investigator‐assessed absolute change in non‐inflammatory lesions (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [‐4.30, 5.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 BPO/erythromycin monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [‐4.30, 5.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Investigator‐assessed absolute change in total lesions (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.60 [‐7.92, 0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 BPO/erythromycin monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.60 [‐7.92, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Investigator‐assessed absolute change in inflammatory lesions (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.10 [‐9.39, ‐2.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 BPO/erythromycin monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.10 [‐9.39, ‐2.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Investigator‐assessed absolute change in non‐inflammatory lesions (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.4 [‐0.71, 5.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 BPO/erythromycin monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.4 [‐0.71, 5.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.84 [1.79, 4.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 BPO/erythromycin monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.84 [1.79, 4.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 'Clear' or 'Almost clear' rated on the IGA scale of acne severity (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.69 [0.91, 49.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 BPO/erythromycin monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>327</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.69 [0.91, 49.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Percentage of participants with any adverse events (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.54, 2.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 BPO/erythromycin plus tazarotene versus tazarotene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.54, 2.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Percentage of participants with any adverse events (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [0.92, 3.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 BPO/erythromycin monotherapy versus placebo or no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [0.92, 3.87]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">BPO/erythromycin versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011154-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">BPO/erythromycin versus clindamycin</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Withdrawal due to adverse effects (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>376</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.50, 4.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 BPO/erythromycin monotherapy versus clindamycin monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.03 [0.32, 28.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 BPO/erythromycin plus tazarotene versus clindamycin plus tazarotene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.34, 4.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Percentage of participants with any adverse events (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.16 [0.77, 6.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 BPO/erythromycin monotherapy versus clindamycin monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.06 [0.74, 49.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 BPO/erythromycin plus tazarotene versus clindamycin plus tazarotene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [0.76, 3.57]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">BPO/erythromycin versus clindamycin</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011154-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">BPO/erythromycin versus viaminate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Percentage of participants with any adverse events (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>23.52 [1.42, 390.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 BPO/erythromycin versus viaminate monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>23.52 [1.42, 390.03]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">BPO/erythromycin versus viaminate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011154-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">BPO/glycolic acid/zinc lactate versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Investigator‐assessed absolute change in total lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.5 [‐12.56, ‐0.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 BPO/glycolic acid/zinc lactate versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.5 [‐12.56, ‐0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Investigator‐assessed absolute change in inflammatory lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.6 [‐10.38, ‐0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 BPO/glycolic acid/zinc lactate versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.6 [‐10.38, ‐0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Investigator‐assessed absolute change in non‐inflammatory lesions (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐4.74, 2.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 BPO/glycolic acid/zinc lactate versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐4.74, 2.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Investigator‐assessed absolute change in total lesions (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐5.26, 3.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 BPO/glycolic acid/zinc lactate versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐5.26, 3.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Investigator‐assessed absolute change in inflammatory lesions (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.60 [‐6.59, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 BPO/glycolic acid/zinc lactate versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.60 [‐6.59, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Investigator‐assessed absolute change in non‐inflammatory lesions (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [‐1.95, 5.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 BPO/glycolic acid/zinc lactate versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [‐1.95, 5.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Investigator‐assessed absolute change in total lesions (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.20 [‐9.29, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 BPO/glycolic acid/zinc lactate versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.20 [‐9.29, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Investigator‐assessed absolute change in inflammatory lesions (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.8 [‐8.66, ‐0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 BPO/glycolic acid/zinc lactate versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.8 [‐8.66, ‐0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Investigator‐assessed absolute change in non‐inflammatory lesions (short‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [‐3.41, 4.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 BPO/glycolic acid/zinc lactate versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [‐3.41, 4.41]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">BPO/glycolic acid/zinc lactate versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011154-tbl-0029"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">BPO/potassium hydroxyquinoline sulphate versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Withdrawal due to adverse effects (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.81 [0.42, 144.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 BPO/potassium hydroxyquinoline sulphate versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.81 [0.42, 144.12]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">BPO/potassium hydroxyquinoline sulphate versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-tbl-0029">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011154-tbl-0030"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">BPO 10% versus BPO 5%</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Withdrawal due to adverse effects (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.06, 2.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 BPO 10% monotherapy versus BPO 5% monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.06, 2.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Percentage of participants with any adverse events (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.40, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 BPO 10% monotherapy versus BPO 5% monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.40, 1.31]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">BPO 10% versus BPO 5%</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-tbl-0030">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011154-tbl-0031"> <div class="table-heading"><span class="table-label">Comparison 25.</span> <span class="table-title">BPO 10% versus BPO 2.5%</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Percentage of participants with any adverse events (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.99, 2.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 BPO 10% monotherapy versus BPO 2.5% monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.99, 2.96]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 25.</span> <span class="table-title">BPO 10% versus BPO 2.5%</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-tbl-0031">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011154-tbl-0032"> <div class="table-heading"><span class="table-label">Comparison 26.</span> <span class="table-title">BPO 5% versus BPO 2.5%</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Withdrawal due to adverse effects (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>906</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [0.65, 2.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 BPO 5% monotherapy versus BPO 2.5% monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>866</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.61, 2.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 BPO (5%)/clindamycin plus tazarotene versus BPO (2.5%)/clindamycin plus tazarotene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 69.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Withdrawal due to adverse effects (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.79 [0.09, 33.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 BPO 5% monotherapy versus BPO 2.5% monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.79 [0.09, 33.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Change in quality of life (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.40 [‐8.68, 3.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 BPO (5%)/clindamycin plus tazarotene versus BPO (2.5%)/clindamycin plus tazarotene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.40 [‐8.68, 3.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Percentage of participants with any adverse events (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1063</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.95, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 BPO 5% monotherapy versus BPO 2.5% monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1023</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.95, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 BPO (5%)/clindamycin plus tazarotene versus BPO (2.5%)/clindamycin plus tazarotene</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.51, 2.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Percentage of participants with any adverse events (medium‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [1.14, 3.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 BPO 5% monotherapy versus BPO 2.5% monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>155</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.86 [1.14, 3.05]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 26.</span> <span class="table-title">BPO 5% versus BPO 2.5%</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-tbl-0032">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011154-tbl-0033"> <div class="table-heading"><span class="table-label">Comparison 27.</span> <span class="table-title">BPO gel (6%) versus BPO cream (5.5%)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Withdrawal due to adverse effects (long‐term data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 70.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 BPO gel (6%) monotherapy versus BPO cream (5.5%) monotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 70.16]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 27.</span> <span class="table-title">BPO gel (6%) versus BPO cream (5.5%)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011154.pub2/references#CD011154-tbl-0033">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011154.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD011154-note-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD011154-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011154-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011154-note-0011">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD011154-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ko#CD011154-note-0009">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD011154-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ro#CD011154-note-0021">Română</a> </li> <li class="section-language"> <a class="" href="ru#CD011154-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD011154-note-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011154-note-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD011154-note-0007">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011154\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011154\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011154\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011154\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011154\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011154\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011154\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011154\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011154\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011154\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011154\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011154\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011154\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011154\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011154\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011154\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011154\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011154\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=p32VIvbS&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011154.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011154.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011154.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011154.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011154.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725935214"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011154.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725935217"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011154.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e87486b4d9371',t:'MTc0MDcyNTkzNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 